FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Lupien, M
Brown, M
AF Lupien, Mathieu
Brown, Myles
TI Cistromics of hormone-dependent cancer
SO ENDOCRINE-RELATED CANCER
LA English
DT Review
ID ESTROGEN-RECEPTOR-ALPHA; PROSTATE-SPECIFIC ANTIGEN; GENOME-WIDE
ANALYSIS; FORKHEAD BOX A1; BREAST-CANCER; HISTONE H3; ANDROGEN RECEPTOR;
GENE-REGULATION; BINDING-SITES; CYCLIN D1
AB Alterations in transcription programs are a fundamental feature of cancer Nuclear receptors, such as the estrogen receptor alpha (ER alpha) and androgen receptors (ARs), are central in this process as they can directly impact gene expression through interaction with the chromatin and subsequent association with coregulators and the transcriptional machinery Unbiased genome-wide investigations have demonstrated the predominant recruitment of both ER alpha and AR to distant (non-promoter)-regulatory elements. Furthermore, these studies revealed a clear relationship between sites of transcription factor recruitment and gene regulation. Indeed, expression profiles from AR-positive primary prostate tumors and cell lines directly relate to the AR cistrome in prostate cancer cells, while the ER alpha cistrome in breast cancer cells relates to expression profiles from ER alpha-positive primary breast tumors. Additionally, cell-type-specific ER alpha cistromes are linked to lineage-specific estrogen-induced expression profiles in different cell types, for example osteosarcoma and breast cancer cells. The pioneer factor forkhead box A1 (FoxA1/HNF3 alpha) plays a central role in AR and ER alpha signaling. It is recruited in a lineage-specific manner translating the epigenetic signature consisting of mono- and dimethylated histone H3 on lysine 4 (H3K4me1/me2) into functional regulatory elements. Hence, through the interplay between the pioneer factor, namely FoxA1, and epigenetic events, the transcriptional potential of a given cell lineage is predefined. Since this directly impacts signaling through nuclear receptors, these discoveries should significantly impact the development of novel therapeutic strategies directed against multiple types of cancer.
C1 [Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA.
[Lupien, Mathieu] Dartmouth Med Sch, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.
[Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Brown, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA.
OI Brown, Myles/0000-0002-8213-1658
FU NIDDK [R01DK074967]; NCI [P01 CA8011105]; US Department of Defense
Breast Cancer Research [W81XWH-08-1-0214]
FX This work was supported by grants from the NIDDK (R01DK074967 to M B),
the NCI (P01 CA8011105, the DF/HCC Breast Cancer SPORE Grant, and the
DF/HCC Prostate Cancer SPORE Grant to M B), and the US Department of
Defense Breast Cancer Research Program Awards (W81XWH-08-1-0214 to M L)
NR 76
TC 51
Z9 51
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD JUN
PY 2009
VL 16
IS 2
BP 381
EP 389
DI 10.1677/ERC-09-0038
PG 9
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 531MK
UT WOS:000272670200006
PM 19369485
ER
PT J
AU Kotoula, V
Sozopoulos, E
Litsiou, H
Fanourakis, G
Koletsa, T
Voutsinas, G
Tseleni-Balafouta, S
Mitsiades, CS
Wellmann, A
Mitsiades, N
AF Kotoula, Vassiliki
Sozopoulos, Elias
Litsiou, Helen
Fanourakis, Galinos
Koletsa, Triantafyllia
Voutsinas, Gerassimos
Tseleni-Balafouta, Sophia
Mitsiades, Constantine S.
Wellmann, Axel
Mitsiades, Nicholas
TI Mutational analysis of the BRAF, RAS and EGFR genes in human
adrenocortical carcinomas
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; THYROID-CARCINOMA;
CLINICAL-RESPONSE; GEFITINIB; TUMORS; RESPONSIVENESS; ACTIVATION;
ONCOGENE; PATTERNS
AB The serine/threonine kinase B-Raf plays a key role in the Ras/Raf/MEK/ERK pathway that relays extracellular signals for cell proliferation and survival Several types of human malignancies harbor activating BRAF mutations, most frequently a V600E substitution. The epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase (TK) receptor that mediates proliferation and survival signaling, is expressed in a wide variety of normal and neoplastic tissues. EGFR inhibitors have produced objective responses in patients with non-small cell lung carcinomas harboring activating EGFR TK domain somatic mutations. We evaluated the presence of mutations in BRAF(exons 11 and 15), KRAS (exons 1 and 2), NRAS (exons 1 and 2), and EGFR (exons 18-21) in adrenal carcinomas (35 tumor specimens and two cell lines) by DNA sequencing. BRAF mutations were found in two carcinomas (5.7%) Four carcinomas (11.4%) carried EGFR TK domain mutations One specimen carried a KRAS mutation, and another carried two NRAS mutations No mutations were found in the two adrenocortical cell lines. BRAF- and EGFR-mutant tumor specimens exhibited stronger immunostaining for the phosphorylated forms of the MEK and ERK kinases than their wild-type counterparts. EGFR-mutant carcinomas exhibited increased phosphorylation of EGFR (Tyr 992) compared with wild-type carcinomas. We conclude that BRAF, RAS, and EGFR mutations occur in a subset of human adrenocortical carcinomas. Inhibitors of the Ras/Raf/MEK/ERK and EGFR pathways represent candidate targeted therapies for future clinical trials in carefully selected patients with adrenocortical carcinomas harboring respective activating mutations.
C1 [Mitsiades, Constantine S.; Mitsiades, Nicholas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kotoula, Vassiliki; Koletsa, Triantafyllia] Aristotle Univ Thessaloniki, Sch Med, Dept Pathol, GR-54006 Thessaloniki, Greece.
[Sozopoulos, Elias; Litsiou, Helen; Fanourakis, Galinos; Tseleni-Balafouta, Sophia] Univ Athens, Dept Pathol, Athens, Greece.
[Mitsiades, Constantine S.; Mitsiades, Nicholas] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Wellmann, Axel] Rhein Westfal TH Aachen, Univ Clin, Inst Pathol, D-52074 Aachen, Germany.
[Mitsiades, Nicholas] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
RP Mitsiades, N (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
FU Greek Secretariat for Research and Technology [PENED03/583]
FX Work supported by PENED03/583 (research project by the Greek Secretariat
for Research and Technology) awarded to V K
NR 29
TC 24
Z9 25
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD JUN
PY 2009
VL 16
IS 2
BP 565
EP 572
DI 10.1677/ERC-08-0101
PG 8
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 531MK
UT WOS:000272670200021
PM 19190079
ER
PT J
AU Wilkinson, CW
AF Wilkinson, Charles W.
TI Adrenocortical Responsiveness to Adrenocorticotropin: StAR Is Ascendant
SO ENDOCRINOLOGY
LA English
DT Editorial Material
ID ACUTE REGULATORY PROTEIN; ADRENAL GLUCOCORTICOID SYNTHESIS; MULTIPLE
SIGNALING PATHWAYS; CORTISOL SECRETION; DIURNAL-VARIATION;
GENE-EXPRESSION; ACTH; CELLS; MELATONIN; RECEPTOR
C1 [Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
RP Wilkinson, CW (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wilkinso@u.washington.edu
NR 34
TC 1
Z9 1
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2009
VL 150
IS 6
BP 2509
EP 2511
DI 10.1210/en.2009-0303
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 448IQ
UT WOS:000266256700005
PM 19458248
ER
PT J
AU Thaler, JP
Cummings, DE
AF Thaler, Joshua P.
Cummings, David E.
TI Hormonal and Metabolic Mechanisms of Diabetes Remission after
Gastrointestinal Surgery
SO ENDOCRINOLOGY
LA English
DT Review
ID GASTRIC-BYPASS-SURGERY; ROUX-EN-Y; DUODENAL-JEJUNAL BYPASS;
GLUCAGON-LIKE PEPTIDE-1; MORBIDLY OBESE-PATIENTS; PLASMA GHRELIN LEVELS;
GOTO-KAKIZAKI RATS; BETA-CELL FUNCTION; WEIGHT-LOSS; BARIATRIC SURGERY
AB Bariatric surgery is the most effective available treatment for obesity. The most frequently performed operation, Roux-en-Y gastric bypass (RYGB), causes profound weight loss and ameliorates obesity-related comorbid conditions, especially type 2 diabetes mellitus (T2DM). Approximately 84% of diabetic patients experience complete remission of T2DM after undergoing RYGB, often before significant weight reduction. The rapid time course and disproportional degree of T2DM improvement after RYGB compared with equivalent weight loss from other interventions suggest surgery-specific, weight-independent effects on glucose homeostasis. Potential mechanisms underlying the direct antidiabetic impact of RYGB include enhanced nutrient stimulation of lower intestinal hormones (e. g. glucagon-like peptide-1), altered physiology from excluding ingested nutrients from the upper intestine, compromised ghrelin secretion, modulations of intestinal nutrient sensing and regulation of insulin sensitivity, and other changes yet to be fully characterized. Research aimed at determining the relative importance of these effects and identifying additional mechanisms promises not only to improve surgical design but also to identify novel targets for diabetes medications. (Endocrinology 150: 2518-2525, 2009)
C1 [Cummings, David E.] Univ Washington, Diabet Endocrinol Res Ctr, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr,Dept Med, Seattle, WA 98195 USA.
Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Cummings, DE (reprint author), Univ Washington, Diabet Endocrinol Res Ctr, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr,Dept Med, Box 358280 Mail Stop 111, Seattle, WA 98195 USA.
EM davidec@u.washington.edu
NR 79
TC 217
Z9 232
U1 3
U2 29
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2009
VL 150
IS 6
BP 2518
EP 2525
DI 10.1210/en.2009-0367
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 448IQ
UT WOS:000266256700007
PM 19372197
ER
PT J
AU Latif, R
Morshed, SA
Zaidi, M
Davies, TF
AF Latif, Rauf
Morshed, Syed A.
Zaidi, Mone
Davies, Terry F.
TI The Thyroid-Stimulating Hormone Receptor: Impact of Thyroid-Stimulating
Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on
Multimerization, Cleavage, and Signaling
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Review
DE TSH receptor; Multimerization; Oligomerization; Signaling; TSHR
antibodies; Autoimmune thyroid disease
ID HUMAN THYROTROPIN RECEPTOR; G-PROTEIN ACTIVATION; EMBRYONIC STEM-CELLS;
HUMAN TSH RECEPTOR; GRAVES-DISEASE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR
DOMAIN; LIGAND-BINDING; STRUCTURAL DETERMINANTS; DEOXYRIBONUCLEIC-ACID
AB The thyroid-stimulating hormone receptor (TSHR) has a central role in thyrocyte function and is also one of the major autoantigens for the autoimmune thyroid diseases. We review the post-translational processing, multimerization, and intramolecular cleavage of TSHR, all of which may modulate its signal transduction. The recent characterization of monoclonal antibodies to the TSHR, including stimulating, blocking, and neutral antibodies, have also revealed unique biologic insights into receptor activation and the variety of these TSHR antibodies may help explain the multiple clinical phenotypes seen in autoimmune thyroid diseases. Knowledge of the structure/function relationship of the TSHR is beginning to provide a greater understanding of thyroid physiology and thyroid autoimmunity.
C1 [Latif, Rauf; Morshed, Syed A.; Davies, Terry F.] Mt Sinai Sch Med, Thyroid Res Unit, Bronx, NY 10468 USA.
[Latif, Rauf; Morshed, Syed A.; Davies, Terry F.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Zaidi, Mone] Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10029 USA.
[Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
RP Latif, R (reprint author), 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rauf.latif@mssm.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK069713, DK052464]; David Owen Segal Endowment
FX Supported in part by DK069713 and DK052464 from National Institute of
Diabetes and Digestive and Kidney Diseases, the VA Merit Award Program,
and the David Owen Segal Endowment.
NR 126
TC 32
Z9 34
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8529
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD JUN
PY 2009
VL 38
IS 2
BP 319
EP +
DI 10.1016/j.ecl.2009.01.006
PG 24
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 438PN
UT WOS:000265567800007
PM 19328414
ER
PT J
AU Reinsberger, C
Tanaka, N
Lee, JW
Dworetzky, BA
Bromfield, EB
Hamiwka, LD
Cole, AJ
Bourgeois, BF
Golby, AJ
Madsen, JR
Stufflebeam, SM
AF Reinsberger, C.
Tanaka, N.
Lee, J. W.
Dworetzky, B. A.
Bromfield, E. B.
Hamiwka, L. D.
Cole, A. J.
Bourgeois, B. F.
Golby, A. J.
Madsen, J. R.
Stufflebeam, S. M.
TI CURRENT DIPOLE ORIENTATION AND DISTRIBUTION OF EPILEPTIFORM ACTIVITY
CORRELATES WITH CORTICAL THINNING IN LEFT-SIDED MESIOTEMPORAL EPILEPSY
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 6th Joint Meeting of the German, Austrian, and Swiss Sections of the
International-League-Against-Epilepsy
CY MAY 20-24, 2009
CL Rostock, GERMANY
SP Int League Against Epilepsy, German Sect, Int League Against Epilepsy, Austrian Sect, Int League Against Epilepsy, Swiss Sect
C1 [Reinsberger, C.] Univ Wurzburg, Wurzburg, Germany.
[Tanaka, N.; Cole, A. J.; Stufflebeam, S. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lee, J. W.; Dworetzky, B. A.; Bromfield, E. B.; Golby, A. J.; Madsen, J. R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hamiwka, L. D.; Bourgeois, B. F.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2009
VL 50
BP 40
EP 40
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 441LM
UT WOS:000265770600131
ER
PT J
AU Leeman, BA
AF Leeman, Beth A.
TI Provocative techniques should not be used for the diagnosis of
psychogenic nonepileptic seizures
SO EPILEPSY & BEHAVIOR
LA English
DT Editorial Material
ID PSEUDOEPILEPTIC SEIZURES; INDUCTION PROCEDURES; INFORMED-CONSENT;
PLACEBO; EEG; DECEPTION; SUGGESTION; ATTITUDES; VIDEO; EPILEPSY
C1 [Leeman, Beth A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Gen Hosp, Sch Med,Dept Neurol, Boston, MA 02215 USA.
[Leeman, Beth A.] Beth Israel Deaconess Med Ctr, Behav Neurol Unit, Boston, MA 02215 USA.
RP Leeman, BA (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Gen Hosp, Sch Med,Dept Neurol, Boston, MA 02215 USA.
EM bleeman1@bidmc.harvard.edu
NR 47
TC 18
Z9 19
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD JUN
PY 2009
VL 15
IS 2
BP 110
EP 114
DI 10.1016/j.yebeh.2009.01.013
PG 5
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 457TR
UT WOS:000266957100004
PM 19435585
ER
PT J
AU Shelton, RC
Puleo, E
Bennett, GG
McNeill, LH
Sorensen, G
Emmons, KM
AF Shelton, Rachel C.
Puleo, Elaine
Bennett, Gary G.
McNeill, Lorna H.
Sorensen, Glorian
Emmons, Karen M.
TI THE ASSOCIATION BETWEEN RACIAL AND GENDER DISCRIMINATION AND BODY MASS
INDEX AMONG RESIDENTS LIVING IN LOWER-INCOME HOUSING
SO ETHNICITY & DISEASE
LA English
DT Article
DE Discrimination; Body Mass Index; Obesity; Health Disparities; Gender
ID INTERNALIZED RACISM; BLOOD-PRESSURE; ABDOMINAL OBESITY; PERCEIVED
RACISM; FASTING GLUCOSE; CARIBBEAN WOMEN; UNITED-STATES; HEALTH;
COMMUNITY; AMERICANS
AB Background: Research on the association between self-reported racial or gender discrimination and body mass index (BMI) has been limited and inconclusive to date, particularly among lower-income populations.
Objectives: The aim of the current study was to examine the association between self-reported racial and gender discrimination and BMI among a sample of adult residents living in 12 urban lower-income housing sites in Boston, Masschusetts (USA).
Methods: Baseline survey data were collected among 1,307 (weighted N = 1907) study participants. For analyses, linear regression models with a cluster design were conducted using SUDAAN and SAS statistical software.
Results: Our sample was predominately Black (weighted n = 956) and Hispanic (weighted n = 857), and female (weighted n = 1420), with a mean age of 49.3 (SE: .40) and mean BMI of 30.2 kg m(-2) (SE: .19). Nearly 47% of participants reported ever experiencing racial discrimination, and 24.8% reported ever experiencing gender discrimination. In bivariate and multivariable linear regression models, no main effect association was found between either racial or gender discrimination and BMI.
Conclusions: While our findings suggest that self-reported discrimination is not a key determinant of BMI among lower-income housing residents, these results should be considered in light of study limitations. Future researchers may want: to investigate this association among other relevant samples, and other social contextual and cultural factors should be explored to understand how they contribute to disparities. (Ethn Dis. 2009;19:251-257)
C1 [Shelton, Rachel C.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
[Puleo, Elaine] Univ Massachusetts, Dept Publ Hlth, Amherst, MA 01003 USA.
[Bennett, Gary G.; Sorensen, Glorian; Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Bennett, Gary G.; Sorensen, Glorian; Emmons, Karen M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bennett, Gary G.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA.
[Bennett, Gary G.] Duke Univ, Duke Global Hlth Inst, Durham, NC USA.
[McNeill, Lorna H.] Univ Texas MD Anderson Canc Ctr, Dept Hlth Dispar Res, Houston, TX 77030 USA.
RP Shelton, RC (reprint author), Mt Sinai Sch Med, Dept Oncol Sci, 1425 Madison Ave,Box 1130, New York, NY 10029 USA.
EM rachel.shelton@mssm.edu
FU National Cancer Institute (NCI) [5R01CA098864-02, 1K22CA126992-01,
K05CA124415, 5 R25-CA057711-14]; Liberty Mutual, National Grid;
Patterson Fellowship; Mount Sinai Program in Cancer Prevention and
Control: Multidisciplinary Training [5R25-CA081137]
FX This research was supported by grants 5R01CA098864-02, 1K22CA126992-01,
and K05CA124415 from the National Cancer Institute (NCI) and support to
the Dana-Farber Cancer Institute by Liberty Mutual, National Grid, and
the Patterson Fellowship. Funding support for the lead author (R.S.) was
also provided through NCI by the Harvard Education Program in Cancer
Prevention Control (5 R25-CA057711-14) and the Mount Sinai Program in
Cancer Prevention and Control: Multidisciplinary Training
(5R25-CA081137).
NR 39
TC 12
Z9 12
U1 2
U2 8
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2009
VL 19
IS 3
BP 251
EP 257
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 490QM
UT WOS:000269516400002
PM 19769005
ER
PT J
AU Rodriguez, AE
Maree, A
Tarragona, S
Fernandez-Pereira, C
Santaera, O
Granillo, AMR
Rodriguez-Granillo, GA
Russo-Felssen, M
Kukreja, N
Antoniucci, D
Palacios, IF
Serruys, PW
AF Rodriguez, Alfredo E.
Maree, Andrew
Tarragona, Sonia
Fernandez-Pereira, Carlos
Santaera, Omar
Rodriguez Granillo, Alfredo M.
Rodriguez-Granillo, Gaston A.
Russo-Felssen, Miguel
Kukreja, Neville
Antoniucci, David
Palacios, Igor F.
Serruys, Patrick W.
CA ORAR III Investigators
TI Percutaneous coronary intervention with oral sirolimus and bare metal
stents has comparable safety and efficacy to treatment with drug eluting
stents, but with significant cost saving: long-term follow-up results
from the randomised, controlled ORAR Ill (Oral Rapamycin in ARgentina)
study
SO EUROINTERVENTION
LA English
DT Article
DE Drug eluting stents; oral Sirolimus; restenosis
AB Aims: Previous randomised studies have shown a significant reduction in restenosis when oral rapamycin (OR) is administered to patients undergoing bare metal stent (BMS) implantation. How this regimen compares to drug eluting stents (DES) is unknown.
Methods and results: Two-hundred patients with de novo coronary lesions were randomised to treatment with OR plus BMS (100 pts) or with DES (100 pts). OR was given as a bolus of 10 mg per day before PCI followed by daily doses of 3 mg during following 13 days. Primary endpoints were to compare hospital, follow-up and overall cost at one, two, three and five years of follow-up. The secondary endpoints included death, myocardial infarction (MI) and stroke and were analysed as major adverse cardiovascular events (MACCE). Target vessel (TVR) and target lesion revascularisation (TLR) were independently analysed. Costs included procedural resources, hospitalisation, medications, repeat revascularisation procedures and professional fees. Baseline demographic, clinical and angiographic characteristics were similar. At 18.3 +/- 7 months of follow-up, the initial strategy of OR plus BMS resulted in significant cost saving when compared to DES (p=0.0001). TLR rate was 8.2% with DES and 7.0% with OR plus BMS (p=0.84), similarly no differences in TVR rate in both groups was seen (10.6% and 10.5% in OR and DES group respectively, p=0.86). Non-inferiority testing, determined that DES therapy failed to be cost saving compared to OR in all possible cost scenarios.
Conclusions: A strategy of OR plus BMS is cost saving compared to DES in patients undergoing PCI for de nova coronary lesions.
C1 [Rodriguez, Alfredo E.; Rodriguez Granillo, Alfredo M.] Sanat Otamendi, Cardiovasc Res Ctr CECI, Buenos Aires, DF, Argentina.
[Rodriguez, Alfredo E.; Fernandez-Pereira, Carlos; Rodriguez-Granillo, Gaston A.] Sanat Otamendi, Intervent Cardiol Dept, Clin Adrogue, Buenos Aires, DF, Argentina.
[Maree, Andrew] Boston Univ, Cardiac Unit, Boston, MA 02215 USA.
[Antoniucci, David] Careggi Hosp, Florence, Italy.
[Palacios, Igor F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA USA.
[Kukreja, Neville; Serruys, Patrick W.] Erasmus MC, Ctr Thorax, Rotterdam, Netherlands.
RP Rodriguez, AE (reprint author), Callao 1441 4B, Buenos Aires, DF, Argentina.
EM rodrigueza@sanatorio-otamendi.com.ar
NR 41
TC 14
Z9 14
U1 0
U2 0
PU EUROPA EDITION
PI TOULOUSE CEDEX 6
PA 5, RUE SAINT-PANTALEON, BP 61508, TOULOUSE CEDEX 6, 31015, FRANCE
SN 1774-024X
J9 EUROINTERVENTION
JI EuroIntervention
PD JUN
PY 2009
VL 5
IS 2
BP 255
EP 264
DI 10.4244/EIJV5I2A40
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA V18YY
UT WOS:000208041300015
PM 20449934
ER
PT J
AU Johri, AM
Yared, K
Durst, R
Cubeddu, RJ
Palacios, IF
Picard, MH
Passeri, J
AF Johri, Amer M.
Yared, Kibar
Durst, Ronen
Cubeddu, Roberto J.
Palacios, Igor F.
Picard, Michael H.
Passeri, Jonathan
TI Three-dimensional echocardiography-guided repair of severe paravalvular
regurgitation in a bioprosthetic and mechanical mitral valve
SO EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY
LA English
DT Article
DE Paravalvular regurgitation; Three-dimensional echocardiography
AB Severe paravalvular mitral regurgitation is a rare but important complication of mitral valve replacement, often producing symptoms associated with refractory heart failure or haemolysis. Explantation and replacement of the prosthesis are required in some patients but may not be possible in patients with high risk of morbidity or mortality with re-operation. We present two patients with symptomatic paravalvular mitral regurgitation who were deemed too high risk for re-operation because of multiple previous sternotomies and comorbidities. Percutaneous three-dimensional (3D) echocardiography-guided repair with septal occluder devices was undertaken in the first case of a paravalvular defect adjacent to a mitral bioprosthesis and in the second case adjacent to a mechanical mitral prosthesis. Both cases illustrate the advantage 3D echocardiography provides by allowing en-face views of the paravalvular leak and unique views of the catheter and device placement. The second case further demonstrates the novel use of full volume colour to define the extent of the regurgitant jet and provides information critical to device sizing and placement.
C1 [Johri, Amer M.; Yared, Kibar; Durst, Ronen; Picard, Michael H.; Passeri, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02115 USA.
[Cubeddu, Roberto J.; Palacios, Igor F.] Harvard Univ, Massachusetts Gen Hosp, Cardiac Catheterizat Lab, Boston, MA 02115 USA.
RP Johri, AM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Boston, MA 02115 USA.
EM amerjohri@gmail.com
OI Picard, Michael/0000-0002-9264-3243
NR 3
TC 6
Z9 6
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1525-2167
J9 EUR J ECHOCARDIOGR
JI Eur. J. Echocardiogr.
PD JUN
PY 2009
VL 10
IS 4
BP 572
EP 575
DI 10.1093/ejechocard/jep019
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 451VI
UT WOS:000266498600024
PM 19273467
ER
PT J
AU Krum, H
Curtis, SP
Kaur, A
Wang, HW
Smugar, SS
Weir, MR
Laine, L
Brater, DC
Cannon, CP
AF Krum, Henry
Curtis, Sean P.
Kaur, Amarjot
Wang, Hongwei
Smugar, Steven S.
Weir, Matthew R.
Laine, Loren
Brater, D. Craig
Cannon, Christopher P.
TI Baseline factors associated with congestive heart failure in patients
receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL
program
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Congestive heart failure; Diclofenac; Etoricoxib; Non-steroidal
anti-inflammatory drugs; NSAIDs; Risk
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SODIUM GASTROINTESTINAL
TOLERABILITY; BLOOD-PRESSURE; RHEUMATOID-ARTHRITIS; CYCLO-OXYGENASE-2
INHIBITORS; CYCLOOXYGENASE-2 INHIBITORS; CARDIOVASCULAR EVENTS;
MYOCARDIAL-INFARCTION; COLORECTAL ADENOMAS; ELDERLY-PATIENTS
AB Non-steroidal anti-inflammatory drugs have been associated with increased risk of congestive heart failure (CHF). We aimed to assess the impact of treatment with etoricoxib or diclofenac on risk of CHF relative to baseline risk factors.
We performed a multivariate analysis of 34 701 patients with arthritis receiving etoricoxib 60 or 90 mg, or diclofenac 150 mg, daily for a mean of 18 months, to assess the incidence of confirmed, adjudicated CHF events resulting in emergency room visit or hospitalization. Analyses were performed using a Cox proportional hazard model to evaluate the hazard ratio (HR) between the levels of each risk marker for the incidence of CHF. Significant risk markers included history of CHF (HR: 6.69, 95% CI 3.59-12.47; P < 0.0001), age >= 65 years (2.56, 1.65-3.98; P < 0.0001), and history of hypertension (1.83, 1.16-2.89; P = 0.0094) or diabetes (1.83, 1.15-2.94; P = 0.0116). Etoricoxib vs. diclofenac was a significant risk factor only when pooling the etoricoxib 90 mg cohorts (1.88; 1.13-3.10; P = 0.0143). Etoricoxib 60 mg did not significantly increase risk vs. diclofenac.
History of CHF was highly associated with risk for CHF hospitalization. Hypertension, diabetes, and older age also increased risk modestly. There appeared to be a dose-related increase in CHF with etoricoxib compared with diclofenac, which reached statistical significance when the etoricoxib 90 mg groups (osteoarthritis and rheumatoid arthritis) were pooled.
(Clinicaltrials.gov: NCT00092703, NCT00092742, NCT00250445).
C1 [Krum, Henry] Monash Univ, Alfred Hosp, NHMRC Ctr Clin Res Excellence Therapeut, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
[Curtis, Sean P.; Kaur, Amarjot; Wang, Hongwei; Smugar, Steven S.] Merck Res Labs, Rahway, NJ USA.
[Weir, Matthew R.] Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA.
[Laine, Loren] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA.
[Brater, D. Craig] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Cannon, Christopher P.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
RP Krum, H (reprint author), Monash Univ, Alfred Hosp, NHMRC Ctr Clin Res Excellence Therapeut, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
EM henry.krum@med.monash.edu.au
NR 45
TC 9
Z9 11
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUN
PY 2009
VL 11
IS 6
BP 542
EP 550
DI 10.1093/eurjhf/hfp054
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 451VJ
UT WOS:000266498700003
PM 19380329
ER
PT J
AU Kemppinen, A
Suvela, M
Tienari, PJ
Elovaara, I
Koivisto, K
Pirttila, T
Reunanen, M
Rautakorpi, I
Hillert, J
Lundmark, F
Oturai, A
Ryder, L
Harbo, HF
Celius, EG
Palotie, A
Daly, M
Peltonen, L
Saarela, J
AF Kemppinen, Anu
Suvela, Minna
Tienari, Pentti J.
Elovaara, Irina
Koivisto, Keijo
Pirttila, Tuula
Reunanen, Mauri
Rautakorpi, Ilkka
Hillert, Jan
Lundmark, Frida
Oturai, Annette
Ryder, Lars
Harbo, Hanne F.
Celius, Elisabeth G.
Palotie, Aarno
Daly, Mark
Peltonen, Leena
Saarela, Janna
TI MYO9B polymorphisms in multiple sclerosis
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE MYO9B; multiple sclerosis; autoimmunity
ID CELIAC-DISEASE; AUTOIMMUNE-DISEASES; SPANISH POPULATION; GENE
POLYMORPHISMS; MYOSIN IXB; MY09B GENE; ASSOCIATION; HAPLOTYPE; COHORT;
VARIANTS
AB Single-nucleotide polymorphisms (SNPs) in the 30 region of myosin IXB (MYO9B) gene have recently been reported to associate with different inflammatory or autoimmune diseases. We monitored for the association of MYO9B variants to multiple sclerosis (MS) in four Northern European populations. First, 18 SNPs including 6 SNPs with previous evidence for association to immune disorders, were tested in 730 Finnish MS families, but no linkage or family-based association was observed. To ensure the power to detect variants with a modest effect size, we further analyzed 10 variants in 899 Finnish cases and 1325 controls, and in a total of 1521 cases and 1476 controls from Denmark, Norway and Sweden, but found no association. Our results thereby do not support a major function of the tested MYO9B variants in MS. European Journal of Human Genetics (2009) 17, 840-843; doi: 10.1038/ejhg.2008.251; published online 14 January 2009
C1 [Saarela, Janna] Natl Publ Hlth Inst, Inst Mol Med Finland, Dept Mol Med, Biomedicum, Helsinki 00251, Finland.
[Kemppinen, Anu; Suvela, Minna; Peltonen, Leena; Saarela, Janna] FIMM, Inst Mol Med Finland, Helsinki, Finland.
[Kemppinen, Anu; Peltonen, Leena; Saarela, Janna] Univ Helsinki, Dept Med Genet, Helsinki, Finland.
[Tienari, Pentti J.] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
[Tienari, Pentti J.] Univ Helsinki, Biomedicum, Mol Neurol Programme, Helsinki, Finland.
[Elovaara, Irina] Tampere Univ Hosp, Dept Neurol, Tampere, Finland.
[Elovaara, Irina] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland.
[Koivisto, Keijo] Seinajoki Cent Hosp, Dept Neurol, Seinajoki, Finland.
[Pirttila, Tuula] Kuopio Univ Hosp, Dept Neurol & Neurosci, SF-70210 Kuopio, Finland.
[Reunanen, Mauri] Oulu Univ Hosp, Dept Neurol, Oulu, Finland.
[Rautakorpi, Ilkka] Lapland Cent Hosp, Dept Neurol, Rovaniemi, Finland.
[Hillert, Jan; Lundmark, Frida] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Neurosci, Div Neurol, Stockholm, Sweden.
[Oturai, Annette] Copenhagen Univ Hosp, Dept Neurol, Danish Multiple Sclerosis Res Ctr, Copenhagen, Denmark.
[Ryder, Lars] Copenhagen Univ Hosp, Dept Clin Immunol, Copenhagen, Denmark.
[Harbo, Hanne F.; Celius, Elisabeth G.] Ullevaal Univ Hosp, Dept Neurol, Oslo, Norway.
[Palotie, Aarno; Daly, Mark; Peltonen, Leena] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
[Palotie, Aarno; Peltonen, Leena] Wellcome Trust Sanger Inst, Cambridge, England.
[Palotie, Aarno] Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland.
[Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland, FIMM, FIN-00014 Helsinki, Finland.
[Daly, Mark] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Daly, Mark] Harvard Univ, Sch Med, Boston, MA USA.
RP Saarela, J (reprint author), Natl Publ Hlth Inst, Inst Mol Med Finland, Dept Mol Med, Biomedicum, PL 104, Helsinki 00251, Finland.
EM janna.saarela@ktl.fi
RI Tienari, Pentti/A-4893-2012; Saarela, Janna/E-5369-2014; ryder,
lars/Q-2060-2015;
OI ryder, lars/0000-0002-4744-3496; Saarela, Janna/0000-0002-0853-6219
FU EU [LSHM-CT-2005-018637]; NIH [43559]; The Center of Excellence for
Disease Genetics of the Academy of Finland; Sigrid Juselius Foundation;
Helsinki University Central Hospital Research Foundation; Helsinki
Biomedical Graduate School
FX We are indebted to the patients and their families for participation to
the study. This work was financially supported by Neuropromise EU grant
LSHM-CT-2005-018637, NIH grant NS 43559, The Center of Excellence for
Disease Genetics of the Academy of Finland, the Sigrid Juselius
Foundation, Helsinki University Central Hospital Research Foundation and
the Helsinki Biomedical Graduate School (AK). Large scale DNA extraction
and storage facility of the National Public Health Institute is
acknowledged for handling of Finnish samples. The Norwegian Bone Marrow
Donor Registry is acknowledged for collaboration in establishment of the
Norwegian control material.
NR 22
TC 0
Z9 0
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JUN
PY 2009
VL 17
IS 6
BP 840
EP 843
DI 10.1038/ejhg.2008.251
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 448VC
UT WOS:000266289100020
PM 19142207
ER
PT J
AU Price, DA
Martinez, AA
Seillier, A
Koek, W
Acosta, Y
Fernandez, E
Strong, R
Lutz, B
Marsicano, G
Roberts, JL
Giuffrida, A
AF Price, David A.
Martinez, Alex A.
Seillier, Alexandre
Koek, Wouter
Acosta, Yolanda
Fernandez, Elizabeth
Strong, Randy
Lutz, Beat
Marsicano, Giovanni
Roberts, James L.
Giuffrida, Andrea
TI WIN55,212-2, a cannabinoid receptor agonist, protects against
nigrostriatal cell loss in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's
disease
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE cannabinoid receptors; neuroinflammation; neurotoxicity; striatum;
substantia nigra
ID LEVODOPA-INDUCED DYSKINESIA; MPTP-TREATED-MOUSE; TOXICITY IN-VIVO;
SUBSTANTIA-NIGRA; KNOCKOUT MICE; NITRIC-OXIDE; ENDOCANNABINOID SYSTEM;
MICROGLIAL ACTIVATION; INDUCED NEUROTOXICITY; MULTIPLE-SCLEROSIS
AB Parkinson's disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail to prevent or slow down the disease progression. In this study, we investigated the molecular mechanisms by which the non-selective cannabinoid receptor agonist WIN55,212-2 (WIN) protects mouse nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and neuroinflammation. Stereological analyses showed that chronic treatment with WIN (4 mg/kg, intraperitoneal), initiated 24 h after MPTP administration, protected against MPTP-induced loss of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta independently of CB(1) cannabinoid receptor activation. The neuroprotective effect of WIN was accompanied by increased dopamine and 3,4-dihydroxyphenylacetic acid levels in the substantia nigra pars compacta and dorsal striatum of MPTP-treated mice. At 3 days post-MPTP, we found significant microglial activation and up-regulation of CB(2) cannabinoid receptors in the ventral midbrain. Treatment with WIN or the CB(2) receptor agonist JWH015 (4 mg/kg, intraperitoneal) reduced MPTP-induced microglial activation, whereas genetic ablation of CB(2) receptors exacerbated MPTP systemic toxicity. Furthermore, chronic WIN reversed MPTP-associated motor deficits, as revealed by the analysis of forepaw step width and percentage of faults using the inverted grid test. In conclusion, our data indicate that agonism at CB(2) cannabinoid receptors protects against MPTP-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that CB(2) receptors represent a new therapeutic target to slow the degenerative process occurring in PD.
C1 [Price, David A.; Martinez, Alex A.; Seillier, Alexandre; Koek, Wouter; Acosta, Yolanda; Fernandez, Elizabeth; Strong, Randy; Roberts, James L.; Giuffrida, Andrea] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Koek, Wouter] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Fernandez, Elizabeth; Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Lutz, Beat] Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-6500 Mainz, Germany.
[Marsicano, Giovanni] Univ Bordeaux 2, INSERM, U682, Neuroctr Magendie,Avenir Grp, F-33076 Bordeaux, France.
[Roberts, James L.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Giuffrida, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,MC 6205, San Antonio, TX 78229 USA.
EM giuffrida@uthscsa.edu
RI Fernandez-Espejo, Emilio/F-9205-2015
OI Fernandez-Espejo, Emilio/0000-0003-0724-6049
FU NIH [NS050401-05, T32 AG021890]; American Parkinson's Disease
Association
FX This work was supported by NIH grants NS050401-05 (A.G.) and T32
AG021890 (D.A.P.) and by a grant from the American Parkinson's Disease
Association (A.G.). We would like to thank Dr Rebecca L. Cunningham
(UTHSCSA) for her technical assistance and Dr Nephi Stella (University
of Washington) for generously providing spleen tissue from
CB2-/- mice and wild-type littermates.
NR 85
TC 83
Z9 84
U1 1
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0953-816X
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD JUN
PY 2009
VL 29
IS 11
BP 2177
EP 2186
DI 10.1111/j.1460-9568.2009.06764.x
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 453FY
UT WOS:000266597000008
PM 19490092
ER
PT J
AU Sroczynski, G
Esteban, E
Conrads-Frank, A
Schwarzer, R
Muhlberger, N
Wright, D
Zeuzem, S
Siebert, U
AF Sroczynski, Gaby
Esteban, Eva
Conrads-Frank, Annette
Schwarzer, Ruth
Muehlberger, Nikolai
Wright, Davene
Zeuzem, Stefan
Siebert, Uwe
TI Long-term effectiveness and cost-effectiveness of screening for
Hepatitis C virus infection
SO EUROPEAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE chronic hepatitis C; cost effectiveness; screening
ID INJECTING DRUG-USERS; NON-A; NON-B; UTILITY ANALYSIS; FOLLOW-UP;
POSTTRANSFUSION HEPATITIS; ECONOMIC-EVALUATION; LIVER-DISEASE;
PROGRESSION; CIRRHOSIS
AB Background: Hepatitis C virus (HCV) infection is an emerging problem in public health. In most countries, the majority of HCV infected people are yet undiagnosed. Early detection and treatment may result in better health outcomes and save costs by preventing future advanced liver disease. The evidence for long-term effectiveness and cost-effectiveness of HCV screening was systematically reviewed. Methods: We performed a systematic literature search on long-term health-economic effects of HCV screening and included Health Technology Assessment (HTA) reports, systematic reviews, long-term clinical trials, full health economic and decision-analytic modelling studies with a sufficiently long time horizon and patient-relevant long-term outcomes such as life-years gained (LYG) or quality-adjusted life years (QALY) gained. Economic results were converted to 2005 Euros. Results: Seven studies were included. Target population, HCV prevalence, study perspective, discount rate, screening and antiviral treatment mode varied. The incremental effectiveness of HCV screening and early treatment compared to no screening and standard care varied from 0.0004 to 0.066 LYG, and from 0.0001 to 0.072 QALY. Incremental cost-effectiveness and cost-utility ratios of HCV screening vs. no screening were 3900243 700 /LYG and 18 3001 151 000 /QALY. HCV screening seems to be cost-effective in populations with high HCV prevalence, but not in low HCV prevalence populations. Conclusions: HCV screening and early treatment have the potential to improve average life-expectancy, but should focus on populations with elevated HCV prevalence to be cost-effective. Further research on the long-term health-economic impact of HCV screening when combined with appropriate monitoring strategies in different European health care systems is needed.
C1 [Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Eduard Wallnoefer Ctr 1, A-6060 Hall In Tirol, Austria.
[Conrads-Frank, Annette; Wright, Davene; Siebert, Uwe] Harvard Univ, Sch Med, Inst Technol Assessment, Boston, MA USA.
[Conrads-Frank, Annette; Wright, Davene; Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Zeuzem, Stefan] Univ Frankfurt, Dept Internal Med Gastroenterol Hepatol Pneumol &, Frankfurt, Germany.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Program Hlth Decis Sci, Boston, MA 02115 USA.
RP Siebert, U (reprint author), UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Eduard Wallnoefer Ctr 1, A-6060 Hall In Tirol, Austria.
EM public-health@umit.at
NR 56
TC 29
Z9 29
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1101-1262
J9 EUR J PUBLIC HEALTH
JI Eur. J. Public Health
PD JUN
PY 2009
VL 19
IS 3
BP 245
EP 253
DI 10.1093/eurpub/ckp001
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 449RC
UT WOS:000266346700008
PM 19196737
ER
PT J
AU Martins, PN
AF Martins, Paulo N.
TI Impact of Donor and Recipient Age on Allograft Tolerance
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Review
DE Aging; Tolerance induction; Transplant; Immunosenescence
ID B-CELL TOLERANCE; CLINICAL TRANSPLANTATION TOLERANCE; INFANT
HEART-TRANSPLANTATION; ISCHEMIA-REPERFUSION INJURY; CD8(+) T-CELLS;
DENDRITIC CELLS; IMMUNE-RESPONSE; ORGAN-TRANSPLANTATION; HEME
OXYGENASE-1; INNATE IMMUNITY
AB The elderly represent the fastest growing segment of the population with end-stage organ disease and the use of aged grafts increased exponentially. Since aging of the immune system, or "immunosenscence" is generally associated with weaker immune responses, one might expect the elderly to be less reactive against transplanted organs than younger patients and therefore to show better results in terms of transplant outcome. Paradoxically, however, experimental studies and clinical data of organ transplantation show that old age of either the recipient or the donor is associated with poorer outcomes. On the other hand transplant tolerance is easier to be induced in the neonatal period. One potential reason for this discrepancy may lie in the effects of immunosenescence on the induction of tolerance. While the impact of aging on acute and chronic allograft rejection has been extensively studied, its role on establishing transplant tolerance is not well known. Since tolerance is an active process, and not just the absence of an immune response, the immunologic changes associated with the aging process may interfere with graft survival. in experimental and clinical transplantation, most successful tolerance induction protocols have been tested on young individuals, using grafts from young donors. However, some experiments that have utilized aged animals have demonstrated resistance to tolerance induction. Extrapolation of these results to humans suggests that protocols for clinical tolerance induction may not be effective in the elderly and may need to be revised for this population. The resistance to achieving immunological tolerance with aging is complex and multifactorial. Here, we review the age associated changes that may interfere with immunologic tolerance. Understanding this phenomenon may help in developing novel therapeutic approaches to reverse the crucial dysfunctions of the aging immune system and achieve effective tolerance regimens for the elderly.
C1 [Martins, Paulo N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Transplant Biol Res Ctr, Boston, MA USA.
RP Martins, PN (reprint author), 95 Grasslands Rd, New York, NY 10595 USA.
EM Paulo_Martins@nymc.edu
NR 175
TC 4
Z9 4
U1 0
U2 2
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD JUN
PY 2009
VL 7
IS 2
BP 67
EP 77
PG 11
WC Transplantation
SC Transplantation
GA 468ZO
UT WOS:000267864200001
PM 19715510
ER
PT J
AU Kumar, S
Kimball, AB
AF Kumar, Sandeep
Kimball, Alexa B.
TI New antifungal therapies for the treatment of onychomycosis
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE onychomycosis; systemic treatment; topical treatment
ID TOENAIL ONYCHOMYCOSIS; PHOTODYNAMIC THERAPY; NAIL PERMEABILITY; TOPICAL
TREATMENT; DRUGS; PREVALENCE; CICLOPIROX; EFFICACY; AGENTS;
DERMATOPHYTES
AB Onychomycosis is a common disorder of nails caused by diverse spectrum of fungi ranging from dermatophytes to nondermatophyte molds and yeasts. Presently, oral and topical therapies are the mainstay of treatment with oral therapies yielding somewhat better results. Though various treatment options are available to treat onychomycosis, search for a convenient, cost effective agent with high and long-lasting cure rates is continuing. Currently, many new therapies for onychomycosis are under investigation which includes new formulations of azoles, improvement of existing topical treatments through addition of ungual enhancers and new drugs with better nail permeation.
C1 [Kimball, Alexa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kumar, Sandeep] Harvard Univ, Med Ctr, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
RP Kimball, AB (reprint author), Massachusetts Gen Hosp, 50 Staniford St 246, Boston, MA 02114 USA.
EM harvardskinstudies@partners.org
NR 55
TC 31
Z9 31
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3784
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD JUN
PY 2009
VL 18
IS 6
BP 727
EP 734
DI 10.1517/13543780902810352
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 461NR
UT WOS:000267274800003
PM 19426118
ER
PT J
AU Anderson, BJ
Holmbeck, G
Iannotti, RJ
Mckay, SV
Lochrie, A
Volkening, LK
Laffel, L
AF Anderson, Barbara J.
Holmbeck, Grayson
Iannotti, Ronald J.
McKay, Siripoom V.
Lochrie, Amanda
Volkening, Lisa K.
Laffel, Lori
TI Dyadic Measures of the Parent-Child Relationship During the Transition
to Adolescence and Glycemic Control in Children With Type 1 Diabetes
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE adolescence; type 1 diabetes; glycemic control; dyadic family variables;
conflict
AB To identify aspects of family behavior associated with glycemic control in youth with type I diabetes mellitus during the transition to adolescence, the authors studied 121 9- to 14-year-olds (M = 12.1 yrs) and their parents, who completed the Diabetes Family Conflict Scale (DFCS) and the Diabetes Family Responsibility Questionnaire (DFRQ). From the DFRQ, the authors derived 2 dyadic variables, frequency of agreement (exact parent and child concurrence about who was responsible for a task) and frequency of discordance (opposite parent and child reports about responsibility). The authors divided the cohort into Younger (n = 57, M = 10.6 yrs) and Older (n = 64, M = 13.5 yrs) groups. Family conflict was significantly related to glycemic control in the entire cohort and in both the Younger and Older groups. However, only in the Younger group was Agreement related to glycemic control, with higher Agreement associated with better glycemic control. Findings suggest that Agreement about sharing of diabetes responsibilities may be an important target for family-based interventions aiming to optimize glycemic control in preteen youth.
C1 [Anderson, Barbara J.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA.
[Holmbeck, Grayson] Loyola Univ Chicago, Chicago, IL USA.
[Iannotti, Ronald J.] NICHHD, Bethesda, MD 20892 USA.
[Lochrie, Amanda] Nemours Childrens Clin, Jacksonville, FL USA.
[Volkening, Lisa K.; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Anderson, BJ (reprint author), Texas Childrens Hosp, Baylor Coll Med, 1100 Bates St, Houston, TX 77030 USA.
EM bja@bcm.tmc.edu
FU National Institutes of Health, National Institute of Child Health and
Human Development; Children's Memorial Hospital, Chicago
[N01-HD-4-3363]; Texas Children's Hospital, Houston, Texas
[N01-HD-4-3362]; Nemours Children's Clinic, Jacksonville, Florida
[N01-HD-4-3361]; Joslin Diabetes Center, Boston [N01-HD-4-3364]; James
Bell Associates, Arlington, Virginia [N01-HD-3-3360]
FX This research was supported by the intramural research program of the
National Institutes of Health, National Institute of Child Health and
Human Development. The following investigators and institutions made up
the steering committee of the Family Management of Childhood Diabetes
multisite trial: Jill Weissberg-Benchell, PhD, and Grayson Holmbeck, PhD
(Contract N01-HD-4-3363), Children's Memorial Hospital, Chicago; Bruce
Simons-Morton, EdD, Tonja R. Nansel, PhD, Ronald J. Iannotti, PhD, and
Rusan Chen, PhD, National Institute of Child Health and Human
Development, Bethesda, Maryland; Barbara Anderson, PhD (Contract
N01-HD-4-3362), Texas Children's Hospital, Houston, Texas; Tim Wysocki,
PhD, and Amanda Lochrie, PhD (Contract N01-HD-4-3361), Nemours
Children's Clinic, Jacksonville, Florida; Lori Laffel, MD, MPH, Deborah
Butler, MSW, Korey Hood, PhD, and Lisa Volkening, MA (Contract
N01-HD-4-3364), Joslin Diabetes Center, Boston; and Cheryl McDonnell,
PhD, and MaryAnn D'Elio (Contract N01-HD-3-3360), James Bell Associates,
Arlington, Virginia.
NR 48
TC 39
Z9 39
U1 8
U2 12
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD JUN
PY 2009
VL 27
IS 2
BP 141
EP 152
DI 10.1037/a0015759
PG 12
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA V19PR
UT WOS:000208084800003
PM 19630455
ER
PT J
AU Williams, Z
Zepf, D
Longtine, J
Anchan, R
Broadman, B
Missmer, SA
Hornstein, MD
AF Williams, Zev
Zepf, Dimity
Longtine, Janina
Anchan, Raymond
Broadman, Betsy
Missmer, Stacey A.
Hornstein, Mark D.
TI Foreign fetal cells persist in the maternal circulation
SO FERTILITY AND STERILITY
LA English
DT Article
DE Fetal microchimerism; stem cells; regenerative medicine; donor eggs
ID PROGENITOR CELLS; MICROCHIMERISM; LONG; BLOOD; LINES; WOMEN
AB Objective: To determine whether allogenic fetal cells resulting from donor egg pregnancies persist in maternal circulation.
Design: Nested polymerase chain reaction (PCR) amplification of the DYS14 sequence, a region of the Y chromosome, from DNA purified from peripheral blood cells.
Setting: Academic medical center.
Patient(s): Healthy 18-60-year-old women who have had donor egg pregnancies resulting in a male offspring (n = 11) or, as a control, female offspring (n = 8), at least I year previously and without any other source for male cells in their peripheral blood or a healthy male.
Intervention(s): None.
Main Outcome Measure(S): Detection of DYS14 sequence by nested PCR.
Result(s): DYS14 was detected in 5/11 (45%) of women who had donor egg pregnancies resulting in a male offspring, but in 0/8 (0) of women who had donor egg pregnancies resulting in a female offspring. The longest interval between delivery of a male offspring and detection of the DYS14 gene was 9 years.
Conclusion(s): Unmatched, allogenic fetal cells from donor egg pregnancies are able to persist in the circulation of healthy women for at least 9 years after delivery. This implies a novel mechanism by which immunologic detection is avoided by these cells and may impact on how they may be used for regenerative and transplant medicine. (Fertil Steril (R) 2009;91:2593-5. (c) 2009 by American Society for Reproductive Medicine.)
C1 [Williams, Zev; Anchan, Raymond; Broadman, Betsy; Missmer, Stacey A.; Hornstein, Mark D.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zepf, Dimity; Longtine, Janina] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Missmer, Stacey A.] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp,Dept Med, Boston, MA 02115 USA.
[Williams, Zev] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Missmer, Stacey A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Williams, Z (reprint author), Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Brigham & Womens Hosp, Boston, MA 02115 USA.
EM zwilliams2@partners.org
FU Department of Obstetrics and Gynecology, Brigham and Women's Hospital
FX Supported by an Expanding the Boundaries grant from the Department of
Obstetrics and Gynecology, Brigham and Women's Hospital.
NR 11
TC 9
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD JUN
PY 2009
VL 91
IS 6
BP 2593
EP 2595
DI 10.1016/j.fertnstert.2008.02.008
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 455XF
UT WOS:000266801400047
PM 18384774
ER
PT J
AU Montgomery, RK
Shivdasani, RA
AF Montgomery, Robert K.
Shivdasani, Ramesh A.
TI Prominin1 (CD133) as an Intestinal Stem Cell Marker: Promise and Nuance
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID PROGENITOR CELLS; SELF-RENEWAL; CANCER; IDENTIFICATION; POLYPOSIS;
IDENTIFY; ORIGIN; MOUSE; COLON; MICE
C1 [Shivdasani, Ramesh A.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Shivdasani, RA (reprint author), Childrens Hosp, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM ramesh_shivdasani@dfci.harvard.edu
NR 23
TC 6
Z9 6
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2009
VL 136
IS 7
BP 2051
EP 2054
DI 10.1053/j.gastro.2009.04.021
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454CK
UT WOS:000266659100007
PM 19409288
ER
PT J
AU Becker, L
Mashimo, H
AF Becker, Laren
Mashimo, Hiroshi
TI Further Promise of Stem Cells Therapies in the Enteric Nervous System
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID NEURAL CREST; INTRINSIC DIFFERENCES; REPROGRAMMING FACTORS;
PARKINSONS-DISEASE; TRANSPLANTATION; GUT; COLON; DIFFERENTIATION;
PROGENITORS; GENERATION
C1 [Becker, Laren; Mashimo, Hiroshi] VA Boston Healthcare Syst, Boston, MA 02132 USA.
[Becker, Laren; Mashimo, Hiroshi] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Becker, Laren] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
RP Mashimo, H (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy,Res 151,Bldg 3,Rm 2B104, Boston, MA 02132 USA.
EM hmashimo@hms.harvard.edu
NR 33
TC 4
Z9 4
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2009
VL 136
IS 7
BP 2055
EP 2058
DI 10.1053/j.gastro.2009.04.022
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454CK
UT WOS:000266659100008
PM 19409291
ER
PT J
AU Tache, Y
Bernstein, CN
AF Tache, Yvette
Bernstein, Charles N.
TI Evidence for the Role of the Brain-Gut Axis in Inflammatory Bowel
Disease: Depression as Cause and Effect?
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID PRIMARY-CARE; RISK-FACTOR; DISORDERS; ANXIETY; ANTIDEPRESSANTS; IMPACT;
MODEL; MOOD
C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE Digest Dis Res Ctr,Dept Med, Los Angeles, CA 90073 USA.
[Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90073 USA.
[Tache, Yvette] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Bernstein, Charles N.] Univ Manitoba, IBD Clin & Res Ctr, Winnipeg, MB, Canada.
[Bernstein, Charles N.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada.
RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE Digest Dis Res Ctr,Dept Med, 11301 Wilshire Blvd,CURE Bldg 115,Room 117, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU NIDDK NIH HHS [P30 DK041301]
NR 27
TC 10
Z9 10
U1 2
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2009
VL 136
IS 7
BP 2058
EP 2061
DI 10.1053/j.gastro.2009.04.032
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454CK
UT WOS:000266659100009
PM 19406133
ER
PT J
AU Chan, AT
Zauber, AG
Hsu, M
Breazna, A
Hunter, DJ
Rosenstein, RB
Eagle, CJ
Hawk, ET
Bertagnolli, MM
AF Chan, Andrew T.
Zauber, Ann G.
Hsu, Meier
Breazna, Aurora
Hunter, David J.
Rosenstein, Rebecca B.
Eagle, Craig J.
Hawk, Ernest T.
Bertagnolli, Monica M.
TI Cytochrome P450 2C9 Variants Influence Response to Celecoxib for
Prevention of Colorectal Adenoma
SO GASTROENTEROLOGY
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER PREVENTION; P4502C9
POLYMORPHISMS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; CYCLOOXYGENASE-2
INHIBITOR; BLEEDING COMPLICATIONS; GENETIC POLYMORPHISMS; CARDIOVASCULAR
RISK; ALLELIC VARIANTS
AB Background & Aims: Variants in the cytochrome P450 2C9 (CYP2C9) gene are associated with impaired metabolism of celecoxib. We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib. Methods: We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>= 1 variant allele) in the Adenoma Prevention with Celecoxib trial. Following adenoma removal, patients were assigned randomly to groups given placebo or low-dose (200 mg twice daily) or high-dose (400 mg twice daily) celecoxib and underwent follow-up colonoscopies at 1 and/or 3 years. Results: Among 1660 patients, 21% were CYP2C9*2, and 12% were CYP2C9*3 genotypes. Overall, celecoxib was associated with a dose-dependent reduction in adenoma, compared with placebo, with relative risks (RR) of 0.65 (95% confidence interval [CI]: 0.56-0.76) for the low-dose and 0.54 (95% CI: 0.46-0.63) for the high-dose groups. However, the additional protective effect of the high dose, compared with the low-dose, was observed only in those with CYP2C9*3 genotypes (RR, 0.51; 95% CI: 0.30-0.87). The high dose, compared with low dose, was not associated with significant risk reduction among those with CYP2C9*2 (RR, 0.83; 95% Cl: 0.57-1.21) or wild-type (RR, 0.89; 95% CI: 0.72-1.11) genotypes. Compared with placebo, a higher incidence of cardiovascular events was associated with both doses among patients with wild-type genotypes but only with the high dose among patients with variant genotypes. Conclusions: The greater efficacy of high-dose celecoxib, compared with the low-dose, in preventing colorectal adenoma appears confined to individuals with slow metabolizer (CYP2C9*3) genotypes. Genetic variability influences susceptibility to the potential benefits and hazards of celecoxib.
C1 [Chan, Andrew T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Chan, Andrew T.; Hunter, David J.; Bertagnolli, Monica M.] Harvard Univ, Sch Med, Boston, MA USA.
[Chan, Andrew T.; Hunter, David J.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Zauber, Ann G.; Hsu, Meier] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Breazna, Aurora; Rosenstein, Rebecca B.; Eagle, Craig J.] Pfizer Inc, New York, NY USA.
[Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hawk, Ernest T.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bertagnolli, Monica M.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
RP Chan, AT (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,GRJ-728A, Boston, MA 02114 USA.
EM achan@partners.org
FU Damon Runyon Cancer Research Foundation Clinical Investigator Award;
National Cancer Institute [CA107412, N01-CN95015]; Pfizer, Inc; NIH
[CA127003, CA131504, CA137178]
FX Supported by the Damon Runyon Cancer Research Foundation Clinical
Investigator Award and a career development award from the National
Cancer Institute (CA107412; to A.T.C.); funding from the National Cancer
Institute (N01-CN95015; to A.G.Z. and M.M.B.); sponsorship for the APC
trial from the National Cancer Institute and Pfizer, Inc, through a
clinical trials agreement; and additional NIH grants CA127003, CA131504,
and CA137178.
NR 44
TC 25
Z9 27
U1 0
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2009
VL 136
IS 7
BP 2127
EP 2136
DI 10.1053/j.gastro.2009.02.045
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454CK
UT WOS:000266659100016
PM 19233181
ER
PT J
AU Catalano, MF
Sahai, A
Levy, M
Romagnuolo, J
Wiersema, M
Brugge, W
Freeman, M
Yamao, K
Canto, M
Hernandez, LV
AF Catalano, Marc F.
Sahai, Amand
Levy, Michael
Romagnuolo, Joseph
Wiersema, Maurits
Brugge, William
Freeman, Martin
Yamao, Kenji
Canto, Marcia
Hernandez, Lyndon V.
TI EUS-based criteria for the diagnosis of chronic pancreatitis: the
Rosemont classification
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ABDOMINAL-PAIN;
ULTRASONOGRAPHY; PANCREATOGRAPHY; ULTRASOUND; AUTOPSY; DISEASE; ERCP;
ORIGIN
AB Background: EUS is increasingly used in the diagnosis of chronic pancreatitis (CP). A number of publications in this field have used different EUS terminology, features, and criteria for CP, making it difficult to reproduce their findings and apply them in clinical practice. Moreover, traditional criteria Such as the Cambridge classification for CP are arguably outdated and have lost their relevance.
Objective: Our purpose was to establish consensus-based criteria for EUS features of CP.
Design: Consensus study.
Main Outcome Measurements: Thirty-two internationally recognized endosonographers anonymously voted on terminology of EUS features, rank order, Bind category (major vs minor criteria). Consensus was defined as greater than two thirds agreement among participants.
Results: Major criteria for CP were (1) hyperechoic foci with shadowing and main pancreatic duct (PD) calculi and (2) lobularity with honeycombing. Minor criteria for CP were cysts, dilated ducts >= 3.5 mm, irregular PD contour, dilated side branches >= 1 mm, hyperechoic duct wall, strands, nonshadowing hyperechoic foci, and lobularity with noncontiguous lobules.
Limitation: Lack of broadly accepted reference standard.
Conclusion: In a complex disease Such as CP that has no universally accepted reference standard, an EUS-based criterion for diagnosis can be determined by expert consensus opinion and the existing body of evidence. Here we present the new "Rosemont criteria" for the EUS diagnosis of CP (Gastrointest Endosc 2009;69:1251-61.)
C1 [Catalano, Marc F.] St Lukes Hosp, Milwaukee, WI USA.
[Hernandez, Lyndon V.] Aurora Med Ctr, Kenosha, WI USA.
[Levy, Michael] Mayo Clin, Rochester, MN USA.
[Freeman, Martin] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Romagnuolo, Joseph] Med Univ S Carolina, Charleston, SC 29425 USA.
[Wiersema, Maurits] Indiana Med Associates, Ft Wayne, IN USA.
[Brugge, William] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Canto, Marcia] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Sahai, Amand] CHUM Hosp St Luc, Montreal, PQ, Canada.
[Yamao, Kenji] Aichi Canc Ctr, Nagoya, Aichi 464, Japan.
RP Hernandez, LV (reprint author), 3805-A Spring St,Suite 212, Racine, WI 53405 USA.
EM lhernan@mcw.edu
NR 34
TC 147
Z9 154
U1 2
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUN
PY 2009
VL 69
IS 7
BP 1251
EP 1261
DI 10.1016/j.gie.2008.07.043
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 455WU
UT WOS:000266800000008
PM 19243769
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI The case of unsedated screening colonoscopy in the United States
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; NITROUS-OXIDE; FLEXIBLE SIGMOIDOSCOPY;
CECAL INTUBATION; US VETERANS; SEDATION; COMPLICATIONS; ENDOSCOPY;
OPTIONS
C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Med Serv, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res & Med Serv, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
NR 34
TC 7
Z9 8
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUN
PY 2009
VL 69
IS 7
BP 1354
EP 1356
DI 10.1016/j.gie.2008.12.234
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 455WU
UT WOS:000266800000024
PM 19249764
ER
PT J
AU Sham, PC
Cherny, SS
Purcell, S
AF Sham, P. C.
Cherny, S. S.
Purcell, S.
TI Application of genome-wide SNP data for uncovering pairwise
relationships and quantitative trait loci
SO GENETICA
LA English
DT Article; Proceedings Paper
CT 3rd International Conference of Quantitative Genetics
CY AUG 18-24, 2007
CL Zheijiang Univ, Hangzhou, PEOPLES R CHINA
HO Zheijiang Univ
DE Genome-wide; Single nucleotide polymorphisms (SNP); Quantitative
genetics; Identity-by-descent (IBD); Heritability; Linkage; Association;
Variance components
ID LINKAGE DISEQUILIBRIUM; NUCLEAR FAMILIES; HAPLOTYPE MAP; ASSOCIATION;
SET
AB The genetic analysis of quantitative traits in humans is changing as a result of the availability of whole-genome SNP data. Heritability analysis can make use of actual genetic sharing between pairs of individuals estimated from the genotype data, rather than the expected genetic sharing implied by their family relationship. This could provide more accurate heritability estimates and help to overcome the equal environment assumption. Quantitative trait locus (QTL) linkage mapping can make use of local genetic sharing inferred from very dense local genotype data from pedigree members or individuals not previously known to be related. This approach may be particularly suited for detecting loci that contain rare variants with major effect on the phenotype. Finally, whole-genome SNP data can be used to measure the genetic similarity between individuals to provide matched sets for association studies, in order to avoid spurious association from population stratification.
C1 [Sham, P. C.; Cherny, S. S.] Univ Hong Kong, Li Ka Shing Fac Med, Genome Res Ctr, Dept Psychiat, Pokfulam, Hong Kong, Peoples R China.
[Sham, P. C.; Cherny, S. S.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China.
[Purcell, S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
RP Sham, PC (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Genome Res Ctr, Dept Psychiat, L10-69,Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM pcsham@hku.hk
RI Cherny, Stacey/B-3315-2008
OI Cherny, Stacey/0000-0002-0269-3352
FU NEI NIH HHS [R01 EY012562, EY-12562]
NR 20
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0016-6707
J9 GENETICA
JI Genetica
PD JUN
PY 2009
VL 136
IS 2
BP 237
EP 243
DI 10.1007/s10709-008-9349-4
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 442DA
UT WOS:000265818900004
PM 19127410
ER
PT J
AU Duffner, PK
Caviness, VS
Erbe, RW
Patterson, MC
Schultz, KR
Wenger, DA
Whitley, C
AF Duffner, Patricia K.
Caviness, Verne S., Jr.
Erbe, Richard W.
Patterson, Marc C.
Schultz, Kirk R.
Wenger, David A.
Whitley, Chester
TI The long-term outcomes of presymptomatic infants transplanted for Krabbe
disease: Report of the workshop held on July 11 and 12, 2008, Holiday
Valley, New York
SO GENETICS IN MEDICINE
LA English
DT Article
DE Krabbe disease; globoid cell leukodystrophy; outcomes transplantation
AB Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive disorder of white matter resulting from deficiency of galactosylceramide beta-galactosidase (GALC) and the consequent accumulation of galactosylceramide and psychosine. Although most patients present within the first 6 months of life, i.e., the early infantile or "classic" phenotype, others present later in life including in adolescence and adulthood. The only available treatment for infants with early infantile Krabbe disease is hematopoietic cell transplantation (HCT), typically using umbilical cord blood. Although transplanted children are far better neurologically than they would have been had they followed the typical fulminant course of early infantile Krabbe disease, anecdotal reports have surfaced suggesting that the majority of presymptomatic children transplanted for Krabbe disease have developed motor and language deterioration. The cause and extent of the deterioration is unknown at this time. With the advent of universal newborn screening for Krabbe disease in New York State and the projected start of screening in Illinois in 2010, understanding the outcome of treatment becomes of paramount importance. Thus, the purpose of this workshop was to bring together child neurologists, geneticists, neurodevelopmental pediatricians, transplanters, neuroradiologists, neurophysiologists, developmental neurobiologists, neuroscientists, and newborn screeners to review the results of the transplantation experience in humans and animals and, if neurologic deterioration was confirmed, develop possible explanations as to causation. This workshop was the first attempt at a multicenter crossdiscipline evaluation of the results of HCT for Krabbe disease. A broad range of individuals participated, including clinicians, academicians, and authorities from the National Institutes of Health, American College of Medical Genetics, and Department of Health and Human Services. Genet Med 2009:11(6):450-454.
C1 [Duffner, Patricia K.] SUNY Buffalo, Hunter James Kelly Res Inst, Sch Med, Buffalo, NY 14203 USA.
[Duffner, Patricia K.] SUNY Buffalo, Dept Neurol, Sch Med, Buffalo, NY 14203 USA.
[Duffner, Patricia K.; Erbe, Richard W.] SUNY Buffalo, Dept Pediat, Sch Med, Buffalo, NY 14203 USA.
[Caviness, Verne S., Jr.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Patterson, Marc C.] Mayo Clin, Dept Med Genet, Rochester, MN USA.
[Patterson, Marc C.] Mayo Clin, Dept Neurol, Rochester, MN USA.
[Patterson, Marc C.] Mayo Clin, Dept Pediat, Rochester, MN USA.
[Schultz, Kirk R.] BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada.
[Wenger, David A.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA.
[Whitley, Chester] Univ Minnesota, Dept Pediat Genet & Metab, Minneapolis, MN USA.
RP Duffner, PK (reprint author), SUNY Buffalo, Hunter James Kelly Res Inst, Sch Med, 701 Ellicott St, Buffalo, NY 14203 USA.
EM duffner@buffalo.edu
OI Patterson, Marc/0000-0002-1116-126X
FU National Institute of Neurological Disorders and Stroke (NINDS)
[NS063609-01]; Office of Rare Diseases; NICHD; Maternal and Child Health
Bureau [1H1TMC10605-01-00]; Hunter's Hope Foundation
FX Funding for this conference was made possible (in part) by a Grant
(NS063609-01) from the National Institute of Neurological Disorders and
Stroke (NINDS), the Office of Rare Diseases, NICHD, a Grant from
Maternal and Child Health Bureau (1H1TMC10605-01-00), and Hunter's Hope
Foundation. The following investigators received funding from the
following sources for part or all of the work they presented: Patricia
K. Duffner, M D, Maternal and Child Health Bureau (1H1TMC10605-01-00 and
Hunter's Hope Foundation; Bruce Bunnell, PhD, NIH-NCRR, R24 RR022826-01;
Marc Patterson MD Actelion pharmaceuticals: a phase I/II randomized
controlled study of OGT 918 in adult and juvenile patients with Niemann
Pick C disease). PI, Mark Haskins, PhD, NIH, Yoichi Kondo MD, PhD and
Ian Duncan, PhD, NIH and the Myelin Project; Florian Eichler, MD, NINDS,
David Wenger, PhD, NIH; Miguel Gama-Sosa, PhD, Alzheimer's Association;
Mark Sands, PhD, NIH and Hunter's Hope Foundation; Elsa Shapiro, PhD, is
funded by the Ryan Foundation and Genzyme; Mark Noble, PhD, is funded by
NIH and the Koman Foundation for the Cure.
NR 1
TC 70
Z9 70
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD JUN
PY 2009
VL 11
IS 6
BP 450
EP 454
DI 10.1097/GIM.0b013e3181a16e04
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 461AY
UT WOS:000267237300011
PM 19346954
ER
PT J
AU Tolstorukov, MY
Kharchenko, PV
Goldman, JA
Kingston, RE
Park, PJ
AF Tolstorukov, Michael Y.
Kharchenko, Peter V.
Goldman, Joseph A.
Kingston, Robert E.
Park, Peter J.
TI Comparative analysis of H2A.Z nucleosome organization in the human and
yeast genomes
SO GENOME RESEARCH
LA English
DT Article
ID VARIANT HISTONE H2A.Z; DNA-SEQUENCE; MICROCOCCAL NUCLEASE;
HIGH-RESOLUTION; CORE PARTICLE; SACCHAROMYCES-CEREVISIAE; ANGSTROM
RESOLUTION; CRYSTAL-STRUCTURE; CHROMATIN DNA; C. ELEGANS
AB Eukaryotic DNA is wrapped around a histone protein core to constitute the fundamental repeating units of chromatin, the nucleosomes. The affinity of the histone core for DNA depends on the nucleotide sequence; however, it is unclear to what extent DNA sequence determines nucleosome positioning in vivo, and if the same rules of sequence-directed positioning apply to genomes of varying complexity. Using the data generated by high-throughput DNA sequencing combined with chromatin immunoprecipitation, we have identified positions of nucleosomes containing the H2A.Z histone variant and histone H3 trimethylated at lysine 4 in human CD4(+)T-cells. We find that the 10-bp periodicity observed in nucleosomal sequences in yeast and other organisms is not pronounced in human nucleosomal sequences. This result was confirmed for a broader set of mononucleosomal fragments that were not selected for any specific histone variant or modification. We also find that human H2A.Z nucleosomes protect only similar to 120 bp of DNA from MNase digestion and exhibit specific sequence preferences, suggesting a novel mechanism of nucleosome organization for the H2A.Z variant.
C1 [Tolstorukov, Michael Y.; Kharchenko, Peter V.; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
[Tolstorukov, Michael Y.; Kharchenko, Peter V.; Park, Peter J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Kharchenko, Peter V.; Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA.
[Goldman, Joseph A.; Kingston, Robert E.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RP Park, PJ (reprint author), Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
EM peter_park@harvard.edu
NR 55
TC 52
Z9 52
U1 2
U2 3
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD JUN
PY 2009
VL 19
IS 6
BP 967
EP 977
DI 10.1101/gr.084830.108
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA 452DZ
UT WOS:000266521500002
PM 19246569
ER
PT J
AU Nishiizumi, K
Welten, KC
Matsumura, H
Caffee, MW
Ninomiya, K
Omoto, T
Nakagaki, R
Shima, T
Takahashi, N
Sekimoto, S
Yashima, H
Shibata, S
Bajo, K
Nagao, K
Kinoshita, N
Imamura, M
Sisterson, J
Shinohara, A
AF Nishiizumi, K.
Welten, K. C.
Matsumura, H.
Caffee, M. W.
Ninomiya, K.
Omoto, T.
Nakagaki, R.
Shima, T.
Takahashi, N.
Sekimoto, S.
Yashima, H.
Shibata, S.
Bajo, K.
Nagao, K.
Kinoshita, N.
Imamura, M.
Sisterson, J.
Shinohara, A.
TI Measurements of high-energy neutron cross sections for accurate
cosmogenic nuclide production rates
SO GEOCHIMICA ET COSMOCHIMICA ACTA
LA English
DT Meeting Abstract
CT 19th Annual VM Goldschmidt Conference
CY JUN 21, 2009
CL Davos, SWITZERLAND
C1 [Nishiizumi, K.; Welten, K. C.; Matsumura, H.] Univ Calif Berkeley, SSL, Berkeley, CA 94720 USA.
[Caffee, M. W.] Purdue Univ, W Lafayette, IN 47907 USA.
[Ninomiya, K.; Omoto, T.; Nakagaki, R.; Shima, T.; Takahashi, N.; Shinohara, A.] Osaka Univ, Dept Chem, Osaka, Japan.
[Ninomiya, K.; Omoto, T.; Nakagaki, R.; Shima, T.; Takahashi, N.; Shinohara, A.] Osaka Univ, RCNP, Osaka, Japan.
[Sekimoto, S.; Yashima, H.; Shibata, S.] Kyoto Univ, Inst Res Reactor, Osaka 590, Japan.
[Bajo, K.; Nagao, K.] Univ Tokyo, Earthquake Chem Lab, Tokyo 113, Japan.
[Matsumura, H.; Kinoshita, N.] KEK, Tsukuba, Ibaraki 305, Japan.
[Imamura, M.] Natl Museum Japan Hist, Chiba 285, Japan.
[Sisterson, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM kuni@ssl.berkeley.edu
NR 3
TC 7
Z9 7
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0016-7037
J9 GEOCHIM COSMOCHIM AC
JI Geochim. Cosmochim. Acta
PD JUN
PY 2009
VL 73
IS 13
BP A945
EP A945
PG 1
WC Geochemistry & Geophysics
SC Geochemistry & Geophysics
GA 460YS
UT WOS:000267229902350
ER
PT J
AU Garcia, JM
Polvino, WJ
AF Garcia, Jose M.
Polvino, William J.
TI Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin
mimetic and growth hormone secretagogue in healthy volunteers
SO GROWTH HORMONE & IGF RESEARCH
LA English
DT Article
DE Ghrelin; Anorexia; Growth hormone secretagogues; IGF-1; Growth hormone
ID CANCER-PATIENTS; OBESE SUBJECTS; FOOD-INTAKE; FACTOR-I; SECRETION;
PEPTIDE; DEFICIENCY; RECEPTOR; RELEASE; MK-677
AB Objective: Activation of ghrelin receptors Stimulates GH secretion and appetite, increasing lean body mass and body weight. However, clinical use of ghrelin is limited because it has a short half-life and must be administered parenterally. Anamorelin is a novel, orally active, non-peptidic ghrelin mimetic and growth hormone secretagogue. Our objective was to evaluate its hormonal effects in healthy subjects.
Design: A double-blind, randomized, placebo-controlled study evaluated the short-term effects of anamorelin on GH, insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), prolactin, ACTH, LH, FSH, TSH, cortisol, insulin and glucose. Normal healthy volunteers (n = 32) recruited from the general population were administered escalating doses of anamorelin (25, 50, and 75 mg daily) vs. placebo.
Results: Anamorelin significantly increased CH levels at all doses (p <= 0.01). Effects on the somatotropic axis were maintained, as evidenced by sustained increases in IGF-1 and IGFBP-3 compared to placebo following 5-6 days of treatment. Negligible effects on other anterior pituitary hormone profiles and on fasting glucose were noted and all mean hormone levels remained within normal range. Some degree of insulin resistance as assessed by HOMA-IR was evident after treatment with 75 mg dose but not with the 25 or the 50 mg doses. Significant dose-related increases in body weight were recorded. Changes in body weight directly correlated with changes in IGF-1 levels. Anamorelin was well tolerated.
Conclusions: Anamorelin increases GH, IGF-1, IGFBP-3 and body weight with good tolerability and selectivity, without affecting other anterior pituitary axes or fasting glucose levels. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
[Polvino, William J.] Sapphire Therapeut Inc, Bridgewater, NJ USA.
RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM jgarcia1@bcm.tmc.edu
NR 34
TC 38
Z9 39
U1 1
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1096-6374
EI 1532-2238
J9 GROWTH HORM IGF RES
JI Growth Horm. IGF Res.
PD JUN
PY 2009
VL 19
IS 3
BP 267
EP 273
DI 10.1016/j.ghir.2008.12.003
PG 7
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 464UN
UT WOS:000267533400014
PM 19196529
ER
PT J
AU Festen, EAM
Goyette, P
Scott, R
Annese, V
Zhernakova, A
Lian, J
Lefebvre, C
Brant, SR
Cho, JH
Silverberg, MS
Taylor, KD
de Jong, DJ
Stokkers, PC
Mcgovern, D
Palmieri, O
Achkar, JP
Xavier, RJ
Daly, MJ
Duerr, RH
Wijmenga, C
Weersma, RK
Rioux, JD
AF Festen, E. A. M.
Goyette, P.
Scott, R.
Annese, V.
Zhernakova, A.
Lian, J.
Lefebvre, C.
Brant, S. R.
Cho, J. H.
Silverberg, M. S.
Taylor, K. D.
de Jong, D. J.
Stokkers, P. C.
Mcgovern, D.
Palmieri, O.
Achkar, J-P
Xavier, R. J.
Daly, M. J.
Duerr, R. H.
Wijmenga, C.
Weersma, R. K.
Rioux, J. D.
TI Genetic variants in the region harbouring IL2/IL21 associated with
ulcerative colitis
SO GUT
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; CELIAC-DISEASE; CROHNS-DISEASE;
SUSCEPTIBILITY LOCI; BARRIER DEFECT; RISK VARIANTS; MYOSIN IXB;
INTERLEUKIN-21
AB Objectives: Genetic susceptibility is known to play a large part in the predisposition to the inflammatory bowel diseases (IBDs) known as Crohn's disease (CD) and ulcerative colitis (UC). The IL2/IL21 locus on 4q27 is known to be a common risk locus for inflammatory disease (shown in coeliac disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and psoriasis), while the roles that interleukin 2 (IL2) and IL21 play in the immune response also make them attractive candidates for IBD. The objective of this study was to test for association between the IL2/IL21 locus and the IBDs.
Methods: The four single nucleotide polymorphisms (SNPs) in the IL2/IL21 locus most associated with coeliac disease were genotyped in 1590 subjects with IBD and 929 controls from The Netherlands, and then replicated in a North American cohort (2387 cases and 1266 controls) and an Italian cohort (805 cases and 421 controls), yielding a total of 4782 cases (3194 UC, 1588 CD) and 2616 controls. Allelic association testing and a pooled analysis using a Cochran-Mantel-Haenszel test were performed.
Results: All four SNPs were strongly associated with UC in all three cohorts and reached genome-wide significance in the pooled analysis (rs13151961 p = 1.35x10(-10), rs13119723 p = 8.60x10(-8), rs6840978 p = 3.07x10(-8), rs6822844 p = 2.77x10(-9)). A moderate association with CD was also found in the pooled analysis (p value range 0.0016-9.86x10(-5)).
Conclusions: A strong association for the IL2/IL21 locus with UC was found, which also confirms it as a general susceptibility locus for inflammatory disease.
C1 [Goyette, P.; Lian, J.; Lefebvre, C.; Wijmenga, C.; Rioux, J. D.] Univ Montreal, Montreal Heart Inst, Lab Genet & Genom Med Inflammat, Montreal, PQ H1T 1C8, Canada.
[Festen, E. A. M.; Weersma, R. K.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands.
[Scott, R.; Duerr, R. H.] Univ Pittsburgh, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
[Annese, V.; Palmieri, O.] IRCCS, UU OO Gastroenterol & Endoscopia Digest, Osped Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
[Zhernakova, A.] Univ Med Ctr Utrecht, Dept Med Genet, Complex Genet Sect, Utrecht, Netherlands.
[Brant, S. R.] Johns Hopkins Univ, Dept Med, Harvey M & Lyn P Meyerhoff Inflammatory Bowel Dis, Baltimore, MD USA.
[Cho, J. H.] Yale Univ, Dept Med, Div Gastroenterol, Inflammatory Bowel Dis IBD Ctr, New Haven, CT 06520 USA.
[Cho, J. H.] Yale Univ, Dept Genet, Div Gastroenterol, Inflammatory Bowel Dis IBD Ctr, New Haven, CT 06520 USA.
[Silverberg, M. S.] Univ Toronto, Mt Sinai Hosp, IBD Ctr, Toronto, ON M5G 1X5, Canada.
[Taylor, K. D.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Taylor, K. D.] Cedars Sinai Med Ctr, Inflammatory Bowel Dis IBD Ctr, Los Angeles, CA 90048 USA.
[de Jong, D. J.] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, NL-6525 ED Nijmegen, Netherlands.
[Stokkers, P. C.; Mcgovern, D.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands.
[Achkar, J-P] Cleveland Clin, Ctr Inflammatory Bowel Dis, Dept Gastroenterol & Hepatol, Cleveland, OH 44106 USA.
[Xavier, R. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Cambridge, MA 02138 USA.
[Xavier, R. J.] Harvard Univ, Ctr Computat & Integrat Biol, Sch Med, Cambridge, MA 02138 USA.
[Daly, M. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
RP Rioux, JD (reprint author), Univ Montreal, Montreal Heart Inst, Lab Genet & Genom Med Inflammat, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.
EM john.david.rioux@umontreal.ca
RI Silverberg, Mark/B-4183-2008; Wijmenga, Cisca/D-2173-2009; Rioux,
John/A-9599-2015; Jong, D.J./L-4417-2015; Palmieri, Orazio/J-7697-2012;
Festen, Eleonora/S-3557-2016;
OI Rioux, John/0000-0001-7560-8326; Palmieri, Orazio/0000-0002-0019-7929;
Duerr, Richard/0000-0001-6586-3905; Zhernakova,
Alexandra/0000-0002-4574-0841; Wijmenga, Cisca/0000-0002-5635-1614
FU Netherlands Organization for Scientific Research [918.66.620];
Netherlands Organization for Scientific Research
FX This study was made possible by a VICI grant from the Netherlands
Organization for Scientific Research (918.66.620) to CW, and an
AGIKO-grant from the Netherlands Organization for Scientific Research to
EF.
NR 32
TC 86
Z9 89
U1 1
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD JUN
PY 2009
VL 58
IS 6
BP 799
EP 804
DI 10.1136/gut.2008.166918
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 444ME
UT WOS:000265984300014
PM 19201773
ER
PT J
AU Orezzoli, JP
Sioletic, S
Olawaiye, A
Oliva, E
del Carmen, MG
AF Orezzoli, Jorge P.
Sioletic, Stefano
Olawaiye, Alexander
Oliva, Esther
del Carmen, Marcela G.
TI Stage II endometrioid adenocarcinoma of the endometrium: Clinical
implications of cervical stromal invasion
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Endometrial; Cancer; Stromal; Invasion
ID GYNECOLOGIC-ONCOLOGY-GROUP; LYMPHVASCULAR SPACE INVOLVEMENT; ADJUVANT
RADIATION-THERAPY; SURGICAL STAGE; PROGNOSTIC-SIGNIFICANCE;
INTERNATIONAL-FEDERATION; TOTAL POPULATION; UTERINE CORPUS;
RISK-FACTORS; FIGO STAGE
AB Objectives. Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor. Cervical involvement (CI), divided into IIA (epithelial involvement) and IIB (stromal invasion), is overall associated with decreased survival (70 vs 90%). However, the impact on prognosis of sub-stages IIA vs IIB is unclear. The purpose of this study was to investigate the prognostic significance of cervical involvement as well as its substaging in patients diagnosed with EEC.
Methods. Eighty-one patients treated for stage 11 EEC were identified (1993-2003) in our institution. They were stratified into Group 1 (46) with available slides for review and Group 2 (35) with information obtained from the pathology report. All pathology reports, for all 81 patients, contained information on cervical glandular and stromal involvement. In Group 1, 1 to 6 slides of cervix (mean 3) were reviewed. Tumors were classified as Stage IIA or IIB according to the most recent FIGO criteria. Stromal invasion (SI) in Group I tumors Was sub-classified in 4 subgroups based on depth of invasion; A) <= 1 mm; B) > 1 mm and <= 3 mm; C) > 3 mm and <= 5 mm and D) > 5 mm. Other histopathologic parameters evaluated include grade, depth of myometrial invasion (MI), and lymphovascular invasion (LI). Clinical data included age, type of surgery, type of radiation, and survival. Statistical analysis was performed.
Results. Patients ranged in age from 33-91 (median 64) years. In Group 1, 11 patients had stage IIA and 35 stage IIB tumors. Depth of SI ranged from 1-12 mm (mean 3.4 mm). The pathologists reviewing the slides in Group I agreed with the initial reported description of cervical glandular and stromal involvement. In Group 2, 15 patients had stage IIA and 20 stage IIB tumors with no further information regarding depth of SI. In Group 1, 12 EECs were Grade 1, 29 Grade 2, and 5 Grade 3. Thirty tumors had < 50% MI, 15 showed > 50% MI and LVI was present in 11. In Group 2. 13 tumors were Grade 1, 13 Grade 2, and 9 Grade 3. Twenty-one had < 50% or no MI and 9 showed LVI. Median follow-up was 73 (range 5-210) months. Five- and 10-year survival rates were 83% and 78% for patients with stage IIA and 71% and 65% for stage IIB EECs respectively. By univariate analysis, age, MI, LVI and type of treatment affected Survival but not substaging into IIA vs IIB or depth of SI. By multivariate analysis, only age (p = 0.001), LVI (p = 0.017), and type of treatment (p = 0.022) were predictors of survival in stage 11 EECs.
Conclusions. This Study showed that the distinction between stage IIA and IIB or depth of SI does not affect Survival in patients with EEC. LVI and type of hysterectomy performed were predictors of survival in stage 11 EECs. Our results suggest that substaging should be eliminated, women with suspect cervical SI should be offered a radical hysterectomy, and that the presence of LVI may be a useful tool in guiding recommendations about the need for adjuvant radiation therapy. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Orezzoli, Jorge P.] Tufts Med Ctr, Dept Obstet & Gynecol, Boston, MA USA.
[Sioletic, Stefano] A Gemelli Catholic Univ, Dept Pathol, Rome, Italy.
[Olawaiye, Alexander] Univ Pittsburgh, Dept Gynecol Oncol, Pittsburgh, PA USA.
[Oliva, Esther] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA.
[del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA.
RP del Carmen, MG (reprint author), 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 57
TC 15
Z9 15
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN
PY 2009
VL 113
IS 3
BP 316
EP 323
DI 10.1016/j.ygyno.2009.03.007
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 449HB
UT WOS:000266320300005
PM 19345400
ER
PT J
AU Farley, J
Fuchiuji, S
Darcy, KM
Tian, CQ
Hoskins, WJ
McGuire, WP
Hanjani, P
Warshal, D
Greer, BE
Belinson, J
Birrer, MJ
AF Farley, John
Fuchiuji, Sartoru
Darcy, Kathleen M.
Tian, Chunqiao
Hoskins, William J.
McGuire, William P.
Hanjani, Parviz
Warshal, David
Greer, Benjamin E.
Belinson, Jerome
Birrer, Michael J.
TI Associations between ERBB2 amplification and progression-free survival
and overall survival in advanced stage, suboptimally-resected epithelial
ovarian cancers: A Gynecologic Oncology Group study
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE ERBB2; Gene amplification; Ovary; Carcinogenesis; FISH
ID HER-2/NEU EXPRESSION; GENE AMPLIFICATION; PROGNOSTIC-SIGNIFICANCE;
BREAST-CANCER; ENDOMETRIAL CARCINOMA; TISSUE MICROARRAYS;
CONTINGENCY-TABLES; OVEREXPRESSION; ONCOGENE; C-ERBB-2
AB Objective(s). The Gynecologic Oncology Group (GOG) examined the association between ERBB2 amplification and clinical covariates, tumor response, disease status post-chemotherapy, progression-free survival (PFS), and overall survival (OS) in epithelial ovarian cancer (EOC).
Methods. Women with suboptimally-resected, advanced stage EOC who participated in GOG-111, a multicenter randomized phase III trial of cyclophosphamide + cisplatin versus paclitaxel + cisplatin, and provided a tumor block through the companion protocol GOG-9404 were eligible. ERBB2 amplification was examined using fluorescence in situ hybridization (FISH) with probes for ERBB2 and the centromere of chromosome 17 (CEP17).
Results. ERBB2 amplification, defined as > 2 copies of ERBB2/CEP17, was a rare event in EOC with 7% (9/133) of women exhibiting between 2.2 and 33.7 copies of ERBB2/CEP17, and was not associated with patient age, race, GOG performance status, stage, cell type, grade, measurable disease status, volume of ascites, tumor response or disease status post-chemotherapy. Women with > 2 verses <= 2 copies of ERBB2/CEP17 did not have a reduced risk of disease progression (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.27-1.16; p = 0.120) or death (HR = 0.57; 95% CI = 0.26-1.23; p = 0.152), and ERBB2 amplification was not an independent prognostic factor for PFS or OS. ERBB2 amplification, defined as > 4 copies of ERBB2/nuclei, was observed in 9% (12/133) of women with levels ranging from 4.2 to 49.2 copies of ERBB2/nuclei, and was associated with older age and Volume of ascites, but not with the other clinical covariates or outcome.
Conclusion(s). ERBB2 amplification is a rare event and has no predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy. (C) 2009 Published by Elsevier Inc.
C1 [Farley, John] Uniformed Serv Univ Hlth Sci, Dept Obstet, Bethesda, MD 20814 USA.
[Farley, John] Uniformed Serv Univ Hlth Sci, Dept Gynecol, Bethesda, MD 20814 USA.
[Fuchiuji, Sartoru] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Darcy, Kathleen M.; Tian, Chunqiao] GOG Stat & Data Ctr, Buffalo, NY 14263 USA.
[Hoskins, William J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[McGuire, William P.] Franklin Sq Hosp Ctr, Harry & Jeanette Weinberg Canc Inst, Baltimore, MD 21237 USA.
[Hanjani, Parviz] Abington Mem Hosp, Abington, PA 19001 USA.
[Warshal, David] Cooper Univ Hosp, Dept Obstet & Oncol, Camden, NJ 08103 USA.
[Greer, Benjamin E.] Univ Washington, Dept Gynecol Oncol, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Belinson, Jerome] Cleveland Clin Fdn, Dept Gynecol, Cleveland, OH 44195 USA.
[Birrer, Michael J.] Ctr Canc Res, Bethesda, MD 20892 USA.
RP Birrer, MJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Yawkey 9072,55 Fruit St, Boston, MA 02114 USA.
EM mbirrer@partners.org
FU National Cancer Institute [CA 27469, CA 37517]
FX This study was supported by National Cancer Institute grants of the
Gynecologic Oncology Group Administrative Office (CA 27469) and the
Gynecologic Oncology Group Statistical Office (CA 37517). The following
Gynecologic Oncology Group (GOG) institutions participated in this
Study: University of Alabama School of Medicine, Abington Memorial
Hospital, University of Rochester Medical Center, Walter Reed Army
Medical Center, Wayne State University, Colorado Gynecologic Oncology
Group RC., University of California at Los Angeles, University of
Washington, Milton S. Hershey Medical Center, Georgetown University
Hospital, Wake Forest University School of Medicine, University of
California Medical Center at Irvine, University of Kentucky, The
Cleveland Clinic Foundation, Johns Hopkins Oncology Center, Eastern
Pennsylvania Gyn/Onc Center, P.C., Cooper Hospital/University Medical
Center, Columbus Cancer Council, University of Massachusetts Medical
Center, University of Oklahoma, and Tacoma General Hospital, as well as
the following resigned or terminated GOG member institutions: Oregon
Health Sciences University, University of Southern California at Los
Angeles and Stanford University Medical Center.
NR 39
TC 20
Z9 20
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN
PY 2009
VL 113
IS 3
BP 341
EP 347
DI 10.1016/j.ygyno.2009.02.009
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 449HB
UT WOS:000266320300010
PM 19272639
ER
PT J
AU Rajpal, R
Dowling, P
Meiller, J
Murphy, WG
O'Connor, R
Anderson, KC
Murphy, P
Clynes, M
O'Gorman, P
AF Rajpal, R.
Dowling, P.
Meiller, J.
Murphy, W. G.
O'Connor, R.
Anderson, K. C.
Murphy, P.
Clynes, M.
O'Gorman, P.
TI PERSONALISED MEDICINE - THE USE OF PROTEOMICS BIOMARKERS TO PREDICT
RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Rajpal, R.; Dowling, P.; Meiller, J.; O'Connor, R.; Clynes, M.] NICB, Dublin 9, Ireland.
[Murphy, W. G.] Univ Coll Dublin, Dublin 2, Ireland.
[Murphy, W. G.] Natl Blood Ctr, Dublin, Ireland.
[Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Murphy, P.] Beaumont Hosp, Dublin 9, Ireland.
[O'Gorman, P.] Mater Misericordiae Univ Hosp, Dublin 7, Ireland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0026
BP 10
EP 11
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900027
ER
PT J
AU Ravandi, F
Stuart, R
Maris, M
Stone, R
Cripe, L
Cooper, M
Turturro, F
Stock, W
Strickland, S
Mahadocon, K
Fox, J
Michelson, G
Berman, C
AF Ravandi, F.
Stuart, R.
Maris, M.
Stone, R.
Cripe, L.
Cooper, M.
Turturro, F.
Stock, W.
Strickland, S.
Mahadocon, K.
Fox, J.
Michelson, G.
Berman, C.
TI A PHASE 2 STUDY OF VORELOXIN AS SINGLE AGENT THERAPY FOR ELDERLY
PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Ravandi, F.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Stuart, R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Maris, M.] Rocky Mt Bone Marrow Transplant Program, Denver, CO USA.
[Stone, R.] Dana Farber Canc Ctr, Boston, MA USA.
[Cripe, L.] Indiana Univ, Indianapolis, IN 46204 USA.
[Cooper, M.] St Francis Hosp, Indianapolis, IN USA.
[Turturro, F.] LSU Hlth Sci Ctr, Shreveport, LA USA.
[Stock, W.] Univ Chicago, Chicago, IL 60637 USA.
[Strickland, S.] Vanderbilt Univ, Nashville, TN USA.
[Mahadocon, K.; Fox, J.; Michelson, G.; Berman, C.] Sunesis Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0302
BP 119
EP 119
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900304
ER
PT J
AU Wierda, G
Roberts, P
Brown, R
Wilson, H
O'Connor, A
Czuczman, S
Busman, A
Xiong, H
Krivoshik, P
Enschede, H
AF Wierda, G.
Roberts, P.
Brown, R.
Wilson, H.
O'Connor, A.
Czuczman, S.
Busman, A.
Xiong, H.
Krivoshik, P.
Enschede, H.
TI PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF ABT-263 IN PATIENTS
WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL
LYMPHOCYTIC LYMPHOMA
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Wierda, G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Roberts, P.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Brown, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wilson, H.] NCI, NIH, Bethesda, MD 20892 USA.
[O'Connor, A.] Columbia Univ, Med Ctr, New York, NY USA.
[Czuczman, S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Busman, A.; Xiong, H.; Krivoshik, P.; Enschede, H.] Abbott Labs, Abbott Pk, IL 60064 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0350
BP 138
EP 138
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900352
ER
PT J
AU Roccaro, M
Sacco, A
Azab, AK
Leleu, X
Thompson, BD
Azab, F
Jia, X
Ngo, HT
Runnels, J
Melhem, MR
Anderson, KC
Witzig, T
Ghobrial, IM
AF Roccaro, M.
Sacco, A.
Azab, A. K.
Leleu, X.
Thompson, B. D.
Azab, F.
Jia, X.
Ngo, H. T.
Runnels, J.
Melhem, M. R.
Anderson, K. C.
Witzig, T.
Ghobrial, I. M.
TI MICRORNAS AS KEY REGULATORS OF MULTIPLE MYELOMA CELL GROWTH
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Roccaro, M.; Sacco, A.; Azab, A. K.; Leleu, X.; Azab, F.; Jia, X.; Ngo, H. T.; Melhem, M. R.; Anderson, K. C.; Ghobrial, I. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Thompson, B. D.; Runnels, J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Witzig, T.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0367
BP 146
EP 147
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900369
ER
PT J
AU Richardson, PG
Chanan-Khan, A
Lonial, S
Krishnan, A
Carroll, M
Alsina, M
Albitar, M
Berman, D
Szatrowski, T
Kaplita, S
Anderson, KC
AF Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Szatrowski, T.
Kaplita, S.
Anderson, K. C.
TI TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND
REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Richardson, P. G.; Anderson, K. C.] Dana Farber Canc Inst, Boston, MA USA.
[Chanan-Khan, A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Lonial, S.] Emory Winship Canc Inst, Atlanta, GA USA.
[Carroll, M.] Sutter Reg Canc Inst, Sacramento, CA USA.
[Alsina, M.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Albitar, M.] Quest Hematopathol, San Juan Capistrano, CA USA.
[Berman, D.; Szatrowski, T.; Kaplita, S.] Bristol Myers Squibb Co, Princeton, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0381
BP 152
EP 153
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900383
ER
PT J
AU Siegel, D
Weber, D
Mitsiades, C
Dimopoulos, M
Harousseau, J
Rizvi, S
Howe, J
Reiser, D
Anderson, K
Richardson, P
AF Siegel, D.
Weber, D.
Mitsiades, C.
Dimopoulos, M.
Harousseau, J.
Rizvi, S.
Howe, J.
Reiser, D.
Anderson, K.
Richardson, P.
TI COMBINED VORINOSTAT, LENALIDOMIDE AND DEXAMETHASONE THERAPY IN PATIENTS
WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE I STUDY
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Siegel, D.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Weber, D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Mitsiades, C.; Anderson, K.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dimopoulos, M.] Univ Athens, Sch Med, GR-11527 Athens, Greece.
[Harousseau, J.] Ctr Rene Gauducheau, St Herblain, France.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0387
BP 155
EP 155
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900389
ER
PT J
AU Baz, R
Dimopoulos, M
Richardson, P
Yu, Z
Hussein, M
Chanan-Khan, A
AF Baz, R.
Dimopoulos, M.
Richardson, P.
Yu, Z.
Hussein, M.
Chanan-Khan, A.
TI LENALIDOMIDE-BASED THERAPY LEADS TO IMPROVEMENT OF HUMORAL IMMUNE SYSTEM
IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS WHO RESPOND TO THE
THERAPY
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Baz, R.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Dimopoulos, M.] Univ Athens, Sch Med, GR-11527 Athens, Greece.
[Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yu, Z.; Hussein, M.] Celgene Corp, Summit, NJ USA.
[Chanan-Khan, A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0395
BP 159
EP 159
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900397
ER
PT J
AU Leiba, M
Jakubikova, J
Klippel, S
Mitsiades, C
Hideshima, T
Tai, YT
Richardson, P
Nagler, A
Anderson, K
AF Leiba, M.
Jakubikova, J.
Klippel, S.
Mitsiades, C.
Hideshima, T.
Tai, Y. T.
Richardson, P.
Nagler, A.
Anderson, K.
TI HALOFUGINONE, AN ORALLY-BIOAVAILABLE AGENT, HAS IN VITRO AND IN VIVO
ANTIMYELOMA ACTIVITY, ASSOCIATED WITH UP REGULATION OF C-JUN, JNK, AND
P-53, PROAPOPTOTIC PROTEINS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Leiba, M.; Jakubikova, J.; Klippel, S.; Mitsiades, C.; Hideshima, T.; Tai, Y. T.; Richardson, P.; Anderson, K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nagler, A.] Sheba Tel Hashomer, Ramat Gan, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0399
BP 161
EP 161
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900401
ER
PT J
AU DeAngelo, DJ
Spencer, A
Ottmann, OG
Fischer, T
Kindler, T
Bhalla, KN
Liu, A
Parker, K
Rupani, H
Homji, N
Ashton, E
Jalauddin, M
Laird, G
Scott, JW
Prince, HM
AF DeAngelo, D. J.
Spencer, A.
Ottmann, O. G.
Fischer, T.
Kindler, T.
Bhalla, K. N.
Liu, A.
Parker, K.
Rupani, H.
Homji, N.
Ashton, E.
Jalauddin, M.
Laird, G.
Scott, J. W.
Prince, H. M.
TI PANOBINOSTAT HAS ACTIVITY IN TREATMENT-REFRACTORY HODGKIN LYMPHOMA
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Spencer, A.] Alfred Hosp, Melbourne, Vic, Australia.
[Ottmann, O. G.] Univ Frankfurt, Frankfurt, Germany.
[Fischer, T.; Kindler, T.] Johannes Gutenberg Univ Mainz, Mainz, Germany.
[Bhalla, K. N.] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA.
[Liu, A.; Parker, K.; Rupani, H.; Homji, N.; Jalauddin, M.; Laird, G.; Scott, J. W.] Nova Pharmaceut Corp, E Hanover, NJ USA.
[Ashton, E.] VirtualScop Inc, Rochester, NY USA.
[Prince, H. M.] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia.
RI Ottmann, Oliver/D-5007-2016
OI Ottmann, Oliver/0000-0001-9559-1330
NR 0
TC 3
Z9 3
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0505
BP 205
EP 206
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900507
ER
PT J
AU Frohling, S
Scholl, C
Dunn, I
Schinzel, A
Barbie, D
Kim, SY
Silver, S
Tamayo, P
Wadlow, R
Ramaswamy, S
Dohner, K
Bullinger, L
Sandy, P
Boehm, J
Root, D
Jacks, T
Hahn, W
Gilliland, G
AF Froehling, S.
Scholl, C.
Dunn, I.
Schinzel, A.
Barbie, D.
Kim, S. Y.
Silver, S.
Tamayo, P.
Wadlow, R.
Ramaswamy, S.
Doehner, K.
Bullinger, L.
Sandy, P.
Boehm, J.
Root, D.
Jacks, T.
Hahn, W.
Gilliland, G.
TI HIGH-THROUGHPUT RNA INTERFERENCE SCREENING IDENTIFIES SYNTHETIC
LETHALITY BETWEEN ONCOGENIC KRAS DEPENDENCY AND SUPPRESSION OF STK33
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Froehling, S.; Scholl, C.; Dunn, I.; Gilliland, G.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Schinzel, A.; Barbie, D.; Kim, S. Y.; Hahn, W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Silver, S.; Tamayo, P.; Boehm, J.; Root, D.] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA.
[Wadlow, R.; Ramaswamy, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Doehner, K.; Bullinger, L.] Univ Hosp, Ulm, Germany.
[Sandy, P.; Jacks, T.] MIT, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0552
BP 226
EP 226
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900554
ER
PT J
AU Raaijmakers, MHGP
Mukherjee, S
Guo, S
Kobayashi, T
Schoonmaker, J
Ebert, B
Al-Shahrour, F
Hasserjian, R
Scadden, E
Merkenschlager, M
Lin, C
Scadden, DT
AF Raaijmakers, M. H. G. P.
Mukherjee, S.
Guo, S.
Kobayashi, T.
Schoonmaker, J.
Ebert, B.
Al-Shahrour, F.
Hasserjian, R.
Scadden, E.
Merkenschlager, M.
Lin, C.
Scadden, D. T.
TI DELETION OF DICER1 FROM OSTEOPROGENITOR CELLS IS SUFFICIENT TO INDUCE
MYELODYSPLASIA AND HEMATOPOIETIC NEOPLASIA
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Raaijmakers, M. H. G. P.; Mukherjee, S.; Guo, S.; Kobayashi, T.; Schoonmaker, J.; Hasserjian, R.; Scadden, E.; Lin, C.; Scadden, D. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Raaijmakers, M. H. G. P.; Mukherjee, S.; Guo, S.; Kobayashi, T.; Schoonmaker, J.; Hasserjian, R.; Scadden, E.; Lin, C.; Scadden, D. T.] Harvard Univ, Sch Med, Boston, MA USA.
[Ebert, B.; Al-Shahrour, F.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
[Merkenschlager, M.] Univ London Imperial Coll Sci Technol & Med, Lymphocyte Dev Grp, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0554
BP 227
EP 227
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900556
ER
PT J
AU Solerno, ML
Jorda, MA
Louwers, IMA
Hofland, LJ
Delwel, HR
AF Solerno, M. L.
Jorda, M. A.
Louwers, I. M. A.
Hofland, L. J.
Delwel, H. R.
TI THE SOMATOSTATIN RECEPTOR 2 INDUCES A REVERSIBLE NEUTROPHILIC
DIFFERENTIATION BLOCK
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Hofland, L. J.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
[Jorda, M. A.] Harvard Stem Cell Inst, Boston, MA USA.
[Jorda, M. A.] BIDMC, Boston, MA USA.
[Louwers, I. M. A.; Delwel, H. R.] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0556
BP 228
EP 228
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900558
ER
PT J
AU Bernimoulin, MP
Waters, EK
Foy, M
Steele, BM
Sullivan, M
Falet, H
Walsh, MT
Barteneva, N
Geng, JG
Hartwig, JH
Maguire, PB
Wagner, DD
AF Bernimoulin, M. P.
Waters, E. K.
Foy, M.
Steele, B. M.
Sullivan, M.
Falet, H.
Walsh, M. T.
Barteneva, N.
Geng, J. -G.
Hartwig, J. H.
Maguire, P. B.
Wagner, D. D.
TI DIFERENTIAL STIMULATION OF MONOCYTIC CELLS RESULTS IN DISTINCT
POPULATIONS OF MICROPARTICLES
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Bernimoulin, M. P.] Hop Necker Enfants Malad, Paris, France.
[Waters, E. K.; Walsh, M. T.; Barteneva, N.; Wagner, D. D.] Immune Dis Inst, Boston, MA USA.
[Foy, M.; Steele, B. M.; Sullivan, M.; Maguire, P. B.] UCD Conway Inst, Dublin, Ireland.
[Falet, H.; Hartwig, J. H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Geng, J. -G.] Vasc Biol Ctr, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0605
BP 246
EP 246
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900606
ER
PT J
AU Flinn, W
Byrd, J
Furman, R
Brown, J
Lin, T
Bello, C
Giese, N
Yu, A
AF Flinn, W.
Byrd, J.
Furman, R.
Brown, J.
Lin, T.
Bello, C.
Giese, N.
Yu, A.
TI PRELIMINARY EVIDENCE OF CLINICAL ACTIVITY IN A PHASE 1 STUDY OF CAL-101,
A POTENT SELECTIVE INHIBITOR OF THE P110DELTA ISOFORM OF
PHOSPHATIDYLINOSITOL 3-KINASE, IN PATIENT WITH B-CELL MALIGNANCIES
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Flinn, W.] Sarah Cannon Res Inst, Nashville, TN USA.
[Byrd, J.; Lin, T.] Ohio State Univ, Columbus, OH 43210 USA.
[Furman, R.] Cornell Univ, New York, NY 10021 USA.
[Brown, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bello, C.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Giese, N.; Yu, A.] Calistoga Pharmaceut Inc, Seattle, WA USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 0744
BP 303
EP 303
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931900744
ER
PT J
AU Kilpivaara, M
Mukherjee, S
Schram, M
Wadleigh, M
Mullally, A
Ebert, L
Bass, A
Marubayashi, S
Heguy, A
Garcia-Manero, G
Kantarjian, H
Offit, K
Stone, M
Gilliland, D
Klein, J
Levine, L
AF Kilpivaara, M.
Mukherjee, S.
Schram, M.
Wadleigh, M.
Mullally, A.
Ebert, L.
Bass, A.
Marubayashi, S.
Heguy, A.
Garcia-Manero, G.
Kantarjian, H.
Offit, K.
Stone, M.
Gilliland, D.
Klein, J.
Levine, L.
TI A GERMLINE JAK2 SNP IS ASSOCIATED WITH PREDISPOSITION TO THE DEVELOPMENT
OF JAK2 V617F-POSITIVE MYELOPROLIFERATIVE NEOPLASMS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Kilpivaara, M.; Mukherjee, S.; Schram, M.; Marubayashi, S.; Heguy, A.; Offit, K.; Klein, J.; Levine, L.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Wadleigh, M.; Mullally, A.; Bass, A.; Stone, M.; Gilliland, D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mullally, A.; Ebert, L.; Gilliland, D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ebert, L.; Bass, A.] MIT, Boston, MA USA.
[Ebert, L.; Bass, A.] Broad Inst Harvard, Boston, MA USA.
[Garcia-Manero, G.; Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1045
BP 420
EP 420
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901134
ER
PT J
AU Pardanani, D
Lasho, T
Lim, K
Abdel-Wahab, O
Patel, J
Gangat, N
Finke, C
Schwager, S
Mullally, A
Li, C
Hanson, C
Mesa, R
Pardanani, A
Gilliland, G
Levine, R
Tefferi, A
AF Pardanani, D.
Lasho, T.
Lim, K.
Abdel-Wahab, O.
Patel, J.
Gangat, N.
Finke, C.
Schwager, S.
Mullally, A.
Li, C.
Hanson, C.
Mesa, R.
Pardanani, A.
Gilliland, G.
Levine, R.
Tefferi, A.
TI TET2 MUTATION PREVALENCE AND CLINICAL CORRELATES IN A SPECTRUM OF
MYELOID NEOPLASMS: A SINGLE INSTITUTION STUDY OF 337 PATIENTS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Pardanani, D.; Lasho, T.; Lim, K.; Gangat, N.; Finke, C.; Schwager, S.; Li, C.; Hanson, C.; Mesa, R.; Pardanani, A.; Tefferi, A.] Mayo Clin, Rochester, MN USA.
[Abdel-Wahab, O.; Patel, J.; Levine, R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Mullally, A.; Gilliland, G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1047
BP 420
EP 421
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901136
ER
PT J
AU Koschmieder, S
Schemionek, M
Elling, C
Baumer, N
Hamilton, A
Spieker, T
Gothert, J
Stehling, M
Huettner, C
Tenen, DG
Tickenbrock, L
Berdel, WE
Serve, HL
Holyoake, TL
Muller-Tidow, C
AF Koschmieder, S.
Schemionek, M.
Elling, C.
Baeumer, N.
Hamilton, A.
Spieker, T.
Goethert, J.
Stehling, M.
Huettner, C.
Tenen, D. G.
Tickenbrock, L.
Berdel, W. E.
Serve, H. L.
Holyoake, T. L.
Mueller-Tidow, C.
TI BCR-ABL ENHANCES DIFFERENTIATION OF LONG-TERM REPOPULATING HEMATOPOIETIC
STEM CELLS
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Koschmieder, S.; Schemionek, M.; Elling, C.; Baeumer, N.; Spieker, T.; Tickenbrock, L.; Berdel, W. E.; Mueller-Tidow, C.] Univ Munster, Munster, Germany.
[Hamilton, A.; Holyoake, T. L.] Univ Glasgow, Glasgow, Lanark, Scotland.
[Goethert, J.] Univ Essen Gesamthsch, Essen, Germany.
[Stehling, M.] Max Planck Inst Mol Biomed, Munster, Germany.
[Huettner, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tenen, D. G.] Ctr Life Sci, Boston, MA USA.
[Tenen, D. G.] Harvard Stem Cell Inst, Boston, MA USA.
[Serve, H. L.] Univ Frankfurt, Frankfurt, Germany.
RI Muller-Tidow, Carsten/B-5257-2014; Muller-Tidow, Carsten/L-4062-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1054
BP 423
EP 423
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901143
ER
PT J
AU Rummel, J
Boccia, R
Macik, BG
Pabinger, I
Selleslag, D
Gehl, L
Wang, X
Berger, DP
Kuter, DJ
AF Rummel, J.
Boccia, R.
Macik, B. G.
Pabinger, I.
Selleslag, D.
Gehl, L.
Wang, X.
Berger, D. P.
Kuter, D. J.
TI EFFICACY AND SAFETY OF ROMIPLOSTIM VERSUS MEDICAL STANDARD OF CARE AS
CHRONIC THERAPY FOR NONSPLENECTOMIZED PATIENTS WITH IMMUNE
THROMBOCYTOPENIA (ITP)
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Rummel, J.] Klinikum Justus Liebig Univ, Giessen, Germany.
[Boccia, R.] Ctr Canc & Blood Disorders, Bethesda, MD USA.
[Macik, B. G.] Univ Virginia, Charlottesville, VA USA.
[Pabinger, I.] Med Univ Wien, Vienna, Austria.
[Selleslag, D.] Agemeen Ziekenhuis Sint Jan, Brugge, Belgium.
[Gehl, L.; Wang, X.; Berger, D. P.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Kuter, D. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1059
BP 425
EP 426
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901148
ER
PT J
AU Pardanani, D
Gotlib, J
Jamieson, C
Cortes, J
Talpaz, M
Stone, R
Silverman, M
Shorr, J
Gilliland, DG
Tefferi, A
AF Pardanani, D.
Gotlib, J.
Jamieson, C.
Cortes, J.
Talpaz, M.
Stone, R.
Silverman, M.
Shorr, J.
Gilliland, D. G.
Tefferi, A.
TI TG101348, A JAK2-SELECTIVE INHIBITOR, IS WELL TOLERATED IN PATIENTS WITH
MYELOFIBROSIS AND SHOWS SUBSTANTIAL THERAPEUTIC ACTIVITY ACCOMPANIED BY
A REDUCTION IN JAK2V617F ALLELE BURDEN
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Pardanani, D.; Tefferi, A.] Mayo Clin, Rochester, MN USA.
[Gotlib, J.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Jamieson, C.] Moores UCSD Canc Ctr, San Diego, CA USA.
[Cortes, J.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Talpaz, M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Silverman, M.; Shorr, J.] Targe Gen Inc, San Diego, CA USA.
[Gilliland, D. G.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1088
BP 439
EP 440
PG 2
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901177
ER
PT J
AU Hochhaus, A
Kim, DW
Kantarjian, HM
Rousselot, P
Dorlhiac-Llacer, P
Milone, J
Shah, NP
Matloub, Y
Lambert, A
Stone, RM
AF Hochhaus, A.
Kim, D. W.
Kantarjian, H. M.
Rousselot, P.
Dorlhiac-Llacer, P.
Milone, J.
Shah, N. P.
Matloub, Y.
Lambert, A.
Stone, R. M.
TI DASATINIB 100 MG ONCE DAILY FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
(CML-CP) FOLLOWING IMATINIB FAILURE: LONG-TERM FOLLOW-UP FROM STUDY
CA180-034
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Hochhaus, A.] Univ Med Mannheim, Mannheim, Germany.
[Kim, D. W.] Catholic Univ Korea, St Marys Hosp, Seoul, South Korea.
[Kantarjian, H. M.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Rousselot, P.] Univ Versailles, Hop Mignot, Le Chesnay, France.
[Rousselot, P.] CIC9504, Le Chesnay, France.
[Dorlhiac-Llacer, P.] Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil.
[Milone, J.] Inst Trasplante Medula Osea, La Plata, Buenos Aires, Argentina.
[Shah, N. P.] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA.
[Matloub, Y.; Lambert, A.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1091
BP 441
EP 441
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901180
ER
PT J
AU Focosi, D
Carson, K
Evens, A
Richey, E
Habermann, T
Seymour, J
Laubach, J
Bawn, S
Gordon, L
Winter, J
Vose, J
Zelenetz, A
Mamtani, R
Raisch, D
Dorshimer, G
Rosen, S
Muro, K
Gottardi-Littell, N
Talley, R
Sartor, O
Green, D
Major, E
Bennett, C
Petrini, M
AF Focosi, D.
Carson, K.
Evens, A.
Richey, E.
Habermann, T.
Seymour, J.
Laubach, J.
Bawn, S.
Gordon, L.
Winter, J.
Vose, J.
Zelenetz, A.
Mamtani, R.
Raisch, D.
Dorshimer, G.
Rosen, S.
Muro, K.
Gottardi-Littell, N.
Talley, R.
Sartor, O.
Green, D.
Major, E.
Bennett, C.
Petrini, M.
TI PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY FOLLOWING RITUXIMAB THERAPY
IN HIV NEGATIVE PATIENTS: A REPORT OF 56 CASES FROM THE RESEARCH ON
ADVERSE DRUG EVENT AND REPORTS (RADAR) PROJECT
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Focosi, D.; Petrini, M.] Univ Pisa, Pisa, Italy.
[Carson, K.] Washington Univ, Sch Med, St Louis, MO USA.
[Evens, A.; Richey, E.; Gordon, L.; Winter, J.; Rosen, S.; Muro, K.; Gottardi-Littell, N.; Sartor, O.; Green, D.; Bennett, C.] Northwestern Univ, Chicago, IL 60611 USA.
[Habermann, T.] Mayo Clin, Coll Med, Rochester, MN USA.
[Seymour, J.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Seymour, J.] Univ Melbourne, Melbourne, Vic, Australia.
[Laubach, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bawn, S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Vose, J.; Zelenetz, A.; Mamtani, R.] New York Presbyterian Hosp, Cornell Med Ctr, New York, NY USA.
[Raisch, D.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Dorshimer, G.] Univ Penn Hlth Syst, Philadelphia, PA USA.
[Talley, R.] Kansas City Canc Ctr, Kansas City, MO USA.
[Major, E.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1099
BP 445
EP 445
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901188
ER
PT J
AU Malagola, M
Skert, C
Damiani, D
Candoni, A
Tiribelli, M
Martinelli, G
Piccaluga, PP
Paolini, S
Lauria, F
Bocchia, M
Gobbi, M
Clavio, M
Miglino, M
Pierri, I
Zaccaria, A
Zuffa, E
Mazza, P
Priccolo, G
Gugliotta, L
Bonini, A
Visani, G
Isidori, A
Bergonzi, C
Roccaro, AM
Peli, A
Fili, C
Fanin, R
Baccarani, M
Russo, D
AF Malagola, M.
Skert, C.
Damiani, D.
Candoni, A.
Tiribelli, M.
Martinelli, G.
Piccaluga, P. P.
Paolini, S.
Lauria, F.
Bocchia, M.
Gobbi, M.
Clavio, M.
Miglino, M.
Pierri, I.
Zaccaria, A.
Zuffa, E.
Mazza, P.
Priccolo, G.
Gugliotta, L.
Bonini, A.
Visani, G.
Isidori, A.
Bergonzi, C.
Roccaro, A. M.
Peli, A.
Fili, C.
Fanin, R.
Baccarani, M.
Russo, D.
TI A SIMPLE PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE LEUKAEMIA
PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 173 CASES
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Malagola, M.; Skert, C.; Damiani, D.; Candoni, A.; Tiribelli, M.; Lauria, F.; Bocchia, M.; Gobbi, M.; Clavio, M.; Miglino, M.; Pierri, I.; Bergonzi, C.; Peli, A.; Fili, C.; Fanin, R.; Russo, D.] Chair Haematol, Brescia, Italy.
[Martinelli, G.; Piccaluga, P. P.; Paolini, S.; Baccarani, M.] Inst Haematol Seragnoli, Bologna, Italy.
[Zaccaria, A.; Zuffa, E.; Mazza, P.; Priccolo, G.; Gugliotta, L.; Bonini, A.; Visani, G.; Isidori, A.] Div Haematol, Ravenna, Italy.
[Roccaro, A. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Miglino, Maria Angelica/B-9519-2012; Paolini, Stefania/K-9514-2016
OI Miglino, Maria Angelica/0000-0003-4979-115X;
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1393
BP 546
EP 546
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901483
ER
PT J
AU Podar, K
Zhang, J
Tonon, G
Grabher, C
Lababidi, S
Zimmerhackl, A
Raab, MR
Sonia, S
Zhou, Y
Cartron, MA
Tai, YT
Hideshima, T
Chauhan, D
Anderson, KA
AF Podar, K.
Zhang, J.
Tonon, G.
Grabher, C.
Lababidi, S.
Zimmerhackl, A.
Raab, M. R.
Sonia, S.
Zhou, Y.
Cartron, M. A.
Tai, Y. T.
Hideshima, T.
Chauhan, D.
Anderson, K. A.
TI TARGETING ANGIOGENESIS VIA A C-MYC/HIF-1 alpha-DEPENDENT PATHWAY IN MM
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the European-Hematology-Association
CY JUN 04-07, 2009
CL Berlin, GERMANY
SP European Hematol Assoc
C1 [Podar, K.; Zhang, J.; Tonon, G.; Grabher, C.; Lababidi, S.; Zimmerhackl, A.; Raab, M. R.; Tai, Y. T.; Hideshima, T.; Chauhan, D.; Anderson, K. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sonia, S.] MGH, Boston, MA USA.
[Zhou, Y.; Cartron, M. A.] Univ Arkansas Med S, Myeloma Inst Res & Therapy, Little Rock, AR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUN
PY 2009
VL 94
MA 1587
BP 613
EP 613
PG 1
WC Hematology
SC Hematology
GA 457MA
UT WOS:000266931901676
ER
PT J
AU Schrag, D
Virnig, BA
Warren, JL
AF Schrag, Deborah
Virnig, Beth A.
Warren, Joan L.
TI Linking Tumor Registry and Medicaid Claims to Evaluate Cancer Care
Delivery
SO HEALTH CARE FINANCING REVIEW
LA English
DT Article
ID DISPARITIES; POPULATION; SURVIVAL; ENROLLMENT; DIAGNOSIS; TRENDS; STAGE
AB The utility of Medicaid claims for studying cancer care is not known. Our objective was to evaluate how well Medicaid claims capture diagnostic and treatment information recorded by the California Cancer Registry (CCR). We compared cancer treatment from Medicaid claims with CCR data, using 1988-2000 cases matched with 1997-1998 Medicaid enrollment data. Medicaid claims corroborated diagnoses for 73 percent of breast and 68 percent of colorectal cancers in CCR. Medicaid claims confirmed surgery for 67 percent of CCR's breast cancers. We found that Medicaid claims have moderate sensitivity for identifying cancer diagnoses and surgery. Linked registry-Medicaid data can identify indigent patients and the timing of Medicaid coverage.
C1 [Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02116 USA.
[Virnig, Beth A.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA.
[Warren, Joan L.] NCI, Bethesda, MD 20892 USA.
RP Schrag, D (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02116 USA.
EM deb_schrag@dfci.harvard.edu
NR 26
TC 7
Z9 8
U1 0
U2 0
PU CENTERS FOR MEDICARE & MEDICAID SERVICES
PI BALTIMORE
PA 7500 SECURITY BOULEVARD, BALTIMORE, MD 21244-1850 USA
SN 0195-8631
J9 HEALTH CARE FINANC R
JI Health Care Finan. Rev.
PD SUM
PY 2009
VL 30
IS 4
BP 61
EP 73
PG 13
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 485EO
UT WOS:000269104000005
PM 19719033
ER
PT J
AU Ettner, SL
Cadwell, BL
Russell, LB
Brown, A
Karter, AJ
Safford, M
Mangione, C
Beckles, G
Herman, WH
Thompson, TJ
AF Ettner, Susan L.
Cadwell, Betsy L.
Russell, Louise B.
Brown, Arleen
Karter, Andrew J.
Safford, Monika
Mangione, Carol
Beckles, Gloria
Herman, William H.
Thompson, Theodore J.
CA TRIAD Study Grp
TI INVESTING TIME IN HEALTH: DO SOCIOECONOMICALLY DISADVANTAGED PATIENTS
SPEND MORE OR LESS EXTRA TIME ON DIABETES SELF-CARE?
SO HEALTH ECONOMICS
LA English
DT Article
DE self-care; opportunity costs of time; diabetes; disparities;
socioeconomic status
ID QUALITY-OF-CARE; MANAGED CARE; TRANSLATING RESEARCH; RACIAL DISPARITIES;
ETHNIC-DIFFERENCES; POPULATION; COMPLICATIONS; MELLITUS; PEOPLE; ADULTS
AB Background: Research on self-care for chronic disease has not examined time requirements. Translating Research into Action for Diabetes (TRIAD), a multi-site study of managed care patients with diabetes, is among the first to assess self-care time.
Objective: To examine associations between socioeconomic position and extra time patients spend on foot care, shopping/cooking, and exercise due to diabetes.
Data: Eleven thousand nine hundred and twenty-seven patient surveys from 2000 to 2001.
Methods: Bayesian two-part models were used to estimate associations of self-reported extra time spent on self-care with race/ethnicity, education, and income, controlling for demographic and clinical characteristics.
Results: Proportions of patients spending no extra time on foot care, shopping/cooking, and exercise were, respectively, 37, 52, and 31%. Extra time spent on foot care and shopping/cooking was greater among racial/ethnic minorities, less-educated and lower-income patients. For example, African-Americans were about 10 percentage points more likely to report spending extra time on foot care than whites and extra time spent was about 3 min more per day.
Discussion: Extra time spent on self-care was greater for socioeconomically disadvantaged patients than for advantaged patients, perhaps because their perceived opportunity cost of time is lower or they cannot afford Substitutes. Our findings suggest that poorly controlled diabetes risk factors among disadvantaged populations may not be attributable to self-care practices. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [Ettner, Susan L.; Brown, Arleen; Mangione, Carol] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA.
[Cadwell, Betsy L.; Beckles, Gloria; Thompson, Theodore J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Russell, Louise B.] Rutgers State Univ, Dept Econ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
[Karter, Andrew J.] Kaiser Permanente, Div Res, Oakland, CA USA.
[Safford, Monika] Univ Alabama Birmingham, Deep S Ctr Effectiveness, Birmingham VA Med Ctr, Birmingham, AL USA.
[Herman, William H.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
RP Ettner, SL (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Dept Med, 911 Broxton Plaza,Room 106, Los Angeles, CA 90095 USA.
EM settner@mednet.ucla.edu
OI Ferrara, Assiamira/0000-0002-7505-4826
FU Centers for Disease Control and Prevention (Division of Diabetes
Translation); National Institute of Diabetes and Digestive and Kidney
Diseases
FX The authors are grateful for the significant contributions to this study
made by members of the Translating Research into Action for Diabetes
(TRIAD) Study Group, including TRIAD participants, other TRIAD
investigators, and staff who made this study possible. The authors also
acknowledge the participation of our health plan partners. This study
was jointly funded by Program Announcement number 04005 from the Centers
for Disease Control and Prevention (Division of Diabetes Translation)
and the National Institute of Diabetes and Digestive and Kidney
Diseases.
NR 45
TC 14
Z9 14
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9230
EI 1099-1050
J9 HEALTH ECON
JI Health Econ.
PD JUN
PY 2009
VL 18
IS 6
BP 645
EP 663
DI 10.1002/hec.1394
PG 19
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 449TT
UT WOS:000266353700003
PM 18709636
ER
PT J
AU Hussey, PS
de Vries, H
Romley, J
Wang, MC
Chen, SS
Shekelle, PG
McGlynn, EA
AF Hussey, Peter S.
de Vries, Han
Romley, John
Wang, Margaret C.
Chen, Susan S.
Shekelle, Paul G.
McGlynn, Elizabeth A.
TI A Systematic Review of Health Care Efficiency Measures
SO HEALTH SERVICES RESEARCH
LA English
DT Review
DE Efficiency; provider profiling; performance measurement; systematic
review
ID HOSPITAL EFFICIENCY; REGIONAL-VARIATIONS; QUALITY; PRODUCTIVITY;
PHYSICIANS; INEFFICIENCIES; INCENTIVES
AB To review and characterize existing health care efficiency measures in order to facilitate a common understanding about the adequacy of these methods.
Review of the MedLine and EconLit databases for articles published from 1990 to 2008, as well as search of the "gray" literature for additional measures developed by private organizations.
We performed a systematic review for existing efficiency measures. We classified the efficiency measures by perspective, outputs, inputs, methods used, and reporting of scientific soundness.
We identified 265 measures in the peer-reviewed literature and eight measures in the gray literature, with little overlap between the two sets of measures. Almost all of the measures did not explicitly consider the quality of care. Thus, if quality varies substantially across groups, which is likely in some cases, the measures reflect only the costs of care, not efficiency. Evidence on the measures' scientific soundness was mostly lacking: evidence on reliability or validity was reported for six measures (2.3 percent) and sensitivity analyses were reported for 67 measures (25.3 percent).
Efficiency measures have been subjected to few rigorous evaluations of reliability and validity, and methods of accounting for quality of care in efficiency measurement are not well developed at this time. Use of these measures without greater understanding of these issues is likely to engender resistance from providers and could lead to unintended consequences.
C1 [de Vries, Han] Westbrook Ctr, RAND, Cambridge, England.
[Shekelle, Paul G.] RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA.
[Romley, John] Occidental Coll, Los Angeles, CA 90041 USA.
[Chen, Susan S.] Michigan State Univ, Coll Agr & Nat Resources, E Lansing, MI 48824 USA.
[Shekelle, Paul G.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
RP Hussey, PS (reprint author), 1200 S Hayes St, Arlington, VA 22202 USA.
EM hussey@rand.org
FU Agency for Healthcare Research and Quality (AHRQ), Rockville, MD
[282-00-0005-21]
FX Disclosures: None.
NR 48
TC 57
Z9 59
U1 5
U2 21
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2009
VL 44
IS 3
BP 784
EP 805
DI 10.1111/j.1475-6773.2008.00942.x
PG 22
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 446HB
UT WOS:000266111600002
PM 19187184
ER
PT J
AU Yan, BP
Clark, DJ
Buxton, B
Ajani, AE
Smith, JA
Duffy, SJ
Shardey, GC
Skillington, PD
Farouque, O
Yii, M
Yap, CH
Andrianopoulos, N
Brennan, A
Dinh, D
Reid, CM
AF Yan, Bryan P.
Clark, David J.
Buxton, Brian
Ajani, Andrew E.
Smith, Julian A.
Duffy, Stephen J.
Shardey, Gil C.
Skillington, Peter D.
Farouque, Omar
Yii, Michael
Yap, Cheng-Hon
Andrianopoulos, Nick
Brennan, Angela
Dinh, Diem
Reid, Christopher M.
CA ASCTS
MIG
TI Clinical characteristics and early mortality of patients undergoing
coronary artery bypass grafting compared to percutaneous coronary
intervention: Insights from the Australasian Society of Cardiac and
Thoracic Surgeons (ASCTS) and the Melbourne Interventional Group (MIG)
Registries
SO HEART LUNG AND CIRCULATION
LA English
DT Article
DE Coronary artery bypass surgery; Percutaneous coronary intervention
ID ACUTE MYOCARDIAL-INFARCTION; SIROLIMUS-ELUTING STENTS;
RANDOMIZED-TRIALS; DISEASE; OUTCOMES
AB Objectives: Controversy continues over the optimal revascularisation strategy for patients with multi-vessel coronary artery disease. Clinical characteristics, risk profile, and mortality of patients undergoing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are thought to differ but there are limited contemporary comparative data.
Methods: We compared clinical characteristics, in-hospital and 30-day mortality of 3841 consecutive patients undergoing isolated CABG and 4417 undergoing PCI. Independent predictors of 30-day mortality were determined by multiple logistic regression analysis.
Results: CABG patients were older (p < 0.01). The CABG group had a higher incidence of diabetes, heart failure, left ventricular ejection fraction <45%, multi-vessel coronary artery, peripheral vascular and cerebro-vascular disease (all p < 0.01). Patients undergoing PCI had a higher incidence of recent myocardial infarction (MI) as the indication for revascularisation (p < 0.01). In-hospital and 30-day mortality was 1.8% and 1.7% in the CABG group, and 1.4% and 1.8% in the PCI group, respectively. Independent predictors of 30-day mortality after CABG were age (odds ratio 1.1 per year, 950% confidence interval 1.0-1.1), cardiogenic shock (4.10, 1.7-10.5) and previous CABG (6.6, 2.4-17.7). Predictors after PCI were diabetes (2.7, 1.4-5.1), female gender (3.0, 1.6-5.5), renal failure (3.2, 1.2-8.0), MI < 24h (4.0, 2.2-7.6), left main intervention (5.4, 1.0-27.7), heart failure (6.0, 2.6-14.0) and cardiogenic shock (11.7, 5.4-25.2).
Conclusions: In contemporary clinical practice, CABG is preferred in patients with multi-vessel coronary and associated non-coronary vascular disease, while PCI is the dominant strategy for acute MI. Despite this, in-hospital and 30-day mortality rates were similar. Predictors of early mortality after CABG differ to those of PCI. (Heart, Lung and Circulation 2009;18:184-190) (C) 2008 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier Inc. All rights reserved.
C1 [Reid, Christopher M.] Monash Univ, NHMRC Ctr Clin Res Excellence Therapeut, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
[Ajani, Andrew E.] Univ Melbourne, Melbourne, Vic, Australia.
[Yan, Bryan P.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Yan, Bryan P.] Harvard Univ, Sch Med, Boston, MA USA.
[Clark, David J.; Farouque, Omar] Dept Cardiol, Austin, Australia.
[Ajani, Andrew E.] Dept Cardiol, Royal Melbourne, Vic, Australia.
[Duffy, Stephen J.] Alfred Hosp, Dept Cardiol, Melbourne, Vic, Australia.
[Buxton, Brian] Dept Cardiothorac Surg, Austin, Australia.
[Smith, Julian A.; Shardey, Gil C.] Monash Med Ctr, Dept Cardiothorac Surg, Melbourne, Vic, Australia.
[Skillington, Peter D.; Yap, Cheng-Hon] Dept Cardiothorac Surg, Royal Melbourne, Vic, Australia.
[Yii, Michael] St Vincent Hosp, Dept Cardiothorac Surg, Melbourne, Vic, Australia.
RP Reid, CM (reprint author), Monash Univ, NHMRC Ctr Clin Res Excellence Therapeut, Dept Epidemiol & Prevent Med, Commercial Rd, Melbourne, Vic 3004, Australia.
EM Chris.Reid@med.monash.edu.au
RI Shaw, James/F-1522-2010; Yan, Bryan/P-5928-2015
NR 16
TC 20
Z9 22
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1443-9506
J9 HEART LUNG CIRC
JI Heart Lung Circ.
PD JUN
PY 2009
VL 18
IS 3
BP 184
EP 190
DI 10.1016/j.hlc.2008.10.005
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 454XH
UT WOS:000266716800003
PM 19268632
ER
PT J
AU Fisher, DE
AF Fisher, David E.
TI Advance in Melanoma - Preface
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 Harvard Univ, Melanoma Program Med Oncol, Massachusetts Gen Hosp, Dept Dermatol,Cutaneous Biol Res Ctr,Med Sch, Charlestown, MA 02129 USA.
RP Fisher, DE (reprint author), Harvard Univ, Melanoma Program Med Oncol, Massachusetts Gen Hosp, Dept Dermatol,Cutaneous Biol Res Ctr,Med Sch, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM dfisher3@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP XIII
EP XIV
DI 10.1016/j.hoc.2009.03.014
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100001
PM 19464591
ER
PT J
AU Berger, MF
Garraway, LA
AF Berger, Michael F.
Garraway, Levi A.
TI Applications of Genomics in Melanoma Oncogene Discovery
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Review
DE Melanoma; Oncogene; DNA sequencing; Microarrays; Gene amplification;
Targeted therapy
ID CUTANEOUS MALIGNANT-MELANOMA; BLADDER-CARCINOMA ONCOGENE; N-RAS
MUTATIONS; HUMAN CANCER; IMATINIB MESYLATE; METASTATIC MELANOMA;
TRANSFORMING GENES; BRAF MUTATIONS; LUNG-CANCER; COPY NUMBER
AB The identification of recurrent alterations in the melanoma genome has provided key insights into the biology of melanoma genesis and progression. These discoveries have come about as a result of the systematic deployment and integration of diverse genomic technologies, including DNA sequencing, chromosomal copy number analysis, and gene expression profiling. Here, the discoveries of several key melanoma oncogenes affecting critical cell pathways are described and the role played by evolving genomics technologies in melanoma oncogene discovery is examined. These advances are being exploited to improve prognosis and treatment of melanoma patients through the development of genome-based diagnostic and targeted therapeutic avenues.
C1 [Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Berger, Michael F.; Garraway, Levi A.] Broad Inst MIT & Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA.
[Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
RP Garraway, LA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,D1542, Boston, MA 02115 USA.
EM levi_garraway@dfci.harvard.edu
FU Burroughs-Wellcome Fund [DP20D002750]
FX This work was supported by Grant No. DP20D002750 (NIH), the
Burroughs-Wellcome Fund, and the Starr Cancer Consortium.
NR 108
TC 14
Z9 14
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 397
EP +
DI 10.1016/j.hoc.2009.03.005
PG 19
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100003
PM 19464593
ER
PT J
AU Udayakumar, D
Tsao, H
AF Udayakumar, Durga
Tsao, Hensin
TI Melanoma Genetics: An Update on Risk-Associated Genes
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Genetics; Melanoma; CDKN2A; Polymorphism; Germline mutations
ID CUTANEOUS MALIGNANT-MELANOMA; MULTIPLE PRIMARY MELANOMAS; CDKN2A
GERMLINE MUTATIONS; NONMELANOMA SKIN-CANCER; CELL-CYCLE INHIBITION;
FAMILIAL MELANOMA; PRONE FAMILIES; PANCREATIC-CANCER; TUMOR-SUPPRESSOR;
MC1R VARIANTS
AB The past 15 years have seen rapid advances in both our understanding of hereditary melanoma genetics and the technologies that enable scientists to make discoveries. Despite great efforts by many groups worldwide, other high-risk melanoma loci besides CDKN2A still remain elusive. A panel of polymorphisms that appears to confer low-to-moderate risk for melanoma has been assembled through functional and genome-wide association studies. The goal of personalized melanoma risk prediction is within our reach, although true clinical use has yet to be established.
C1 [Udayakumar, Durga; Tsao, Hensin] Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed,Med Sch, Boston, MA 02114 USA.
[Tsao, Hensin] Massachusetts Gen Hosp, Melanoma & Pigmented Les Ctr, Boston, MA 02114 USA.
RP Tsao, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed,Med Sch, Bartlett 622,48 Blossom St, Boston, MA 02114 USA.
EM htsao@partners.org
NR 71
TC 14
Z9 14
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 415
EP +
DI 10.1016/j.hoc.2009.03.011
PG 16
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100004
PM 19464594
ER
PT J
AU Marneros, AG
AF Marneros, Alexander G.
TI Tumor Angiogenesis in Melanoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Melanoma; Angiogenesis; Vascular endothelial growth factor; Bone
marrow-derived cells; Antiangiogenesis; Endothelial cells
ID ENDOTHELIAL GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; BREAST-CANCER
METASTASIS; IN-SITU HYBRIDIZATION; PROGENITOR CELLS; LUNG METASTASIS;
MYELOID CELLS; MULTISTAGE CARCINOGENESIS; THROMBOEMBOLIC EVENTS;
LYMPHATIC METASTASIS
AB A large number of clinical studies are being conducted to assess the effects of angiogenesis inhibitors in the treatment of patients who have metastatic melanoma. It has become increasingly clear that a therapeutic approach that combines angiogenesis inhibitors with cytotoxic agents or other treatment modalities is more likely to result in a clinical benefit for patients rather than antiangiogenesis treatments alone. However, a targeted treatment approach with antiangiogenic agents needs to be based on an in-depth understanding of the complex mechanisms involved in melanoma tumor angiogenesis.
C1 [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
RP Marneros, AG (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM alexander_marneros@yahoo.com
NR 80
TC 12
Z9 12
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 431
EP +
DI 10.1016/j.hoc.2009.03.007
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100005
PM 19464595
ER
PT J
AU Mitra, D
Fisher, DE
AF Mitra, Devarati
Fisher, David E.
TI Transcriptional Regulation in Melanoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Review
DE Melanoma; Transcriptional regulation; Microphthalmia-associated
transcription factor; Therapeutic opportunities in melanoma; Melanocyte
survival
ID WAARDENBURG SYNDROME TYPE-2; CUTANEOUS MALIGNANT-MELANOMA; ENDOTHELIN-B
RECEPTOR; BETA-CATENIN; NEURAL CREST; STIMULATING HORMONE; PROGNOSTIC
MARKER; GENE-EXPRESSION; FACTOR MITF; ZIPPER TRANSCRIPTION
AB Transcriptional regulation in melanoma is a complex process that tends to hijack the normal melanocyte signaling pathways involved in melanocyte development, pigmentation, and survival. At the center of these often overlapping networks of transcriptional activation and repression is microphthalmia-associated transcription factor (MITF), a melanocyte lineage marker that increases pigment production and exhibits diverse effects on cell survival, proliferation, and cell cycle arrest. The particular conditions that allow MITF to produce these potentially contradictory roles have not yet been fully elucidated, but analysis of the pathways involved provides opportunities to learn about new therapeutic strategies.
C1 [Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol,Melanoma Program Med Oncol,Med Sch, Charlestown, MA 02129 USA.
[Mitra, Devarati] Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Biol & Biomed Sci Program,Med Sch, Charlestown, MA 02129 USA.
RP Fisher, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol,Melanoma Program Med Oncol,Med Sch, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM dfisher3@partners.org
FU NIGMS NIH HHS [T32 GM007753]
NR 106
TC 14
Z9 14
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 447
EP +
DI 10.1016/j.hoc.2009.03.003
PG 20
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100006
PM 19464596
ER
PT J
AU Piris, A
Mihm, MC
AF Piris, Adriano
Mihm, Martin C., Jr.
TI Progress in Melanoma Histopathology and Diagnosis
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Melanoma; Histopathology; Borderline lesions; Prognosis; Dermal mitoses
ID SENTINEL LYMPH-NODES; PIGMENTED-EPITHELIOID-MELANOCYTOMA; PRIMARY
CUTANEOUS MELANOMA; AMERICAN JOINT COMMITTEE; STAGE-I MELANOMA;
MALIGNANT-MELANOMA; PROGNOSTIC-SIGNIFICANCE; METASTATIC MELANOMA;
MICROSCOPIC SATELLITES; TUMOR PROGRESSION
AB This article reviews the main aspects of the histopathology of cutaneous melanoma with emphasis on recent advances in the morphological evaluation of these lesions. The limitations of morphology for the "so called" borderline lesions are briefly discussed, with a list of diagnostic criteria to help predict behavior for these challenging lesions. The prognostic factors are described with emphasis on the ones that are currently being used by the American Joint Committee on Cancer staging system. Ancillary tests, such as immunohistochemistry and molecular techniques, are also briefly touched upon as complimentary tools to help understand the biology of malignant melanoma. The conclusion is that an accurate morphological evaluation remains the most efficient approach to establish the diagnosis and predict behavior of this challenging neoplasm.
C1 [Piris, Adriano] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[Mihm, Martin C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol & Dermatopathol, Boston, MA 02114 USA.
RP Piris, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
EM apiris@partners.org
NR 51
TC 12
Z9 12
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 467
EP +
DI 10.1016/j.hoc.2009.03.012
PG 15
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100007
PM 19464597
ER
PT J
AU Duncan, LM
AF Duncan, Lyn McDivitt
TI The Classification of Cutaneous Melanoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Melanoma; Classification; Staging; Prognosis; BRAF
ID PIGMENTED-EPITHELIOID-MELANOCYTOMA; MALIGNANT-MELANOMA; SPITZOID
MELANOMA; MOLECULAR CLASSIFICATION; DESMOPLASTIC MELANOMA; NEVOID
MELANOMA; COPY NUMBER; NEVUS; TUMOR; EXPRESSION
AB Forty years ago, a clinical and histological classification scheme and prognostic factors were described for cutaneous melanoma. This scheme included the subtypes superficial spreading, nodular and lentigo maligna, and prognostic factors including tumor thickness, ulceration, and mitotic activity. There have been some tweaks to the classification scheme, but these basic findings form the foundation for melanoma diagnosis and staging today. Currently, no molecular marker or target has proved reliably useful in the staging or treatment of melanoma. Measurement with a simple ruler serves as the basis for the staging of primary cutaneous melanoma, while the recognition of primary tumor mitotic activity and ulceration also remain significant factors. Recently, mutational analysis has revealed a correlation of activating mutations with the morphological descriptors from decades ago. Future classification schemes may have more power in predicting response to therapy by integrating specific genomic and intra-tumoral expression profiles with histologic findings.
C1 Harvard Univ, Massachusetts Gen Hosp, MGH Dermatopathol Unit WRN827, Dept Pathol,Med Sch, Boston, MA 02114 USA.
RP Duncan, LM (reprint author), Harvard Univ, Massachusetts Gen Hosp, MGH Dermatopathol Unit WRN827, Dept Pathol,Med Sch, 55 Fruit St, Boston, MA 02114 USA.
EM duncan@helix.mgh.harvard.edu
NR 60
TC 15
Z9 16
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 501
EP +
DI 10.1016/j.hoc.2009.03.013
PG 14
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100009
PM 19464599
ER
PT J
AU Wargo, JA
Tanabe, K
AF Wargo, Jennifer A.
Tanabe, Kenneth
TI Surgical Management of Melanoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Melanoma; Surgery; Margins; Lymphadenectomy; Sentinel node
ID SENTINEL LYMPH-NODE; PRIMARY CUTANEOUS MELANOMA; MOHS MICROGRAPHIC
SURGERY; ISOLATED LIMB PERFUSION; MALIGNANT-MELANOMA; STAGE-I;
PROGNOSTIC-FACTORS; EXCISION MARGINS; HYPOFRACTIONATED RADIATION;
METASTATIC MELANOMA
AB Melanoma is an increasing health care problem worldwide. Up to 80,000 cases of melanoma are diagnosed per year and it is the sixth leading cause of cancer death in the United States. The lifetime risk is estimated to be 1 in 75 individuals for the development of melanoma. Surgery remains the mainstay of treatment of melanoma, and in most cases it is curative. Several important surgical issues are discussed in this review, including the extent of surgical margins, Mohs micrographic surgery for melanoma in situ, the use of sentinel lymph node biopsy, the usefulness of lymphadenectomy, isolated limb perfusion, and the role of metastasectomy.
C1 [Wargo, Jennifer A.; Tanabe, Kenneth] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Wargo, Jennifer A.; Tanabe, Kenneth] Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, Boston, MA 02114 USA.
RP Wargo, JA (reprint author), Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
EM ajwargo@partners.org
NR 77
TC 12
Z9 13
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2009
VL 23
IS 3
BP 565
EP +
DI 10.1016/j.hoc.2009.03.002
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA 458ME
UT WOS:000267027100013
PM 19464603
ER
PT J
AU Lok, AS
Everhart, JE
Chung, RT
Kim, HY
Everson, GT
Hoefs, JC
Greenson, JK
Sterling, RK
Lindsay, KL
Lee, WM
Di Bisceglie, AM
Bonkovsky, HL
Ghany, MG
Morishima, C
AF Lok, Anna S.
Everhart, James E.
Chung, Raymond T.
Kim, Hae-Young
Everson, Gregory T.
Hoefs, John C.
Greenson, Joel K.
Sterling, Richard K.
Lindsay, Karen L.
Lee, William M.
Di Bisceglie, Adrian M.
Bonkovsky, Herbert L.
Ghany, Marc G.
Morishima, Chihiro
CA Halt-C Trial Grp
TI Evolution of Hepatic Steatosis in Patients with Advanced Hepatitis C:
Results from the Hepatitis C Antiviral Long-Term Treatment Against
Cirrhosis (HALT-C) Trial
SO HEPATOLOGY
LA English
DT Article
ID FIBROSIS PROGRESSION; INSULIN-RESISTANCE; UNTREATED PATIENTS; INFECTION;
THERAPY; INTERFERON; HISTORY
AB Hepatic steatosis is a common histologic feature in patients with chronic hepatitis C (CHC) but there are no large longitudinal studies describing the progression of steatosis in CHC. We examined changes in steatosis on serial biopsies among CHC patients participating in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. All 1050 patients in the trial had advanced fibrosis at baseline biopsy and were documented not to have had a sustained virological response to peginterferon and ribavirin. Most (94%) patients had genotype 1 infection. At least one protocol follow-up biopsy was read on 892 patients, and 699 had the last biopsy performed 3.5 years after randomization. At enrollment, 39% had cirrhosis and 61% had bridging fibrosis; 18%, 41%, 31%, and 10% had steatosis scores of 0, 1, 2, and 3 or 4, respectively. The mean steatosis score decreased in the follow-up biopsies in both the interferon-treated patients and controls with no effect of treatment assignment (P = 0.66). A decrease in steatosis score by >= 1 point was observed in 30% of patients and was associated with both progression to cirrhosis and continued presence of cirrhosis (P = 0.02). Compared to patients without a decrease in steatosis, those with a decrease in steatosis had worse metabolic parameters at enrollment, and were more likely to have a decrease in alcohol intake, improvement in metabolic parameters, and worsening liver disease (cirrhosis, esophageal varices, and deterioration in liver function). Conclusion: Serial biopsies demonstrated that in patients with CHC, steatosis recedes during progression from advanced fibrosis to cirrhosis. Decreased alcohol intake and improved metabolic parameters are associated with a decline in steatosis and may modulate hepatitis C progression. (HEPATOLOGY 2009;49:1828-1837.)
C1 [Lok, Anna S.] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA.
[Everhart, James E.] NIDDK, Div Digest Dis & Nutr, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
[Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA.
[Kim, Hae-Young] New England Res Inst, Watertown, MA 02172 USA.
[Everson, Gregory T.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
[Hoefs, John C.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA.
[Greenson, Joel K.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA.
[Sterling, Richard K.] Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA USA.
[Lindsay, Karen L.] Univ So Calif, Keck Sch Med, Div Gastrointestinal & Liver Dis, Sch Med, Los Angeles, CA 90033 USA.
[Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA.
[Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Infect Dis, Dallas, TX 75390 USA.
[Di Bisceglie, Adrian M.] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA.
[Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA.
[Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Mol & Struct Biol, Farmington, CT USA.
[Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT USA.
[Ghany, Marc G.] NIDDK, Liver Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
[Morishima, Chihiro] Univ Washington, Dept Lab Med, Div Virol, Seattle, WA 98195 USA.
RP Lok, AS (reprint author), Univ Michigan Hlth System, Div Gastroenterol, 3912 Taubman Ctr,SPC 5362, Ann Arbor, MI 48109 USA.
EM aslok@med.umich.edu
RI Lok, Anna /B-8292-2009;
OI Yang, Shuman/0000-0002-9638-0890
FU National Institute of Diabetes & Digestive & Kidney Diseases [P60
DK020572]; National Institute of Allergy and Infectious Diseases
(NIAID); National Cancer Institute; National Center for Minority Health
and Health Disparities; National Center for Research Resources, National
Institutes of Health; Hoffmann-La Roche, Inc.
FX This study was supported by the National Institute of Diabetes &
Digestive & Kidney Diseases (contract numbers are listed below).
Additional support was provided by the National Institute of Allergy and
Infectious Diseases (NIAID), the National Cancer Institute, the National
Center for Minority Health and Health Disparities and by General
Clinical Research Center grants from the National Center for Research
Resources, National Institutes of Health (grant numbers are listed
below). Additional funding to conduct this study was supplied by
Hoffmann-La Roche, Inc., through a Cooperative Research and Development
Agreement (CRADA) with the National Institutes of Health. The insulin
assays were performed in the Michigan Diabetes Research and Training
Center, which is supported by National Institute of Diabetes & Digestive
& Kidney Diseases grant P60 DK020572.
NR 27
TC 28
Z9 28
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JUN
PY 2009
VL 49
IS 6
BP 1828
EP 1837
DI 10.1002/hep.22865
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 456KY
UT WOS:000266846400009
PM 19291787
ER
PT J
AU Welzel, TM
Morgan, TR
Bonkovsky, HL
Naishadham, D
Pfeiffer, RM
Wright, EC
Hutchinson, AA
Crenshaw, AT
Bashirova, A
Carrington, M
Dotrang, M
Sterling, RK
Lindsay, KL
Fontana, RJ
Lee, WM
Di Bisceglie, AM
Ghany, MG
Gretch, DR
Chanock, SJ
Chung, RT
O'Brien, TR
AF Welzel, Tania Mara
Morgan, Timothy R.
Bonkovsky, Herbert L.
Naishadham, Deepa
Pfeiffer, Ruth M.
Wright, Elizabeth C.
Hutchinson, Amy A.
Crenshaw, Andrew T.
Bashirova, Arman
Carrington, Mary
Dotrang, Myhanh
Sterling, Richard K.
Lindsay, Karen L.
Fontana, Robert J.
Lee, William M.
Di Bisceglie, Adrian M.
Ghany, Marc G.
Gretch, David R.
Chanock, Stephen J.
Chung, Raymond T.
O'Brien, Thomas R.
CA Halt-C Trial Grp
TI Variants in Interferon-Alpha Pathway Genes and Response to Pegylated
Interferon-Alpha2a Plus Ribavirin for Treatment of Chronic Hepatitis C
Virus Infection in the Hepatitis C Antiviral Long-Term Treatment Against
Cirrhosis Trial
SO HEPATOLOGY
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISM; PEGINTERFERON ALPHA-2A; VIRAL-INFECTION;
PROTEIN-KINASE; THERAPY; PKR; MXA; ASSOCIATION; EXPRESSION; ROLES
AB Combination treatment with pegylated-interferon-alpha (PEG IFN-alpha) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may affect antiviral responses, we analyzed the relationship between variants in these genes and SVR among participants in the Hepatitis C Antiviral Long-Term treatment Against Cirrhosis (HALT-C) trial. Patients had advanced chronic hepatitis C that had previously failed to respond to interferon-based treatment. Participants were treated with peginterferonce-alpha 2a and ribavirin during the trial. Subjects with undetectable HCV RNA at week 72 were considered to have had an SVR. Subjects with detectable HCV RNA at week 20 were considered nonresponders. We used TaqMan assays to genotype 56 polymorphisms found in 13 genes in the interferon-alpha pathway. This analysis compares genotypes for participants with an SVR to nonresponders. The primary analysis was restricted to European American participants because a priori statistical power was low among the small number (n = 131) of African American patients. We used logistic regression to control the effect of other variables that are associated with treatment response. Among 581 European American patients, SVR was associated with IFNAR1 IVSI-22G (adjusted odds ratio, 0.57; P = 0.02); IFNAR2 Ex2-33C (adjusted odds ratio, 2.09; P = 0.02);JAK1 IVS22 + 112T (adjusted odds ratio, 1.66; P = 0.04); and ADAR Ex9 + 14A (adjusted odds ratio, 1.67; P = 0.03). For the TYK2-2256A promoter region variant, a borderline association was present among European American participants (OR, 1.51; P = 0.05) and a strong relationship among, African American patients; all 10 with SVR who were genotyped for TYK2-2256 carried the A variant compared with 68 of 120 (57%) nonresponders (P = 0.006). Conclusion. Genetic polymorphisms in the interferon-alpha pathway may affect responses to antiviral therapy of chronic hepatitis C. (HEPATOLOGY 2009;49:1847-1858.)
C1 [Welzel, Tania Mara; Pfeiffer, Ruth M.; Chanock, Stephen J.; O'Brien, Thomas R.] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Morgan, Timothy R.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA.
[Morgan, Timothy R.] VA Long Beach Healthcare Syst, Gastroenterol Serv, Long Beach, CA USA.
[Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA.
[Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT USA.
[Bonkovsky, Herbert L.] Carolinas Med Ctr, Charlotte, NC 28203 USA.
[Naishadham, Deepa] New England Res Inst, Watertown, MA 02172 USA.
[Wright, Elizabeth C.] NIDDK, Off Director, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
[Ghany, Marc G.] NIDDK, Liver Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
[Hutchinson, Amy A.; Crenshaw, Andrew T.] NCI, Core Genotyping Facil, Div Canc Epidemiol & Genet, Adv Technol Program,SAIC Frederick Inc, Frederick, MD 21701 USA.
[Bashirova, Arman] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Carrington, Mary] NCI Frederick Inc, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick Inc, Frederick, MD USA.
[Dotrang, Myhanh] Comp Sci Corp, Rockville, MD USA.
[Sterling, Richard K.] Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA USA.
[Lindsay, Karen L.] Univ So Calif, Keck Sch Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA.
[Fontana, Robert J.] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA.
[Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA.
[Di Bisceglie, Adrian M.] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA.
[Gretch, David R.] Univ Washington, Dept Lab Med, Div Virol, Seattle, WA 98195 USA.
[Chung, Raymond T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA.
RP O'Brien, TR (reprint author), 6120 Execut Blvd,Room 6111,MSC 7246, Rockville, MD 20892 USA.
EM obrient@mail.nih.gov
RI Pfeiffer, Ruth /F-4748-2011
FU National Institute of Diabete & Digestive & Kidney Diseases; National
Institute of Allergy and Infectious Diseases (NIAID); National Cancer
Institute; National Center for Minority Health and Health Disparities;
National Center for Research Resources; National Institutes of Health;
Hoffmann-La Roche, Inc.
FX The HALT-C Trial was supported by the National Institute of Diabete &
Digestive & Kidney Diseases (contract numbers are listed below).
Additional support was provided by the National Institute of Allergy and
Infectious Diseases (NIAID), the National Cancer Institute, the National
Center for Minority Health and Health Disparities and by General
Clinical Research Center grants from the National Center for Research
Resources, National Institutes of Health (grant numbers are listed
below). Additional funding for HALT-C was supplied by Hoffmann-La Roche,
Inc. through a Cooperative Research and Development Agreement (CRADA)
with the National Institutes of Health. Supported by the Intramural
Research Program of the National Institutes of Health, National Cancer
Institute, Division of Cancer Epidemiology and Genetics This is
publication #32 of the HALT-C Trial.
NR 28
TC 52
Z9 54
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JUN
PY 2009
VL 49
IS 6
BP 1847
EP 1858
DI 10.1002/hep.22877
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 456KY
UT WOS:000266846400011
PM 19434718
ER
PT J
AU Wang, WL
Farris, AB
Lauwers, GY
Deshpande, V
AF Wang, Wei-Lia
Farris, Alton B.
Lauwers, Gregory Y.
Deshpande, Vikram
TI Autoimmune pancreatitis-related cholecystitis: a morphologically and
immunologically distinctive form of lymphoplasmacytic sclerosing
cholecystitis
SO HISTOPATHOLOGY
LA English
DT Article
DE autoimmune pancreatitis; chronic cholecystitis; gallbladder; primary
sclerosing cholangitis
ID PLASMA-CELL INFILTRATION; INFLAMMATORY PSEUDOTUMOR; CHOLANGITIS;
DISEASE; DIAGNOSIS; FEATURES; BIOPSY
AB Gallbladder involvement in autoimmune pancreatitis (AIP) is reported to be histologically similar to that seen in primary sclerosing cholangitis (PSC) and biliary obstruction secondary to pancreatic ductal adenocarcinoma (PDAC). The aim was to identify unique morphological and immunological features that could help distinguish gallbladders of AIP from those associated with PSC and PDACs.
Archival gallbladders from well-characterized individuals with AIP (n = 22), PSC (n = 13) and PDAC (n = 23) were examined. Quantitative immunohistochemical analysis for IgG and IgG4 plasma cells was performed and an IgG4/IgG ratio was derived. Dense extramural infiltrates were almost exclusively seen in AIP cases (41%), but seen in only 4% of PDAC-associated cases and 0% of PSC cases (P = 0.001). Phlebitis was more frequently noted in AIP cases (41%) (P = 0.03). Inflammatory nodules were almost exclusively seen in AIP (27%) (P = 0.04). AIP gallbladders showed higher IgG4/IgG ratios (P = 0.0001) than PDAC-associated and PSC gallbladders.
The findings support our hypothesis that gallbladder involvement in AIP is a primary manifestation of this disease and not a secondary phenomenon related to biliary obstruction. In conjunction with imaging and serology, examination of the gallbladder could provide collaborative evidence of AIP. Evaluation of the gallbladder could also distinguish PSC from AIP-related cholangitis.
C1 [Deshpande, Vikram] Harvard Univ, Massachusetts Gen Hosp, Sch Med,James Homer Wright Pathol Labs, Dept Pathol,Gastrointestinal Pathol Serv, Boston, MA 02114 USA.
RP Deshpande, V (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,James Homer Wright Pathol Labs, Dept Pathol,Gastrointestinal Pathol Serv, Warren 2,55 Fruit St, Boston, MA 02114 USA.
EM vdeshpande@partners.org
NR 24
TC 33
Z9 35
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0309-0167
J9 HISTOPATHOLOGY
JI Histopathology
PD JUN
PY 2009
VL 54
IS 7
BP 829
EP 836
DI 10.1111/j.1365-2559.2009.03315.x
PG 8
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 453GC
UT WOS:000266597400006
PM 19635102
ER
PT J
AU Stufflebeam, SM
Tanaka, N
Ahlfors, SP
AF Stufflebeam, Steven M.
Tanaka, Naoaki
Ahlfors, Seppo P.
TI Clinical Applications of Magnetoencephalography
SO HUMAN BRAIN MAPPING
LA English
DT Review
DE MEG; EEG; imaging; brain tumors; epilepsy; presurgical mapping;
interictal; ictal; eloquent cortex; motor
ID TO-NOISE-RATIOS; HUMAN BRAIN; EPILEPSY PATIENTS; MEG; OSCILLATIONS;
CORTEX; SCHIZOPHRENIA; SPIKE; EEG; ELECTROENCEPHALOGRAPHY
AB Magnetoencephalography (MEG), in which magnetic fields generated by brain activity are recorded outside of the head, is now in routine clinical practice throughout the world. MEG has become a recognized and vital part of the presurgical evaluation of patients with epilepsy and patients with brain tumors. We review investigations that show an improvement in the postsurgical outcomes of patients with epilepsy by localizing epileptic discharges. We also describe the most common clinical MEG applications that affect the management of patients, and discuss some applications that are close to having a clinical impact on patients. Hum Brain Mapp 30:1813-1823, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Stufflebeam, Steven M.; Tanaka, Naoaki; Ahlfors, Seppo P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA.
[Stufflebeam, Steven M.; Ahlfors, Seppo P.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Stufflebeam, SM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Athinoula A Martinos Ctr Biomed Imagi, 149 13th St,Mail Code 2301, Charlestown, MA 02129 USA.
EM smstuff@mit.edu
RI Ahlfors, Seppo/P-3644-2016
FU The National Center for Research Resources [P41RR14074]; The Mental
Illness and Neuroscience Discovery (MIND) Institute; National Institutes
of Health [EY-07891, K08MH067966-05]; National Association of
Schizophrenia and Depression (NARSAD)
FX Contract grant sponsor: The National Center for Research Resources;
Contract grant number: P41RR14074; Contract grant sponsor: The Mental
Illness and Neuroscience Discovery (MIND) Institute; Contract grant
sponsor: NIH; Contract grant number: EY-07891; Contract grant sponsor:
National Institutes of Health,Contract grant number: K08MH067966-05;
Contract grant sponsors: National Association of Schizophrenia and
Depression (NARSAD); Harvard Catalyst Grant, and the Partners
Collaboration Radiology grant.
NR 52
TC 36
Z9 38
U1 2
U2 16
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1065-9471
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JUN
PY 2009
VL 30
IS 6
BP 1813
EP 1823
DI 10.1002/hbm.20792
PG 11
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 454VL
UT WOS:000266710900007
PM 19378272
ER
PT J
AU Lin, FH
Hara, K
Solo, V
Vangel, M
Belliveau, JW
Stufflebeam, SM
Hamalainen, MS
AF Lin, Fa-Hsuan
Hara, Keiko
Solo, Victor
Vangel, Mark
Belliveau, John W.
Stufflebeam, Steven M.
Hamalainen, Matti S.
TI Dynamic Granger-Geweke Causality Modeling With Application to Interictal
Spike Propagation
SO HUMAN BRAIN MAPPING
LA English
DT Article
DE epilepsy; Granger causality; connectivity
ID MULTIVARIATE AUTOREGRESSIVE MODELS/; DIRECTED TRANSFER-FUNCTION;
STATISTICAL ASSESSMENT; CORTICAL CONNECTIVITY; NONLINEAR CAUSALITY;
NEURAL SYSTEMS; FUNCTIONAL MRI; BRAIN; FMRI; EEG
AB A persistent problem in developing plausible neurophysiological models of perception, cognition, and action is the difficulty of characterizing the interactions between different neural systems. Previous studies have approached this problem by estimating causal influences across brain areas activated during cognitive processing using structural equation modeling (SEM) and, more recently, with Granger-Geweke causality. While SEM is complicated by the need for a priori directional connectivity information, the temporal resolution of dynamic Granger-Geweke estimates is limited because the Underlying autoregressive (AR) models assume stationarity over the period of analysis. We have developed a novel optimal method for obtaining data-driven directional causality estimates with high temporal resolution in both time and frequency domains. This is achieved by simultaneously optimizing the length of the analysis window and the chosen AR model order using the SURE criterion. Dynamic Granger-Geweke causality in time and frequency domains is Subsequently calculated within a moving analysis window. We tested our algorithm by calculating the Granger-Geweke causality of epileptic spike propagation from the right frontal lobe to the left frontal lobe. The results quantitatively Suggested that the epileptic activity at the left frontal lobe was propagated from the right frontal lobe, in agreement with the clinical diagnosis. Our novel computational tool can be used to help elucidate complex directional interactions in the human brain. Hum Brain Mapp 30:1877-1886, 2009. (C) 2009 Wilev-Liss, Inc.
C1 [Lin, Fa-Hsuan; Hara, Keiko; Solo, Victor; Vangel, Mark; Belliveau, John W.; Stufflebeam, Steven M.; Hamalainen, Matti S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, HST, Charlestown, MA 02129 USA.
[Lin, Fa-Hsuan] Natl Taiwan Univ, Inst Biomed Engn, Taipei 106, Taiwan.
[Solo, Victor] Univ New S Wales, Sch Elect Engn, Sydney, NSW, Australia.
RP Lin, FH (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, HST, 149 13th St,Rm 2301, Charlestown, MA 02129 USA.
EM fhlin@ntu.edu.tw
RI Hamalainen, Matti/C-8507-2013; Lin, Fa-Hsuan/G-6988-2012
OI Lin, Fa-Hsuan/0000-0002-9539-1731
FU National Institutes of Health [R01DA14178, R01HD040712, R01NS037462, P41
RR14075, R21EB007298]; National Science Council (NSC), Taiwan
[97-2320-B-002-058, 97-2221-E-002-005]; National Health Research
Institute, Taiwan [NHIU-EX98-9715EC]; Mental Illness and Neuroscience
Discovery Institute (MIND)
FX Contract grant sponsor: National Institutes of Health; Contract grant
numbers: R01DA14178, R01HD040712, R01NS037462, P41 RR14075, R21EB007298;
Contract grant sponsor: National Science Council (NSC), Taiwan; Contract
grant number: 97-2320-B-002-058, 97-2221-E-002-005; Contract grant
sponsor: National Health Research Institute, Taiwan; Contract grant
number: NHIU-EX98-9715EC; Contract grant sponsor: Mental Illness and
Neuroscience Discovery Institute (MIND).
NR 44
TC 22
Z9 22
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1065-9471
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JUN
PY 2009
VL 30
IS 6
BP 1877
EP 1886
DI 10.1002/hbm.20772
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 454VL
UT WOS:000266710900013
PM 19378280
ER
PT J
AU Gennari, F
Lopes, L
Verhoeyen, E
Marasco, W
Collins, MK
AF Gennari, Francesca
Lopes, Luciene
Verhoeyen, Els
Marasco, Wayne
Collins, Mary K.
TI Single-Chain Antibodies That Target Lentiviral Vectors to MHC Class II
on Antigen-Presenting Cells
SO HUMAN GENE THERAPY
LA English
DT Article
ID THERAPEUTIC ANTITUMOR IMMUNITY; RESPONSES IN-VIVO; DENDRITIC CELLS;
INTRAVENOUS-INJECTION; POTENT CD8(+); IMMUNIZATION; VACCINE;
LENTIVECTOR; INDUCTION; VIRUS
AB Lentiviral vectors are promising vaccines because they can transduce and express antigens in dendritic cells in vivo, leading to potent immunization. To improve the safety and efficacy of lentivector vaccination, we sought to target vector transduction to antigen-presenting cells by modifying the viral envelope. To do this we screened a nonimmunized human single-chain antibody phage display library for phage that bound mouse bone marrow-derived dendritic cells (BMDCs) and isolated three single-chain antibodies (scFvs) that bound to more than 20% of cells in the BMDC culture. The three scFvs also bound to dendritic cells, macrophages, monocytes, and B cells from mouse spleen, but not to neutrophils, eosinophils, or T cells. Immunoblotting demonstrated that two unique scFvs, C2 and C7, recognized MHC class II. We constructed chimeric envelope proteins, by fusing these two scFvs to the amino terminus of the amphotropic murine leukemia virus envelope (MLV-A). These chimeric envelopes were expressed on the surface of lentiviral vector particles and enhanced infection (5- to 10-fold) of BMDC cultures, compared with lentiviral vectors with unmodified MLV-A envelope. Similarly, the chimeric envelopes enhanced (10- to 20-fold) the infection of primary lymph node class II-positive cells. One of the envelopes, C2, gave increased interferon-g production from splenocytes of vaccinated mice compared with MLV-A, achieving a level similar to that obtained with vesicular stomatitis virus glycoprotein G, when used to deliver an ovalbumin model antigen gene. These results demonstrate that surface-targeting lentiviral vector transduction of antigen-presenting cells gives efficient and potentially safer immunization.
C1 [Gennari, Francesca; Lopes, Luciene; Collins, Mary K.] UCL, London W1T 4JF, England.
[Verhoeyen, Els] Ecole Normale Super Lyon, INSERM, U412, F-69364 Lyon, France.
[Marasco, Wayne] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Collins, MK (reprint author), UCL, 46 Cleveland St, London W1T 4JF, England.
EM mary.collins@ucl.ac.uk
RI Verhoeyen, Els/H-6360-2016
FU MRC Programme Grant; Cancer Research UK
FX This work was supported by an MRC Programme Grant (R. Weiss, PI) and a
Cancer Research UK Programme Grant. The authors thank Philip Taylor
(Cardiff University) for analysis of scFv binding to splenocytes.
NR 34
TC 16
Z9 16
U1 1
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD JUN
PY 2009
VL 20
IS 6
BP 554
EP 562
DI 10.1089/hum.2008.189
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 455BG
UT WOS:000266729800002
PM 19260768
ER
PT J
AU Mulligan, JK
Day, TA
Gillespie, MB
Rosenzweig, SA
Young, MRI
AF Mulligan, Jennifer K.
Day, Terry A.
Gillespie, M. Boyd
Rosenzweig, Steven A.
Young, M. Rita I.
TI Secretion of vascular endothelial growth factor by oral squamous cell
carcinoma cells skews endothelial cells to suppress T-cell functions
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE Oral squamous cell carcinoma (OSCC); Vascular endothelial growth factor
(VEGF); Endothelial cell; T-cell; Immune suppression
ID NECK-CANCER; DENDRITIC CELLS; IMMUNE SUPPRESSION; FACTOR VEGF; HEAD;
TUMOR; ANGIOGENESIS; CYTOKINES; SURVIVAL; DIFFERENTIATION
AB Patients with oral squamous cell carcinoma (OSCC) have severe defects in antitumor immune function. Endothelial cells are potential regulators of immune cell function and have therefore been examined to determine their role in tumor-induced immune suppression. The present Studies demonstrated that supernatants from endothelial cells exposed to OSCC-conditioned media (endo(OSCC-sup)) exhibited elevated levels of the immune suppressive products prostaglandin E(2) (PGE(2)) and Vascular endothelial growth factor (VEGF) compared with supernatants from endothelial cells treated with medium alone (endo(medium)) or with keratinocyte-conditioned medium (endo(ker-sup)). Antibody neutralization of OSCC-derived VEGF prevented tumor-conditioned media from inducing endothelial cells to increase production of PGE(2) and VEGF. Furthermore, treatment of T-cells with supernatants from endo(OSCC-sup) resulted in diminished T-cell proliferation and decreased interferon-gamma (IFN-gamma) production compared with T-cells treated with medium or supernatants from endo(medium) or endo(ker-sup) controls. T-cell levels of granzyme B and perform were reduced after treatment with Supernatant from endo(OSCC-sup) Compared with control treatments. The addition of VEGF neutralizing antibody to the OSCC-conditioned medium prevented endothelial cells from being skewed to downregulate T-cell proliferation and production of IFN-gamma, perform, and granzyme B. Taken together, these studies provide support for the use of VEGF-targeting therapies as an immunotherapeutic agent to block induction of immune Suppressive endothelial cells in patients with OSCC. (C) 2009 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Mulligan, Jennifer K.; Gillespie, M. Boyd; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
[Mulligan, Jennifer K.; Day, Terry A.; Gillespie, M. Boyd; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA.
[Rosenzweig, Steven A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA.
[Rosenzweig, Steven A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM rita.young@va.gov
FU Research Service of the Department of Veterans Affairs; National
Institutes of Health [R01CA85266, R01CA97813]
FX This work was supported by the Research Service of the Department of
Veterans Affairs and by Grants R01CA85266 and R01CA97813 from the
National Institutes of Health to MRIY. The authors thank Bridgette
Ransom and Kiki Gibbs for their assistance in preparing OSCC samples and
Andrea Selmer for her technical assistance.
NR 32
TC 24
Z9 24
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD JUN
PY 2009
VL 70
IS 6
BP 375
EP 382
DI 10.1016/j.humimm.2009.01.014
PG 8
WC Immunology
SC Immunology
GA 455ZF
UT WOS:000266806900001
PM 19480853
ER
PT J
AU Ceylan-Isik, AF
Guo, KK
Carlson, EC
Privratsky, JR
Liao, SJ
Cai, L
Chen, AF
Ren, J
AF Ceylan-Isik, Asli F.
Guo, Kelly K.
Carlson, Edward C.
Privratsky, Jamie R.
Liao, Song-Jie
Cai, Lu
Chen, Alex F.
Ren, Jun
TI Metallothionein Abrogates GTP Cyclohydrolase I Inhibition-Induced
Cardiac Contractile and Morphological Defects Role of Mitochondrial
Biogenesis
SO HYPERTENSION
LA English
DT Article
DE BH4; eNOS uncoupling; cardiomyocyte mechanics; metallothionein;
superoxide
ID NITRIC-OXIDE SYNTHASE; LOW-RENIN HYPERTENSION; ENDOTHELIAL DYSFUNCTION;
VASCULAR-DISEASE; BLOOD-PRESSURE; GENE-TRANSFER; TETRAHYDROBIOPTERIN;
PHOSPHORYLATION; OVEREXPRESSION; MICE
AB One key mechanism for endothelial dysfunction is endothelial NO synthase (eNOS) uncoupling, whereby eNOS generates O(2)(center dot-) rather than NO because of deficient eNOS cofactor tetrahydrobiopterin (BH4). This study was designed to examine the effect of BH4 deficiency on cardiac morphology and function, as well as the impact of metallothionein (MT) on BH4 deficiency induced abnormalities, if any. Friend virus B (FVB) and cardiac specific MT transgenic mice were exposed to 2,4-diamino-6-hydroxypyrimidine (DAHP; 10 mmol/L, 3 weeks), an inhibitor of the BH4 synthetic enzyme GTP cyclohydrolase I. DAHP reduced plasma BH4 levels by 85% and elevated blood pressure in both FVB and MT mice. Echocardiography found decreased fractional shortening and increased end systolic diameter in DAHPtreated FVB mice. Cardiomyocytes from DAHP treated FVB mice displayed enhanced O(2)(center dot-) production, contractile and intracellular Ca(2+) defects including depressed peak shortening and maximal velocity of shortening/relengthening, prolonged duration of relengthening, reduced intracellular Ca(2+) rise, and clearance. DAHP triggered mitochondrial swelling/myocardial filament aberrations and mitochondrial O(2)(center dot-) accumulation, assessed by transmission electron microscopy and MitoSOX Red fluorescence, respectively. DAHP also promoted the N(G-)nitro-L-arginine methyl ester inhibitable O(2)(center dot-) production and eNOS phosphorylation at Thr497. Although MT had little effect on cardiac mechanics and ultrastructure, it attenuated DAHP induced defects in cardiac function, morphology,O(2)(center dot) production, and eNOS phosphorylation (Thr497). The DAHP induced cardiomyocyte mechanical responses were alleviated by in vitro BH4 treatment. DAHP inhibited mitochondrial biogenesis, mitochondrial uncoupling protein 2, and chaperone heat shock protein 90, and all but uncoupling protein 2 were rescued by MT. Our data suggest a role for BH4 deficiency in cardiac dysfunction and the therapeutic potential of antioxidants against eNOS uncoupling in the heart. (Hypertension. 2009; 53: 10231031.)
C1 [Ceylan-Isik, Asli F.; Guo, Kelly K.; Ren, Jun] Univ Wyoming, Coll Hlth Sci, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA.
[Carlson, Edward C.; Privratsky, Jamie R.; Ren, Jun] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58203 USA.
[Cai, Lu] Univ Louisville, Dept Pediat, Louisville, KY 40202 USA.
[Liao, Song-Jie; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.
[Liao, Song-Jie; Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
RP Ren, J (reprint author), Univ Wyoming, Coll Hlth Sci, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA.
EM jren@uwyo.edu
FU NCRR NIH HHS [P20 RR016474, P20 RR016474-08, P20 RR016474-086660]; NIGMS
NIH HHS [R01 GM077352]
NR 35
TC 30
Z9 31
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD JUN
PY 2009
VL 53
IS 6
BP 1023
EP U243
DI 10.1161/HYPERTENSIONAHA.108.123422
PG 16
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 448CG
UT WOS:000266239300025
PM 19398661
ER
PT J
AU Vakoc, BJ
Tearney, GJ
Bouma, BE
AF Vakoc, Benjamin J.
Tearney, Guillermo J.
Bouma, Brett E.
TI Statistical Properties of Phase-Decorrelation in Phase-Resolved Doppler
Optical Coherence Tomography
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Decorrelation noise; Doppler optical coherence tomography; optical
coherence tomography; phase-resolved
ID PHOTODYNAMIC THERAPY; BLOOD-VESSELS; ANIMAL-MODEL; FLOW; VELOCITY;
SPEED; FEASIBILITY; ARTIFACTS; SKIN
AB Decorrelation noise limits the ability of phase-resolved Doppler optical coherence tomography systems to detect smaller vessels exhibiting slower flow velocities, which limits the utility of the technique in many clinical and biological settings. An understanding of the statistical properties of decorrelation noise can aid in the optimal design of these systems and guide the development of noise mitigating strategies. In this work, the statistical properties of decorrelation noise are derived from the underlying statistics of the coherent imaging system and validated through comparison with empirical results and Monte Carlo modeling. Expressions for the noise distribution and the noise variance as a function of relevant imaging system parameters are given, and the implications of these results on both system and algorithm design are discussed.
C1 [Vakoc, Benjamin J.; Tearney, Guillermo J.; Bouma, Brett E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Vakoc, Benjamin J.; Tearney, Guillermo J.; Bouma, Brett E.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Vakoc, BJ (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM bvakoc@partners.org
FU NCI NIH HHS [K25 CA127465, K25 CA127465-01, K25 CA127465-02, R21
CA125560, R21 CA125560-01]
NR 32
TC 33
Z9 33
U1 0
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 0278-0062
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD JUN
PY 2009
VL 28
IS 6
BP 814
EP 821
DI 10.1109/TMI.2009.2012891
PG 8
WC Computer Science, Interdisciplinary Applications; Engineering,
Biomedical; Engineering, Electrical & Electronic; Imaging Science &
Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
SC Computer Science; Engineering; Imaging Science & Photographic
Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 454IV
UT WOS:000266676500003
PM 19164078
ER
PT J
AU Van Leemput, K
AF Van Leemput, Koen
TI Encoding Probabilistic Brain Atlases Using Bayesian Inference
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Atlas formation; Bayesian inference; brain modeling; computational
anatomy; image registration; mesh generation; model comparison
ID MAGNETIC-RESONANCE IMAGES; MODEL-BASED SEGMENTATION; MR-IMAGES; TISSUE
CLASSIFICATION; AUTOMATIC SEGMENTATION; MUTUAL-INFORMATION;
REGISTRATION; ALGORITHM; CONSTRUCTION; TEMPLATE
AB This paper addresses the problem of creating probabilistic brain atlases from manually labeled training data. Probabilistic atlases are typically constructed by counting the relative frequency of occurrence of labels in corresponding locations across the training images. However, such an "averaging" approach generalizes poorly to unseen cases when the number of training images is limited, and provides no principled way of aligning the training datasets using deformable registration. In this paper, we generalize the generative image model implicitly underlying standard "average" atlases, using mesh-based representations endowed with an explicit deformation model. Bayesian inference is used to infer the optimal model parameters from the training data, leading to a simultaneous group-wise registration and atlas estimation scheme that encompasses standard averaging as a special case. We also use Bayesian inference to compare alternative atlas models in light of the training data, and show how this leads to a data compression problem that is intuitive to interpret and computationally feasible. Using this technique, we automatically determine the optimal amount of spatial blurring, the best deformation field flexibility, and the most compact mesh representation. We demonstrate, using 2-D training datasets, that the resulting models are better at capturing the structure in the training data than conventional probabilistic atlases. We also present experiments of the proposed atlas construction technique in 3-D, and show the resulting atlases' potential in fully-automated, pulse sequence-adaptive segmentation of 36 neuroanatomical structures in brain MRI scans.
C1 [Van Leemput, Koen] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Van Leemput, Koen] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
RP Van Leemput, K (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM koen@nmr.mgh.harvard.edu
RI Van Leemput, Koen/A-9197-2009
OI Van Leemput, Koen/0000-0001-6466-5309
FU NCRR NIH HHS [P41 RR013218-02, P41 RR013218, P41 RR014075, P41
RR014075-02, P41-RR13218, P41-RR14075, U24 RR021382, U24 RR021382-01];
NIBIB NIH HHS [R01 EB006758, R01 EB006758-02, R01EB006758, U54 EB005149,
U54 EB005149-06, U54-EB005149]; NINDS NIH HHS [R01 NS051826, R01
NS051826-01, R01 NS052585, R01 NS052585-01, R01 NS052585-02,
R01-NS051826]
NR 60
TC 28
Z9 28
U1 0
U2 6
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 0278-0062
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD JUN
PY 2009
VL 28
IS 6
BP 822
EP 837
DI 10.1109/TMI.2008.2010434
PG 16
WC Computer Science, Interdisciplinary Applications; Engineering,
Biomedical; Engineering, Electrical & Electronic; Imaging Science &
Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
SC Computer Science; Engineering; Imaging Science & Photographic
Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 454IV
UT WOS:000266676500004
PM 19068424
ER
PT J
AU Wu, YB
Catana, C
Farrell, R
Dokhale, PA
Shah, KS
Qi, JY
Cherry, SR
AF Wu, Yibao
Catana, Ciprian
Farrell, Richard
Dokhale, Purushottam A.
Shah, Kanai S.
Qi, Jinyi
Cherry, Simon R.
TI PET Performance Evaluation of an MR-Compatible PET Insert
SO IEEE TRANSACTIONS ON NUCLEAR SCIENCE
LA English
DT Article
DE Avalanche photodiodes; positron emission tomography (PET); magnetic
resonance imaging (MRI)
ID POSITRON-EMISSION-TOMOGRAPHY; SENSITIVE AVALANCHE PHOTODIODES; SMALL
ANIMAL PET; SIMULTANEOUS PET/MRI; SCANNER; MICROPET; DETECTOR; DESIGN;
ACQUISITION; RESOLUTION
AB A magnetic resonance (MR) compatible positron emission tomography (PET) insert has been developed in our laboratory for simultaneous small animal PET/MR imaging. This system is based on lutetium oxyorthosilicate (LSO) scintillator arrays with position-sensitive avalanche photodiode (PSAPD) photodetectors. The PET performance of this insert has been measured. The average reconstructed image spatial resolution was 1.51 mm. The sensitivity at the center of the field of view (CFOV) was 0.35%, which is comparable to the simulation predictions of 0.40%. The average photopeak energy resolution was 25%. The scatter fraction inside the MRI scanner with a line source was 12% (with a mouse-sized phantom and standard 35 mm Bruker 1H RF coil), 7% (with RF coil only) and 5% (without phantom or RF coil) for an energy window of 350-650 keV. The front-end electronics had a dead time of 390 ns, and a trigger extension dead time of 7.32 mu s that degraded counting rate performance for injected doses above similar to 0.75 mCi (28 MBq). The peak noise-equivalent count rate (NECR) of 1.27 kcps was achieved at 290 mu Ci (10.7 MBq). The system showed good imaging performance inside a 7-T animal MRI system; however improvements in data acquisition electronics and reduction of the coincidence timing window are needed to realize improved NECR performance.
C1 [Wu, Yibao; Qi, Jinyi; Cherry, Simon R.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
[Catana, Ciprian] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Farrell, Richard; Dokhale, Purushottam A.; Shah, Kanai S.] Radiat Monitoring Devices Inc, Watertown, MA 02472 USA.
RP Wu, YB (reprint author), Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
EM ybwu@ucdavis.edu
RI Qi, Jinyi/A-1768-2010
OI Qi, Jinyi/0000-0002-5428-0322
FU National Institutes of Health [R0 1 EB000993, R44 NS055377]
FX This work was supported by the National Institutes of Health under Grant
R0 1 EB000993 and Grant R44 NS055377.
NR 28
TC 16
Z9 16
U1 0
U2 5
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 0018-9499
J9 IEEE T NUCL SCI
JI IEEE Trans. Nucl. Sci.
PD JUN
PY 2009
VL 56
IS 3
BP 574
EP 580
DI 10.1109/TNS.2009.2015448
PG 7
WC Engineering, Electrical & Electronic; Nuclear Science & Technology
SC Engineering; Nuclear Science & Technology
GA 463LX
UT WOS:000267434800007
PM 21072320
ER
PT J
AU Ruseva, M
Kolev, M
Dagnaes-Hansen, F
Hansen, SB
Takahashi, K
Ezekowitz, A
Thiel, S
Jensenius, JC
Gadjeva, M
AF Ruseva, Marieta
Kolev, Martin
Dagnaes-Hansen, Frederik
Hansen, Soren B.
Takahashi, Kazue
Ezekowitz, Alan
Thiel, Steffen
Jensenius, Jens C.
Gadjeva, Mihaela
TI Mannan-binding lectin deficiency modulates the humoral immune response
dependent on the genetic environment
SO IMMUNOLOGY
LA English
DT Article
DE complement; hepatitis B surface antigen; immune response; mannan-binding
lectin; mannan-binding lectin double knock-out mice
ID B-VIRUS INFECTION; CAPSULAR POLYSACCHARIDE; COMPLEMENT ACTIVATION;
MOLECULAR ADJUVANT; ANTIBODY-RESPONSE; C3D ENHANCEMENT; SERINE-PROTEASE;
IGG-ANTIBODIES; MICE; HEPATITIS
AB Mannan-binding lectin (MBL) is a plasma protein implicated in innate immune defence against a broad range of microorganisms, including viruses. It is also thought that MBL plays a role in the recruitment of the specific clonal immune response. This was studied by injecting soluble hepatitis B surface antigen (HBsAg) intravenously into mice deficient in both MBL-A and MBL-C (MBL DKO mice). The MBL DKO animals on mixed genetic background(SV129EvSv x C57BL/6) produced higher antibody titres than the wild-type littermates. After primary challenge with the antigen the immunoglobulin M anti-HBsAg antibody titres were threefold higher in the MBL DKO mice than in the wild-type mice. Following the boost, the immunoglobulin G anti-HBsAg antibody titres were 10-fold higher in the MBL DKO mice, suggesting that MBL plays a role in a negative feedback regulation of adaptive immunity. However, the modulating effect of MBL was dependent on the genetic environment. The MBL DKO mice backcrossed on a C57BL/6 background showed the opposite response with the MBL DKO mice now producing fewer antibodies than the wild-type animals, whereas MBL deficiency in mice with the SV129EvSv background did not show any effect in antibody production. These findings indicate that the modifying effect of MBL on the humoral immune response is influenced by the genetic environment.
C1 [Ruseva, Marieta; Kolev, Martin; Dagnaes-Hansen, Frederik; Thiel, Steffen; Jensenius, Jens C.; Gadjeva, Mihaela] Univ Aarhus, Dept Med Microbiol & Immunol, Aarhus, Denmark.
[Ruseva, Marieta; Kolev, Martin] Cardiff Univ, Cardiff, Wales.
[Hansen, Soren B.] Aarhus Univ Hosp, PET Ctr, DK-8000 Aarhus, Denmark.
[Takahashi, Kazue; Ezekowitz, Alan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Gadjeva, M (reprint author), Harvard Univ, Sch Med, Dept Med, Channing Labs,BWH, Boston, MA 02115 USA.
EM mgadjeva@rics.bwh.harvard.edu
RI kolev, mihail/D-1476-2015
OI kolev, mihail/0000-0002-5226-4759
FU Danish Ministry of Finance; Danish Medical Research Council; Novo Nordic
Foundation
FX This work was supported by the Danish Ministry of Finance grant to MG,
the Danish Medical Research Council and the Novo Nordic Foundation.
NR 43
TC 20
Z9 21
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD JUN
PY 2009
VL 127
IS 2
BP 279
EP 288
DI 10.1111/j.1365-2567.2008.03016.x
PG 10
WC Immunology
SC Immunology
GA 453GI
UT WOS:000266598500015
PM 19476514
ER
PT J
AU Su, L
Zhai, RH
Sheu, CC
Gallagher, DC
Gong, MN
Tejera, P
Thompson, BT
Christiani, DC
AF Su, Li
Zhai, Rihong
Sheu, Chau-Chyun
Gallagher, Diana C.
Gong, Michelle N.
Tejera, Paula
Thompson, B. Taylor
Christiani, David C.
TI Genetic variants in the angiopoietin-2 gene are associated with
increased risk of ARDS
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Angiopoietin-2; Genetic susceptibility; ARDS; Tagging single nucleotide
polymorphism; Haplotype; Molecular epidemiology
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; ENDOTHELIAL-CELLS;
CIRCULATING ANGIOPOIETIN-2; CRITICALLY-ILL; GROWTH-FACTOR; IN-VIVO;
PULMONARY; INFLAMMATION; SEPSIS
AB Angiopoietin-2 (Ang-2) is a potent regulator of vascular permeability and inflammation in acute lung injury and acute respiratory distress syndrome (ARDS). Genetic variants in the Ang-2 gene may lead to altered activities of Ang-2 (or ANGPT2) gene. The aim of this study was to assess if genetic variants of Ang-2 are associated with the risk of ARDS.
Unmatched, case-control study nested within a prospectively enrolled cohort.
Intensive care units (ICU) of an academic medical center.
About 1,529 critically ill patients with risk factors for ARDS consecutively admitted to the ICUs from 1999 to 2006. Cases were 449 patients who developed ARDS and controls were 1,080 subjects who did not developed ARDS.
None.
Nine tagging SNPs (tSNPs) spanning the entire Ang-2 gene were genotyped in all patients. The results were analyzed using logistic regression models, adjusting for covariates. The variant T allele of one tSNP (rs2515475) was significantly associated with increased risk of ARDS (OR(adjusted) = 1.28; P = 0.042). This association was stronger in subjects with extrapulmonary injuries (OR(adjusted) = 1.79; P = 0.004). Haplotype TT in block 2 containing the T allele of the rs2515475 was also significantly associated with higher risk of ARDS (OR(adjusted) = 1.42; P = 0.009), particularly in subjects with extrapulmonary injuries (OR(adjusted) = 1.90; P = 0.004).
Common genetic variation in the Ang-2 gene may be associated with increased risk of ARDS, especially among patients with extrapulmonary injuries.
C1 [Su, Li; Zhai, Rihong; Sheu, Chau-Chyun; Tejera, Paula; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Gallagher, Diana C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02115 USA.
[Gong, Michelle N.] Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY USA.
[Thompson, B. Taylor; Christiani, David C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA 02115 USA.
RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM dchris@hsph.harvard.edu
FU National Institute of Health [HL60710, ES00002]; Flight Attendant
Medical Research Institute [062459-YCSA]
FX This research was supported by grants from National Institute of Health
(HL60710, ES00002) and Flight Attendant Medical Research Institute
(062459-YCSA). The authors would like to thank Weiling Zhang, Kelly
McCoy, Thomas McCabe, Julia Shin, and Hanae Fujii-Rios for patient
recruitment; Andrea Shafer and Starr Sumpter for research support;
Maureen Convery for laboratory expertise; Janna Frelich for data
management; and the patients and staff of ICUs at Massachusetts General
Hospital.
NR 38
TC 31
Z9 35
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD JUN
PY 2009
VL 35
IS 6
BP 1024
EP 1030
DI 10.1007/s00134-009-1413-8
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 450EW
UT WOS:000266384800010
PM 19271210
ER
PT J
AU Johnson, E
Ricketts, T
Hornsby, B
AF Johnson, Earl
Ricketts, Todd
Hornsby, Benjamin
TI The effect of extending high-frequency bandwidth on the Acceptable Noise
Level (ANL) of hearing-impaired listeners
SO INTERNATIONAL JOURNAL OF AUDIOLOGY
LA English
DT Article
CT Annual Meeting of the American-Auditory-Society
CY MAR 04-06, 2007
CL Scottsdale, AZ
SP Amer Auditory Soc
DE Acceptable noise level; Background noise; Bandwidth; Reverberation;
Hearing aid outcome; Hearing aid usage
ID BINAURAL SPEECH-PERCEPTION; BACKGROUND-NOISE; SOUND QUALITY; MEDIAN
PLANE; AID USE; REVERBERATION; INTELLIGIBILITY; AMPLIFICATION;
LOCALIZATION; CANCELLATION
AB This study examined the effects of extending high-frequency bandwidth, for both a speech signal and a background noise, on the acceptable signal-to-noise ratio (SNR) of listeners with mild sensorineural hearing loss through utilization of the Acceptable Noise Level (ANL) procedure. In addition to extending high-frequency bandwidth. the effects of reverberation time and background noise type and shape were also examined. The study results showed a significant increase in the mean ANL (i.e, participants requested a better SNR for an acceptable listening situation) when high-frequency bandwidth was extended from 3 to 9 kHz and from 6 to 9 kHz. No change in the ANL of study participants was observed as a result of isolated modification to reverberation time or background noise stimulus. An interaction effect. however, of reverberation time and background noise Stimulus was demonstrated, These Findings may have implications for future design of hearing aid memory programs for listening to speech in the presence of broadband background noise.
C1 [Johnson, Earl] US Dept Vet Affairs, Tennessee Med Ctr, Mountain Home, TN 37684 USA.
[Johnson, Earl] E Tennessee State Univ, Johnson City, TN 37614 USA.
[Ricketts, Todd; Hornsby, Benjamin] Vanderbilt Univ, Vanderbilt Bill Wilkerson Ctr, Nashville, TN USA.
RP Johnson, E (reprint author), US Dept Vet Affairs, Tennessee Med Ctr, POB 4000,Audiol 126, Mountain Home, TN 37684 USA.
EM earl.johnson@va.gov
NR 56
TC 9
Z9 9
U1 1
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1499-2027
J9 INT J AUDIOL
JI Int. J. Audiol.
PD JUN
PY 2009
VL 48
IS 6
BP 353
EP 362
DI 10.1080/14992020802662964
PG 10
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 478GT
UT WOS:000268576500005
PM 19925343
ER
PT J
AU Nitin, N
Carlson, AL
Muldoon, T
El-Naggar, AK
Gillenwater, A
Richards-Kortum, R
AF Nitin, Nitin
Carlson, Alicia L.
Muldoon, Tim
El-Naggar, Adel K.
Gillenwater, Ann
Richards-Kortum, Rebecca
TI Molecular imaging of glucose uptake in oral neoplasia following topical
application of fluorescently labeled deoxy-glucose
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE molecular imaging; fluorescent glucose analogs; oral cancer; epithelial
cancer
ID IN-VIVO; VIABILITY ASSESSMENT; DEOXYGLUCOSE ANALOG; ESCHERICHIA-COLI;
CONTRAST AGENTS; CANCER; METABOLISM; 2-NBDG; CELLS; PET
AB The clinical value of assessing tumor glucose metabolism via F-18 fluorodeoxyglucose (FDG) PET imaging in oncology is well established; however, the poor spatial resolution of PET is a significant limitation especially for early stage lesions. An alternative technology is optical molecular imaging, which allows for subcellular spatial resolution and can be effectively used with topical contrast agents for imaging epithelial derived cancers. The goal of this study was to evaluate the potential of optical molecular imaging of glucose metabolism to aid in early detection of oral neoplasia. Fluorescently labeled deoxyglucose (2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose)) was applied topically to tissue phantoms, fresh oral biopsies (n = 32) and resected tumors specimens (n = 2). High-resolution imaging results show that 2-NBDG can be rapidly delivered to oral epithelium using topical application. In normal epithelium, the uptake of 2-NBDG is limited to basal epithelial cells. In contrast, high-grade dysplasia and cancers show uptake of 2-NBDG in neoplastic cells throughout the lesion. Following 2-NBDG labeling, the mean fluorescence intensity of neoplastic tissue averages 3.7 times higher than that of matched nonneoplastic oral biopsies in samples from 20 patients. Widefield fluorescence images of 8-paired oral specimens were obtained pre and postlabeling with 2-NBDG. Prior to labeling, neoplastic samples showed significantly lower autofluorescence than nonneoplastic samples. The fluorescence of neoplastic samples increased dramatically after labeling; the differential increase in fluorescence was on average 30 times higher in neoplastic samples than in normal samples. Topical application of 2-NBDG can therefore provide image contrast in both widefield and high-resolution fluorescence imaging modalities, highlighting its potential in early detection of oral neoplasia. (C) 200 Wiley-Liss, Inc.
C1 [Muldoon, Tim; Richards-Kortum, Rebecca] Rice Univ, Dept Bioengn, Houston, TX 77005 USA.
[Nitin, Nitin] SW Res Inst, Dept Microencapsulat & Biomat, San Antonio, TX USA.
[Carlson, Alicia L.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[El-Naggar, Adel K.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Gillenwater, Ann] Univ Texas Houston, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
RP Richards-Kortum, R (reprint author), Rice Univ, Dept Bioengn, 6100 Main St, Houston, TX 77005 USA.
EM rkortum@rice.edu
RI Nitin, Nitin/I-6422-2013; Richards-Kortum, Rebecca/P-4074-2014
OI Richards-Kortum, Rebecca/0000-0003-2347-9467
FU NCI [BRP R01CA103830]
FX NCI: Grant number: BRP R01CA103830.
NR 36
TC 39
Z9 41
U1 1
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 1
PY 2009
VL 124
IS 11
BP 2634
EP 2642
DI 10.1002/ijc.24222
PG 9
WC Oncology
SC Oncology
GA 442NT
UT WOS:000265848600015
PM 19173294
ER
PT J
AU Garcia, JA
Movassaghi, B
Casserly, IP
Klein, AJ
Chen, SYJ
Messenger, JC
Hansgen, A
Wink, O
Groves, BM
Carroll, JD
AF Garcia, Joel A.
Movassaghi, Babak
Casserly, Ivan P.
Klein, Andrew J.
Chen, S. -Y. James
Messenger, John C.
Hansgen, Adam
Wink, Onno
Groves, Bertron M.
Carroll, John D.
TI Determination of optimal viewing regions for X-ray coronary angiography
based on a quantitative analysis of 3D reconstructed models
SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
LA English
DT Article
DE Angiography; Imaging; Radiography; Optimal view map, coronary;
Three-dimensional
ID ARTERIAL TREE
AB Current expert-recommended views for coronary angiography are based on heuristic experience and have not been scientifically studied. We sought to identify optimal viewing regions for first and second order vessel segments of the coronary arteries that provide optimal diagnostic value in terms of minimizing vessel foreshortening and overlap. Using orthogonal 2D images of the coronary tree, 3D models were created from which patient-specific optimal view maps (OVM) allowing quantitative assessment of vessel foreshortening and overlap were generated. Using a novel methodology that averages 3D-based optimal projection geometries, a universal OVM was created for each individual coronary vessel segment that minimized both vessel foreshortening and overlap. A universal OVM model for each coronary segment was generated based on data from 137 patients undergoing coronary angiography. We identified viewing regions for each vessel segment achieving a mean vessel foreshortening value of 5.8 +/- A 3.9% for the left coronary artery (LCA) and 5.6 +/- A 3.6% for the right coronary artery (RCA). The overall mean overlap values achieved were 8.7 +/- A 7.9% for the LCA and 4.6 +/- A 3.2% for the RCA. This scientifically-based OVM evaluation of coronary vessel segments provides the means to facilitate acquisitions during coronary angiography and interventions that minimize imaging inaccuracies related to foreshortening and overlap, improving the accuracy, efficiency, and safety of diagnostic and interventional coronary procedures.
C1 [Garcia, Joel A.; Casserly, Ivan P.; Klein, Andrew J.; Chen, S. -Y. James; Messenger, John C.; Hansgen, Adam; Groves, Bertron M.; Carroll, John D.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA.
[Garcia, Joel A.] Denver Hlth Med Ctr, Denver, CO 80204 USA.
[Movassaghi, Babak; Wink, Onno] PMS, Clin Res, Denver, CO USA.
[Casserly, Ivan P.] Denver VA Med Ctr, Div Cardiol, Denver, CO 80220 USA.
RP Garcia, JA (reprint author), Univ Colorado, Hlth Sci Ctr, Div Cardiol, 4200 E 9th Ave,Box B-132, Denver, CO 80262 USA.
EM joel.garcia@dhha.org
FU Philips Medical Systems
FX John D. Carroll, M. D and S.-Y. James Chen, Ph. D. are Co-inventor of
patented 3-D vascular reconstruction and analysis software. The patents
have been assigned to the University of Chicago and the University of
Colorado. They both received Research grants from Philips Medical
Systems.
NR 17
TC 11
Z9 11
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1569-5794
J9 INT J CARDIOVAS IMAG
JI Int. J. Cardiovasc. Imaging
PD JUN
PY 2009
VL 25
IS 5
BP 455
EP 462
DI 10.1007/s10554-008-9402-5
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 446TV
UT WOS:000266145000002
PM 19101820
ER
PT J
AU Dinh, T
Scovell, S
Veves, A
AF Dinh, Thanh
Scovell, Sherry
Veves, Aristidis
TI Peripheral Arterial Disease and Diabetes: A Clinical Update
SO INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS
LA English
DT Review
DE diabetic foot; peripheral arterial disease; microvascular reactivity
ID CRITICAL LIMB ISCHEMIA; VENOUS LEG ULCERS; VASCULAR-DISEASE;
LOWER-EXTREMITY; FOOT; NEUROPATHY; BYPASS; ANGIOPLASTY; EXPRESSION;
MELLITUS
AB Peripheral arterial disease is characterized by a gradual reduction in blood to the extremities secondary to atherosclerosis. In diabetes, the pattern of atherosclerotic occlusion typically shows a propensity toward the infrapopliteal vessels. Additionally, impairment of the microcirculation manifests in diminished vasoreactivity and a functional ischemia that is not always correctable with surgery. However, when a nonhealing wound is complicated by peripheral arterial disease, revascularization is paramount to wound healing. Revascularization can be accomplished through traditional bypass surgery or newer endovascular interventions, such as angioplasty and stenting. These less invasive techniques of revascularization offer the advantages of quicker recovery and lower morbidity but durability may be compromised. Ultimately, the choice of revascularization procedure should be based on the clinical characteristics of the atherosclerotic lesion along with the individual patient history.
C1 [Dinh, Thanh; Veves, Aristidis] Harvard Univ, Beth Israel Deaconess Med Ctr, Microcirculat Lab, Sch Med, Boston, MA 02215 USA.
[Dinh, Thanh; Veves, Aristidis] Harvard Univ, Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, Sch Med, Boston, MA 02215 USA.
[Scovell, Sherry] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Veves, A (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Microcirculat Lab, Sch Med, Palmer 318,West Campus,1 Deaconess Rd, Boston, MA 02215 USA.
EM aveves@bidmc.harvard.edu
NR 44
TC 11
Z9 12
U1 3
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7346
J9 INT J LOW EXTR WOUND
JI Int. J. Low. Extrem. Wounds
PD JUN
PY 2009
VL 8
IS 2
BP 75
EP 81
DI 10.1177/1534734609336768
PG 7
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V20CZ
UT WOS:000208119400006
PM 19443896
ER
PT J
AU Song, JY
Chen, KY
Kim, SY
Kim, MR
Ryu, KS
Cha, JH
Kang, CS
MacLaughlin, DT
Kim, JH
AF Song, Jae Yen
Chen, Keun Young
Kim, Sue Yeon
Kim, Mee Ran
Ryu, Ki Sung
Cha, Jung Ho
Kang, Chang Suk
MacLaughlin, David T.
Kim, Jang Heub
TI The expression of Mullerian inhibiting substance/anti-Mullerian hormone
type II receptor protein and mRNA in benign, borderline and malignant
ovarian neoplasia
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE Mullerian inhibiting substance; Mullerian inhibiting
substance/anti-Mullerian hormone type II receptor; ovarian neoplasia;
immuno-histochemistry; in situ hybridization
ID CANCER CELL-GROWTH; IN-VIVO; DUCT REGRESSION; BETA-CATENIN;
TUMOR-GROWTH; PATHWAY; TARGET; BREAST; VITRO; ALK2
AB This study investigated the expression patterns of Mullerian inhibiting substance/anti-Mullerian hormone type II receptor (MIS/AMHRII) and mRNA in various types of ovarian neoplasia and evaluated the clinical significance of MIS/AMH as a biological response modifier for MIS/AMHR-positive tumors. Reverse transcriptase polymerase chain reaction was used to detect MIS/AMHRII mRNA expression and in situ hybridization and immunohistochemistry were used to localize MIS/AMHRII mRNA and protein expression. The degree of expression was scored from 0 (no staining) to 3 (strong staining). There was no significant difference in expression intensity between MIS/AMHRII protein and mRNA on all ovarian samples whether benign or malignant. MIS/AMHRII protein and mRNA were weakly expressed on 45.45% of benign ovarian tumors. In borderline tumors, expression rates of MIS/AMHRII protein and mRNA were 77.78% with score 1.22 and 55.56% with score 1, respectively. In malignant ovarian tumors, expression rates of MIS/AMHRII protein and mRNA were 70% with score 1.23 and 75% with score 1.43, respectively. Among malignant ovarian tumors, sex cord stromal tumors showed the highest expression rate and the strongest intensity of MIS/AMHRII protein and mRNA followed by germ cell tumor and epithelial ovarian tumor. Non-epithelial malignant tumors showed stronger expression than that of epithelial tumors (P<0.05, P<0.001, respectively). In serous borderline malignant and malignant tumors, MIS/AMHRII protein and mRNA expression was 63.64 and 81.82% with expression intensity of 1.27 and 1.46, respectively, which were not statistically different from non-epithelial malignant tumors. MIS/AMHRII and MIS/AMHRII mRNA demonstrate significantly variable expression among different ovarian tumor types. Non-epithelial cell tumors show higher expression than those of epithelial cell tumors. The highest expression rate and intensity were observed on sex cord stromal tumors. MIS/AMHRII expression was not different according to the differentiation, but showed tissue-type specificity. These data support that MIS/AMH may be used as a biological modifier or therapeutic modulator in MIS/AMHRII-expressed ovarian tumors.
C1 [Song, Jae Yen; Chen, Keun Young; Kim, Sue Yeon; Kim, Mee Ran; Ryu, Ki Sung; Kim, Jang Heub] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 150713, South Korea.
[Cha, Jung Ho] Catholic Univ Korea, Coll Med, Dept Anat, Seoul 150713, South Korea.
[Kang, Chang Suk] Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 150713, South Korea.
[MacLaughlin, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Surg Res Labs, Boston, MA USA.
RP Kim, JH (reprint author), Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, 62 Yeouido Dong, Seoul 150713, South Korea.
EM janghkim@catholic.ac.kr
NR 33
TC 11
Z9 14
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUN
PY 2009
VL 34
IS 6
BP 1583
EP 1591
DI 10.3892/ijo_00000288
PG 9
WC Oncology
SC Oncology
GA 447FB
UT WOS:000266175900013
PM 19424576
ER
PT J
AU Yin, L
Kharbanda, S
Kufe, D
AF Yin, Li
Kharbanda, Surender
Kufe, Donald
TI MUC1 oncoprotein promotes autophagy in a survival response to glucose
deprivation
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE MUC1; glucose deprivation; oxidative stress; autophagy; ATG7; LC3-II;
AMP-activated protein kinase
ID CARCINOMA-ASSOCIATED ANTIGEN; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR
RECEPTOR; OXIDATIVE STRESS; BETA-CATENIN; CELL-DEATH; C-SRC; INDUCED
CYTOTOXICITY; TRANSCRIPTION FACTOR; APOPTOTIC RESPONSE
AB Tumor cells survive under conditions of nutrient deprivation by mechanisms that are not fully understood. The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and blocks oxidative stress-induced death. The present studies show that MUC1 inhibits the induction of necrosis in response to the deprivation of glucose. MUC1 suppressed glucose deprivation-induced increases in reactive oxygen species (ROS) and thereby depletion of ATP and cell death. Cells respond to oxidative stress and energy depletion with the induction of autophagy. Our results demonstrate that MUC1 blocks depletion of ATP and sustains growth of glucose-deprived cells by a mechanism sensitive to the autophagy inhibitor, 3-methyladenine. Silencing expression of ATG7, a protein essential for the formation of autophagic vacuoles, also attenuated the MUC1-sustained increases in ATP and growth in response to glucose deprivation. Moreover, we found that MUC1 stimulates AMPK activation and thereby promotes lysosomal turnover of LC3-II, a marker of starvation-induced autophagic activity. These results indicate that MUC1 suppresses glucose deprivation-induced increases in ROS and thereby promotes ATP production and survival. The findings also indicate that the overexpression of MUC1 as found in human cancers could provide a survival advantage in microenvironments with low glucose levels.
C1 [Yin, Li; Kharbanda, Surender; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Kufe, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM donald_kufe@dfci.harvard.edu
FU National Cancer Institute [CA42802, CA97098]
FX This work was supported by Grants CA42802 and CA97098 awarded by the
National Cancer Institute.
NR 66
TC 32
Z9 33
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUN
PY 2009
VL 34
IS 6
BP 1691
EP 1699
DI 10.3892/ijo_00000300
PG 9
WC Oncology
SC Oncology
GA 447FB
UT WOS:000266175900025
PM 19424588
ER
PT J
AU Lawton, CAF
Michalski, J
El-Naqa, I
Kuban, D
Lee, WR
Rosenthal, SA
Zietman, A
Sandler, H
Shipley, W
Ritter, M
Valicenti, R
Catton, C
Roach, M
Pisansky, TM
Seider, M
AF Lawton, Colleen A. F.
Michalski, Jeff
El-Naqa, Issam
Kuban, Deborah
Lee, W. Robert
Rosenthal, Seth A.
Zietman, Anthony
Sandler, Howard
Shipley, William
Ritter, Mark
Valicenti, Richard
Catton, Charles
Roach, Mack, III
Pisansky, Thomas M.
Seider, Michael
TI VARIATION IN THE DEFINITION OF CLINICAL TARGET VOLUMES FOR PELVIC NODAL
CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Prostate cancer; Pelvic lymph nodes; Target volume
ID EXTERNAL-BEAM RADIOTHERAPY; PHASE-III TRIAL; ANDROGEN SUPPRESSION;
NEOADJUVANT; IRRADIATION; DEPRIVATION; ADJUVANT
AB Purpose: We conducted a comparative study of clinical target volume (CTV) definition of pelvic lymph nodes by multiple genitourinary (GU) radiation oncologists looking at the levels of discrepancies amongst this group.
Methods and Materials: Pelvic computed tomography (CT) scans from 2 men were distributed to 14 Radiation Therapy Oncology Group GU radiation oncologists with instructions to define CTVs for the iliac and presacral lymph nodes. The CT data with contours were then returned for analysis. In addition, a questionnaire was completed that described the physicians' method for target volume definition.
Results: Significant variation in the definition of the iliac and presacral CTVs was seen among the physicians. The minimum, maximum, mean (SD) iliac volumes (mL) were 81.8, 876.6, 337.6 +/- 203 for case 1 and 60.3, 627.7, 251.8 +/- 159.3 for case 2. The volume of 100% agreement was 30.6 and 17.4 for case 1 and 2 and the volume of the union of all contours was 1,012.0 and 807.4 forcase 1 and 2, respectively. The overall agreement was judged to be moderate in both cases (kappa = 0.53 (p < 0.0001) and kappa = 0.48 (p < 0.0001). There was no volume of 100% agreement for either of the two presacral volumes. These variations were confirmed in the responses to the associated questionnaire.
Conclusions: Significant disagreement exists in the definition of the CTV for pelvic nodal radiation therapy among GU radiation oncology specialists. A consensus needs to be developed so as to accurately assess the merit and safety of such treatment. (C) 2009 Elsevier Inc.
C1 [Lawton, Colleen A. F.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Michalski, Jeff] Washington Univ, St Louis, MO USA.
[El-Naqa, Issam] Mallinckrodt Inst Radiol, St Louis, MO USA.
[Kuban, Deborah] MD Anderson, Houston, TX USA.
[Lee, W. Robert] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
[Rosenthal, Seth A.] Radiol Associates Sacramento, Radiat Oncol Ctr, Sacramento, CA USA.
[Zietman, Anthony; Shipley, William] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sandler, Howard] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Ritter, Mark] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Valicenti, Richard] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Catton, Charles] Princess Margaret Hosp, Toronto, ON, Canada.
[Roach, Mack, III] UCSF Comprehens Canc Ctr, San Francisco, CA USA.
[Pisansky, Thomas M.] Mayo Clin, Rochester, MN USA.
[Seider, Michael] Akron City Hosp, Akron, OH USA.
RP Lawton, CAF (reprint author), Med Coll Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM clawton@mcw.edu
FU NCI NIH HHS [U24 CA081647, U24 CA081647-11, U24 CA81647]
NR 12
TC 27
Z9 28
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2009
VL 74
IS 2
BP 377
EP 382
DI 10.1016/j.ijrobp.2008.08.003
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 445NQ
UT WOS:000266057900008
PM 18947941
ER
PT J
AU Sher, DJ
Wittenberg, E
Suh, WW
Taghian, AG
Punglia, RS
AF Sher, Davit J.
Wittenberg, Eve
Suh, W. Warren
Taghian, Alphonse G.
Punglia, Rinaa S.
TI PARTIAL-BREAST IRRADIATION VERSUS WHOLE-BREAST IRRADIATION FOR
EARLY-STAGE BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article; Proceedings Paper
CT 44th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2008
CL Chicago, IL
SP Amer Soc Clin Oncol
DE Breast cancer; Cost-effectiveness analysis; Partial-breast irradiation;
Whole-breast radiotherapy
ID ROUTINE RADIATION-THERAPY; CONSERVATIVE SURGERY; CONSERVING SURGERY;
DECISION-ANALYSIS; RANDOMIZED-TRIAL; RECURRENCE; RADIOTHERAPY;
CARCINOMA; SURVIVAL
AB Purpose: Accelerated partial-breast irradiation (PBI) is a new treatment paradigm for patients with early-stage breast cancer. Although PBI may lead to greater local recurrence rates, it may be cost-effective because of better tolerability and lower cost. We aim to determine the incremental cost-effectiveness of PBI compared with whole-breast radiation therapy (WBRT) for estrogen receptor-positive postmenopausal women treated for early-stage breast cancer.
Methods and Materials: We developed a Markov model to describe health states in the 15 years after radiotherapy for early-stage breast cancer. External beam (EB) and MammoSite (MS) PBI were considered and assumed to be equally effective, but carried different costs. Patients received tamoxifen, but not chemotherapy. Utilities, recurrence risks, and costs were adapted from the literature; the baseline utility for no disease after radiotherapy was set at 0.92. Probabilistic sensitivity analyses were performed to model uncertainty in the PBI hazard ratio, recurrence pattern, and patient utilities. Costs (in 2004 US dollars) and quality-adjusted life-years were discounted at 3%/y.
Results: The incremental cost-effectiveness ratio for WBRT compared with EB-PBI was $630,000/quality-adjusted life-year; WBRT strongly dominated MS-PBI. One-way sensitivity analysis found that results were sensitive to PBI hazard ratio, recurrence pattern, baseline recurrence risk, and no evidence of disease PBI utility values. Probabilistic sensitivity showed that EB-PBI was the most cost-effective technique over a wide range of assumptions and societal willingness-to-pay values.
Conclusions: EB-PBI was the most cost-effective strategy for postmenopausal women with early-stage breast cancer. Unless the quality of life after MS-PBI proves to be superior, it is unlikely to be cost-effective. (C) 2009 Elsevier Inc.
C1 [Suh, W. Warren; Punglia, Rinaa S.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Suh, W. Warren; Punglia, Rinaa S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Sher, Davit J.] Harvard Radiat Oncol Program, Boston, MA USA.
[Wittenberg, Eve] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA.
[Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Punglia, RS (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM rpunglia@lroc.harvard.edu
FU NCI NIH HHS [K07 CA118269-02, K07 CA118269, 1K07 CA118629]
NR 23
TC 37
Z9 37
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2009
VL 74
IS 2
BP 440
EP 446
DI 10.1016/j.ijrobp.2008.08.015
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 445NQ
UT WOS:000266057900018
PM 18963542
ER
PT J
AU Zhang, F
Haberer, J
Wei, H
Wang, N
Chu, A
Zhao, Y
Zhao, H
AF Zhang, F.
Haberer, J.
Wei, H.
Wang, N.
Chu, A.
Zhao, Y.
Zhao, H.
TI Drug resistance in the Chinese National Pediatric Highly Active
Antiretroviral Therapy Cohort: implications for paediatric treatment in
the developing world
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE paediatric; drug resistance; highly active antiretroviral therapy
ID CHILDREN
AB China's National Pediatric ART Program began in 2005, in which 32 ART-experienced and 51 antiretroviral therapy (ART)-naive children received paediatric formulations of (zidovudine or stavudine) plus lamivudine plus (nevirapine or efavirenz). Reverse transcriptase sequencing and analysis was performed on plasma samples with > 1000 HIV copies/mL after one year of treatment. Thirty-four samples were sequenced. Nearly all patients had nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor mutations. High/intermediate resistance was found to lamivudine/emtricitabine in 31 patients; to didanosine, abacavir, stavudine and zidovudine in 18 patients; and to tenofovir in 11 patients. All had high-level resistance to nevirapine; all but one had high/intermediate-level resistance to efavirenz. Viral load was the only cohort characteristic significantly associated with developing resistance. Resistance to zidovudine, stavudine and tenofovir was more common in ART-experienced versus ART-naive patients (P = 0.02-0.05). Drug resistance is high in this cohort. Second-line therapy will require additional ART strategies and options, which are currently unavailable in most developing settings.
C1 [Zhang, F.; Haberer, J.; Wang, N.; Chu, A.; Zhao, Y.] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Kunming, Peoples R China.
[Zhang, F.; Wei, H.; Zhao, H.] Beijing Ditan Hosp, Beijing, Peoples R China.
[Haberer, J.] Massachusetts Gen Hosp, Boston, MA 02138 USA.
RP Haberer, J (reprint author), Harvard Initiat Global Hlth, 104 Mt Auburn St,3rd Floor, Cambridge, MA 02138 USA.
EM jhaberer@partners.org
FU Chinese Ministry of Science and Technology [2004BA719A11]; Chinese
National Basic Research Program [973:2006CB504201]; United States
National Institutes of Health [U2RTW006918]; Stanford University
FX The authors would like to thank the clinical and public health staff in
Shangcai County, Henan, the staff at the Shangcai County CDC and Beijing
Ditan Hospital laboratories, and Drs. David Katzenstein and Nancy
Shulman at Stanford University. This study was funded by the Chinese
Ministry of Science and Technology Grant (2004BA719A11), Chinese
National Basic Research Program (973:2006CB504201) and United States
National Institutes of Health (U2RTW006918). Alex Chu and Nancy Wang
were supported partly by Stanford University.
NR 16
TC 10
Z9 15
U1 0
U2 6
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD JUN
PY 2009
VL 20
IS 6
BP 406
EP 409
DI 10.1258/ijsa.2008.008357
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 459WR
UT WOS:000267143900009
PM 19451326
ER
PT J
AU Patel, SP
Bourne, WM
AF Patel, Sangita P.
Bourne, William M.
TI Corneal Endothelial Cell Proliferation: A Function of Cell Density
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DONORS; YOUNG
AB PURPOSE. To determine how stimuli that increase corneal endothelial cell proliferation of human corneas in culture relate to changes in endothelial cell density in the central and peripheral cornea.
METHODS. Human donor cadaver corneas not suitable for transplantation were divided into four pie-shaped wedges and incubated at 37 degrees C in medium supplemented with fetal bovine serum, epidermal growth factor, fibroblast growth factor, and gentamicin. To promote a proliferative response, samples were treated with EDTA at concentrations of 0, 0.5, 2.5, and 5.0 mM for 1 hour and then returned to culture medium. Endothelial cell proliferation was assayed with Ki-67 immunolocalization 48 and 96 hours after EDTA treatment. Samples were mounted with propidium iodide or DAPI. The total number of cells and the number of Ki-67-positive cells were counted in three regions, defined as central, mid, and peripheral cornea, to determine endothelial cell density and percentage of proliferation.
RESULTS. A proliferative response to EDTA was not found. However, increased proliferation was noted in the central compared with the peripheral corneal region. Unexpectedly, the increased proliferation in the central region corresponded to a trend of lower endothelial cell density in the central region compared with the peripheral region. Corneal endothelial cell proliferation under our culture conditions is noted primarily when cell density is less than 2000 cells/mm(2).
CONCLUSIONS. Corneal endothelial cell proliferation under our culture conditions does not lead to supranormal endothelial cell density. Rather, cell proliferation is noted in those regions that may be experiencing a greater burden of cell loss. (Invest Ophthalmol Vis Sci. 2009; 50: 2742-2746) DOI: 10.1167/iovs.08-3002
C1 [Patel, Sangita P.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Bourne, William M.] Mayo Clin, Rochester, MN USA.
RP Patel, SP (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM sangitapatel@meei.harvard.edu
OI Patel, Sangita/0000-0001-6969-490X
FU National Eye Institute [EY02037]; Research to Prevent Blindness; Mayo
Foundation
FX Supported by National Eye Institute Grant EY02037, Research to Prevent
Blindness, and the Mayo Foundation.
NR 13
TC 11
Z9 12
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2742
EP 2746
DI 10.1167/iovs.08-3002
PG 5
WC Ophthalmology
SC Ophthalmology
GA 450ME
UT WOS:000266403800031
PM 19218607
ER
PT J
AU Von Zee, CL
Richards, MP
Bu, P
Perlman, JI
Stubbs, EB
AF Von Zee, Cynthia L.
Richards, Michael P.
Bu, Ping
Perlman, Jay I.
Stubbs, Evan B., Jr.
TI Increased RhoA and RhoB Protein Accumulation in Cultured Human
Trabecular Meshwork Cells by Lovastatin
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COENZYME-A REDUCTASE; GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; OUTFLOW
FACILITY; MEVALONATE PATHWAY; FOCAL ADHESIONS; ANIMAL-MODEL; RAS;
GTPASES; PRENYLATION
AB PURPOSE. This study aimed to determine the effect of lovastatin on Rho G-protein expression and activation in human trabecular meshwork (TM) cells.
METHODS. Confluent cultures of low-passage (primary) or transformed (GTM3) human TM cells were incubated overnight with vehicle (0.01% ethanol) or activated lovastatin (10 mu M). Changes in Rho mRNA, protein content, and activation were quantified by qRT-PCR, immunoblotting, and ELISA, respectively. F-actin organization was determined using Alexa Fluor 488- conjugated phalloidin.
RESULTS. Low-passage or transformed TM cells treated with lovastatin exhibited marked increases in RhoA and RhoB mRNA and protein content. Actinomycin D prevented lovastatin-dependent increases in RhoB, but not RhoA, protein accumulation. In contrast, cycloheximide prevented lovastatin from increasing both RhoA and RhoB. Supplementation with mevalonate or geranylgeranyl pyrophosphate prevented, whereas inhibition of geranylgeranyl transferase mimicked, the effects of lovastatin on RhoA and RhoB accumulation. The effect of lovastatin was dose dependent, with newly synthesized protein accumulating in the cytosol. The amount of functionally active (GTP-bound) RhoA in cell lysates was significantly reduced by lovastatin. Lovastatin altered the morphology of TM cells by disrupting F-actin organization.
CONCLUSIONS. Lovastatin enhances the accumulation of RhoA and RhoB in human TM cells, in part, by limiting geranylgeranyl isoprenylation of these G-proteins. We propose that post-translational geranylgeranylation serves as a regulator of both RhoA and RhoB protein expression and processing in human TM cells. Increased accumulation of unprenylated forms of RhoA and RhoB may disrupt Rho-dependent regulation of TM cell cytoskeletal organization. (Invest Ophthalmol Vis Sci. 2009; 50: 2816-2823) DOI: 10.1167/iovs.08-2466
C1 [Von Zee, Cynthia L.; Richards, Michael P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
[Perlman, Jay I.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA.
[Stubbs, Evan B., Jr.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA.
[Bu, Ping; Perlman, Jay I.; Stubbs, Evan B., Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Ophthalmol, Maywood, IL USA.
[Perlman, Jay I.] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL USA.
[Von Zee, Cynthia L.; Stubbs, Evan B., Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL USA.
RP Stubbs, EB (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv 151, 5th & Roosevelt, Hines, IL 60141 USA.
EM evan.stubbs@med.va.gov
FU Department of Veterans Affairs [C3638R]; Illinois Society for the
Prevention of Blindness; Richard A. Peritt Charitable Foundation
FX Supported in part by grants from the Department of Veterans Affairs
(C3638R), the Illinois Society for the Prevention of Blindness, and the
Richard A. Peritt Charitable Foundation. CVZ is a recipient of a
Pre-Doctoral Associated Health Rehabilitation Research Fellowship from
the Department of Veterans Affairs.
NR 39
TC 9
Z9 9
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2816
EP 2823
DI 10.1167/iovs.08-2466
PG 8
WC Ophthalmology
SC Ophthalmology
GA 450ME
UT WOS:000266403800040
PM 19151402
ER
PT J
AU Sarwar, A
Shaw, LJ
Shapiro, MD
Blankstein, R
Hoffman, U
Cury, RC
Abbara, S
Brady, TJ
Budoff, MJ
Blumenthal, RS
Nasir, K
AF Sarwar, Ammar
Shaw, Leslee J.
Shapiro, Michael D.
Blankstein, Ron
Hoffman, Udo
Cury, Ricardo C.
Abbara, Suhny
Brady, Thomas J.
Budoff, Matthew J.
Blumenthal, Roger S.
Nasir, Khurram
TI Diagnostic and Prognostic Value of Absence of Coronary Artery
Calcification
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE computed tomography; coronary calcification; outcomes; meta-analysis
ID BEAM COMPUTED-TOMOGRAPHY; RANDOMIZED CONTROLLED-TRIAL; ACUTE CHEST-PAIN;
MYOCARDIAL-ISCHEMIA; RISK-FACTORS; ASYMPTOMATIC INDIVIDUALS;
CARDIOVASCULAR EVENTS; HEART-DISEASE; CALCIUM SCORE; SUBCLINICAL
ATHEROSCLEROSIS
AB OBJECTIVES In this study, we systematically assessed the diagnostic and prognostic value of absence of coronary artery calcification (CAC) in asymptomatic and symptomatic individuals. BACKGROUND Presence of CAC is a well-established marker of coronary plaque burden and is associated with a higher risk of adverse cardiovascular outcomes. Absence of CAC has been suggested to be associated with a very low risk of significant coronary artery disease, as well as minimal risk of future events.
METHODS We searched online databases ( e. g., PubMed and MEDLINE) for original research articles published in English between January 1990 and March 2008 examining the diagnostic and prognostic utility of CAC.
RESULTS A systematic review of published articles revealed 49 studies that fulfilled our criteria for inclusion. These included 13 studies assessing the relationship of CAC with adverse cardiovascular outcomes in 64,873 asymptomatic patients. In this cohort, 146 of 25,903 patients without CAC (0.56%) had a cardiovascular event during a mean follow-up period of 51 months. In the 7 studies assessing the prognostic value of CAC in a symptomatic population, 1.80% of patients without CAC had a cardiovascular event. Overall, 18 studies demonstrated that the presence of any CAC had a pooled sensitivity and negative predictive value of 98% and 93%, respectively, for detection of significant coronary artery disease on invasive coronary angiography. In 4,870 individuals undergoing myocardial perfusion and CAC testing, in the absence of CAC, only 6% demonstrated any sign of ischemia. Finally, 3 studies demonstrated that absence of CAC had a negative predictive value of 99% for ruling out acute coronary syndrome.
CONCLUSIONS On the basis of our review of more than 85,000 patients, we conclude that the absence of CAC is associated with a very low risk of future cardiovascular events, with modest incremental value of other diagnostic tests in this very low-risk group. (J Am Coll Cardiol Img 2009; 2: 675-88) (C) 2009 by the American College of Cardiology Foundation
C1 [Sarwar, Ammar; Shapiro, Michael D.; Blankstein, Ron; Hoffman, Udo; Cury, Ricardo C.; Abbara, Suhny; Brady, Thomas J.; Nasir, Khurram] Massachusetts Gen Hosp, Cardiac PET CT MRI Program, Boston, MA 02114 USA.
[Sarwar, Ammar; Shapiro, Michael D.; Blankstein, Ron; Hoffman, Udo; Cury, Ricardo C.; Abbara, Suhny; Brady, Thomas J.; Nasir, Khurram] Harvard Univ, Sch Med, Baltimore, MD 21287 USA.
[Shaw, Leslee J.] Emory Univ, Dept Cardiol, Atlanta, GA 30322 USA.
[Budoff, Matthew J.] Univ Calif Los Angeles, Los Angeles Biomed Res Inst Harbor, Los Angeles, CA USA.
[Nasir, Khurram] Boston Med Ctr, Dept Internal Med, Boston, MA USA.
[Nasir, Khurram] Johns Hopkins Univ, Div Cardiol, Ciccarone Prevent Cardiol Ctr, Sch Med, Baltimore, MD 21287 USA.
RP Nasir, K (reprint author), Johns Hopkins Univ, Div Cardiol, Ciccarone Prevent Cardiol Ctr, Sch Med, Baltimore, MD 21287 USA.
EM knasir1@jhmi.edu
FU NHLBI NIH HHS [1 T32 HL076136-02]
NR 67
TC 251
Z9 260
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JUN
PY 2009
VL 2
IS 6
BP 675
EP 688
DI 10.1016/j.jcmg.2008.12.031
PG 14
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 725OD
UT WOS:000287654000001
PM 19520336
ER
PT J
AU Hajjiri, MM
Leavitt, MB
Zheng, H
Spooner, AE
Fischman, AJ
Gewirtz, H
AF Hajjiri, Mohammad M.
Leavitt, Marcia B.
Zheng, Hui
Spooner, Amy E.
Fischman, Alan J.
Gewirtz, Henry
TI Comparison of Positron Emission Tomography Measurement of
Adenosine-Stimulated Absolute Myocardial Blood Flow Versus Relative
Myocardial Tracer Content for Physiological Assessment of Coronary
Artery Stenosis Severity and Location
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE PET; myocardial blood flow; coronary artery disease
ID ISCHEMIC-HEART-DISEASE; VASODILATOR FUNCTION; N-13 AMMONIA; RESERVE;
HUMANS; PERFUSION; PET; QUANTIFICATION; HYPERLIPIDEMIA; PRESSURE
AB OBJECTIVES This study tests the hypothesis that absolute measurement of adenosine (Ado)stimulated myocardial blood flow (MBFado) is superior to measurement of relative tracer uptake for identification of hemodynamically significant coronary artery disease (CAD).
BACKGROUND Positron emission tomography measurement of absolute myocardial blood flow (MBF) ((13)N-ammonia) with Ado has the capability to more accurately assess hemodynamic severity of CAD than measurement of relative tracer content (TC) (nCi/ml) during Ado, which by definition depends on at least 1 normal zone to which others are compared.
METHODS A total of 27 patients (20 male, 58 +/- 11 years, mean +/- SD) with known or suspected CAD and 21 normal subjects (13 male, 38 +/- 10 years) were studied. Parametric (K1) MBF images and TC sum images were analyzed. A stenosis >= 70% defined significant CAD. The receiver-operator characteristic curve (ROC) analysis area under the curve (AUC) compared MBF and TC results. Cut-point analysis for sensitivity, specificity, and accuracy showed the best MBF criteria for CAD as MBFado <1.85 ml/min/g and the best TC as <70% maximum. The myocardial blood flow reserve ratio (MBFR) (optimal <2.0x) also was studied. R E S U L T S The ROC analysis of PET parameters showed that MBFado was superior to <70% maximum uptake for CAD detection (n = 144 vessels; AUC 0.900 vs. 0.690, respectively, p < 0.0001) and was marginally greater than MBFR (0.856; p = 0.10). For CAD cut-point analysis, MBFado accuracy exceeded TC (0.84 vs. 0.72, respectively, p = 0.005), as did sensitivity (0.81 vs. 0.48, respectively; p = 0.001). Specificity of MBFado for CAD classification (0.85) was comparable to TC (0.82; p = NS). Sensitivity, specificity, and predictive accuracy for MBFR were 0.62, 0.85, and 0.79, respectively. The difference in specificity was not significant versus MBFado. However, MBFado was more sensitive than MBFR (p = 0.01). The difference in predictive accuracy was borderline (p = 0.06) in favor of MBFado.
CONCLUSIONS Measurement of Ado-stimulated absolute MBF is superior to relative measurement of myocardial tracer retention for identification of CAD and can be accomplished with a single MBFado measurement. (J Am Coll Cardiol Img 2009; 2:751-8) (C) 2009 by the American College of Cardiology Foundation
C1 [Gewirtz, Henry] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Dept Med,Cardiac Unit Yawkey 5E, Boston, MA 02114 USA.
[Zheng, Hui] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA 02114 USA.
[Fischman, Alan J.] Shriner Burns Hosp, Dept Nucl Med, Boston, MA USA.
RP Gewirtz, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Dept Med,Cardiac Unit Yawkey 5E, 55 Fruit St, Boston, MA 02114 USA.
EM hgewirtz@partners.org
FU Astellas Pharma US
FX Supported in part by unrestricted grants from Astellas Pharma US to Dr.
Gewirtz.
NR 29
TC 69
Z9 69
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JUN
PY 2009
VL 2
IS 6
BP 751
EP 758
DI 10.1016/j.jcmg.2009.04.004
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 725OD
UT WOS:000287654000012
PM 19520347
ER
PT J
AU Chacko, R
Mulhearn, M
Novack, V
Novack, L
Mauri, L
Cohen, SA
Moses, J
Leon, MB
Cutlip, DE
AF Chacko, Riya
Mulhearn, Meredith
Novack, Victor
Novack, Lena
Mauri, Laura
Cohen, Sidney A.
Moses, Jeffrey
Leon, Martin B.
Cutlip, Donald E.
TI Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year
Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE stent; restenosis; atherosclerosis
ID NATIVE CORONARY-ARTERY; TRIALS; IMPLANTATION; MULTICENTER; EFFICACY;
SAFETY
AB Objectives We sought to compare patient-oriented outcomes related to target vessel or nontarget vessel events for sirolimus-eluting stents (SES) versus bare-metal stents.
Background SES significantly reduce restenosis but the influence of reduced restenosis on overall patient-oriented outcome has not been reported.
Methods The study population included 1,057 patients randomized in the SIRIUS (Sirolimus-Eluting Stent in De Novo Native Coronary Lesions) study and followed clinically for 5 years. The primary end point was a composite of all-cause mortality, any myocardial infarction, or any repeat revascularization. In secondary analyses, myocardial infarction and repeat revascularization events attributed to the target vessel or a nontarget vessel were compared by stent type.
Results Patients with an SES were more likely to be free from the primary composite end point at 5 years (60.4% vs. 47.8%, p < 0.001) chiefly due to a sustained reduction in target lesion revascularization for SES (cumulative incidence: 12.5% vs. 28.8%, p < 0.001). There was no difference in the cumulative incidence of myocardial infarction or revascularization attributed to remote segments of the target vessel. Events attributed to the nontarget vessel were frequent and not different for SES versus bare-metal stents (25.7% vs. 25.8%).
Conclusions The benefit of SES over bare-metal stents for reduced target lesion revascularization is maintained for 5 years. Remote coronary segments of the target vessel and nontarget vessel remain an important cause of future adverse events despite sustained restenosis benefit. (J Am Coll Cardiol Intv 2009;2:498-503) (c) 2009 by the American College of Cardiology Foundation
C1 [Chacko, Riya; Mulhearn, Meredith; Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Chacko, Riya; Mulhearn, Meredith; Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02215 USA.
[Novack, Victor; Novack, Lena; Mauri, Laura; Cutlip, Donald E.] Harvard Clin Res Inst, Boston, MA USA.
[Mauri, Laura] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA.
[Cohen, Sidney A.] Cordis Inc, Warren, NJ USA.
[Cohen, Sidney A.] Hosp Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA.
[Moses, Jeffrey; Leon, Martin B.] New York Presbyterian Hosp, Div Cardiol, New York, NY USA.
[Moses, Jeffrey; Leon, Martin B.] Columbia Univ, New York, NY USA.
RP Cutlip, DE (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.
EM dcutlip@bidmc.harvard.edu
FU Cordis, Inc; Abbott Vascular; Boston Scientific; Medtronic Vascular;
Cordis; Johnson Johnson; Medtronic
FX Division of Cardiology, New York Presbyterian Hospital and Columbia
University, New York, New York. Funded by a research grant from Cordis,
Inc. Dr. Mauri has received honoraria from Abbott Vascular, Boston
Scientific, Cordis, and Medtronic Vascular. Dr. Cohen is a full-time
employee of Cordis. Dr. Moses has received consulting fees from Johnson
& Johnson. Dr. Leon has received either consulting fees or honoraria
from Cordis, Boston Scientific, Medtronic, and Abbott Vascular.
NR 17
TC 24
Z9 24
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUN
PY 2009
VL 2
IS 6
BP 498
EP 503
DI 10.1016/j.jcin.2009.03.013
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 613HY
UT WOS:000278971200004
PM 19539252
ER
PT J
AU Alter, G
Kavanagh, D
Rihn, S
Martin, M
Carrington, M
Altfeld, M
AF Alter, Galit
Kavanagh, Daniel
Rihn, Suzannah
Martin, Maureen
Carrington, Mary
Altfeld, Marcus
TI NK cells: friends or foes?
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 11th Annual International Meeting of the Institute-of-Human-Virology
CY SEP 11-13, 2008
CL Univ Maryland Sch Med, Inst Human Virol, Bethesda, MD
SP Inst Human Virol
HO Univ Maryland Sch Med, Inst Human Virol
C1 [Alter, Galit; Kavanagh, Daniel; Rihn, Suzannah; Altfeld, Marcus] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.
[Alter, Galit; Kavanagh, Daniel; Rihn, Suzannah; Altfeld, Marcus] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.
[Alter, Galit; Kavanagh, Daniel; Rihn, Suzannah; Altfeld, Marcus] Harvard Med Sch Boston, Div AIDS, Boston, MA USA.
[Martin, Maureen; Carrington, Mary] SAIC Frederick Inc, Basic Res Program, Lab Genom Divers, Frederick, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2009
VL 51
SU 2
MA 124
BP 47
EP 47
DI 10.1097/01.qai.0000351081.04956.24
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 645RY
UT WOS:000281483700027
ER
PT J
AU Yan, N
Cherepanov, P
Daigle, JE
Alan
Lieberman, J
AF Yan, Nan
Cherepanov, Peter
Daigle, Janet E.
Alan
Lieberman, Judy
TI The SET complex acts as a barrier to autointegration of HIV-1
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 11th Annual International Meeting of the Institute-of-Human-Virology
CY SEP 11-13, 2008
CL Univ Maryland Sch Med, Inst Human Virol, Bethesda, MD
SP Inst Human Virol
HO Univ Maryland Sch Med, Inst Human Virol
C1 [Cherepanov, Peter] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA.
[Daigle, Janet E.; Alan] Univ London Imperial Coll Sci Technol & Med, Div Med, London SW7 2AZ, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2009
VL 51
SU 2
MA 158
BP 81
EP 81
DI 10.1097/01.qai.0000351113.80299.b3
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 645RY
UT WOS:000281483700060
ER
PT J
AU Brass, A
AF Brass, Abraham
TI Finding Host Proteins Required for HIV Replication
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 11th Annual International Meeting of the Institute-of-Human-Virology
CY SEP 11-13, 2008
CL Univ Maryland Sch Med, Inst Human Virol, Bethesda, MD
SP Inst Human Virol
HO Univ Maryland Sch Med, Inst Human Virol
C1 [Brass, Abraham] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2009
VL 51
SU 2
MA 159
BP 82
EP 82
DI 10.1097/01.qai.0000351114.80299.7d
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 645RY
UT WOS:000281483700061
ER
PT J
AU Bassett, IV
Wang, BX
Chetty, S
Mazibuko, M
Bearnot, B
Giddy, J
Lu, ZG
Losina, E
Walensky, RP
Freedberg, KA
AF Bassett, Ingrid V.
Wang, Bingxia
Chetty, Senica
Mazibuko, Matilda
Bearnot, Benjamin
Giddy, Janet
Lu, Zhigang
Losina, Elena
Walensky, Rochelle P.
Freedberg, Kenneth A.
TI Loss to Care and Death Before Antiretroviral Therapy in Durban, South
Africa
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 15th Conference on Retroviruses and Opportunistic Infections
CY FEB 03-06, 2008
CL Boston, MA
DE Africa; HIV healthcare; linkage to care; lost to follow-up; pre-ART
mortality
ID MORTALITY; SERVICE; ADULTS
AB Objective: To examine the loss to care and mortality rates before starting antiretroviral therapy (ART) among ART eligible HIV infected patients in Durban, South Africa.
Design: Retrospective cohort study.
Methods: We reviewed data from ART eligible adults (>= 18 years) at an urban HIV clinic that charges a monthly fee from July to December 2006. ART eligibility was based on CD4 count <= 200 cells per microliter or clinical criteria and a psychosocial assessment. Patients who did not start ART and were lost within 3 months were phoned. Correlates of loss to care were evaluated using logistic regression.
Results: During the study period, 501 patients registered for ART training. Mean time from initial CD4 count to first ART training was 3.6 months (interquartile range 2.3-3.9 months). Four hundred eight patients (81.4%) were in care and on ART at 3-month follow-up, and 11 (2.2%) were in care but had not initiated ART. Eighty-two ART eligible patients (16.4%) were lost before ART initiation. Of these, 28 (34.1%) had died; two thirds of deaths occurred before or within 2 months after the first ART training. Despite multiple attempts, 32 patients (39%) were unreachable by phone. Lower baseline CD4 counts (<= 100 cells/mu L) and unemployment were independently associated with being lost.
Conclusions: Loss to care and death occur frequently before starting ART at an HIV clinic in Durban, South Africa. This delay from CD4 count to ART training, even among those with the lowest CD4 counts, highlights the need for interventions that improve linkage to care and prioritize ART initiation for those with low baseline CD4 counts.
C1 [Bassett, Ingrid V.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.
[Bassett, Ingrid V.; Wang, Bingxia; Lu, Zhigang; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Chetty, Senica; Mazibuko, Matilda; Bearnot, Benjamin; Giddy, Janet] McCord Hosp, Durban, South Africa.
[Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Walensky, Rochelle P.; Freedberg, Kenneth A.] Harvard Univ, Harvard Ctr AIDS Res, Boston, MA 02115 USA.
[Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Bassett, IV (reprint author), 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM ibassett@partners.org
FU NIAID NIH HHS [K23 AI 068458, K23 AI068458, K23 AI068458-02, K24
AI062476, P30 AI060354, R01 AI058736]; NIMH NIH HHS [R01 MH073445]
NR 17
TC 98
Z9 101
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2009
VL 51
IS 2
BP 135
EP 139
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 451IJ
UT WOS:000266463600005
PM 19504725
ER
PT J
AU O'Gorman, DE
White, JA
Shera, CA
AF O'Gorman, David E.
White, John A.
Shera, Christopher A.
TI Dynamical Instability Determines the Effect of Ongoing Noise on Neural
Firing
SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY
LA English
DT Article
DE cochlear implant; electrical stimulation; chaos; firing irregularity;
desynchronization; auditory nerve; Lyapunov exponent
ID AUDITORY-NERVE FIBERS; DESYNCHRONIZING PULSE TRAINS; GLOBAL BIFURCATION
STRUCTURE; HODGKIN-HUXLEY OSCILLATOR; SPIRAL GANGLION NEURONS; THRESHOLD
FLUCTUATIONS; ELECTRIC-STIMULATION; EXCITABLE SYSTEMS; INDUCED ORDER;
DIFFERENTIAL-EQUATIONS
AB At low stimulation rates, electrically stimulated auditory nerve fibers typically fire regularly, in lock-step to the applied stimulus. At high stimulation rates, however, these same fibers fire irregularly. Firing irregularity has been attributed to the random opening and closing of voltage-gated sodium channels at the spike generation site. We demonstrate, however, that the nonlinear dynamics of neural excitation and refractoriness embodied in the FitzHugh-Nagumo (FN) model produce realistic firing irregularity at high stimulus rates, even in the complete absence of ongoing physiological noise. Indeed, we show that ongoing noise can actually regularize the response at low discharge rates. The degree of stimulus-dependent irregularity is determined not so much by the level of ongoing physiological noise as by the dynamical instability. Our work suggests that the dynamical instability, quantified by the Lyapunov exponent, controls neural sensitivity to input signals and to physiological noise, as well the amount of mutual desynchronization between similarly stimulated fibers. This instability, quantified by the value of the Lyapunov exponent, may play a critical role in determining modulation sensitivity and dynamic range in cochlear implants.
C1 [O'Gorman, David E.; Shera, Christopher A.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, Boston, MA 02114 USA.
[O'Gorman, David E.; Shera, Christopher A.] Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA.
[O'Gorman, David E.] Boston Univ, Dept Biomed Engn, Hearing Res Ctr, Neuronal Dynam Lab, Boston, MA 02215 USA.
[O'Gorman, David E.; White, John A.] Boston Univ, Dept Biomed Engn, Ctr BioDynam, Boston, MA 02215 USA.
[Shera, Christopher A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP O'Gorman, DE (reprint author), Boston Univ, Dept Biomed Engn, Hearing Res Ctr, Neuronal Dynam Lab, Boston, MA 02215 USA.
EM ogorman@bu.edu
RI X, Simon/F-4678-2011;
OI White, John/0000-0003-1073-2638
FU NIDCD [T32-DC00038]; Kirschstein Award [F31DC006188]; MIT-Poitras
Fellowship; MIT-Zakhartchenko Fellowship; Burroughs-Wellcome Fund; NIH
[R01-NS34425]; Hearing Research Center
FX This work was supported by a Speech and Hearing Science Training Grant
from the NIDCD (T32-DC00038), the Kirschstein Award (NIH F31DC006188),
an MIT-Poitras Fellowship, and the MIT-Zakhartchenko Fellowship.
Additional support was provided by the Burroughs-Wellcome Fund, a grant
from the NIH to J. A. White (R01-NS34425), and the Hearing Research
Center at Boston University.
NR 85
TC 10
Z9 10
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1525-3961
J9 JARO-J ASSOC RES OTO
JI JARO
PD JUN
PY 2009
VL 10
IS 2
BP 251
EP 267
DI 10.1007/s10162-008-0148-5
PG 17
WC Neurosciences; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 438PR
UT WOS:000265568200008
PM 19308644
ER
PT J
AU Leiderman, YI
Lessell, S
Cestari, DM
AF Leiderman, Yannek I.
Lessell, Simmons
Cestari, Dean M.
TI Recurrent isolated sixth nerve palsy after consecutive annual influenza
vaccinations in a child
SO JOURNAL OF AAPOS
LA English
DT Article
AB Recurrent sixth nerve palsy in children in the absence of structural or other neurological abnormality is a rare occurrence. We report the case of recurrent isolated sixth (abducens) nerve palsy after consecutive annual influenza vaccinations in an otherwise-healthy 2-year-old boy. Investigations including magnetic resonance imaging of the brain and orbits after each episode failed to reveal any abnormality. The temporal relation to the immunizations supports but does not prove that the influenza immunization regimen was responsible.
C1 [Lessell, Simmons; Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Neuro Ophthalmol Serv, Boston, MA 02114 USA.
[Leiderman, Yannek I.] Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA.
[Leiderman, Yannek I.; Lessell, Simmons; Cestari, Dean M.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Cestari, DM (reprint author), Massachusetts Eye & Ear Infirm, Neuro Ophthalmol Serv, 243 Charles St,9th Floor, Boston, MA 02114 USA.
EM Dean_Cestari@meei.harvard.edu
FU Massachusetts Eve and Ear Infirmary and Harvard Medical School
FX This study was conducted at the Massachusetts Eve and Ear Infirmary and
Harvard Medical School.
NR 7
TC 8
Z9 8
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
J9 J AAPOS
JI J. AAPOS
PD JUN
PY 2009
VL 13
IS 3
BP 317
EP 318
DI 10.1016/j.jaapos.2008.12.137
PG 2
WC Ophthalmology; Pediatrics
SC Ophthalmology; Pediatrics
GA 462ID
UT WOS:000267343700027
PM 19285888
ER
PT J
AU Meredith, CW
Jaffe, C
Cherrier, M
Robinson, JP
Malte, CA
Yanasak, EV
Kennedy, A
Ferguson, LC
Tapp, AM
Saxon, AJ
AF Meredith, Charles W.
Jaffe, Craig
Cherrier, Monique
Robinson, Joseph P.
Malte, Carol A.
Yanasak, Elisia V.
Kennedy, Annette
Ferguson, Laura C.
tapp, Andre M.
Saxon, Andrew J.
TI Open Trial of Injectable Risperidone for Methamphetamine Dependence
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE methamphetamine; risperidone; injection; neuropsychological function;
psychiatric symptoms; addiction severity
ID PLACEBO-CONTROLLED TRIAL; RATING-SCALE; D-AMPHETAMINE; DRUG-SEEKING;
OPEN-LABEL; COCAINE; ANTIPSYCHOTICS; DISORDER; RELAPSE; ABUSERS
AB We tested acceptability and tolerability of long-acting injectable risperidone for methamphetamine (MA) dependence in all open trial with the hypothesis that participants would reduce MA use. Participants were also evaluated for changes in neurocognitive function and psychiatric symptomology. Participants with MA dependence (n = 34) entered a 7-day open-label run-in with oral risperidone. Participants who tolerated oral risperidone (n = 22) were begun on long-acting injectable risperidone 25 mg intramuscular medication with subsequent injections q 2 weeks to a total of 4 injections. Participants remained on oral risperidone during the first 3 weeks after initial injection. Participants were offered 8 weekly individual sessions of relapse prevention counseling. At baseline, participants reported using MA an average of 4.1 days per week (SD = 1.9). Estimated mean days of MA use per week while on injections was 1.0 (95% confidence interval = 0.6-1.4), with days of use decreasing significantly from baseline through week 8 (beta = -0.27; 95% confidence interval: -0.38--0.16; P < 0.001). Mean week 6 risperidone + 9-OH risperidone plasma levels for participants abstinent from MA from weeks 5 to 8 (n = 7, 63.6%) were 18.8 ng/mL (SD = 6.6) compared with 12.3 (SD = 4.0) for those not abstinent n = 4; P = 0.075). No serious adverse events Occurred. Verbal memory improved at week 4 compared with baseline (P < 0.05). Participation in this trial of injectable risperidone was associated with reductions in MA use as well as some positive benefits on verbal memory. However, these results are limited by the use of an open trial design with a high dropout rate. Risperidone deserves further study in controlled trials as a pharmacotherapy for MA dependence.
C1 [Meredith, Charles W.; Robinson, Joseph P.; Malte, Carol A.; Yanasak, Elisia V.; Kennedy, Annette; Ferguson, Laura C.; tapp, Andre M.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA.
[Malte, Carol A.; Ferguson, Laura C.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Meredith, Charles W.; Jaffe, Craig; Cherrier, Monique; Ferguson, Laura C.; tapp, Andre M.; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Meredith, CW (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv, S-116A,1660 S Columbian Wy, Seattle, WA USA.
EM Charles.meredith@va.gov
FU Ortho-McNeil Janssen Scientific Affairs LLC; Center of Excellence in
Substance Abuse Treatment and Education, VA Puget Sound Health Care
System; AstraZeneca; Eli Lilly
FX Supported by a grant from Ortho-McNeil Janssen Scientific Affairs LLC
and by the Center of Excellence in Substance Abuse Treatment and
Education, VA Puget Sound Health Care System.; Dr. Cherrier has provided
consultation to Solvay, file. and Merck, Inc.; Dr. Tapp has been on the
speaker's bureau and has received honoraria from AstraZeneca, Eli Lilly,
and Janssen and has received research support front AstraZeneca and Eli
Lilly.
NR 63
TC 6
Z9 6
U1 3
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD JUN
PY 2009
VL 3
IS 2
BP 55
EP 65
PG 11
WC Substance Abuse
SC Substance Abuse
GA 452BT
UT WOS:000266515300002
PM 21769001
ER
PT J
AU Hesterberg, PE
Banerji, A
Oren, E
Penson, RT
Krasner, CN
Seiden, MV
Wong, JT
AF Hesterberg, Paul E.
Banerji, Aleena
Oren, Eyal
Penson, Richard T.
Krasner, Carolyn N.
Seiden, Michael V.
Wong, Johnson T.
TI Risk stratification for desensitization of patients with carboplatin
hypersensitivity: Clinical presentation and management
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Desensitization; drug allergy; carboplatin; ovarian cancer; skin
testing; hypersensitivity
ID OVARIAN-CANCER; PROTOCOL; EXPERIENCE; CISPLATIN; ANAPHYLAXIS; CARCINOMA;
CHEMOTHERAPY; REPLACEMENT; PACLITAXEL; ALLERGY
AB Background: Women with ovarian cancer treated with chemotherapeutic platinum agents frequently develop hypersensitivity reactions (HSRs). How best to risk-stratify patients for desensitization is uncertain.
Objectives: To evaluate skin test (ST) reactivity to carboplatin in patients with recent and remote histories of carboplatin HSR and to review the relationship between skin test reactivity and tolerance of subsequent carboplatin desensitization.
Methods: Thirty-eight women with carboplatin HSR were evaluated by ST to carboplatin. Thirty women subsequently underwent 106 desensitizations to carboplatin.
Results: Carboplatin ST was positive in 25 of 38 patients (66%). Of patients with recent HSR (<3 months), 20 of 24 (83%) tested positive, whereas 5 of 14 (36%) with remote HSR (>9 months) tested positive (P < .01). Nineteen carboplatin ST(+) and 11 ST(-) patients underwent desensitization to carboplatin. Seven ST+ patients (37%) had mild HSR during desensitization but completed the desensitization with additional treatment or protocol modification. ST(-) patients with a recent history of HSR (n = 3) tolerated a rapid protocol without HSR and remained ST- with repeated testing. Six of 8 ST(-) patients (75%) with remote HSR reacted during desensitization. The HSRs were more severe and often associated with an elevated tryptase level. Five of 7 patients retested became ST(+) before the second desensitization. Carboplatin desensitization was successfully completed in 105 of 106 (99%) treatment courses.
Conclusions: The timing of carboplatin ST in relation to initial HSR is vital for risk stratification and subsequent desensitization. Initial ST(-) patients with a remote history of HSR are at high risk for conversion to ST(+) and can develop more severe HSR. (J Allergy Clin Immunol 2009;123:1262-7.)
C1 [Hesterberg, Paul E.; Banerji, Aleena; Oren, Eyal; Wong, Johnson T.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Penson, Richard T.; Krasner, Carolyn N.] Massachusetts Gen Hosp, Gillette Ctr, Boston, MA 02114 USA.
[Penson, Richard T.; Krasner, Carolyn N.] Dana Farber Canc Res Ctr, Boston, MA USA.
[Seiden, Michael V.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
RP Hesterberg, PE (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Cox 201,100 Blossom St, Boston, MA 02114 USA.
EM phesterberg@partners.org
FU Lev Pharmaceuticals; Genentech, Inc; DARA Biosciences, Inc; Berlex
Laboratories; CuraGen Corp; PDL BioPharma; Imclone Systems Inc;
Endocyte, Inc; Johnson Johnson; Frewn
FX Disclosure of potential conflict of interest: A. Banerji has received
research support from Lev Pharmaceuticals. E. Oren has served on the
speakers'bureau for GlaxoSmithKline and Meda Pharmaceuticals, Inc. R. T.
Penson has received research support from Genentech, Inc, DARA
Biosciences, Inc, Berlex Laboratories, CuraGen Corp, PDL BioPharma,
Imclone Systems Inc, and Endocyte, Inc, and has served as an expert
witness for Eli Lilly & Co. C. N. Krasner has received research support
from Johnson & Johnson, Genentech, and Frewn. J. T Wong has served as an
expert witness regarding drug infringement. The rest of the authors have
declared that they have no conflict of interest.
NR 35
TC 39
Z9 44
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUN
PY 2009
VL 123
IS 6
BP 1262
EP 1267
DI 10.1016/j.jaci.2009.02.042
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 455WO
UT WOS:000266799100016
PM 19501233
ER
PT J
AU Gupta, RS
Zhang, XY
Sharp, LK
Shannon, JJ
Weiss, KB
AF Gupta, Ruchi S.
Zhang, Xingyou
Sharp, Lisa K.
Shannon, John J.
Weiss, Kevin B.
TI The protective effect of community factors on childhood asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Asthma; prevalence; community; neighborhood; childhood; environment;
social capital; disparity
ID INNER-CITY ASTHMA; SCHOOL-AGE-CHILDREN; HOUSE-DUST MITE;
SOCIOECONOMIC-STATUS; AIR-POLLUTION; BIRTH-COHORT; ENVIRONMENTAL
INTERVENTION; PSYCHOSOCIAL FACTORS; COCKROACH ALLERGEN; NITROGEN-DIOXIDE
AB Background: Asthma burden in the US is not evenly distributed. Although asthma prevalence varies widely across urban neighborhoods, little attention has been paid to the community as a key contributor.
Objective: To determine the effect of positive socio-environmental community factors on childhood asthma prevalence in Chicago.
Methods: From 2003 to 2005, an asthma screening survey was conducted among children attending Chicago Public/Catholic schools from kindergarten through eighth grade. One hundred five schools participated, yielding a stratified representation of 4 race-income groups. Positive community factors, such as social capital, economic potential, and community amenities, were assessed by using the Metro Chicago Information Center's Community Vitality Index.
Results: Of the surveys returned, 45,177 (92%) were geocoded into 287 neighborhoods. Neighborhoods were divided into quartile groups by asthma prevalence (mean, 8%, 12%, 17%, 25%). Community vitality (54% vs 44%; P < .0001) and economic potential (64% vs 38%; P < .0001) were significantly higher in neighborhoods with low asthma prevalence. Neighborhood interaction (36% vs 73%; P < .0001) and stability (40% vs 53%; P < .0001) were significantly higher in neighborhoods with high asthma prevalence. Overall, positive factors explained 21% of asthma variation. Childhood asthma increased as the black population increased in a community (P < .0001). Accordingly, race/ethnicity was controlled. In black neighborhoods, these factors remained significantly higher in neighborhoods with low asthma prevalence. When considered alongside socio-demographic/individual characteristics, overall community vitality as well as social capital continued to contribute significantly to asthma variation.
Conclusion: Asthma prevalence in Chicago is strongly associated with socio-environmental factors thought to enrich a community. A deeper understanding of this impact may lend insight into interventions to reduce childhood asthma. (J Allergy Clin Immunol 2009;123:1297-304.)
C1 [Gupta, Ruchi S.] Childrens Mem Hosp, Chicago, IL 60614 USA.
[Gupta, Ruchi S.; Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA.
[Zhang, Xingyou] Amer Acad Family Physicians, Robert Graham Ctr Policy Studies Family Med & Pri, Washington, DC USA.
[Sharp, Lisa K.] Univ Illinois, Dept Med, Sect Hlth Promot, Chicago, IL USA.
[Shannon, John J.] Cook Cty Hosp, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA.
[Weiss, Kevin B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
RP Gupta, RS (reprint author), Childrens Mem Hosp, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA.
EM rugupta@childrensmemorial.org
FU National Heart, Lung, and Blood Institute [5U01 HL072478-05]; National
Institute of Child Health and Human Development [K 12 HD052902]
FX Supported by National Heart, Lung, and Blood Institute grant 5U01
HL072478-05 and National Institute of Child Health and Human Development
grant K 12 HD052902.
NR 59
TC 21
Z9 21
U1 5
U2 12
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUN
PY 2009
VL 123
IS 6
BP 1297
EP 1304
DI 10.1016/j.jaci.2009.03.039
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 455WO
UT WOS:000266799100020
PM 19450873
ER
PT J
AU Frueh, BC
Grubaugh, AL
Cusack, KJ
Kimble, MO
Elhai, JD
Knapp, RG
AF Frueh, B. Christopher
Grubaugh, Anoluk L.
Cusack, Karen J.
Kimble, Matthew O.
Elhai, Jon D.
Knapp, Rebecca G.
TI Exposure-based cognitive-behavioral treatment of PTSD in adults with
schizophrenia or schizoaffective disorder: A pilot study
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE PTSD; Trauma; Severe mental illness (SMI); Schizophrenia; Exposure
therapy; Cognitive-behavioral therapy
ID POSTTRAUMATIC-STRESS-DISORDER; SEVERE MENTAL-ILLNESS; RANDOMIZED
CONTROLLED-TRIAL; TRAUMA MANAGEMENT THERAPY; COMBAT-RELATED PTSD;
SOUTH-CAROLINA; HEALTH; VICTIMS; SCALE; VETERANS
AB In an open trial design, adults (n = 20) with posttraumatic stress disorder (PTSD) and either schizophrenia or schizoaffective disorder were treated via an 11-week cognitive-behavioral intervention for PTSD that consisted of education, anxiety management therapy, social skills training and exposure, therapy, provided at Community mental health centers. Results offer preliminary hope for effective treatment of PTSD among adults with schizophrenia or schizoaffective disorder, especially among treatment completers (n = 13). Data showed significant PTSD symptom improvement maintained at 3, month follow-tip. Further, 12 of 13 completers no longer met criteria for PTSD or were considered treatment responders. Clinical Outcomes for other targeted domains (e.g., anger, general mental health) also improved and were maintained at 3-month follow-up. Participants evidenced high treatment satisfaction, with no adverse events. Significant improvements were not noted on depression, general anxiety,or physical health status. Future directions include the need for randomized controlled trials and dissemination efforts. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Frueh, B. Christopher] Baylor Coll Med, Menninger Clin, Houston, TX 77080 USA.
[Frueh, B. Christopher] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77080 USA.
[Grubaugh, Anoluk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Grubaugh, Anoluk L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Cusack, Karen J.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA.
[Kimble, Matthew O.] Middlebury Coll, Dept Psychol, Middlebury, VT 05753 USA.
[Elhai, Jon D.] Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA.
[Knapp, Rebecca G.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
RP Frueh, BC (reprint author), Baylor Coll Med, Menninger Clin, 2801 Gessner Dr, Houston, TX 77080 USA.
EM frueh@hawaii.edu
FU NIMH NIH HHS [K24 MH074468, K24 MH074468-01A1, K24 MH074468-02, K24
MH074468-03, MH065248, MH074468, R21 MH065248, R21 MH065248-01A1, R21
MH065248-02, R21 MH065248-02S1, R21 MH065248-03]
NR 82
TC 64
Z9 64
U1 8
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD JUN
PY 2009
VL 23
IS 5
BP 665
EP 675
DI 10.1016/j.janxdis.2009.02.005
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 439WG
UT WOS:000265657700015
PM 19342194
ER
PT J
AU Bensing, BA
Sullam, PM
AF Bensing, Barbara A.
Sullam, Paul M.
TI Characterization of Streptococcus gordonii SecA2 as a Paralogue of SecA
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID BINDING-PROTEIN-GSPB; SURFACE GLYCOPROTEINS GSPB; ESCHERICHIA-COLI SECA;
MYCOBACTERIUM-TUBERCULOSIS; TRANSLOCASE MOTOR; HUMAN PLATELETS; ATPASE
ACTIVITY; IB-ALPHA; SECRETION; EXPORT
AB The accessory Sec system of Streptococcus gordonii is essential for transport of the glycoprotein GspB to the bacterial cell surface. A key component of this dedicated transport system is SecA2. The SecA2 proteins of streptococci and staphylococci are paralogues of SecA and are presumed to have an analogous role in protein transport, but they may be specifically adapted for the transport of large, serine-rich glycoproteins. We used a combination of genetic and biochemical methods to assess whether the S. gordonii SecA2 functions similarly to SecA. Although mutational analyses demonstrated that conserved amino acids are essential for the function of SecA2, replacing such residues in one of two nucleotide binding folds had only minor effects on SecA2 function. SecA2-mediated transport is highly sensitive to azide, as is SecA-mediated transport. Comparison of the S. gordonii SecA and SecA2 proteins in vitro revealed that SecA2 can hydrolyze ATP at a rate similar to that of SecA and is comparably sensitive to azide but that the biochemical properties of these enzymes are subtly different. That is, SecA2 has a lower solubility in aqueous solutions and requires higher Mg(2+) concentrations for maximal activity. In spite of the high degree of similarity between the S. gordonii paralogues, analysis of SecA-SecA2 chimeras indicates that the domains are not readily interchangeable. This suggests that specific, unique contacts between SecA2 and other components of the accessory Sec system may preclude cross-functioning with the canonical Sec system.
C1 San Francisco VA Med Ctr, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Sullam, PM (reprint author), Vet Adm Med Ctr, Div Infect Dis, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu
FU National Institutes of Health [RO1AI41513, RO1AI057433]
FX We thank R. Seepersaud for critical reading of the manuscript.
NR 57
TC 20
Z9 20
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD JUN
PY 2009
VL 191
IS 11
BP 3482
EP 3491
DI 10.1128/JB.00365-09
PG 10
WC Microbiology
SC Microbiology
GA 445HG
UT WOS:000266041300007
PM 19363114
ER
PT J
AU Spokas, M
Luterek, JA
Heimberg, RG
AF Spokas, Megan
Luterek, Jane A.
Heimberg, Richard G.
TI Social anxiety and emotional suppression: The mediating role of beliefs
SO JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY
LA English
DT Article
DE Social anxiety; Emotion; Emotional suppression; Beliefs
ID PHOBIA SCALE; PSYCHOLOGICAL-RESEARCH; POSITIVE EMOTIONS; PANIC DISORDER;
EXPRESSION; ALEXITHYMIA; VALIDATION; ATTITUDES; VALIDITY; MODEL
AB There is mounting evidence to suggest that social anxiety is associated with the suppression of emotional expression. The current study examined self-reported emotional suppression and beliefs about expressing emotions among undergraduate students (n = 95). Socially anxious undergraduates reported greater use of emotional suppression compared to their non-socially anxious peers. They also reported greater ambivalence about emotional expression, more difficulties in emotional responding, more fears of emotional experiences, and more negative beliefs about emotional expression. Believing that emotional expression must be kept in control and is a sign of weakness partially mediated the association between social anxiety and emotional suppression. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Spokas, Megan] Univ Penn, Dept Psychiat, Psychopathol Res Unit, Philadelphia, PA 19104 USA.
[Luterek, Jane A.] Mental Illness Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Luterek, Jane A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Heimberg, Richard G.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA.
RP Spokas, M (reprint author), Univ Penn, Dept Psychiat, Psychopathol Res Unit, 3535 Market St,Room 2029, Philadelphia, PA 19104 USA.
EM mspokas@mail.med.upenn.edu; jane.luterek@va.gov; heimberg@temple.edu
NR 40
TC 40
Z9 41
U1 4
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7916
J9 J BEHAV THER EXP PSY
JI J. Behav. Ther. Exp. Psychiatry
PD JUN
PY 2009
VL 40
IS 2
BP 283
EP 291
DI 10.1016/j.jbtep.2008.12.004
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 443EI
UT WOS:000265892600011
PM 19135648
ER
PT J
AU Shih, WM
Douglas, SM
Dietz, H
Liedl, T
Hogberg, B
Graf, F
AF Shih, William M.
Douglas, Shawn M.
Dietz, Hendrik
Liedl, Tim
Hogberg, Bjorn
Graf, Franziska
TI Self-assembly of DNA into Nanoscale Three-Dimensional Shapes
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Meeting Abstract
C1 Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM William_Shih@dfci.harvard.edu
RI Liedl, Tim/O-7539-2014
OI Liedl, Tim/0000-0002-0040-0173
NR 0
TC 1
Z9 1
U1 1
U2 23
PU ADENINE PRESS
PI SCHENECTADY
PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA
SN 0739-1102
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD JUN
PY 2009
VL 26
IS 6
MA 17
BP 799
EP 799
PG 1
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 448ZO
UT WOS:000266300700029
ER
PT J
AU Tolstorukov, MY
Kharchenko, PV
Goldman, JA
Kingston, RE
Park, PJ
AF Tolstorukov, Michael Y.
Kharchenko, Peter V.
Goldman, Joseph A.
Kingston, Robert E.
Park, Peter J.
TI Comparative Analysis of Nucleosome Sequence Organization in Human and
Yeast Genomes
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Meeting Abstract
C1 [Tolstorukov, Michael Y.; Kharchenko, Peter V.; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
[Tolstorukov, Michael Y.; Kharchenko, Peter V.; Park, Peter J.] Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA.
[Kharchenko, Peter V.; Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA.
[Goldman, Joseph A.; Kingston, Robert E.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM tolstorukov@gmail.com; peter_park@harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ADENINE PRESS
PI SCHENECTADY
PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA
SN 0739-1102
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD JUN
PY 2009
VL 26
IS 6
MA 200
BP 917
EP 917
PG 1
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 448ZO
UT WOS:000266300700211
ER
PT J
AU Kim, JY
Ali, R
Cremers, SL
Yun, SC
Henderson, BA
AF Kim, Jae Yong
Ali, Rasha
Cremers, Sandra Lora
Yun, Sung-Cheol
Henderson, Bonnie An
TI Incidence of intraoperative complications in cataract surgery performed
by left-handed residents
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID PSEUDOEXFOLIATION SYNDROME; VITREOUS LOSS; RISK-FACTORS;
PHACOEMULSIFICATION; EXTRACTION; OUTCOMES; DISPLACEMENT; DOMINANCE;
GENDER; EYES
AB PURPOSE: To compare the incidence of intraoperative complications during cataract surgery performed by left-handed and right-handed residents and to find predictor variables for complications in resident-performed surgery.
SETTING: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
METHODS: This retrospective chart review comprised cataract extractions performed by postgraduate fourth-year residents from July 1, 2001, to June 30, 2006. The incidence of posterior capsule tear and vitreous loss were the main outcomes. Univariate and multivariate logistic analyses incorporated the variables of patient age and sex; laterality of surgical eye; presence of diabetes mellitus, glaucoma, or age-related macular degeneration; history of vitrectomy; axial length; pseudoexfoliation; small pupils; white cataract; posterior polar cataract; handedness of resident; and academic quarter during which surgery occurred.
RESULTS: Left-handed residents performed 170 (9.8%) of the 1730 surgeries. The incidence of posterior capsule tear and vitreous loss was significantly lower in surgeries performed by left-handed residents than in those performed by right-handed residents (P = .03 and P<.001, respectively). Multivariate logistic analysis showed that resident right-handedness and older patient age were predictive of an increased incidence of posterior capsule tear and vitreous loss. A small pupil was predictive of an increased incidence of vitreous loss.
CONCLUSIONS: The incidence of posterior capsule tear and vitreous loss was significantly lower in cataract surgeries performed by left-handed residents. Handedness and patient age were significant predictor variables for these complications. J Cataract Refract Surg 2009; 35:1019-1025 (C) 2009 ASCRS and ESCRS
C1 [Kim, Jae Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul 138736, South Korea.
[Yun, Sung-Cheol] Univ Ulsan, Coll Med, Dept Prevent Med, Seoul 138736, South Korea.
[Ali, Rasha] Univ Maryland, Dept Internal Med, Baltimore, MD 21201 USA.
[Kim, Jae Yong; Ali, Rasha; Cremers, Sandra Lora] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Cambridge, MA 02138 USA.
RP Kim, JY (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, 388-1 Pungnab,2 Dong, Seoul 138736, South Korea.
EM jykim2311@amc.seoul.kr
NR 34
TC 11
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUN
PY 2009
VL 35
IS 6
BP 1019
EP 1025
DI 10.1016/j.jcrs.2009.01.025
PG 7
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 455WF
UT WOS:000266797900023
PM 19465287
ER
PT J
AU Matioc, AA
AF Matioc, Adrian A.
TI The adult ergonomic face mask concept: historical and theoretical
perspectives
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE Airway management; Airway obstruction; Face mask: Ergonomic face mask
ID UNCONSCIOUS PATIENT; UNPROTECTED AIRWAY; GENERAL-ANESTHESIA;
VENTILATION; RESUSCITATION; DIFFICULT; OBSTRUCTION; GUIDELINES;
MANAGEMENT; POSITION
AB The fundamental skill required of the anesthesiologist and rescuer is to treat upper airway obstruction and maintain adequate ventilation. Adult one-hand face mask ventilation is a complex technique, often applied with suboptimal results. The adult face mask in use today was not designed for one-handed ventilation but inherited its features from the 19(th) century face piece. The airway maneuver used with one-handed ventilation is not standardized. An ergonomic face mask has an asymmetrical dome that accommodates the hand grip required for chin lift and may be better for one-hand ventilation. The historical and theoretical considerations patent to the design and technique of the ergonomic face mask are reviewed. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Matioc, Adrian A.] William S Middleton Mem Vet Adm Med Ctr, Dept Anesthesiol, VA Med Ctr, Madison, WI 53705 USA.
[Matioc, Adrian A.] Univ Wisconsin, Hosp & Clin, Dept Anesthesiol, Madison, WI 53792 USA.
RP Matioc, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Anesthesiol, VA Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM adrian.matioc@va.gov
NR 40
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD JUN
PY 2009
VL 21
IS 4
BP 300
EP 304
DI 10.1016/j.jclinane.2008.08.018
PG 5
WC Anesthesiology
SC Anesthesiology
GA 464JP
UT WOS:000267501500014
PM 19502042
ER
PT J
AU Bredella, MA
Fazeli, PK
Miller, KK
Misra, M
Torriani, M
Thomas, BJ
Ghomi, RH
Rosen, CJ
Klibanski, A
AF Bredella, Miriam A.
Fazeli, Pouneh K.
Miller, Karen K.
Misra, Madhusmita
Torriani, Martin
Thomas, Bijoy J.
Ghomi, Reza Hosseini
Rosen, Clifford J.
Klibanski, Anne
TI Increased Bone Marrow Fat in Anorexia Nervosa
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PROTON MR SPECTROSCOPY; ADOLESCENT GIRLS; MINERAL DENSITY; HEALTHY
ADOLESCENTS; SECRETORY DYNAMICS; LEPTIN LEVELS; PEPTIDE-YY; WOMEN;
OSTEOPOROSIS; WEIGHT
AB Context: Although women with anorexia nervosa (AN) have severe depletion of body fat, a paradoxical increase in bone marrow fat has been described. Recent data suggest that marrow fat measured by 1H-magnetic resonance spectroscopy (MRS) in combination with bone mineral density (BMD) may be more valuable than either parameter alone in detecting bone weakness.
Objective: The objective of the study was to investigate the effect of AN on accumulation of marrow fat in spine and femur using 1H-MRS and the relationship between marrow fat, BMD, and body composition in subjects with AN and normal-weight controls.
Design: This was a cross-sectional study.
Setting: The study was conducted at a referral center.
Patients: Patients included 10 women with AN (29.8 +/- 7.6 yr) and 10 normal-weight age-matched women (29.2 +/- 5.2 yr).
Interventions: There were no interventions.
Main Outcomes Measure: Marrow fat content of the fourth lumbar vertebra and femur measured by 1H-MRS. BMD of spine and hip measured by dual-energy x-ray absorptiometry.
Results: Subjects with AN had higher marrow fat at the fourth lumbar vertebra and femur compared with controls (P = 0.004-0.01). There was an inverse correlation between marrow fat of L4 and femur and BMD of the spine and hip (r = -0.56 to -0.71, P = 0.01-0.0002) and body mass index and sc adipose tissue of the thigh (r = -0.49 to -0.71, P = 0.03-0.0007). There was an inverse correlation between femur marrow fat and sc and total abdominal adipose tissue (r = -0.53 to -0.67, P = 0.003-0.03).
Conclusion: Women with AN have greater lumbar and femoral marrow fat than controls, and marrow fat correlates inversely with BMD. This paradoxical increase in marrow fat at a time when sc and visceral fat are markedly reduced raises important questions about functional consequences of this process. (J Clin Endocrinol Metab 94: 2129-2136, 2009)
C1 [Bredella, Miriam A.; Torriani, Martin; Thomas, Bijoy J.; Ghomi, Reza Hosseini] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Fazeli, Pouneh K.; Miller, Karen K.; Misra, Madhusmita; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Rosen, Clifford J.] Maine Med Ctr Res Inst, Scarborough, ME 04074 USA.
RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Yawkey 6E,55 Fruit St, Boston, MA 02114 USA.
EM mbredella@partners.org
OI Hosseini Ghomi, Reza/0000-0003-4369-8237
FU National Institutes of Health [RO1 DK052625, MO1 RR01066, UL1 RR025758]
FX Address all correspondence and requests for reprints to: Miriam A.
Bredella, M. D., Massachusetts General Hospital, Yawkey 6E, 55 Fruit
Street, Boston, Massachusetts 02114. E-mail: mbredella@partners.org.;
This work was supported by the following National Institutes of Health
Grants: RO1 DK052625, MO1 RR01066, UL1 RR025758.; Disclosure Summary:
The authors have nothing to disclose.
NR 40
TC 122
Z9 123
U1 0
U2 3
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2009
VL 94
IS 6
BP 2129
EP 2136
DI 10.1210/jc.2008-2532
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 453CM
UT WOS:000266587800044
PM 19318450
ER
PT J
AU Doupis, J
Lyons, TE
Wu, SH
Gnardellis, C
Dinh, T
Veves, A
AF Doupis, John
Lyons, Thomas E.
Wu, Szuhuei
Gnardellis, Charalambos
Dinh, Thanh
Veves, Aristidis
TI Microvascular Reactivity and Inflammatory Cytokines in Painful and
Painless Peripheral Diabetic Neuropathy
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID INTERCELLULAR-ADHESION MOLECULE-1; REFLEX-RELATED VASODILATION; SKIN
BLOOD-FLOW; MYOCARDIAL-INFARCTION; FOOT ULCERATION; RISK; DISEASE;
CELLS; DYSFUNCTION; EXPRESSION
AB Objective: We investigated the association between inflammation, microvascular reactivity, and the development of peripheral diabetic neuropathy.
Research Design and Methods: We studied three groups: 55 healthy control subjects, 80 nonneuropathic patients, and 77 neuropathic diabetic patients. We also subdivided the neuropathic patients into a subgroup of 31 subjects with painless neuropathy and 46 with painful neuropathy. We measured the foot skin endothelium-dependent and -independent vasodilation, the nerve axon reflex-related vasodilation (NARV), and inflammatory cytokines and biochemical markers of endothelial function.
Results: The endothelium-dependent and -independent vasodilation and NARV were lower in the neuropathic group (P < 0.05). NARV was further reduced in the subgroup of painless neuropathy when compared to painful neuropathy (P < 0.05). Compared to the other two groups, the neuropathic group also had higher serum levels of PDGF AA/BB (P < 0.05), RANTES (P < 0.01), leptin (P < 0.0001), osteoprotegerin (P < 0.01), G-CSF (P < 0.05), sE-Selectin (P < 0.01), sICAM (P < 0.0001), sVCAM (P < 0.001), CRP (P < 0.0001), TNF alpha (P < 0.05), and fibrinogen (P < 0.05). Patients with painful neuropathy had higher sICAM-1 (P < 0.05) and CRP levels (P < 0.01) when compared to painless neuropathy. No major changes in the above results were observed in 78 diabetic patients who were seen for a second visit 21 months after the first visit.
Conclusions: Peripheral diabetic neuropathy is associated with increased biochemical markers of inflammation and endothelial dysfunction. Painful neuropathy is associated with further increase in inflammation and markers of endothelial dysfunction and preservation of the nerve axon reflex. (J Clin Endocrinol Metab 94: 2157-2163, 2009)
C1 [Doupis, John; Lyons, Thomas E.; Wu, Szuhuei; Dinh, Thanh; Veves, Aristidis] Harvard Univ, Microcirculat Lab, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Doupis, John; Lyons, Thomas E.; Wu, Szuhuei; Dinh, Thanh; Veves, Aristidis] Harvard Univ, Joslin Beth Israel Deaconess Foot Ctr, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Gnardellis, Charalambos] Technol Educ Inst Messolonghi, Mesolongion 30200, Greece.
RP Veves, A (reprint author), Harvard Univ, Microcirculat Lab, Beth Israel Deaconess Med Ctr, Sch Med, Palmer 318,1 Deaconess Rd, Boston, MA 02215 USA.
EM aveves@bidmc.harvard.edu
FU National Institutes of Health [R01-HL075678, R01-NS046710, R01 DK076937]
FX Disclosure Summary: The authors have nothing to disclose.
NR 33
TC 82
Z9 91
U1 2
U2 4
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2009
VL 94
IS 6
BP 2157
EP 2163
DI 10.1210/jc.2008-2385
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 453CM
UT WOS:000266587800048
PM 19276232
ER
PT J
AU Little, J
Higgins, JPT
Ioannidis, JPA
Moher, D
Gagnon, F
von Elm, E
Khoury, MJ
Cohen, B
Davey-Smith, G
Grimshaw, J
Scheet, P
Gwinn, M
Williamson, RE
Zou, GY
Hutchings, K
Johnson, CY
Tait, V
Wiens, M
Golding, J
van Duijn, C
McLaughlin, J
Paterson, A
Wells, G
Fortier, I
Freedman, M
Zecevic, M
King, R
Infante-Rivard, C
Stewart, AF
Birkett, N
AF Little, Julian
Higgins, Julian P. T.
Ioannidis, John P. A.
Moher, David
Gagnon, France
von Elm, Erik
Khoury, Muin J.
Cohen, Barbara
Davey-Smith, George
Grimshaw, Jeremy
Scheet, Paul
Gwinn, Marta
Williamson, Robin E.
Zou, Guang Yong
Hutchings, Kim
Johnson, Candice Y.
Tait, Valerie
Wiens, Miriam
Golding, Jean
van Duijn, Cornelia
McLaughlin, John
Paterson, Andrew
Wells, George
Fortier, Isabel
Freedman, Matthew
Zecevic, Maja
King, Richard
Infante-Rivard, Claire
Stewart, Alex F.
Birkett, Nick
TI STrengthening the REporting of Genetic Association studies (STREGA)-an
extension of the strengthening the reporting, of observational studies
in epidemiology (STROBE) statement
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Review
DE Gene-disease associations; Genetics; Gene-environment interaction;
Systematic review; Reporting recommendations; Epidemiology; Genome-wide
association
ID GENOME-WIDE ASSOCIATION; HARDY-WEINBERG EQUILIBRIUM; SINGLE-NUCLEOTIDE
POLYMORPHISMS; POPULATION STRATIFICATION; RANDOMIZED-TRIALS; DISEASE
ASSOCIATIONS; GENOTYPING ERRORS; COMPLEX DISEASES; PROSTATE-CANCER;
LINKAGE-DISEQUILIBRIUM
AB Making sense of rapidly evolving evidence on genetic associations is crucial to making genuine advances in human genomics and the eventual integration of this information in the practice of medicine and public health. Assessment of the strengths and weaknesses of this evidence, and hence, the ability to synthesize it, has been limited by inadequate reporting Of results. The STrengthening the REporting of Genetic Association (STREGA) studies initiative builds on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement and provides additions to 12 of the 22 items on the STROBE checklist. The additions concern population stratification, genotyping errors, modeling haplotype variation, Hardy-Weinberg equilibrium, replication, selection of participants, rationale for choice of genes and variants, treatment effects in studying quantitative traits, statistical methods, relatedness, reporting of descriptive and outcome data, and the volume of data issues that are important to consider in genetic association studies. The STREGA recommendations (to not prescribe or dictate how a genetic association study Should be designed, but seek to enhance the transparency of its reporting, regardless of choices made during design, conduct, or analysis. (C) 2009 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Little, Julian; Moher, David; Hutchings, Kim; Johnson, Candice Y.; Tait, Valerie; Wiens, Miriam; Birkett, Nick] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada.
[Higgins, Julian P. T.] MRC, Biostat Unit, Cambridge CB2 2BW, England.
[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
[Ioannidis, John P. A.] Tufts Univ, Sch Med, Ctr Genet Epidemiol & Modeling, Boston, MA 02111 USA.
[Gagnon, France] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
[von Elm, Erik] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
[von Elm, Erik] Univ Med Ctr, German Cochrane Ctr, Dept Med Biometry & Med Informat, Freiburg, Germany.
[Khoury, Muin J.; Gwinn, Marta] Ctr Dis Control & Prevent, Natl Off Publ Hlth Genom, Atlanta, GA USA.
[Cohen, Barbara] Publ Lib Sci, San Francisco, CA USA.
[Davey-Smith, George] Univ Bristol, Dept Social Med, MRC, Ctr Causal Analyses Translat Epidemiol, Bristol, Avon, England.
[Grimshaw, Jeremy] Univ Ottawa, Clin Epidemiol Program, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada.
[Scheet, Paul] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Williamson, Robin E.] Amer Journal Human Genet, Boston, MA USA.
[Zou, Guang Yong] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada.
[Zou, Guang Yong] Robarts Res Inst, Robarts Clin Trials, London, ON N6A 5C1, Canada.
[Golding, Jean] Paediat & Perinatal Epidemiol, Bristol, Avon, England.
[van Duijn, Cornelia] Europeon Journal Epidemiol, Rotterdam, Netherlands.
[McLaughlin, John] Canc Care Ontario, Populat Studies & Surveillance, Toronto, ON, Canada.
[McLaughlin, John] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada.
[Paterson, Andrew] Hosp Sick Children SickKids, Toronto, ON, Canada.
[Fortier, Isabel] McGill Univ, Genome Quebec & P3G Observ, Montreal, PQ, Canada.
[Fortier, Isabel] Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
[Freedman, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zecevic, Maja] Lancet, New York, NY USA.
[King, Richard] Genet Med, Minneapolis, MN USA.
[Infante-Rivard, Claire] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
[Wells, George] Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON K1H 8M5, Canada.
RP Little, J (reprint author), Univ Ottawa, Dept Epidemiol & Community Med, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.
EM jlittle@uottawa.ca
RI Ioannidis, John/G-9836-2011; Higgins, Julian/H-4008-2011; Grimshaw,
Jeremy/D-8726-2013; McLaughlin, John/E-4577-2013; Zou,
Guangyong/K-6408-2013; Paterson, Andrew/A-4088-2011; Davey Smith,
George/A-7407-2013;
OI Higgins, Julian/0000-0002-8323-2514; von Elm, Erik/0000-0002-7412-0406;
Stewart, Alexandre/0000-0003-2673-9164; Grimshaw,
Jeremy/0000-0001-8015-8243; Golding, Jean/0000-0003-2826-3307; Paterson,
Andrew/0000-0002-9169-118X; Davey Smith, George/0000-0002-1407-8314;
Moher , David /0000-0003-2434-4206
FU Medical Research Council [G0600705, MC_U105285807]
NR 155
TC 50
Z9 51
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD JUN
PY 2009
VL 62
IS 6
BP 597
EP 608
DI 10.1016/j.jclinepi.2008.12.004
PG 12
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 448WB
UT WOS:000266291600009
PM 19217256
ER
PT J
AU Sos, ML
Michel, K
Zander, T
Weiss, J
Frommolt, P
Peifer, M
Li, D
Ullrich, R
Koker, M
Fischer, F
Shimamura, T
Rauh, D
Mermel, C
Fischer, S
Stuckrath, I
Heynck, S
Beroukhim, R
Lin, W
Winckler, W
Shah, K
LaFramboise, T
Moriarty, WF
Hanna, M
Tolosi, L
Rahnenfuhrer, J
Verhaak, R
Chiang, D
Getz, G
Hellmich, M
Wolf, J
Girard, L
Peyton, M
Weir, BA
Chen, TH
Greulich, H
Barretina, J
Shapiro, GI
Garraway, LA
Gazdar, AF
Minna, JD
Meyerson, M
Wong, KK
Thomas, RK
AF Sos, Martin L.
Michel, Kathrin
Zander, Thomas
Weiss, Jonathan
Frommolt, Peter
Peifer, Martin
Li, Danan
Ullrich, Roland
Koker, Mirjam
Fischer, Florian
Shimamura, Takeshi
Rauh, Daniel
Mermel, Craig
Fischer, Stefanie
Stueckrath, Isabel
Heynck, Stefanie
Beroukhim, Rameen
Lin, William
Winckler, Wendy
Shah, Kinjal
LaFramboise, Thomas
Moriarty, Whei F.
Hanna, Megan
Tolosi, Laura
Rahnenfuehrer, Joerg
Verhaak, Roel
Chiang, Derek
Getz, Gad
Hellmich, Martin
Wolf, Juergen
Girard, Luc
Peyton, Michael
Weir, Barbara A.
Chen, Tzu-Hsiu
Greulich, Heidi
Barretina, Jordi
Shapiro, Geoffrey I.
Garraway, Levi A.
Gazdar, Adi F.
Minna, John D.
Meyerson, Matthew
Wong, Kwok-Kin
Thomas, Roman K.
TI Predicting drug susceptibility of non-small cell lung cancers based on
genetic lesions
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; COMPARATIVE GENOMIC HYBRIDIZATION; MESSENGER-RNA
EXPRESSION; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; GEFITINIB
SENSITIVITY; BREAST-CANCER; K-RAS; MUTATIONS; INHIBITOR
AB Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large panel of human non-small cell lung cancer (NSCLC) cell lines are highly representative of those of primary NSCLC tumors. Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, we identified molecular and genomic predictors of therapeutic response to clinically relevant compounds. Using this approach, we showed that v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations confer enhanced Hsp90 dependency and validated this finding in mice with KRAS-driven lung adenocarcinoma, as these mice exhibited dramatic tumor regression when treated with an Hsp90 inhibitor. In addition, we found that cells with copy number enhancement of v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2) and ephrin receptor kinase and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC) kinase family genes were exquisitely sensitive to treatment with the SRC/ABL inhibitor dasatinib, both in vitro and when it xenografted into mice. Thus, genomically annotated cell-line collections may help translate cancer genomics information into clinical practice by defining critical pathway dependencies amenable to therapeutic inhibition.
C1 [Sos, Martin L.; Michel, Kathrin; Weiss, Jonathan; Peifer, Martin; Ullrich, Roland; Koker, Mirjam; Fischer, Florian; Fischer, Stefanie; Stueckrath, Isabel; Heynck, Stefanie; Thomas, Roman K.] Max Planck Inst Neurol Res, Klaus Joachim Zulch Labs, Max Planck Soc, D-53931 Cologne, Germany.
[Sos, Martin L.; Michel, Kathrin; Weiss, Jonathan; Peifer, Martin; Ullrich, Roland; Koker, Mirjam; Fischer, Florian; Fischer, Stefanie; Stueckrath, Isabel; Heynck, Stefanie; Thomas, Roman K.] Univ Cologne, Fac Med, D-5000 Cologne 41, Germany.
[Zander, Thomas; Wolf, Juergen; Thomas, Roman K.] Univ Cologne, Dept Internal Med 1, Cologne, Germany.
[Zander, Thomas; Wolf, Juergen; Thomas, Roman K.] Univ Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany.
[Frommolt, Peter; Hellmich, Martin] Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany.
[Li, Danan; Shimamura, Takeshi; Mermel, Craig; Beroukhim, Rameen; Lin, William; Winckler, Wendy; Shah, Kinjal; Moriarty, Whei F.; Hanna, Megan; Verhaak, Roel; Chiang, Derek; Weir, Barbara A.; Chen, Tzu-Hsiu; Greulich, Heidi; Barretina, Jordi; Shapiro, Geoffrey I.; Garraway, Levi A.; Meyerson, Matthew; Wong, Kwok-Kin] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Rauh, Daniel; Thomas, Roman K.] Max Planck Soc, Chem Genom Ctr, Dortmund, Germany.
[Mermel, Craig; Beroukhim, Rameen; Lin, William; Winckler, Wendy; Shah, Kinjal; Moriarty, Whei F.; Hanna, Megan; Verhaak, Roel; Chiang, Derek; Getz, Gad; Weir, Barbara A.; Chen, Tzu-Hsiu; Greulich, Heidi; Barretina, Jordi; Garraway, Levi A.; Meyerson, Matthew] Broad Inst MIT & Harvard, Cambridge, MA USA.
[LaFramboise, Thomas] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.
[Tolosi, Laura] Max Planck Inst Informat, Saarbrucken, Germany.
[Rahnenfuehrer, Joerg] Tech Univ Dortmund, Dept Stat, Dortmund, Germany.
[Girard, Luc; Peyton, Michael; Gazdar, Adi F.; Minna, John D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
[Barretina, Jordi; Garraway, Levi A.; Meyerson, Matthew] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Garraway, Levi A.; Meyerson, Matthew] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Gazdar, Adi F.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
[Minna, John D.] Univ Texas SW Med Ctr Dallas, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA.
[Wong, Kwok-Kin] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA.
RP Thomas, RK (reprint author), Max Planck Inst Neurol Res, Klaus Joachim Zulch Labs, Max Planck Soc, Gleueler Str 50, D-53931 Cologne, Germany.
EM matthew_meyerson@dfci.harvard.edu; kwong1@partners.org; nini@nf.mpg.de
RI Peyton, Michael/A-8728-2008; Meyerson, Matthew/E-7123-2012; Rauh,
Daniel/G-1595-2013; Frommolt, Peter/L-9656-2016;
OI Frommolt, Peter/0000-0002-1966-8014; Rauh, Daniel/0000-0002-1970-7642;
wong, kwok kin/0000-0001-6323-235X
FU NCI NIH HHS [R01 CA122794, P50 CA070907, P50 CA090578, P50CA70907]; NIA
NIH HHS [R01 AG2400401]; NIGMS NIH HHS [T32 GM007753]
NR 79
TC 148
Z9 151
U1 0
U2 13
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2009
VL 119
IS 6
BP 1727
EP 1740
DI 10.1172/JCI37127
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 453HH
UT WOS:000266601000037
PM 19451690
ER
PT J
AU Swenson, JM
Brasso, WB
Ferraro, MJ
Hardy, DJ
Knapp, CC
Lonsway, D
McAllister, S
Reller, LB
Sader, HS
Shortridge, D
Skov, R
Weinstein, MP
Zimmer, BL
Patel, JB
AF Swenson, Jana M.
Brasso, William B.
Ferraro, Mary Jane
Hardy, Dwight J.
Knapp, Cynthia C.
Lonsway, David
McAllister, Sigrid
Reller, L. Barth
Sader, Helio S.
Shortridge, Dee
Skov, Robert
Weinstein, Melvin P.
Zimmer, Barbara L.
Patel, Jean B.
TI Correlation of Cefoxitin MICs with the Presence of mecA in
Staphylococcus spp.
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; METHICILLIN RESISTANCE; DIFFUSION;
MOXALACTAM; AUREUS; SYSTEM
AB This report describes the results of an 11-laboratory study to determine if a cefoxitin broth microdilution MIC test could predict the presence of mecA in staphylococci. Using breakpoints of <= 4 mu g/ml for mecA-negative and >= 6 or 8 mu g/ml for mecA-positive isolates, sensitivity and specificity based on mecA or presumed mecA for Staphylococcus aureus at 18 h of incubation were 99.7 to 100% in three cation-adjusted Mueller-Hinton broths tested. For coagulase-negative strains at 24 h of incubation, breakpoints of <= 2 mu g/ml for mecA-negative and >= 4 mu g/ml for mecA-positive isolates gave sensitivity and specificity of 94 to 99% and 69 to 80%, respectively.
C1 [Swenson, Jana M.; Lonsway, David; McAllister, Sigrid; Patel, Jean B.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Ferraro, Mary Jane] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Brasso, William B.] BD Diagnost Syst, Sparks, MD 21152 USA.
[Hardy, Dwight J.] Univ Rochester, Med Ctr Hosp, Rochester, NY 14642 USA.
[Knapp, Cynthia C.] Trek Diagnost Syst, Cleveland, OH 44131 USA.
[Reller, L. Barth] Duke Univ, Med Ctr, Durham, NC 27710 USA.
[Sader, Helio S.] JMI Labs, N Liberty, IA 52317 USA.
[Shortridge, Dee] BioMerieux Inc, Hazelwood, MO 63042 USA.
[Skov, Robert] Statens Serum Inst, DK-2300 Copenhagen, Denmark.
[Weinstein, Melvin P.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.
[Zimmer, Barbara L.] Siemens Healthcare Diagnost MicroScan, W Sacramento, CA 95691 USA.
RP Swenson, JM (reprint author), Mailstop G08,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM jms1@cdc.gov
NR 9
TC 8
Z9 9
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2009
VL 47
IS 6
BP 1902
EP 1905
DI 10.1128/JCM.02304-08
PG 4
WC Microbiology
SC Microbiology
GA 451EV
UT WOS:000266454400047
PM 19357210
ER
PT J
AU Sequist, LV
Engelman, JA
Lynch, TJ
AF Sequist, Lecia V.
Engelman, Jeffrey A.
Lynch, Thomas J.
TI Toward Noninvasive Genomic Screening of Lung Cancer Patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID GROWTH-FACTOR-RECEPTOR; PROSPECTIVE PHASE-II; ACTIVATING MUTATIONS;
ACQUIRED-RESISTANCE; EGFR MUTATIONS; GENE-MUTATIONS; KINASE DOMAIN;
GEFITINIB; ERLOTINIB; TRIAL
C1 [Sequist, Lecia V.; Engelman, Jeffrey A.; Lynch, Thomas J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Sequist, LV (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
NR 31
TC 12
Z9 12
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 1
PY 2009
VL 27
IS 16
BP 2589
EP 2591
DI 10.1200/JCO.2008.20.4875
PG 3
WC Oncology
SC Oncology
GA 451EX
UT WOS:000266454600006
PM 19414671
ER
PT J
AU Huang, YT
Heist, RS
Chirieac, LR
Lin, XH
Skaug, V
Zienolddiny, S
Haugen, A
Wu, MC
Wang, ZX
Su, L
Asomaning, K
Christiani, DC
AF Huang, Yen-Tsung
Heist, Rebecca S.
Chirieac, Lucian R.
Lin, Xihong
Skaug, Vidar
Zienolddiny, Shanbeh
Haugen, Aage
Wu, Michael C.
Wang, Zhaoxi
Su, Li
Asomaning, Kofi
Christiani, David C.
TI Genome-Wide Analysis of Survival in Early-Stage Non-Small-Cell Lung
Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID SUSCEPTIBILITY LOCUS; ARRAY; INSTABILITY; EXPRESSION; GENES; SPAK
AB Purpose
Lung cancer, of which 85% is non-small-cell (NSCLC), is the leading cause of cancer-related death in the United States. We used genome-wide analysis of tumor tissue to investigate whether single nucleotide polymorphisms (SNPs) in tumors are prognostic factors in early-stage NSCLC.
Patients and Methods
One hundred early-stage NSCLC patients from Massachusetts General Hospital (MGH) were used as a discovery set and 89 NSCLC patients collected by the National Institute of Occupational Health, Norway, were used as a validation set. DNA was extracted from flash-frozen lung tissue with at least 70% tumor cellularity. Genome-wide genotyping was done using the high-density SNP chip. Copy numbers were inferred using median smoothing after intensity normalization. Cox models were used to screen and validate significant SNPs associated with the overall survival.
Results
Copy number gains in chromosomes 3q, 5p, and 8q were observed in both MGH and Norwegian cohorts. The top 50 SNPs associated with overall survival in the MGH cohort (P <= 2.5 x 10(-4)) were selected and examined using the Norwegian cohort. Five of the top 50 SNPs were validated in the Norwegian cohort with false discovery rate lower than 0.05 (P<.016) and all five were located in known genes: STK39, PCDH7, A2BP1, and EYA2. The numbers of risk alleles of the five SNPs showed a cumulative effect on overall survival (P(trend) = 3.80 x 10(-12) and 2.48 x 10(-7) for MGH and Norwegian cohorts, respectively).
Conclusion
Five SNPs were identified that may be prognostic of overall survival in early-stage NSCLC. J Clin Oncol 27:2660-2667. (C) 2009 by American Society of Clinical Oncology
C1 [Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Dept Biostat, Dept Epidemiol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
Natl Inst Occupat Hlth, Dept Biol & Chem Working Environm, Sect Toxicol, Oslo, Norway.
RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM dchris@hsph.harvard.edu
RI Huang, Yen-Tsung/I-1003-2014; Zienolddiny, Shanbeh/O-7392-2015;
OI Wu, Michael C./0000-0002-3357-6570
FU NCI NIH HHS [CA090578, CA092824, P20 CA090578, P50 CA090578, R01
CA074386, R01 CA092824, CA074386]
NR 28
TC 65
Z9 67
U1 0
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 1
PY 2009
VL 27
IS 16
BP 2660
EP 2667
DI 10.1200/JCO.2008.18.7906
PG 8
WC Oncology
SC Oncology
GA 451EX
UT WOS:000266454600016
PM 19414679
ER
PT J
AU Miller, DS
Blessing, JA
Krasner, CN
Mannel, RS
Hanjani, P
Pearl, ML
Waggoner, SE
Boardman, CH
AF Miller, David S.
Blessing, John A.
Krasner, Carolyn N.
Mannel, Robert S.
Hanjani, Parviz
Pearl, Michael L.
Waggoner, Steven E.
Boardman, Cecelia H.
TI Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or
Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A
Study of the Gynecologic Oncology Group
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CELL LUNG-CANCER; MALIGNANT PLEURAL MESOTHELIOMA; REFRACTORY OVARIAN;
MULTITARGETED ANTIFOLATE; 1ST-LINE TREATMENT; CLINICAL-TRIALS;
BREAST-CANCER; SOLID TUMORS; CARBOPLATIN; CISPLATIN
AB Purpose
To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities.
Patients and Methods
A phase II trial was conducted by the Gynecologic Oncology Group. Patients must have had cancer that had progressed on platinum-based primary chemotherapy or recurred within 6 months. Pemetrexed at a dose of 900 mg/m(2) was to be administered as an intravenous infusion over 10 minutes every 21 days. Dose delay and adjustment was permitted for toxicity. Treatment was continued until disease progression or unacceptable adverse effects.
Results
From July 6, 2004, to August 23, 2006, 51 patients were entered. A total of 259 cycles (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients receiving six or more cycles. Overall, the treatment was well tolerated. More serious toxicities (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in 15% of patients. No treatment-related deaths were reported. One patient (2%) had a complete and nine patients (19%) had partial responses, with a median duration response of 8.4 months. Seventeen patients (35%) had stable disease for a median of 4.1 months. Eighteen patients (38%) had increasing disease. Three patients (6%) were not assessable. Median progression-free survival was 2.9 months, and overall survival was 11.4 months.
Conclusion
Pemetrexed has sufficient activity in the treatment of recurrent platinum-resistant ovarian cancer at the dose and schedule tested to warrant further investigation. J Clin Oncol 27:2686-2691. (C) 2009 by American Society of Clinical Oncology
C1 [Miller, David S.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Div Gynecol Oncol, Dallas, TX 75390 USA.
Roswell Pk Canc Inst, Stat & Data Ctr, Gynecol Oncol Grp, Buffalo, NY 14263 USA.
Long Isl Gynecol Oncologists, Smithtown, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Oklahoma, Oklahoma City, OK USA.
Abington Mem Hosp, Rosenfeld Canc Ctr, Abington, PA 19001 USA.
Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
Virginia Commonwealth Univ, Richmond, VA USA.
RP Miller, DS (reprint author), Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Div Gynecol Oncol, 5323 Harry Hines Blvd,J7-124, Dallas, TX 75390 USA.
EM david.miller@utsouthwestern.edu
RI Miller, David/H-4604-2011
OI Miller, David/0000-0002-8215-5887
FU NCI NIH HHS [U10 CA037517, CA 27469, CA 37517, U10 CA027469]
NR 54
TC 68
Z9 71
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 1
PY 2009
VL 27
IS 16
BP 2686
EP 2691
DI 10.1200/JCO.2008.19.2963
PG 6
WC Oncology
SC Oncology
GA 451EX
UT WOS:000266454600019
PM 19332726
ER
PT J
AU Calleo, J
Stanley, MA
Greisinger, A
Wehmanen, O
Johnson, M
Novy, D
Wilson, N
Kunik, M
AF Calleo, Jessica
Stanley, Melinda A.
Greisinger, Anthony
Wehmanen, Oscar
Johnson, Michael
Novy, Diane
Wilson, Nancy
Kunik, Mark
TI Generalized Anxiety Disorder in Older Medical Patients: Diagnostic
Recognition, Mental Health Management and Service Utilization
SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS
LA English
DT Article
DE Generalized anxiety disorder; Primary care; Older patients; Database
study; Medical record review
ID PRIMARY-CARE PATIENTS; UNITED-STATES; PREVALENCE; SYMPTOMS; QUALITY;
ISSUES; COST
AB Background Primary care physicians often treat older adults with Generalized Anxiety Disorder. Objective To estimate physician diagnosis and recognition of anxiety and compare health service use among older adults with GAD with two comparison samples with and without other DSM diagnoses. Methods Participants were 60+ patients of a multi-specialty medical organization. Administrative database and medical records were reviewed for a year. Differences in frequency of health service use were analyzed with logistic regression and between-subjects analysis of covariance. Results Physician diagnosis of GAD was 1.5% and any anxiety was 9%, and recognition of anxiety symptoms was 34% in older adults with GAD. After controlling for medical comorbidity, radiology appointments were increased in the GAD group relative to those with and without other psychiatric diagnoses, chi(2) (2, N = 225) = 4.75, p < .05. Conclusions Most patients with anxiety do not have anxiety or symptoms documented in their medical records.
C1 [Stanley, Melinda A.; Johnson, Michael; Wilson, Nancy; Kunik, Mark] Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA.
[Calleo, Jessica; Stanley, Melinda A.; Wilson, Nancy; Kunik, Mark] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Greisinger, Anthony; Wehmanen, Oscar] Kelsey Res Fdn, Houston, TX USA.
[Johnson, Michael] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA.
[Novy, Diane] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX 77030 USA.
[Kunik, Mark] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Kunik, Mark] Educ & Clin Ctr, VA S Cent Mental Illness Res, N Little Rock, AR USA.
[Kunik, Mark] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Kunik, M (reprint author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe, Houston, TX 77030 USA.
EM mkunik@bcm.tmc.edu
FU NIMH NIH HHS [R01 MH053932, R01 MH053932-09, R01MH053932]
NR 28
TC 25
Z9 26
U1 1
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9583
J9 J CLIN PSYCHOL MED S
JI J. Clin. Psychol. Med. Settings
PD JUN
PY 2009
VL 16
IS 2
BP 178
EP 185
DI 10.1007/s10880-008-9144-5
PG 8
WC Psychology, Clinical
SC Psychology
GA 443NZ
UT WOS:000265918300005
PM 19152056
ER
PT J
AU Fava, M
Asnis, GM
Shrivastava, R
Lydiard, B
Bastani, B
Sheehan, D
Roth, T
AF Fava, Maurizio
Asnis, Gregory M.
Shrivastava, Ram
Lydiard, Bruce
Bastani, Bijan
Sheehan, David
Roth, Thomas
TI Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in
Comorbid Insomnia and Generalized Anxiety Disorder
SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE zolpidem extended-release; insomnia; generalized anxiety disorder;
randomized controlled trial; concomitant pharmacotherapy; escitalopram
ID DOUBLE-BLIND; DEPRESSION; FLUOXETINE; EFFICACY; SAFETY
AB A multicenter, double-blind, parallel-group study was designed to assess the efficacy and safety of zolpidem extended-release coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Patients (N = 383) received open-label escitalopram 10 mg/d and were randomized to either adjunct zolpidem extended-release 12.5 mg or placebo. The primary efficacy measure was change from baseline to week 8 in subjective total sleep time. Secondary efficacy measures included subjective sleep onset latency, number of awakenings, wake time after sleep onset, sleep quality, the Hamilton Rating Scale for Anxiety, the Beck Anxiety Inventory, the Sleep Impact Scale, the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire, and the Sheehan Disability Scale. The last-observation-carried-forward method was used to impute missing values for most efficacy measures. Safety was monitored at each visit. At week 8 and all time points, there was a significant improvement in the zolpidem extended-release/escitalopram group compared with placebo/escitalopram for total sleep time (P < 0.0001). Most of the secondary efficacy measures also significantly favored zolpidem at most visits (P < 0.0001). The most common treatment-emergent adverse events in both groups were nausea, dizziness, headache, fatigue, and dry mouth. Concurrent zolpidem extended-release/escitalopram, compared with placebo/escitalopram, significantly improved insomnia and sleep-related next-day symptoms, but not anxiety symptoms, in patients with comorbid insomnia and generalized anxiety disorder.
C1 [Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA.
[Asnis, Gregory M.] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Shrivastava, Ram] Eastside Comprehens Med Center, New York, NY USA.
[Lydiard, Bruce] SE Hlth Consultants, Charleston, SC USA.
[Bastani, Bijan] NorthCoast Clin Trials Inc, Beachwood, OH USA.
[Sheehan, David] Univ S Florida, Coll Med, Tampa, FL USA.
[Roth, Thomas] Henry Ford Hosp, Sleep Disorders Ctr, Detroit, MI 48202 USA.
RP Fava, M (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, 55 Fruit St,BUL 351, Boston, MA 02114 USA.
EM MFAVA@PARTNERS.ORG
FU Sanofi-Aventis US
FX Funding for this trial was provided by Sanofi-Aventis US. The authors of
this article were fully responsible for the content and editorial
decisions and received no financial support or other form of
compensation related to the development of this article.
NR 25
TC 35
Z9 36
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-0749
J9 J CLIN PSYCHOPHARM
JI J. Clin. Psychopharmacol.
PD JUN
PY 2009
VL 29
IS 3
BP 222
EP 230
DI 10.1097/JCP.0b013e3181a390ba
PG 9
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 445VF
UT WOS:000266078900006
PM 19440075
ER
PT J
AU Adler, LA
Zimmerman, B
Starr, HL
Silber, S
Palumbo, J
Orman, C
Spencer, T
AF Adler, Lenard A.
Zimmerman, Brenda
Starr, H. Lynn
Silber, Steve
Palumbo, Joseph
Orman, Camille
Spencer, Thomas
TI Efficacy and Safety of OROS Methylphenidate in Adults With
Attention-Deficit/Hyperactivity Disorder A Randomized,
Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study
SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE Concerta; OROS methylphenidate; adult ADHD; stimulant
ID DEFICIT HYPERACTIVITY DISORDER; ORAL SYSTEM METHYLPHENIDATE; SALTS
EXTENDED-RELEASE; OPEN-LABEL TRIAL; LATE-ONSET; ADHD; CHILDREN;
PERFORMANCE; OUTCOMES; MULTICENTER
AB Objective: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the management of attentiondeficit/hyperactivity, disorder (ADHD) in adults.
Methods: A randomized, 7-week, double-blind, placebo-controlled, dose-escalation, parallel-group study of OROS methylphenidate 36, 54, 72, 90, or 108 mg/d versus placebo was conducted in adults with ADHD, The primary end point was the Adult ADHD Investigator Symptom Report Scale. Other assessments included the Clinical Global Impressions-Improvement scale, a post hoc responder analysis, adverse events, and vital signs.
Results: Two hundred twenty-six subjects (56.2% male; mean age, 39.0 years; range, 18-65 years) were included in the intention-to-treat population (110 subjects on OROS methylphenidate; 116 subjects on placebo). OROS methylphenidate resulted in greater ADHD symptom improvement than placebo as demonstrated by a statistically significantly lower least squares mean change from baseline in Adult ADHD Investigator Symptom Report Scale total score at the final visit (last observation carried forward [LOCF]; P = 0.012). Subjects on OROS methylphenidate also had a significantly lower least squares mean Clinical Global Impressions-improvement score at the final visit (LOCF; P = 0.008). A significantly greater proportion of subjects on OROS methylphenidate (36.9%, 38/103 subjects) were responders at the final visit (LOCF) compared with placebo (20.9%, 24/115 subjects; P = 0.009). OROS methylphenidate was well tolerated. Adverse events were reported by 93 (84.5%) of the 110 OROS methylphenidate-treated subjects versus 74 (63.8%) of the 116 placebo-treated subjects. No serious treatment-emergent adverse events and no deaths were reported. Similar mean changes from baseline to final visit (LOCF) for systolic and diastolic blood pressures for the OROS methylphenidate and placebo groups were observed.
Conclusions: in a dose escalation ranging from 36 to 108 mg/d, OROS methylphenidate is effective and well tolerated in the management of ADHD in adults.
C1 [Adler, Lenard A.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA.
[Adler, Lenard A.] New York VA Harbor Healthcare Syst, New York, NY USA.
[Zimmerman, Brenda] McNeil Consumer Healthcare, Philadelphia, PA USA.
[Starr, H. Lynn] OrthoMcNeil Janssen Sci Affairs LLC, Titusville, NJ USA.
[Silber, Steve; Palumbo, Joseph; Orman, Camille] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Spencer, Thomas] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Spencer, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
RP Adler, LA (reprint author), NYU, Sch Med, Dept Psychiat, Suite 7D,530 1st Ave, New York, NY 10016 USA.
EM lenard.adler@med.nyu.edu
OI Adler, Len/0000-0002-9812-8234
FU Johnson & Johnson Pharmaceutical Research and Development, Titusville,
NJ
FX The study reported and the production of the manuscript were funded by
Johnson & Johnson Pharmaceutical Research and Development, Titusville,
NJ.
NR 48
TC 59
Z9 61
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-0749
J9 J CLIN PSYCHOPHARM
JI J. Clin. Psychopharmacol.
PD JUN
PY 2009
VL 29
IS 3
BP 239
EP 247
DI 10.1097/JCP.0b013e3181a390ce
PG 9
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 445VF
UT WOS:000266078900008
PM 19440077
ER
PT J
AU Goodson, JM
Groppo, D
Halem, S
Carpino, E
AF Goodson, J. M.
Groppo, D.
Halem, S.
Carpino, E.
TI Is Obesity an Oral Bacterial Disease?
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE bacterial physiology; obesity; overweight; infectobesity saliva; body
mass index; oral health
ID PERIODONTAL TREATMENT; GINGIVITIS; MICROBIOTA; HEALTH; ALPHA
AB The world-wide explosion of overweight people has been called an epidemic. The inflammatory nature of obesity is widely recognized. Could it really be an epidemic involving an infectious agent? In this climate of concern over the increasing prevalence of overweight conditions in our society, we focus on the possible role of oral bacteria as a potential direct contributor to obesity. To investigate this possibility, we measured salivary bacterial populations of overweight women. Saliva was collected from 313 women with a body mass index between 27 and 32, and bacterial populations were measured by DNA probe analysis. Levels in this group were compared with data from a population of 232 healthy individuals from periodontal disease studies. The median percentage difference of 7 of the 40 bacterial species measured was greater than 2% in the saliva of overweight women. Classification tree analysis of salivary microbiological composition revealed that 98.4% of the overweight women could be identified by the presence of a single bacterial species (Selenomonas noxia) at levels greater than 1.05% of the total salivary bacteria. Analysis of these data suggests that the composition of salivary bacteria changes in overweight women. It seems likely that these bacterial species could serve as biological indicators of a developing overweight condition. Of even greater interest, and the subject of future research, is the possibility that oral bacteria may participate in the pathology that leads to obesity.
C1 [Goodson, J. M.; Halem, S.; Carpino, E.] Forsyth Inst, Boston, MA USA.
[Groppo, D.] Univ Estadual Campinas, Piracicaba Dent Sch, Piracicaba, SP, Brazil.
RP Goodson, JM (reprint author), Forsyth Inst, 140 Fenway, Boston, MA USA.
EM mgoodson@forsyth.org
RI Groppo, Francisco/C-3516-2012
OI Groppo, Francisco/0000-0002-8513-773X
FU Interleukin Genetics of Waltham, MA, USA; National Institute of Dental
and Craniofacial Research [DE018184]
FX Special appreciation to those who aided in this study, including B.
Newman, J. Leonel, C. Floros, M. Chvetchkova, M. Sweeney, and E. Regan.
This study was funded by Interleukin Genetics of Waltham, MA, USA, and
by DE018184 from the National Institute of Dental and Craniofacial
Research.
NR 16
TC 55
Z9 57
U1 7
U2 28
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD JUN
PY 2009
VL 88
IS 6
BP 519
EP 523
DI 10.1177/0022034509338353
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 468FD
UT WOS:000267801300004
PM 19587155
ER
PT J
AU Shum, WWC
Da Silva, N
Brown, D
Breton, S
AF Shum, Winnie W. C.
Da Silva, Nicolas
Brown, Dennis
Breton, Sylvie
TI Regulation of luminal acidification in the male reproductive tract via
cell-cell crosstalk
SO JOURNAL OF EXPERIMENTAL BIOLOGY
LA English
DT Review
DE H(+)-ATPase; pseudostratified epithelia; basal cells; clear cells
ID VACUOLAR H+-ATPASE; ANGIOTENSIN-CONVERTING ENZYME; RENAL
TUBULAR-ACIDOSIS; PROTON PUMP ATPASE; MEDULLARY COLLECTING DUCT; SOLUBLE
ADENYLYL-CYCLASE; VAS-DEFERENS EPITHELIA; AMINO-TERMINAL DOMAIN; IN-VIVO
DISSOCIATION; ACTIN-BINDING SITE
AB In the epididymis, spermatozoa acquire their ability to become motile and to fertilize an egg. A luminal acidic pH and a low bicarbonate concentration help keep spermatozoa in a quiescent state during their maturation and storage in this organ. Net proton secretion is crucial to maintain the acidity of the luminal fluid in the epididymis. A sub-population of epithelial cells, the clear cells, express high levels of the proton-pumping V-ATPase in their apical membrane and are important contributors to luminal acidification. This review describes selected aspects of V-ATPase regulation in clear cells. The assembly of a particular set of V-ATPase subunit isoforms governs the targeting of the pump to the apical plasma membrane. Regulation of V-ATPase-dependent proton secretion occurs via recycling mechanisms. The bicarbonate-activated adenylyl cyclase is involved in the nonhormonal regulation of V-ATPase recycling, following activation of bicarbonate secretion by principal cells. The V-ATPase is also regulated in a paracrine manner by luminal angiotensin II by activation of the angiotensin II type 2 receptor (AGTR2), which is located in basal cells. Basal cells have the remarkable property of extending long and slender cytoplasmic projections that cross the tight junction barrier to monitor the luminal environment. Clear cells are activated by a nitric oxide signal that originates from basal cells. Thus, a complex interplay between the different cell types present in the epithelium leads to activation of the luminal acidifying capacity of the epididymis, a process that is crucial for sperm maturation and storage.
C1 [Breton, Sylvie] Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Div Nephrol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Breton, S (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Div Nephrol, Boston, MA 02114 USA.
EM sbreton@partners.org
FU National Institutes of Health [HD40793, DK38452, HD045821]; Center for
the Study of Inflammatory Bowel Disease [DK43351]; Boston Area Diabetes
and Endocrinology Research Center [DK57521]
FX We would like to thank Eric Hill for his excellent technical assistance.
This work was supported by National Institutes of Health Grants HD40793,
DK38452 and HD045821. The work performed in the Microscopy Core Facility
of the Massachusetts General Hospital Program in Membrane Biology was
supported by Center for the Study of Inflammatory Bowel Disease Grant
DK43351 and Boston Area Diabetes and Endocrinology Research Center Award
DK57521. Deposited in PMC for release after 12 months.
NR 87
TC 54
Z9 60
U1 0
U2 1
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0022-0949
J9 J EXP BIOL
JI J. Exp. Biol.
PD JUN 1
PY 2009
VL 212
IS 11
BP 1753
EP 1761
DI 10.1242/jeb.027284
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 446HY
UT WOS:000266113900017
PM 19448084
ER
PT J
AU Brown, D
Paunescu, TG
Breton, S
Marshansky, V
AF Brown, Dennis
Paunescu, Teodor G.
Breton, Sylvie
Marshansky, Vladimir
TI Regulation of the V-ATPase in kidney epithelial cells: dual role in
acid-base homeostasis and vesicle trafficking
SO JOURNAL OF EXPERIMENTAL BIOLOGY
LA English
DT Review
DE H(+)-ATPase; soluble adenylyl cyclase; intercalated cells; proton
secretion; acidification; pH sensing
ID VACUOLAR H+-ATPASE; MEDULLARY COLLECTING DUCT; SOLUBLE ADENYLYL-CYCLASE;
RENAL INTERCALATED CELLS; CARBONIC-ANHYDRASE ACTIVITY; EPIDIDYMAL CLEAR
CELLS; IN-VIVO DISSOCIATION; ROD-SHAPED PARTICLES; B2 SUBUNIT ISOFORM;
ACTIN-BINDING SITE
AB The proton-pumping V-ATPase is a complex, multi-subunit enzyme that is highly expressed in the plasma membranes of some epithelial cells in the kidney, including collecting duct intercalated cells. It is also located on the limiting membranes of intracellular organelles in the degradative and secretory pathways of all cells. Different isoforms of some V-ATPase subunits are involved in the targeting of the proton pump to its various intracellular locations, where it functions in transporting protons out of the cell across the plasma membrane or acidifying intracellular compartments. The former process plays a critical role in proton secretion by the kidney and regulates systemic acid-base status whereas the latter process is central to intracellular vesicle trafficking, membrane recycling and the degradative pathway in cells. We will focus our discussion on two cell types in the kidney: (1) intercalated cells, in which proton secretion is controlled by shuttling V-ATPase complexes back and forth between the plasma membrane and highly-specialized intracellular vesicles, and (2) proximal tubule cells, in which the endocytotic pathway that retrieves proteins from the glomerular ultrafiltrate requires V-ATPase-dependent acidification of post-endocytotic vesicles. The regulation of both of these activities depends upon the ability of cells to monitor the pH and/or bicarbonate content of their extracellular environment and intracellular compartments. Recent information about these pH-sensing mechanisms, which include the role of the V-ATPase itself as a pH sensor and the soluble adenylyl cyclase as a bicarbonate sensor, will be addressed in this review.
C1 [Brown, Dennis] Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Div Nephrol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Brown, D (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Div Nephrol, Boston, MA 02114 USA.
EM brown.dennis@mgh.harvard.edu
FU NIH [R37 DK42956, PO1 DK38452, HD40793, KO1 DK73266]
FX We thank all of our colleagues who have made important contributions to
the work from the MGH Program in Membrane Biology that is included in
this review. We have received critical support for this work from
several grants from the NIH over the years, including R37 DK42956 (D.
B.), PO1 DK38452 (D. B., S. B. and V. M.), HD40793 (S. B.) and KO1
DK73266 (T. G. P.). Deposited in PMC for release after 12 months.
NR 119
TC 69
Z9 74
U1 1
U2 5
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0022-0949
J9 J EXP BIOL
JI J. Exp. Biol.
PD JUN 1
PY 2009
VL 212
IS 11
BP 1762
EP 1772
DI 10.1242/jeb.028803
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 446HY
UT WOS:000266113900018
PM 19448085
ER
PT J
AU Tatum, RP
Pellegrini, CA
AF Tatum, Roger P.
Pellegrini, Carlos A.
TI How I Do It: Laparoscopic Heller Myotomy with Toupet Fundoplication for
Achalasia
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
DE Achalasia; Heller myotomy; Antireflux procedure
ID MINIMALLY INVASIVE SURGERY; 8-YEAR EXPERIENCE
AB Achalasia, an esophageal motility disorder characterized by aperistalsis and failure of lower esophageal sphincter (LES) relaxation, is most effectively treated by surgical ablation of the LES. In this report, we describe our technique of laparoscopic extended Heller myotomy with Toupet partial posterior fundoplication. The technical details of this procedure include careful division of the longitudinal and circular muscle fibers of the LES anteriorly, including extension of the myotomy 3 cm distal to the esophagogastric junction onto the gastric cardia. The Toupet procedure, involving a posterior wrap of the gastric fundus which is secured to both edges of the myotomy as well as to the crura of the hiatus, is added to prevent post-myotomy gastroesophageal reflux. From a recently published report, mean dysphagia scores remained low (3 out of 10 severity on a visual analog scale) and symptoms of reflux were reported minimally in a series of 63 patients followed for a median of 45 months. This technique provides excellent and durable relief of dysphagia associated with achalasia while minimizing post-myotomy acid reflux symptoms.
C1 [Tatum, Roger P.; Pellegrini, Carlos A.] Univ Washington, Dept Surg, VA Puget Sound HCS, Seattle, WA 98108 USA.
RP Tatum, RP (reprint author), Univ Washington, Dept Surg, VA Puget Sound HCS, 1660 S Columbian Way,S-112 Gs, Seattle, WA 98108 USA.
EM rtatum@u.washington.edu
NR 13
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD JUN
PY 2009
VL 13
IS 6
BP 1120
EP 1124
DI 10.1007/s11605-008-0585-9
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 440FM
UT WOS:000265686200019
PM 18622657
ER
PT J
AU Weingart, SN
Saadeh, MG
Simchowitz, B
Gandhi, TK
Nekhlyudov, L
Studdert, DM
Puopolo, AL
Shulman, LN
AF Weingart, Saul N.
Saadeh, Mark G.
Simchowitz, Brett
Gandhi, Tejal K.
Nekhlyudov, Larissa
Studdert, David M.
Puopolo, Ann Louise
Shulman, Lawrence N.
TI Process of Care Failures in Breast Cancer Diagnosis
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Patient Safety Congress 2007
CY MAY 02-04, 2007
CL Washington, DC
DE breast cancer; diagnostic errors; medical errors; quality of health care
ID CLOSED MALPRACTICE CLAIMS; 4 LIABILITY INSURERS; ADVERSE EVENTS; DELAYED
DIAGNOSES; NEGLIGENT CARE; FOLLOW-UP; WOMEN; STAGE; MAMMOGRAPHY;
PHYSICIANS
AB Process of care failures may contribute to diagnostic errors in breast cancer care.
To identify patient- and provider-related process of care failures in breast cancer screening and follow-up in a non-claims-based cohort.
Retrospective chart review of a cohort of patients referred to two Boston cancer centers with new breast cancer diagnoses between January 1, 1999 and December 31, 2004.
We identified 2,275 women who reported a parts per thousand yen90 days between symptom onset and breast cancer diagnosis or presentation with at least stage II disease. We then selected the 340 (14.9%) whose physicians shared an electronic medical record. We excluded 238 subjects whose records were insufficient for review, yielding a final cohort of 102 patients.
None
We tabulated the number and types of process of care failures and examined risk factors using bivariate analyses and multivariable Poisson regression.
Twenty-six of 102 patients experienced a parts per thousand yen1 process of care failure. The most common failures occurred when physicians failed to perform an adequate physical examination, when patients failed to seek care, and when diagnostic or laboratory tests were ordered but patients failed to complete them. Failures were attributed in similar numbers to provider- and patient-related factors (n = 30 vs. n = 25, respectively). Process of care failures were more likely when the patient's primary care physician was male (IRR 2.8, 95% CI 1.2 to 6.5) and when the patient was non-white (IRR 2.8, 95% CI 1.4 to 5.7).
Process failures were common in this patient cohort, with both clinicians and patients contributing to breakdowns in the diagnostic process.
C1 [Weingart, Saul N.; Saadeh, Mark G.; Simchowitz, Brett; Shulman, Lawrence N.] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA.
[Nekhlyudov, Larissa] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
[Gandhi, Tejal K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Nekhlyudov, Larissa] Harvard Vanguard Med Associates, Boston, MA USA.
[Studdert, David M.] Univ Melbourne, Melbourne Law Sch, Melbourne, Vic, Australia.
[Puopolo, Ann Louise] Harvard Med Inst, Risk Management Fdn, Boston, MA USA.
RP Weingart, SN (reprint author), Dana Farber Canc Inst, Ctr Patient Safety, 44 Binney St, Boston, MA 02115 USA.
EM saul_weingart@dfci.harvard.edu
NR 35
TC 10
Z9 11
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 702
EP 709
DI 10.1007/s11606-009-0982-0
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300002
PM 19387748
ER
PT J
AU Krebs, EE
Lorenz, KA
Bair, MJ
Damush, TM
Wu, JW
Sutherland, JM
Asch, SM
Kroenke, K
AF Krebs, Erin E.
Lorenz, Karl A.
Bair, Matthew J.
Damush, Teresa M.
Wu, Jingwei
Sutherland, Jason M.
Asch, Steven M.
Kroenke, Kurt
TI Development and Initial Validation of the PEG, a Three-item Scale
Assessing Pain Intensity and Interference
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE pain; measurement; primary care
ID LOW-BACK-PAIN; PRIMARY-CARE; IMMPACT RECOMMENDATIONS; CLINICAL-TRIALS;
HEALTH-STATUS; SHORT-FORM; VALIDITY; OUTCOMES; RESPONSIVENESS;
RELIABILITY
AB Inadequate pain assessment is a barrier to appropriate pain management, but single-item "pain screening" provides limited information about chronic pain. Multidimensional pain measures such as the Brief Pain Inventory (BPI) are widely used in pain specialty and research settings, but are impractical for primary care. A brief and straightforward multidimensional pain measure could potentially improve initial assessment and follow-up of chronic pain in primary care.
To develop an ultra-brief pain measure derived from the BPI.
Development of a shortened three-item pain measure and initial assessment of its reliability, validity, and responsiveness.
We used data from 1) a longitudinal study of 500 primary care patients with chronic pain and 2) a cross-sectional study of 646 veterans recruited from ambulatory care.
Selected items assess average pain intensity (P), interference with enjoyment of life (E), and interference with general activity (G). Reliability of the three-item scale (PEG) was alpha = 0.73 and 0.89 in the two study samples. Overall, construct validity of the PEG was good for various pain-specific measures (r = 0.60-0.89 in Study 1 and r = 0.77-0.95 in Study 2), and comparable to that of the BPI. The PEG was sensitive to change and differentiated between patients with and without pain improvement at 6 months.
We provide strong initial evidence for reliability, construct validity, and responsiveness of the PEG among primary care and other ambulatory clinic patients. The PEG may be a practical and useful tool to improve assessment and monitoring of chronic pain in primary care.
C1 [Krebs, Erin E.; Bair, Matthew J.; Damush, Teresa M.; Kroenke, Kurt] Regenstrief Inst Inc, Indianapolis, IN USA.
[Krebs, Erin E.; Bair, Matthew J.; Damush, Teresa M.; Wu, Jingwei; Kroenke, Kurt] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA.
[Sutherland, Jason M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03756 USA.
[Lorenz, Karl A.; Asch, Steven M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Lorenz, Karl A.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA.
[Lorenz, Karl A.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Krebs, Erin E.; Bair, Matthew J.; Damush, Teresa M.; Kroenke, Kurt] Roudebush VAMC, Ctr Implementing Evidence Based Practice, Indianapolis, IN 46202 USA.
RP Krebs, EE (reprint author), Roudebush VAMC, Ctr Implementing Evidence Based Practice, 11H,1481 W 10th St, Indianapolis, IN 46202 USA.
EM krebse@iupui.edu
FU National Institute of Mental Health [MH-071268]; Health Services
Research & Development (HSRD); US Department of Veterans Affairs
[IIR-03-150]; VA HSRD
FX SCAMP was supported by a grant from the National Institute of Mental
Health to Dr. Kroenke (MH-071268). HELP-Vets was supported by the Health
Services Research & Development (HSR&D) service of the US Department of
Veterans Affairs (IIR-03-150). Drs. Krebs, Lorenz, and Bair were
supported by VA HSR&D Research Career Development Awards.
NR 41
TC 67
Z9 67
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 733
EP 738
DI 10.1007/s11606-009-0981-1
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300007
PM 19418100
ER
PT J
AU Kramer, BJ
Vivrette, RL
Satter, DE
Jouldjian, S
McDonald, LR
AF Kramer, B. Josea
Vivrette, Rebecca L.
Satter, Delight E.
Jouldjian, Stella
McDonald, Leander Russell
TI Dual Use of Veterans Health Administration and Indian Health Service:
Healthcare Provider and Patient Perspectives
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE veterans; rural health; qualitative research; patient preferences;
health services research
ID AMERICAN-INDIANS; AMBULATORY-CARE; AFFAIRS; ACCESS; MEDICARE; VA;
NATIVES; POLICY
AB Many American Indian and Alaska Native veterans are eligible for healthcare from Veterans Health Administration (VHA) and from Indian Health Service (IHS). These organizations executed a Memorandum of Understanding in 2003 to share resources, but little was known about how they collaborated to deliver healthcare.
To describe dual use from the stakeholders' perspectives, including incentives that encourage cross-use, which organization's primary care is "primary," and the potential problems and opportunities for care coordination across VHA and IHS.
VHA healthcare staff, IHS healthcare staff and American Indian and Alaska Native veterans.
Focus groups were conducted using a semi-structured guide. A software-assisted text analysis was performed using grounded theory to develop analytic categories.
Dual use was driven by variation in institutional resources, leading patients to actively manage health-seeking behaviors and IHS providers to make ad hoc recommendations for veterans to seek care at VHA. IHS was the "primary" primary care for dual users. There was little coordination between VHA and IHS resulting in delays and treatment conflicts, but all stakeholder groups welcomed future collaboration.
Fostering closer alignment between VHA and IHS would reduce care fragmentation and improve accountability for patient care.
C1 [Kramer, B. Josea; Vivrette, Rebecca L.; Jouldjian, Stella] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA.
[Kramer, B. Josea] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Satter, Delight E.] Univ Calif Los Angeles, Ctr Healthcare Policy & Res, Los Angeles, CA 90024 USA.
[McDonald, Leander Russell] Cankdeska Cikana Community Coll, Ft Totten, ND 58335 USA.
RP Kramer, BJ (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, 16111 Plummer St, Sepulveda, CA 91343 USA.
EM Josea.Kramer@va.gov
FU VA Health Services Research and Development Service [ACC 03-304]
FX This study, "VA and Indian Health Service: Access for American Indian
Veterans," was funded by the VA Health Services Research and Development
Service, ACC 03-304. We gratefully acknowledge the advice of the study's
national VHA-IHS Advisory Committee and Elizabeth M. Yano, PhD, MSPH, of
the VA Center for the Study of Healthcare Provider Behavior, for their
comments and suggestions on this article. The project also benefited
from technical assistance in developing the moderator discussion guide
from Melissa Scherwinski, MSW of the VA Employee Education System,
Steven P. Wallace, PhD of UCLA Center for Healthcare Policy and Diane
Weiner, PhD, consulting anthropologist. We also acknowledge the
assistance of local site principle investigators at the participating
Veterans Health Administration (VHA) and Indian Health Service (IHS)
facilities, and thank the Tribal Councils for allowing us to conduct
focus groups with stakeholders in their respective communities. This
report presents findings and conclusions of the authors; it does not
necessarily reflect the opinions or policies of the Department of
Veterans Affairs or the Indian Health Service.
NR 38
TC 12
Z9 12
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 758
EP 764
DI 10.1007/s11606-009-0962-4
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300012
PM 19381730
ER
PT J
AU Dhaliwal, G
AF Dhaliwal, Gurpreet
TI Teaching Medicine to Non-English Speaking Background Learners in a
Foreign Country
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE Non-English speaking background; English as a second language; Medical
education; International teaching
ID EDUCATION; REFORM; JAPAN
AB Teaching abroad exposes medical educators to unfamiliar teaching methods and learning styles that can enhance their overall teaching repertoire. Based on the author's experience teaching residents for one month at a community hospital in Japan and a review of the non-English speaking background (NESB) educational literature, pedagogical principles and lessons for successful international NESB instruction are outlined. These methods include understanding the dissimilar linguistic, cultural, and academic backgrounds of the learners, emphasizing pace and clarity of speech, presenting a conceptual framework instead of detailed discourse on subjects, and regular visual reinforcement of spoken words. The limitations introduced by the language barrier and the use of interpreters are briefly discussed. As society and institutions of higher learning become more global and multicultural, clinician-educators may benefit from teaching in other countries in order to enhance their teaching skills with NESB learners, both abroad and in their own institutions.
C1 [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA.
EM gurpreet.dhaliwal@va.gov
NR 15
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 771
EP 773
DI 10.1007/s11606-009-0967-z
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300014
PM 19381729
ER
PT J
AU Yi, K
Mujat, M
Sun, W
Burnes, D
Latina, MA
Lin, DT
Deschler, DG
Rubin, PAD
Park, BH
de Boer, JF
Chen, TC
AF Yi, Kayoung
Mujat, Mircea
Sun, Wei
Burnes, Daina
Latina, Mark A.
Lin, Derrick T.
Deschler, Daniel G.
Rubin, Peter A. D.
Park, Boris Hyle
de Boer, Johannes F.
Chen, Teresa C.
TI Imaging of Optic Nerve Head Drusen Improvements With Spectral Domain
Optical Coherence Tomography
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE optic nerve head drusen (ONHD); spectral domain optical coherence
tomography (SDOCT); histology; glaucoma; imaging
ID FIBER LAYER THICKNESS; DISC DRUSEN; SPEED; EYES
AB Objective: To demonstrate a new algorithm that can determine the shape, location, and volume of optic nerve head drusen (ONHD), which were imaged with spectral domain optical coherence tomography (SDOCT).
Methods: one exenteration patient and 4 glaucoma patients with bilateral ONHD were recruited from the Massachusetts Eye and Ear Infirmary and from a private practice office. Images were obtained using an experimental SDOCT system developed at the Wellman Center for Photomedicine, Massachusetts General Hospital, With axial resolutions of about 6 mu m, SDOCT can obtain 2-dimensional images in 1/29 of a second, compared with commercially available time domain OCT instruments with Wpm resolution images in 1.28 seconds. The volumes of ONHD were calculated with a new algorithm and were then correlated with visual Field mean deviation.
Results: SDOCT can display 2-dimensional images comparable with histology and 3-dimensional videos of ONHD. ONHD are signal-poor regions with high-signaled borders. Larger ONHD volumes are directly correlated with larger mean deviation absolute values on Humphrey Visual field testing.
Conclusions: SDOCT is a potentially better technique for ONHD imaging and may improve the diagnosis and management of patients with both OHND and glaucoma.
C1 [Chen, Teresa C.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Dept Ophthalmol, Boston, MA 02114 USA.
[Yi, Kayoung; Mujat, Mircea; Burnes, Daina; Lin, Derrick T.; Deschler, Daniel G.; Park, Boris Hyle; de Boer, Johannes F.; Chen, Teresa C.] Harvard Univ, Sch Med, Boston, MA USA.
[Lin, Derrick T.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Mujat, Mircea; Sun, Wei; Burnes, Daina; Park, Boris Hyle; de Boer, Johannes F.] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Sun, Wei] Boston Univ, Dept Phys, Boston, MA 02215 USA.
[Latina, Mark A.] Andover Eye Associates, Andover, MA USA.
[Rubin, Peter A. D.] Eye Plast Consultants, Brookline, MA USA.
[Yi, Kayoung] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Ophthalmol, Seoul, South Korea.
[de Boer, Johannes F.] Vrije Univ Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands.
RP Chen, TC (reprint author), Massachusetts Eye & Ear Infirm, Glaucoma Serv, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM teresa_chen@meei.harvard.edu
RI de Boer, Johannes/B-7590-2012
OI de Boer, Johannes/0000-0003-1253-4950
FU National Institute of Health NIH [R01 EY014975]; NEI [EY014104]
FX Sponsored by the National Institute of Health NIH-R01 EY014975, and NEI
Supported Vision-Core Grant EY014104.
NR 25
TC 16
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1057-0829
J9 J GLAUCOMA
JI J. Glaucoma
PD JUN-JUL
PY 2009
VL 18
IS 5
BP 373
EP 378
DI 10.1097/IJG.0b013e31818624a4
PG 6
WC Ophthalmology
SC Ophthalmology
GA 458XK
UT WOS:000267062400005
PM 19525727
ER
PT J
AU Joseph, J
Pencina, MJ
Wang, TJ
Hayes, L
Tofler, GH
Jacques, P
Selhub, J
Levy, D
D'Agostino, RB
Benjamin, EJ
Vasan, RS
AF Joseph, Jacob
Pencina, Michael J.
Wang, Thomas J.
Hayes, Laura
Tofler, Geoffrey H.
Jacques, Paul
Selhub, Jacob
Levy, Daniel
D'Agostino, Ralph B., Sr.
Benjamin, Emelia J.
Vasan, Ramachandran S.
TI Cross-sectional relations of multiple biomarkers representing distinct
biological pathways to plasma markers of collagen metabolism in the
community
SO JOURNAL OF HYPERTENSION
LA English
DT Article
DE biomarkers; cardiac remodeling; collagen; hyperhomocysteinemia; matrix
ID ATRIAL-NATRIURETIC-PEPTIDE; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR
RISK-FACTORS; CORONARY-HEART-DISEASE; SMOOTH-MUSCLE-CELLS;
HYPERHOMOCYSTEINEMIA LEADS; HYPERTENSIVE RATS; CARDIAC STRUCTURE;
HOMOCYSTEINE; FIBROSIS
AB Objective Hyperhomocysteinemia, neurohormonal activation, inflammation and altered fibrinolysis have been linked to atherothrombosis as well as to myocardial fibrosis and heart failure. Hence, we related a panel of biomarkers representing these pathways to plasma markers of collagen metabolism in a large community-based sample.
Methods We related nine biomarkers representing select biologic pathways (independent variables: C-reactive protein, B-type natriuretic peptide, N-terminal proatrial natriuretic peptide, aldosterone, renin, fibrinogen, D-dimer, plasminogen activator inhibitor-1 and homocysteine) to three plasma markers of collagen turnover [dependent variables, separate models for each: aminoterminal propeptide of type III collagen, tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-9 (present versus absent)] in 921 Framingham Heart study participants (mean age 57 years; 58% women). Participants were separated a priori into those with left ventricular end-diastolic dimensions and wall thickness below sex-specific median values (referent group) and either measure at least 90th sex-specific percentile ('remodeled' group). We used stepwise multivariable regression analysis adjusting for cardiovascular risk factors to relate the panel of systemic biomarkers to the three biomarkers of collagen metabolism.
Results Plasma homocysteine was positively related to all three markers of collagen metabolism in the remodeled group and to aminoterminal propeptide of type III collagen and tissue inhibitor of metalloproteinases-1 in the referent group. Plasminogen activator inhibitor-1 was positively related to aminoterminal propeptide of type III collagen and tissue inhibitor of metalloproteinases-1 in both groups, whereas the natriuretic peptides were associated positively with these collagen markers in the referent group.
Conclusion In our large community-based sample, plasma homocysteine and plasminogen activator inhibitor-1 were positively related to circulating collagen biomarkers, consistent with experimental studies implicating these pathways in cardiovascular collagen turnover. J Hypertens 27:1317-1324 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Joseph, Jacob] VA Boston Healthcare Syst, Boston, MA USA.
[Joseph, Jacob; Pencina, Michael J.; Hayes, Laura; Benjamin, Emelia J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Wang, Thomas J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tofler, Geoffrey H.; Levy, Daniel; D'Agostino, Ralph B., Sr.; Benjamin, Emelia J.; Vasan, Ramachandran S.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Jacques, Paul; Selhub, Jacob] Tufts Univ, Boston, MA 02111 USA.
RP Joseph, J (reprint author), VA Boston Healthcare Syst, Cardiol Sect 111, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Jacob.joseph@bmc.org
OI Ramachandran, Vasan/0000-0001-7357-5970; Benjamin,
Emelia/0000-0003-4076-2336
FU National Heart, Lung and Blood Institute's Framingham Heart Study
[N01-HC-25195]; NIH [K23-HL-074077, RO1 HL67288, HL080124, K24-HL04334]
FX This work was supported by the National Heart, Lung and Blood
Institute's Framingham Heart Study (contract No. N01-HC-25195) and NIH
grants K23-HL-074077 (T. J. W.), RO1 HL67288, HL080124 and K24-HL04334
(R. S. V.).
NR 34
TC 4
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0263-6352
J9 J HYPERTENS
JI J. Hypertens.
PD JUN
PY 2009
VL 27
IS 6
BP 1317
EP 1324
DI 10.1097/HJH.0b013e328329fc20
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 507MP
UT WOS:000270858600009
PM 19357531
ER
PT J
AU Andersson, A
Yang, SC
Huang, M
Zhu, L
Kar, UK
Batra, RK
Elashoff, D
Strieter, RM
Dubinett, SM
Sharma, S
AF Andersson, Asa
Yang, Seok-Chul
Huang, Min
Zhu, Li
Kar, Upendra K.
Batra, Rai K.
Elashoff, David
Strieter, Robert M.
Dubinett, Steven M.
Sharma, Sherven
TI IL-7 Promotes CXCR3 Ligand-Dependent T Cell Antitumor Reactivity in Lung
Cancer
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY CELLS; OVARIAN-CANCER; CUTTING EDGE; INTERLEUKIN-7; FOXP3;
EXPRESSION; CARCINOMA; LYMPHOCYTES; HOMEOSTASIS; PROGNOSIS
AB We are evaluating the immune enhancing activities of cytokines for their optimum utility in augmenting cellular immune responses against lung cancer. In this study, we evaluated the mechanism of antitumor responses following IL-7 administration to mice bearing established Lewis lung cancer. IL-7 decreased tumor burden with concomitant increases in the frequency of CD4 and CD8 T lymphocyte subsets, T cell activation markers CXCR3, CD69, and CD127(low), effector memory T cells, and T cell cytolytic activity against parental tumor cells. Accompanying the antitumor responses were increases in IFN-gamma, CXCL9, CXCL10, and IL-12. Individual neutralization of CD4, CD8 T lymphocytes, or the CXCR3 ligands CXCL9 and CXCL10 reversed the antitumor benefit of IL-7, indicating their importance for optimal responses in vivo. Furthermore, IL-7 decreased the tumor-induced apoptosis of T cells with subsequent decrease of the proapoptotic marker Bim. We assessed the impact of IL-7 treatment on regulatory T cells that negatively impact antitumor immune responses. IL-7 decreased regulatory T Foxp3 as well as cell suppressive activity with a reciprocal increase in SMAD7. These results indicate that IL-7 induces CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. The Journal of Immunology, 2009, 182: 6951-6958.
C1 [Andersson, Asa; Huang, Min; Zhu, Li; Kar, Upendra K.; Batra, Rai K.; Elashoff, David; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, Lung Canc Program, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA.
[Huang, Min; Zhu, Li; Batra, Rai K.; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Yang, Seok-Chul] Seoul Natl Univ Hosp, Dept Med, Div Pulm & Crit Care Med, Seoul 110744, South Korea.
[Huang, Min; Zhu, Li; Batra, Rai K.; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA 90073 USA.
[Strieter, Robert M.] Univ Virginia, Dept Med, Div Cardiol, Charlottesville, VA 22903 USA.
[Strieter, Robert M.] Univ Virginia, Div Pulm & Crit Care Med, Charlottesville, VA 22903 USA.
RP Sharma, S (reprint author), Univ Calif Los Angeles, Lung Canc Program, Div Pulm & Crit Care Med, Dept Med, 10833 Conte Ave, Los Angeles, CA 90095 USA.
EM ssharma@mednet.ucla.edu
OI Batra, Raj K./0000-0002-1126-543X
FU National Institutes of Health [R01 CA85686, R01 CA 126944]; University
of California Los Angeles Lung Cancer SPORE [P50 CA90388]; Department of
Veteran Affairs Medical Research Funds; Tobacco Related Disease Program
Award Program of the University of California
FX This work was supported by National Institutes of Health Grants R01
CA85686 and R01 CA 126944 and University of California Los Angeles Lung
Cancer SPORE P50 CA90388, Department of Veteran Affairs Medical Research
Funds, and Tobacco Related Disease Program Award Program of the
University of California.
NR 47
TC 41
Z9 45
U1 2
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2009
VL 182
IS 11
BP 6951
EP 6958
DI 10.4049/jimmunol.0803340
PG 8
WC Immunology
SC Immunology
GA 448JG
UT WOS:000266258300039
PM 19454692
ER
PT J
AU Johnson, S
AF Johnson, Stuart
TI Recurrent Clostridium difficile infection: A review of risk factors,
treatments, and outcomes
SO JOURNAL OF INFECTION
LA English
DT Review
DE Clostridum difficile; Vancomycin; Metronidazole; Diarrhea
ID PLACEBO-CONTROLLED TRIAL; IN-VITRO ACTIVITY; SACCHAROMYCES-BOULARDII;
MULTIPLE RELAPSES; ANTIBODY-RESPONSE; TOXIN-A; DIARRHEA; DISEASE;
COLITIS; METRONIDAZOLE
AB Episodes of recurrent Clostridium difficile infection (CDI) are difficult to treat for several reasons. Foremost, data are tacking to support any particular treatment strategy. In addition, treatment of recurrent episodes is not always successful, and repeated, prolonged treatment is often necessary. Identification of subgroups at risk for recurrent CDI may aid in diagnosing and treating these patients. Two likely mechanistic factors increasing the risk of recurrent CDI are an inadequate immune response to C. difficile toxins and persistent disruption of the normal colonic flora. Important epidemiologic risk factors include advanced age, continuation of other antibiotics, and prolonged hospital stays. Current guidelines recommend that the first recurrent episode be treated with the same agent (i.e., metronidazole or vancomycin) used for the index episode. However, if the first recurrence is characterized as severe, vancomycin should be used. A reasonable strategy for managing a subsequent episode involves tapering followed by pulsed doses of vancomycin. Other potentially effective strategies for recurrent CDI include vancomycin with adjunctive treatments, such as Socchoromyces boulardii, rifaximin "chaser" therapy after vancomycin, nitazoxanide, fecal transplantation, and intravenous immunoglobutin. New treatment agents that are active against C. difficile, but spare critical components of the normal flora, may decrease the incidence of recurrent CDI. Published by Elsevier Ltd on behalf of The British Infection Society.
C1 [Johnson, Stuart] Loyola Univ, Med Ctr, Infect Dis Sect, Stritch Sch Med, Maywood, IL 60153 USA.
[Johnson, Stuart] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
RP Johnson, S (reprint author), Loyola Univ, Med Ctr, Infect Dis Sect, Stritch Sch Med, 2160 S 1st Ave,Fahey Ctr Bldg 54,Room 149, Maywood, IL 60153 USA.
EM sjohnson@lumc.edu
FU ViroPharma Incorporated
FX The author thanks Marie Bialek, PharmD, and Robert Michael Healthcare
Alliance LLC for assistance in preparing this article. This work was
supported by a grant from ViroPharma Incorporated.
NR 59
TC 164
Z9 170
U1 3
U2 24
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD JUN
PY 2009
VL 58
IS 6
BP 403
EP 410
DI 10.1016/j.jinf.2009.03.010
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 461UK
UT WOS:000267297400001
PM 19394704
ER
PT J
AU Bosch, JL
Beinfeld, MT
Muller, JE
Brady, T
Gazelle, GS
AF Bosch, Johanna L.
Beinfeld, Molly T.
Muller, James E.
Brady, Thomas
Gazelle, G. Scott
TI A Cost-Effectiveness Analysis of a Hypothetical Catheter-Based Strategy
for the Detection and Treatment of Vulnerable Coronary Plaques with
Drug-Eluting Stents (vol 5, pg 339, 2005)
SO JOURNAL OF INTERVENTIONAL CARDIOLOGY
LA English
DT Correction
C1 [Muller, James E.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0896-4327
J9 J INTERV CARDIOL
JI J. Interv. Cardiol.
PD JUN
PY 2009
VL 22
IS 3
BP 309
EP 309
DI 10.1111/j.1540-8183.2009.00472.x
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 453GU
UT WOS:000266599700019
ER
PT J
AU Garasic, JM
Marin, L
Anderson, RD
AF Garasic, Joseph M.
Marin, Linda
Anderson, R. David
TI Acute Evaluation of the Mynx (TM) Vascular Closure Device during
Arterial Re-Puncture in an Ovine Model
SO JOURNAL OF INVASIVE CARDIOLOGY
LA English
DT Article
AB Background. The Mynx (TM) vascular closure device (VCD) (AccessClosure, Inc., Mountain View, California) is used for extravascular closure of the common femoral artery (CFA) after diagnostic or interventional endovascular procedures. Although it is common clinical practice to re-puncture a CFA, for some VCDs, acute repuncture is discouraged, while for other VCDs the safety of direct re-puncture through a previously placed VCD is still in question. The objective of this preclinical study was to evaluate the acute performance of the Mynx device where direct re-puncture has occurred through the hydrogel sealant, followed by delivery of a second Mynx device to close the re-access puncture site. Methods. Two ovine models with a total of 24 punctures (12 sets of puncture and re-puncture) were used for this study. Success was measured utilizing angiographic and observational endpoints. Results. There was no evidence of hydrogel sealant prolapse into the artery, distal embolization of sealant following repuncture, groin site bleeding or hematoma. Successful hemostasis was achieved in all punctures (mean activated clotting time = 357 secs) with the exception of a minor (non-clinically significant) contrast extravasation in the tissue tract, which resolved with 2 minutes of adjunctive compression. Conclusion. Arterial re-puncture in an ovine model directly through a recently placed Mynx closure device and subsequent re-closure with a second Mynx device can be successfully accomplished.
C1 [Garasic, Joseph M.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Marin, Linda] Access Closure Inc, Mountain View, CA USA.
[Anderson, R. David] Univ Florida, Div Cardiol, Gainesville, FL USA.
RP Garasic, JM (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 8, Boston, MA 02114 USA.
EM jgarasic@partners.org
NR 6
TC 4
Z9 4
U1 0
U2 0
PU H M P COMMUNICATIONS
PI MALVERN
PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA
SN 1042-3931
J9 J INVASIVE CARDIOL
JI J. Invasive Cardiol.
PD JUN
PY 2009
VL 21
IS 6
BP 283
EP 285
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 687VQ
UT WOS:000284806700007
PM 19494406
ER
PT J
AU Paulson, KG
Lemos, BD
Feng, B
Jaimes, N
Penas, PF
Bi, XH
Maher, E
Cohen, L
Leonard, JH
Granter, SR
Chin, L
Nghiem, P
AF Paulson, Kelly G.
Lemos, Bianca D.
Feng, Bin
Jaimes, Natalia
Penas, Pablo F.
Bi, Xiaohui
Maher, Elizabeth
Cohen, Lisa
Leonard, J. Helen
Granter, Scott R.
Chin, Lynda
Nghiem, Paul
TI Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma
Including Amplification of L-Myc
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID COPY NUMBER CHANGES; LUNG-CANCER; HYBRIDIZATION; EXPRESSION; PATHWAY;
DNA; POLYOMAVIRUS; MICROARRAY; MUTATIONS; TUMORS
AB Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with poorly characterized genetics. We performed high resolution comparative genomic hybridization on 25 MCC specimens using a high-density oligonucleotide microarray. Tumors frequently carried extra copies of chromosomes 1, 3q, 5p, and 6 and lost chromosomes 3p, 4, 5q, 7, 10, and 13. MCC tumors with less genomic aberration were associated with improved survival (P=0.04). Tumors from 13 of 22 MCC patients had detectable Merkel cell polyomavirus DNA, and these tumors had fewer genomic deletions. Three regions of genomic alteration were of particular interest: a deletion of 5q12-21 occurred in 26% of tumors, a deletion of 13q14-21 was recurrent in 26% of tumors and contains the well-characterized tumor suppressor RB1, and a previously unreported focal amplification at 1p34 was present in 39% of tumors and centers on L-Myc (MYCL1). L-Myc is related to the c-Myc proto-oncogene, has transforming activity, and is amplified in the closely related small cell lung cancer. Normal skin showed no L-Myc expression, whereas 4/4 MCC specimens tested expressed L-Myc RNA in relative proportion to the DNA copy number gain. These findings suggest several genes that may contribute to MCC pathogenesis, most notably L-Myc.
C1 [Paulson, Kelly G.; Lemos, Bianca D.; Nghiem, Paul] Univ Washington, Dept Med, Seattle, WA 98109 USA.
[Paulson, Kelly G.; Lemos, Bianca D.; Nghiem, Paul] Univ Washington, Dept Dermatol, Seattle, WA 98109 USA.
[Chin, Lynda] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Penas, Pablo F.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
[Jaimes, Natalia] Univ Pontificia Bolivariana, Medellin, Colombia.
[Bi, Xiaohui] Univ Med & Dent New Jersey, Univ Hosp Canc Ctr, Newark, NJ 07103 USA.
[Maher, Elizabeth] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Cohen, Lisa] Caris Cohen Dx, Newton, MA USA.
[Cohen, Lisa] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Leonard, J. Helen] Queensland Inst Med Res, Neuroendocrine Biol Grp, Brisbane, Qld 4006, Australia.
[Granter, Scott R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Chin, Lynda] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Nghiem, P (reprint author), Univ Washington, Dept Med Dermatol, 815 Mercer St, Seattle, WA 98109 USA.
EM pnghiem@u.washington.edu
RI Paulson, Kelly/E-5761-2010; Nghiem, Paul/A-9210-2011; Leonard,
Helen/F-2022-2013;
OI Paulson, Kelly/0000-0002-0033-3708; Nghiem, Paul/0000-0003-2784-963X;
Lemos, Bianca/0000-0002-2222-0499; Fernandez Penas,
Pablo/0000-0003-4882-1564
FU Harvard Skin Cancer SPORE; American Cancer Society Jerry Wachter Fund
for MCC Research,; Skin Cancer Foundation; MCC Patient Gift Fund at the
University of Washington; [NIH-K02-AR050993]
FX We thank the Bomsztyk Lab at the University of Washington for advice and
reagents and the Eisenman Lab at the Fred Hutchison Cancer Research
Center for the gift of an L-Myc plasmid. Array-CGH profiling was
performed at the Belfer Center for Cancer Genomics in the Center for
Applied Cancer Science at Dana-Farber Cancer Institute. This project was
supported by the Harvard Skin Cancer SPORE, NIH-K02-AR050993, the
American Cancer Society Jerry Wachter Fund for MCC Research, the Skin
Cancer Foundation, and the MCC Patient Gift Fund at the University of
Washington.
NR 38
TC 52
Z9 53
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2009
VL 129
IS 6
BP 1547
EP 1555
DI 10.1038/jid.2008.365
PG 9
WC Dermatology
SC Dermatology
GA 447UU
UT WOS:000266218200027
PM 19020549
ER
PT J
AU Ashe, M
Bennett, G
Economos, C
Goodman, E
Schilling, J
Quintiliani, L
Rosenbaum, S
Vincent, J
Must, A
AF Ashe, Marice
Bennett, Gary
Economos, Christina
Goodman, Elizabeth
Schilling, Joe
Quintiliani, Lisa
Rosenbaum, Sara
Vincent, Jeff
Must, Aviva
TI Assessing Coordination of Legal-Based Efforts across Jurisdictions and
Sectors for Obesity Prevention and Control
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID PHYSICAL-ACTIVITY; HEALTH; CHILDHOOD
C1 [Ashe, Marice] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
[Bennett, Gary] Duke Univ, Dept Psychol, Durham, NC 27706 USA.
[Bennett, Gary] Duke Univ, Duke Global Hlth Inst, Durham, NC 27706 USA.
[Bennett, Gary] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
[Bennett, Gary] Dana Farber Canc Inst, Boston, MA USA.
[Economos, Christina] Tufts Univ Sch, Friedman Sch Nutr Sci & Policy, Medford, MA USA.
[Goodman, Elizabeth] Tufts Med Ctr, Child & Adolescent Obes Program, Medford, MA USA.
[Rosenbaum, Sara] George Washington Univ, Dept Hlth Policy, Sch Publ Hlth & Hlth Serv, Washington, DC USA.
[Schilling, Joe] Virginia Tech, Metropolitan Inst, Sustainabil Policy & Res Programs, Blacksburg, VA USA.
[Schilling, Joe] Techs Urban Affairs & Planning Program, Alexandria, VA USA.
[Vincent, Jeff] Univ Calif Berkeley, Ctr Cities & Sch, Inst Urban & Reg Dev, Berkeley, CA 94720 USA.
[Must, Aviva] Tufts Univ, Sch Med, Dept Publ Hlth & Family Med, Medford, MA 02155 USA.
OI Quintiliani, Lisa/0000-0002-3328-6768
FU NIDDK NIH HHS [P30 DK046200]
NR 24
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1073-1105
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2009
VL 37
IS 2
BP 45
EP 54
DI 10.1111/j.1748-720X.2009.00391.x
PG 10
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA 453KQ
UT WOS:000266609700008
PM 19493091
ER
PT J
AU Must, A
Bennett, G
Economos, C
Goodman, E
Schilling, J
Quintiliani, L
Rosenbaum, S
Vincent, J
Ashe, M
AF Must, Aviva
Bennett, Gary
Economos, Christina
Goodman, Elizabeth
Schilling, Joe
Quintiliani, Lisa
Rosenbaum, Sara
Vincent, Jeff
Ashe, Marice
TI Improving Coordination of Legal-Based Efforts across Jurisdictions and
Sectors for Obesity Prevention and Control
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
C1 [Must, Aviva] Tufts Univ, Sch Med, Dept Publ Hlth & Family Med, Medford, MA 02155 USA.
[Bennett, Gary] Duke Univ, Dept Psychol, Durham, NC 27706 USA.
[Bennett, Gary] Duke Univ, Duke Global Hlth Inst, Durham, NC 27706 USA.
[Bennett, Gary] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
[Bennett, Gary] Dana Farber Canc Inst, Boston, MA USA.
[Economos, Christina] Tufts Univ Sch, Friedman Sch Nutr Sci & Policy, Medford, MA USA.
[Goodman, Elizabeth] Tufts Med Ctr, Child & Adolescent Obes Program, Medford, MA USA.
[Goodman, Elizabeth] Floating Hosp Children, Boston, MA USA.
[Schilling, Joe] Virginia Tech, Metropolitan Inst, Sustainabil Policy & Res Programs, Nashville, TN USA.
[Schilling, Joe] Techs Urban Affairs & Planning Program, Alexandria, VA USA.
[Rosenbaum, Sara] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Hlth Policy, Washington, DC USA.
[Vincent, Jeff] Univ Calif Berkeley, Inst Urban & Reg Dev, Ctr Cities & Sch, Berkeley, CA 94720 USA.
[Ashe, Marice] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Must, A (reprint author), Tufts Univ, Sch Med, Dept Publ Hlth & Family Med, Medford, MA 02155 USA.
OI Quintiliani, Lisa/0000-0002-3328-6768
FU NIDDK NIH HHS [P30 DK046200]
NR 5
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1073-1105
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2009
VL 37
IS 2
BP 90
EP 98
DI 10.1111/j.1748-720X.2009.00395.x
PG 9
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA 453KQ
UT WOS:000266609700012
PM 19493095
ER
PT J
AU Doolittle, MH
Ben-Zeev, O
Bassilian, S
Whitelegge, JP
Peterfy, M
Wong, H
AF Doolittle, Mark H.
Ben-Zeev, Osnat
Bassilian, Sara
Whitelegge, Julian P.
Peterfy, Miklos
Wong, Howard
TI Hepatic lipase maturation: a partial proteome of interacting factors
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE protein folding; endoplasmic reticulum; chaperones; calnexin; tandem
affinity purification; mass spectrometry
ID COLLAGEN TRIPLE-HELIX; TANDEM AFFINITY PURIFICATION; ER QUALITY-CONTROL;
MULTIPLE EF-HAND; ENDOPLASMIC-RETICULUM; LIPOPROTEIN-LIPASE; SECRETORY
PATHWAY; MAMMALIAN-CELLS; CHAPERONE HSP47; MULTIPROTEIN COMPLEXES
AB Tandem affinity purification (TAP) has been used to isolate proteins that interact with human hepatic lipase (HL) during its maturation in Chinese hamster ovary cells. Using mass spectrometry and Western blotting, we identified 28 proteins in HL-TAP isolated complexes, 16 of which localized to the endoplasmic reticulum (ER), the site of HL folding and assembly. Of the 12 remaining proteins located outside the ER, five function in protein translation or ER-associated degradation (ERAD). Components of the two major ER chaperone systems were identified, the BiP/Grp94 and the calnexin (CNX)/calreticulin (CRT) systems. All factors involved in CNX/CRT chaperone cycling were identified, including UDP-glucose: glycoprotein glucosyltransferase 1 (UGGT), glucosidase II, and the 57 kDa oxidoreductase (ERp57). We also show that CNX, and not CRT, is the lectin chaperone of choice during HL maturation. Along with the 78 kDa glucose-regulated protein (Grp78; BiP) and the 94 kDa glucose-regulated protein (Grp94), an associated peptidyl-prolyl cis-trans isomerase and protein disulfide isomerase were also detected. Finally, several factors in ERAD were identified, and we provide evidence that terminally misfolded HL is degraded by the ubiquitin-mediated proteasomal pathway. We propose that newly synthesized HL emerging from the translocon first associates with CNX, ERp57, and glucosidase II, followed by repeated posttranslational cycles of CNX binding that is mediated by UGGT. BiP/Grp94 may stabilize misfolded HL during its transition between cycles of CNX binding and may help direct its eventual degradation.-Doolittle, M. H., O. Ben-Zeev, S. Bassilian, J. P. Whitelegge, M. Peterfy, and H. Wong. Hepatic lipase maturation: a partial proteome of interacting factors. J. Lipid Res. 2009. 50: 1173-1184.
C1 [Doolittle, Mark H.; Ben-Zeev, Osnat; Bassilian, Sara; Whitelegge, Julian P.; Peterfy, Miklos; Wong, Howard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Doolittle, Mark H.; Ben-Zeev, Osnat; Peterfy, Miklos; Wong, Howard] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Bassilian, Sara; Whitelegge, Julian P.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA.
[Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
RP Doolittle, MH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
EM markdool@ucla.edu
FU Cedars-Sinai Medical Center; Department of Veterans Affairs; National
Institutes of Health [HL-24841]
FX This work was supported by the Cedars-Sinai Medical Center, the
Department of Veterans Affairs, and Grant HL-24841 from the National
Institutes of Health.
NR 69
TC 15
Z9 15
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD JUN
PY 2009
VL 50
IS 6
BP 1173
EP 1184
DI 10.1194/jlr.M800603-JLR200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 446IE
UT WOS:000266114500015
PM 19136429
ER
PT J
AU Slocum, AH
Bosworth, WR
Mazumdar, A
Saez, MA
Culpepper, ML
Levine, RA
AF Slocum, Alexander H., Jr.
Bosworth, William R.
Mazumdar, Anirban
Saez, Miguel A.
Culpepper, Martin L.
Levine, Robert A.
TI Design of a Catheter-Based Device for Performing Percutaneous
Chordal-Cutting Procedures
SO JOURNAL OF MEDICAL DEVICES-TRANSACTIONS OF THE ASME
LA English
DT Article
DE percutaneous catheter; mitral valve minimally invasive heart chordae
tendinae
ID ISCHEMIC MITRAL REGURGITATION
AB This paper focuses on the design and implementation of a percutaneous catheter based device to provide physicians with an externally controlled tool capable of manipulating and cutting specific chordae tendinae within the heart to alleviate problems associated with some forms of mural valve (MV) regurgitation In the United States alone approximately 500 000 people develop :schema, or functional mitral regurgitation per year Many of there patients do not possess the required level of health neces sary to survive open-heart surgery and the development of a chordal cutting procedure and device is needed to allow these patients to receive treatment A deterministic design process was used to generate several design concepts and awn evaluate and compare each concept based on a set of functional requirements A final concept to be alpha prototyped was then chosen, further developed, and fabricated Experiments showed that the design was capable of locating and grabbing a chord and that ultrasound imaging is a viable method for navigating the device inside of the human buds Once contact between the chord and radio frequency (RF) ablation tip was confirmed the chord was successfully ablated [DOI 10 1115/1 3139835]
C1 [Slocum, Alexander H., Jr.; Bosworth, William R.; Mazumdar, Anirban; Saez, Miguel A.; Culpepper, Martin L.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Levine, Robert A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Slocum, AH (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
FU CIMIT MIT
FX This project would not have been possible without the support of CIMIT
MIT, and the fall 2007 2 75 course administrative staff Dr Rajiv Gupta
of MGH Neuroradiology was an exceptionally helpful consultant He was
also very adept at answering our questions regarding the use of
catheters and helping to orientate us with standard hospital facilities
and practices Dr Vivek Reddy of the MGH Cardiac Arrhythmia Department
was very helpful, providing us with detailed insight into the world of
existing catheter technologies J Luis Guerrero. BS helped with anatomic
correlations and modeling of the anatomical system for our experiment,
and also prepared the heart used in the second experiment The help and
generosity of Jacob Dal-Bianco Lori Foley. Adam Mauskapf, Susan Sullivan
and the rest of the Edwards EP Laboratory staff helped to make the
second experiment a success Greg Mostovoy and the staff at Vaupell Rapid
Solutions provided fast and efficient rapid-prototyping services for the
project
NR 12
TC 3
Z9 3
U1 0
U2 0
PU ASME-AMER SOC MECHANICAL ENG
PI NEW YORK
PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA
SN 1932-6181
J9 J MED DEVICES
JI J. Med. Devices
PD JUN
PY 2009
VL 3
IS 2
AR 025001
DI 10.1115/1.3139835
PG 8
WC Engineering, Biomedical
SC Engineering
GA 674QZ
UT WOS:000283763700006
PM 20352058
ER
PT J
AU Mescher, MJ
Swan, EEL
Fiering, J
Holmboe, ME
Sewell, WF
Kujawa, SG
McKenna, MJ
Borenstein, JT
AF Mescher, Mark J.
Swan, Erin E. Leary
Fiering, Jason
Holmboe, Maria E.
Sewell, William F.
Kujawa, Sharon G.
McKenna, Michael J.
Borenstein, Jeffrey T.
TI Fabrication Methods and Performance of Low-Permeability Microfluidic
Components for a Miniaturized Wearable Drug Delivery System
SO JOURNAL OF MICROELECTROMECHANICAL SYSTEMS
LA English
DT Article
DE Fluidics; implantable biomedical devices; micromachining; permeability;
polyimide films; printed-circuit fabrication
ID TECHNOLOGY; DEVICES; AMANDA
AB In this paper, we describe low-permeability components of a microfluidic drug delivery system fabricated with versatile micromilling and lamination techniques. The fabrication process uses laminate sheets which are machined using XY milling tables commonly used in the printed-circuit industry. This adaptable platform for polymer microfluidics readily accommodates integration with silicon-based sensors, printed-circuit, and surface-mount technologies. We have used these methods to build components used in a wearable liquid-drug delivery system for in vivo studies. The design, fabrication, and performance of membrane-based fluidic capacitors and manual screw valves provide detailed examples of the capability and limitations of the fabrication method. We demonstrate fluidic capacitances ranging from 0.015 to 0.15 mu L/kPa, screw valves with on/off flow ratios greater than 38000, and a 45X reduction in the aqueous fluid loss rate to the ambient due to permeation through a silicone diaphragm layer. [2008-0148]
C1 [Mescher, Mark J.; Swan, Erin E. Leary; Fiering, Jason; Holmboe, Maria E.; Borenstein, Jeffrey T.] Charles Stark Draper Lab Inc, Cambridge, MA 02139 USA.
[Swan, Erin E. Leary] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Sewell, William F.; Kujawa, Sharon G.; McKenna, Michael J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Sewell, William F.; Kujawa, Sharon G.; McKenna, Michael J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Mescher, MJ (reprint author), Charles Stark Draper Lab Inc, Cambridge, MA 02139 USA.
EM mmescher@draper.com; eswan@draper.com; jfiering@draper.com;
mholmboe@draper.com; wfs@epl.meei.harvard.edu; jborenstein@draper.com
FU NIDCD
FX The authors would like to thank E. Kim and C. Cardoso for their
contributions. The contents of this paper are solely the responsibility
of the authors and do not necessarily represent the official views of
the NIDCD.
NR 26
TC 20
Z9 21
U1 1
U2 14
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 1057-7157
J9 J MICROELECTROMECH S
JI J. Microelectromech. Syst.
PD JUN
PY 2009
VL 18
IS 3
BP 501
EP 510
DI 10.1109/JMEMS.2009.2015484
PG 10
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
Instruments & Instrumentation; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Instruments &
Instrumentation; Physics
GA 454ZK
UT WOS:000266723700001
PM 20852729
ER
PT J
AU Marentis, TC
Vacanti, JP
Hsiao, JC
Borenstein, JT
AF Marentis, Theodore C.
Vacanti, Joseph P.
Hsiao, James C.
Borenstein, Jeffrey T.
TI Elastic Averaging for Assembly of Three-Dimensional Constructs From
Elastomeric Micromolded Layers
SO JOURNAL OF MICROELECTROMECHANICAL SYSTEMS
LA English
DT Article
DE Alignment; biomedical engineering; elastic averaging; lab-on-a-chip;
microassembly; microfluidics; micromachining; poly-(dimethylsiloxane)
(PDMS); precision engineering; silicone rubbers; surface fitting; tissue
engineering
ID MICROFLUIDIC SYSTEMS; BIODEGRADABLE ELASTOMER; FABRICATION; CELLS;
SCAFFOLDS; SENSORS; STRESS; LIVER; PDMS
AB Precision engineering has been used in the macro-world and in the microscale only with rigid materials. Soft flexible materials commonly used for microfluidics and other bio-MEMS applications have not been aligned with elastic averaging. We report the use of complementary raised and recessed circular features to align polymer layers and demonstrate alignment accuracy and repeatability. The alignment is accomplished in a Petri dish with a thin layer of liquid between the two surfaces of micromolded elastomeric polymer sheets. The layers are aligned with simple hand-eye manipulation. We test circular geometries of varying diameters, obtaining accuracy and repeatability values in the range of 1-3 mu m across thin polymer sheets molded from silicon masters. This is a significant improvement over existing manual, moving stage, and self-alignment techniques and a novel proof of concept that paves the way for complex 3-D polymer constructs. [2008-0093]
C1 [Marentis, Theodore C.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Marentis, Theodore C.; Hsiao, James C.; Borenstein, Jeffrey T.] Charles Stark Draper Lab Inc, Cambridge, MA 02139 USA.
[Marentis, Theodore C.; Vacanti, Joseph P.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Marentis, Theodore C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Vacanti, Joseph P.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
RP Marentis, TC (reprint author), Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
EM marentis@gmail.com
FU Massachusetts General Hospital and the Howard Hughes Medical Institute
FX The authors would like to thank C. Cardoso, M. Bancu, M. Healey, D.
Pulver, E. Weinberg, R. Caruso, B. Orrick, and C. Sundback and also the
Charles Stark Draper Laboratory, the Massachusetts General Hospital and
the Howard Hughes Medical Institute for supporting this research.
NR 47
TC 4
Z9 4
U1 1
U2 9
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 1057-7157
J9 J MICROELECTROMECH S
JI J. Microelectromech. Syst.
PD JUN
PY 2009
VL 18
IS 3
BP 531
EP 538
DI 10.1109/JMEMS.2009.2018372
PG 8
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
Instruments & Instrumentation; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Instruments &
Instrumentation; Physics
GA 454ZK
UT WOS:000266723700004
ER
PT J
AU Riddle, RC
Khatri, R
Schipani, E
Clemens, TL
AF Riddle, Ryan C.
Khatri, Richa
Schipani, Ernestina
Clemens, Thomas L.
TI Role of hypoxia-inducible factor-1 alpha in angiogenic-osteogenic
coupling
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review
DE Hypoxia-inducible factor; VEGF; Endochondral bone formation; Fracture
repair
ID ENDOTHELIAL GROWTH-FACTOR; ENDOCHONDRAL BONE-FORMATION;
COLONY-STIMULATING FACTOR; MESENCHYMAL STEM-CELLS; OSTEOBLAST-LIKE
CELLS; FACTOR VEGF; DISTRACTION OSTEOGENESIS; FRACTURE REPAIR; VASCULAR
CONTRIBUTION; MOLECULAR-MECHANISMS
AB Angiogenesis and osteogenesis are tightly coupled during bone development and regeneration. The vasculature supplies oxygen to developing and regenerating bone and also delivers critical signals to the stroma that stimulate mesenchymal cell specification to promote bone formation. Recent studies suggest that the hypoxia-inducible factors (HIFs) are required for the initiation of the angiogenic-osteogenic cascade. Genetic manipulation of individual components of the HIF/vascular endothelial growth factor (VEGF) pathway in mice has provided clues to how coupling is achieved. In this article, we review the current understanding of the cellular and molecular mechanisms responsible for angiogenic-osteogenic coupling. We also briefly discuss the therapeutic manipulation of HIF and VEGF in skeletal repair. Such discoveries suggest promising approaches for the development of novel therapies to improve bone accretion and repair.
C1 [Riddle, Ryan C.; Clemens, Thomas L.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
[Clemens, Thomas L.] Vet Adm Med Ctr, Birmingham, AL USA.
[Khatri, Richa; Schipani, Ernestina] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Khatri, Richa; Schipani, Ernestina] Harvard Univ, Sch Med, Boston, MA USA.
RP Clemens, TL (reprint author), Univ Alabama, Dept Pathol, 1670 Univ Blvd,G001, Birmingham, AL 35294 USA.
EM tclemens@uab.edu
FU NIAMS NIH HHS [R01 AR049410, R01 AR049410-08]
NR 86
TC 60
Z9 70
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-2716
J9 J MOL MED-JMM
JI J. Mol. Med.
PD JUN
PY 2009
VL 87
IS 6
BP 583
EP 590
DI 10.1007/s00109-009-0477-9
PG 8
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 451NB
UT WOS:000266475800005
PM 19415227
ER
PT J
AU Wolf, EJ
Miller, MW
McKinney, AE
AF Wolf, Erika J.
Miller, Mark W.
McKinney, Ann E.
TI Emotional Processing in PTSD Heightened Negative Emotionality to
Unpleasant Photographic Stimuli
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE PTSD; emotional processing; IAPS; assessment
ID POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; AMYGDALA;
IMAGERY; SPECIFICITY; MODULATION; DEPRESSION; RESPONSES; PICTURES; WOMEN
AB This study evaluated evidence for 2 forms of emotional abnormality in posttraumatic stress disorder (PTSD): numbing and heightened negative emotionality. Forty-nine male veterans with PTSD and 75 without the disorder rated their emotional responses to photographs that depicted scenes of Vietnam combat or were drawn from the International Affective Picture System (Lang et al., 2005). Images varied in their trauma-relatedness and affective qualities. A series of repeated measures ANOVAs revealed that Vietnam combat veterans with PTSD responded to unpleasant images with greater negative emotionality (i.e., enhanced arousal and lower valence ratings) than those without the disorder and this effect was modified by the trauma-relatedness of the image with stronger effects for trauma-related images. In contrast, the 2 groups showed equivalent patterns of responses to pleasant images. Findings raise questions about the sensitivity of the International Affective Picture System rating protocol for the assessment of PTSD-related emotional numbing.
C1 [Wolf, Erika J.; Miller, Mark W.; McKinney, Ann E.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Wolf, Erika J.; Miller, Mark W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Miller, Mark W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave,116B-2, Boston, MA 02130 USA.
EM mark.miller5@va.gov
RI Miller, Mark/G-7322-2011;
OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435
FU National Institute of Mental Health [5F31MH074267]
FX Supported by National Institute of Mental Health grant (5F31MH074267)
awarded (to E.J.W.).
NR 37
TC 12
Z9 12
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD JUN
PY 2009
VL 197
IS 6
BP 419
EP 426
DI 10.1097/NMD.0b013e3181a61c68
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 457OQ
UT WOS:000266941800007
PM 19525742
ER
PT J
AU Jensen, RJ
Rizzo, JF
AF Jensen, Ralph J.
Rizzo, Joseph F., III
TI Activation of ganglion cells in wild-type and rd1 mouse retinas with
monophasic and biphasic current pulses
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
CT Eye and the Chip Meeting 2008
CY JUN 12-14, 2008
CL Detroit, MI
SP Detroit Inst Ophthalmol
ID ISOLATED CHICKEN RETINA; ELECTRICAL-STIMULATION; DEGENERATION;
PROSTHESIS; MICE
AB We and other research groups are designing all electronic retinal prosthesis to provide vision for patients who are blind due to photoreceptor degeneration. In this Study, we examined the effect Of stimulus waveform Oil the amount Of Current needed to activate retinal ganglion cells (RGCs) when the retinal neural network is stimulated. Isolated retinas of wild-type and rd1 mice were stimulated with cathodal and anodal monophasic Current Pulses of 1 ms duration and symmetric biphasic current pulses (1 ms per phase) delivered through all electrode that was located subretinally. For both wild-type and rd1 Mouse retinas, cathodal current pulses were least effective in activating most RGCs. The median threshold Current for a cathodal current pulse was 2.0-4.4 fold higher than the median threshold current for either all anodal or a biphasic current pulse. In wild-type mouse retinas, the median threshold Current for activating RGCs with anodal Current pulses was 23% lower than that with biphasic Current pulses. In rd1 mouse retinas, the median threshold currents for anodal and biphasic Current pulses were about the same. However, the variance in thresholds of rd1 RGCs for biphasic pulse stimulation was Much smaller than for anodal pulse stimulation. Thus. a symmetric biphasic current pulse may be the best Stimulus for activating the greatest number of RGCs in retinas devoid of photoreceptors.
C1 [Jensen, Ralph J.; Rizzo, Joseph F., III] VA Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Boston, MA 02130 USA.
[Rizzo, Joseph F., III] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Jensen, RJ (reprint author), VA Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Mail Stop 151E,150 S Huntington Ave, Boston, MA 02130 USA.
EM Ralph.Jensen@va.gov
NR 19
TC 27
Z9 28
U1 0
U2 1
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN
PY 2009
VL 6
IS 3
AR 035004
DI 10.1088/1741-2560/6/3/035004
PG 7
WC Engineering, Biomedical; Neurosciences
SC Engineering; Neurosciences & Neurology
GA 461AM
UT WOS:000267235600005
PM 19458401
ER
PT J
AU Garcia-Alloza, M
Prada, C
Lattarulo, C
Fine, S
Borrelli, LA
Betensky, R
Greenberg, SM
Frosch, MP
Bacskai, BJ
AF Garcia-Alloza, Monica
Prada, Claudia
Lattarulo, Carli
Fine, Sara
Borrelli, Laura A.
Betensky, Rebecca
Greenberg, Steven M.
Frosch, Matthew P.
Bacskai, Brian J.
TI Matrix metalloproteinase inhibition reduces oxidative stress associated
with cerebral amyloid angiopathy in vivo in transgenic mice
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE antioxidant; matrix metalloproteinases; MMP inhibitor; multiphoton
microscopy; oxidative stress; transgenic mouse
ID SMOOTH-MUSCLE-CELLS; ALZHEIMER MOUSE MODEL; A-BETA; INDUCED
MATRIX-METALLOPROTEINASE-9; INTRACEREBRAL HEMORRHAGE;
CEREBROVASCULAR-DISEASE; MULTIPHOTON MICROSCOPY; PLASMINOGEN-ACTIVATOR;
PLAQUES; BRAIN
AB Cerebral amyloid angiopathy (CAA), characterized by extracellular beta-amyloid peptide (A beta) deposits in vessel walls, is present in the majority of cases of Alzheimer's disease and is a major cause of hemorrhagic stroke. Although the molecular pathways activated by vascular A beta are poorly understood, extracellular matrix metalloproteinases (MMP) and A beta-induced oxidative stress appear to play important roles. We adapted fluorogenic assays for MMP activity and reactive oxygen species generation for use in vivo. Using multiphoton microcopy in APPswe/PS1dE9 and Tg-2576 transgenic mice, we observed strong associations between MMP activation, oxidative stress, and CAA deposition in leptomeningeal vessels. Antioxidant treatment with alpha-phenyl-N-tert-butyl-nitrone reduced oxidative stress associated with CAA (similar to 50% reduction) without affecting MMP activation. Conversely, a selection of agents that inhibit MMP by different mechanisms of action, including minocycline, simvastatin, and GM6001, reduced not only CAA-associated MMP activation (similar to 30-40% reduction) but also oxidative stress (similar to 40% reduction). The inhibitors of MMP did not have direct antioxidant effects. Treatment of animals with alpha-phenyl-N-tert-butyl-nitrone or minocycline did not have a significant effect on CAA progression rates. These data suggest a close association between A beta-related MMP activation and oxidative stress in vivo and raise the possibility that treatment with MMP inhibitors may have beneficial effects by indirectly reducing the oxidative stress associated with CAA.
C1 [Garcia-Alloza, Monica; Prada, Claudia; Lattarulo, Carli; Fine, Sara; Borrelli, Laura A.; Greenberg, Steven M.; Frosch, Matthew P.; Bacskai, Brian J.] Massachusetts Gen Hosp, Dept Neurol, Alzheimer Res Unit, Charlestown, MA 02129 USA.
[Betensky, Rebecca] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Pathol, CS Kubik Lab Neuropathol, Charlestown, MA 02129 USA.
[Garcia-Alloza, Monica] Univ Cadiz, Fac Med, Area Fisiol, Cadiz, Spain.
[Garcia-Alloza, Monica; Prada, Claudia; Lattarulo, Carli; Fine, Sara; Borrelli, Laura A.; Greenberg, Steven M.; Frosch, Matthew P.; Bacskai, Brian J.] Harvard Univ, Sch Med, Charlestown, MA USA.
[Frosch, Matthew P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bacskai, BJ (reprint author), Massachusetts Gen Hosp, Dept Neurol, Alzheimer Res Unit, B114,114 16th St, Charlestown, MA 02129 USA.
EM bbacskai@partners.org
OI Garcia-Alloza, Monica/0000-0003-1610-4114
FU NIH [EB000768, AG203658, AG021084]; Bugher Foundation; contrato Ramon y
Cajal
FX The study was supported by Grants NIH EB000768, AG203658, AG021084,
Bugher Foundation fellowship and contrato Ramon y Cajal (to M.G-A). We
would like to thank Dr Eng Lo for helpful discussions.
NR 52
TC 31
Z9 31
U1 0
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD JUN
PY 2009
VL 109
IS 6
BP 1636
EP 1647
DI 10.1111/j.1471-4159.2009.06096.x
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 448ND
UT WOS:000266268400007
PM 19457117
ER
PT J
AU Kinkel, RP
Simon, J
O'Connor, PW
Kollman, C
AF Kinkel, R. P.
Simon, J.
O'Connor, P. W.
Kollman, C.
TI Long-term study of high-risk patients after a clinically isolated
syndrome: 10-year follow-up from CHAMPIONS
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 19th Meeting of the European-Neurological-Society
CY JUN 20-24, 2009
CL Milan, ITALY
SP European Neurol Soc
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Portland VA Med Ctr, Portland, OR USA.
St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
Hlth Res Fdn Inc, Jaeb Ctr, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU DR DIETRICH STEINKOPFF VERLAG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2009
VL 256
BP S10
EP S10
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 473YO
UT WOS:000268248700022
ER
PT J
AU San-Juan, D
Chiappa, K
Quiroz, A
Costello, D
Cole, A
AF San-Juan, D.
Chiappa, K.
Quiroz, A.
Costello, D.
Cole, A.
TI Periodic epileptiform discharges: prognostic implications
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 19th Meeting of the European-Neurological-Society
CY JUN 20-24, 2009
CL Milan, ITALY
SP European Neurol Soc
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU DR DIETRICH STEINKOPFF VERLAG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2009
VL 256
BP S19
EP S20
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 473YO
UT WOS:000268248700049
ER
PT J
AU Lopez, OL
Becker, JT
Wahed, AS
Saxton, J
Sweet, RA
Wolk, DA
Klunk, W
DeKosky, ST
AF Lopez, O. L.
Becker, J. T.
Wahed, A. S.
Saxton, J.
Sweet, R. A.
Wolk, D. A.
Klunk, W.
DeKosky, S. T.
TI Long-term effects of the concomitant use of memantine with
cholinesterase inhibition in Alzheimer disease
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; LAST 2 DECADES;
RATING-SCALE; DOUBLE-BLIND; RECEIVING DONEPEZIL; NATURAL-HISTORY;
OPEN-LABEL; DEMENTIA; EFFICACY
AB Background: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission.
Methods: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (45.0%) used only ChEIs, and 416 (40.1%) used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications).
Results: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death.
Conclusions: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
C1 [Lopez, O. L.; Becker, J. T.; Saxton, J.; Sweet, R. A.; Wolk, D. A.; Klunk, W.; DeKosky, S. T.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Lopez, O. L.; Becker, J. T.; Saxton, J.; Sweet, R. A.; Klunk, W.; DeKosky, S. T.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Lopez, O. L.; Becker, J. T.; Saxton, J.; Sweet, R. A.; Wolk, D. A.; Klunk, W.; DeKosky, S. T.] Univ Pittsburgh, Sch Med, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA.
[Becker, J. T.] Univ Pittsburgh, Sch Med, Dept Psychol, Pittsburgh, PA 15261 USA.
[Wahed, A. S.] Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15261 USA.
[Sweet, R. A.] VA Pittsburgh Hlth Care Syst, MIRECC, VISN 4, Pittsburgh, PA USA.
RP Lopez, OL (reprint author), 3501 Forbers Ave,Oxford Bldg,Suite 830, Pittsburgh, PA 15213 USA.
EM lopezol@upmc.edu
OI Klunk, William/0000-0001-5512-0251; Wahed, Abdus/0000-0001-6911-7221
FU National Institute on Aging [AG03705, AG05133, AG16976, AG20098,
AG027224]; VISN 4 Mental Illness Research Education and Clinical Center
(MIRECC); VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania
FX This study was fully supported by grants AG03705, AG05133, AG16976,
AG20098 and AG027224 from the National Institute on Aging, and by VISN 4
Mental Illness Research Education and Clinical Center (MIRECC), VA
Pittsburgh Health Care System, Pittsburgh, Pennsylvania.
NR 55
TC 122
Z9 125
U1 2
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JUN
PY 2009
VL 80
IS 6
BP 600
EP 607
DI 10.1136/jnnp.2008.158964
PG 8
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 446HU
UT WOS:000266113500008
PM 19204022
ER
PT J
AU Gorgulho, AA
Shields, DC
Malkasian, D
Behnke, E
DeSalles, AAF
AF Gorgulho, Alessandra A.
Shields, Donald C.
Malkasian, Dennis
Behnke, Eric
DeSalles, Antonio A. F.
TI Stereotactic coordinates associated with facial musculature contraction
during high-frequency stimulation of the subthalamic nucleus
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE corticobulbar tract; deep brain stimulation; facial contraction;
internal capsule; subthalamic nucleus
ID DEEP BRAIN-STIMULATION; ELECTRICAL-STIMULATION; MOVEMENT-DISORDERS;
CELL-BODIES; MOTOR; AXONS
AB Object. High-frequency stimulation of the subthalamic nucleus (STN) in patients with parkinsonian symptoms is often used to ameliorate debilitating motor symptoms associated with this condition. However, individual variability in the shape and orientation of this relatively small nucleus results in Multiple side effects related to the spread of electrical current to Surrounding structures. Specifically, contraction of the muscles of facial expression is noted in a small percentage of patients, although the precise mechanism remains poorly understood.
Methods. Facial Muscle contraction was triggered by high-frequency stimulation of 49 contacts in 18 patients Undergoing deep brain Stimulation of the STN. The mean coordinates of these individual contacts relative to the anterior commissure-posterior commissure midpoint (also called the midcommissural point) were calculated to determine the location or structure(s) most often associated with facial contraction during physiological macrostimulation.
Results. The x, y, and z coordinates associated with contraction of the facial musculature were found to be 11.52, 1.29, and 1.15 mm lateral, posterior, and inferior to the midcommissural point, respectively. This location, along the lateral-anterior-superior border of the STN, may allow for the spread of electrical Current to the fields of Forel, zona incerta, and/or descending corticospinal/corticobulbar tracts. Because stimulation of corticobulbar tracts produces similar findings,these results are best explained by the spread of electrical current to nearby internal capsule axons coursing lateral to the STN.
Conclusions. Thus, if intraoperative deep brain stimulation lead testing results in facial musculature contraction, placement of the electrode in a more medial, posterior position may reduce the amount Of Current spread to corticobulbar fibers and resolve this side effect. (DOI: 10.3171/JNS.2008.10.JNS08835)
C1 [Gorgulho, Alessandra A.; Malkasian, Dennis; Behnke, Eric; DeSalles, Antonio A. F.] Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA.
[Shields, Donald C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA.
RP Gorgulho, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Box 690118,300 Med Plaza,Suite B212, Los Angeles, CA 90095 USA.
EM agorgulho@mednet.ucla.edu
NR 20
TC 11
Z9 11
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JUN
PY 2009
VL 110
IS 6
BP 1317
EP 1321
DI 10.3171/JNS.2008.10.JNS08835
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 451HH
UT WOS:000266460800032
PM 19284244
ER
PT J
AU Dykes, PC
Benoit, A
Carroll, DL
Hurley, AC
Middleton, B
AF Dykes, Patricia C.
Benoit, Angela
Carroll, Diane L.
Hurley, Ann C.
Middleton, Blackford
TI Why Do Patients in Acute Care Hospitals Fall? Can Falls Be Prevented?
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Article
ID PROGRAMS; METAANALYSIS; VIEWS
AB Objective: Obtain the views of nurses and assistants as to why patients in acute care hospitals fall.
Background: Despite a large quantitative evidence base for guiding fall risk assessment and not needing highly technical, scarce, or expensive equipment to prevent falls, falls are serious problems in hospitals.
Methods: Basic content analysis methods were used to interpret descriptive data from 4 focus groups with nurses (n = 23) and 4 with assistants (n = 19). A 2-person consensus approach was used for analysis.
Results: Positive and negative components of 6 concepts-patient report, information access, sign-age, environment, teamwork, and involving patient/family-formed 2 core categories: knowledge/communication and capability/actions that are facilitators or barriers, respectively, to preventing falls.
Conclusion: Two conditions are required to reduce patient falls. A patient care plan including current and accurate fall risk status with associated tailored and feasible interventions needs to be easily and immediately accessible to all stakeholders (entire healthcare team, patients, and family). Second, stakeholders must use that information plus their own knowledge and skills and patient and hospital resources to carry out the plan.
C1 [Dykes, Patricia C.] Partners Healthcare, Nursing Informat & Res, Clin Informat Res & Dev, Wellesley, MA 02481 USA.
[Dykes, Patricia C.; Middleton, Blackford] Brigham & Womens Hosp, Dept Gen Med, Boston, MA 02115 USA.
[Hurley, Ann C.] Brigham & Womens Hosp, Ctr Nursing Excellence, Boston, MA 02115 USA.
[Dykes, Patricia C.; Middleton, Blackford] Harvard Univ, Sch Med, Boston, MA USA.
[Carroll, Diane L.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Inst Patient Care, Boston, MA 02114 USA.
[Carroll, Diane L.; Hurley, Ann C.] Northeastern Univ, Sch Nursing, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
RP Dykes, PC (reprint author), Partners Healthcare, Nursing Informat & Res, Clin Informat Res & Dev, 93 Worcester St, Wellesley, MA 02481 USA.
EM pdykes@partners.org
OI Middleton, Blackford/0000-0002-1819-1234
FU Robert Wood Johnson Foundation
FX This article is an outgrowth of work from an interdisciplinary quality
improvement nursing research endeavor funded by a Robert Wood Johnson
Foundation: Interdisciplinary Nursing Quality Research Initiative award
to Brigham and Women's Hospital.
NR 20
TC 28
Z9 30
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-0443
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD JUN
PY 2009
VL 39
IS 6
BP 299
EP 304
PG 6
WC Nursing
SC Nursing
GA 458LQ
UT WOS:000267025300010
PM 19509605
ER
PT J
AU Rumawas, ME
Dwyer, JT
Mckeown, NM
Meigs, JB
Rogers, G
Jacques, PF
AF Rumawas, Marcella E.
Dwyer, Johanna T.
Mckeown, Nicola M.
Meigs, James B.
Rogers, Gail
Jacques, Paul F.
TI The Development of the Mediterranean-Style Dietary Pattern Score and Its
Application to the American Diet in the Framingham Offspring Cohort
SO JOURNAL OF NUTRITION
LA English
DT Article
ID FOOD FREQUENCY QUESTIONNAIRE; ENERGY-INTAKE; CARDIOVASCULAR-DISEASE; US
ADULTS; HEALTH; REPRODUCIBILITY; VALIDITY; RISK; CONSUMPTION; VALIDATION
AB Previous Mediterranean diet scores were simple to apply but may not be appropriate for non-Mediterranean populations. We developed a Mediterranean-Style Dietary Pattern Score (MSDPS) to assess the conformity of an individual's diet to a traditional Mediterranean-style diet. The MSDPS is based on the recommended intakes of 13 food groups in the Mediterranean diet pyramid. Each food group is scored from 0 to 10 depending on the degree of correspondence with recommendations. Exceeding the recommendations results in a lower score proportional to the degree of overconsumption. The sum of the component scores is standardized to a 0-100 scale and weighted by the proportion of energy consumed from Mediterranean diet foods. We applied the MSDPS to dietary data collected at the 7th examination of the Framingham Offspring Cohort and tested the content validity of the score against selected nutrients known to be associated with the Mediterranean-style dietary pattern. The mean MSDPS was 24.8 (range, 3.1-60.7). Participants with a higher MSDPS were more likely to be women, older, multivitamin users, to have lower BMI and waist circumferences, and less likely to be current smokers. The MSDPS demonstrated content validity through expected positive associations with intakes of dietary fiber, (n-3) fatty acids, antioxidant vitamins, calcium, magnesium, and potassium, and inverse associations with those of added sugar, glycemic index, saturated fat, and trans-fat, and the (n-6):(n-3) fatty acid ratio. The MSDPS is a useful instrument to measure overall diet quality according to the principles of a Mediterranean-style dietary pattern. J. Nutr. 139: 1150-1156, 2009.
C1 [Rumawas, Marcella E.; Dwyer, Johanna T.; Mckeown, Nicola M.; Rogers, Gail; Jacques, Paul F.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
[Rumawas, Marcella E.; Mckeown, Nicola M.; Jacques, Paul F.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
[Dwyer, Johanna T.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Dwyer, Johanna T.] Tufts Med Ctr Hosp, Boston, MA 02111 USA.
[Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Jacques, PF (reprint author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
EM paul.jacques@tufts.edu
OI Dwyer, Johanna/0000-0002-0783-1769
FU USDA [58-1950-7-707]; Framingham Heart Study of the National Heart Lung
and Blood Institute of the NIH [N01-HC-25195]; Helen Smith Brownstein
Memorial Scholarship; General Mills Bell Institute of Health; American
Diabetes Association's Career Development Award; National Institute of
Diabetes and Digestive and Kidney Diseases [K24 DK080140]
FX Supported by the USDA (agreement 58-1950-7-707) and the Framingham Heart
Study of the National Heart Lung and Blood Institute of the NIH
(contract N01-HC-25195). M. E. Rumawas was a recipient of the Helen
Smith Brownstein Memorial Scholarship. N. M. McKeown was supported in
part by the General Mills Bell Institute of Health. J. B. Meigs was
supported by the American Diabetes Association's Career Development
Award and by National Institute of Diabetes and Digestive and Kidney
Diseases Grant K24 DK080140.
NR 37
TC 53
Z9 54
U1 2
U2 16
PU AMER SOC NUTRITIONAL SCIENCE
PI BETHESDA
PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD JUN
PY 2009
VL 139
IS 6
BP 1150
EP 1156
DI 10.3945/jn.109.103424
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 448VQ
UT WOS:000266290500015
PM 19357215
ER
PT J
AU Arjomandi, M
Haight, T
Redberg, R
Gold, WM
AF Arjomandi, Mehrdad
Haight, Thaddeus
Redberg, Rita
Gold, Warren M.
TI Pulmonary Function Abnormalities in Never-Smoking Flight Attendants
Exposed to Secondhand Tobacco Smoke in the Aircraft Cabin
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; CARDIO2000 CASE-CONTROL; INDOOR AIR-POLLUTION;
TOTAL LUNG CAPACITY; PASSIVE SMOKING; HEART-DISEASE; CARBON-MONOXIDE;
HEALTH; ASSOCIATION; RISK
AB Objective: To determine whether the flight attendants who were exposed to secondhand tobacco smoke in the aircraft cabin have abnormal pulmonary function. Methods: We administered questionnaires and performed pulmonary function testing in 61 never-smoking female flight attendants who worked in active air crews before the smoking ban on commercial aircraft (preban). Results: Although the preban flight attendants had normal FVC, FEV(1) and FEV(1)/FVC ratio, they had significantly decreased flow at mid- and low-lung volumes, curvilinear flow-volume curves, and evidence of air trapping Furthermore, the flight attendants had significantly decreased diffusing capacity (77.5% +/- 11.2% predicted normal) with 51% having a diffusing copacity below their 95% normal prediction limit. Conclusions. This cohort of healthy never-smoking flight attendants who were exposed. to secondhand tobacco smoke in the aircraft cabin showed pulmonary function abnormalities suggestive of airway obstruction and impaired diffusion. (J Occup Environ Med. 2009;5.1:639-646)
C1 [Gold, Warren M.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA.
[Arjomandi, Mehrdad; Redberg, Rita; Gold, Warren M.] Univ Calif San Francisco, FAMRI Ctr Excellence, San Francisco, CA 94143 USA.
[Gold, Warren M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
[Arjomandi, Mehrdad] San Francisco VA Med Ctr, San Francisco, CA USA.
[Haight, Thaddeus] Univ Calif San Francisco, Sch Publ Hlth, San Francisco, CA 94143 USA.
RP Gold, WM (reprint author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, Box 0111, San Francisco, CA 94143 USA.
EM warren.gold@ucsf.edu
FU Flight Attendants Medical Research Institute (FAMRI); National
Institutes of Health [K23 HL083099]
FX Supported by the Flight Attendants Medical Research Institute (FAMRI),
and the National Institutes of Health (K23 HL083099).
NR 53
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD JUN
PY 2009
VL 51
IS 6
BP 639
EP 646
DI 10.1097/JOM.0b013e3181a7f048
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 456YO
UT WOS:000266890800002
PM 19448573
ER
PT J
AU Lorenz, KA
Dy, SM
Naeim, A
Walling, AM
Sanati, H
Smith, P
Shanman, R
Roth, CP
Asch, SM
AF Lorenz, Karl A.
Dy, Sydney M.
Naeim, Arash
Walling, Anne M.
Sanati, Homayoon
Smith, Patricia
Shanman, Roberta
Roth, Carol P.
Asch, Steven M.
TI Quality Measures for Supportive Cancer Care: The Cancer Quality-ASSIST
Project
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
CT Conference of the Australia-New-Zealand-Health-Services-Association
CY DEC, 2007
CL Auckland, NEW ZEALAND
SP Australia New Zealand Hlth Serv Assoc
DE Quality of care; supportive care; palliative care; cancer
ID EVIDENCE-BASED RECOMMENDATIONS; OF-LIFE CARE; END; INDICATORS; DELIRIUM;
PERFORMANCE
AB Patients and physicians often cite symptom control as one of their most important goals in cancer care. Despite this, a previous systematic review found few tools for evaluating the quality of supportive cancer management. We developed a comprehensive set of quality indicators for evaluating pain and nonpain symptom management as well as care planning needs in cancer patients. Based on the prevalence and quality-of-life data, clinician-researchers prioritized pain, psychosocial distress, dyspnea, nausea and vomiting, fatigue and anorexia, treatment-associated toxicities, and information and care planning for quality-indicator development. Using search terms and selection criteria, we identified English-language documents from Medline (1997-2007) and Internet-based searches. Based on this evidence, clinician-reviewers Proposed process quality indicators. We then used the VA Health Services Research and Development (VA HSR & D) appropriateness methods to compile the ratings of a multidisciplinary, international expert panel of the validity and feasibility of each indicator The panel judged 92 out of 133 (69%) proposed quality indicators valid and feasible (15 out of 23 pain, 5 out of 6 depression, 8 out of 11 dyspnea, 15 out of 19 nausea and vomiting, 13 out of 26 fatigue and anorexia, 23 out of 32 other treatment-associated toxicities, and 13 out of 16 information and care planning). Of the final indicators, 67 are potentially useful for inpatient and 81 for outpatient evaluation, and 26 address screening, 12 diagnostic evaluation, 20 management, and 21 follow-up. These quality indicators provide evidence explicit tools for measuring processes critical to ensuring high-quality supportive cancer care. Research is needed to characterize adherence to recommended practices and to evaluate the use of these measures in quality improvement efforts. J Pain Symptom Manage 2009;37:943-964. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Lorenz, Karl A.; Smith, Patricia; Shanman, Roberta; Roth, Carol P.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA.
[Lorenz, Karl A.; Naeim, Arash; Walling, Anne M.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Dy, Sydney M.] Johns Hopkins Univ, Sydney Kimmel Canc Ctr, Baltimore, MD USA.
[Sanati, Homayoon] Univ Calif Irvine, Dept Oncol, Irvine, CA USA.
RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, 11301,Wilshire Blvd,Code 3-G, Los Angeles, CA 90073 USA.
EM karl.lorenz@med.va.gov
FU NCI NIH HHS [K07-CA096783]
NR 27
TC 34
Z9 34
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUN
PY 2009
VL 37
IS 6
BP 943
EP 964
DI 10.1016/j.jpainsymman.2008.05.018
PG 22
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 460JG
UT WOS:000267183400001
PM 19359135
ER
PT J
AU Downey, L
Diehr, P
Standish, LJ
Patrick, DL
Kozak, L
Fisher, D
Congdon, S
Lafferty, WE
AF Downey, Lois
Diehr, Paula
Standish, Leanna J.
Patrick, Donald L.
Kozak, Leila
Fisher, Douglass
Congdon, Sean
Lafferty, William E.
TI Might Massage or Guided Meditation Provide "Means to a Better End"?
Primary outcomes from an efficacy trial with patients at the end of life
SO JOURNAL OF PALLIATIVE CARE
LA English
DT Article
ID QUALITY-OF-LIFE; ALTERNATIVE MEDICINE; AROMATHERAPY MASSAGE; PALLIATIVE
CARE; CLINICAL-TRIALS; COMPLEMENTARY; TRENDS; PREFERENCES; DEPRESSION;
CANCER
AB This article reports findings from a randomized controlled trial of massage and guided meditation with patients at the end of life. Using data from 167 randomized patients, the authors considered patient outcomes through 10 weeks post-enrolment, as well as next-of-kin ratings of the quality of the final week of life for 106 patients who died during study participation. Multiple regression models demonstrated no significant treatment effects of either massage or guided meditation, delivered up to twice a week, when compared with outcomes of an active control group that received visits from hospice-trained volunteers on a schedule similar to that of the active treatment arms. The authors discuss the implications of their findings for integration of these complementary and alternative
C1 [Downey, Lois] Univ Washington, Sch Med, Harborview Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seattle, WA 98104 USA.
[Diehr, Paula; Patrick, Donald L.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Diehr, Paula] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA.
[Standish, Leanna J.] Bastyr Univ, Sch Naturopath Med, Kenmore, WA 98028 USA.
[Kozak, Leila] Vet Affairs Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Serv Ctr Excellence, Seattle, WA 98101 USA.
[Fisher, Douglass] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Congdon, Sean] Bastyr Univ Res Ctr, Kenmore, WA 98028 USA.
[Lafferty, William E.] Univ Missouri, Sch Med, Dept Informat, Off Hlth Serv & Publ Hlth Outcomes Res, Kansas City, MO 64108 USA.
RP Downey, L (reprint author), Univ Washington, Sch Med, Harborview Med Ctr, Div Pulm & Crit Care Med,Dept Med, Box 359765,325 9th Ave, Seattle, WA 98104 USA.
FU NCI NIH HHS [5R01-CA106204, R01 CA106204, R01 CA106204-04]
NR 30
TC 9
Z9 10
U1 5
U2 7
PU CENTER BIOETHICS CLIN RES INST MONTREAL
PI MONTREAL
PA 110 PINE AVE W, MONTREAL, QUEBEC H2W 1R7, CANADA
SN 0825-8597
J9 J PALLIAT CARE
JI J. Palliative Care
PD SUM
PY 2009
VL 25
IS 2
BP 100
EP 108
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 461UR
UT WOS:000267298200004
PM 19678461
ER
PT J
AU Peteet, JR
Meyer, F
Thomas, JD
Vitagliano, HL
AF Peteet, John R.
Meyer, Fremonta
Thomas, Jane deLima
Vitagliano, Halyna L.
TI Psychiatric Indications for Admission to an Inpatient Palliative Care
Unit
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID CANCER-PATIENTS; BENZODIAZEPINE; POPULATION; ADHERENCE
AB As inpatient palliative care units (IPCUs) have become more widespread, experience grows regarding the patients for whom they are best suited. We report here on the use of an IPCU in the treatment of several individuals with comorbid psychiatric and advanced life-threatening illness during a 1-year period. At least four categories of such patients-those with suicide risk, dangerous noncompliance, anxiety with substance dependence and diagnostic dilemmas-may benefit uniquely from the individualized, whole person, interdisciplinary approach of an IPCU. Effective referral and comanagement of these patients requires both close collaboration between psychiatric and palliative care clinicians, and awareness of the advantages and limitations of alternatives such as inpatient medical and psychiatric units.
C1 [Peteet, John R.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Peteet, JR (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 44 Binney St, Boston, MA 02115 USA.
EM jpeteet@partners.org
NR 17
TC 3
Z9 3
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN
PY 2009
VL 12
IS 6
BP 521
EP 524
DI 10.1089/jpm.2009.0015
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 456FD
UT WOS:000266826100006
PM 19508137
ER
PT J
AU Ozanne, EM
Partridge, A
Moy, B
Ellis, KJ
Sepucha, KR
AF Ozanne, Elissa M.
Partridge, Ann
Moy, Beverly
Ellis, Katherine J.
Sepucha, Karen R.
TI Doctor-Patient Communication about Advance Directives in Metastatic
Breast Cancer
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID OF-LIFE CARE; TREATMENT DECISIONS; ONCOLOGY PRACTICE; PALLIATIVE CARE;
END; PREFERENCES; INFORMATION; PROGNOSIS; QUALITY; PHYSICIAN
AB Purpose: Oncology providers often find it difficult to discuss end-of-life issues with patients and assume that patients are reluctant to think about the issues involved. This study examined whether or not patients with metastatic breast cancer had advance directives, and if so, with whom they discussed written plans for end-of-life decisions.
Patients and methods: A cross-sectional sample of 32 women with metastatic breast cancer and their providers from two academic medical centers in the United States were surveyed at baseline and again 3 months later about advance directives, decision-making goals, and their expectations. After the baseline assessment, patients viewed a decision aid that discussed choices for treatment of metastatic disease. The patients' experience with advance directives in addition to associations between advance directives and patient preferences regarding end-of-life care, demographics, and clinical characteristics were analyzed.
Results: At baseline, the majority of women had gathered information (75%) about or had written (66%) advance directives. These percentages increased at 3 months. Providers were only aware of the presence of an advance directive in a minority of cases (14%). Patients were more than three times as likely to talk to and share written plans with family and friends than with their providers.
Conclusions: The majority of patients gathered information about advance directives and had made written plans, yet few discussed these plans with their providers. Explicit discussion of advance directives and patient preferences regarding end-of-life care are lacking in this setting. Facilitation of doctor-patient communication about end-of-life care is needed in order to provide quality patient care at this difficult time.
C1 [Sepucha, Karen R.] Massachusetts Gen Hosp, Hlth Decis Res Unit, Boston, MA 02114 USA.
[Ozanne, Elissa M.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Moy, Beverly; Ellis, Katherine J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Ozanne, Elissa M.; Partridge, Ann; Moy, Beverly; Ellis, Katherine J.; Sepucha, Karen R.] Harvard Univ, Sch Med, Boston, MA USA.
[Partridge, Ann] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Sepucha, KR (reprint author), Massachusetts Gen Hosp, Hlth Decis Res Unit, 50 Staniford St,Suite 936, Boston, MA 02114 USA.
EM ksepucha@partners.org
FU Lance Armstrong Foundation; American Cancer Society
FX This research was supported by a grant from the Lance Armstrong
Foundation. Two authors (Sepucha and Ozanne) also received salary
support from the Foundation for Informed Medical Decision Making. Dr.
Ozanne is also supported in part by a career development grant from the
American Cancer Society. These funding agreements ensured the authors'
independence in designing the study, interpreting the data, writing, and
publishing the report.
NR 42
TC 20
Z9 20
U1 2
U2 10
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN
PY 2009
VL 12
IS 6
BP 547
EP 553
DI 10.1089/jpm.2008.0254
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 456FD
UT WOS:000266826100010
PM 19508141
ER
PT J
AU Teles, RP
Likhari, V
Socransky, SS
Haffajee, AD
AF Teles, R. P.
Likhari, V.
Socransky, S. S.
Haffajee, A. D.
TI Salivary cytokine levels in subjects with chronic periodontitis and in
periodontally healthy individuals: a cross-sectional study
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE saliva; cytokines; diagnosis; chronic periodontitis; periodontal health
ID BETA-GLUCURONIDASE ACTIVITY; GINGIVAL CREVICULAR FLUID; ORAL
EPITHELIAL-CELLS; ADULT PERIODONTITIS; DISEASE; BIOMARKERS; DIAGNOSIS;
FLOW
AB Saliva has been proposed as a noninvasive diagnostic fluid that could be used in the diagnosis of oral and systemic diseases. The levels of salivary biomarkers, such as cytokines, could potentially be used as a surrogate to distinguish periodontally healthy individuals from subjects with periodontitis. Therefore, the goal of the present investigation was to determine if the levels of 10 different cytokines in saliva differed between a group of periodontally healthy individuals and a group of subjects with periodontitis. Correlations between the concentrations of these 10 cytokines and clinical parameters of periodontal disease were also examined.
In this cross-sectional study, 74 subjects with chronic periodontitis and 44 periodontally healthy individuals were periodontally examined and had the levels of granulocyte-macrophage colony-stimulating factor, interleukin-1 beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interferon-gamma and tumor necrosis factor-alpha measured in whole saliva using a multiplexed bead immunoassay (Luminex). Significance of statistical differences in the levels of salivary cytokines between groups was determined using nonparametric analysis of covariance, adjusting for age and smoking status. The Spearman rank correlation coefficient was used to explore associations between the mean levels of salivary cytokines and mean clinical parameters.
There were no statistically significant differences between groups for any of the cytokines. There were weak, statistically significant positive associations between salivary interleukin-8 and pocket depth (r(s) = 0.2, p < 0.05) and bleeding on probing (r(s) = 0.2, p < 0.05), and weak negative correlations between salivary interleukin-10 and attachment level (r(s) = -0.2, p < 0.05) and bleeding on probing (r(s) = -0.3, p < 0.001).
Mean salivary levels of granulocyte-macrophage colony-stimulating factor, interleukin-1 beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interferon-gamma and tumor necrosis factor-alpha could not discriminate between periodontal health and disease.
C1 [Teles, R. P.; Socransky, S. S.; Haffajee, A. D.] Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA.
[Likhari, V.] Tufts Univ, Sch Dent Med, Dept Periodontol, Boston, MA 02111 USA.
RP Teles, RP (reprint author), Forsyth Inst, Dept Periodontol, 140 Fenway, Boston, MA 02115 USA.
EM rteles@forsyth.org
FU National Institute of Dental and Craniofacial Research [DE-016700,
DE-012861, DE-014242]
FX This work was supported in part by research grants DE-016700, DE-012861
and DE-014242 from the National Institute of Dental and Craniofacial
Research.
NR 24
TC 53
Z9 57
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3484
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2009
VL 44
IS 3
BP 411
EP 417
DI 10.1111/j.1600-0765.2008.01119.x
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 438LD
UT WOS:000265556000018
PM 19210336
ER
PT J
AU Heimonen, A
Janket, SJ
Kaaja, R
Ackerson, LK
Muthukrishnan, P
Meurman, JH
AF Heimonen, Aura
Janket, Sok-Ja
Kaaja, Risto
Ackerson, Leland K.
Muthukrishnan, Preetika
Meurman, Jukka H.
TI Oral Inflammatory Burden and Preterm Birth
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE Infections; inflammation; preterm birth; weight gain
ID ADVERSE PREGNANCY OUTCOMES; PERIODONTAL-DISEASE; RISK-FACTOR; MATERNAL
PERIODONTITIS; POSSIBLE ASSOCIATION; GROWTH RESTRICTION; INFECTION;
DELIVERY; WEIGHT; WOMEN
AB Background: Earlier studies on the association between oral inflammation and preterm birth limited the inflammation source to periodontal disease. This might have caused an underestimation of the total inflammatory burden from the oral cavity.
Methods: We conducted a postpartum cross-sectional study of 328 Finnish women with singleton births, of whom 77 had preterm births and 251 had full-term births. Gingival bleeding on probing, probing depth, and the presence of dental calculus and mouth ulcers were recorded; the oral inflammatory burden index (OIBI) was constructed based on these clinical findings. A data-driven oral inflammation score (OIS) was also created by stochastically combining the same parameters assessed independently. We used the t, Mann-Whitney, and chi(2) tests for univariate analyses and multivariate logistic regression methods to examine the association between OIBI/OIS and preterm birth. The confounders adjusted for were age, smoking (past, present, and never), diabetes (type 1, type 2, and gestational), primiparity, antimicrobial treatment as a proxy for systemic infection, infertility treatment, and weight gain during pregnancy.
Results: OIBI was significantly associated with preterm birth after adjusting for confounding factors (odds ratio [OR], 1.85; 95% confidence interval [CI]: 1.10 to 3.10; P = 0.02). Without adjusting for weight gain, OIS was significantly associated with preterm birth (OR, 1.97; 95% Cl: 1.09 to 3.57; P = 0.03); however, this association became non-significant after adding weight gain to the model.
Conclusion: The combined effects of multiple oral infections were significantly associated with preterm birth. J Periodontol 2009;80:884-891.
C1 [Heimonen, Aura] Univ Helsinki, Inst Dent, Fac Med, FIN-00014 Helsinki, Finland.
[Heimonen, Aura; Meurman, Jukka H.] Univ Helsinki, Cent Hosp, Dept Oral & Maxillofacial Dis, FIN-00014 Helsinki, Finland.
[Heimonen, Aura] Oulu Univ & Hosp, Inst Dent, Oulu, Finland.
[Janket, Sok-Ja; Muthukrishnan, Preetika] Boston Univ, Dept Gen Dent, Boston, MA 02215 USA.
[Kaaja, Risto] Univ Helsinki, Cent Hosp, Dept Gynecol & Obstet, FIN-00014 Helsinki, Finland.
[Ackerson, Leland K.] Univ Massachusetts Lowell, Dept Community Hlth & Sustainabil, Lowell, MA USA.
[Muthukrishnan, Preetika] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Heimonen, A (reprint author), Univ Helsinki, Inst Dent, Fac Med, PB 41, FIN-00014 Helsinki, Finland.
EM aura.heimonen@helsinki.fi
OI Janket, Sok-Ja/0000-0003-0078-3992; Meurman, Jukka/0000-0001-6702-6836
FU Helsinki University Central Hospital [TYH2119, TI020Y0003]; Finnish
Association of Health Center; National Scientist Development; American
Heart Association [0635351N]
FX The authors acknowledge the following funding support: grants TYH2119
and TI020Y0003 from the Helsinki University Central Hospital to J.H.
Meurman, a grant from the Finnish Association of Health Center Dentists
to A. Heimonen, and the National Scientist Development Grant (#0635351N)
from the American Heart Association to S-J. Janket. We also thank dental
nurse A. Sinkkonen, Institute of Dentistry, University of Helsinki, and
midwife E. Kortelainen, Department of Gynecology and Obstetrics,
Helsinki University Central Hospital, for help with the recruitment
process and medical record search. The authors report no conflicts of
interest related to this study.
NR 35
TC 18
Z9 18
U1 0
U2 3
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA
SN 0022-3492
J9 J PERIODONTOL
JI J. Periodont.
PD JUN
PY 2009
VL 80
IS 6
BP 884
EP 891
DI 10.1902/jop.2009.080560
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 457AJ
UT WOS:000266896600004
PM 19485817
ER
PT J
AU Yehuda, R
Bierer, LM
Andrew, R
Schmeidler, J
Seckl, JR
AF Yehuda, Rachel
Bierer, Linda M.
Andrew, Ruth
Schmeidler, James
Seckl, Jonathan R.
TI Enduring effects of severe developmental adversity, including
nutritional deprivation, on cortisol metabolism in aging Holocaust
survivors
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Posttraumatic stress disorder; Glucocorticoid metabolism; Biological
markers; 5 alpha-Tetrahydrocortisol; 11 beta-hydroxysteroid
dehydrogenase; Child psychiatry
ID POSTTRAUMATIC-STRESS-DISORDER; PITUITARY-ADRENAL AXIS;
11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; BETA-HYDROXYSTEROID
DEHYDROGENASE; PRENATAL EXPOSURE; BLOOD-PRESSURE; PTSD SCALE; LIVER;
ENZYMES; 5-ALPHA-REDUCTASE
AB Objective: In animal models, early life exposure to major environmental challenges such as malnutrition and stress results in persisting cardiometabolic, neuroendocrine and affective effects. While such effects have been associated with pathogenesis, the widespread occurrence of 'developmental programming' suggests it has adaptive function. Glucocorticoids may mediate 'programming' and their metabolism is known to be affected by early life events in rodents. To examine these relationships in humans, cortisol metabolism and cardiometabolic disease manifestations were examined in Holocaust survivors in relation to age at exposure and affective dysfunction, notably lifetime posttraumatic stress disorder (PTSD).
Methods: Fifty-one Holocaust survivors and 22 controls without Axis I disorder collected 24-h urine samples and were evaluated for psychiatric disorders and cardiometabolic diagnoses. Corticosteroids and their metabolites were assayed by gas chromatography-mass spectroscopy (GC-MS); cortisol was also measured by radioimmunoassay (RIA).
Results: Holocaust survivors showed reduced cortisol by RIA, and decreased levels of 5 alpha-tetrahydrocortisol (5 alpha-THF) and total glucocorticoid production by GC-MS. The latter was associated with lower cortisol metabolism by 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) type-2. The greatest decrements were associated with earliest age of Holocaust exposure and less severe PTSD symptomatology. Cardiometabolic manifestations were associated with decreased 11 beta-HSD-2 activity. In controls, 5 alpha-reductase was positively associated with trauma-related symptoms (i.e., to traumatic exposures unrelated to the Holocaust).
Conclusion: Extreme malnutrition and related stress during development is associated with long-lived alterations in specific pathways of glucocorticoid metabolism. These effects may be adaptive and link with lower risks of cardiometabolic and stress-related disorders in later life. Published by Elsevier Ltd.
C1 [Yehuda, Rachel; Bierer, Linda M.; Schmeidler, James] Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY 10468 USA.
[Yehuda, Rachel; Bierer, Linda M.; Schmeidler, James] James J Peters Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Andrew, Ruth; Seckl, Jonathan R.] Univ Edinburgh, Queens Med Res Inst, Endocrinol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland.
RP Yehuda, R (reprint author), Mt Sinai Sch Med, Traumat Stress Studies Div, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@va.gov
RI Seckl, Jonathan/C-3555-2013; Andrew, Ruth/C-2727-2008
FU NIMH [5 R01 MH064675-02]; Wellcome Trust
FX This work was supported by NIMH 5 R01 MH064675-02 to Rachel Yehuda and
by grants from the Wellcome Trust to Ruth Andrew and Jonathan R. Seckl.
Neither the NIMH nor the Wellcome Trust had any further role in study
design; in the collection, analysis or interpretation of data; in
manuscript preparation; or in the decision to submit the paper for
publication.
NR 44
TC 41
Z9 43
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2009
VL 43
IS 9
BP 877
EP 883
DI 10.1016/j.jpsychires.2008.12.003
PG 7
WC Psychiatry
SC Psychiatry
GA 452XC
UT WOS:000266573500009
PM 19162277
ER
PT J
AU Buchi, S
Zwahlen, D
Hagenbuch, N
Carley, MI
Sullivan, AM
Jenewein, J
AF Buchi, S.
Zwahlen, D.
Hagenbuch, N.
Carley, M., I
Sullivan, A. M.
Jenewein, J.
TI Measuring distress in couples facing cancer with the distress
thermometer (DT)
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Meeting Abstract
C1 [Buchi, S.] Clin Psychotherapy & Psychosomat Hohenegg, Meilen, Switzerland.
[Buchi, S.; Zwahlen, D.; Hagenbuch, N.; Jenewein, J.] Univ Zurich Hosp, Dept Psychiat, Zurich, Switzerland.
[Zwahlen, D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sullivan, A. M.] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD JUN
PY 2009
VL 66
IS 6
MA 15
BP 552
EP 553
PG 2
WC Psychiatry
SC Psychiatry
GA 452BR
UT WOS:000266515100027
ER
PT J
AU Beigi, RH
Switzer, GE
Meyn, LA
AF Beigi, Richard H.
Switzer, Galen E.
Meyn, Leslie A.
TI Acceptance of a Pandemic Avian Influenza Vaccine in Pregnancy
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article; Proceedings Paper
CT 34th Annual Scientific Meeting of the
Infectious-Diseases-Society-for-Obstetrics-and-Gynecology
CY AUG 09-11, 2007
CL Boston, MA
SP Infect Dis Soc Obstet & Gynecol
DE avian influenza; pandemics; pregnancy; vaccination
ID ASIAN INFLUENZA; WOMEN; HOSPITALIZATIONS; EPIDEMIC; ILLNESS; H5N1
AB OBJECTIVE: To evaluate acceptance of a pandemic avian influenza vaccine among obstetric patients and nonphysician obstetric office personnel.
STUDY DESIGN: Two separate office-based questionnaires were administered to patients and nonphysician personnel. Questions included demographics, vaccine beliefs and acceptance of a potential pandemic avian influenza vaccine in pregnancy.
RESULTS: Questionnaires were completed by 394 of 600 (65.7%) eligible patients and 101 of 134 (75.3%) eligible office personnel. Only 15.4% of the patients stated they would definitely accept a pandemic influenza vaccine in pregnancy despite most (68%) reporting they would first consult their obstetrician for information. Fifty percent of the office personnel would not recommend a pandemic influenza vaccine to pregnant women and 40% reported unwillingness to accept the same vaccine if they were pregnant.
CONCLUSION: Barriers exist that may hinder mass vaccination efforts among the pregnant population during the next influenza pandemic. Preemptive educational efforts may assist in the acceptance of a pandemic vaccine among pregnant women and enable obstetricians to better provide disease prevention during the next influenza pandemic. (J Reprod Med 2009;54:341-346)
C1 [Beigi, Richard H.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci,Div Reprod Infec, Pittsburgh, PA 15213 USA.
Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA.
Magee Womens Res Inst, Pittsburgh, PA USA.
RP Beigi, RH (reprint author), Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci,Div Reprod Infec, 300 Halket St, Pittsburgh, PA 15213 USA.
EM rbeigi@mail.magee.edu
NR 22
TC 22
Z9 22
U1 1
U2 5
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD JUN
PY 2009
VL 54
IS 6
BP 341
EP 346
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 461EW
UT WOS:000267248400003
PM 19639922
ER
PT J
AU Becker, MA
Schumacher, HR
MacDonald, PA
Lloyd, E
Lademacher, C
AF Becker, Michael A.
Schumacher, H. Ralph
MacDonald, Patricia A.
Lloyd, Eric
Lademacher, Christopher
TI Clinical Efficacy and Safety of Successful Longterm Urate Lowering with
Febuxostat or Allopurinol in Subjects with Gout
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GOUT; HYPERURICEMIA; FEBUXOSTAT; ALLOPURINOL; SERUM URATE
ID SERUM URIC-ACID; HYPERURICEMIA; ARTHRITIS; MANAGEMENT; REDUCTION;
THERAPY; ATTACKS; CARE
AB Objective. To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout.
Methods. Subjects (n = 1086) in this open-label extension Study were assigned to fixed-dose daily Urate-lowering treatment (ULT) with febuxostat (80 mg or 120 mg) or allopurinol (300 tug). ULT reassignment was permitted during months I to 6 to achieve serum urate (SUA) concentrations between 3.0 and < 6.0 mg/dl. Flares requiring treatment, tophus size, safety, and SUA levels were monitored during up to 40 months of ULT maintenance. C,
Results. After 1 month initial treatment, > 80% of Subjects receiving either febuxostat close, but Only 46% of subjects receiving allopurinol, achieved SUA < 6.0 mg/dl. After ULT reassignment, > 80% of all remaining subjects maintained the primary efficacy endpoint of SUA < 6.0 mg/dl at each visit. More Subjects initially randomized to allopurinol required ULT reassignment to achieve SUA < 6.0 mg/dl compared with subjects receiving febuxostat. Maintenance of SUA < 6.0 mg/dl resulted in progressive reduction to nearly 0 in proportion of subjects requiring gout flare treatment. Baseline tophus resolution was achieved by 46% 36%, and 29% of subjects maintained on febuxostat 80 mg, febuxostat 120 mg, and allopurinol, respectively. Overall adverse event rates (including cardiovascular adverse event rates), adjusted for 10-fold greater febuxostat than allopurinol exposure, did not differ significantly among treatment groups.
Conclusion. Durable maintenance of goal range SUA level with either dose of febuxostat or in smaller numbers of subjects with allopurinol resulted in near elimination of gout flares and improved tophus status over time. Registered as NCT00175019. (First Release March 15 2009; J Rheumatol 2009;36:1273-82; doi: 10.3899/jrheum.080814)
C1 [Becker, Michael A.] Univ Chicago, Med Ctr, Pritzker Sch Med, Chicago, IL 60637 USA.
[Schumacher, H. Ralph] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
Vet Affairs Med Ctr, Philadelphia, PA USA.
[Lloyd, Eric; Lademacher, Christopher] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA.
RP Becker, MA (reprint author), Univ Chicago, Med Ctr, Pritzker Sch Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM mbecker@medicine.bsd.uchicago.edu
FU Takeda Global Research & Development Center, Inc.
FX Supported by Takeda Global Research & Development Center, Inc. (TAP
Pharmaceutical Products Inc. is now a part of Takeda Global Research &
Development Center, Inc.). Dr Becker and Dr. Schumacher are consultants
for Takeda Global Research & Development Center, Inc.
NR 23
TC 97
Z9 102
U1 1
U2 8
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2009
VL 36
IS 6
BP 1273
EP 1282
DI 10.3899/jrheum.080814
PG 10
WC Rheumatology
SC Rheumatology
GA 456YU
UT WOS:000266891500030
PM 19286847
ER
PT J
AU Malik, A
Dinnella, JE
Kwoh, CK
Schumacher, HR
AF Malik, Aarti
Dinnella, Janet E.
Kwoh, C. Kent
Schumacher, H. Ralph
TI Poor Validation of Medical Record ICD-9 Diagnoses of Gout in a Veterans
Affairs Database
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE DIAGNOSES; GOUT; EPIDEMIOLOGIC STUDIES
ID POSITIVE PREDICTIVE-VALUE; EPIDEMIOLOGY; PREVALENCE; ARTHRITIS;
ACCURACY; CRITERIA; CLAIMS
AB Objective. Diagnostic codes based on medical records or claims data have been used to identify patient Populations with gout For important epidemiologic and Clinical Studies. We evaluated whether we can document the accuracy Of Such diagnoses by review of medical records and then on direct interviews with a Subset of patients.
Methods. Electronic medical records of 289 patients with 2 visits with ICD-9 codes for gout were extensively reviewed to search for documentation of features that Would classify patients as having gout by 3 sets of proposed criteria, the American College of Rheumatology (ACR), New York, or Rome criteria. Records of patients who had been seen by rheumatologists were compared with all others. A subset of patients seen in clinic were directly interviewed for comparison with the results front the records.
Results. Based on medical records review there was documentation of gout by the ACR criteria in only 36%, Rome criteria in 30%, and New York criteria in 33%. Records of patients who had seen rheumatologists had better documentation of classification features. Interview in clinic of 37 patients also improved documentation of the 3 sets of criteria features of gout in 65%-81% of those with ICD-9 codes for gout.
Conclusion. We found it difficult to confirm ICD-9 coded diagnoses of gout using currently available proposed criteria from details recorded in medical records. This may reflect a problem with available criteria and with documentation. Direct interview of patients may be needed to confirm the presence of typical features when high specificity is desired. (First Release May 15 2009: J Rheumatol 2009;36:1283-6: doi: 10.3899/jrheum.081195)
C1 [Malik, Aarti; Dinnella, Janet E.; Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA.
[Malik, Aarti; Dinnella, Janet E.; Schumacher, H. Ralph] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA.
[Kwoh, C. Kent] Vet Affairs Med Ctr, Pittsburgh, PA USA.
RP Malik, A (reprint author), Evanston NW Healthcare, Div Rheumatol, 2650 Ridge Ave,Room 5313, Evanston, IL 60201 USA.
FU TAP Pharmaceuticals
FX Supported in part by an Investigator Initiated grant from TAP
Pharmaceuticals.
NR 13
TC 20
Z9 20
U1 0
U2 0
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2009
VL 36
IS 6
BP 1283
EP 1286
DI 10.3899/jrheum.081195
PG 4
WC Rheumatology
SC Rheumatology
GA 456YU
UT WOS:000266891500031
PM 19447931
ER
PT J
AU Rosen, RC
Shifren, JL
Monz, BU
Odom, DM
Russo, PA
Johannes, CB
AF Rosen, Raymond C.
Shifren, Jan L.
Monz, Brigitta U.
Odom, Dawn M.
Russo, Patricia A.
Johannes, Catherine B.
TI Correlates of Sexually Related Personal Distress in Women with Low
Sexual Desire
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Low Sexual Desire; Sexual Distress; Female; Hypoactive Sexual Desire
Disorder; Epidemiology; Correlates
ID DISORDER; DYSFUNCTIONS; RELIABILITY; POPULATION; PREVALENCE; VALIDATION;
VALIDITY; SAMPLE; HEALTH; SCALE
AB Sexual distress is an important component of diagnostic criteria for sexual dysfunctions, but little is known about the factors associated with sexual distress in women with low sexual desire.
To investigate the correlates of sexual distress in women with self-reported low sexual desire.
The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking study was a cross-sectional, nationally representative, mailed survey of U.S. adult women. There were 31,581 respondents (response rate 63.2%) to the 42-item questionnaire that measured sexual function, sexual distress, demographic, and health-related factors. Multivariable logistic regression was used to explore the correlates of distress.
Low sexual desire was defined as a response of "never" or "rarely" to the question, "How often do you desire to engage in sexual activity?" Sexual distress was measured with the Female Sexual Distress Scale (range 0-48), with a score of 15 or higher indicating presence of distress.
Of 10,429 women with low desire, 2,868 (27.5%) had sexual distress (mean age 48.6 years, 81% with a current partner). Women without distress were 10 years older on average, and 44% had a current partner. Having a partner was strongly related to distress (odds ratio 4.6, 95% confidence interval 4.1-5.2). Other correlates were age, race, current depression, anxiety, lower social functioning, hormonal medication use, urinary incontinence, and concurrent sexual problems (arousal or orgasm). Dissatisfaction with sex life was more common in women with low desire and distress (65%) than in those without distress (20%).
Age has a curvilinear relationship with distress, and the strongest correlate of sexual distress was having a current partner. Sexual distress and dissatisfaction with sex life are strongly correlated. Distress is higher in women with low sexual desire in a partner relationship; further research on this factor is needed. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, and Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6:1549-1560.
C1 [Rosen, Raymond C.] New England Res Inst Chief Sci, Watertown, MA USA.
[Shifren, Jan L.] Massachusetts Gen Hosp, Vincent OBGYN Serv, Boston, MA 02114 USA.
[Monz, Brigitta U.] Boehringer Ingelheim GmbH Global Hlth Econ & Outc, Ingelheim, Germany.
[Odom, Dawn M.] Res Triangle Inst Hlth Solut Biostat, Res Triangle Pk, NC USA.
[Russo, Patricia A.] PRC Hlth Serv Res & Management Consulting, Washington, DC USA.
[Johannes, Catherine B.] Res Triangle Inst Hlth Solut Pharmacoepidemiol &, Waltham, MA USA.
RP Rosen, RC (reprint author), New England Res Inst Inc, 9 Galen St, Watertown, MA 02472 USA.
EM rrosen@neriscience.com
NR 20
TC 81
Z9 82
U1 4
U2 8
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD JUN
PY 2009
VL 6
IS 6
BP 1549
EP 1560
DI 10.1111/j.1743-6109.2009.01252.x
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA 451JA
UT WOS:000266465300006
PM 19473457
ER
PT J
AU Ward, CP
McCarley, RW
Strecker, RE
AF Ward, Christopher P.
McCarley, Robert W.
Strecker, Robert E.
TI Experimental sleep fragmentation impairs spatial reference but not
working memory in Fischer/Brown Norway rats
SO JOURNAL OF SLEEP RESEARCH
LA English
DT Article
DE hippocampus; sleep deprivation; sleepiness; water maze
ID WATER MAZE; DEPRIVATION; CONSOLIDATION; HIPPOCAMPAL; PERFORMANCE; PLACE;
TASK; WAKEFULNESS; DISRUPTION; PLASTICITY
AB Sleep fragmentation is a common symptom in sleep disorders and other medical complaints resulting in excessive daytime sleepiness. The present study seeks to explore the effects of sleep fragmentation on learning and memory in a spatial reference memory task and a spatial working memory (WM) task. Fischer/Brown Norway rats lived in custom treadmills designed to induce locomotor activity every 2 min throughout a 24-h period. Separate rats were either on a treadmill schedule that allowed for consolidated sleep or experienced no locomotor activation. Rats were tested in one of two water maze-based tests of learning and memory immediately following 24 h of sleep interruption. Rats tested in a spatial reference memory task (eight massed acquisition trials) with a 24-h follow-up probe trial to assess memory retention showed no differences in acquisition performance but were impaired on the 24 h retention of the platform location. In contrast, the performance of rats tested in a spatial WM task (delayed matching to position task) was not impaired. Therefore, sleep fragmentation prior to testing impairs the ability to retain spatial reference memories but does not impair spatial reference memory acquisition or spatial WM in Fischer-Norway rats.
C1 [Ward, Christopher P.] Univ Houston Clear Lake, Dept Psychol, Houston, TX 77058 USA.
[Ward, Christopher P.; McCarley, Robert W.; Strecker, Robert E.] VA Boston Healthcare Syst, Brockton, MA USA.
[Ward, Christopher P.; McCarley, Robert W.; Strecker, Robert E.] Harvard Univ, Sch Med, Dept Psychiat, Brockton, MA 02401 USA.
RP Ward, CP (reprint author), Univ Houston Clear Lake, Dept Psychol, 2700 Bay Area Blvd,Box 22, Houston, TX 77058 USA.
EM wardchris@uhcl.edu
RI McCarley, Robert/N-5562-2014;
OI McCarley, Robert/0000-0001-5705-7495; Ward,
Christopher/0000-0001-9932-3894
FU NIH [HL060292]; Department of Veterans Affairs
FX The authors wish to thank Matthew Heard and Amy Blanchette of Stonehill
College for their excellent technical assistance. This research was
supported by NIH HL060292 and the Department of Veterans Affairs.
NR 36
TC 17
Z9 17
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0962-1105
J9 J SLEEP RES
JI J. Sleep Res.
PD JUN
PY 2009
VL 18
IS 2
BP 238
EP 244
DI 10.1111/j.1365-2869.2008.00714.x
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 448DS
UT WOS:000266243900013
PM 19645967
ER
PT J
AU Tatlidede, S
McCormack, MC
Eberlin, KR
Nguyen, JT
Randolph, MA
Austen, WG
AF Tatlidede, Soner
McCormack, Michael C.
Eberlin, Kyle R.
Nguyen, John T.
Randolph, Mark A.
Austen, William G., Jr.
TI A Novel Murine Island Skin Flap for Ischemic Preconditioning
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE island skin flap; murine; ischemia reperfusion; ischemic preconditioning
ID ISCHEMIA/REPERFUSION INJURY; VASCULAR TERRITORIES; SKELETAL-MUSCLE;
MODEL; DELAY; RAT; SURVIVAL
AB Background. Ischemia reperfusion injury is a well-known phenomenon affecting skin flap viability. One method to improve flap viability is ischemic preconditioning. Previous murine flap models used random flaps. We developed a single pedicle island skin flap which allows us to create true ischemia by clamping the single pedicle. Our first aim was to describe a novel murine skin flap model with a definable, reproducible injury. Our second aim was to test the usefulness of this model by demonstrating mitigation of injury via ischemic preconditioning.
Materials and methods. Dorsal lateral thoracic artery pedicle island skin flaps (3.5 x 1.5 cm) were elevated in 39 male C57/BL6 mice: a Control group (n = 7), 10 h of ischemia (n = 21), and Preconditioning (2 cycles of 20 min ischemia: 20 minutes reperfusion) + 10-h ischemia (n = 11). After flap elevation, a silicon sheet barrier was placed. The axial pedicles were occluded, and the flaps were inset with 6-0 prolene. In all mice, ischemia was followed by 1 wk of reperfusion. At I wk, percent necrosis was measured and an analysis of variance was performed.
Results. The percent of flap necrosis was 1.1% +/- 1.11% in controls. Animals that were subjected to 10 h of ischemia developed 33.14% +/- 7.23% necrosis. Preconditioned animals that underwent 10 h of ischemia demonstrated a 43% reduction in necrosis (18.82% +/- 5.68%). There was a statistically significant difference among all groups (P <= 0.001).
Conclusion. Rat models have been the standard for skin flap experiments. We have developed a novel murine single pedicle island skin flap model with reproducible injury. This model has numerous advantages, including case of handling, low cost, appropriateness for biomedical studies, and the availability of genetically altered animals. We also confirmed this model's usefulness in a study of mitigation of ischemia reperfusion injury through ischemic preconditioning. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Tatlidede, Soner; McCormack, Michael C.; Eberlin, Kyle R.; Nguyen, John T.; Randolph, Mark A.; Austen, William G., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast Surg,Plast Surg Res Lab, Boston, MA 02114 USA.
RP McCormack, MC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast Surg,Plast Surg Res Lab, Room WAC 435,15 Parkman St, Boston, MA 02114 USA.
EM wausten@partners.org
FU Plastic Surgery Development Fund of the Massachusetts Genereal Hospital
FX Funding for this study was provided by the Plastic Surgery Development
Fund of the Massachusetts Genereal Hospital.
NR 23
TC 13
Z9 14
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JUN 1
PY 2009
VL 154
IS 1
BP 112
EP 117
DI 10.1016/j.jss.2008.05.029
PG 6
WC Surgery
SC Surgery
GA 445VQ
UT WOS:000266080000017
PM 19101697
ER
PT J
AU Lafleur, D
AF Lafleur, Daniel
TI Say You're One of Them
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Book Review
C1 [Lafleur, Daniel] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lafleur, Daniel] McLean Hosp, Boston, MA USA.
RP Lafleur, D (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM daniel.lafleur@mail.mcgill.ca
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUN
PY 2009
VL 48
IS 6
BP 671
EP 672
DI 10.1097/01.CHI.0000314069.12285.a9
PG 2
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 448YO
UT WOS:000266298100012
ER
PT J
AU Okpokwasili-Johnson, E
AF Okpokwasili-Johnson, Ebele
TI A World of Gangs: Armed Young Men and Gangsta Culture
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Book Review
C1 [Okpokwasili-Johnson, Ebele] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Okpokwasili-Johnson, Ebele] McLean Hosp, Boston, MA USA.
RP Okpokwasili-Johnson, E (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM eokpokwasili@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUN
PY 2009
VL 48
IS 6
BP 674
EP 674
DI 10.1097/01.CHI.0000346416.61226.18
PG 1
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 448YO
UT WOS:000266298100014
ER
PT J
AU Cohen, ME
Bilimoria, KY
Ko, CY
Hall, BL
AF Cohen, Mark E.
Bilimoria, Karl Y.
Ko, Clifford Y.
Hall, Bruce Lee
TI Development of an American College of Surgeons National Surgery Quality
Improvement Program: Morbidity and Mortality Risk Calculator for
Colorectal Surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID POSSUM SCORING SYSTEMS; POSTOPERATIVE MORTALITY; CANCER SURGERY;
P-POSSUM; OPERATIVE RISK; RESECTION; VALIDATION; SCORES; SCALE
AB BACKGROUND: Surgical decision-making and informed patient consent both benefit from having accurate information about risk. But currently available risk estimating systems have one or more limitations associated with lack of specificity to operation type, size of sample (reliability), range of outcomes predicted, and appreciation of hospital effects.
STUDY DESIGN: Data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) patients who underwent colorectal surgery in 2006 to 2007 were used to generate logistic prediction models for 30-day morbidity, serious morbidity, and mortality. Results for these three models were then used to construct a universal multivariable model to predict risk for all three outcomes. Model performance was externally validated against 2005 data.
RESULTS: For 2006 to 2007, 28,863 patients were identified who underwent major colorectal operations at 182 hospitals. A single 15-variable predictor model exhibited discrimination (c-statistic) close to that observed for the separate models on all three outcomes. Similar discrimination was found when the 2006 to 2007 universal model was applied to 3,037 operations conducted in 2005 at 37 hospitals.
CONCLUSIONS: The ACS NSQIP colorectal risk calculator allows surgeons to preoperatively provide patients with detailed information about their personal risks of overall morbidity, serious morbidity, and mortality. Because ACS NSQIP can also categorize hospitals as performing better or worse than expected (or as expected), surgeons have the opportunity to adjust risk probabilities for patients at their institutions accordingly. (J Am Coll Surg 2009;208:1009-1016. (C) 2009 by the American College of Surgeons)
C1 [Cohen, Mark E.; Bilimoria, Karl Y.; Ko, Clifford Y.] Northwestern Univ, Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Hall, Bruce Lee] Washington Univ, John Cochran Vet Affairs Med Ctr, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, Sch Med, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA.
RP Cohen, ME (reprint author), Northwestern Univ, Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM markcohen@facs.org
NR 24
TC 147
Z9 149
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2009
VL 208
IS 6
BP 1009
EP 1016
DI 10.1016/j.jamcollsurg.2009.01.043
PG 8
WC Surgery
SC Surgery
GA 459TY
UT WOS:000267134300002
PM 19476884
ER
PT J
AU Alvord, LA
Henderson, WG
Benton, K
Buchwald, D
AF Alvord, Lori Arviso
Henderson, William G.
Benton, Kathryn
Buchwald, Dedra
TI Surgical Outcomes in American Indian Veterans: A Closer Look
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID RISK ADJUSTMENT; GALLBLADDER DISEASE; PIMA INDIANS; QUALITY; CARE;
MISCLASSIFICATION; PREVALENCE; MORBIDITY; MORTALITY; RATES
AB BACKGROUND: American Indian/Alaska Native (AI/ANs) male veterans have considerably higher postoperative mortality rates than their Caucasian Counterparts, but similar postoperative morbidity rates even after adjusting for major preoperative risk factors. This Study seeks to explain the discrepancy in morbidity and mortality.
STUDY DESIGN: We obtained data from the Veterans Affairs National Surgical Quality Improvement Program on major, noncardiac, surgical procedures performed from 1991 to 2002 for all AI/AN men (n = 2,155), and a random sample of Caucasian men (n = 2,264), matched by site. We compared the number and types of postoperative complications and mortality rates for those patients in whom complications developed. We also examined complication and mortality rates by whether they Occurred after hospital discharge, or by specific type of surgical procedure. Preoperative risk factors were assessed in patients who died. Chi-square or Fisher's exact tests were used for all comparisons.
RESULTS: AI/ANs and Caucasians did not differ by number of complications but Caucasian patients had considerably higher rates for three specific complications. There was no difference in deaths after discharge or in mortality rates after specific surgical procedures. The groups differed considerably in the types of procedures performed. Among patients who died, three preoperative risk factors, ie, hemiplegia, diabetes, and wound infection, occurred more frequently among AI/AN than Caucasian veterans.
CONCLUSIONS: We cannot fully explain higher postoperative mortality rates experienced by AI/AN relative to Caucasian veterans after examining complications, types of procedures, and other relevant factors. AI/ANs with certain preoperative risk factors can be Vulnerable to 30-day postoperative mortality and benefit from closer postoperative surveillance. (J Am Coll Surg 2009;208:, 1085-1092. (C) 2009 by the American College of Surgeons)
C1 [Alvord, Lori Arviso] Dartmouth Med Sch, Dept Surg, Lebanon, NH USA.
[Alvord, Lori Arviso] White River Junct VA Med Ctr, White River Jct, VT USA.
[Henderson, William G.] Univ Colorado Denver, Dept Prevent Med & Biometr, Denver, CO USA.
[Henderson, William G.] Univ Colorado Denver, Hlth Outcomes Program, Denver, CO USA.
[Henderson, William G.] Denver VA Med Ctr, Denver, CO USA.
[Benton, Kathryn] Univ Colorado Denver, Colorado Hlth Outcomes Program, Denver, CO USA.
[Buchwald, Dedra] Univ Washington, Dept Med, Seattle, WA USA.
RP Alvord, LA (reprint author), Dartmouth Med Sch, Dept Surg, Hinman Box 7010, Hanover, NH 03755 USA.
EM lori.arivso.alvord@dartmouth.edu
FU University of Washington; University of Colorado Denver
FX We wish to thank Spero Manson, PhD, and the Native Elder Research Center
at the University of Colorado Denver and the University of Washington
for grant and statistical support. We also thank Shukri F Khuri, MD, and
the NSQIP for the data used in this study.
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2009
VL 208
IS 6
BP 1085
EP 1092
DI 10.1016/j.jamcollsurg.2009.02.058
PG 8
WC Surgery
SC Surgery
GA 459TY
UT WOS:000267134300014
PM 19476896
ER
PT J
AU Friedlander, AH
Mahler, M
Norman, KM
Ettinger, RL
AF Friedlander, Arthur H.
Mahler, Michael
Norman, Keith M.
Ettinger, Ronald L.
TI Parkinson disease Systemic and orofacial manifestations, medical and
dental management
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Review
DE Parkinson disease; local anesthetics; saliva
ID BOTULINUM-TOXIN-A; ORAL-HEALTH; NONMOTOR SYMPTOMS; FOLLOW-UP; DIAGNOSIS;
DYSFUNCTION; DOPAMINE; DEMENTIA; LEVODOPA; THERAPY
AB Background. More than 1.5 million Americans have Parkinson disease (PD), and this figure is expected to rise as the population ages. However, the dental literature offers little information about the illness.
Types of Studies Reviewed. The authors conducted a MEDLINE search using the key terms "Parkinson's disease, "medical management" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials.
Results. PD is a progressive neurodegenerative disorder caused by loss of dopaminergic and nondopaminergic neurons in the brain. These deficits result in tremor, slowness of movement, rigidity, postural instability and autonomic and behavioral dysfunction. Treatment consists of administering medications that replace dopamine, stimulate dopamine receptors and modulate other neurotransmitter systems.
Clinical Implications. Oral health may decline because of tremors, muscle rigidity and cognitive deficits. The dentist should consult with the patient's physician to establish the patient's competence to provide informed consent and to determine the presence of comorbid illnesses. Scheduling short morning appointments that begin 90 minutes after administration of PD medication enhances the patient's ability to cooperate with care. Inclination of the dental chair at 45 degrees, placement of a bite prop, use of a rubber dam and high-volume oral evacuation enhance airway protection. To avoid adverse drug interactions with levodopa and entacapone, the dentist should limit administration of local anesthetic agents to three cartridges of 2 percent lidocaine with 1:100,000 epinephrine per half hour, and patients receiving selegiline should not be given agents containing epinephrine or levonordefrin. The dentist should instruct the patient and the caregiver in good oral hygiene techniques.
C1 [Friedlander, Arthur H.] VA Greater Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Mahler, Michael] VA Greater Angeles Healthcare Syst, Neurobehav Clin, Los Angeles, CA 90073 USA.
[Mahler, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Ettinger, Ronald L.] Univ Iowa, Dept Prosthodont, Iowa City, IA USA.
[Ettinger, Ronald L.] Univ Iowa, Dows Inst Dent Res, Iowa City, IA USA.
RP Friedlander, AH (reprint author), VA Greater Angeles Healthcare Syst, Dept Vet Affairs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
NR 102
TC 13
Z9 16
U1 2
U2 9
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD JUN
PY 2009
VL 140
IS 6
BP 658
EP 669
PG 12
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 456KQ
UT WOS:000266845300014
PM 19491161
ER
PT J
AU Lee, SJ
Sudore, RL
Williams, BA
Lindquist, K
Chen, HL
Covinsky, KE
AF Lee, Sei J.
Sudore, Rebecca L.
Williams, Brie A.
Lindquist, Karla
Chen, Helen L.
Covinsky, Kenneth E.
TI Functional Limitations, Socioeconomic Status, and All-Cause Mortality in
Moderate Alcohol Drinkers
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article; Proceedings Paper
CT 31st Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 09-12, 2008
CL Pittsburgh, PA
SP Soc Gen Internal Med
DE alcohol; function; socioeconomic status; risk adjustment
ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED TRIAL; ESTROGEN PLUS
PROGESTIN; POSTMENOPAUSAL WOMEN; SOCIAL INTEGRATION; PROPENSITY SCORE;
ELDERLY-PEOPLE; RISK-FACTORS; BRITISH MEN; US ADULTS
AB To determine whether the survival benefit associated with moderate alcohol use remains after accounting for nontraditional risk factors such as socioeconomic status (SES) and functional limitations.
Prospective cohort.
The Health and Retirement Study (HRS), a nationally representative study of U.S. adults aged 55 and older.
Twelve thousand five hundred nineteen participants were enrolled in the 2002 wave of the HRS.
Participants were asked about their alcohol use, functional limitations (activities of daily living, instrumental activities of daily living, and mobility), SES (education, income, and wealth), psychosocial factors (depressive symptoms, social support, and the importance of religion), age, sex, race and ethnicity, smoking, obesity, and comorbidities. Death by December 31, 2006, was the outcome measure.
Moderate drinkers (1 drink/d) had a markedly more-favorable risk factor profile, with higher SES and fewer functional limitations. After adjusting for demographic factors, moderate drinking (vs no drinking) was strongly associated with less mortality (odds ratio (OR)=0.50, 95% confidence interval (CI)=0.40-0.62). When traditional risk factors (smoking, obesity, and comorbidities) were also adjusted for, the protective effect was slightly attenuated (OR=0.57, 95% CI=0.46-0.72). When all risk factors including functional status and SES were adjusted for, the protective effect was markedly attenuated but still statistically significant (OR=0.72, 95% CI=0.57-0.91).
Moderate drinkers have better risk factor profiles than nondrinkers, including higher SES and fewer functional limitations. Although these factors explain much of the survival advantage associated with moderate alcohol use, moderate drinkers maintain their survival advantage even after adjustment for these factors.
C1 [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
[Lee, Sei J.; Sudore, Rebecca L.; Williams, Brie A.; Lindquist, Karla; Chen, Helen L.; Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, Bldg 1,Room 306,Box 181G,4150 Clement St, San Francisco, CA 94121 USA.
EM seijlee@gmail.com
FU NCRR NIH HHS [KL2 RR024130, KL2 RR024130-04, KL2RR024130]; NIA NIH HHS
[K24-AG029812, K24 AG029812, L30 AG030755, L30 AG030755-02, R01
AG023626, R01-AG023626, U01 AG009740, U01AG09740]
NR 58
TC 31
Z9 31
U1 1
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2009
VL 57
IS 6
BP 955
EP 962
DI 10.1111/j.1532-5415.2009.02184.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 451SM
UT WOS:000266490500001
PM 19473456
ER
PT J
AU Mount, DB
AF Mount, David B.
TI Splicing a Kinase and the Regulation of Salt Transport
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID NA-CL COTRANSPORTER; BLOOD-PRESSURE; WNK KINASES; HOMEOSTASIS;
MUTATIONS; PATHWAY
C1 [Mount, David B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvard Inst Med,Div Renal, Boston, MA 02115 USA.
[Mount, David B.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RP Mount, DB (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvard Inst Med,Div Renal, Room 542,4 Blackfan Circle, Boston, MA 02115 USA.
EM dmount@rics.bwh.harvard.edu
FU NIDDK NIH HHS [DK070756, DK57708]
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2009
VL 20
IS 6
BP 1166
EP 1168
DI 10.1681/ASN.2009040410
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 453NK
UT WOS:000266617200005
PM 19470669
ER
PT J
AU Anderson, S
Halter, JB
Hazzard, WR
Himmelfarb, J
Horne, FM
Kaysen, GA
Kusek, JW
Nayfield, SG
Schmader, K
Tian, Y
Ashworth, JR
Clayton, CP
Parker, RP
Tarver, ED
Woolard, NF
High, KP
AF Anderson, Sharon
Halter, Jeffrey B.
Hazzard, William R.
Himmelfarb, Jonathan
Horne, Frances McFarland
Kaysen, George A.
Kusek, John W.
Nayfield, Susan G.
Schmader, Kenneth
Tian, Ying
Ashworth, John R.
Clayton, Charles P.
Parker, Ryan P.
Tarver, Erika D.
Woolard, Nancy F.
High, Kevin P.
TI Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older
Adults
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Review
ID STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; CYCLE INHIBITOR
P16(INK4A); CARDIOVASCULAR RISK-FACTOR; URINARY ALBUMIN EXCRETION;
CHRONIC-HEMODIALYSIS PATIENTS; POLYUNSATURATED FATTY-ACIDS; TYPE-2
DIABETES-MELLITUS; LOW-DENSITY-LIPOPROTEIN; COGNITIVE FUNCTION
AB Chronic kidney disease is a large and growing problem among aging populations. Although progression of chronic kidney disease to end-stage renal disease (ESRD) is a costly and important clinical event with substantial morbidity, it appears less frequently in aging people compared with cardiovascular mortality. The measurement of kidney function and management of kidney disease in older individuals remain challenging, partly because the pathophysiologic mechanisms underlying age-related decline in kidney function, the interactions between age and other risk factors in renal progression, and the associations of chronic kidney disease with other comorbidities in older people are understudied and poorly understood. The Association of Specialty Professors, the American Society of Nephrology, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Diabetes and Digestive and Kidney Diseases held a workshop, summarized in this article, to review what is known about chronic kidney disease, identify research gaps and resources available to address them, and identify priority areas for future research. Answers to emerging research questions will support the integration of geriatrics and nephrology and thus improve care for older patients at risk for chronic kidney disease.
C1 [High, Kevin P.] Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, Winston Salem, NC 27157 USA.
[Anderson, Sharon] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Halter, Jeffrey B.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Hazzard, William R.] Univ Washington, Dept Med, Seattle, WA USA.
[Hazzard, William R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Himmelfarb, Jonathan] Maine Med Ctr, Dept Med, Portland, ME 04102 USA.
[Horne, Frances McFarland; Ashworth, John R.; Clayton, Charles P.; Parker, Ryan P.; Tarver, Erika D.] Assoc Specialty Professors, Washington, DC USA.
[Kaysen, George A.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
[Kusek, John W.] NIDDKD, Kidney & Urol Branch, Bethesda, MD 20892 USA.
[Nayfield, Susan G.; Tian, Ying] NIA, Geriatr & Clin Gerontol Branch, Bethesda, MD 20892 USA.
[Schmader, Kenneth] Duke Univ, Dept Med, Durham, NC USA.
[Schmader, Kenneth] Durham VA Med Ctr, Durham, NC USA.
RP High, KP (reprint author), Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, 100 Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM khigh@wfubmc.edu
FU John A. Hartford Foundation
FX This workshop was supported by a generous grant from the John A.
Hartford Foundation to the Association of Specialty Professors. For a
list of the planning cornmittee and attendees of the conference, please
visit http:// www.im.org/CarcerDevelopinent/Grantsand
Scholarships/IGP/ExpandingResearch Efforts/
Pages/Workshoponprediction,Progression and Outcomes of Chronic Kidney
Diseasein OlderAdults.aspx.
NR 146
TC 77
Z9 84
U1 0
U2 9
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2009
VL 20
IS 6
BP 1199
EP 1209
DI 10.1681/ASN.2008080860
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 453NK
UT WOS:000266617200012
PM 19470680
ER
PT J
AU Burstein, HJ
AF Burstein, Harold J.
TI Live Blogging from ASCO 2009
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Editorial Material
C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA USA.
[Burstein, Harold J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JONES AND BARTLETT PUBLISHERS
PI SUDBURY
PA 40 TALL PINE DR, SUDBURY, MA 01776 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2009
VL 7
IS 6
BP 613
EP 613
PG 1
WC Oncology
SC Oncology
GA 499ZI
UT WOS:000270265200001
ER
PT J
AU Saylor, PJ
Michaelson, MD
AF Saylor, Philip J.
Michaelson, M. Dror
TI New Treatments for Renal Cell Carcinoma: Targeted Therapies
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
DE Renal cell carcinoma; tyrosine kinase inhibitors; vascular endothelial
growth factor; mammalian target of rapamycin; von Hippel-Lindau; hypoxia
inducible factor
ID GROWTH-FACTOR RECEPTOR; REFRACTORY SOLID TUMORS; PHASE-III TRIAL;
HYPOXIA-INDUCIBLE FACTORS; DAYS ON/7 DAYS; INTERFERON-ALPHA; SUPPRESSOR
GENE; RAF KINASE; HISTOLOGIC SUBTYPES; DOSE INTERLEUKIN-2
AB Systemic treatment options for advanced renal cell carcinoma (RCC) have expanded considerably with the development of targeted therapies. Clear cell RCC commonly features mutation or inactivation of the von Hippel-Lindau gene and resultant overexpression of vascular endothelial growth factor (VEGF). The first drug to validate VEGF as a target in the treatment of clear cell RCC was the monoclonal antibody bevacizumab. Since then, anti-VEGF receptor therapy with multitargeted kinase inhibitors also has shown substantial efficacy. Sunitinib is now a standard first-line therapy for advanced disease and sorafenib is among the second-line treatment options. Other kinase inhibitors are in development. Mammalian target of rapamycin (mTOR) is a second validated therapeutic target as the mTOR inhibitor temsirolimus has been shown to prolong survival in first-line treatment of poor prognosis RCC of all histologies. Everolimus is an oral mTOR inhibitor and has been shown to prolong progression-free survival when used in second-line treatment. Non-clear cell and sarcomatoid RCC are both underrepresented in completed trials but are the subject of active research. Ongoing and planned studies will also evaluate the use of combinations of targeted agents, a strategy that is not advisable outside of clinical trials. Finally, postnephrectomy adjuvant treatment with targeted agents is not yet standard but is under investigation in phase III trials. (JNCCN 2009;7:645-656)
C1 [Saylor, Philip J.; Michaelson, M. Dror] Massachusetts Gen Hosp, Ctr Canc, Dept Oncol, Boston, MA 02114 USA.
RP Saylor, PJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Oncol, Lawrence House POB,2nd Floor, Boston, MA 02114 USA.
EM psaylor@partners.org
NR 65
TC 16
Z9 16
U1 0
U2 2
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2009
VL 7
IS 6
BP 645
EP 656
PG 12
WC Oncology
SC Oncology
GA 499ZI
UT WOS:000270265200004
PM 19555586
ER
PT J
AU Heng, DYC
Choueiri, TK
AF Heng, Daniel Y. C.
Choueiri, Toni K.
TI Non-Clear Cell Renal Cancer: Features and Medical Management
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
DE Renal cell cancer; non-clear cell; papillary; chromophobe; collecting
duct; sunitinib; sorafenib; temsirolimus; c-MET
ID COLLECTING DUCT CARCINOMA; INTERFERON-ALPHA; SARCOMATOID
DIFFERENTIATION; METASTATIC PAPILLARY; HISTOLOGIC SUBTYPES; PROGNOSTIC
UTILITY; CLASSIFICATION; SURVIVAL; TUMORS; EXPERIENCE
AB The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies against vascular endothelial growth factor and the mammalian target of rapamycin. Because patients with clear cell histology account for more than 80% of patients with RCC, little evidence is available on treating patients with non-clear cell histologies. Most clinical trials have excluded them from enrollment, except for a randomized study investigating temsirolimus. Many retrospective studies on the use of sunitinib, sorafenib, and temsirolimus in patients with non-clear cell histology have shown response rates ranging from 3.7% to 16%. Prospective studies in non-clear cell histologies are ongoing. Although response rates may not be as high as those in patients with clear cell histologies, targeted therapy may provide a clinically meaningful response. New investigational therapies are on the horizon for papillary RCC-the most-common non-clear cell RCC histology-targeting pathways specific to this histology, such as the c-MET pathway. (JNCCN 2009;7:659-665)
C1 [Choueiri, Toni K.] Harvard Univ, Sch Med, Lank Ctr Genitourinary Oncol, Brigham & Womens Hosp,Dana Farber Canc Inst, Boston, MA 02115 USA.
[Heng, Daniel Y. C.] Tom Baker Canc Clin, Calgary, AB, Canada.
RP Choueiri, TK (reprint author), Harvard Univ, Sch Med, Lank Ctr Genitourinary Oncol, Brigham & Womens Hosp,Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM Toni_Choueiri@dfci.harvard.edu
NR 39
TC 22
Z9 22
U1 0
U2 0
PU JONES AND BARTLETT PUBLISHERS
PI SUDBURY
PA 40 TALL PINE DR, SUDBURY, MA 01776 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2009
VL 7
IS 6
BP 659
EP 665
PG 7
WC Oncology
SC Oncology
GA 499ZI
UT WOS:000270265200005
PM 19555587
ER
PT J
AU Gralow, JR
Biermann, JS
Farooki, A
Fornier, MN
Gagel, RF
Kumar, RN
Shapiro, CL
Shields, A
Smith, MR
Srinivas, S
Van Poznak, CH
AF Gralow, Julie R.
Biermann, J. Sybil
Farooki, Azeez
Fornier, Monica N.
Gagel, Robert F.
Kumar, Rashmi N.
Shapiro, Charles L.
Shields, Andrew
Smith, Matthew R.
Srinivas, Sandy
Van Poznak, Catherine H.
TI NCCN Task Force Report: Bone Health in Cancer Care
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
DE NCCN Clinical Practice Guidelines; bone health; breast cancer; prostate
cancer; dual x-ray absorptiometry; bone mineral density; FRAX (TM)
analysis; osteopenia; osteoporosis; bisphosphonates; aromatase
inhibitors; chemotherapy; imaging; bone metastases
ID ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL;
PLACEBO-CONTROLLED TRIAL; EARLY BREAST-CANCER; NONMETASTATIC
PROSTATE-CANCER; LONG-TERM EFFICACY; PHASE-II TRIAL; POSTMENOPAUSAL
OSTEOPOROTIC WOMEN; ADJUVANT CLODRONATE TREATMENT;
POSITRON-EMISSION-TOMOGRAPHY
AB Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting. (JNCCN 2009;7[Suppl 3]:1-32)
C1 [Gralow, Julie R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Biermann, J. Sybil; Van Poznak, Catherine H.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Farooki, Azeez; Fornier, Monica N.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gagel, Robert F.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Shapiro, Charles L.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Shields, Andrew] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
[Smith, Matthew R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Srinivas, Sandy] Stanford Comprehens Canc Ctr, Stanford, CA USA.
RP Gralow, JR (reprint author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
FU NCI NIH HHS [K24 CA121990-04, K24 CA121990, K24 CA121990-05]
NR 217
TC 116
Z9 118
U1 0
U2 7
PU JONES AND BARTLETT PUBLISHERS
PI SUDBURY
PA 40 TALL PINE DR, SUDBURY, MA 01776 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2009
VL 7
BP S1
EP S32
PG 32
WC Oncology
SC Oncology
GA 501DR
UT WOS:000270360200001
PM 19555589
ER
PT J
AU Salmon, S
Chen, H
Chen, S
Herbst, R
Tsao, A
Tran, H
Sandler, A
Billheimer, D
Shyr, Y
Lee, JW
Massion, P
Brahmer, J
Schiller, J
Carbone, D
Dang, TP
AF Salmon, Stuart
Chen, Heidi
Chen, Shuo
Herbst, Roy
Tsao, Anne
Tran, Hai
Sandler, Alan
Billheimer, Dean
Shyr, Yu
Lee, Ju-Whei
Massion, Pierre
Brahmer, Julie
Schiller, Joan
Carbone, David
Dang, Thao P.
TI Classification by Mass Spectrometry Can Accurately and Reliably Predict
Outcome in Patients with Non-small Cell Lung Cancer Treated with
Erlotinib-Containing Regimen
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Lung cancer; Biomarkers; Proteomics
ID PROTEOMIC PATTERNS; OVARIAN-CANCER; SERUM; BEVACIZUMAB
AB Purpose: Although many lung cancers express the epidermal growth factor receptor and the vascular endothelial growth factor, only a small fraction of patients will respond to inhibitors of these pathways. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MS) has shown promise in biomarker discovery, potentially allowing the selection of patients who may benefit from such therapies. Here, we use a matrix-assisted laser desorption/ionization MS proteomic algorithm developed from a small dataset of erlotinib-bevacizumab treated patients to predict the clinical outcome of patients treated with erlotinib alone.
Methods: Pretreatment serum collected from patients in a phase I/II study of erlotinib in combination with bevacizumab for recurrent or refractory non-small cell lung cancer was used to develop a proteomic classifier. This classifier was validated using an independent treatment cohort and a control population.
Result: A proteomic profile based on 11 distinct m/z features was developed. This predictive algorithm was associated with outcome using the univariate Cox proportional hazard model in the training set (p = 0.0006 for overall survivall; p = 0.0012 for progression-free survival). The signature also predicted overall survival and progression-free survival outcome when applied to a blinded test set of patients treated with erlotinib alone on Eastern Cooperative Oncology Group 3503 (n = 82, p < 0.0001 and p = 0.0018, respectively) but not when applied to a cohort of patients treated with chemotherapy alone (n = 6 1, p = 0.128).
Conclusion: The independently derived classifier supports the hypothesis that MS can reliably predict the outcome of patients treated with epidermal growth factor receptor kinase inhibitors.
C1 [Dang, Thao P.] Vanderbilt Univ, Dept Med & Canc Biol, Med Ctr, Nashville, TN 37232 USA.
[Salmon, Stuart] Carolinas Hematol Oncol Assoc, Charlotte, NC USA.
[Herbst, Roy; Tsao, Anne; Tran, Hai] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Billheimer, Dean] Univ Utah, Salt Lake City, UT USA.
[Lee, Ju-Whei] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Brahmer, Julie] Johns Hopkins Univ Hosp, Baltimore, MD 21205 USA.
[Schiller, Joan] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Dang, TP (reprint author), Vanderbilt Univ, Dept Med & Canc Biol, Med Ctr, 648 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.
EM thao.p.dang@vanderbilt.edu
FU SPORE in Lung Cancer [P50 CA 090949]
FX Supported by SPORE in Lung Cancer P50 CA 090949
NR 12
TC 21
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2009
VL 4
IS 6
BP 689
EP 696
PG 8
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 449RO
UT WOS:000266347900005
PM 19404214
ER
PT J
AU Bernimoulin, M
Waters, EK
Foy, M
Steele, BM
Sullivan, M
Falet, H
Walsh, MT
Barteneva, N
Geng, JG
Hartwig, JH
Maguire, PB
Wagner, DD
AF Bernimoulin, M.
Waters, E. K.
Foy, M.
Steele, B. M.
Sullivan, M.
Falet, H.
Walsh, M. T.
Barteneva, N.
Geng, J-G.
Hartwig, J. H.
Maguire, P. B.
Wagner, D. D.
TI Differential stimulation of monocytic cells results in distinct
populations of microparticles
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE LPS; microparticles; monocytes; phosphatidylserine; proteomics;
P-selectin
ID P-SELECTIN; TISSUE FACTOR; LEUKOCYTE MICROPARTICLES; MEMBRANE
MICROPARTICLES; ACTIVATED PLATELETS; FLUORESCENCE ASSAY;
ENDOTHELIAL-CELLS; RECEPTOR LAIR-1; PLASMA-MEMBRANE; DEFICIENT MICE
AB Background: Microparticles (MPs), small vesicles shed from stimulated cells, permit cross-talk between cells within a particular environment. Their composition is thought to reflect their cell of origin, and differs according to whether they are produced by stimulation or by apoptosis. Whether MP properties vary according to stimulus is not yet known. Methods: We studied the characteristics of MPs produced from monocytic THP-1 cells upon stimulation with lipopolysaccharide or a soluble P-selectin chimera, using proteomics, flow cytometry, western blotting, and electron microscopy. Results: Utilizing a novel criterion of calcein-AM staining to define MPs, we found that MP populations were similar with respect to size, presence and organization of cytoskeleton, and expression of certain antigens. The MPs shared the same level of procoagulant activity. We found that MPs also have distinct characteristics, depending on stimuli. These include differences in phosphatidylserine expression and expression of proteins from specific subcellular locations such as the mitochondria, and of unique antigens such as leukocyte-associated immunoglobin-like-receptor (LAIR)-1, which was found only upon stimulation with the soluble P-selectin chimera. Conclusion: We found that the properties of MPs depend on the stimulus that produced them. This supports the concept that monocytic MPs differentially modulate thrombosis, inflammation and immune regulation according to stimulus.
C1 [Bernimoulin, M.; Waters, E. K.; Foy, M.; Walsh, M. T.; Barteneva, N.; Wagner, D. D.] Immune Dis Inst, Boston, MA 02115 USA.
[Bernimoulin, M.; Waters, E. K.; Foy, M.; Wagner, D. D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Foy, M.; Steele, B. M.; Sullivan, M.; Maguire, P. B.] Univ Coll Dublin, Sch Biomol & Biomed Sci, UCD Conway Inst, Dublin 4, Ireland.
[Falet, H.; Hartwig, J. H.] Brigham & Womens Hosp, Translat Med Div, Boston, MA 02115 USA.
[Geng, J-G.] Univ Minnesota, Sch Med, Vasc Biol Ctr, Div Hematol Oncol & Transplantat,Dept Med, Minneapolis, MN 55455 USA.
RP Wagner, DD (reprint author), Immune Dis Inst, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM patricia.maguire@ucd.ie; wagner@idi.harvard.edu
OI Falet, Herve/0000-0003-0788-9204
FU National Heart, Lung and Blood Institute of the National Institutes of
Health [P01 HL056949, T32HL066987]; European Hematology Association
Fellowship; Swiss National Science Foundation [109593]
FX We thank the Conway Mass Spectrometry Core Facility, particularly G.
Elia and K. Wynne, for technical assistance, J. Polgar for contributions
to preliminary MP studies, L. Burke for assistance with the FACSAria II,
and L. Cowan for help with manuscript preparation. This work was
supported by the National Heart, Lung and Blood Institute of the
National Institutes of Health grants P01 HL056949 (D. D. Wagner and J.H.
Hartwig) and T32HL066987 (E. K. Waters), European Hematology Association
Fellowship 2006/04 (M. Bernimoulin), Swiss National Science Foundation
Fellowship PBLAB - 109593 (M. Bernimoulin), and research grants from the
Health Research Board of Ireland (P. B. Maguire) and funding from the
Programme for Research in Third-Level Institutions (PRTLI), administered
by the Higher Education Authority of Ireland (P. B. Maguire).
NR 38
TC 67
Z9 68
U1 0
U2 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1538-7933
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUN
PY 2009
VL 7
IS 6
BP 1019
EP 1028
DI 10.1111/j.1538-7836.2009.03434.x
PG 10
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 448DT
UT WOS:000266244000016
PM 19548909
ER
PT J
AU Amstadter, AB
Acierno, R
Richardson, LK
Kilpatrick, DG
Gros, DF
Gaboury, MT
Trinh, LT
Lam, TT
Nguyen, TT
Tran, T
La, TB
Tran, TH
Tran, DT
Galea, S
AF Amstadter, Ananda B.
Acierno, Ron
Richardson, Lisa K.
Kilpatrick, Dean G.
Gros, Daniel F.
Gaboury, Mario T.
Trinh Luong Tran
Lam Tu Trung
Nguyen Thanh Tam
Tran Tuan
La Thi Buoi
Tran Thu Ha
Tran Duc Thach
Galea, Sandro
TI Posttyphoon Prevalence of Posttraumatic Stress Disorder, Major
Depressive Disorder, Panic Disorder, and Generalized Anxiety Disorder in
a Vietnamese Sample
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID DISASTER VICTIMS SPEAK; HURRICANE-KATRINA; MENTAL-HEALTH; NATURAL
DISASTER; COMORBIDITY; POPULATION; SEQUELAE; EXPOSURE; TRAUMA; IMPACT
AB In 2006 typhoon Xangsane disrupted a multiagency health needs study of 4,982 individuals in Vietnam. Following this disaster, 798 of the original participants were reinterviewed to determine prevalence and risk factors associated with posmaumatic stress disorder (PTSD), major depressive disorder (MDD), panic disorder (PD), and generalized anxiety disorder (GAD). Posttyphoon prevalences were PTSD 2.6%, MDD 5.9%, PD 9.3%, and GAD 2.2%. Of those meeting criteria for a disorder, 70% reported only one disorder 15% had two, 14% had three, and 1% met criteria for all four disorders. Risk factors for posttyphoon psychopathology differed among disorders, but generally were related to high typhoon exposure, prior trauma exposure, and in contrast to Western populations, higher age, but not gender.
C1 [Amstadter, Ananda B.; Acierno, Ron; Richardson, Lisa K.; Kilpatrick, Dean G.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Gaboury, Mario T.] Univ New Haven, New Haven, CT USA.
[Gaboury, Mario T.] Oskar Schindler Humanities Fdn, New Haven, CT USA.
[Trinh Luong Tran] Hlth Dept Da Nang City, Da Nang City, Vietnam.
[Lam Tu Trung] Da Nang Mental Hlth Hosp, Da Nang City, Vietnam.
[Nguyen Thanh Tam] Vietnam Vet Amer Fdn, Hanoi, Vietnam.
[Tran Tuan; La Thi Buoi; Tran Thu Ha; Tran Duc Thach] Res & Training Ctr Community Dev, Hanoi, Vietnam.
[Galea, Sandro] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
RP Amstadter, AB (reprint author), Natl Crime Victims Res & Treatment Ctr, POB 250852, Charleston, SC 29425 USA.
EM amstadt@musc.edu
RI Tran, Thach/H-7734-2014
OI Tran, Thach/0000-0002-4686-8601
FU NIMH NIH HHS [F32 MH083469-01, F32 MH083469]
NR 31
TC 31
Z9 31
U1 2
U2 5
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2009
VL 22
IS 3
BP 180
EP 188
DI 10.1002/jts.20404
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 468JR
UT WOS:000267814300003
PM 19455707
ER
PT J
AU Galovski, TE
Monson, C
Bruce, SE
Resick, PA
AF Galovski, Tara E.
Monson, Candice
Bruce, Steven E.
Resick, Patricia A.
TI Does Cognitive-Behavioral Therapy for PTSD Improve Perceived Health and
Sleep Impairment?
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; REPORTED PHYSICAL HEALTH; PROCESSING
THERAPY; RESIDUAL INSOMNIA; COMBAT VETERANS; QUALITY INDEX; NIGHTMARES;
SYMPTOMS; VICTIMS; DISTURBANCE
AB There is a paucity of empirical study about the effects of evidence-based psychotherapy for posttraumatic stress disorder (PTSD) on concurrent health concerns including sleep impairment. This study compares the differential effects of cognitive processing therapy (CPT) and prolonged exposure (PE) on health-related concerns and sleep impairment within a PTSD sample of female, adult rape survivors (N = 108). Results showed that participants in both treatments reported lower health-related concerns over treatment and follow-up, but there were relatively more improvements in the CPT condition. Examination of sleep quality indicated significant improvement in both CPT and PE across treatment and follow-up and no significant differences between treatments. These results are discussed with regard to the different mechanisms thought to underlie the treatments and future innovations in PTSD treatment.
C1 [Galovski, Tara E.; Bruce, Steven E.] Univ Missouri, Ctr Trauma Recovery, Dept Psychol, St Louis, MO 63121 USA.
[Monson, Candice; Resick, Patricia A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Monson, Candice; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
RP Galovski, TE (reprint author), Univ Missouri, Ctr Trauma Recovery, Dept Psychol, 1 Univ Blvd, St Louis, MO 63121 USA.
EM galovskit@msx.umsl.edu
FU NIMH NIH HHS [R01 MH051509, R01 MH051509-09, R01-MH51509]
NR 43
TC 68
Z9 68
U1 2
U2 7
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2009
VL 22
IS 3
BP 197
EP 204
DI 10.1002/jts.20418
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 468JR
UT WOS:000267814300005
PM 19466746
ER
PT J
AU Sobel, AA
Resick, PA
Rabalais, AE
AF Sobel, Ana A.
Resick, Patricia A.
Rabalais, Aline E.
TI The Effect of Cognitive Processing Therapy on Cognitions: Impact
Statement Coding
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL-ABUSE SURVIVORS; TRAUMA-RELATED
GUILT; PROLONGED EXPOSURE; PTSD; RAPE; DISTORTIONS; VALIDATION; VICTIMS;
EVENTS
AB This study compared the cognitions of 37 female rape survivors before and after completing cognitive processing therapy (CPT). It was hypothesized that CPT would be associated with reductions in posttraumatic stress disorder (PTSD)symptoms and problematic (i.e., assimilated and over accommodated) thoughts as well as increases in the number of realistic (i.e., accommodated) cognitions. Cognitions were assessed via coding and analyses of participants written impact statements at the beginning and end of treatment. Posttraumatic stress disorder symptoms were assessed with the Clinician-Administered PTSD Scale and PTSD Symptom Scale. As predicted, there were significant increases in accommodated statements and significant decreases in overaccommodated and assimilated statements. The hypothesis that cognitive changes would be related to symptom reduction was partially supported.
C1 [Resick, Patricia A.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA.
[Sobel, Ana A.] Capital Psychol Associates, Albany, NY USA.
[Resick, Patricia A.] Boston Univ, Boston, MA 02215 USA.
[Rabalais, Aline E.] Lamar Univ, Dept Psychol, Beaumont, TX 77710 USA.
RP Resick, PA (reprint author), VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, WHSD 116B-3,150 S Huntington Ave, Boston, MA 02130 USA.
EM Patricia.Resick@va.gov
FU NIMH NIH HHS [MH66324, R01 MH051509, R01 MH051509-09, R03 MH066324]
NR 29
TC 25
Z9 25
U1 1
U2 7
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2009
VL 22
IS 3
BP 205
EP 211
DI 10.1002/jts.20408
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 468JR
UT WOS:000267814300006
PM 19479979
ER
PT J
AU Lu, M
Wagner, A
Van Male, L
Whitehead, A
Boehnlein, J
AF Lu, Mary
Wagner, Amy
Van Male, Lynn
Whitehead, Ashlee
Boehnlein, James
TI Imagery Rehearsal Therapy for Posttraumatic Nightmares in US Veterans
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID SEXUAL ASSAULT SURVIVORS; COMBAT-RELATED PTSD; STRESS-DISORDER
AB Imagery rehearsal therapy (IRT) may help reduce residual nightmares and posttraumatic stress disorder (PTSD) symptoms in veterans after trauma-focused PTSD treatment. Fifteen male U. S. veterans with PTSD and trauma-related nightmares, who had not previously completed trauma-focused PTSD treatment, attended 6 IRT group sessions. No benefits were observed immediately posttreatment. At 3- and 6-month follow-up, however, trauma related nightmare frequency (nights/week) decreased (p < .01). The number of trauma-related nightmares/week (P < .01), number of total nightmares/week (p < .05), and PTSD symptoms (p <. 05) also decreased at 3 months. The overall F test for time was significant (p < .05) for nightmare severity and fear of sleep. No effects were found on measures of the impact of nightmares, sleep quality, or depression. Clinical and research implications are discussed.
C1 [Lu, Mary; Wagner, Amy; Van Male, Lynn; Boehnlein, James] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Lu, Mary; Wagner, Amy; Van Male, Lynn; Whitehead, Ashlee; Boehnlein, James] Portland VA Med Ctr, Div Mental Hlth, Portland, OR USA.
RP Lu, M (reprint author), 3710 SW US Vet Hosp Rd,POB 1035,V3SATP, Portland, OR 97239 USA.
EM Mary.Lu@va.gov
FU NCRR NIH HHS [UL1 RR024140]
NR 16
TC 27
Z9 27
U1 0
U2 6
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2009
VL 22
IS 3
BP 236
EP 239
DI 10.1002/jts.20407
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 468JR
UT WOS:000267814300010
PM 19444882
ER
PT J
AU Medioni, J
Choueiri, TK
Zinzindohoue, F
Cho, D
Fournier, L
Oudard, S
AF Medioni, Jacques
Choueiri, Toni K.
Zinzindohoue, Franck
Cho, Daniel
Fournier, Laure
Oudard, Stephane
TI Response of Renal Cell Carcinoma Pancreatic Metastasis to Sunitinib
Treatment: A Retrospective Analysis
SO JOURNAL OF UROLOGY
LA English
DT Article
DE kidney; kidney neoplasms; pancreas; neoplasm metastasis; sunitinib
ID OF-THE-LITERATURE; RESECTION; TUMORS
AB Purpose: Pancreatic metastasis accounts for 2% of metastatic renal cell carcinoma cases. Surgical management is typically recommended because of the limited value of immunotherapy as an effective treatment. Sunitinib recently showed clinical efficacy in patients with advanced renal cell carcinoma. We report a series of patients with pancreatic metastasis treated with sunitinib.
Materials and Methods: We retrospectively studied a population of 15 adults with pancreatic metastasis of renal cell carcinoma at 1 center in France and at 2 in the United States who were treated with sunitinib between 2005 and 2007. Sunitinib monotherapy was given at a dose of 50 mg orally in 6-week cycles, consisting of 4 weeks of treatment followed by 2 weeks of rest. All clinical and radiological data were analyzed.
Results: At a median followup of 20 months the overall tumor response using Response Evaluation Criteria in Solid Tumors was 34%. Median time to relapse was 20 months. Two deaths were noted and median survival was not attained. Responses in the pancreatic metastasis were seen in 28% of patients and were stable in 72%. The main grade 3 and 4 adverse events were diarrhea in 7% of cases and fatigue in 7%. Only grade 1 increased lipase was noted. in 27% of patients and no increase in amylase was noted.
Conclusions: Sunitinib is effective in patients with pancreatic metastasis. This raises the question of whether patients with metastatic renal cell carcinoma limited to the pancreas may derive greater clinical benefit from anti-angiogenic agents, rather than from aggressive surgical resection. However, surgery remains the only potential cure in patients with isolated pancreatic metastasis.
C1 [Medioni, Jacques; Oudard, Stephane] Georges Pompidou European Hosp, Dept Med Oncol, F-75015 Paris, France.
[Zinzindohoue, Franck] Georges Pompidou European Hosp, Dept Digest Surg, F-75015 Paris, France.
[Fournier, Laure] Georges Pompidou European Hosp, Dept Radiol, F-75015 Paris, France.
[Oudard, Stephane] Univ Paris 05, Georges Pompidou European Hosp, AP HP, Ecole Natl Vet Alfort,EA 4054, Paris, France.
[Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cho, Daniel] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Medioni, J (reprint author), Georges Pompidou European Hosp, Dept Med Oncol, 20 Rue Leblanc, F-75015 Paris, France.
EM Jacques.medioni@egp.aphp.fr
NR 14
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2009
VL 181
IS 6
BP 2470
EP 2475
DI 10.1016/j.juro.2009.02.020
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 444ZX
UT WOS:000266020500021
PM 19371877
ER
PT J
AU Smith, MR
Bae, K
Efstathiou, JA
Hanks, GE
Pilepich, MV
Sandler, HM
Shipley, WU
AF Smith, M. R.
Bae, K.
Efstathiou, J. A.
Hanks, G. E.
Pilepich, M. V.
Sandler, H. M.
Shipley, W. U.
TI Diabetes and Mortality in Men With Locally Advanced Prostate Cancer:
RTOG 92-02 Editorial Comment
SO JOURNAL OF UROLOGY
LA English
DT Editorial Material
AB Purpose: Diabetes is associated with lower risk of prostate cancer. Most men with diabetes are obese, and obesity is associated with greater prostate cancer mortality. Whether diabetes influences outcome is after prostate cancer diagnosis is unknown. Patients and Methods: We assessed the relationship between prevalent diabetes and mortality using data from Radiation Therapy Oncology Group Protocol 92-02, a large randomized trial of men (N = 1,554) treated with radiation therapy and short-term versus long-term adjuvant goserelin for locally advanced prostate cancer. Regression and proportional hazard models were performed to evaluate relationships between prevalent diabetes and all-cause mortality, prostate cancer mortality, and non-prostate cancer mortality. Covariates included age, race, tumor stage, Gleason score, prostate-specific antigen, weight, and treatment arm. Results: There were a total of 765 deaths; 210 (27%) were attributed to prostate cancer. In univariate analyses, prevalent diabetes was associated with greater all-cause mortality and non-prostate cancer mortality but not prostate cancer mortality. After controlling for other covariates, prevalent diabetes remained significantly associated with greater all-cause mortality and non-prostate cancer mortality (hazard ratio [HR] = 2.12; 95% CI, 1.69 to 2.66; P < .0001) but not prostate cancer mortality (HR = -0.80; 95% Cl, 0.51 to 1.25; P = .34). In contrast, weight was associated with greater prostate cancer mortality (HR = 1.77; 95% Cl, 1.22 to 2.55; P = .002) but not all-cause or non-prostate cancer mortality. Conclusion: Weight but not prevalent diabetes is associated with greater prostate cancer mortality in men receiving combined modality treatment for locally advanced disease. These observations suggest that the association between obesity and greater prostate cancer mortality is mediated by mechanism(s) other than the characteristic metabolic alterations of diabetes.
C1 [Smith, M. R.; Bae, K.; Efstathiou, J. A.; Hanks, G. E.; Pilepich, M. V.; Sandler, H. M.; Shipley, W. U.] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Hematol & Oncol, Boston, MA 02114 USA.
RP Smith, MR (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Div Hematol & Oncol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2009
VL 181
IS 6
BP 2533
EP 2533
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 444ZX
UT WOS:000266020500044
ER
PT J
AU Jha, RM
Yoo, AJ
Hirsch, AE
Growney, M
Hirsch, JA
AF Jha, Ruchira M.
Yoo, Albert J.
Hirsch, Ariel E.
Growney, Marion
Hirsch, Joshua A.
TI Predictors of Successful Palliation of Compression Fractures with
Vertebral Augmentation: Single-center Experience of 525 Cases
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
ID SACRAL INSUFFICIENCY FRACTURES; LOW-BACK-PAIN; PERCUTANEOUS
VERTEBROPLASTY; CLINICAL-OUTCOMES; BALLOON KYPHOPLASTY; MANAGEMENT;
COMPLICATIONS; EFFICACY; TRIAL
AB PURPOSE: To determine the effectiveness of vertebral augmentation in relieving pain, differences in pain relief outcomes based on procedure type were investigated. Variables that potentially influence outcomes were identified.
MATERIALS AND METHODS: A database of 525 cases (740 levels) treated for compression fractures with vertebroplasty, kyphoplasty, or S1-level sacroplasty was compiled. Average age was 75 years +/- 12, and 72.4% of patients were female. Variables evaluated included age, sex, fracture etiology, procedure type, vertebral level treated, number of levels treated per procedure, and technical approach. Outcomes were assessed by a binary system of "responders" (ie, patients with improvement/resolution of pain) versus "non-responders" (ie, those with no change/worsening of pain) and with a four-level pain scale (1, pain resolution; 2, pain improvement; 3, no change; 4, worse pain) retrospectively applied from medical records. Univariate and multivariate analyses determined outcomes.
RESULTS: Four-hundred and sixty-seven patients (89%) showed a response to treatment: 40% had pain resolution and 49% had pain improvement. Multivariate analysis showed that women and older patients had greater odds of being responders (odds ratios [ORs], 0.56 and 0.98, respectively; P = .016 and P = .048, respectively). Patients without cancer (OR, 1.60; P = .012) and women (OR, 2.05; P = .0002) were more likely to experience pain resolution. Increasing numbers of levels treated per case were associated with decreased odds of pain resolution (OR, 0.69; P = .0081). Sex and number of levels treated were independently predictive of pain scale outcomes (ORs, 2.0 and 0.71, respectively; P = .0003 and P = .015).
CONCLUSIONS: Vertebral augmentation procedures provide pain relief for a majority of patients regardless of underlying fracture etiology. There was no difference in pain outcomes among procedure types. Age and sex may be predictive of pain outcomes.
C1 [Jha, Ruchira M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Internal Med, Boston, MA USA.
[Hirsch, Ariel E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Yoo, Albert J.; Growney, Marion; Hirsch, Joshua A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Neurointervent Radiol, Boston, MA USA.
RP Jha, RM (reprint author), 9 Hawthorne Pl,Unit 6F, Boston, MA 02114 USA.
EM rjha@partners.org
NR 43
TC 24
Z9 25
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD JUN
PY 2009
VL 20
IS 6
BP 760
EP 768
DI 10.1016/j.jvir.2009.01.037
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
Cardiology
GA 453YY
UT WOS:000266650000009
PM 19465306
ER
PT J
AU Patel, VI
Conrad, MF
Kwolek, CJ
LaMuraglia, GM
Chung, TK
Cambria, RP
AF Patel, Virendra I.
Conrad, Mark F.
Kwolek, Christopher J.
LaMuraglia, Glenn M.
Chung, Thomas K.
Cambria, Richard P.
TI Renal artery revascularization: Outcomes stratified by indication for
intervention
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID ATHEROSCLEROTIC RENOVASCULAR DISEASE; HYPERTENSIVE PATIENTS; BALLOON
ANGIOPLASTY; STENOSIS; MANAGEMENT; STENT; RECONSTRUCTION; PRESERVATION;
PREDICTORS; MORTALITY
AB Objectives. Application of endovascular therapy has led to increasing rates of renal artery intervention with unclear effect on hypertension (HTN) and/or renal salvage (RS). We evaluated the role of procedure indication on outcomes of both open (OR) and percutaneous (PR) revascularization.
Methods: Retrospective review of all consecutive renal artery interventions performed from January 1, 2002 to December 31, 2006 was conducted. OR patients were included for analysis only if independent renovascular indications for revascularization existed.
Results: Forty-seven OR and 203 PR(97% stent) patients were treated with 98% initial technical success. Patients with OR were younger (65 +/- 11 vs 72 +/- 9; P < .01), on more blood pressure (BP) medications (2.3 +/- 1.2 vs 1.8 +/- 1.2; P < .05), had more peripheral arterial disease (75% vs 37%; P < .01), and higher baseline creatinine (2.2 +/- 1.6 mg% vs 1.8 +/- 1 mg%; P < .05). Indications for PR were HTN in 46% and RS in 54%, and indications for OR were HTN in 51% and RS in 49% of cases. PR was unilateral in 169 (83%) and bilateral in 44/203 (17%). OR consisted of bypass in 26 (53%) and endarterectomy in 21/47 (47%) with 20 (43%) bilateral procedures. Peri-procedural complications were different (P < .01) and more frequent in OR (23% vs 12%). Survival was similar at three years (72% +/- 4% PR vs 71% +/- 9% OR, P = .9). Assisted patency was similar (P = .6) at one (94% +/- 2% PR vs 97% +/- 3% OR) and three years (90% +/- 3% PR vs 91% +/- 5% OR). One year (97% +/- 1% PR vs 97% +/- 3% OR) and three year (93% +/- 3% PR vs 91% +/- 7% OR) freedom from reintervention was similar (P = .8). Clinical outcomes showed patients with OR and PR having similar rates of cure or improvement in BP (76% PR vs 90% OB, P = .1) and favored OR with stable or improved renal function (97% vs 89%; P < .01) by the first postoperative visit. Hypertension control remained similar (P = .2) in both groups with cure/improvement in BP in 74% of PR and 89% of OR patients at one year. OR remained durable in regards to renal salvage with 52% of OR patients having improved renal function compared with 24% of PR (P < .01) patients at one year. At one year, BP control was achieved if treatment indication was HTN in 100% (18/18) of OR patients and 74% (46/63) (P = .04) of those having PR. Renal function stabilized or improved in 16/19 (85%) of OR and 70/81 (86%) of PR patients when performed for RS (P = .4).
Conclusions. PR and OR are similarly efficacious for treatment of HTN associated with renal artery stenosis. While immediate and long-term outcomes favor OR for RS, this may impart from the triage of patients more likely to benefit from renal artery revascularization to OR. (J Vasc Surg 2009;49:1480-9.)
C1 [Patel, Virendra I.; Conrad, Mark F.; Kwolek, Christopher J.; LaMuraglia, Glenn M.; Chung, Thomas K.; Cambria, Richard P.] Massachusetts Gen Hosp, Dept Vasc & Endovasc Surg, Boston, MA 02114 USA.
RP Patel, VI (reprint author), Massachusetts Gen Hosp, Dept Vasc & Endovasc Surg, 15 Parkman St,WAC 458, Boston, MA 02114 USA.
EM vpatel4@partners.org
OI Chung, Thomas/0000-0001-6148-1184
NR 28
TC 4
Z9 5
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2009
VL 49
IS 6
BP 1480
EP 1489
DI 10.1016/j.jvs.2009.02.004
PG 10
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 454KO
UT WOS:000266681000017
PM 19497511
ER
PT J
AU Gray, L
Roche, M
Churchill, MJ
Sterjovski, J
Ellett, A
Poumbourios, P
Sheffief, S
Wang, B
Saksena, N
Purcell, DFJ
Wesselingh, S
Cunningham, AL
Brew, BJ
Gabuzda, D
Gorry, PR
AF Gray, Lachlan
Roche, Michael
Churchill, Melissa J.
Sterjovski, Jasminka
Ellett, Anne
Poumbourios, Pantelis
Sheffief, Shameem
Wang, Bin
Saksena, Nitin
Purcell, Damian F. J.
Wesselingh, Steven
Cunningham, Anthony L.
Brew, Bruce J.
Gabuzda, Dana
Gorry, Paul R.
TI Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus
Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of
Dual-Tropic Virus in the Brain
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; R5 HIV-1 INFECTION; V3 LOOP; CORECEPTOR USAGE;
CHEMOKINE RECEPTORS; MACROPHAGE TROPISM; ANTIRETROVIRAL THERAPY;
FUNCTIONAL-ANALYSIS; ADAPTIVE MUTATIONS; LYMPHOID-TISSUES
AB Most human immunodeficiency virus type 1 (HIV-1) strains isolated from the brain use CCR5 for entry into macrophages and microglia. Strains that use both CCR5 and CXCR4 for entry (R5X4 strains) have been identified in the brains of some individuals, but mechanisms underlying the persistence of R5X4 viruses compartmentalized between the brain and other tissue reservoirs are unknown. Here, we characterized changes in the HIV-1 envelope (Env) that enhance the tropism of R5X4 variants for brain or lymphoid tissue. R5X4 Envs derived from the brains of two individuals had enhanced CCR5 usage in fusion assays compared to R5X4 Envs derived from matched spleen or blood, which was associated with reduced dependence on specific residues in the CCR5 N terminus and extracellular loop 1 (ECL1) and ECL3 regions. In contrast, spleen/blood-derived Envs had enhanced CXCR4 usage compared to brain-derived Envs, which was associated with reduced dependence on residues in the CXCR4 N terminus and ECL2 region. Consequently, brain-derived Envs had preferential CCR5 usage for HIV-1 entry into the JC53 cell line, could use either CCR5 or CXCR4 for entry into monocyte-derived macrophages (MDM), and could use CCR5 ( albeit inefficiently) for entry into peripheral blood mononuclear cells (PBMC), whereas the entry of spleen-derived Envs was CXCR4 dependent in all three cell types. Mutagenesis studies of Env amino acid variants influencing coreceptor usage showed that S306 in the gp120 V3 region of brain-derived Envs reduces dependence on the CCR5 N terminus and enhances CCR5 usage for HIV-1 entry into PBMC and MDM, whereas R306 in spleen-derived Envs reduces dependence on the CXCR4 N terminus and confers the CXCR4 restricted phenotype. These results identify mechanisms underlying R5X4 HIV-1 persistence in different tissue reservoirs. Tissue-specific changes in the gp120 V3 region that increase the efficiency of CCR5 or CXCR4 usage, and thereby influence coreceptor preference, may enhance the tropism of R5X4 strains for CCR5-expressing macrophage lineage cells in the brain and CXCR4-expressing T cells in lymphoid tissues, respectively.
C1 [Gray, Lachlan; Roche, Michael; Churchill, Melissa J.; Sterjovski, Jasminka; Ellett, Anne; Poumbourios, Pantelis; Gorry, Paul R.] Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3004, Australia.
[Gray, Lachlan; Purcell, Damian F. J.; Wesselingh, Steven; Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
[Roche, Michael; Churchill, Melissa J.; Sterjovski, Jasminka; Wesselingh, Steven; Gorry, Paul R.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia.
[Sheffief, Shameem; Wang, Bin; Saksena, Nitin; Cunningham, Anthony L.] Westmead Millennium Inst, Westmead, NSW, Australia.
[Brew, Bruce J.] St Vincents Hosp, Dept Neurol, Darlinghurst, NSW 2010, Australia.
[Brew, Bruce J.] St Vincents Hosp, St Vincents Ctr Appl Med Res, Darlinghurst, NSW 2010, Australia.
[Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Gorry, PR (reprint author), Macfarlane Burnet Inst Med Res & Publ Hlth, 85 Commercial Rd, Melbourne, Vic 3004, Australia.
EM gorry@burnet.edu.au
RI Purcell, Damian/G-5068-2011; Brew, Bruce/J-6513-2012;
OI Gray, Lachlan/0000-0002-9894-1049; Sterjovski,
Jasminka/0000-0002-2471-3000; Roche, Michael/0000-0001-8819-0096;
Cunningham, Anthony/0000-0002-6744-5667
FU Australian National Health and Medical Research Council (NHMRC) [433915,
433920, 358399]; NIH [MH83588]
FX We thank J. Sodroski and B. Etemad-Gilbertson for providing Cf2CD4/CCR5
This study was supported in part by project grants from the Australian
National Health and Medical Research Council (NHMRC) to P. R. G.
(433915) and M. J. C. (433920) and a multicenter program grant from the
Australian NHMRC to S. W., A. L. C., and B. J. B. (358399). D. G. was
supported by NIH MH83588. J. S. and L. G. were supported by Australian
NHMRC Dora Lush Biomedical Research Scholarships. P. R. G. is the
recipient of an Australian NHMRC R. Douglas Wright Biomedical Career
Development Award.
NR 75
TC 35
Z9 36
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN 1
PY 2009
VL 83
IS 11
BP 5430
EP 5441
DI 10.1128/JVI.02648-08
PG 12
WC Virology
SC Virology
GA 445EZ
UT WOS:000266034100013
PM 19321618
ER
PT J
AU Miura, T
Brockman, MA
Schneidewind, A
Lobritz, M
Pereyra, F
Rathod, A
Block, BL
Brumme, ZL
Brumme, CJ
Baker, B
Rothchild, AC
Li, B
Trocha, A
Cutrell, E
Frahm, N
Brander, C
Toth, I
Arts, EJ
Allen, TM
Walker, BD
AF Miura, Toshiyuki
Brockman, Mark A.
Schneidewind, Arne
Lobritz, Michael
Pereyra, Florencia
Rathod, Almas
Block, Brian L.
Brumme, Zabrina L.
Brumme, Chanson J.
Baker, Brett
Rothchild, Alissa C.
Li, Bin
Trocha, Alicja
Cutrell, Emily
Frahm, Nicole
Brander, Christian
Toth, Ildiko
Arts, Eric J.
Allen, Todd M.
Walker, Bruce D.
TI HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers
Select for Rare Gag Variants Associated with Reduced Viral Replication
Capacity and Strong Cytotoxic T-Lymphocyte Recognition (vol 83, pg 2743,
2009)
SO JOURNAL OF VIROLOGY
LA English
DT Correction
C1 [Miura, Toshiyuki] Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA 02129 USA.
Howard Hughes Med Inst, Chevy Chase, MD USA.
Harvard Univ, Sch Med, Boston, MA USA.
Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Miura, T (reprint author), Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA 02129 USA.
RI Allen, Todd/F-5473-2011
NR 1
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN 1
PY 2009
VL 83
IS 11
BP 5961
EP 5961
DI 10.1128/JVI.00579-09
PG 1
WC Virology
SC Virology
GA 445EZ
UT WOS:000266034100068
ER
PT J
AU Gavin, AR
Chae, DH
Mustillo, S
Kiefe, CI
AF Gavin, Amelia R.
Chae, David H.
Mustillo, Sarah
Kiefe, Catarina I.
TI Prepregnancy Depressive Mood and Preterm Birth in Black and White Women:
Findings from the CARDIA Study
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL-FUNCTION;
AFRICAN-AMERICAN WOMEN; PREGNANCY OUTCOMES; MATERNAL STRESS;
PSYCHOSOCIAL FACTORS; BACTERIAL VAGINOSIS; ETHNIC-DIFFERENCES; SOCIAL
SUPPORT; FETAL-GROWTH
AB Objectives: We examine associations among race, prepregnancy depressive mood, and preterm birth (<37 weeks gestation) in a cohort study of black and white women.
Methods: We tested for mediation of the association between race and preterm birth by prepregnancy depressive mood among 555 women enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Results: Black women had significantly higher levels of prepregnancy depressive mood ( modified CES-D score 13.0 vs. 9.5, t=-4.64, p<0.001). After adjustment for covariates, black women had 2.70 times the odds of preterm birth as white women (95% confidence interval [CI] 1.41, 5.17). When adding prepregnancy depressive mood to this model, higher depressive mood was associated with greater odds of preterm birth (odds ratio [ OR] 1.04; 95% CI 1.01, 1.07), and the effect of black race was attenuated (OR 2.47, 95% CI 1.28, 4.77).
Conclusions: Our data suggest that prepregnancy depressive mood may be a risk factor for preterm birth among black and white women.
C1 [Gavin, Amelia R.] Univ Washington, Sch Social Work, Seattle, WA 98105 USA.
[Chae, David H.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
[Mustillo, Sarah] Purdue Univ, Dept Sociol, E Lafeyette, IN USA.
[Kiefe, Catarina I.] Univ Alabama, Sch Med, Birmingham, AL USA.
[Kiefe, Catarina I.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Gavin, AR (reprint author), Univ Washington, Sch Social Work, 4101 15th Ave NE, Seattle, WA 98105 USA.
EM gavina@u.washington.edu
RI Chae, David/F-6956-2015
FU Robert Wood Johnson Health and Society Scholars program; W. K. Kellogg
Doctoral Fellowship in Health Policy
FX D. H. C. was supported by the Robert Wood Johnson Health and Society
Scholars program and was also supported by the W. K. Kellogg Doctoral
Fellowship in Health Policy.
NR 77
TC 13
Z9 13
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2009
VL 18
IS 6
BP 803
EP 811
DI 10.1089/jwh.2008.0984
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 457BW
UT WOS:000266901200006
PM 19445645
ER
PT J
AU McCall-Hosenfeld, JS
Liebschutz, JM
Spiro, A
Seaver, MR
AF McCall-Hosenfeld, Jennifer S.
Liebschutz, Jane M.
Spiro, Avron, III
Seaver, Margaret R.
TI Sexual Assault in the Military and Its Impact on Sexual Satisfaction in
Women Veterans: A Proposed Model
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article; Proceedings Paper
CT 30th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 25-28, 2007
CL Toronto, CANADA
SP Soc Gen Internal Med
ID POSTTRAUMATIC-STRESS-DISORDER; HEALTH SURVEY SF-36; QUALITY-OF-LIFE;
ADMINISTRATION OUTPATIENTS; COMBAT VETERANS; CHRONIC ILLNESS;
UNITED-STATES; DYSFUNCTION; PREVALENCE; PTSD
AB Aims: Sexual assault in the military (SAIM) is associated with decreased sexual satisfaction. However, mediators of this association have not been fully described.
Methods: Using a retrospective analysis of cross-sectional data collected for the national Veterans Affairs (VA) Women's Health Survey, we propose a mediator model to explain the association between SAIM and decreased sexual satisfaction among women veterans. Four mediators of the association between SAIM and decreased sexual satisfaction are tested: (1) emotional health-related quality of life, (2) physical health-related quality of life, (3) lack of a close partner, and (4) gynecological illness. These mediators were chosen to encompass independent domains potentially relevant to sexual satisfaction, including emotional, physical, and relational.
Results: Of 3161 women (87%) who answered the sexual satisfaction question, the mean age was 45 (SD 15) years; 85% were white. Twenty-four percent reported a history of SAIM, and 39% reported sexual dissatisfaction. In age-adjusted logistic regression analyses, both SAIM and sexual dissatisfaction were strongly associated with each of the proposed mediators. However, of the four mediators, emotional health-related quality of life most strongly attenuated the association between SAIM and sexual dissatisfaction. After including all mediators, the association between SAIM and decreased sexual satisfaction was markedly attenuated.
Conclusions: SAIM's negative impact on sexual satisfaction in women veterans operates both directly and through its physical and mental health sequelae. Of the proposed mediators in this association, the most prominent is mental health-related quality of life; the other proposed mediators were minimally related.
C1 [McCall-Hosenfeld, Jennifer S.] Penn State Univ, Milton S Hershey Med Ctr, Div Gen Internal Med, Coll Med, Hershey, PA 17033 USA.
[Liebschutz, Jane M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Spiro, Avron, III] VA Boston Healthcare Syst, Boston, MA USA.
[Seaver, Margaret R.] Lahey Clin Fdn, Burlington, MA USA.
RP McCall-Hosenfeld, JS (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Div Gen Internal Med, Coll Med, 500 Univ Drive,MC-HU15, Hershey, PA 17033 USA.
EM jsm31@psu.edu
OI Liebschutz, Jane/0000-0003-3492-1521; Spiro III,
Avron/0000-0003-4080-8621
FU NIDA NIH HHS [K23 DA016665-05, K23 DA016665]
NR 64
TC 13
Z9 13
U1 3
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2009
VL 18
IS 6
BP 901
EP 909
DI 10.1089/jwh.2008.0987
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 457BW
UT WOS:000266901200019
PM 19514833
ER
PT J
AU Varadhan, R
Chaves, PHM
Lipsitz, LA
Stein, PK
Tian, J
Windham, BG
Berger, RD
Fried, LP
AF Varadhan, Ravi
Chaves, Paulo H. M.
Lipsitz, Lewis A.
Stein, Phyllis K.
Tian, Jing
Windham, B. Gwen
Berger, Ronald D.
Fried, Linda P.
TI Frailty and Impaired Cardiac Autonomic Control: New Insights From
Principal Components Aggregation of Traditional Heart Rate Variability
Indices
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Frailty; Mortality; Homeostatic impairment; Frequency domain indices;
Time-domain indices; Principal components analysis
ID ACUTE MYOCARDIAL-INFARCTION; MIDDLE-AGED PERSONS; COMPLEXITY;
FLUCTUATION; PHENOTYPE; DYNAMICS; HEALTHY
AB Background. Age-related deterioration in homeostatic regulatory mechanisms leads to decreased complexity in their output. For example, the degradation of cardiac autonomic control results in loss of complexity in the heart rate signal. Frailty is a state of critically impaired homeostasis that results in heightened vulnerability to stressors. We propose a new measure of heart rate variability (HRV) to capture the impairment in cardiac autonomic control associated with frailty.
Methods. Traditional time and frequency domain indices of HRV were obtained from 2-hour ambulatory electrocardiograms (ECGs) of 276 women (65-101 years old) in the Women's Health and Aging Study-I. Principal components analysis was conducted on the correlation matrix of HRV indices. Frailty was defined using a validated instrument. Regression models were used to evaluate associations of HRV measures with age, frailty, and 5-year mortality.
Results. The first two principal components (PCs), PC1 and PC2, explained 90% of the variance in HRV indices. PC I is the mean of log-transformed HRV indices. PC2 is a linear combination of log-transformed indices, with positive weights for very low frequency (VLF), low frequency (LF), and standard deviation of N-N intervals (SDNN), and negative weights for high frequency (HF), root-mean-squared differences of successive N-N intervals (RMSSD), and proportion of all N-N intervals that are larger than 50 ms (pNN50). Decreases in SDNN, VLF, LF, and LF/HF were associated with an increased risk of frailty. PC2 was more strongly associated with age (beta = -.23, p <.001) and frailty (0 = -73. p < 10(-5)) than were the individual HRV indices and LF/HF. PC2 was also the best predictor of 5-year mortality (beta = -.60, p < 10(-6)).
Conclusions. Cardiac autonomic control, as reflected by HRV, is impaired in frailty. A new measure derived from PC aggregation of traditional HRV indices provides a compact summary of this impairment.
C1 [Varadhan, Ravi; Chaves, Paulo H. M.; Tian, Jing; Fried, Linda P.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21205 USA.
[Varadhan, Ravi; Chaves, Paulo H. M.; Fried, Linda P.] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA.
[Lipsitz, Lewis A.] Harvard Univ, Sch Med, Beth Deaconess Med Ctr, Boston, MA USA.
[Stein, Phyllis K.] Washington Univ, Sch Med, St Louis, MO USA.
[Windham, B. Gwen] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Berger, Ronald D.] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21205 USA.
RP Varadhan, R (reprint author), Johns Hopkins Univ, Ctr Aging & Hlth, 2024 E Monument St,Suite 2-700, Baltimore, MD 21205 USA.
EM rvaradhan@jhmi.edu
FU National Institute oil Aging [P30 AG021334]; National Institutes of
Heallh-National Center [R37AGt9905]
FX This research was supported by the National Institute oil Aging. Claude
D. Pepper Older Americans Independence Centers. grant P30 AG021334. and
National Institutes of Heallh-National Center for Research Resources
grant R37AGt9905 at theJohns Hopkins University School of Medicine.
NR 23
TC 20
Z9 20
U1 0
U2 5
PU GERONTOLOGICAL SOC AMER
PI WASHINGTON
PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD JUN
PY 2009
VL 64
IS 6
BP 682
EP 687
DI 10.1093/gerona/glp013
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 473YB
UT WOS:000268247100010
PM 19223607
ER
PT J
AU Carvunis, AR
Gomez, E
Thierry-Mieg, N
Trilling, L
Vidal, M
AF Carvunis, Anne-Ruxandra
Gomez, Elisa
Thierry-Mieg, Nicolas
Trilling, Laurent
Vidal, Marc
TI Systems biology: from yesterday's concepts to tomorrow's discoveries
SO M S-MEDECINE SCIENCES
LA French
DT Article
ID COMPLEX NETWORKS; VIRUS
AB The idea that genes and their products are the fundamental units of biology has profoundly influenced our scientific thinking during the second half of the past century. Today, this reductionism is challenged by a renaissance of a systems understanding of biology, focusing on the systems formed by interacting gene products rather than on individual gene products. This discipline, based on a complementary and more holistic approach, keeps expanding its scope thanks to biotechnological innovations as well as theoretical modeling. This review aims at showing how and why, since the beginning of the 21st century, in fundamental as well as biomedical research, systems biology is proving a promising paradigm for understanding emerging properties of complex biological systems.
C1 [Carvunis, Anne-Ruxandra; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Carvunis, Anne-Ruxandra; Vidal, Marc] Dana Farber Canc Inst, Ctr Canc Syst Biol CCSB, Boston, MA 02115 USA.
[Carvunis, Anne-Ruxandra; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Gomez, Elisa] Coll France, INSERM, Chaire Med Expt, U833, F-75005 Paris, France.
[Carvunis, Anne-Ruxandra; Thierry-Mieg, Nicolas; Trilling, Laurent] TIMC IMAG, CNRS, Fac Med, UMR5525, F-38706 La Tronche, France.
RP Vidal, M (reprint author), Dana Farber Canc Inst, Ctr Canc Syst Biol CCSB, 1 Jimmy Fund Way, Boston, MA 02115 USA.
EM anne-ruxandra_carvunis@dfci.harvard.edu; marc_vidal@dfci.harvard.edu
RI Thierry-Mieg, Nicolas/M-6007-2014
NR 16
TC 4
Z9 4
U1 0
U2 5
PU EDITIONS EDK
PI SEVRES CEDEX
PA 2 RUE TROYON, SEVRES CEDEX, 92316, FRANCE
SN 0767-0974
J9 M S-MED SCI
JI M S-Med. Sci.
PD JUN-JUL
PY 2009
VL 25
IS 6-7
BP 578
EP 584
DI 10.1051/medsci/2009256-7578
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 474WZ
UT WOS:000268316800012
PM 19602354
ER
PT J
AU Rathi, Y
Michailovich, O
Shenton, ME
Bouix, S
AF Rathi, Yogesh
Michailovich, Oleg
Shenton, Martha E.
Bouix, Sylvain
TI Directional functions for orientation distribution estimation
SO MEDICAL IMAGE ANALYSIS
LA English
DT Article
DE Q-ball imaging; Orientation distribution function (ODF); HARDI;
Directional functions; Watson function
ID DIFFUSION-WEIGHTED MRI; DENSITY-FUNCTION; DECONVOLUTION; PROFILES;
TRACTS; MODEL
AB Computing the orientation distribution function (ODF) from high angular resolution diffusion imaging (HARDI) signals makes it possible to determine the orientation of fiber bundles of the brain. The HARDI signals are samples measured from a spherical shell and thus require processing on the sphere. Past work on ODF estimation involved using the spherical harmonics or spherical radial basis functions. In this work, we propose three novel directional functions able to represent the measured signals in a very compact manner, i.e., they require very few parameters to completely describe the measured signal. Analytical expressions are derived for computing the corresponding ODF. The directional functions can represent diffusion in a particular direction and mixture models can be used to represent multi-fiber orientations. We show how to estimate the parameters of this mixture model and elaborate on the differences between these functions. We also compare this general framework with estimation of ODF using spherical harmonics on some real and synthetic data. The proposed method could be particularly useful in applications such as tractography and segmentation.
Details are also given on different ways in which interpolation can be performed using directional functions. In particular, we discuss a complete Euclidean as well as a "hybrid" framework, comprising of the Riemannian as well as Euclidean spaces, to perform interpolation and compute geodesic distances between two ODFs. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Rathi, Yogesh; Shenton, Martha E.; Bouix, Sylvain] Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Sch Med, Boston, MA 02115 USA.
[Michailovich, Oleg] Univ Waterloo, Dept Elect & Comp Engn, Waterloo, ON N2L 3G1, Canada.
[Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA.
RP Rathi, Y (reprint author), Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Sch Med, Boston, MA 02115 USA.
EM yogesh@bwh.harvard.edu
OI Bouix, Sylvain/0000-0003-1326-6054
FU Department of Veteran Affairs Merit Award; VA Schizophrenia Center; NIH
[P41 RR13218, K05 MH 070047, 1P50MH080272-01, R01 MH 52807, R01 MH
50740, U54 GM072977-01]
FX The authors would like to thank Marc Neithammer for interesting
discussions on this topic. This work was supported in part by a
Department of Veteran Affairs Merit Award (Dr. M. Shenton, Dr. R.
McCarley), the VA Schizophrenia Center Grant (RM, MS) and NIH grants:
P41 RR13218 (MS), K05 MH 070047 (MS), 1P50MH080272-01 (MS), R01 MH 52807
(RM), R01 MH 50740 (MS) and NA-MIC (NIH) grant U54 GM072977-01 (Dr. Ron
Kikinis).
NR 38
TC 28
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1361-8415
J9 MED IMAGE ANAL
JI Med. Image Anal.
PD JUN
PY 2009
VL 13
IS 3
BP 432
EP 444
DI 10.1016/j.media.2009.01.004
PG 13
WC Computer Science, Artificial Intelligence; Computer Science,
Interdisciplinary Applications; Engineering, Biomedical; Radiology,
Nuclear Medicine & Medical Imaging
SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical
Imaging
GA 459IX
UT WOS:000267096400005
PM 19269242
ER
PT J
AU Engelsman, M
Lu, HM
Herrup, D
Bussiere, M
Kooy, HM
AF Engelsman, M.
Lu, H. -M.
Herrup, D.
Bussiere, M.
Kooy, H. M.
TI Commissioning a passive-scattering proton therapy nozzle for accurate
SOBP delivery
SO MEDICAL PHYSICS
LA English
DT Article
DE biomedical equipment; dosimetry; nozzles; proton beams; radiation
therapy
ID BRAGG PEAK FIELDS; COLLIMATOR SCATTER; DOSE DISTRIBUTIONS; CURRENT
MODULATION; OUTPUT FACTORS; BEAMS
AB Proton radiotherapy centers that currently use passively scattered proton beams do field specific calibrations for a non-negligible fraction of treatment fields, which is time and resource consuming. Our improved understanding of the passive scattering mode of the IBA universal nozzle, especially of the current modulation function, allowed us to re-commission our treatment control system for accurate delivery of SOBPs of any range and modulation, and to predict the output for each of these fields. We moved away from individual field calibrations to a state where continued quality assurance of SOBP field delivery is ensured by limited system-wide measurements that only require one hour per week. This manuscript reports on a protocol for generation of desired SOBPs and prediction of dose output.
C1 [Engelsman, M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Engelsman, M (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA.
EM mengelsman@partners.org
FU Daniel Ashley
FX The authors would like to thank Harald Paganetti for performing the
Monte Carlo calculations to assess the neutron dose and Daniel Ashley
for patiently performing the weekly verification measurements.
NR 13
TC 20
Z9 21
U1 3
U2 6
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2009
VL 36
IS 6
BP 2172
EP 2180
DI 10.1118/1.3121489
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 451AB
UT WOS:000266442000026
PM 19610306
ER
PT J
AU Sevick, MA
Millers, GD
Loeser, RF
Williamson, JD
Messier, SP
AF Sevick, Mary A.
Millers, Gary D.
Loeser, Richard F.
Williamson, Jeff D.
Messier, Stephen P.
TI Cost-Effectiveness of Exercise and Diet in Overweight and Obese Adults
with Knee Osteoarthritis
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE OSTEOARTHRITIS; OBESITY; WEIGHT LOSS; INTERVENTION STUDIES; RANDOMIZED
CONTROLLED TRIAL
ID ACTIVITY PROMOTION TRIAL; RHEUMATOID-ARTHRITIS; PHYSICAL-ACTIVITY;
SELF-MANAGEMENT; OLDER-ADULTS; WEIGHT-LOSS; RESISTANCE EXERCISE;
ECONOMIC-EVALUATION; WESTERN ONTARIO; OSTEO-ARTHRITIS
AB SEVICK. M. A., G. D. MILLER, R. F. LOESER, J. D. WILLIAMSON, and S. P. MESSIER. Cost-Effectiveness of Exercise and Diet in Overweight and Obese Adults with Knee Osteoarthritis. riled. Sci. Spoils Exerc., Vol. 41, No. 6, pp. 1167-1174, 2009. Purpose: The purpose of this study was to compare the cost-effectiveness of dietary and exercise interventions in overweight or obese elderly patients with knee osteoarthritis (OA) enrolled in the Arthritis. Diet, and Physical Activity Promotion Trial (ADAPT). Methods: ADAPT was a single-blinded, controlled trial of 316 adults with knee OA, randomized to one of four groups: Healthy Lifestyle Control group, Diet group, Exercise group, or Exercise and Diet group. A cost analysis was performed from a payer perspective, incorporating those costs and benefits that would be realized by a managed care organization interested in maintaining the health and satisfaction of its enrollees while reducing unnecessary utilization of health care services. Results: The Diet intervention was most cost-effective for reducing weight, at $35 for each percentage point reduction in baseline body weight. The Exercise intervention was most cost-effective for improving mobility, costing $10 for each percentage point improvement in a 6-min walking distance and $9 for each percentage point improvement in the timed stair climbing task. The Exercise and Diet intervention was most cost-effective for improving self-reported function and symptoms of arthritis, costing $24 for each percentage point improvement in subjective function, $20 for each percentage point improvement in self-reported pain, and $56 for each percentage point improvement in self-reported stiffness. Conclusions: The Exercise and Diet intervention consistently yielded the greatest improvements in weight, physical performance, and symptoms of knee OA. However, it was also the most expensive and was the most cost-effective approach only for the subjective outcomes of knee OA (self-reported function, pain, and stiffness). Perceived function and symptoms of knee OA are likely to be stronger drivers of downstream health service utilization than weight, or objective performance measures and may be the most cost-effective in the long term.
C1 [Sevick, Mary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Sevick, Mary A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Sevick, Mary A.] Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Sevick, Mary A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Millers, Gary D.; Messier, Stephen P.] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA.
[Loeser, Richard F.; Williamson, Jeff D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA.
RP Sevick, MA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 230 McKee Pl, Pittsburgh, PA 15213 USA.
EM sevick@pitt.edu
FU National Institutes of Health; Claude D. Pepper Older Americans
Independence Center [5P60 AG10484-07, M01-RR00211]
FX Support for this study was provided by the following grants from the
National Institutes of Health: Claude D. Pepper Older Americans
Independence Center 5P60 AG10484-07 and M01-RR00211. The results of this
study as presented in this report do not constitute endorsement by the
ACSM.
NR 46
TC 16
Z9 17
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD JUN
PY 2009
VL 41
IS 6
BP 1167
EP 1174
DI 10.1249/MSS.0b013e318197ece7
PG 8
WC Sport Sciences
SC Sport Sciences
GA 450JY
UT WOS:000266398000001
PM 19461553
ER
PT J
AU Van De Velde, SK
Gill, TJ
Li, GA
AF Van De Velde, Samuel K.
Gill, Thomas J.
Li, Guoan
TI Dual Fluoroscopic Analysis of the Posterior Cruciate Ligament-Deficient
Patellofemoral Joint during Lunge
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE DUAL FLUOROSCOPIC IMAGING; PATELLOFEMORAL COMPLICATIONS; PATELLAR
TRACKING; PATELLOFEMORAL CARTILAGE CONTACT; SINGLE-LEG LUNGE
ID SIMULATED MUSCLE LOADS; IN-SITU FORCES; TERM-FOLLOW-UP; KNEE-JOINT;
CONTACT PRESSURES; FLEXION; RECONSTRUCTION; INJURIES; KINEMATICS; MOTION
AB VAN DE VELDE, S. K., T. J. GILL, and G. LI. Dual Fluoroscopic Analysis of the Posterior Cruciate Ligament-Deficient Patellofemoral Joint during Lunge. Med. Sci. Sports Exerc., Vol. 41, No. 6, pp. 1198-1205, 2009. Purpose: To investigate the effect of posterior cruciate ligament (PCL) deficiency on the kinematics and the cartilage contact characteristics of the patellofemoral joint during an in vivo single-leg lunge. Methods: Ten patients with an isolated PCL injury in one knee and the contralateral side intact participated in the study. Magnetic resonance and dual fluoroscopic imaging techniques were used to analyze the patellofemoral kinematics and cartilage contact of the intact and the PCL-deficient knee during a quasi-static single-leg lunge from 0 degrees to 120 degrees of flexion. Results: PCL deficiency significantly changed the patellofemoral kinematics between 90 degrees and 120 degrees of knee flexion (P < 0.007): an increased patellar flexion angle by 10.7 degrees on average and a decreased lateral shift (on average -1.9 mm), patellar tilt (approximately -2.7 degrees), and valgus rotation (approximately -1.8 degrees) were observed in the PCL-deficient knee compared with the intact contralateral joint. The changes in patellofemoral kinematics resulted in significant changes in patellofemoral cartilage contact (P < 0.007). PCL deficiency caused a distal (approximately -3.3 mm) and medial (approximately + 2.7 mm) shift of cartilage contact from 75 degrees to 120 degrees of flexion. Conclusion: The altered tibiofemoral kinematics that were previously described in PCL deficiency resulted in changes in patellofemoral joint function at flexion angles greater than 75 degrees. This abnormal loading of the patellofemoral joint might predispose the patellofemoral cartilage to degenerative changes. Because we did not detect differences in the patellofemoral joint behavior of the intact and the PCL-deficient knee between 0 degrees and 60 degrees of flexion, rehabilitation exercises might be safely performed in this range of flexion. On the other hand, repetitive deep knee squats should be avoided in PCL-deficient patients, so as not to excessively disturb the patellofemoral cartilage contact kinematics.
C1 [Van De Velde, Samuel K.; Gill, Thomas J.; Li, Guoan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02114 USA.
RP Li, GA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed Surg,Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM gli1@partners.org
FU National Institutes of Health [NIH R01AR052408-02]; National Football
League Charities Foundation; Belgian American Educational Foundation
FX The authors thank Dr. Louis DeFrate, Dr. Dain Allred, and Jeffrey
Bingham, Ramprasad Papannagari, and Kartik Varadarajan for their
technical assistance. The authors gratefully acknowledge the financial
support of the National Institutes of Health (NIH R01AR052408-02) (GL),
the National Football League Charities Foundation (TJG), and the Belgian
American Educational Foundation (SKV). The results of the present study
do not constitute endorsement by the American College of Sports
Medicine.
NR 39
TC 7
Z9 7
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD JUN
PY 2009
VL 41
IS 6
BP 1198
EP 1205
DI 10.1249/MSS.0b013e3181981eb5
PG 8
WC Sport Sciences
SC Sport Sciences
GA 450JY
UT WOS:000266398000006
PM 19461548
ER
PT J
AU McEllistrem, MC
Scott, JR
Zuniga-Castillo, J
Khan, SA
AF McEllistrem, M. Catherine
Scott, Jennifer R.
Zuniga-Castillo, Jacobo
Khan, Saleem A.
TI Marked Increase in Biofilm-Derived Rough Pneumococcal Variants and
Rifampin-Resistant Strains Not Due to hex Gene Mutations
SO MICROBIAL DRUG RESISTANCE
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; CAPSULAR POLYSACCHARIDE;
COLONY MORPHOLOGY; MISMATCH REPAIR; PHASE VARIATION; OTITIS-MEDIA;
TRANSFORMATION; DISEASE; COMPETENCE
AB Otitis, pneumonia, and meningitis are tissue-based pneumococcal infections that can be associated with biofilms. The emergence of phenotypic rough variants, also known as acapsular small-colony variants, is essential for pneumococcal biofilm formation. These rough variants can increase nearly 100-fold in biofilms over time and can arise through single nucleotide polymorphisms (SNPs), deletions, or tandem duplications in the first gene of the capsular operon, cps3D. We detected a 100-fold increase in rifampin-resistant (Rif(r)) mutants in biofilms compared to planktonic cultures using a nonvaccine serotype 3 strain, which is causing an increasing number of cases of otitis in the 7-valent pneumococcal conjugate vaccine era. Since both rough variants and Rif(r) strains can arise through SNPs, they could emerge due to alteration of the mismatch repair (MMR) system. The Hex system, a pneumococcal MMR system, repairs mismatches during replication and transformation. In this study, no mutations were detected in the hexAB gene sequences among several rough variants with unique mutations in the cps3D gene. Within a hexA null mutant grown in broth, we detected only a 17.5-fold increase in rough variants compared to the wild-type parental strain. Taken together, these data suggest that mutations in the hex genes and modulation of hexA activity are unlikely to account for the generation of biofilm-derived rough variants.
C1 [McEllistrem, M. Catherine] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[McEllistrem, M. Catherine] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Scott, Jennifer R.] Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USA.
[Zuniga-Castillo, Jacobo; Khan, Saleem A.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
RP McEllistrem, MC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,Mailstop 130-U, Pittsburgh, PA 15240 USA.
EM mary.mcellistrem@va.gov
NR 27
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1076-6294
J9 MICROB DRUG RESIST
JI Microb. Drug Resist.
PD JUN
PY 2009
VL 15
IS 2
BP 85
EP 90
DI 10.1089/mdr.2009.0866
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 453VE
UT WOS:000266640200003
PM 19496673
ER
PT J
AU Kertesz, SG
Crouch, K
Milby, JB
Cusimano, RE
Schumacher, JE
AF Kertesz, Stefan G.
Crouch, Kimberly
Milby, Jesse B.
Cusimano, Robert E.
Schumacher, Joseph E.
TI Housing First for Homeless Persons with Active Addiction: Are We
Overreaching ?
SO MILBANK QUARTERLY
LA English
DT Review
DE Homeless persons; housing; addiction treatment; review literature;
public policy
ID SEVERE MENTAL-ILLNESS; MODIFIED THERAPEUTIC-COMMUNITY; SUBSTANCE-ABUSING
HOMELESS; TREATMENT OUTCOMES; HEALTH-CARE; PSYCHIATRIC DISABILITIES;
CONTINGENCY-MANAGEMENT; SEVERITY INDEX; ADULTS; COCAINE
AB Context: More than 350 communities in the United States have committed to ending chronic homelessness. One nationally prominent approach, Housing First, offers early access to permanent housing without requiring completion of treatment or, for clients with addiction, proof of sobriety.
Methods: This article reviews studies of Housing First and more traditional rehabilitative (e.g., "linear") recovery interventions, focusing on the outcomes obtained by both approaches for homeless individuals with addictive disorders.
Findings: According to reviews of comparative trials and case series reports, Housing First reports document excellent housing retention, despite the limited amount of data pertaining to homeless clients with active and severe addiction. Several linear programs cite reductions in addiction severity but have shortcomings in long-term housing success and retention.
Conclusions: This article suggests that the current research data are not sufficient to identify an optimal housing and rehabilitation approach for an important homeless subgroup. The research regarding Housing First and linear approaches can be strengthened in several ways, and policymakers should be cautious about generalizing the results of available Housing First studies to persons with active addiction when they enter housing programs.
C1 [Kertesz, Stefan G.; Milby, Jesse B.] Univ Alabama, Sch Med, Div Prevent Med, Dept Psychol, Birmingham, AL 35294 USA.
[Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Milby, Jesse B.] Univ Alabama, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA.
[Schumacher, Joseph E.] Univ Alabama, Ctr AIDS Res, Birmingham, AL 35294 USA.
RP Kertesz, SG (reprint author), Univ Alabama, Sch Med, Div Prevent Med, Dept Psychol, 1530 3rd Ave S,MT608, Birmingham, AL 35294 USA.
EM skertesz@uab.edu
OI Kertesz, Stefan/0000-0001-6101-8421
FU National Institute on Drug Abuse [K23-DA-15487]
FX We thank the National Institute on Drug Abuse (K23-DA-15487) for its
support for this work. The opinions expressed in this article do not
reflect formal positions of the National Institute on Drug Abuse or the
Department of Veterans Affairs.
NR 101
TC 86
Z9 86
U1 3
U2 33
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0887-378X
J9 MILBANK Q
JI Milbank Q.
PD JUN
PY 2009
VL 87
IS 2
BP 495
EP 534
DI 10.1111/j.1468-0009.2009.00565.x
PG 40
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 454VM
UT WOS:000266711000007
PM 19523126
ER
PT J
AU Ebrahimzadeh, MH
Hariri, S
AF Ebrahimzadeh, Mohamad H.
Hariri, Sanaz
TI Long-Term Outcomes of Unilateral Transtibial Amputations
SO MILITARY MEDICINE
LA English
DT Article
ID FOLLOW-UP; VIETNAM-WAR; EMPLOYMENT STATUS; LIMB AMPUTEES; BACK-PAIN;
EXPERIENCE; IRAN
AB Background: the long-term outcomes of wartime transtibial amputations have not been well documented. The purpose of this case series is to present the long-term functional, social, and psychological outcomes of modern-day military unilateral transtibial amputees. Patients and Methods: the Iranian Veterans Administration of the Khorasan province invited their Iranian military amputees from the Iran Iraq War (1980-1988) to its medical center for evaluation. The patients filled out a detailed questionnaire and were interviewed and examined by each team member. Results: two hundred (77%) of the 260 invited amputees were willing and able to come back for follow-up. Ninety-six of these patients (48%) were unilateral transtibial amputation. The average follow-up was 17.4 years (range 15-22 years). Land mines were the leading cause of war injury necessitating a transtibial amputation (68%). The most common symptoms about their amputated limbs were phantom sensations (54%), phantom pain (17%), and stump pain (42%). Lower back pain, contralateral (nonamputated limb) knee pain, and ipsilateral (amputated limb) knee pain were reported by 44%, 38%, and 13% of subjects, respectively. Sixty-five percent of patients were employed or had been employed for multiple years after their war injury. All patients were married, and 97% had children. Fifty-four percent of amputees reported psychological problems; 26% were currently utilizing psychological support services. Conclusions: at long-term follow-up, most military transtibial amputees experienced phantom sensation or some type of stump pain. More than half had persistent psychiatric problems, but only about half of these patients were receiving psychological treatment. Although this case series reports the status of these amputees, the next step would be to prospectively follow modern wartime amputees using standardized, validated outcome measures. With the goal of optimizing long-term amputee outcomes, researchers should correlate outcomes with demographics, injury characteristics, and treatments to identify and modify factors affecting the amputees' prognosis.
C1 [Ebrahimzadeh, Mohamad H.] Mashad Univ Med Sci, Dept Orthoped Surg, Mashhad, Iran.
[Hariri, Sanaz] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA.
RP Ebrahimzadeh, MH (reprint author), Mashad Univ Med Sci, Dept Orthoped Surg, Mashhad, Iran.
FU Veterans Administration of the Khorasan province of Iran
FX The authors do not have any financial or personal relationships with
other people or organizations that could inappropriately influence
(bias) this work. The Veterans Administration of the Khorasan province
of Iran sponsored the case series. However, it had no involvement in the
collection, analysis, and interpretation of data; the writing of the
manuscript; or the decision to submit the manuscript for publication.
NR 20
TC 14
Z9 14
U1 0
U2 3
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD JUN
PY 2009
VL 174
IS 6
BP 593
EP 597
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 601LD
UT WOS:000278059900007
PM 19585771
ER
PT J
AU Young, RH
AF Young, Robert H.
TI Tumor-like lesions of the urinary bladder
SO MODERN PATHOLOGY
LA English
DT Article
DE pseudocarcinomatous proliferations; nephrogenic adenoma; mullerian
lesions; spindle cell proliferations
ID PSEUDOSARCOMATOUS MYOFIBROBLASTIC PROLIFERATIONS; SPINDLE-CELL
PROLIFERATIONS; NEPHROGENIC ADENOMA; INFLAMMATORY PSEUDOTUMOR; PROSTATIC
ADENOCARCINOMA; DIFFERENTIAL-DIAGNOSIS; FIBROEPITHELIAL POLYP;
GENITOURINARY TRACT; EXPRESSION; CYSTITIS
AB Tumor-like lesions of the urinary bladder are reviewed emphasizing those that are most diagnostically challenging for the pathologist and may result in serious errors in patient care if misinterpreted. The first category considered, pseudocarcinomatous proliferations, represents an area of bladder pathology only recently appreciated as being particularly treacherous because of the extent to which irregular islands of benign epithelial cells may seemingly penetrate the lamina propria and cause confusion with carcinoma. Somewhat orderly proliferations of this type have been known for years, von Brunn's nests, and are rarely a challenge for the experienced, but proliferations of an irregular nature such as may be seen most often as a result of prior radiation therapy, but sometimes due to chemotherapy or even ischemia, represent a challenging interpretation. The clinical history may be very important in arriving at the correct diagnosis as is the appreciation that the morphology, although architecturally problematic, is different from that of any of the familiar patterns of invasive carcinoma. Florid epithelial proliferations in fibroepithelial polyps are also briefly noted. Within the category of glandular proliferations, emphasis is placed on the wide spectrum of morphology of nephrogenic adenoma including its pseudoinfiltrative pattern and occasional propensity for tiny tubules to be misconstrued as signet-ring cells. The spectrum of mullerian glandular lesions including the relatively recently described mucinous variant, endocervicosis, is reviewed. The reactive papillary proliferation, papillary-polypoid cystitis, is then discussed. This entity has long been known but has recently been re-emphasized. Other non-neoplastic papillary lesions include florid papillary forms of nephrogenic adenoma. The past 25 years has seen a great expansion of knowledge concerning non-neoplastic spindle cell proliferations, including those related to a prior procedure, the postoperative spindle cell nodule and those without such a history, variously designated inflammatory pseudotumor, pseudosarcomatous myofibroblastic proliferation, or even other terms. The morphologic spectrum is explored and it is recommended that the two categories be retained. Modern Pathology (2009) 22, S37-S52; doi: 10.1038/modpathol.2008.201
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Pathol, James Homer Wright Pathol Labs, Boston, MA 02115 USA.
RP Young, RH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Pathol, James Homer Wright Pathol Labs, Warren Bldg, Boston, MA 02115 USA.
EM rhyoung@partners.org
NR 36
TC 22
Z9 22
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD JUN
PY 2009
VL 22
BP S37
EP S52
DI 10.1038/modpathol.2008.201
PG 16
WC Pathology
SC Pathology
GA 451XJ
UT WOS:000266503900004
PM 19494852
ER
PT J
AU Wippo, CJ
Krstulovic, BS
Ertel, F
Musladin, S
Blaschke, D
Sturzl, S
Yuan, GC
Horz, W
Korber, P
Barbaric, S
AF Wippo, Christian J.
Krstulovic, Bojana Silic
Ertel, Franziska
Musladin, Sanja
Blaschke, Dorothea
Stuerzl, Sabrina
Yuan, Guo-Cheng
Hoerz, Wolfram
Korber, Philipp
Barbaric, Slobodan
TI Differential Cofactor Requirements for Histone Eviction from Two
Nucleosomes at the Yeast PHO84 Promoter Are Determined by Intrinsic
Nucleosome Stability
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID CHROMATIN REMODELING COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO;
TRANSCRIPTIONAL ACTIVATION; LYSINE-4 METHYLATION; H3K56 ACETYLATION;
CHAPERONE ASF1; BUDDING YEAST; TARGET SITE; H3 EXCHANGE
AB We showed previously that the strong PHO5 promoter is less dependent on chromatin cofactors than the weaker coregulated PHO8 promoter. In this study we asked if chromatin remodeling at the even stronger PHO84 promoter was correspondingly less cofactor dependent. The repressed PHO84 promoter showed a short hypersensitive region that was flanked upstream and downstream by a positioned nucleosome and contained two transactivator Pho4 sites. Promoter induction generated an extensive hypersensitive and histone-depleted region, yielding two more Pho4 sites accessible. This remodeling was strictly Pho4 dependent, strongly dependent on the remodelers Snf2 and Ino80 and on the histone acetyltransferase Gcn5, and more weakly on the acetyltransferase Rtt109. Importantly, remodeling of each of the two positioned nucleosomes required Snf2 and Ino80 to different degrees. Only remodeling of the upstream nucleosome was strictly dependent on Snf2. Further, remodeling of the upstream nucleosome was more dependent on Ino80 than remodeling of the downstream nucleosome. Both nucleosomes differed in their intrinsic stabilities as predicted in silico and measured in vitro. The causal relationship between the different nucleosome stabilities and the different cofactor requirements was shown by introducing destabilizing mutations in vivo. Therefore, chromatin cofactor requirements were determined by intrinsic nucleosome stabilities rather than correlated to promoter strength.
C1 [Wippo, Christian J.; Ertel, Franziska; Blaschke, Dorothea; Stuerzl, Sabrina; Hoerz, Wolfram; Korber, Philipp] Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany.
[Yuan, Guo-Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Krstulovic, Bojana Silic; Musladin, Sanja; Barbaric, Slobodan] Univ Zagreb, Fac Food Technol & Biotechnol, Biochem Lab, Zagreb 41000, Croatia.
RP Korber, P (reprint author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.
EM pkorber@lmu.de
FU German Research Community; European Union; Ministry of Education,
Science, and Technology of the Republic of Croatia [058-0580477-0247]
FX This paper is dedicated by P. K. to his wife Marion Rouette, who became
indirectly involved enough during the preparation of the manuscript to
earn her an honorary coauthorship.
NR 86
TC 26
Z9 26
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN 1
PY 2009
VL 29
IS 11
BP 2960
EP 2981
DI 10.1128/MCB.01054-08
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 444US
UT WOS:000266006500005
PM 19307305
ER
PT J
AU Assmann, A
Ueki, K
Winnay, JN
Kadowaki, T
Kulkarni, RN
AF Assmann, Anke
Ueki, Kohjiro
Winnay, Jonathon N.
Kadowaki, Takahashi
Kulkarni, Rohit N.
TI Glucose Effects on Beta-Cell Growth and Survival Require Activation of
Insulin Receptors and Insulin Receptor Substrate 2
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID GENE-EXPRESSION; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; ADIPOCYTE
DIFFERENTIATION; AUTOCRINE REGULATION; SIGNALING PATHWAY; SECRETORY
DEFECT; MICE; RESISTANCE; ISLETS
AB Insulin and insulin-like growth factor I (IGF-I) are ubiquitous hormones that regulate growth and metabolism of most mammalian cells, including pancreatic beta-cells. In addition to being an insulin secretagogue, glucose regulates proliferation and survival of beta-cells. However, it is unclear whether the latter effects of glucose occur secondary to autocrine activation of insulin signaling proteins by secreted insulin. To examine this possibility we studied the effects of exogenous glucose or insulin in beta-cell lines completely lacking either insulin receptors (beta IRKO) or insulin receptor substrate 2 (beta IRS2KO). Exogenous addition of either insulin or glucose activated proteins in the insulin signaling pathway in control beta-cell lines with the effects of insulin peaking earlier than glucose. Insulin stimulation of beta IRKO and beta IRS2KO cells led to blunted activation of phosphatidylinositol 3-kinase and Akt kinase, while surprisingly, glucose failed to activate either kinase but phosphorylated extracellular signal-regulated kinase. Control beta-cells exhibited low expression of IGF-1 receptors compared to compensatory upregulation in beta IRKO cells. The signaling data support the slow growth and reduced DNA and protein synthesis in beta IRKO and beta IRS2KO cells in response to glucose stimulation. Together, these studies provide compelling evidence that the growth and survival effects of glucose on beta-cells require activation of proteins in the insulin signaling pathway.
C1 [Assmann, Anke; Ueki, Kohjiro; Winnay, Jonathon N.; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Assmann, Anke; Ueki, Kohjiro; Winnay, Jonathon N.; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
[Ueki, Kohjiro; Kadowaki, Takahashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan.
RP Kulkarni, RN (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Room 602,1 Joslin Pl, Boston, MA 02215 USA.
EM Rohit.Kulkarni@joslin.harvard.edu
FU NIH [RO1 DK 67536, RO1 DK 68721]; DERC [P30 DK36836]
FX This work was supported by NIH RO1 DK 67536 (R. N. K.) and RO1 DK 68721
(R. N. K.) and the DERC Specialized Assay Core (P30 DK36836).
NR 62
TC 68
Z9 70
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN 1
PY 2009
VL 29
IS 11
BP 3219
EP 3228
DI 10.1128/MCB.01489-08
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 444US
UT WOS:000266006500024
PM 19273608
ER
PT J
AU Herl, L
Thomas, AV
Lill, CM
Banks, M
Deng, A
Jones, PB
Spoelgen, R
Hyman, BT
Berezovska, O
AF Herl, Lauren
Thomas, Anne V.
Lill, Christina M.
Banks, Mary
Deng, Amy
Jones, Phill B.
Spoelgen, Robert
Hyman, Bradley T.
Berezovska, Oksana
TI Mutations in amyloid precursor protein affect its interactions with
presenilin/gamma-secretase
SO MOLECULAR AND CELLULAR NEUROSCIENCE
LA English
DT Article
ID FAMILIAL ALZHEIMERS-DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
C-TERMINAL FRAGMENT; AFFECT A-BETA; GAMMA-SECRETASE; PLASMA-MEMBRANE;
CATALYTIC PORE; HUMAN BRAIN; APP; CONFORMATION
AB Alzheimer's disease is characterized by accumulation of toxic beta-amyloid (AO) in the brain and neuronal death. Several mutations in presenilin (PS1) and beta-amyloid precursor protein (APP) associate with an increased A beta(42/40) ratio. A beta(42), a highly fibrillogenic species, is believed to drive A beta aggregation. Factors shifting gamma-secretase cleavage of APP to produce A beta(42) are unclear. We investigate the molecular mechanism underlying altered A beta(42/40) ratios associated with APP mutations at codon 716 and 717. Using FRET-based fluorescence lifetime imaging to monitor APP-PS1 interactions, we show that 1716F and V7171 APP mutations increase the proportion of interacting molecules earlier in the secretory pathway, resulting in an increase in Al generation. A PSI conformation assay reveals that, in the presence of mutant APP, PSI adopts a conformation reminiscent of FAD-associated PS1 mutations, thus influencing APP binding to PS1/gamma-secretase. Mutant APP affects both intracellular location and efficiency of APP-PS1 interactions, thereby changing the A beta(42/40) ratio. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Herl, Lauren; Thomas, Anne V.; Lill, Christina M.; Banks, Mary; Deng, Amy; Jones, Phill B.; Spoelgen, Robert; Hyman, Bradley T.; Berezovska, Oksana] Massachusetts Gen Hosp, Alzheimer Res Unit, MassGen Inst Neurodegenerat, Charlestown, MA 02129 USA.
RP Berezovska, O (reprint author), Massachusetts Gen Hosp, Alzheimer Res Unit, MassGen Inst Neurodegenerat, 114 16th St, Charlestown, MA 02129 USA.
EM oberezovska@partners.org
RI Lill, Christina/J-9449-2015;
OI Lill, Christina/0000-0002-2805-1307; Jones, Phillip/0000-0003-0525-6323
FU NIH [AG 15379, AG026593]; MGH ADRC; Deutsche Forschungsgemeinschaft
FX This work was supported by NIH AG 15379 and AG026593, as well as MGH
ADRC pilot grant (to O.B) and Deutsche Forschungsgemeinschaft (to AVT).
NR 48
TC 23
Z9 23
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1044-7431
J9 MOL CELL NEUROSCI
JI Mol. Cell. Neurosci.
PD JUN 1
PY 2009
VL 41
IS 2
BP 166
EP 174
DI 10.1016/j.mcn.2009.02.008
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 453OB
UT WOS:000266619000007
PM 19281847
ER
PT J
AU Walker, SR
Nelson, EA
Zou, LH
Chaudhury, M
Signoretti, S
Richardson, A
Frank, DA
AF Walker, Sarah R.
Nelson, Erik A.
Zou, Lihua
Chaudhury, Mousumi
Signoretti, Sabina
Richardson, Andrea
Frank, David A.
TI Reciprocal Effects of STAT5 and STAT3 in Breast Cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID MAMMARY-GLAND INVOLUTION; EMBRYONIC STEM-CELLS; SIGNAL TRANSDUCER;
GENE-EXPRESSION; TRANSGENIC MICE; EPITHELIAL-CELLS; ACTIVATION;
TRANSCRIPTION; APOPTOSIS; DIFFERENTIATION
AB Breast cancer is often associated with inappropriate activation of transcription factors involved in normal mammary development. Two related transcription factors, signal transducer and activator of transcription (STAT) 5 and STAT3, play important and distinct roles in mammary development and both can be activated in breast cancer. However, the relative contribution of these STATs to mammary tumorigenesis is unknown. We have found that primary human breast tumors displaying activation of both STATs are more differentiated than those with STAT3 activation alone and display more favorable prognostic characteristics. To understand this difference, we have analyzed the effect of these STATs on gene regulation and phenotype of mammary carcinoma cells. STAT5 and STAT3 mediate opposing effects on several key target genes, with STAT5 exerting a dominant role. Using a model system of paired breast cancer cell lines, we found that coactivation of STAT5 and STAT3 leads to decreased proliferation and increased sensitivity to the chemotherapeutic drugs paclitaxel and vinorelbine compared with cells that have only STAT3 activation. Thus, STAT5 can modify the effects of STAT3 from the level of gene expression to cellular phenotype and analysis of the activation state of both STAT5 and STAT3 may provide important diagnostic and prognostic information in breast cancer. (Mol Cancer Res 2009;7(6):966-76)
C1 [Walker, Sarah R.; Nelson, Erik A.; Chaudhury, Mousumi; Frank, David A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Walker, Sarah R.; Nelson, Erik A.; Chaudhury, Mousumi; Frank, David A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Walker, Sarah R.; Nelson, Erik A.; Chaudhury, Mousumi; Signoretti, Sabina; Richardson, Andrea; Frank, David A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Zou, Lihua] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Signoretti, Sabina; Richardson, Andrea] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Frank, DA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM david_frank@dfci.harvard.edu
FU Mary Kay Ash Charitable Foundation; Friends of the DanaFarber Cancer
Institute
FX Mary Kay Ash Charitable Foundation, the Friends of the DanaFarber Cancer
Institute, and donations in honor of Filen Minna Jacobson.
NR 49
TC 63
Z9 65
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD JUN
PY 2009
VL 7
IS 6
BP 966
EP 976
DI 10.1158/1541-7786.MCR-08-0238
PG 11
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 461YX
UT WOS:000267312500020
PM 19491198
ER
PT J
AU Smith, A
Blois, J
Yuan, H
Aikawa, E
Ellson, C
Figueiredo, JL
Weissleder, R
Kohler, R
Yaffe, MB
Cantley, LC
Josephson, L
AF Smith, Adam
Blois, Joseph
Yuan, Hushan
Aikawa, Elena
Ellson, Christian
Figueiredo, Jose-Luiz
Weissleder, Ralph
Kohler, Rainer
Yaffe, Michael B.
Cantley, Lewis C.
Josephson, Lee
TI The anti proliferative cytostatic effects of a self-activating viridin
prodrug
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE;
ANTITUMOR-ACTIVITY; FUNGAL METABOLITE; DRUG CARRIERS; IN-VITRO;
WORTMANNIN; INHIBITION; CHEMOTHERAPY; ANALOGS
AB Although viridins like wortmannin (Wm) have long been examined as anticancer agents, their ability to self-activate has only recently been recognized. Here, we describe the cytostatic effects of a self-activating viridin (SAV), which is an inactive, polymeric prodrug. SAV self-activates to generate a bioactive, fluorescent viridin NBD-Wm with a half-time of 9.2 hours. With cultured A549 cells, 10 mu mol/L SAV caused growth arrest without inducing apoptosis or cell death, a cytostatic action markedly different from other chemotherapeutic agents (vinblastine, camptothecin, and paclitaxel). In vivo, a SAV dosing of 1 mg/kg once in 48 hours (i.p.) resulted in growth arrest of an A549 tumor xenograft, with growth resuming when dosing ceased. With a peak serum concentration of SAV of 2.36 mu mol/L (at 2 hours post i.p. injection), the concentration of bioactive NBD-Wm was 41 nmol/L based on the partial inhibition of neutrophil respiratory burst. Therefore, SAV was present as an inactive prodrug in serum (peak = 2.36 mu mol/L), which generated low concentrations of active viridin (41 nmol/L). SAV is a prodrug, the slow release and cytostatic activities of which suggest that it might be useful as a component of metronomic-based chemotherapeutic strategies. [Mol Cancer Ther 2009;8(6):1666-75]
C1 [Smith, Adam; Blois, Joseph; Yuan, Hushan; Aikawa, Elena; Figueiredo, Jose-Luiz; Kohler, Rainer; Josephson, Lee] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
[Smith, Adam; Blois, Joseph; Yuan, Hushan; Aikawa, Elena; Figueiredo, Jose-Luiz; Kohler, Rainer; Josephson, Lee] Harvard Univ, Sch Med, Charlestown, MA USA.
[Weissleder, Ralph; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.
[Weissleder, Ralph; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
[Ellson, Christian; Yaffe, Michael B.] Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA USA.
RP Josephson, L (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, 149 13th St, Charlestown, MA 02129 USA.
EM ljosephson@mgh.harvard.edu
RI Cantley, Lewis/D-1800-2014; Wang, Gaoqian/K-8528-2015
OI Cantley, Lewis/0000-0002-1298-7653;
FU NIH [T32P50-CA86355, R01-ES004472, R01-GM059281, T32-CA079443]; Charles
A. King Trust; Bank of America
FX NIH grants T32P50-CA86355, R01-ES004472, R01-GM059281, and T32-CA079443.
C. Ellson was funded by the Charles A. King Trust, Bank of America,
Co-Trustee.
NR 25
TC 12
Z9 13
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2009
VL 8
IS 6
BP 1666
EP 1675
DI 10.1158/1535-7163.MCT-08-1012
PG 10
WC Oncology
SC Oncology
GA 458SF
UT WOS:000267043100027
PM 19509266
ER
PT J
AU Kumar, P
Kamat, A
Mendelson, CR
AF Kumar, Premlata
Kamat, Amrita
Mendelson, Carole R.
TI Estrogen Receptor alpha (ER alpha) Mediates Stimulatory Effects of
Estrogen on Aromatase (CYP19) Gene Expression in Human Placenta
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HUMAN TROPHOBLAST DIFFERENTIATION; BREAST-CANCER CELLS; FACTOR-KAPPA-B;
TRANSCRIPTION FACTOR; IN-VITRO; CYTOTROPHOBLAST DIFFERENTIATION; HISTONE
ACETYLATION; TRANSGENIC MICE; UP-REGULATION; ACTIVATION
AB A 246-bp region upstream of placenta-specific exon L1 of the human aromatase (hCYP19) gene mediates placenta-specific, developmental, and O(2) regulation of expression. In this study, trophoblast differentiation and associated induction of CYP19 expression were prevented when cytotrophoblasts were cultured in phenol red-free medium containing charcoal-stripped serum or with the estrogen receptor (ER) antagonist, ICI 182,780, suggesting a stimulatory role of estrogen/ER. ER alpha protein was expressed in human trophoblasts and increased during syncytiotrophoblast differentiation, whereas ER beta was undetectable. Mutational analysis revealed that an estrogen response element-like sequence (ERE-LS) at -208 bp is required for inductive effects of estradiol/ER alpha on hCYP19L1 promoter activity in transfected COS-7 cells. Increased binding of syncytiotrophoblast compared with cytotrophoblast nuclear proteins to the ERE-LS was observed in vitro; however, ER alpha antibodies failed to supershift the complex and in vitro-transcribed/translated ER alpha did not bind. Nonetheless, chromatin immunoprecipitation assays in cultured trophoblasts revealed recruitment of endogenous ER alpha to the -255- to -155- bp region containing the ERE-LS before induction of hCYP19 expression; this was inhibited by ICI 182,780. Chromatin immunoprecipitation also revealed increased acetylated histone H3(K9/14) and decreased methylated histone H3(K9) associated with this region during trophoblast differentiation. These modifications were prevented when trophoblasts were incubated with ICI 182,780, suggesting that ER alpha recruitment to the -255- to -155-bp region promotes histone modifications leading to increased hCYP19 transcription. Thus, during trophoblast differentiation, estrogen/ER alpha exerts a positive feedback role, which promotes permissive histone modifications that are associated with induction of hCYP19 gene transcription. (Molecular Endocrinology 23: 784-793, 2009)
C1 [Kumar, Premlata; Mendelson, Carole R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, N Texas March Dimes Birth Defects Ctr, Dallas, TX 75390 USA.
[Kumar, Premlata; Mendelson, Carole R.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, N Texas March Dimes Birth Defects Ctr, Dallas, TX 75390 USA.
[Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Div, Ctr Geriatr Res Educ & Clin, S Texas Vet Hlth Care Syst,Dept Med, San Antonio, TX 78229 USA.
RP Mendelson, CR (reprint author), Univ Texas SW Med Ctr Dallas, Dept Biochem, N Texas March Dimes Birth Defects Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM carole.mendelson@utsouthwestern.edu
OI Mendelson, Carole/0000-0003-1696-9791
FU National Institutes of Health [5 R01 DK031206]
FX This work was supported by National Institutes of Health Grant 5 R01
DK031206 (C. R. M.).
NR 47
TC 31
Z9 34
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUN
PY 2009
VL 23
IS 6
BP 784
EP 793
DI 10.1210/me.2008-0371
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 450MC
UT WOS:000266403600006
PM 19299445
ER
PT J
AU Ramadoss, P
Unger-Smith, NE
Lam, FS
Hollenberg, AN
AF Ramadoss, Preeti
Unger-Smith, Nathan E.
Lam, Francis S.
Hollenberg, Anthony N.
TI STAT3 Targets the Regulatory Regions of Gluconeogenic Genes in Vivo
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HEPATIC GLUCOSE-PRODUCTION; NUCLEAR-PROTEIN CBP; PHOSPHOENOLPYRUVATE
CARBOXYKINASE; INSULIN ACTION; CYCLIC-AMP; KINASE B; TRANSCRIPTION;
EXPRESSION; PROMOTER; GLUCOSE-6-PHOSPHATASE
AB The regulation of expression of gluconeogenic genes including glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) in the liver plays an important role in glucose homeostasis, because aberrant expression of these genes contributes to the development of type 2 diabetes. Previous reports demonstrate that signal transducer and activator of transcription 3 (STAT3) plays a key role in regulating gluconeogenic gene expression, but the mechanism remains unclear. Herein we demonstrate that phosphorylated STAT3 is required for repression of G6Pase expression by IL-6 in both HepG2 cells and mouse liver. Interestingly, PEPCK expression is regulated by STAT3 independent of IL-6 activation. Using in vivo chromatin immunoprecipitation, we demonstrate that STAT3 binds to the promoters of the G6Pase, PEPCK, and suppressor of cytokine signaling (SOCS) 3 genes, and its recruitment increases at the G6Pase and SOCS3 promoters with IL-6 treatment. Whereas persistent recruitment of RNA polymerase II is seen on the SOCS3 promoter, consistent with its induction by IL-6, a decrease in polymerase II recruitment and histone H4 acetylation is seen at the G6Pase promoter with IL-6 treatment. Thus STAT3 mediates negative regulation of hepatic gluconeogenic gene expression in vivo by interacting with regulatory regions of these genes. (Molecular Endocrinology 23: 827-837, 2009)
C1 Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Hollenberg, AN (reprint author), 330 Brookline Ave,BIDMC CLS 0738, Boston, MA 02215 USA.
EM thollenb@bidmc.harvard.edu
FU Smith Family Pinnacle Award from the American Diabetes Association
FX This work was supported by the Smith Family Pinnacle Award from the
American Diabetes Association (to A. N. H.).
NR 35
TC 49
Z9 50
U1 1
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUN
PY 2009
VL 23
IS 6
BP 827
EP 837
DI 10.1210/me.2008-0264
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 450MC
UT WOS:000266403600009
PM 19264844
ER
PT J
AU Brea, J
Castro, M
Giraldo, J
Lopez-Gimenez, JF
Padin, JF
Quintian, F
Cadavid, MI
Vilaro, MT
Mengod, G
Berg, KA
Clarke, WP
Vilardaga, JP
Milligan, G
Loza, MI
AF Brea, Jose
Castro, Marian
Giraldo, Jesus
Lopez-Gimenez, Juan F.
Fernando Padin, Juan
Quintian, Fatima
Isabel Cadavid, Maria
Teresa Vilaro, Maria
Mengod, Guadalupe
Berg, Kelly A.
Clarke, William P.
Vilardaga, Jean-Pierre
Milligan, Graeme
Isabel Loza, Maria
TI Evidence for Distinct Antagonist-Revealed Functional States of
5-Hydroxytryptamine(2A) Receptor Homodimers
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; RESONANCE ENERGY-TRANSFER;
BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; INVERSE AGONISTS;
LIGAND-BINDING; LIVING CELLS; BETA(2)-ADRENERGIC RECEPTOR;
CONFORMATIONAL-CHANGES; MEMBRANE MICRODOMAINS
AB The serotonin (5-hydroxytryptamine; 5-HT) 2A receptor is a cell surface class A G protein-coupled receptor that regulates a multitude of physiological functions of the body and is a target for antipsychotic drugs. Here we found by means of fluorescence resonance energy transfer and immunoprecipitation studies that the 5-HT(2A)-receptor homodimerized in live cells, which we linked with its antagonist-dependent fingerprint in both binding and receptor signaling. Some antagonists, like the atypical antipsychotics clozapine and risperidone, differentiate themselves from others, like the typical antipsychotic haloperidol, antagonizing these 5-HT(2A) receptor-mediated functions in a pathway-specific manner, explained here by a new model of multiple active interconvertible conformations at dimeric receptors.
C1 [Brea, Jose; Castro, Marian; Fernando Padin, Juan; Quintian, Fatima; Isabel Cadavid, Maria; Isabel Loza, Maria] Univ Santiago de Compostela, Dept Farmacol, Inst Farm Ind, Fac Farm, Santiago De Compostela, Spain.
[Giraldo, Jesus] Univ Autonoma Barcelona, Inst Neurociencies, Bellaterra, Spain.
[Giraldo, Jesus] Univ Autonoma Barcelona, Unitat Bioestadist, Bellaterra, Spain.
[Lopez-Gimenez, Juan F.; Mengod, Guadalupe] Univ Glasgow, Dept Biochem & Mol Biol, Glasgow, Lanark, Scotland.
[Teresa Vilaro, Maria; Mengod, Guadalupe] IDIBAPS, Consejo Super Invest Cient, Inst Invest Biomed Barcelona, Dept Neurochem & Neuropharmacol, Barcelona, Spain.
[Berg, Kelly A.; Clarke, William P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Vilardaga, Jean-Pierre] Univ Pittsburgh, Med Ctr, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
[Vilardaga, Jean-Pierre] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Vilardaga, Jean-Pierre] Harvard Univ, Sch Med, Boston, MA USA.
RP Loza, MI (reprint author), Fac Farm, Dpto Farmacol, Campus Sur, Santiago De Compostela 15782, Spain.
EM mabel.loza@usc.es
RI Giraldo, Jesus/F-9881-2011; Milligan, Graeme/F-9426-2011; Castro,
Marian/K-5747-2014; Lopez-Gimenez, Juan /K-5823-2014; Vilaro, M.
Teresa/P-6906-2015;
OI Giraldo, Jesus/0000-0001-7082-4695; Milligan,
Graeme/0000-0002-6946-3519; Castro, Marian/0000-0002-4732-1966;
Lopez-Gimenez, Juan /0000-0003-3021-6200; Vilaro, M.
Teresa/0000-0002-9665-0766; Mengod, Guadalupe/0000-0001-7223-7873; Padin
Nogueira, Juan Fernando/0000-0003-4585-9401
FU Ministerio de Educacion y Ciencia, Spain [SAF2007-65913,
SAF2005-08025-C03]; Xunta de Galicia [PGIDIT06PXID203186PR, 2007/118];
Instituto de Salud Carlos III; Fundacio La Marato de TV3 [070530]
FX This work was supported by the Ministerio de Educacion y Ciencia, Spain
[Grants SAF2007-65913, SAF2005-08025-C03]; the Xunta de Galicia [Grant
PGIDIT06PXID203186PR, 2007/118]; and by Red Tematica de Investigacion
Cooperativa COMBIOMED from Instituto de Salud Carlos III and Fundacio La
Marato de TV3 [Reference 070530].
NR 61
TC 24
Z9 24
U1 0
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD JUN
PY 2009
VL 75
IS 6
BP 1380
EP 1391
DI 10.1124/mol.108.054395
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 448BZ
UT WOS:000266238400015
PM 19279328
ER
PT J
AU Muller, LUW
Daley, GQ
Williams, DA
AF Mueller, Lars U. W.
Daley, George Q.
Williams, David A.
TI Upping the Ante: Recent Advances in Direct Reprogramming
SO MOLECULAR THERAPY
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; HUMAN SOMATIC-CELLS; NUCLEAR TRANSFER;
GENE-THERAPY; TARGETED DISRUPTION; DEFINED FACTORS; HUMAN FIBROBLASTS;
PROGENITOR CELLS; MOUSE MODEL; GENERATION
AB The concept of reversing the characteristics of differentiated tissues to pluripotency through reprogramming was introduced over 50 years ago in the first somatic cell nuclear transfer (SCNT) experiments. More recently, direct reprogramming of differentiated somatic cells by gene transfer of a small number of defined transcription factors has been shown to yield cells that are indistinguishable from inner cell mass-derived embryonic stem (ES) cells. These cells, termed induced pluripotent stem (iPS) cells, offer exciting possibilities for studying mechanism of pluripotency, establishing models for disease-specific investigations, and enabling future applications in regenerative medicine. In this review, we discuss the basic foundation of reestablishing pluripotency and recent progress toward enhancing the efficiency and safety of the process through optimization of the reprogramming factor combination, identification of small molecules that augment efficiency, and assessment of distinct target cells in reprogramming efficiency. We also highlight recent advances that eliminate stable genetic modification from the reprogramming process, and summarize preclinical models that provide proof-of-concept for ES/iPS cell-based regenerative medicine.
C1 [Mueller, Lars U. W.; Daley, George Q.; Williams, David A.] Childrens Hosp, Div Pediat Hematol Oncol, Dept Med, Boston, MA 02115 USA.
[Mueller, Lars U. W.; Daley, George Q.; Williams, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mueller, Lars U. W.; Daley, George Q.; Williams, David A.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA.
[Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Williams, DA (reprint author), Childrens Hosp, Div Pediat Hematol Oncol, Dept Med, 300 Longwood Ave,Karp 08125-4, Boston, MA 02115 USA.
EM DAWilliams@childrens.harvard.edu
FU St Baldrick's Foundation; NIH [R01 HL081499, DK074310]
FX This work was supported by a fellowship grant from the St Baldrick's
Foundation (to L. U. W. M.) and NIH R01 HL081499 and DK074310 (to D. A.
W.).
NR 67
TC 41
Z9 43
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JUN
PY 2009
VL 17
IS 6
BP 947
EP 953
DI 10.1038/mt.2009.72
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 452KY
UT WOS:000266540100005
PM 19337233
ER
PT J
AU Ceccarelli, A
Filippi, M
Neema, M
Arora, A
Valsasina, P
Rocca, MA
Healy, BC
Bakshi, R
AF Ceccarelli, A.
Filippi, M.
Neema, M.
Arora, A.
Valsasina, P.
Rocca, M. A.
Healy, B. C.
Bakshi, R.
TI T2 hypointensity in the deep gray matter of patients with benign
multiple sclerosis
SO MULTIPLE SCLEROSIS
LA English
DT Article
DE benign multiple sclerosis; diffusion tensor; EDSS; gray matter T2
hypointensity; iron deposition; magnetic resonance imaging
ID VOXEL-BASED MORPHOMETRY; MAGNETIC-RESONANCE; FOLLOW-UP; IN-VIVO;
COGNITIVE IMPAIRMENT; CLINICAL-COURSE; BRAIN-DAMAGE; AXONAL LOSS; BLACK
T2; MRI
AB Background Gray matter (GM) magnetic resonance imaging (MRI) T2 hypointensity, a putative marker of iron deposition, commonly occurs in multiple sclerosis (MS). However, GM T2 hypointensity in benign MS (BMS) has not yet been characterized.
Objective To determine the presence of deep GM T2 hypointensity in BMS, compare it to secondary progressive (SP) MS and assess its association with clinical and diffusion tensor (DT) MRI measures.
Methods Thirty-five cognitively unimpaired BMS, 26 SPMS patients, and 25 healthy controls were analyzed for normalized T2-intensity in the basal ganglia and thalamus, global T2 hyperintense lesion volume, global atrophy, and white matter and GM DT metrics.
Results BMS and SPMS patients showed deep GM T2 hypointensity compared with controls. T2 hypointensity was similar in both MS subgroups and moderately correlated (r = -0.45 to 0.42) with DT MRI metrics. GM T2 hypointensity in BMS showed a weak to moderate correlation (r = -0.44 to -0.35) with disability.
Conclusions GM in BMS is not spared from structural change including iron deposition. However, while T2 hypointensity is related to global tissue disruption reflected in DT MRI, the expression of benign versus non-benign MS is likely related to other factors. Multiple Sclerosis 2009; 15: 678-686. http://msj.sagepub.com
C1 [Ceccarelli, A.] Inst Sci, Dept Neurol, Neuroimaging Res Unit, I-20132 Milan, Italy.
[Ceccarelli, A.; Filippi, M.; Valsasina, P.; Rocca, M. A.] Univ Osped San Raffaele, I-20132 Milan, Italy.
[Neema, M.; Arora, A.; Healy, B. C.; Bakshi, R.] Brigham & Womens Hosp, Div Neurol, Lab Neuroimaging Res, Boston, MA 02115 USA.
[Healy, B. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA USA.
[Bakshi, R.] Brigham & Womens Hosp, Dept Radiol, Lab Neuroimaging Res, Boston, MA 02115 USA.
RP Filippi, M (reprint author), Inst Sci, Dept Neurol, Neuroimaging Res Unit, Via Olgettina 60, I-20132 Milan, Italy.
EM m.filippi@hsr.it
RI Valsasina, Paola/K-5820-2016
OI Valsasina, Paola/0000-0001-5390-2655
NR 57
TC 35
Z9 36
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER
JI Mult. Scler.
PD JUN
PY 2009
VL 15
IS 6
BP 678
EP 686
DI 10.1177/1352458509103611
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 460KG
UT WOS:000267186000004
PM 19482861
ER
PT J
AU Newton-Cheh, C
Johnson, T
Gateva, V
Tobin, MD
Bochud, M
Coin, L
Najjar, SS
Zhao, JH
Heath, SC
Eyheramendy, S
Papadakis, K
Voight, BF
Scott, LJ
Zhang, F
Farrall, M
Tanaka, T
Wallace, C
Chambers, JC
Khaw, KT
Nilsson, P
van der Harst, P
Polidoro, S
Grobbee, DE
Onland-Moret, NC
Bots, ML
Wain, LV
Elliott, KS
Teumer, A
Luan, J
Lucas, G
Kuusisto, J
Burton, PR
Hadley, D
McArdle, WL
Brown, M
Dominiczak, A
Newhouse, SJ
Samani, NJ
Webster, J
Zeggini, E
Beckmann, JS
Bergmann, S
Lim, N
Song, K
Vollenweider, P
Waeber, G
Waterworth, DM
Yuan, X
Groop, L
Orho-Melander, M
Allione, A
Di Gregorio, A
Guarrera, S
Panico, S
Ricceri, F
Romanazzi, V
Sacerdote, C
Vineis, P
Barroso, I
Sandhu, MS
Luben, RN
Crawford, GJ
Jousilahti, P
Perola, M
Boehnke, M
Bonnycastle, LL
Collins, FS
Jackson, AU
Mohlke, KL
Stringham, HM
Valle, TT
Willer, CJ
Bergman, RN
Morken, MA
Doring, A
Gieger, C
Illig, T
Meitinger, T
Org, E
Pfeufer, A
Wichmann, HE
Kathiresan, S
Marrugat, J
O'Donnell, CJ
Schwartz, SM
Siscovick, DS
Subirana, I
Freimer, NB
Hartikainen, AL
McCarthy, MI
O'Reilly, PF
Peltonen, L
Pouta, A
de Jong, PE
Snieder, H
van Gilst, WH
Clarke, R
Goel, A
Hamsten, A
Peden, JF
Seedorf, U
Syvanen, AC
Tognoni, G
Lakatta, EG
Sanna, S
Scheet, P
Schlessinger, D
Scuteri, A
Dorr, M
Ernst, F
Felix, SB
Homuth, G
Lorbeer, R
Reffelmann, T
Rettig, R
Volker, U
Galan, P
Gut, IG
Hercberg, S
Lathrop, GM
Zelenika, D
Deloukas, P
Soranzo, N
Williams, FM
Zhai, G
Salomaa, V
Laakso, M
Elosua, R
Forouhi, NG
Volzke, H
Uiterwaal, CS
van der Schouw, YT
Numans, ME
Matullo, G
Navis, G
Berglund, G
Bingham, SA
Kooner, JS
Connell, JM
Bandinelli, S
Ferrucci, L
Watkins, H
Spector, TD
Tuomilehto, J
Altshuler, D
Strachan, DP
Laan, M
Meneton, P
Wareham, NJ
Uda, M
Jarvelin, MR
Mooser, V
Melander, O
Loos, RJF
Elliott, P
Abecasis, GR
Caulfield, M
Munroe, PB
AF Newton-Cheh, Christopher
Johnson, Toby
Gateva, Vesela
Tobin, Martin D.
Bochud, Murielle
Coin, Lachlan
Najjar, Samer S.
Zhao, Jing Hua
Heath, Simon C.
Eyheramendy, Susana
Papadakis, Konstantinos
Voight, Benjamin F.
Scott, Laura J.
Zhang, Feng
Farrall, Martin
Tanaka, Toshiko
Wallace, Chris
Chambers, John C.
Khaw, Kay-Tee
Nilsson, Peter
van der Harst, Pim
Polidoro, Silvia
Grobbee, Diederick E.
Onland-Moret, N. Charlotte
Bots, Michiel L.
Wain, Louise V.
Elliott, Katherine S.
Teumer, Alexander
Luan, Jian'an
Lucas, Gavin
Kuusisto, Johanna
Burton, Paul R.
Hadley, David
McArdle, Wendy L.
Brown, Morris
Dominiczak, Anna
Newhouse, Stephen J.
Samani, Nilesh J.
Webster, John
Zeggini, Eleftheria
Beckmann, Jacques S.
Bergmann, Sven
Lim, Noha
Song, Kijoung
Vollenweider, Peter
Waeber, Gerard
Waterworth, Dawn M.
Yuan, Xin
Groop, Leif
Orho-Melander, Marju
Allione, Alessandra
Di Gregorio, Alessandra
Guarrera, Simonetta
Panico, Salvatore
Ricceri, Fulvio
Romanazzi, Valeria
Sacerdote, Carlotta
Vineis, Paolo
Barroso, Ines
Sandhu, Manjinder S.
Luben, Robert N.
Crawford, Gabriel J.
Jousilahti, Pekka
Perola, Markus
Boehnke, Michael
Bonnycastle, Lori L.
Collins, Francis S.
Jackson, Anne U.
Mohlke, Karen L.
Stringham, Heather M.
Valle, Timo T.
Willer, Cristen J.
Bergman, Richard N.
Morken, Mario A.
Doering, Angela
Gieger, Christian
Illig, Thomas
Meitinger, Thomas
Org, Elin
Pfeufer, Arne
Wichmann, H. Erich
Kathiresan, Sekar
Marrugat, Jaume
O'Donnell, Christopher J.
Schwartz, Stephen M.
Siscovick, David S.
Subirana, Isaac
Freimer, Nelson B.
Hartikainen, Anna-Liisa
McCarthy, Mark I.
O'Reilly, Paul F.
Peltonen, Leena
Pouta, Anneli
de Jong, Paul E.
Snieder, Harold
van Gilst, Wiek H.
Clarke, Robert
Goel, Anuj
Hamsten, Anders
Peden, John F.
Seedorf, Udo
Syvanen, Ann-Christine
Tognoni, Giovanni
Lakatta, Edward G.
Sanna, Serena
Scheet, Paul
Schlessinger, David
Scuteri, Angelo
Doerr, Marcus
Ernst, Florian
Felix, Stephan B.
Homuth, Georg
Lorbeer, Roberto
Reffelmann, Thorsten
Rettig, Rainer
Voelker, Uwe
Galan, Pilar
Gut, Ivo G.
Hercberg, Serge
Lathrop, G. Mark
Zelenika, Diana
Deloukas, Panos
Soranzo, Nicole
Williams, Frances M.
Zhai, Guangju
Salomaa, Veikko
Laakso, Markku
Elosua, Roberto
Forouhi, Nita G.
Volzke, Henry
Uiterwaal, Cuno S.
van der Schouw, Yvonne T.
Numans, Mattijs E.
Matullo, Giuseppe
Navis, Gerjan
Berglund, Goran
Bingham, Sheila A.
Kooner, Jaspal S.
Connell, John M.
Bandinelli, Stefania
Ferrucci, Luigi
Watkins, Hugh
Spector, Tim D.
Tuomilehto, Jaakko
Altshuler, David
Strachan, David P.
Laan, Maris
Meneton, Pierre
Wareham, Nicholas J.
Uda, Manuela
Jarvelin, Marjo-Riitta
Mooser, Vincent
Melander, Olle
Loos, Ruth J. F.
Elliott, Paul
Abecasis, Goncalo R.
Caulfield, Mark
Munroe, Patricia B.
CA Wellcome Trust Case Control Consor
TI Genome-wide association study identifies eight loci associated with
blood pressure
SO NATURE GENETICS
LA English
DT Article
ID METHYLENETETRAHYDROFOLATE REDUCTASE GENE; LOW-RENIN HYPERTENSION; COMMON
VARIANTS; CELL-DIFFERENTIATION; BARTTERS-SYNDROME; PUBLIC-HEALTH; RISK;
POLYMORPHISM; POPULATION; MUTATIONS
AB Elevated blood pressure is a common, heritable cause of cardiovascular disease worldwide. To date, identification of common genetic variants influencing blood pressure has proven challenging. We tested 2.5 million genotyped and imputed SNPs for association with systolic and diastolic blood pressure in 34,433 subjects of European ancestry from the Global BPgen consortium and followed up findings with direct genotyping (N <= 71,225 European ancestry, N <= 12,889 Indian Asian ancestry) and in silico comparison (CHARGE consortium, N 29,136). We identified association between systolic or diastolic blood pressure and common variants in eight regions near the CYP17A1 (P = 7 x 10(-24)), CYP1A2 (P = 1 x 10(-23)), FGF5 (P = 1 x 10(-21)), SH2B3 (P = 3 x 10(-18)), MTHFR (P = 2 x 10(-13)), c10orf107 (P = 1 x 10(-9)), ZNF652 (P = 5 x 10(-9)) and PLCD3 (P = 1 x 10(-8)) genes. All variants associated with continuous blood pressure were associated with dichotomous hypertension. These associations between common variants and blood pressure and hypertension offer mechanistic insights into the regulation of blood pressure and may point to novel targets for interventions to prevent cardiovascular disease.
C1 [Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Newton-Cheh, Christopher; Voight, Benjamin F.; Kathiresan, Sekar; Altshuler, David] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Newton-Cheh, Christopher; Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Newton-Cheh, Christopher; Voight, Benjamin F.; Crawford, Gabriel J.; Kathiresan, Sekar; Altshuler, David] Harvard & Massachusetts Inst Technol, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02138 USA.
[Johnson, Toby; Beckmann, Jacques S.; Bergmann, Sven] Univ Lausanne, Dept Med Genet, Lausanne, Switzerland.
[Johnson, Toby; Bochud, Murielle] CHU Vaudois, Univ Inst Social & Preventat Med, CH-1011 Lausanne, Switzerland.
[Johnson, Toby; Bergmann, Sven] Swiss Inst Bioinformat, Lausanne, Switzerland.
[Gateva, Vesela; Scott, Laura J.; Boehnke, Michael; Jackson, Anne U.; Stringham, Heather M.; Willer, Cristen J.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Gateva, Vesela; Scott, Laura J.; Boehnke, Michael; Jackson, Anne U.; Stringham, Heather M.; Willer, Cristen J.] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Tobin, Martin D.; Wain, Louise V.; Burton, Paul R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.
[Tobin, Martin D.; Wain, Louise V.; Burton, Paul R.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England.
[Coin, Lachlan; Chambers, John C.; Vineis, Paolo; O'Reilly, Paul F.; Jarvelin, Marjo-Riitta; Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England.
[Najjar, Samer S.; Lakatta, Edward G.] NIA, Cardiovasc Sci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
[Zhao, Jing Hua; Luan, Jian'an; Sandhu, Manjinder S.; Forouhi, Nita G.; Wareham, Nicholas J.; Loos, Ruth J. F.] Addenbrookes Hosp, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
[Zhao, Jing Hua; Khaw, Kay-Tee; Barroso, Ines; Sandhu, Manjinder S.; Luben, Robert N.; Deloukas, Panos; Bingham, Sheila A.; Wareham, Nicholas J.; Loos, Ruth J. F.] Cambridge Genet Energy Metab GEM Consortium, Cambridge, England.
[Heath, Simon C.; Gut, Ivo G.; Lathrop, G. Mark; Zelenika, Diana] Ctr Natl Genotypage, Evry, France.
[Eyheramendy, Susana] Pontificia Univ Catolica Chile, Fac Matemat, Santiago, Chile.
[Eyheramendy, Susana; Doering, Angela; Gieger, Christian; Illig, Thomas; Wichmann, H. Erich] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany.
[Papadakis, Konstantinos; Hadley, David; Strachan, David P.] Univ London, Div Community Hlth Sci, London, England.
[Zhang, Feng; Soranzo, Nicole; Williams, Frances M.; Zhai, Guangju; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
[Farrall, Martin; Goel, Anuj; Peden, John F.; Watkins, Hugh] Univ Oxford, Dept Cardiovasc Med, Oxford, England.
[Farrall, Martin; Elliott, Katherine S.; Zeggini, Eleftheria; McCarthy, Mark I.; Goel, Anuj; Watkins, Hugh] Wellcome Trust Ctr Human Genet, Oxford, England.
[Tanaka, Toshiko] Medstar Res Inst, Baltimore, MD USA.
[Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Wallace, Chris; Newhouse, Stephen J.; Caulfield, Mark; Munroe, Patricia B.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Genome Ctr, London, England.
[Wallace, Chris] Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Juvenile Diabet Res Fdn,Wellcome Trust Diabet & I, Cambridge CB2 2QQ, England.
[Khaw, Kay-Tee; Sandhu, Manjinder S.; Luben, Robert N.] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.
[Nilsson, Peter; Orho-Melander, Marju; Berglund, Goran; Melander, Olle] Lund Univ, Malmo Univ Hosp, Dept Clin Sci, Malmo, Sweden.
[van der Harst, Pim; van Gilst, Wiek H.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Polidoro, Silvia; Di Gregorio, Alessandra; Guarrera, Simonetta; Ricceri, Fulvio; Romanazzi, Valeria; Vineis, Paolo; Matullo, Giuseppe] ISI Fdn Inst Sci Interchange, Turin, Italy.
[Grobbee, Diederick E.; Onland-Moret, N. Charlotte; Bots, Michiel L.; Uiterwaal, Cuno S.; van der Schouw, Yvonne T.; Numans, Mattijs E.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
[Onland-Moret, N. Charlotte] Univ Med Ctr Utrecht, Dept Med Genet DBG, Complex Genet Sect, Utrecht, Netherlands.
[Teumer, Alexander; Ernst, Florian; Homuth, Georg; Voelker, Uwe] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany.
[Lucas, Gavin; Marrugat, Jaume; Subirana, Isaac; Elosua, Roberto] Inst Municipal Invest Med, E-08003 Barcelona, Spain.
[Kuusisto, Johanna; Laakso, Markku] Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland.
[McArdle, Wendy L.] Univ Bristol, Dept Social Med, ALSPAC Lab, Bristol, Avon, England.
[Brown, Morris] Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England.
[Dominiczak, Anna; Connell, John M.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Samani, Nilesh J.] Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester, Leics, England.
[Webster, John] Aberdeen Royal Infirm, Aberdeen, Scotland.
[Zeggini, Eleftheria; Barroso, Ines; Peltonen, Leena; Deloukas, Panos; Soranzo, Nicole] Wellcome Trust Sanger Inst, Cambridge, England.
[Beckmann, Jacques S.] CHU Vaudois, Serv Med Genet, CH-1011 Lausanne, Switzerland.
[Lim, Noha; Song, Kijoung; Waterworth, Dawn M.; Yuan, Xin; Mooser, Vincent] GlaxoSmithKline Inc, Div Genet, King Of Prussia, PA USA.
[Vollenweider, Peter; Waeber, Gerard] CHU Vaudois, Dept Internal Med, CH-1011 Lausanne, Switzerland.
[Groop, Leif] Univ Hosp, Diabet & Endocrinol Res Unit, Dept Clin Sci, Malmo, Sweden.
[Groop, Leif] Lund Univ, Malmo, Sweden.
[Di Gregorio, Alessandra; Matullo, Giuseppe] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.
[Panico, Salvatore] Univ Naples Federico 2, Dept Clin & Expt Med, Naples, Italy.
[Sacerdote, Carlotta; Peltonen, Leena] Univ Turin, Canc Epidemiol Unit, Turin, Italy.
[Sacerdote, Carlotta; Peltonen, Leena] Ctr Canc Epidemiol & Prevent CPO Piemonte, Turin, Italy.
[Jousilahti, Pekka; Perola, Markus; Salomaa, Veikko] Natl Inst Welf & Hlth, Helsinki, Finland.
[Perola, Markus] Univ Helsinki, Inst Mol Med Finland FIMM, FIN-00014 Helsinki, Finland.
[Bonnycastle, Lori L.; Collins, Francis S.] NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA.
[Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Valle, Timo T.; Morken, Mario A.; Tuomilehto, Jaakko] Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet Unit, Helsinki, Finland.
[Bergman, Richard N.] Univ So Calif, Sch Med, Los Angeles, CA USA.
[Meitinger, Thomas; Pfeufer, Arne] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany.
[Meitinger, Thomas; Pfeufer, Arne] Tech Univ Munich, Inst Human Genet, Munich, Germany.
[Org, Elin; Laan, Maris] Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia.
[Wichmann, H. Erich] Univ Munich, IBE, Chair Epidemiol, Munich, Germany.
[O'Donnell, Christopher J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[O'Donnell, Christopher J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[O'Donnell, Christopher J.] Framingham Heart Study & Natl Heart Lung & Bloo, Framingham, MA USA.
[Schwartz, Stephen M.; Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Schwartz, Stephen M.; Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Subirana, Isaac; Elosua, Roberto] CIBER Epidemiol & Salud Publ, Barcelona, Spain.
[Freimer, Nelson B.] Univ Calif Los Angeles, Gonda Ctr, Ctr Neurobehav Genet, Los Angeles, CA USA.
[Hartikainen, Anna-Liisa; Pouta, Anneli] Univ Oulu, Dept Clin Sci Obstet & Gynecol, Oulu, Finland.
[McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[McCarthy, Mark I.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford OX3 7LJ, England.
[Pouta, Anneli; Jarvelin, Marjo-Riitta] Natl Publ Hlth Inst KTL, Dept Child & Adolescent Hlth, Oulu, Finland.
[de Jong, Paul E.; Navis, Gerjan] Univ Groningen, Univ Med Ctr Groningen, Dept Med, Div Nephrol, Groningen, Netherlands.
[Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Unit Genet Epidemiol & Bioinformat, Groningen, Netherlands.
[Clarke, Robert] Univ Oxford, Clin Trial Serv Unit, Oxford, England.
[Clarke, Robert] Univ Oxford, Epidemiol Studies Unit CTSU, Oxford, England.
[Hamsten, Anders] Karolinska Univ, Hosp Solna, Karolinska Inst, Dept Med Solna,Atherosclerosis Res Unit, Stockholm, Sweden.
[Syvanen, Ann-Christine] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[Tognoni, Giovanni] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Chieti, Italy.
[Sanna, Serena; Uda, Manuela] CNR, Inst Neurogenet & Neurofarmacol, Cagliari, Italy.
[Scheet, Paul] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Schlessinger, David] NIA, Genet Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
[Scuteri, Angelo] IRCCS, INRCA, Unita Operat Geriatria, Rome, Italy.
[Doerr, Marcus; Felix, Stephan B.; Reffelmann, Thorsten] Ernst Moritz Arndt Univ Greifswald, Dept Internal Med B, Greifswald, Germany.
[Lorbeer, Roberto; Navis, Gerjan] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany.
[Rettig, Rainer] Ernst Moritz Arndt Univ Greifswald, Inst Physiol, Greifswald, Germany.
[Galan, Pilar; Hercberg, Serge] Univ Paris 13, Inst Natl Rech Agron, Inst Natl Sante & Rech Med, U557, Bobigny, France.
[Bingham, Sheila A.] Wellcome Trust Res Labs, MRC Dunn Human Nutr Unit, Cambridge, England.
[Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.
[Bandinelli, Stefania] ASF, Geriatr Rehabil Unit, Florence, Italy.
[Tuomilehto, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
[Tuomilehto, Jaakko] S Ostrobothnia Cent Hosp, Seinajoki, Finland.
[Altshuler, David] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Altshuler, David] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Meneton, Pierre] Fac Med Paris Descartes, Inst Natl Sante & Rech Med, U872, Paris, France.
[Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland.
[Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland.
[Seedorf, Udo] Univ Munster, Leibniz Inst Arterioskleroseforsch, Munster, Germany.
RP Abecasis, GR (reprint author), Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
EM cnewtoncheh@chgr.mgh.harvard.edu; goncalo@umich.edu;
m.j.caulfield@qmul.ac.uk; p.b.munroe@qmul.ac.uk
RI Deloukas, Panos/B-2922-2013; Pfeufer, Arne/B-6634-2013; Colaus,
PsyColaus/K-6607-2013; Grobbee, Diederick/C-7651-2014; van der Schouw,
Yvonne/F-8327-2014; Worthington, Jane/M-9770-2014; Hinks,
Anne/E-1853-2015; Onland-Moret, N. Charlotte/G-9185-2011; Breen,
Gerome/A-5540-2010; Meitinger, Thomas/O-1318-2015; Mathew,
Christopher/G-3434-2015; Burton, Paul/H-7527-2016; Matullo,
Giuseppe/K-6383-2016; Dominiczak, Anna/D-2262-2009; Abecasis,
Goncalo/B-7840-2010; van Gilst, Wiek/C-3828-2008; Bochud,
Murielle/A-3981-2010; Heath, Simon/J-4138-2012; Altshuler,
David/A-4476-2009; Laan, Maris/A-4100-2011; Voight,
Benjamin/F-1775-2011; Beckmann, Jacques S /A-9772-2008; Lucas,
Gavin/D-4346-2012; Spector, Tim/F-6533-2012; Newhouse,
Stephen/C-9330-2011; Hadley, David/I-6902-2012; Panico,
Salvatore/K-6506-2016; Coin, Lachlan/A-9001-2014;
OI Deloukas, Panos/0000-0001-9251-070X; Grobbee,
Diederick/0000-0003-4472-4468; van der Schouw,
Yvonne/0000-0002-4605-435X; Worthington, Jane/0000-0003-0544-042X;
Hinks, Anne/0000-0001-8843-3967; Breen, Gerome/0000-0003-2053-1792;
Mathew, Christopher/0000-0003-4178-1838; Bochud,
Murielle/0000-0002-5727-0218; Altshuler, David/0000-0002-7250-4107;
Laan, Maris/0000-0002-8519-243X; Beckmann, Jacques S
/0000-0002-9741-1900; Newhouse, Stephen/0000-0002-1843-9842; Wallace,
Chris/0000-0001-9755-1703; Marrugat, Jaume/0000-0003-3320-554X; Watkins,
Hugh/0000-0002-5287-9016; Eyre, Stephen/0000-0002-1251-6974; Bruce,
Ian/0000-0003-3047-500X; Prescott, Natalie/0000-0002-5901-7371; Evans,
David/0000-0003-0663-4621; Bergmann, Sven/0000-0002-6785-9034; Wain,
Louise/0000-0003-4951-1867; Symmons, Deborah/0000-0002-8625-1200;
Soranzo, Nicole/0000-0003-1095-3852; Gieger,
Christian/0000-0001-6986-9554; Sacerdote, Carlotta/0000-0002-8008-5096;
Bishop, Tim/0000-0002-8752-8785; Forouhi, Nita/0000-0002-5041-248X;
Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Thomson,
Wendy/0000-0002-9022-5179; Barrett, Jenny/0000-0002-1720-7724; sanna,
serena/0000-0002-3768-1749; Johnson, Toby/0000-0002-5998-3270; MATULLO,
Giuseppe/0000-0003-0674-7757; Org, Elin/0000-0003-1451-9375; Abecasis,
Goncalo/0000-0003-1509-1825; Dunger, Professor
David/0000-0002-2566-9304; Luben, Robert/0000-0002-5088-6343; Panico,
Salvatore/0000-0002-5498-8312; Coin, Lachlan/0000-0002-4300-455X;
Seedorf, Udo/0000-0003-4652-5358; Willer, Cristen/0000-0001-5645-4966;
Allione, Alessandra/0000-0001-9599-309X; Lango Allen,
Hana/0000-0002-7803-8688; Zeggini, Eleftheria/0000-0003-4238-659X;
Williams, Frances/0000-0002-2998-2744; Simmonds,
Matt/0000-0003-3154-3510; Conway, David/0000-0002-8711-3037; O'Donovan,
Michael/0000-0001-7073-2379
FU British Heart Foundation [FS/05/061/19501, PG02/128, SP/04/002]; Cancer
Research UK [, 10589]; Chief Scientist Office [CZB/4/540]; Intramural
NIH HHS; Medical Research Council [85374, G0000934, G0400874, G0401527,
G0501942, G0600329, G0701863, G0800675, G0800759, G0801056, G9521010,
G9521010D, MC_QA137934, MC_U105630924, MC_U106188470, MC_U137686857];
NCRR NIH HHS [U54 RR020278, U54RR020278]; NHGRI NIH HHS [1Z01HG000024,
Z01 HG000024]; NHLBI NIH HHS [K23 HL080025, K23 HL080025-04, K23
HL083102, K23HL083102, K23HL80025, R01 HL056931, R01 HL056931-02, R01
HL056931-03, R01 HL056931-04, R01 HL087676, R01 HL087679, R01HL056931,
R01HL087676, R01HL087679]; NIA NIH HHS [N01-AG-1-2109, N01AG-821336,
N01AG-916413]; NICHD NIH HHS [N01-HD-1-3107]; NIDA NIH HHS [U54
DA021519, U54DA021519]; NIDDK NIH HHS [DK062370, DK072193, R01 DK029867,
R01 DK062370, R01 DK072193, R56 DK062370, U01 DK062370, U01 DK062418,
U01DK062418]; NIEHS NIH HHS [P30 ES007033, P30ES007033]; NIMH NIH HHS
[RL1 MH083268, RL1MH083268]; NIMHD NIH HHS [263MD821336, 263MD916413];
PHS HHS [263-MA-410953]; Wellcome Trust [076113, 061858, 068545/Z/02,
070191/Z/03/Z, 076113/B/04/Z, 077011, 077016, 077016/Z/05/Z, 079557,
079895, 088885, 089061, 090532, WT088885/Z/09/Z]; Associazione Italiana
per la Ricerca sul Cancro
NR 49
TC 613
Z9 642
U1 6
U2 82
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2009
VL 41
IS 6
BP 666
EP 676
DI 10.1038/ng.361
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 450OW
UT WOS:000266411700015
PM 19430483
ER
PT J
AU Levy, D
Ehret, GB
Rice, K
Verwoert, GC
Launer, LJ
Dehghan, A
Glazer, NL
Morrison, AC
Johnson, AD
Aspelund, T
Aulchenko, Y
Lumley, T
Kottgen, A
Vasan, RS
Rivadeneira, F
Eiriksdottir, G
Guo, XQ
Arking, DE
Mitchell, GF
Mattace-Raso, FUS
Smith, AV
Taylor, K
Scharpf, RB
Hwang, SJ
Sijbrands, EJG
Bis, J
Harris, TB
Ganesh, SK
O'Donnell, CJ
Hofman, A
Rotter, JI
Coresh, J
Benjamin, EJ
Uitterlinden, AG
Heiss, G
Fox, CS
Witteman, JCM
Boerwinkle, E
Wang, TJ
Gudnason, V
Larson, MG
Chakravarti, A
Psaty, BM
van Duijn, CM
AF Levy, Daniel
Ehret, Georg B.
Rice, Kenneth
Verwoert, Germaine C.
Launer, Lenore J.
Dehghan, Abbas
Glazer, Nicole L.
Morrison, Alanna C.
Johnson, Andrew D.
Aspelund, Thor
Aulchenko, Yurii
Lumley, Thomas
Koettgen, Anna
Vasan, Ramachandran S.
Rivadeneira, Fernando
Eiriksdottir, Gudny
Guo, Xiuqing
Arking, Dan E.
Mitchell, Gary F.
Mattace-Raso, Francesco U. S.
Smith, Albert V.
Taylor, Kent
Scharpf, Robert B.
Hwang, Shih-Jen
Sijbrands, Eric J. G.
Bis, Joshua
Harris, Tamara B.
Ganesh, Santhi K.
O'Donnell, Christopher J.
Hofman, Albert
Rotter, Jerome I.
Coresh, Josef
Benjamin, Emelia J.
Uitterlinden, Andre G.
Heiss, Gerardo
Fox, Caroline S.
Witteman, Jacqueline C. M.
Boerwinkle, Eric
Wang, Thomas J.
Gudnason, Vilmundur
Larson, Martin G.
Chakravarti, Aravinda
Psaty, Bruce M.
van Duijn, Cornelia M.
TI Genome-wide association study of blood pressure and hypertension
SO NATURE GENETICS
LA English
DT Article
ID GENETIC-VARIANTS; CALCIUM-CHANNEL; COMMON VARIANTS; CELIAC-DISEASE;
SUSCEPTIBILITY; EXPRESSION; MUTATIONS; POPULATION; PROJECT; HAPMAP
AB Blood pressure is a major cardiovascular disease risk factor. To date, few variants associated with interindividual blood pressure variation have been identified and replicated. Here we report results of a genome-wide association study of systolic (SBP) and diastolic (DBP) blood pressure and hypertension in the CHARGE Consortium (n = 29,136), identifying 13 SNPs for SBP, 20 for DBP and 10 for hypertension at P < 4 x 10(-7). The top ten loci for SBP and DBP were incorporated into a risk score; mean BP and prevalence of hypertension increased in relation to the number of risk alleles carried. When ten CHARGE SNPs for each trait were included in a joint meta-analysis with the Global BPgen Consortium (n = 34,433), four CHARGE loci attained genome-wide significance (P < 5 x 10(-8)) for SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), six for DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4) and one for hypertension (ATP2B1). Identifying genes associated with blood pressure advances our understanding of blood pressure regulation and highlights potential drug targets for the prevention or treatment of hypertension.
C1 [Levy, Daniel; Johnson, Andrew D.; Vasan, Ramachandran S.; Hwang, Shih-Jen; O'Donnell, Christopher J.; Benjamin, Emelia J.; Fox, Caroline S.; Wang, Thomas J.; Larson, Martin G.] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
[Levy, Daniel; Johnson, Andrew D.; Hwang, Shih-Jen; O'Donnell, Christopher J.; Fox, Caroline S.] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[Ehret, Georg B.; Arking, Dan E.; Ganesh, Santhi K.; Chakravarti, Aravinda] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Ehret, Georg B.] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland.
[Rice, Kenneth; Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Verwoert, Germaine C.; Dehghan, Abbas; Aulchenko, Yurii; Rivadeneira, Fernando; Mattace-Raso, Francesco U. S.; Hofman, Albert; Uitterlinden, Andre G.; Witteman, Jacqueline C. M.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Mattace-Raso, Francesco U. S.] Erasmus MC, Dept Internal Med, Geriatr Med Sect, Rotterdam, Netherlands.
[Launer, Lenore J.; Harris, Tamara B.] NIA, Lab Epidemiol Dermog & Biometry, Bethesda, MD 20892 USA.
[Glazer, Nicole L.; Bis, Joshua] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Glazer, Nicole L.; Bis, Joshua] Univ Washington, Dept Med, Seattle, WA USA.
[Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Houston, Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA.
[Aspelund, Thor; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
[Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
[Koettgen, Anna; Coresh, Josef; Chakravarti, Aravinda] Johns Hopkins Univ, Dept Epidemiol & Med, Baltimore, MD USA.
[Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Cardiol, Boston, MA 02118 USA.
[Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Prevent Med, Boston, MA 02118 USA.
[Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA.
[Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Epidemiol Sect, Boston, MA USA.
[Guo, Xiuqing; Taylor, Kent; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Mitchell, Gary F.] Cardiovasc Engn Inc, Norwood, MA USA.
[Scharpf, Robert B.] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA.
[Ganesh, Santhi K.] NHGRI, Vasc Biol Sect, Bethesda, MD 20892 USA.
[Heiss, Gerardo] Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA.
[Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA.
RP Levy, D (reprint author), Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
EM levyd@nhlbi.nih.gov; c.vanduijn@erasmusmc.nl
RI Aspelund, Thor/C-5983-2008; Aspelund, Thor/F-4826-2011; EHRET,
Georg/A-9532-2009; Kottgen, Anna/D-2920-2012; Rice, Kenneth/A-4150-2013;
Johnson, Andrew/G-6520-2013; Aulchenko, Yurii/M-8270-2013; Gudnason,
Vilmundur/K-6885-2015; Mattace- Raso, Francesco/L-2541-2015;
Rivadeneira, Fernando/O-5385-2015; Smith, Albert/K-5150-2015;
OI Sijbrands, Eric/0000-0001-8857-7389; Ramachandran,
Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336;
Dehghan, Abbas/0000-0001-6403-016X; Aspelund, Thor/0000-0002-7998-5433;
EHRET, Georg/0000-0002-5730-0675; Rice, Kenneth/0000-0001-5779-4495;
Aulchenko, Yurii/0000-0002-7899-1575; Gudnason,
Vilmundur/0000-0001-5696-0084; Rivadeneira,
Fernando/0000-0001-9435-9441; Smith, Albert/0000-0003-1942-5845; Larson,
Martin/0000-0002-9631-1254
FU Intramural NIH HHS; NCRR NIH HHS [UL1 RR025005, UL1 RR025005-01,
UL1RR025005]; NHGRI NIH HHS [U01 HG004402, U01 HG004402-01,
U01HG004402]; NHLBI NIH HHS [N01-HC-85085, N01 HC-55222, N01 HC015103,
N01 HC025195, N01 HC035129, N01 HC045133, N01 HC055015, N01 HC055016,
N01 HC055018, N01 HC055019, N01 HC055020, N01 HC055021, N01 HC055022,
N01 HC055222, N01 HC075150, N01 HC085079, N01 HC085086, N01-HC-25195,
N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020,
N01-HC-55021, N01-HC-55022, N01-HC-75150, N01-HC-85079, N01-HC-85080,
N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85086,
N01HC25195, N01HC55015, N01HC55016, N01HC55018, N01HC55019, N01HC55020,
N01HC55021, N01HC55022, N01HC55222, N01HC75150, N01HC85079, N01HC85086,
N02 HL64278, N02-HL-6-4278, R01 HL059367, R01 HL059367-02, R01 HL086694,
R01 HL086694-01A1, R01 HL087641, R01 HL087641-01, R01 HL087652, R01
HL087652-01, R01HL086694, R01HL087641, R01HL59367, R37 HL051021, R37
HL051021-06, R37 HL051021-10, R37 HL051021-11, R37 HL051021-12, R37
HL051021-13, R37 HL051021-14, R37 HL051021-15, R37HL051021, U01
HL080295, U01 HL080295-01, U10 HL054512, U10 HL054512-05, U10HL054512];
NIA NIH HHS [N01 AG012100, N01AG12100]; NIDDK NIH HHS [P30 DK063491, P30
DK063491-019004, P30 DK063491-029004, P30 DK063491-039004, P30
DK063491-049004]; PHS HHS [HHSN268200625226C]
NR 47
TC 602
Z9 634
U1 6
U2 53
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2009
VL 41
IS 6
BP 677
EP 687
DI 10.1038/ng.384
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 450OW
UT WOS:000266411700016
PM 19430479
ER
PT J
AU Kottgen, A
Glazer, NL
Dehghan, A
Hwang, SJ
Katz, R
Li, M
Yang, Q
Gudnason, V
Launer, LJ
Harris, TB
Smith, AV
Arking, DE
Astor, BC
Boerwinkle, E
Ehret, GB
Ruczinski, I
Scharpf, RB
Chen, YDI
de Boer, IH
Haritunians, T
Lumley, T
Sarnak, M
Siscovick, D
Benjamin, EJ
Levy, D
Upadhyay, A
Aulchenko, YS
Hofman, A
Rivadeneira, F
Uitterlinden, AG
van Duijn, CM
Chasman, DI
Pare, G
Ridker, PM
Kao, WHL
Witteman, JC
Coresh, J
Shlipak, MG
Fox, CS
AF Koettgen, Anna
Glazer, Nicole L.
Dehghan, Abbas
Hwang, Shih-Jen
Katz, Ronit
Li, Man
Yang, Qiong
Gudnason, Vilmundur
Launer, Lenore J.
Harris, Tamara B.
Smith, Albert V.
Arking, Dan E.
Astor, Brad C.
Boerwinkle, Eric
Ehret, Georg B.
Ruczinski, Ingo
Scharpf, Robert B.
Chen, Yii-Der Ida
de Boer, Ian H.
Haritunians, Talin
Lumley, Thomas
Sarnak, Mark
Siscovick, David
Benjamin, Emelia J.
Levy, Daniel
Upadhyay, Ashish
Aulchenko, Yurii S.
Hofman, Albert
Rivadeneira, Fernando
Uitterlinden, Andre G.
van Duijn, Cornelia M.
Chasman, Daniel I.
Pare, Guillaume
Ridker, Paul M.
Kao, W. H. Linda
Witteman, Jacqueline C.
Coresh, Josef
Shlipak, Michael G.
Fox, Caroline S.
TI Multiple loci associated with indices of renal function and chronic
kidney disease
SO NATURE GENETICS
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; CARDIOVASCULAR-DISEASE;
POOLED ANALYSIS; RISK-FACTOR; STANNIOCALCIN-1; HERITABILITY; PREVALENCE;
STATEMENT; BIOLOGY
AB Chronic kidney disease (CKD) has a heritable component and is an important global public health problem because of its high prevalence and morbidity(1). We conducted genome-wide association studies (GWAS) to identify susceptibility loci for glomerular filtration rate, estimated by serum creatinine (eGFRcrea) and cystatin C (eGFRcys), and CKD (eGFRcrea < 60ml/min/1.73 m(2)) in European-ancestry participants of four population-based cohorts (ARIC, CHS, FHS, RS; n = 19,877; 2,388 CKD cases), and tested for replication in 21,466 participants (1,932 CKD cases). We identified significant SNP associations (P < 5 x 10(-8)) with CKD at the UMOD locus, with eGFRcrea at UMOD, SHROOM3 and GATM-SPATA5L1, and with eGFRcys at CST and STC1. UMOD encodes the most common protein in human urine, Tamm-Horsfall protein(2), and rare mutations in UMOD cause mendelian forms of kidney disease(3). Our findings provide new insights into CKD pathogenesis and underscore the importance of common genetic variants influencing renal function and disease.
C1 [Hwang, Shih-Jen; Levy, Daniel; Fox, Caroline S.] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
[Hwang, Shih-Jen; Levy, Daniel; Fox, Caroline S.] Ctr Populat Studies, Framingham, MA USA.
[Koettgen, Anna; Li, Man; Astor, Brad C.; Kao, W. H. Linda; Coresh, Josef] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Glazer, Nicole L.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, DC USA.
[Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Dehghan, Abbas; Aulchenko, Yurii S.; Hofman, Albert; van Duijn, Cornelia M.; Witteman, Jacqueline C.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Katz, Ronit; Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Yang, Qiong] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
[Gudnason, Vilmundur; Smith, Albert V.] Iceland Heart Assoc Res Inst, Kopavogur, Iceland.
[Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
[Launer, Lenore J.; Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Arking, Dan E.; Ehret, Georg B.] Johns Hopkins Med Inst, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol, Houston, TX USA.
[Ehret, Georg B.] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland.
[Ruczinski, Ingo; Scharpf, Robert B.; Coresh, Josef] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA.
[Chen, Yii-Der Ida; Haritunians, Talin] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Sarnak, Mark] Tufts Univ New England Med Ctr, Boston, MA USA.
[Siscovick, David] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Upadhyay, Ashish] Boston Med Ctr, Renal Sect, Boston, MA USA.
[Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Chasman, Daniel I.; Pare, Guillaume; Ridker, Paul M.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, Gen Internal Med Div, San Francisco, CA 94143 USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Fox, CS (reprint author), Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
EM j.witteman@erasmusmc.nl; coresh@jhu.edu; michael.shlipak@ucsf.edu;
foxca@nhlbi.nih.gov
RI EHRET, Georg/A-9532-2009; Kottgen, Anna/D-2920-2012; Aulchenko,
Yurii/M-8270-2013; Yang, Qiong/G-5438-2014; Gudnason,
Vilmundur/K-6885-2015; Rivadeneira, Fernando/O-5385-2015; Smith,
Albert/K-5150-2015;
OI Dehghan, Abbas/0000-0001-6403-016X; EHRET, Georg/0000-0002-5730-0675;
Aulchenko, Yurii/0000-0002-7899-1575; Gudnason,
Vilmundur/0000-0001-5696-0084; Rivadeneira,
Fernando/0000-0001-9435-9441; Smith, Albert/0000-0003-1942-5845;
Upadhyay, Ashish/0000-0002-0536-5776; Benjamin,
Emelia/0000-0003-4076-2336
FU Intramural NIH HHS; NCATS NIH HHS [UL1 TR000423]; NCI NIH HHS [CA
047988, R01 CA047988]; NCRR NIH HHS [KL2 RR025015, KL2 RR025015-03, M01
RR000069, M01RR00069, UL1 RR025005, UL1 RR025005-01, UL1RR025005]; NHGRI
NIH HHS [U01 HG004402, U01 HG004402-01, U01HG004402]; NHLBI NIH HHS
[N01-HC-55019, HL 043851, N01 HC015103, N01 HC025195, N01 HC035129, N01
HC045133, N01 HC055015, N01 HC055016, N01 HC055018, N01 HC055019, N01
HC055020, N01 HC055021, N01 HC055022, N01 HC055222, N01 HC075150, N01
HC085079, N01 HC085086, N01-HC-25195, N01-HC-55015, N01-HC-55016,
N01-HC-55018, N01-HC-55020, N01-HC-55021, N01-HC-55022, N01-HC-55222,
N01-HC-75150, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082,
N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01HC25195,
N01HC55015, N01HC55016, N01HC55018, N01HC55019, N01HC55020, N01HC55021,
N01HC55022, N01HC55222, N01HC75150, N01HC85079, N01HC85086, N02 HL64278,
N02-HL-6-4278, R01 HL043851, R01 HL043851-09, R01 HL059367, R01
HL059367-02, R01 HL086694, R01 HL086694-01A1, R01 HL087641, R01
HL087641-01, R01 HL087652, R01 HL087652-01, R01HL086694, R01HL087641,
R01HL59367, U01 HL080295, U01 HL080295-01]; NIA NIH HHS [N01 AG012100,
N01AG12100, R01 AG027002, R01 AG027002-01]; NIDDK NIH HHS [DK063491, K01
DK067207, K01 DK067207-01A1, K01DK067207, P30 DK063491, P30
DK063491-019004, P30 DK063491-05, R01 DK076770]; PHS HHS
[HHSN268200625226C]
NR 30
TC 248
Z9 255
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2009
VL 41
IS 6
BP 712
EP 717
DI 10.1038/ng.377
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 450OW
UT WOS:000266411700021
PM 19430482
ER
PT J
AU Glimcher, LH
Lieberman, J
AF Glimcher, Laurie H.
Lieberman, Judy
TI Harvard's women four years later
SO NATURE IMMUNOLOGY
LA English
DT Editorial Material
AB How have women fared at Harvard since the events of four years ago? Here, Judy Lieberman and Laurie Glimcher reflect on progress made and barriers still to be breached.
C1 [Glimcher, Laurie H.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Glimcher, Laurie H.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Lieberman, Judy] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
RP Glimcher, LH (reprint author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.
EM lieberman@idi.med.harvard.edu; lglimcher@hsph.harvard.edu
RI Lieberman, Judy/A-2717-2015
NR 0
TC 3
Z9 3
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2009
VL 10
IS 6
BP 559
EP 561
DI 10.1038/ni0609-559
PG 3
WC Immunology
SC Immunology
GA 450EP
UT WOS:000266384100003
PM 19448653
ER
PT J
AU Derudder, E
Cadera, EJ
Vahl, JC
Wang, J
Fox, CJ
Zha, S
van Loo, G
Pasparakis, M
Schlissel, MS
Schmidt-Supprian, M
Rajewsky, K
AF Derudder, Emmanuel
Cadera, Emily J.
Vahl, J. Christoph
Wang, Jing
Fox, Casey J.
Zha, Shan
van Loo, Geert
Pasparakis, Manolis
Schlissel, Mark S.
Schmidt-Supprian, Marc
Rajewsky, Klaus
TI Development of immunoglobulin lambda-chain-positive B cells, but not
editing of immunoglobulin kappa-chain, depends on NF-kappa B signals
SO NATURE IMMUNOLOGY
LA English
DT Article
ID LYMPHOCYTE DEVELOPMENT; GENE REARRANGEMENT; RECEPTOR SIGNALS; DEFICIENT
MICE; TRANSCRIPTION; EXPRESSION; TOLERANCE; PROMOTES; DIFFERENTIATION;
ACTIVATION
AB By genetically ablating I kappa B kinase (IKK)-mediated activation of the transcription factor NF-kappa B in the B cell lineage and by analyzing a mouse mutant in which immunoglobulin lambda-chain-positive B cells are generated in the absence of rearrangements in the locus encoding immunoglobulin kappa-chain, we define here two distinct, consecutive phases of early B cell development that differ in their dependence on IKK-mediated NF-kappa B signaling. During the first phase, in which NF-kappa B signaling is dispensable, predominantly kappa-chain-positive B cells are generated, which undergo efficient receptor editing. In the second phase, predominantly lambda-chain-positive B cells are generated whose development is ontogenetically timed to occur after rearrangements of the locus encoding kappa-chain. This second phase of development is dependent on NF-kappa B signals, which can be substituted by transgenic expression of the prosurvival factor Bcl-2.
C1 [Derudder, Emmanuel; Vahl, J. Christoph; Wang, Jing; Schmidt-Supprian, Marc; Rajewsky, Klaus] Immune Dis Inst, Boston, MA USA.
[Cadera, Emily J.; Schlissel, Mark S.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Vahl, J. Christoph; Schmidt-Supprian, Marc] Max Planck Inst Biochem, D-82152 Martinsried, Germany.
[Fox, Casey J.] Jackson Lab, Bar Harbor, ME 04609 USA.
[Zha, Shan] Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Immune Dis Inst,Dept Genet, Boston, MA 02115 USA.
[van Loo, Geert] VIB, Dept Mol Biomed Res, Ghent, Belgium.
[van Loo, Geert] Univ Ghent, B-9000 Ghent, Belgium.
[Pasparakis, Manolis] Univ Cologne, Inst Genet, Ctr Mol Med, D-5000 Cologne, Germany.
[Pasparakis, Manolis] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-5000 Cologne, Germany.
RP Derudder, E (reprint author), Immune Dis Inst, Boston, MA USA.
EM derudder@idi.harvard.edu; supprian@biochem.mpg.de;
rajewsky@idi.harvard.edu
RI van Loo, Geert/C-1505-2009; Schmidt-Supprian, Marc/F-5893-2011;
OI Schmidt-Supprian, Marc/0000-0002-8543-6166; Vahl,
Christoph/0000-0002-1683-8196; Pasparakis, Manolis/0000-0002-9870-0966
FU US National Institutes of Health; Deutsche Forschungsgemeinschaft
FX We regret that for space reasons we often had to quote reviews instead
of the original papers. We thank S. Akira (Osaka University), F. Alt
(Children's Hospital, Boston), R. Bram (Mayo Medical School, Rochester),
R. Geha (Children's Hospital, Boston), T. Mak (Campbell Family Institute
for Cancer Research), D. Nemazee (The Scripps Research Institute) and M.
Reth (University of Freiburg) for Myd88-/-,
Atm-/-, Taci-/-, Bcl10-/-,
kappa-macroself and mb1-cre cells and mouse strains; S. Weiss (Helmholtz
Centre for Infection Research) for anti-lambda1-chain; N.
Rice (US National Cancer Institute) for anti-p52; T. Chakraborty, G.
Galler and S. Koralov for help with quantitative real-time PCR, EMSA and
cell-cycle analysis; M. Bamberg for antibody preparation; N. Barteneva
for cell sorting; and D. Ghitza, A. Pellerin, J. Grundy and J. Xia for
technical assistance with mouse work. Supported by the US National
Institutes of Health (M. S. S. and K. R.) and Deutsche
Forschungsgemeinschaft (Emmy Noether grant to M.S.-S.).
NR 48
TC 40
Z9 42
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2009
VL 10
IS 6
BP 647
EP U118
DI 10.1038/ni.1732
PG 9
WC Immunology
SC Immunology
GA 450EP
UT WOS:000266384100017
PM 19412180
ER
PT J
AU Goldfine, AB
Shoelson, SE
Aguirre, V
AF Goldfine, Allison B.
Shoelson, Steven E.
Aguirre, Vincent
TI Expansion and contraction Treating diabetes with bariatric surgery
SO NATURE MEDICINE
LA English
DT Editorial Material
ID GASTRIC BYPASS-SURGERY; MORBIDLY OBESE SUBJECTS; WEIGHT-LOSS; MELLITUS;
MORTALITY; SATIETY; SLEEVE
AB Bariatric surgery is not only one of the most immediate and effective ways to slim down: recent clinical data show that certain procedures are also particularly good at quelling type 2 diabetes. In "Bedside to Bench," Allison Goldfine, Steven Shoelson and Vincent Aguirre outline how researchers can better understand these new clinical findings at the mechanistic level. In the accompanying "Bench to Bedside," Jorge Plutzky takes a look how proper regulation of the storage of fatty acids helps maintain their effectiveness as signaling molecules and reins in their potential pathological effects. Such research is leading to new ways of thinking about how to combat type 2 diabetes.
C1 [Goldfine, Allison B.; Shoelson, Steven E.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Goldfine, Allison B.; Shoelson, Steven E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Aguirre, Vincent] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA.
[Aguirre, Vincent] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
RP Goldfine, AB (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
EM allison.goldfine@joslin.harvard.edu
NR 15
TC 22
Z9 22
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2009
VL 15
IS 6
BP 616
EP 617
DI 10.1038/nm0609-616
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 455BS
UT WOS:000266731600018
PM 19498374
ER
PT J
AU Jain, RK
Duda, DG
Willett, CG
Sahani, DV
Zhu, AX
Loeffler, JS
Batchelor, TT
Sorensen, AG
AF Jain, Rakesh K.
Duda, Dan G.
Willett, Christopher G.
Sahani, Dushyant V.
Zhu, Andrew X.
Loeffler, Jay S.
Batchelor, Tracy T.
Sorensen, A. Gregory
TI Biomarkers of response and resistance to antiangiogenic therapy
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; METASTATIC
COLORECTAL-CANCER; PACLITAXEL PLUS BEVACIZUMAB; ADVANCED
HEPATOCELLULAR-CARCINOMA; COOPERATIVE-ONCOLOGY-GROUP; ADVANCED
BREAST-CANCER; ADVANCED SOLID TUMORS; ANTI-VEGF THERAPY; LUNG-CANCER
AB No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1 alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. we discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
C1 [Jain, Rakesh K.] Massachusetts Gen Hosp, Steele Lab, Dept Radiat Oncol, Boston, MA 02114 USA.
[Sahani, Dushyant V.] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Zhu, Andrew X.] Massachusetts Gen Hosp, T Gosnell Ctr Gastrointestinal Canc, Boston, MA 02114 USA.
[Batchelor, Tracy T.] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
[Sorensen, A. Gregory] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Willett, Christopher G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Steele Lab, Dept Radiat Oncol, 100 Blossom St,Cox 7, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
FU National Cancer Institute [P01-CA80124, P41-RR14075, R01-CA115767,
R01-CA85140, R01CA126642, R21-CA99237, R21-CA117079, R01-CA129371,
R01CA57683, K24-CA125440]; Federal Share/NCI Proton Beam Program Income
[M01-RR-01066]; Harvard Clinical and Translational Science Center
(CTSC); National Foundation for Cancer Research; Nancy Simches Endowment
for Brain Tumor Research; Montesi Family Fund; MIND Institute
FX The authors thank the members of the steele Lab, especially M.
Ancukiewicz, Y. Boucher, E. di Tomaso, and L. Xu and M. Buyse, H. Chen,
A. Grothey, C. Hudis, R. Horvitz, and A. Marshall for their helpful
comments on this manuscript. The authors' work is supported by grants
from the National Cancer Institute P01-CA80124, P41-RR14075,
R01-CA115767, R01-CA85140, R01CA126642, R21-CA99237, R21-CA117079,
R01-CA129371, R01CA57683, K24-CA125440, Federal Share/NCI Proton Beam
Program Income, M01-RR-01066, Harvard Clinical and Translational Science
Center (CTSC) grant; the National Foundation for Cancer Research; the
Richard and Nancy Simches Endowment for Brain Tumor Research; the
Montesi Family Fund; and MIND Institute.
NR 81
TC 331
Z9 339
U1 7
U2 54
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD JUN
PY 2009
VL 6
IS 6
BP 327
EP 338
DI 10.1038/nrclinonc.2009.63
PG 12
WC Oncology
SC Oncology
GA 452GO
UT WOS:000266528500008
PM 19483739
ER
PT J
AU Carmack, SW
Genta, RM
Graham, DY
Lauwers, GY
AF Carmack, Susanne W.
Genta, Robert M.
Graham, David Y.
Lauwers, Gregory Y.
TI Management of gastric polyps: a pathology-based guide for
gastroenterologists
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID GASTROINTESTINAL STROMAL TUMORS; FUNDIC GLAND POLYPS; FAMILIAL
ADENOMATOUS POLYPOSIS; INFLAMMATORY FIBROID POLYPS; HELICOBACTER-PYLORI
INFECTION; PEUTZ-JEGHERS-SYNDROME; HYPERPLASTIC POLYPS; MALIGNANT
TRANSFORMATION; DIFFERENTIAL-DIAGNOSIS; EPITHELIAL DYSPLASIA
AB 1-4% of patients who undergo gastric biopsy have gastric polyps. These lesions may be true epithelial polyps, heterotopias, lymphoid tissue, or stromal lesions. Hyperplastic polyps, which arise in patients with underlying gastritis, and fundic-gland polyps, which are associated with PPI therapy, are the most common gastric polyps; however, prevalence varies widely relative to the local prevalence of Helicobacter pylori infection and use of PPI therapy. some polyps have characteristic topography, size, and endoscopic appearance. Approximately 20% of biopsy specimens identified endoscopically as polyps have no definite pathological diagnosis. evaluation of the phenotype of the gastric mucosa that surrounds a lesion will provide significant information crucial to the evaluation, diagnosis and management of a patient. The presence of a gastric adenoma should prompt the search for a coexistent carcinoma. The endoscopic characteristics, histopathology, pathogenesis, and management recommendations of polyps and common polypoid lesions in the stomach are discussed in this Review.
C1 [Carmack, Susanne W.; Genta, Robert M.] Univ SW Med Ctr, Vet Affairs N Texas Hlth Care Syst, Dallas, TX USA.
[Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Lauwers, Gregory Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Genta, RM (reprint author), Caris Diagnost, 8400 Esters Blvd, Irving, TX 75063 USA.
EM robert.genta@utsouthwestern.edu
NR 84
TC 48
Z9 52
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2009
VL 6
IS 6
BP 331
EP 341
DI 10.1038/nrgastro.2009.70
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 453KC
UT WOS:000266608300007
PM 19421245
ER
PT J
AU Sepe, PS
Brugge, WR
AF Sepe, Paul S.
Brugge, William R.
TI A guide for the diagnosis and management of gastrointestinal stromal
cell tumors
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID FINE-NEEDLE-ASPIRATION; OF-FUNCTION MUTATIONS; TERM-FOLLOW-UP;
ENDOSCOPIC ULTRASOUND; C-KIT; TRUCUT BIOPSY; SUBMUCOSAL LESIONS;
ENDOSONOGRAPHIC DIFFERENTIATION; LAPAROSCOPIC RESECTION; SUBEPITHELIAL
MASSES
AB Gastrointestinal stromal cell tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract and are frequently detected on routine endoscopy. Although only similar to 10-30% of GISTs are clinically malignant, all may have some degree of malignant potential. Preoperative determination of malignancy risk can be estimated from tumor size and location, but reliable histopathologic criteria are not currently available. Given such biological uncertainty, accurate diagnosis is essential to differentiate these lesions from other truly benign, subepithelial tumors. endoscopic ultrasound-guided fine-needle aspiration has emerged as an important procedure to secure a tissue diagnosis of a GIST. when encountering GISTs, gastroenterologists are faced with challenging management decisions, especially in the face of small, incidentally discovered lesions. The majority of localized GISTs are managed via surgical resection, although a select few may be observed using serial endoscopic ultrasound examinations. This review provides a general overview of GISTs, with an emphasis on their endoscopic diagnosis, the management of localized disease, and the management of incidentally discovered GISTs.
C1 [Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Sepe, Paul S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA.
EM wbrugge@partners.org
NR 91
TC 42
Z9 44
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2009
VL 6
IS 6
BP 363
EP 371
DI 10.1038/nrgastro.2009.43
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 453KC
UT WOS:000266608300010
PM 19365407
ER
PT J
AU Coen, JJ
Zietman, AL
AF Coen, John J.
Zietman, Anthony L.
TI Proton radiation for localized prostate cancer
SO NATURE REVIEWS UROLOGY
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; INDUCED 2ND CANCERS; CONFORMAL
RADIOTHERAPY; METASTATIC DISSEMINATION; DOSE-ESCALATION; BEAM RADIATION;
THERAPY; GY; ADENOCARCINOMA; IRRADIATION
AB Proton radiation is an emerging therapy for localized prostate cancer that is being sought with increasing frequency by patients. The physical properties of a proton beam make it ideal for clinical applications; the Bragg peak allows for deposition of dose at a well-defined depth with essentially no exit dose. Thus, high doses can be delivered to a target while largely sparing adjacent normal tissue. Proton radiation has proven effective in dose escalation for prostate cancer. This is important, as high-dose conformal radiation is now the standard form of external radiation for this disease. intensity-modulated radiation therapy, which uses X-rays, is another means of delivering high radiation doses to the prostate and is currently the most widely used form of external radiation in the Us. At present prices, it is probably more cost-effective than proton radiation; this could change. Clear dosimetric superiority of protons in the high-dose region has not yet been demonstrated. A dosimetric advantage may emerge as pencil-beam scanning replaces passive scanning, and intensity-modulated proton therapy becomes possible. This technique would be particularly well suited to partial prostate 'boosts', hypofractionation regimens and stereotactic delivery of radiation, all new approaches to prostate cancer that are being investigated.
C1 [Coen, John J.; Zietman, Anthony L.] Harvard Univ, Dept Radiat Oncol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Coen, JJ (reprint author), Harvard Univ, Dept Radiat Oncol, Massachusetts Gen Hosp, Sch Med, 100 Blossom St, Boston, MA 02114 USA.
EM jcoen@partners.org
NR 43
TC 8
Z9 8
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4812
J9 NAT REV UROL
JI Nat. Rev. Urol.
PD JUN
PY 2009
VL 6
IS 6
BP 324
EP 330
DI 10.1038/nrurol.2009.83
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 455OY
UT WOS:000266773900009
PM 19434101
ER
PT J
AU Kwong, J
Chan, FL
Wong, KK
Birrer, MJ
Archibald, KM
Balkwill, FR
Berkowitz, RS
Mok, SC
AF Kwong, Joseph
Chan, Franky Leung
Wong, Kwong-kwok
Birrer, Michael J.
Archibald, Kyra M.
Balkwill, Frances R.
Berkowitz, Ross S.
Mok, Samuel C.
TI Inflammatory Cytokine Tumor Necrosis Factor alpha Confers Precancerous
Phenotype in an Organoid Model of Normal Human Ovarian Surface
Epithelial Cells
SO NEOPLASIA
LA English
DT Article
ID INCLUSION CYSTS; CANCER CELLS; TNF-ALPHA; RISK; METASTASIS; EXPRESSION;
PATHOGENESIS; PROMOTION; MICE; CARCINOGENESIS
AB In this study, we established an in vitro organoid model of normal human ovarian surface epithelial (HOSE) cells. The spheroids of these normal HOSE cells resembled epithelial inclusion cysts in human ovarian cortex, which are the cells of origin of ovarian epithelial tumor. Because there are strong correlations between chronic inflammation and the incidence of ovarian cancer, we used the organoid model to test whether protumor inflammatory cytokine tumor necrosis factor a would induce malignant phenotype in normal HOSE cells. Prolonged treatment of tumor necrosis factor a induced phenotypic changes of the HOSE spheroids, which exhibited the characteristics of precancerous lesions of ovarian epithelial tumors, including reinitiation of cell proliferation, structural disorganization, epithelial stratification, loss of epithelial polarity, degradation of basement membrane, cell invasion, and overexpression of ovarian cancer markers. The result of this study provides not only an evidence supporting the link between chronic inflammation and ovarian cancer formation but also a relevant and novel in vitro model for studying of early events of ovarian cancer.
C1 [Kwong, Joseph; Berkowitz, Ross S.; Mok, Samuel C.] Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol,Div Gynecol Oncol, Boston, MA 02115 USA.
[Kwong, Joseph; Archibald, Kyra M.; Balkwill, Frances R.] Queen Mary Univ London, Ctr Canc & Inflammat, Inst Canc, Barts & London Sch Med & Dent, London EC1M 6BQ, England.
[Chan, Franky Leung] Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China.
[Wong, Kwong-kwok] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA.
[Birrer, Michael J.] Natl Canc Inst, Cell & Canc Biol Branch, Bethesda, MD USA.
[Berkowitz, Ross S.; Mok, Samuel C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA.
RP Kwong, J (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Block E,1-F, Shatin, Hong Kong, Peoples R China.
EM josephkwong@cuhk.edu.hk
RI Kwong, Joseph/H-2368-2013;
OI Balkwill, Frances/0000-0002-5587-9759
FU The Ovarian Cancer Fund Inc (Research Training Program of Excellence
Grant); Association for International Cancer Research (AICR)
[R33CA103595]; The Ovarian Cancer SPORE; National Institutes of Health,
Department of Health and Human Service [P50CA165009]; The Gillette
Center for Women's Cancer; Adler Foundation Inc.; The Morse Family Fund;
The Natalie Pihl Fund; HEFCE; Cancer Research UK Studentship
FX This study was supported by The Ovarian Cancer Fund Inc (Research
Training Program of Excellence Grant) and Association for International
Cancer Research (AICR) to J. K.; R33CA103595 and The Ovarian Cancer
SPORE P50CA165009 from National Institutes of Health, Department of
Health and Human Service; The Gillette Center for Women's Cancer; Adler
Foundation Inc.; The Morse Family Fund; and The Natalie Pihl Fund (to S.
C. M. and R. S. B.); HEFCE for F. R. B.; Cancer Research UK Studentship
for K. M. A.
NR 56
TC 13
Z9 15
U1 0
U2 1
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD JUN
PY 2009
VL 11
IS 6
BP 529
EP 541
DI 10.1593/neo.09112
PG 13
WC Oncology
SC Oncology
GA 449WJ
UT WOS:000266360800003
PM 19484142
ER
PT J
AU Coble, JB
Dosemeci, M
Stewart, PA
Blair, A
Bowman, J
Fine, HA
Shapiro, WR
Selker, RG
Loeffler, JS
Black, PM
Linet, MS
Inskip, PD
AF Coble, Joseph B.
Dosemeci, Mustafa
Stewart, Patricia A.
Blair, Aaron
Bowman, Joseph
Fine, Howard A.
Shapiro, William R.
Selker, Robert G.
Loeffler, Jay S.
Black, Peter M.
Linet, Martha S.
Inskip, Peter D.
TI Occupational exposure to magnetic fields and the risk of brain tumors
SO NEURO-ONCOLOGY
LA English
DT Article
DE glioma; job modules; magnetic fields; meningioma; occupation
ID CENTRAL-NERVOUS-SYSTEM; RADIATION EXPOSURE; UNITED-STATES; CANCER;
MORTALITY; LEUKEMIA; WORKERS; UTILITY; DESIGN; SWEDEN
AB We investigated the association between occupational exposure to extremely low-frequency magnetic fields (MFs) and the risk of glioma and meningioma. Occupational exposure to MF was assessed for 489 glioma cases, 197 meningioma cases, and 799 controls enrolled in a hospital-based case-control study. Lifetime occupational history questionnaires were administered to all subjects; for 24% of jobs, these were supplemented with job-specific questionnaires, or "job modules," to obtain information on the use of electrically powered tools or equipment at work. Job-specific quantitative estimates for exposure to MF in milligauss were assigned using a previously published job exposure matrix (JEM) with modification based on the job modules. Jobs were categorized as <= 1.5 mG, >1.5 to <3.0 mG, and >= 3.0 mG. Four exposure metrics were evaluated: (1) maximum exposed job; (2) total years of exposure >1.5 mG; (3) cumulative lifetime exposure; and (4) average lifetime exposure. Odds ratios (ORs) were calculated using unconditional logistic regression with adjustment for the age, gender, and hospital site. The job modules increased the number of jobs with exposure >= 3.0 mG from 4% to 7% relative to the JEM. No statistically significant elevation in ORs or trends in ORs across exposure categories was observed using four different exposure metrics for the three tumor types analyzed. Occupational exposure to MFs assessed using job modules was not associated with an increase in the risk for glioma, glioblastoma, or meningioma among the subjects evaluated in this study. Neuro-Oncology 11, 242-249, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00200, February 20, 2009. URL http://neuro-oncology.dukejournals.org; DOI:10.1215/15228517-2009-002)
C1 [Coble, Joseph B.; Dosemeci, Mustafa; Stewart, Patricia A.; Blair, Aaron] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Fine, Howard A.] NCI, Neurooncol Branch, Bethesda, MD 20892 USA.
[Linet, Martha S.; Inskip, Peter D.] NCI, Radiat Epidemiol Branch, Bethesda, MD 20892 USA.
[Bowman, Joseph] NIOSH, Engn & Phys Hazards Branch, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Shapiro, William R.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Shapiro, William R.] Med Ctr, Phoenix, AZ USA.
[Selker, Robert G.] Western Penn Hosp, Pittsburgh, PA 15224 USA.
[Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Black, Peter M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Coble, JB (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd, Bethesda, MD 20892 USA.
EM jcoble@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
FX This project has been funded in part through an intramural program from
the National Cancer Institute, National Institutes of Health. The
content of this publication does not necessarily reflect the views or
policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply
endorsement by the U. S. government.
NR 35
TC 12
Z9 15
U1 2
U2 2
PU DUKE UNIV PRESS
PI DURHAM
PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2009
VL 11
IS 3
BP 242
EP 249
DI 10.1215/15228517-2009-002
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 459TH
UT WOS:000267132300002
PM 19234232
ER
PT J
AU O'Sullivan, M
Ngo, E
Viswanathan, A
Jouvent, E
Gschwendtner, A
Saemann, PG
Duering, M
Pachai, C
Bousser, MG
Chabriat, H
Dichgans, M
AF O'Sullivan, Mike
Ngo, Elmar
Viswanathan, Anand
Jouvent, Eric
Gschwendtner, Andreas
Saemann, Philipp G.
Duering, Marco
Pachai, Chahin
Bousser, Marie-Germaine
Chabriat, Hugues
Dichgans, Martin
TI Hippocampal volume is an independent predictor of cognitive performance
in CADASIL
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Hippocampus; Vascular dementia; CADASIL; Small vessel disease
ID ISCHEMIC VASCULAR DEMENTIA; ALZHEIMERS-DISEASE; ENTORHINAL CORTEX;
CORTICAL ATROPHY; AD; IMPAIRMENT; MRI; MEMORY; LESIONS; RATES
AB Recent evidence suggests that hippocampal changes are present in vascular cognitive impairment but their importance and relationship with ischaemic mechanisms remain controversial. To investigate these issues we performed MRI and cognitive assessment in a large cohort (n = 144) of patients with CADASIL, a hereditary small vessel disease and model of pure vascular cognitive impairment. Dementia status was ascribed according to DSM-IV and global cognitive function assessed with the Minimental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Hippocampal volume (HV) correlated with age (r= -0.33, p < 0.001), brain volume (r= 0.39, p < 0.001.) and lacunar lesion volume (r= -0.23, p = 0.008), but not white matter lesions or microhaemorrhages. HV was reduced in dementia (2272 +/- 333 mm(3) versus 2642 +/- 349 mm(3), p < 0.001) in the whole cohort and the subgroup progressing to dementia before age 60. HV correlated with MMSE (r = 0.30, p < 0.001), MDRS (r= 0.40, p < 0.001) and in a multivariate model predicted cognition independent of typical vascular lesions and whole brain atrophy. These findings strengthen the view that hippocampal atrophy is an important pathway of cognitive impairment in vascular as well as degenerative disease. (C) 2007 Elsevier Inc. All rights reserved.
C1 [O'Sullivan, Mike; Ngo, Elmar; Gschwendtner, Andreas; Duering, Marco; Dichgans, Martin] Univ Munich, Neurol Klin, Klinikum Grosshadern, D-81377 Munich, Germany.
[Viswanathan, Anand; Jouvent, Eric; Bousser, Marie-Germaine; Chabriat, Hugues] Hop Lariboisiere, Neurol Serv, F-75475 Paris, France.
[Viswanathan, Anand] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Boston, MA 02114 USA.
[Saemann, Philipp G.] Max Planck Inst Psychiat, D-80804 Munich, Germany.
[Pachai, Chahin] Bioimaging Technol SAS, Lyon, France.
RP O'Sullivan, M (reprint author), Univ Munich, Neurol Klin, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.
EM michael.osullivan@med.uni-muenchen.de
RI O'Sullivan, Michael/A-1796-2010; Jouvent, Eric/B-4320-2014; Chabriat,
Hugues/G-5699-2010
OI Jouvent, Eric/0000-0001-7797-2236; Chabriat, Hugues/0000-0001-8436-6074
FU PHRC [AOR 02-001]; Association de Recherche en Neurologie VAsculaire
(ARNEVA); Hopital Lariboisiere, France; Deutsche Forschungsgemeinschaft
[SFB596/TPA4]; EISAI Medical Res. Inc. (Germany); European Neurological
Society; Peel Medical Research Trust
FX This work was supported by PHRC grant AOR 02-001 (DRC/APHP) and
performed with the help of Association de Recherche en Neurologie
VAsculaire (ARNEVA), Hopital Lariboisiere, France, a grant from the
"Journees de Neurologie de Langue Francaise, France", the Deutsche
Forschungsgemeinschaft (SFB596/TPA4), and a grant from EISAI Medical
Res. Inc. (Germany). M.O'S. is an Alexander von Humboldt Fellow and is
also supported by the European Neurological Society and the Peel Medical
Research Trust.
NR 32
TC 28
Z9 28
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUN
PY 2009
VL 30
IS 6
BP 890
EP 897
DI 10.1016/j.neurobiolaging.2007.09.002
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 445PH
UT WOS:000266062300004
PM 17963999
ER
PT J
AU Mayer, EA
Aziz, Q
Coen, S
Kern, M
Labus, JS
Lane, R
Kuo, B
Naliboff, B
Tracey, I
AF Mayer, E. A.
Aziz, Q.
Coen, S.
Kern, M.
Labus, J. S.
Lane, R.
Kuo, B.
Naliboff, B.
Tracey, I.
TI Brain imaging approaches to the study of functional GI disorders: A Rome
Working Team Report
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Review
DE attention; emotion; functional magnetic resonance imaging; irritable
bowel syndrome; positron emission tomography; sex differences; visceral
pain
ID IRRITABLE-BOWEL-SYNDROME; POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR
CINGULATE CORTEX; AVERSIVE VISCERAL STIMULATION; PRIMARY SOMATOSENSORY
CORTEX; GASTRIC FUNDIC DISTENSION; CEREBRAL ACTIVATION;
GENDER-DIFFERENCES; PAIN PERCEPTION; CUTANEOUS PAIN
AB Progresses in the understanding of human brain-gut interactions in health and disease have been limited by the lack of non-invasive techniques to study brain activity. The advent of neuroimaging techniques has made it possible not only to study the structure and function of the brain, but also to characterize signaling system underlying brain function. This article gives a brief overview of relevant functional neuroanatomy, and of the most commonly used brain imaging techniques. It summarizes published functional brain imaging studies using acute visceral stimulation of the oesophagus, stomach and colon in healthy control subjects and patients with functional GI disorders, and briefly discusses pertinent findings from these studies. The article concludes with a critical assessment of published studies, and with recommendations for improved study paradigms and analysis strategies.
C1 [Mayer, E. A.; Labus, J. S.; Naliboff, B.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Med, Los Angeles, CA 90073 USA.
[Mayer, E. A.; Labus, J. S.; Naliboff, B.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Physiol, Los Angeles, CA 90073 USA.
[Mayer, E. A.; Labus, J. S.; Naliboff, B.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Psychiat, Los Angeles, CA 90073 USA.
[Aziz, Q.; Coen, S.] Queen Mary Univ London, Sch Med & Dent, Wingate Inst Neurogastroenterol, Neurogastroenterol Grp, London, England.
[Kern, M.] Med Coll Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA.
[Lane, R.] Univ Arizona, Dept Psychiat, Tucson, AZ USA.
[Lane, R.] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA.
[Lane, R.] Univ Arizona, Dept Neurosci, Tucson, AZ USA.
[Kuo, B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastro Intestinal Unit, Boston, MA USA.
[Tracey, I.] Univ Oxford, John Radcliffe Hosp, FMRIB Ctr,Dept Clin Neurol, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England.
RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Med, Bldg 115 CURE,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM emayer@ucla.edu
RI Coen, Steven/I-4029-2012
FU National Institutes of Health (NIH) [DK 48351, DK 64530, AT 00268];
Department of Veteran's Affairs Medical Research and NIH [NR007768];
[K23DK069614]
FX This review (including Appendix S1 available online as Supporting
Information) is a working team report that was commissioned and
sponsored by the Rome Foundation. The sequence of the authors reflects
their roles in the working team (working team leader and senior author
listed as first and second author). The following authors are supported
by National Institutes of Health (NIH) grants: Emeran A. Mayer (DK
48351, DK 64530 and AT 00268), Bruce Naliboff (Department of Veteran's
Affairs Medical Research and NIH NR007768) and Braden Kuo (K23DK069614).
NR 128
TC 90
Z9 93
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
EI 1365-2982
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD JUN
PY 2009
VL 21
IS 6
BP 579
EP 596
DI 10.1111/j.1365-2982.2009.01304.x
PG 18
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 448DV
UT WOS:000266244200002
PM 19646070
ER
PT J
AU Blackwell, ML
Farrar, CT
Fischl, B
Rosen, BR
AF Blackwell, Megan L.
Farrar, Christian T.
Fischl, Bruce
Rosen, Bruce R.
TI Target-specific contrast agents for magnetic resonance microscopy
SO NEUROIMAGE
LA English
DT Article
ID HUMAN CEREBRAL-CORTEX; HIGH-RESOLUTION MRI; CORTICAL AREAS; HUMAN BRAIN;
CYTOARCHITECTURE; CLASSIFICATION; COMPLEXES; SPECIMENS; STRIATE; SYSTEM
AB High-resolution ex vivo magnetic resonance (MR) imaging can be used to delineate prominent architectonic features in the human brain, but increased contrast is required to visualize more subtle distinctions. To aid MR sensitivity to cell density and myelination, we have begun the development of target-specific paramagnetic contrast agents. This work details the first application of luxol fast blue (LFB), an optical stain for myelin, as a white matter-selective MR contrast agent for human ex vivo brain tissue. Formalin-fixed human visual cortex was imaged with an isotropic resolution between 80 and 150 mu m at 4.7 and 14 T before and after en bloc staining with LFB. Longitudinal (R1) and transverse (R2) relaxation rates in LFB-stained tissue increased proportionally with myelination at both field strengths. Changes in R1 resulted in larger contrast-to-noise ratios (CNR), per unit time, on T1-weighted images between more myelinated cortical layers (IV-VI) and adjacent, superficial layers (I-III) at both field strengths. Specifically, CNR for LFB-treated samples increased by 229 +/- 13% at 4.7 T and 269 +/- 25% at 14 T when compared to controls. Also, additional cortical layers (IVca, IVd, and Va) were resolvable in 14T-MR images of LFB-treated samples but not in control samples. After imaging, samples were sliced in 40-micron sections, mounted, and photographed. Both the macroscopic and microscopic distributions of LFB were found to mimic those of traditional histological preparations. Our results suggest target-specific contrast agents will enable more detailed MR images with applications in imaging pathological ex vivo samples and constructing better MR atlases from ex vivo brains. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Blackwell, Megan L.; Farrar, Christian T.; Fischl, Bruce; Rosen, Bruce R.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Blackwell, Megan L.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Farrar, Christian T.; Fischl, Bruce; Rosen, Bruce R.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA.
RP Blackwell, ML (reprint author), 149 13th St, Charlestown, MA 02129 USA.
EM mlb@nmr.mgh.harvard.edu
FU NCRR NIH HHS [P41 RR014075, P41 RR014075-11, P41-RR14075, U24 RR021382,
U24 RR021382-03]; NIA NIH HHS [K25 AG029415, K25 AG029415-01A1, K25
AG029415-02, K25 AG029415-03, K25 AG029415-04, K25 AG029415-05]; NIBIB
NIH HHS [R01 EB001550, R01 EB001550-04, R01 EB006758, R01 EB006758-03,
R01EB006758, T32 EB001680, T32 EB001680-03, T32EB001680, U54 EB005149,
U54 EB005149-050017]; NINDS NIH HHS [R01 NS052585-01, R01 NS052585, R01
NS052585-01A1]
NR 50
TC 14
Z9 14
U1 5
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUN
PY 2009
VL 46
IS 2
BP 382
EP 393
DI 10.1016/j.neuroimage.2009.01.030
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 440UD
UT WOS:000265724300006
PM 19385012
ER
PT J
AU Islam, T
Kupsch, A
Bruhn, H
Scheurig, C
Schmidt, S
Hoffmann, KT
AF Islam, Tina
Kupsch, Andreas
Bruhn, Harald
Scheurig, Christian
Schmidt, Sein
Hoffmann, Karl-Titus
TI Decreased bilateral cortical representation patterns in writer's cramp:
a functional magnetic resonance imaging study at 3.0 T
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Functional magnetic resonance imaging; Dystonia; Writer's cramp; Brain
activation study
ID TASK-SPECIFIC DYSTONIA; HAND DYSTONIA; MOTOR CORTEX; ACTIVATION;
STIMULATION; INHIBITION; RESPONSES; MRI
AB Functional magnetic resonance imaging was used to characterize patterns of cortical activation in response to sensory and motor tasks in patients with writer's cramp. 17 patients and 17 healthy subjects were examined during finger-tapping, index finger flexion, and electrical median nerve stimulation of both hands during electromyographic monitoring. SPM2 was used to evaluate Brodmann area (BA) 4, 1, 2, 3, 6, 40. Patients showed decreased activation in the left BA 4 with motor tasks of both hands and the left BA 1-3 with right finger-tapping. With left finger-tapping there was bilateral underactivation of single areas of the somatosensory cortex. Patients exhibited decreased activation in the bilateral BA 6 with left motor tasks and in the right BA 6 with right finger-tapping. Patients had decreased activation in bilateral BA 40 with finger-tapping of both hands. The findings suggest decreased baseline activity or an impaired activation in response to motor tasks in BA 1-4, 6, 40 in patients with writer's cramp for the dystonic and the clinically unaffected hand.
C1 [Islam, Tina] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Islam, Tina; Bruhn, Harald; Scheurig, Christian; Hoffmann, Karl-Titus] Charite Univ Med Berlin, Dept Radiol, Berlin, Germany.
[Kupsch, Andreas; Schmidt, Sein] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany.
RP Islam, T (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM tislam1@partners.org
NR 29
TC 12
Z9 12
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1590-1874
J9 NEUROL SCI
JI Neurol. Sci.
PD JUN
PY 2009
VL 30
IS 3
BP 219
EP 226
DI 10.1007/s10072-009-0045-7
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 446SX
UT WOS:000266142600007
PM 19277833
ER
PT J
AU Gorman, AA
Foley, JM
Ettenhofer, ML
Hinkin, CH
van Gorp, WG
AF Gorman, Ashley A.
Foley, Jessica M.
Ettenhofer, Mark L.
Hinkin, Charles H.
van Gorp, Wilfred G.
TI Functional Consequences of HIV-Associated Neuropsychological Impairment
SO NEUROPSYCHOLOGY REVIEW
LA English
DT Review
DE HIV/AIDS; Neuropsychology; Medication adherence; Employment; Driving
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; OLDER-ADULT
DRIVERS; QUALITY-OF-LIFE; MEDICATION ADHERENCE; INFECTED ADULTS;
DRUG-USERS; DRIVING SIMULATOR; SOCIAL SUPPORT; PSYCHIATRIC-DISORDERS
AB This review focuses on the "real world" implications of infection with HIV/AIDS from a neuropsychological perspective. Relevant literature is reviewed which examines the relationships between HIV-associated neuropsychological impairment and employment, driving, medication adherence, mood, fatigue, and interpersonal functioning. Specifically, the relative contributions of medical, cognitive, psychosocial, and psychiatric issues on whether someone with HIV/AIDS will be able to return to work, adhere to a complicated medication regimen, or safely drive a vehicle will be discussed. Methodological issues that arise in the context of measuring medication adherence or driving capacity are also explored. Finally, the impact of HIV/AIDS on mood state, fatigue, and interpersonal relationships are addressed, with particular emphasis on how these variables interact with cognition and independent functioning. The purpose of this review is to integrate neuropsychological findings with their real world correlates of functional behavior in the HIV/AIDS population.
C1 [Gorman, Ashley A.; van Gorp, Wilfred G.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10027 USA.
[Foley, Jessica M.; Ettenhofer, Mark L.; Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Hinkin, Charles H.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Gorman, AA (reprint author), Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10027 USA.
EM ashleyanngorman@yahoo.com
FU NIMH NIH HHS [R01 MH058552, R01 MH058552-02, T32 MH019535]
NR 126
TC 65
Z9 66
U1 5
U2 8
PU CONSULTANTS BUREAU/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-7308
J9 NEUROPSYCHOL REV
JI Neuropsychol. Rev.
PD JUN
PY 2009
VL 19
IS 2
BP 186
EP 203
DI 10.1007/s11065-009-9095-0
PG 18
WC Psychology, Clinical; Neurosciences
SC Psychology; Neurosciences & Neurology
GA 454EQ
UT WOS:000266665400005
PM 19472057
ER
PT J
AU Perlis, RH
Laje, G
Smoller, JW
Fava, M
Rush, AJ
McMahon, FJ
AF Perlis, Roy H.
Laje, Gonzalo
Smoller, Jordan W.
Fava, Maurizio
Rush, A. John
McMahon, Francis J.
TI Genetic and Clinical Predictors of Sexual Dysfunction in
Citalopram-Treated Depressed Patients
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE antidepressant; pharmacogenetic; serotonin; glutamate; adverse effect
ID MEDIAL PREOPTIC AREA; STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES;
ILLNESS RATING-SCALE; REPORT QIDS-SR; QUICK INVENTORY; NITRIC-OXIDE;
ANTIDEPRESSANT TREATMENT; PSYCHOMETRIC EVALUATION; RECEPTOR ANTAGONISTS
AB Sexual dysfunction is a major contributor to treatment discontinuation and nonadherence among patients treated with selective serotonin reuptake inhibitors (SSRIs). The mechanisms by which depressive symptoms in general, as well as SSRI exposure in particular, may worsen sexual function are not known. We examined genetic polymorphisms, including those of the serotonin and glutamate systems, for association with erectile dysfunction, anorgasmia, and decreased libido during citalopram treatment. Clinical data were drawn from a nested case-control cohort derived from the STAR*D study, a multicenter, prospective, effectiveness trial in outpatients with nonpsychotic major depressive disorder (MDD). Self-reports of erectile dysfunction, decreased libido, or difficulty achieving orgasm based on the Patient-Rated Inventory of Side Effects were examined among Caucasian subjects (n = 1473) for whom DNA and adverse effect measures were available, and who were treated openly with citalopram for up to 14 weeks. Of 1473 participants, 799 (54%) reported decreased libido; 525 (36%) reported difficulty achieving orgasm. Of 574 men, 211 (37%) reported erectile dysfunction. Using a set-based test for association, single nucleotide polymorphisms in glutamatergic genes were associated with decreased libido (GRIA3; GRIK2), difficulty achieving orgasm (GRIA1), and difficulty achieving erection (GRIN3A) (experiment-wide permuted p<0.05 for each). Evidence of association persisted after adjustment for baseline clinical and sociodemographic differences. Likewise, evidence of association was similar when the cohort was limited to those who did not report a given adverse event at the first post-baseline visit (ie, those whose adverse events were known to be treatment emergent). These hypothesis-generating analyses suggest the potential for glutamatergic treatment targets for sexual dysfunction during major depressive episodes. Neuropsychopharmacology (2009) 34, 1819-1828; doi:10.1038/npp.2009.4; published online 18 March 2009
C1 [Perlis, Roy H.; Smoller, Jordan W.; Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Perlis, Roy H.; Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Laje, Gonzalo; McMahon, Francis J.] NIMH, Intramural Res Program, Bethesda, MD 20892 USA.
[Rush, A. John] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 185 Cambridge St,6th Floor, Boston, MA 02114 USA.
EM rperlis@partners.org
RI Laje, Gonzalo/L-2654-2014;
OI Laje, Gonzalo/0000-0003-2763-3329; Rush, Augustus/0000-0003-2004-2382;
McMahon, Francis/0000-0002-9469-305X
FU NIMH [N01 MH-90003, K23MH67060]; NARSAD Young Investigator/Sidney R Baer
Jr Foundation Award; Bowman Family Foundation award
FX The Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
study is supported by federal funds from NIMH under contract N01
MH-90003 to the University of Texas Southwestern Medical Center at
Dallas (AJ Rush, principal investigator). Dr Perlis is supported by NIMH
K23MH67060, a NARSAD Young Investigator/Sidney R Baer Jr Foundation
Award, and a Bowman Family Foundation award. Additional support provided
by NIMH Intramural program. We thank Rutgers Cell and DNA Repository for
extracting DNA and providing samples. We appreciate the support of
Forest Laboratories for providing citalopram at no cost to the STAR*D
study. We thank Stephen Wisniewski and Heather Eng for providing the
clinical data. We thank the STAR*D Research Team for conducting the
clinical study and obtaining clinical data and the blood samples for
these analyses. Finally, we thank the study participants without whom
this study would not have been possible.
NR 47
TC 53
Z9 54
U1 4
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2009
VL 34
IS 7
BP 1819
EP 1828
DI 10.1038/npp.2009.4
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 444KR
UT WOS:000265980400018
PM 19295509
ER
PT J
AU Janakiraman, V
Gantz, M
Maynard, S
El-Mohandes, A
AF Janakiraman, Vanitha
Gantz, Marie
Maynard, Sharon
El-Mohandes, Ayman
TI Association of cotinine levels and preeclampsia among African-American
women
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID CIGARETTE SMOKERS; TOBACCO EXPOSURE; PREGNANCY; SMOKING; RISK; NICOTINE
AB Although prior studies have shown that smoking reduces preeclampsia risk, the relationship between nicotine level and preeclampsia risk is not known. Our objective was to study the effects of smoking on the incidence of preeclampsia in African-American women using cotinine, a quantitative marker of nicotine.
We performed a secondary analysis of data collected prospectively in Project District of Columbia Healthy Outcomes of Pregnancy Education. Our study included 724 African-American women. Self-reported smoking, cotinine levels, and pregnancy outcomes were examined.
Some 18% of participants were smokers. Women with salivary cotinine levels greater than 200 ng/ml had infants with lower birth weights and a higher incidence of small-for-gestational-age infants than women with cotinine levels of 200 ng/ml or less. Exact logistic regression analysis revealed that women with salivary cotinine levels greater than 200 ng/ml had a significantly lower incidence of preeclampsia, compared with women with cotinine levels of 200 ng/ml or less, in unadjusted analysis (odds ratio [OR] = 0.16, 95% CI = 0-0.90). After controlling for age, parity, and medical comorbidities, the trend was observed, but the effect was no longer significant (adjusted odds ratio [AOR] = 0.19, 95% CI = 0-1.11). We found no significant differences in preeclampsia rates using lower cutoffs of cotinine exposure. We did not observe a decrease in preeclampsia incidence at low or moderate cotinine levels.
Women with the highest cotinine levels may have a decreased risk for preeclampsia, although this effect was not significant after controlling for other risk factors.
C1 [Janakiraman, Vanitha] George Washington Univ Hosp, Dept Obstet & Gynecol, Washington, DC USA.
[Gantz, Marie] RTI Int, Res Triangle Pk, NC USA.
[Maynard, Sharon] George Washington Univ Hosp, Dept Renal Dis & Hypertens, Washington, DC USA.
[El-Mohandes, Ayman] George Washington Univ Hosp, Sch Publ Hlth, Washington, DC USA.
[El-Mohandes, Ayman] George Washington Univ Hosp, Hlth Serv, Washington, DC USA.
RP Janakiraman, V (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Founders 4th Floor,55 Fruit St, Boston, MA 02114 USA.
EM vjanakiraman@partners.org
FU National Institute of Child Health and Human Development
[5U10HDO36104-10]
FX National Institute of Child Health and Human Development (Grant #
5U10HDO36104-10).
NR 18
TC 3
Z9 3
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD JUN
PY 2009
VL 11
IS 6
BP 679
EP 684
DI 10.1093/ntr/ntp049
PG 6
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 454QX
UT WOS:000266698600014
PM 19395687
ER
PT J
AU Martin, LF
Davalos, DB
Kisley, MA
AF Martin, Laura F.
Davalos, Deana B.
Kisley, Michael A.
TI Nicotine enhances automatic temporal processing as measured by the
mismatch negativity waveform
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID AUDITORY SENSORY MEMORY; EVENT-RELATED POTENTIALS; ELECTROPHYSIOLOGICAL
INDEXES; SCHIZOPHRENIC-PATIENTS; COGNITIVE PERFORMANCE; SELECTIVE
ATTENTION; RECEPTOR ACTIVATION; INTERVAL DURATION; PREFRONTAL CORTEX;
DOPAMINE
AB Cholinergic agonists and, more specifically, nicotine, have been found to enhance a number of cognitive processes. The effect of nicotine on temporal processing is not known. The use of behavioral measures of temporal processing to measure its effect could be confounded by the general effects of nicotine on attention. Mismatch negativity (MMN) has been used as a physiological measure of automatic temporal processing to avoid this potential confound.
A total of 20 subjects (11 nonsmokers and 9 smokers following 2 hr of abstinence) participated in a two-visit single-blind, placebo-controlled crossover study of the effect of nicotine on MMN indices in response to an interstimulus interval deviant.
Nicotine-enhanced MMN amplitudes from baseline recording to postdrug recording greater than did the placebo condition. This enhancement was seen in both nonsmokers and smokers. Nicotine had no significant effect on MMN latency or N100 amplitude or latency.
This is the first study to demonstrate a nicotine-related enhancement of MMN amplitude to an interstimulus interval duration deviant and confirms our hypothesis that nicotine enhances preattentive temporal processing. Nicotinic agonists may represent a potential therapeutic option for individuals with abnormalities in early sensory or temporal processing related to cholinergic system abnormalities. Methodologically, our paradigm of nicotine administration in abstinent smokers is important because it resulted in both minimal withdrawal symptoms and meaningful data that are not attributable solely to relief of withdrawal.
C1 [Martin, Laura F.; Davalos, Deana B.] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA.
[Martin, Laura F.; Davalos, Deana B.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA.
[Davalos, Deana B.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA.
[Kisley, Michael A.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA.
RP Martin, LF (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, 4200 E 9th Ave,C268-71, Denver, CO 80262 USA.
EM laura.martin@uchsc.edu
FU The Veterans Affairs Medical Research Service
FX The Veterans Affairs Medical Research Service
NR 60
TC 21
Z9 21
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD JUN
PY 2009
VL 11
IS 6
BP 698
EP 706
DI 10.1093/ntr/ntp052
PG 9
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 454QX
UT WOS:000266698600017
PM 19436039
ER
PT J
AU Park, ER
Chang, YC
Quinn, V
Regan, S
Cohen, L
Viguera, A
Psaros, C
Ross, K
Rigotti, N
AF Park, Elyse R.
Chang, Yuchiao
Quinn, Virginia
Regan, Susan
Cohen, Lee
Viguera, Adele
Psaros, Christina
Ross, Kaile
Rigotti, Nancy
TI The association of depressive, anxiety, and stress symptoms and
postpartum relapse to smoking: A longitudinal study
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID MAJOR DEPRESSION; NICOTINE DEPENDENCE; PREGNANT-WOMEN; UNITED-STATES;
CESSATION; PREDICTORS; DISORDERS; INTERVENTIONS; PREVENTION; MOTHERS
AB The aim of this prospective repeated measures, mixed-methods observational study was to assess whether depressive, anxiety, and stress symptoms are associated with postpartum relapse to smoking.
A total of 65 women who smoked prior to pregnancy and had not smoked during the last month of pregnancy were recruited at delivery and followed for 24 weeks. Surveys administered at baseline and at 2, 6, 12, and 24 weeks postpartum assessed smoking status and symptoms of depression (Beck Depression Inventory [BDI]), anxiety (Beck Anxiety Inventory [BAI]), and stress (Perceived Stress Scale [PSS]). In-depth interviews were conducted with women who reported smoking.
Although 92% of the participants reported a strong desire to stay quit, 47% resumed smoking by 24 weeks postpartum. Baseline factors associated with smoking at 24 weeks were having had a prior delivery, not being happy about the pregnancy, undergoing counseling for depression or anxiety during pregnancy, and ever having struggled with depression (p < .05). In a repeated measures regression model, the slope of BDI scores from baseline to the 12-week follow-up differed between nonsmokers and smokers (-0.12 vs. +0.11 units/week, p = .03). The slope of PSS scores also differed between nonsmokers and smokers (-0.05 vs. +0.08 units/week, p = .04). In qualitative interviews, most women who relapsed attributed their relapse and continued smoking to negative emotions.
Among women who quit smoking during pregnancy, a worsening of depressive and stress symptoms over 12 weeks postpartum was associated with an increased risk of smoking by 24 weeks.
C1 [Park, Elyse R.; Rigotti, Nancy] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr,Inst Hlth Policy, Boston, MA 02114 USA.
[Park, Elyse R.; Cohen, Lee; Psaros, Christina] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Chang, Yuchiao; Regan, Susan; Rigotti, Nancy] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Quinn, Virginia] Kaiser Permanente So Calif, Res & Evaluat Dept, Pasadena, CA USA.
[Viguera, Adele] Cleveland Clin, Dept Psychiat, Cleveland, OH 44106 USA.
RP Park, ER (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr,Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM epark@partners.org
FU Robert Wood Johnson Smoke Free Families Initiative; American Cancer
Society's Mentored Research Scholar Award [MRSG-005-05-CPPB]; National
Heart, Lung and Blood Institute Midcareer Investigator Award in
Patient-Oriented Research [K24-HL04440]
FX Robert Wood Johnson Smoke Free Families Initiative; American Cancer
Society's Mentored Research Scholar Award (MRSG-005-05-CPPB) to ERP's
work. A National Heart, Lung and Blood Institute Midcareer Investigator
Award in Patient-Oriented Research (# K24-HL04440) to NR's effort.
NR 35
TC 53
Z9 56
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD JUN
PY 2009
VL 11
IS 6
BP 707
EP 714
DI 10.1093/ntr/ntp053
PG 8
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 454QX
UT WOS:000266698600018
PM 19436040
ER
PT J
AU Cauwels, A
Buys, E
Thoonen, R
Ceary, L
Delanghe, J
Shiva, S
Brouckaert, P
AF Cauwels, Anie
Buys, Emmanuel
Thoonen, Robrecht
Ceary, Lisa
Delanghe, Joris
Shiva, Sruti
Brouckaert, Peter
TI Nitrite protection against morbidity and mortality associated with
inflammatory shock in mice
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Meeting Abstract
CT 3rd International Role of Nitrite in Physiology, Pathophysiology and
Therapeutics Meeting
CY JUN 17-18, 2009
CL Stockholm, SWEDEN
SP Karolinska Inst, Dept Physiol Pharmacol, Univ Pittsburgh, Vasc Med Inst, Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hope Pharmaceut
C1 [Cauwels, Anie; Thoonen, Robrecht; Brouckaert, Peter] Univ Ghent, Ghent, Belgium.
[Buys, Emmanuel] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Buys, Emmanuel] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ceary, Lisa; Shiva, Sruti] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Delanghe, Joris] Ghent Univ Hosp, Ghent, Belgium.
RI Ji, Haofeng/G-6206-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD JUN
PY 2009
VL 20
BP S49
EP S49
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 455LL
UT WOS:000266761400088
ER
PT J
AU Cauwels, A
Buys, E
Thoonen, R
Geary, L
Delanghe, J
Shiva, S
Brouckaert, P
AF Cauwels, Anje
Buys, Emmanuel
Thoonen, Robrecht
Geary, Lisa
Delanghe, Joris
Shiva, Sruti
Brouckaert, Peter
TI Nitrite protection against morbidity and mortality associated with
inflammatory shock in mice
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Meeting Abstract
CT 3rd International Role of Nitrite in Physiology, Pathophysiology and
Therapeutics Meeting
CY JUN 17-18, 2009
CL Stockholm, SWEDEN
SP Karolinska Inst, Dept Physiol Pharmacol, Univ Pittsburgh, Vasc Med Inst, Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hope Pharmaceut
C1 [Cauwels, Anje; Thoonen, Robrecht; Brouckaert, Peter] Univ Ghent, Ghent, Belgium.
[Buys, Emmanuel] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Buys, Emmanuel] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Geary, Lisa; Shiva, Sruti] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Delanghe, Joris] Ghent Univ Hosp, Ghent, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD JUN
PY 2009
VL 20
BP S32
EP S32
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 455LL
UT WOS:000266761400036
ER
PT J
AU Huang, P
Kashiwagi, S
Atochin, D
Li, Q
Schleicher, M
Earle, J
Pong, T
Lee-Huang, S
Moncada, S
Sessa, W
AF Huang, Paul
Kashiwagi, Satoshi
Atochin, Dmitriy
Li, Qian
Schleicher, Michael
Earle, John
Pong, Terrence
Lee-Huang, Sylvia
Moncada, Salvador
Sessa, William
TI Enos S1177 phosphorylation mediates metabolic energy expenditure and
insulin sensitivity in knockin mice
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Meeting Abstract
CT 3rd International Role of Nitrite in Physiology, Pathophysiology and
Therapeutics Meeting
CY JUN 17-18, 2009
CL Stockholm, SWEDEN
SP Karolinska Inst, Dept Physiol Pharmacol, Univ Pittsburgh, Vasc Med Inst, Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hope Pharmaceut
C1 [Huang, Paul; Kashiwagi, Satoshi; Atochin, Dmitriy; Li, Qian; Earle, John; Pong, Terrence] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Schleicher, Michael; Sessa, William] Yale Univ, Sch Med, New Haven, CT 06520 USA.
[Lee-Huang, Sylvia] NYU, Sch Med, New York, NY 10003 USA.
[Moncada, Salvador] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England.
RI Atochin, Dmitriy/Q-3150-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD JUN
PY 2009
VL 20
BP S36
EP S36
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 455LL
UT WOS:000266761400049
ER
PT J
AU Ney, DM
Weiss, JM
Kind, AJH
Robbins, J
AF Ney, Denise M.
Weiss, Jennifer M.
Kind, Amy J. H.
Robbins, JoAnne
TI Senescent Swallowing: Impact, Strategies, and Interventions
SO NUTRITION IN CLINICAL PRACTICE
LA English
DT Review
DE aging; deglutition disorders; enteral nutrition; pneumonia;
malnutrition; dehydration
ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ACUTE ISCHEMIC-STROKE; QOL OUTCOMES
TOOL; OF-THE-LITERATURE; OLDER-ADULTS; SKELETAL-MUSCLE; OROPHARYNGEAL
DYSPHAGIA; DIETARY-PROTEIN; BOUNCING-BACK; SWAL-QOL
AB The risk for disordered oropharyngeal swallowing (dysphagia) increases with age. Loss of swallowing function can have devastating health implications, including dehydration, malnutrition, pneumonia, and reduced quality of life. Age-related changes increase risk for dysphagia. First, natural, healthy aging takes its toll on head and neck anatomy and physiologic and neural mechanisms underpinning swallowing function. This progression of change contributes to alterations in the swallowing in healthy older adults and is termed presbyphagia, naturally diminishing functional reserve. Second, disease prevalence increases with age, and dysphagia is a comorbidity of many age-related diseases and/or their treatments. Sensory changes, medication, sarcopenia, and age-related diseases are discussed herein. Recent findings that health complications are associated with dysphagia are presented. Nutrient requirements, fluid intake, and nutrition assessment for older adults are reviewed relative to dysphagia. Dysphagia screening and the pros and Coils Of tube feeding as a solution are discussed. Optimal intervention strategies for elders with dysphagia ranging from compensatory interventions to more rigorous exercise approaches are presented. Compelling evidence of improved functional swallowing and eating Outcomes resulting from active rehabilitation focusing on increasing strength of head and neck Musculature is provided. In summary, although oropharyngeal dysphagia may be life threatening, so are some of the traditional alternatives, particularly for frail, elderly patients. Although the state of the evidence calls for more research, this review indicates that the behavioral, dietary, and environmental modifications emerging in this past decade are compassionate, promising, and, in many cases, preferred alternatives to the always present option of tube feuding. (Nutr Clin Pract. 2009;24:395-413)
C1 Univ Wisconsin, Dept Nutr Sci, Madison, WI 53705 USA.
Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA.
RP Robbins, J (reprint author), Univ Wisconsin, VA Hosp GRECC, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA.
EM jrobbin2@wisc.edu
FU AHRQ HHS [HS000083, HS000083-12, T32 HS000083]; NCRR NIH HHS [UL1
RR025011-03, UL1 RR025011, UL1 RR025011-01, UL1 RR025011-02]; None [T32
HS000083-12]
NR 105
TC 84
Z9 95
U1 6
U2 30
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0884-5336
J9 NUTR CLIN PRACT
JI Nutr. Clin. Pract.
PD JUN-JUL
PY 2009
VL 24
IS 3
BP 395
EP 413
DI 10.1177/0884533609332005
PG 19
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 454YA
UT WOS:000266719000011
PM 19483069
ER
PT J
AU Walsh, JR
White, AA
Greaney, ML
AF Walsh, Jennifer R.
White, Adrienne A.
Greaney, Mary L.
TI Using focus groups to identify factors affecting healthy weight
maintenance in college men
SO NUTRITION RESEARCH
LA English
DT Article
DE Obesity; Weight perception; Focus groups; Male; Young adult; Internet;
Health behavior; Human
ID 3-FACTOR EATING QUESTIONNAIRE; PHYSICAL-ACTIVITY; YOUNG-ADULTS;
PERCEIVED BENEFITS; GENDER-DIFFERENCES; DIETARY RESTRAINT; FOOD CHOICE;
BODY-IMAGE; STUDENTS; WOMEN
AB Healthful eating and physical activity are important for healthy weight maintenance. The hypothesis for this study was that college-aged men would perceive factors affecting eating and physical activity as both contributing to and inhibiting healthy weight maintenance. The overall objective was to explore how men view weight maintenance in the context of these aspects. Subjects (n = 47, mean age = 20.3 +/- 1.7 years) completed an online survey, including the 51-item Three-Factor Eating Questionnaire, and participated in I of 6 focus groups. Three face-to-face and 3 online synchronous groups were conducted using a 15-question discussion guide to identify weight maintenance issues around eating, physical activity, and body perceptions. Weight satisfaction decreased with increase in both dietary restraint and disinhibition. Number of attempts to lose weight was positively associated with BMI (r [44] = .465, P = .01) and dietary restraint (r [44] = .515, P = .01). Findings from both focus group formats were similar. Motivators (sports performance/fitness, self-esteem, attractiveness, long-term health) were similar for eating healthfully and being physically active; however, more motivators to be physically active than to eat healthfully emerged. Enablers for eating healthfully included liking the taste, availability of healthful foods, using food rules to guide intake, having a habit of healthful eating, and internal drive/will. Barriers to healthful eating included fat in dairy foods, fruit and vegetable taste, and quick spoilage. Barriers to being physically active included lack of time/time management, obligations, being lazy, and girlfriends. Results may be used to inform future obesity prevention interventions. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Walsh, Jennifer R.; White, Adrienne A.] Univ Maine, Dept Food Sci & Human Nutr, Orono, ME 04469 USA.
[Greaney, Mary L.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
RP White, AA (reprint author), Univ Maine, Dept Food Sci & Human Nutr, Orono, ME 04469 USA.
EM adrienne.white@umit.maine.edu
FU Maine Agricultural and Forest Experiment Station [3051]; Graduate
Student Government; Initiative for Future Agriculture and Food Systems
FX This research was supported by the Maine Agricultural and Forest
Experiment Station #3051, Graduate Student Government, and an Initiative
for Future Agriculture and Food Systems grant. We thank Katherine
LaChance for her assistance with conducting the focus groups, Breanna
Lynch for focus group analyses, Dr. Philip Pratt for statistical
analysis, and Dr. Julie Milan and Kimberly Yerxa for their technical
support of the online survey.
NR 45
TC 13
Z9 13
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD JUN
PY 2009
VL 29
IS 6
BP 371
EP 378
DI 10.1016/j.nutres.2009.04.002
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 481RX
UT WOS:000268830500002
PM 19628102
ER
PT J
AU Berman, P
Collins, M
Baumgarten, I
Seoighe, C
Jennings, CL
Joffe, Y
Lambert, EV
Levitt, NS
Faulenbach, MV
Kahn, SE
Goedecke, JH
AF Berman, Peter
Collins, Malcolm
Baumgarten, Ingrid
Seoighe, Cathal
Jennings, Courtney L.
Joffe, Yael
Lambert, Estelle V.
Levitt, Naomi S.
Faulenbach, Mirjam V.
Kahn, Steven E.
Goedecke, Julia H.
TI Association Between the 4 bp Proinsulin Gene Insertion Polymorphism
(IVS-69) and Body Composition in Black South African Women
SO OBESITY
LA English
DT Article
ID SPLICE-VARIANT; OBESITY; TRANSLATION
AB The objective of the study was to examine the association between a functional 4 bp proinsulin gene insertion polymorphism (IVS-69), fasting insulin concentrations, and body composition in black South African women. Body composition, body fat distribution, fasting glucose and insulin concentrations, and IVS-69 genotype were measured in 115 normal-weight (BMI < 25 kg/ m(2)) and 138 obese (BMI >= 30 kg/m(2)) premenopausal women. The frequency of the insertion allele was significantly higher in the class 2 obese (BMI >= 35kg/m(2)) compared with the normal-weight group (P = 0.029). Obese subjects with the insertion allele had greater fat mass (42.3 +/- 0.9 vs. 38.9 +/- 0.9 kg, P = 0.034) and fat-free soft tissue mass (47.4 +/- 0.6 vs. 45.1 +/- 0.6 kg, P = 0.014), and more abdominal subcutaneous adipose tissue (SAT, 595 +/- 17 vs. 531 +/- 17 cm(2), P = 0.025) but not visceral fat (P = 0.739), than obese homozygotes for the wild-type allele. Only SAT was greater in normal-weight subjects with the insertion allele (P = 0.048). There were no differences in fasting insulin or glucose levels between subjects with the insertion allele or homozygotes for the wild-type allele in the normal-weight or obese groups. In conclusion, the 4 bp proinsulin gene insertion allele is associated with extreme obesity, reflected by greater fat-free soft tissue mass and fat mass, particularly SAT, in obese black South African women.
C1 [Berman, Peter; Baumgarten, Ingrid] Univ Cape Town, Div Chem Pathol, ZA-7925 Cape Town, South Africa.
[Collins, Malcolm; Jennings, Courtney L.; Joffe, Yael; Lambert, Estelle V.; Goedecke, Julia H.] Univ Cape Town, MRC Res Unit Exercise Sci & Sports Med, Dept Human Biol, ZA-7925 Cape Town, South Africa.
[Collins, Malcolm; Goedecke, Julia H.] S African MRC, Cape Town, South Africa.
[Seoighe, Cathal] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
[Seoighe, Cathal] Natl Univ Ireland, Dept Math Stat & Appl Math, Galway, Ireland.
[Levitt, Naomi S.] Univ Cape Town, Dept Med, Endocrine Unit, ZA-7925 Cape Town, South Africa.
[Faulenbach, Mirjam V.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Faulenbach, Mirjam V.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Berman, P (reprint author), Univ Cape Town, Div Chem Pathol, ZA-7925 Cape Town, South Africa.
EM peter.berman@uct.ac.za
RI Collins, Malcolm/G-4046-2011; Goedecke, Julia/J-8628-2013; Goedecke,
Julia/E-1820-2016;
OI Collins, Malcolm/0000-0002-2564-0480; Goedecke,
Julia/0000-0001-6795-4771; Goedecke, Julia/0000-0001-6795-4771; Kahn,
Steven/0000-0001-7307-9002
FU National Research Foundation of South Africa; South African Medical
Research Council; International Atomic Energy Agency; University of Cape
Town; United States Department of Veterans Affairs
FX We are grateful to Hendriena Victor and Judy Belonje for their technical
assistance. We also thank Jack Bergman, Naomi Fenton, and Linda
Bewerunge for performing the scans. This study was funded by the
National Research Foundation of South Africa, the South African Medical
Research Council, the International Atomic Energy Agency, the University
of Cape Town and the United States Department of Veterans Affairs.
NR 11
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD JUN
PY 2009
VL 17
IS 6
BP 1298
EP 1300
DI 10.1038/oby.2009.40
PG 3
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 450EG
UT WOS:000266383200032
PM 19247282
ER
PT J
AU Ahmad, SM
Esmaeli, B
Williams, M
Nguyen, J
Fay, A
Woog, J
Selvadurai, D
Rootman, J
Weis, E
Selva, D
Mcnab, A
DeAngelis, D
Calle, A
Lopez, A
AF Ahmad, S. Mehdi
Esmaeli, Bita
Williams, Michelle
Nguyen, John
Fay, Aaron
Woog, John
Selvadurai, Deepan
Rootman, Jack
Weis, Ezekiel
Selva, Dinesh
McNab, Alan
DeAngelis, Dan
Calle, Alberto
Lopez, Adriana
TI American Joint Committee on Cancer Classification Predicts Outcome of
Patients with Lacrimal Gland Adenoid Cystic Carcinoma
SO OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT 111th Annual Meeting of the American-Academy-of-Ophthalmology
CY NOV 09-13, 2007
CL New Orleans, LA
SP Amer Acad Ophthalmol
ID EPITHELIAL TUMORS; ADENOCYSTIC CARCINOMA; SURGICAL-MANAGEMENT;
CHEMOTHERAPY; RADIOTHERAPY; NEOPLASMS; NECK; HEAD
AB Purpose: To investigate whether American Joint Committee on Cancer (AJCC) classification at initial diagnosis of lacrimal gland adenoid cystic carcinoma predicts outcome of treatment on local recurrence.
Design: Retrospective chart review.
Participants: Consecutive patients with adenoid cystic carcinoma of the lacrimal gland treated at 8 institutions between January 1986 and December 2007.
Methods: Clinical records, including pathology reports and imaging studies, were reviewed.
Main Outcome Measures: AJCC classification, histologic subtype, local recurrence rate, and survival.
Results: AJCC classification at initial diagnosis was assessable for 53 patients and was as follows: T1N0M0, 7 patients; T2N0M0, 8 patients; T3aN0M0, 14 patients; T3aNxM0, 1 patient; T3aN0M1, 1 patient; T3bN0M0, 13 patients; T3bN0M1, 1 patient; T4aN0M0, 2 patients; T4bN0M0, 4 patients; T4bN0M1, 1 patient; and T4bNXM0, 1 patient. Thirty-eight (72%) of the 53 patients had >T3 tumors at presentation. Of the 38 patients with >T3 tumors, 20 were treated with orbital exenteration and postoperative adjuvant radiotherapy (RT), 6 were treated with orbital exenteration without RT, and 12 were treated with globe-preserving surgery (110 with RT and 2 without RT). Of the 15 patients with T3 tumors, the risk of local recurrence (in the orbit or skull base) was higher in patients treated with conservative surgery as opposed to orbital exenteration and RT. Only 4 (20%) of the 20 patients treated with orbital exenteration and RT had local recurrence, compared with 3 (50%) of the 6 patients treated with orbital exenteration without RT and 8 (67%) of the 12 patients treated with globe-preserving surgery. Overall, 17 (45%) of the 38 patients with >T3 tumors and only 1 (7%) of the 15 patients with T3 disease at initial diagnosis correlates with worse outcomes than does AJCC .99).
Conclusion: ASL imaging provides clinically relevant information regarding tumor viability in RCC lines that respond to sorafenib. (C) RSNA, 2009
C1 [Schor-Bardach, Rachel; Solazzo, Stephanie A.; Goldberg, S. Nahum] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Minimally Invas Tumor Therapy Lab, Boston, MA 02215 USA.
[Alsop, David C.; Pedrosa, Ivan; Wang, Xiaoen; Marquis, Robert P.; Lenkinski, Robert E.; Goldberg, S. Nahum] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
[Atkins, Michael B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA.
[Regan, Meredith] Brigham & Womens Hosp, Dept Stat, Boston, MA 02115 USA.
[Signoretti, Sabina] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Schor-Bardach, Rachel; Alsop, David C.; Pedrosa, Ivan; Solazzo, Stephanie A.; Wang, Xiaoen; Marquis, Robert P.; Atkins, Michael B.; Regan, Meredith; Signoretti, Sabina; Lenkinski, Robert E.; Goldberg, S. Nahum] Dana Farber Harvard Canc Ctr Renal Canc SPORE, Dana Farber Canc Inst, Boston, MA USA.
RP Goldberg, SN (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Minimally Invas Tumor Therapy Lab, 1 Deaconess Rd,WCC 308-B, Boston, MA 02215 USA.
EM sgoldber@bidmc.harvard.edu
RI Alsop, David/J-5764-2013; Lenkinski, Robert/F-9045-2014;
OI Alsop, David/0000-0002-8206-1995; Lenkinski, Robert/0000-0001-7371-5048
FU National Cancer Institute Dana-Farber/Harvard Cancer Center Renal Center
SPORE [1 P50 CA10194-01, 5 R21 CA121570]
FX This research was supported by National Cancer Institute
Dana-Farber/Harvard Cancer Center Renal Center SPORE grants (1 P50
CA10194-01 and 5 R21 CA121570).
NR 54
TC 54
Z9 56
U1 1
U2 21
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUN
PY 2009
VL 251
IS 3
BP 731
EP 742
DI 10.1148/radiol.2521081059
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 475MD
UT WOS:000268362700015
PM 19474376
ER
PT J
AU Sheth, RA
Tam, JM
Maricevich, MA
Josephson, L
Mahmood, U
AF Sheth, Rahul A.
Tam, Jenny M.
Maricevich, Marco A.
Josephson, Lee
Mahmood, Umar
TI Quantitative Endovascular Fluorescence-based Molecular Imaging through
Blood of Arterial Wall Inflammation
SO RADIOLOGY
LA English
DT Article
ID ABDOMINAL AORTIC-ANEURYSM; INTRAVASCULAR ULTRASOUND; MICE
AB Purpose: To evaluate an author-developed normalization algorithm for quantitative imaging of optical molecular probes through blood and to assess, in the rat aorta after focal aortic injury, the feasibility of measuring protease activity by using this method.
Materials and Methods: This study was performed according to a protocol approved by the institutional animal care committee. A Monte Carlo simulation was used to determine the pair of near-infrared (NIR) dyes that was best suited for the normalization algorithm. The authors tested the correction method in vitro and in vivo by injecting free dye mixtures intramurally in the aortas of four rats. The potential clinical utility was then evaluated by applying the method to the endovascular measurement of protease activity in a rat model of focal aortic injury.
Results: When the Monte Carlo simulation was used in the normalization algorithm, it was predicted that the intensities of signals from two NIR dyes would vary +/- 3% across 1 mm of blood compared with the intensity of the raw fluorochrome signal, which would vary +/- 60%. This result was validated in vitro. Endovascular imaging of free dye collections revealed that clinically relevant, uncontrollable differences in the amount of blood intervening between the imaging catheter and the dye collection precipitated dramatic variations in raw NIR fluorescence. However, use of the correction method resolved these variations such that the measured signal intensity correlated well with the different dye concentrations in the different animals. Moreover, endovascular imaging of the focal aortic injury model enabled successful measurement of enzyme activity in the walls of the rat aortas.
Conclusion: The authors implemented a correction method for quantitative real-time endovascular imaging of fluorescence that enables one to resolve the attenuating effects of blood on NIR signal. (C) RSNA, 2009
C1 [Sheth, Rahul A.; Tam, Jenny M.; Maricevich, Marco A.; Josephson, Lee; Mahmood, Umar] Harvard Univ, Sch Med, Ctr Mol Imaging Res, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mahmood, U (reprint author), Harvard Univ, Sch Med, Ctr Mol Imaging Res, Massachusetts Gen Hosp, 185 Charles St,Simches 8226, Boston, MA 02114 USA.
EM mahmood@helix.mgh.harvard.edu
FU National Institutes of Health [R01-EB001872, R24-CA92782]
FX This research was supported by the National Institutes of Health (grants
R01-EB001872, R24-CA92782).
NR 16
TC 11
Z9 11
U1 0
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUN
PY 2009
VL 251
IS 3
BP 813
EP 821
DI 10.1148/radiol.2513081450
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 475MD
UT WOS:000268362700024
PM 19474377
ER
PT J
AU Woods, DC
Schorey, JS
Johnson, AL
AF Woods, Dori C.
Schorey, Jeffrey S.
Johnson, A. L.
TI Toll-like receptor signaling in hen ovarian granulosa cells is dependent
on stage of follicle maturation
SO REPRODUCTION
LA English
DT Article
ID ENTERICA SEROVAR TYPHIMURIUM; MESSENGER-RIBONUCLEIC-ACID;
FUNCTIONAL-CHARACTERIZATION; SALMONELLA-ENTERITIDIS; OVULATORY FOLLICLE;
MOLECULAR-CLONING; DOMESTIC HEN; IN-VITRO; EXPRESSION; IDENTIFICATION
AB The recent identification of toll-like receptor (TLR) signaling within ovarian granulosa cells has broad implications for ovarian physiology. Functions of TLRs within granulosa cells of the laying hen are of particular interest due to the method of transovarian transmission of Salmonella enteritidis, which results in egg contamination. This study utilized hen granulosa cells to evaluate the expression and function of Callus TLR-signaling at distinct stages of follicular maturity. Data presented herein demonstrate the presence of TLR2, TLR4, and TLR15 mRNAs in undifferentiated granulosa cells from prehierarchal follicles and differentiated granulosa cells from preovulatory follicles, together with mRNAs encoding adaptor proteins and signaling components required for TLR signaling gene. Treatment with lipopolysaccharide (LPS) or LH, in vitro, led to the differential regulation of TLRs based on the stage of follicle maturation, with the largest (H) follicle granulosa cells having the most rapid response. Furthermore, treatment with LIPS resulted in attenuation of agonist-induced progesterone synthesis in undifferentiated, but not differentiated, granulosa cells. Additionally, undifferentiated granulosa cells were significantly more sensitive to LPS-induced apoptosis than differentiated granulosa cells from the F1 follicle. Together, these data provide evidence for a complete and functional TLR signaling pathway in hen granulosa cells, with effects on steroidogenesis and cell viability dependent upon stage of maturation. These differences may reflect the susceptibility of granulosa cells at early stages of maturation to undergo apoptosis in response to select pathogenic stimuli, thus attenuating transovarian transmission, whereas granulosa cells from preovulatory follicles are comparably resistant to LPS-mediated apoptosis. Reproduction (2009) 137 987-996
C1 [Woods, Dori C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Ctr Reprod Biol Vincent Obstet & Gynecol, Cambridge, MA 02138 USA.
[Woods, Dori C.; Schorey, Jeffrey S.; Johnson, A. L.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.
[Woods, Dori C.; Schorey, Jeffrey S.; Johnson, A. L.] Univ Notre Dame, Walther Canc Res Ctr, Notre Dame, IN 46556 USA.
RP Woods, DC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Ctr Reprod Biol Vincent Obstet & Gynecol, Cambridge, MA 02138 USA.
EM dwoods2@partners.org
FU National Research Initiative Competitive [2007-35203-18085]; USDA
Cooperative State Research, Education, and Extension Service.
FX This work was supported by National Research Initiative Competitive
Grant no. 2007-35203-18085 from the USDA Cooperative State Research,
Education, and Extension Service.
NR 43
TC 28
Z9 30
U1 1
U2 8
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1470-1626
J9 REPRODUCTION
JI Reproduction
PD JUN
PY 2009
VL 137
IS 6
BP 987
EP 996
DI 10.1530/REP-08-0320
PG 10
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA 454LK
UT WOS:000266683200010
PM 19336472
ER
PT J
AU Sun, Y
Park, J
Stephens, DN
Jo, JA
Sun, L
Cannata, JM
Saroufeem, RMG
Shung, KK
Marcu, L
AF Sun, Yang
Park, Jesung
Stephens, Douglas N.
Jo, Javier A.
Sun, Lei
Cannata, Jonathan M.
Saroufeem, Ramez M. G.
Shung, K. Kirk
Marcu, Laura
TI Development of a dual-modal tissue diagnostic system combining
time-resolved fluorescence spectroscopy and ultrasonic backscatter
microscopy
SO REVIEW OF SCIENTIFIC INSTRUMENTS
LA English
DT Article
DE backscatter; biochemistry; biological tissues; biomedical optical
imaging; biomedical transducers; biomedical ultrasonics; cardiology;
diseases; fluorescence; laser applications in medicine; optical
microscopy; phantoms; time resolved spectroscopy
ID INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; CORONARY-ARTERIES;
IN-VIVO; VULNERABLE PLAQUE; TRANSDUCERS; ULTRAVIOLET; LESIONS; MODEL
AB We report a tissue diagnostic system which combines two complementary techniques of time-resolved laser-induced fluorescence spectroscopy (TR-LIFS) and ultrasonic backscatter microscopy (UBM). TR-LIFS evaluates the biochemical composition of tissue, while UBM provides tissue microanatomy and enables localization of the region of diagnostic interest. The TR-LIFS component consists of an optical fiber-based time-domain apparatus including a spectrometer, gated multichannel plate photomultiplier, and fast digitizer. It records the fluorescence with high sensitivity (nM concentration range) and time resolution as low as 300 ps. The UBM system consists of a transducer, pulser, receiving circuit, and positioning stage. The transducer used here is 45 MHz, unfocused, with axial and lateral resolutions 38 and 200 mu m. Validation of the hybrid system and ultrasonic and spectroscopic data coregistration were conducted both in vitro (tissue phantom) and ex vivo (atherosclerotic tissue specimens of human aorta). Standard histopathological analysis of tissue samples was used to validate the UBM-TRLIFS data. Current results have demonstrated that spatially correlated UBM and TR-LIFS data provide complementary characterization of both morphology (necrotic core and calcium deposits) and biochemistry (collagen, elastin, and lipid features) of the atherosclerotic plaques at the same location. Thus, a combination of fluorescence spectroscopy with ultrasound imaging would allow for better identification of features associated with tissue pathologies. Current design and performance of the hybrid system suggests potential applications in clinical diagnosis of atherosclerotic plaque.
C1 [Saroufeem, Ramez M. G.; Marcu, Laura] Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA.
[Park, Jesung] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol,Wellman Ctr Photomed, Boston, MA 02114 USA.
[Jo, Javier A.] Texas A&M Univ, College Stn, TX 77843 USA.
[Sun, Lei] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China.
[Sun, Lei; Cannata, Jonathan M.; Shung, K. Kirk] Univ So Calif, Los Angeles, CA 90089 USA.
RP Marcu, L (reprint author), Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA.
EM lmarcu@ucdavis.edu
RI SUN, Lei/G-3350-2014
OI SUN, Lei/0000-0001-7047-9529
FU National Institutes of Health Research [2R01HL067377]
FX The authors would like to acknowledge Dr. Qifa Zhou, Dr. Ruibin Liu, and
Jay Williams for making the ultrasound transducers. We would like to
thank Dr. Yinghua Sun for fabrication of optical fibers and Jen Phipps
for assisting with the histopathology evaluation, Dr. Kuo-Chih Liao for
guidance of the phantom design, and Jerry Wu for fabrication of UBM
motor enclosure. We also want to thank Dr. Paul Dayton and Jonathan Poon
for fabrication of the motion stage adapter, and Dr. Yibao Wu for many
helpful discussions about hardware design. This work was supported by
the National Institutes of Health Research Grant No. 2R01HL067377.
NR 33
TC 18
Z9 18
U1 0
U2 4
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
MELVILLE, NY 11747-4501 USA
SN 0034-6748
J9 REV SCI INSTRUM
JI Rev. Sci. Instrum.
PD JUN
PY 2009
VL 80
IS 6
AR 065104
DI 10.1063/1.3142478
PG 7
WC Instruments & Instrumentation; Physics, Applied
SC Instruments & Instrumentation; Physics
GA 465PZ
UT WOS:000267600600037
PM 19566223
ER
PT J
AU Kreher, DA
Goff, D
Kuperberg, GR
AF Kreher, Donna A.
Goff, Donald
Kuperberg, Gina R.
TI Why all the confusion? Experimental task explains discrepant semantic
priming effects in schizophrenia under "automatic" conditions: Evidence
from Event-Related Potentials
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Semantic priming; Schizophrenia; ERPs; Task
ID THOUGHT-DISORDER; COMMUNICATION DISORDERS; SPREADING ACTIVATION; WORD
PRONUNCIATION; LEXICAL DECISION; NETWORK; FACILITATION; REPETITION;
HANDEDNESS; RETRIEVAL
AB The schizophrenia research literature contains many differing accounts of semantic memory function in schizophrenia as assessed through the semantic priming paradigm. Most recently, Event-Related Potentials (ERPs) have been used to demonstrate both increased and decreased semantic priming at a neural level in schizophrenia patients, relative to healthy controls. The present study used ERPs to investigate the role of behavioral task in determining neural semantic priming effects in schizophrenia. The same schizophrenia patients and healthy controls completed two experiments in which word stimuli were identical, and the time between the onset of prime and target remained constant at 350 ms: in the first, participants monitored for words within a particular semantic category that appeared only in filler items (implicit task); in the second, participants explicitly rated the relatedness of word-pairs (explicit task). In the explicit task, schizophrenia patients showed reduced direct and indirect semantic priming in comparison with healthy controls. In contrast, in the implicit task, schizophrenia patients showed normal or, in positively thought-disordered patients, increased direct and indirect N400 priming effects compared with healthy controls. These data confirm that, although schizophrenia patients with positive thought disorder may show an abnormally increased automatic spreading activation, the introduction of semantic decision-making can result in abnormally reduced semantic priming in schizophrenia, even when other experimental conditions bias toward automatic processing. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Kreher, Donna A.; Kuperberg, Gina R.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA.
[Goff, Donald; Kuperberg, Gina R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02129 USA.
[Goff, Donald; Kuperberg, Gina R.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
RP Kreher, DA (reprint author), Univ Massachusetts, 135 Hicks Way, Amherst, MA 01003 USA.
EM dkreher@psych.umass.edu
FU NICHD NIH HHS [R01 HD025889-12, R01 HD025889, R37 HD025889, R01
HD043251-03, R01 HD043251, R01 HD25889]; NIMH NIH HHS [R01 MH071635-04,
R01 MH071635]
NR 49
TC 35
Z9 36
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2009
VL 111
IS 1-3
BP 174
EP 181
DI 10.1016/j.schres.2009.03.013
PG 8
WC Psychiatry
SC Psychiatry
GA 455GH
UT WOS:000266745900023
PM 19386472
ER
PT J
AU Dave, ZS
Li, Y
AF Dave, Zhao Sihai
Li Yi
TI A note on Optimal weights and variable selections for multivariate
survival data
SO SCIENCE IN CHINA SERIES A-MATHEMATICS
LA English
DT Article
C1 [Dave, Zhao Sihai; Li Yi] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
RP Dave, ZS (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
EM szhao@fas.harvard.edu; yili@jimmy.harvard.edu
FU NCI NIH HHS [R01 CA095747-07, R01 CA095747]
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9283
J9 SCI CHINA SER A
JI Sci. China Ser. A-Math.
PD JUN
PY 2009
VL 52
IS 6
BP 1131
EP 1133
PG 3
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 457KT
UT WOS:000266927600009
PM 20414478
ER
PT J
AU San-Juan, OD
Chiappa, KH
Costello, DJ
Cole, AJ
AF San-juan, O. D.
Chiappa, K. H.
Costello, D. J.
Cole, A. J.
TI Periodic epileptiform discharges in hypoxic encephalopathy: BiPLEDs and
GPEDs as a poor prognosis for survival
SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
LA English
DT Article
DE PLEDs; BiPLEDs; GPEDs; Hypoxic encephalopathy; Prognosis
ID TRAUMATIC ENCEPHALOPATHIES; CLINICAL-SIGNIFICANCE; POSTANOXIC COMA; EEG
PATTERNS; NEUROLOGY; ARREST
AB Introduction: Electrophysiologic tests in hypoxic encephalopathy consist of EEG and evoked/event-related potential studies. In most studies the generalized periodic epileptiform complexes have been reported combined with other EEG patterns and were indicators of a poor outcome in different etiologies of hypoxic encephalopathy (HE), but these have rarely been examined independently.
Methodology: We analyzed from 2000 to 2007 the outcome of patients with HE and generalized periodic epileptiform complexes. We abstracted and tabulated clinical information, imaging findings, and outcome from the medical records.
Results: We found 52 patients in our database. Fourteen patients (eight BiPLEDs and six GPEDs) were associated with HE. Patients with BIPLEDs were 68 +/- 19.4 years old, 5 female (62%) and 3 (38%) men. GPEDs patients were 52.5 +/- 19.1 years old, 2 women (20%) and 4 (80%) men. Myocardial infarction and ventricular tachycardia were responsible of 57% of the HE cases. Neuroimaging studies in both groups showed cortical structural lesions in 84%. All patients were comatose and died. Two GPEDs patients developed status epilepticus.
Conclusion: GPEDs and BIPLEDs after an anoxic insult carried a poor prognosis for survival. Aggressive treatment of patients may not be warranted when these EEG patterns are seen after anoxic brain injury. (C) 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
C1 [San-juan, O. D.; Chiappa, K. H.; Costello, D. J.; Cole, A. J.] Massachusetts Gen Hosp, Epilepsy Serv, Dept Neurophysiol, Boston, MA 02114 USA.
RP San-Juan, OD (reprint author), Massachusetts Gen Hosp, Epilepsy Serv, Dept Neurophysiol, 55 Furit St, Boston, MA 02114 USA.
EM pegaso31@yahoo.com
FU Foundation Mexico (FMH) in Harvard; FMH Fellowship
FX The study was funded by grant from the Foundation Mexico (FMH) in
Harvard. San-Juan OD is Supported by FMH Fellowship.
NR 20
TC 28
Z9 30
U1 0
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1059-1311
J9 SEIZURE-EUR J EPILEP
JI Seizure
PD JUN
PY 2009
VL 18
IS 5
BP 365
EP 368
DI 10.1016/j.seizure.2009.01.003
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 453VM
UT WOS:000266641000011
PM 19196524
ER
PT J
AU Bhide, PG
AF Bhide, Pradeep G.
TI Dopamine, cocaine and the development of cerebral cortical
cytoarchitecture: A review of current concepts
SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE Neurogenesis; Neuronal migration; GABA; Cocaine; Dopamine; Animal model
ID LATERAL GANGLIONIC EMINENCE; ANTERIOR CINGULATE CORTEX; NONHUMAN PRIMATE
MODEL; GABA NEURON MIGRATION; FETAL-RAT BRAIN; PRENATAL COCAINE;
IN-UTERO; CELL-CYCLE; POSTNATAL-DEVELOPMENT; ADENYLYL-CYCLASE
AB Exposure of the developing fetus to cocaine produces lasting adverse effects on brain structure and function. Animal models show that cocaine exerts its effects by interfering with monoamine neurotransmitter function and that dopamine is cocaine's principal monoamine target in the fetal brain. This review will examine the role of dopamine receptor signaling in the regulation of normal development of the cerebral cortex, the seat of higher cognitive functions, and discuss whether dopamine receptor signaling mechanisms are the principal mediators of cocaine's deleterious effects on the ontogeny of cerebral cortical cytoarchitecture. (C) 2009 Elsevier Ltd. All rights reserved.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Charlestown, MA 02129 USA.
RP Bhide, PG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 149,13th St, Charlestown, MA 02129 USA.
EM Bhide@helix.mgh.harvard.eduailto
OI Bhide, Pradeep/0000-0003-4236-9415
FU US Public Health Service [DARO1-020796, NSRO1-43426, NSP30-045776]
FX The author's work described in this review was supported by US Public
Health Service grants DARO1-020796, NSRO1-43426, NSP30-045776.
NR 85
TC 26
Z9 28
U1 1
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1084-9521
J9 SEMIN CELL DEV BIOL
JI Semin. Cell Dev. Biol.
PD JUN
PY 2009
VL 20
IS 4
BP 395
EP 402
DI 10.1016/j.semcdb.2009.01.006
PG 8
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 503XY
UT WOS:000270576700004
PM 19560044
ER
PT J
AU Hough, S
AF Hough, Sigmund
TI From the Editor Inclusion of the Past to Ensure a Future Sexuality
SO SEXUALITY AND DISABILITY
LA English
DT Editorial Material
C1 VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, W Roxbury, MA 02132 USA.
RP Hough, S (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Sigmund_Hough@hms.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0146-1044
J9 SEX DISABIL
JI Sex. Disabil.
PD JUN
PY 2009
VL 27
IS 2
BP 69
EP 69
DI 10.1007/s11195-009-9117-0
PG 1
WC Rehabilitation
SC Rehabilitation
GA 445LC
UT WOS:000266051300001
ER
PT J
AU Kuemmel, A
AF Kuemmel, Angela M.
TI Enhancing Self-Esteem: A Self-Esteem Training Package for Individuals
with Disabilities
SO SEXUALITY AND DISABILITY
LA English
DT Book Review
C1 [Kuemmel, Angela M.] VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, W Roxbury, MA 02132 USA.
[Kuemmel, Angela M.] Nova SE Univ, Boston Consortium Psychol Internship Program, Davie, FL USA.
RP Kuemmel, A (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Kuemmel@nova.edu
NR 3
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0146-1044
J9 SEX DISABIL
JI Sex. Disabil.
PD JUN
PY 2009
VL 27
IS 2
BP 119
EP 120
DI 10.1007/s11195-009-9118-z
PG 2
WC Rehabilitation
SC Rehabilitation
GA 445LC
UT WOS:000266051300006
ER
PT J
AU Hough, S
AF Hough, Sigmund
TI The Guide to Getting It On
SO SEXUALITY AND DISABILITY
LA English
DT Book Review
C1 [Hough, Sigmund] VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, W Roxbury, MA 02132 USA.
[Hough, Sigmund] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Hough, Sigmund] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Hough, S (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Sigmund_Hough@hms.harvard.edu
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0146-1044
J9 SEX DISABIL
JI Sex. Disabil.
PD JUN
PY 2009
VL 27
IS 2
BP 121
EP 122
DI 10.1007/s11195-009-9116-1
PG 2
WC Rehabilitation
SC Rehabilitation
GA 445LC
UT WOS:000266051300007
ER
PT J
AU Chen, LY
Reisner, AT
Gribok, A
McKenna, TM
Reifman, J
AF Chen, Liangyou
Reisner, Andrew T.
Gribok, Andrei
McKenna, Thomas M.
Reifman, Jaques
TI CAN WE IMPROVE THE CLINICAL UTILITY OF RESPIRATORY RATE AS A MONITORED
VITAL SIGN?
SO SHOCK
LA English
DT Article
DE Data quality; respiratory rate; physiological monitoring;
decision-support; trauma; vital signs
ID INTENSIVE-CARE UNIT; TRAUMA PATIENTS; SHOCK INDEX; SYSTEM; ROC;
HYPOVOLEMIA; ALGORITHMS; HEMORRHAGE; TRIAGE; BLOOD
AB Respiratory rate (RR) is a basic vital sign, measured and monitored throughout a wide spectrum of health care settings, although FIR is historically difficult to measure in a reliable fashion. We explore an automated method that computes FIR only during intervals of clean, regular, and consistent respiration and investigate its diagnostic use in a retrospective analysis of prehospital trauma casualties. At least 5 s of basic vital signs, including heart rate, RR, and systolic, diastolic, and mean arterial blood pressures, were continuously collected from 326 spontaneously breathing trauma casualties during helicopter transport to a level I trauma center. "Reliable" FIR data were identified retrospectively using automated algorithms. The diagnostic performances of reliable versus standard FIR were evaluated by calculation of the receiver operating characteristic curves using the maximum-likelihood method and comparison of the summary areas under the receiver operating characteristic curves (AUCs). Respiratory rate shows significant data-reliability differences. For identifying prehospital casualties who subsequently receive a respiratory intervention (hospital intubation or tube thoracotomy), standard FIR yields an AUC of 0.59 (95% confidence interval, 0.48 - 0.69), whereas reliable FIR yields an AUC of 0.67 (0.57 - 0.77), P < 0.05. For identifying casualties subsequently diagnosed with a major hemorrhagic injury and requiring blood transfusion, standard FIR yields an AUC of 0.60 (0.49 - 0.70), whereas reliable RR yields 0.77 (0.67 - 0.85), P < 0.001. Reliable FIR, as determined by an automated algorithm, is a useful parameter for the diagnosis of respiratory pathology and major hemorrhage in a trauma population. It may be a useful input to a wide variety of clinical scores and automated decision-support algorithms.
C1 [Chen, Liangyou; Reisner, Andrew T.; Gribok, Andrei; McKenna, Thomas M.; Reifman, Jaques] USA, Med Res & Mat Command, ATTN MCMR TT, TATRC, Ft Detrick, MD 21702 USA.
[Reisner, Andrew T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Reifman, J (reprint author), USA, Med Res & Mat Command, ATTN MCMR TT, TATRC, Bldg 363 Miller Dr, Ft Detrick, MD 21702 USA.
EM jaques.reifman@us.army.mil
FU US Army Medical Research and Materiel Command
FX This work was partially supported by the Combat Casualty Care
Directorate of the US Army Medical Research and Materiel Command, Fort
Detrick, MD.
NR 43
TC 14
Z9 14
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2009
VL 31
IS 6
BP 574
EP 580
DI 10.1097/SHK.0b013e318193e885
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 463NC
UT WOS:000267437900006
PM 19008777
ER
PT J
AU Waisel, DB
Simon, R
Truog, RD
Baboolal, H
Raemer, DB
AF Waisel, David B.
Simon, Robert
Truog, Robert D.
Baboolal, Hemanth
Raemer, Daniel B.
TI Anesthesiologist Management of Perioperative Do-Not-Resuscitate Orders:
A Simulation-Based Experiment
SO SIMULATION IN HEALTHCARE
LA English
DT Article
DE Ethics; DNR; Resuscitation
ID CARDIAC-ARREST; DNR
AB Introduction: This study was performed to assess perioperative reevaluation of Do-Not-Resuscitate (DNR) orders by practicing anesthesiologists.
Methods: As part of an Anesthesia Crisis Resource Management course, an anesthesiologist interviewed a patient-actor with prostate cancer and bone metastases scheduled for a central venous catheter placement. The chart included a properly documented DNR order and the patient-actor's scripted responses emphasized that he would accept resuscitative efforts only "if the adverse clinical events were believed to be both temporary and reversible." Later, the subject assumed responsibility for the anesthesia in which the patient subsequently developed an iatrogenically induced pneumothorax, became apneic, and had a cardiovascular arrest requiring a prolonged resuscitation. Responses to these events and a following survey were evaluated.
Results: Fifty-seven percent of the subjects (17/30) addressed resuscitation during the preoperative interview; 27% (8/30) decided to suspend the DNR order and 30% (9/30) instituted a goal-directed or procedure-directed DNR order. Ninety percent (27/30) of the groups chose to continue resuscitative efforts until the simulation ended. Of the surveyed participants, over 90% would place a chest tube, intubate the trachea, do chest compressions, and perform cardiac defibrillation. Common reasons for intervening were reversibility, iatrogenicity, and that intervention would be consistent with the patient's goals.
Conclusions: Inadequacies in perioperative reevaluation of DNR orders existed at all stages. Simulation of perioperative DNR orders is a useful way to elicit anesthesiologist's actions in the heat of the moment, which may bring us closer to understanding the actions of anesthesiologists during clinical practice. (Sim Healthcare 4: 70-76, 2009)
C1 [Waisel, David B.; Truog, Robert D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Simon, Robert; Baboolal, Hemanth; Raemer, Daniel B.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA.
[Waisel, David B.; Simon, Robert; Truog, Robert D.; Baboolal, Hemanth; Raemer, Daniel B.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
[Simon, Robert; Raemer, Daniel B.] Ctr Med Simulat, Cambridge, MA USA.
RP Waisel, DB (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
EM David.Waisel@childrens.harvard.edu
OI Waisel, David/0000-0002-5307-4092
NR 17
TC 11
Z9 12
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-2332
J9 SIMUL HEALTHC
JI Simul. Healthc.
PD SUM
PY 2009
VL 4
IS 2
BP 70
EP 76
DI 10.1097/SIH.0b013e31819e137b
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 588EI
UT WOS:000277049900002
PM 19444043
ER
PT J
AU Pian-Smith, MCM
Simon, R
Minehart, RD
Podraza, M
Rudolph, J
Walzer, T
Raemer, D
AF Pian-Smith, May C. M.
Simon, Robert
Minehart, Rebecca D.
Podraza, Marjorie
Rudolph, Jenny
Walzer, Toni
Raemer, Daniel
TI Teaching Residents the Two-Challenge Rule: A Simulation-Based Approach
to Improve Education and Patient Safety
SO SIMULATION IN HEALTHCARE
LA English
DT Article
DE Education; Communication; Authority; Patient Safety; Residency
ID CRISIS RESOURCE-MANAGEMENT; OPERATING-ROOM; EMERGENCY; TEAMS
AB Introduction: Residents train in a historically hierarchical system. They may be compelled to question their teachers if they do not understand or disagree with a clinical decision, have a patient safety concern, or when treatment plans are unclear. We sought to determine whether a debriefing intervention that emphasizes (1) joint responsibility for safety and (2) the "two-challenge rule" (a rubric for challenging others) using a conversational technique that is assertive and collaborative (advocacy-inquiry) can improve the frequency and effectiveness with which residents "speak up" to superiors.
Methods: In a simulated operating room, anesthesiology trainees were presented with opportunities to challenge coworkers (eg, orders to administer a relatively contraindicated medication). Opportunities to challenge the attending faculty anesthesiologist, attending faculty surgeon, and nurse (all confederates) were presented. When debriefed, subjects were taught the two-challenge rule and a communication technique that paired advocacy (stating trainee's observation) and inquiry (request for the other's reasoning). A second scenario offered new opportunities to challenge. Video recorded scenarios were evaluated by two investigators and trainee use of the prescribed advocacy-inquiry language was rated on a 5-point scale.
Results: Forty subjects participated. Overall use of the two-challenge rule and advocacy-inquiry increased after debriefing. The debriefing and instruction specifically improved the frequency and quality of challenges directed toward superordinate physicians, without improving resident challenges toward nurses.
Conclusions: This instructional intervention improves "speaking up" by residents to other physicians during simulated obstetric cases. Providing increased opportunities for resident learning, sharing responsibility for patient safety, and overcoming communication barriers within the medical hierarchy may improve teamwork and patient safety. (Sim Healthcare 4: 84-91, 2009)
C1 [Pian-Smith, May C. M.; Simon, Robert; Minehart, Rebecca D.; Podraza, Marjorie; Rudolph, Jenny; Raemer, Daniel] Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Boston, MA 02114 USA.
[Pian-Smith, May C. M.; Simon, Robert; Minehart, Rebecca D.; Podraza, Marjorie; Rudolph, Jenny; Walzer, Toni; Raemer, Daniel] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Pian-Smith, May C. M.; Simon, Robert; Minehart, Rebecca D.; Rudolph, Jenny; Walzer, Toni; Raemer, Daniel] Ctr Med Simulat, Cambridge, MA USA.
[Walzer, Toni] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
RP Pian-Smith, MCM (reprint author), Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, 55 Fruit St, Boston, MA 02114 USA.
EM mpiansmith@partners.org
OI Minehart, Rebecca/0000-0001-8504-8967
NR 37
TC 53
Z9 54
U1 0
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-2332
J9 SIMUL HEALTHC
JI Simul. Healthc.
PD SUM
PY 2009
VL 4
IS 2
BP 84
EP 91
DI 10.1097/SIH.0b013e31818cffd3
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 588EI
UT WOS:000277049900004
PM 19444045
ER
PT J
AU Szymusiak, R
AF Szymusiak, Ronald
TI Sleepy Synapses
SO SLEEP
LA English
DT Editorial Material
ID LONG-TERM POTENTIATION; MOTOR CORTEX; RAT
C1 [Szymusiak, Ronald] VA Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
RP Szymusiak, R (reprint author), VA Greater Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA.
EM rszym@ucla.edu
NR 11
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2009
VL 32
IS 6
BP 713
EP 714
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 452WE
UT WOS:000266571100001
PM 19544744
ER
PT J
AU Gottlieb, DJ
Young, TB
AF Gottlieb, Daniel J.
Young, Terry B.
TI Natural History of Sleep-Disordered Breathing: Shedding Light on the
Early Years
SO SLEEP
LA English
DT Editorial Material
ID CHILDREN; PREVALENCE; APNEA
C1 [Gottlieb, Daniel J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Gottlieb, Daniel J.] VA Boston Healthcare Syst, Boston, MA USA.
[Young, Terry B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
RP Gottlieb, DJ (reprint author), Boston Univ, Sch Med, 715 Albany St, Boston, MA 02118 USA.
EM gottlieb@bu.edu
NR 10
TC 2
Z9 2
U1 0
U2 0
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2009
VL 32
IS 6
BP 715
EP 716
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 452WE
UT WOS:000266571100002
PM 19544745
ER
PT J
AU Winkelman, JW
Redline, S
Baldwin, CM
Resnick, HE
Newman, AB
Gottlieb, DJ
AF Winkelman, John W.
Redline, Susan
Baldwin, Carol M.
Resnick, Helaine E.
Newman, Anne B.
Gottlieb, Daniel J.
TI Polysomnographic and Health-related Quality of Life Correlates of
Restless Legs Syndrome in the Sleep Heart Health Study
SO SLEEP
LA English
DT Article
DE Restless legs syndrome; quality of life; community based sample; sleep
latency; polysomnography
ID SYNDROME RLS; SYMPTOMS; IMPACT; EPIDEMIOLOGY; POPULATION; DIAGNOSIS;
ASSOCIATION; PREVALENCE; COMPLAINTS; DISEASE
AB Study Objectives: Sleep disturbance is the primary clinical morbidity of restless legs syndrome (RLS). To date, sleep disturbance in RLS has been measured in (1) clinical samples with polysomnography (PSG) or (2) population-based samples by self-report. The objective of this study was to analyze sleep by PSG in a population-based sample with symptoms of RLS.
Design: Cross-sectional observational study
Setting: Community-based
Participants: 3433 older men and women
Interventions: None
Measurements and Results: RLS was evaluated using an 8-item self-administered questionnaire based on NIH diagnostic criteria and required symptoms occurring >= five times per month and associated with at least moderate distress. Health-related quality of life (HRQOL) was determined using the SF-36. Unattended, in-home PSG was performed. Data were assessed using general linear models with adjustment for demographic, health-related variables, and apnea-hypopnea index (AHI). Subjects with RLS had longer adjusted mean sleep latency (39.8 vs 26.4 min, P < 0.0001) and higher arousal index (20.1 vs 18.0, P = 0.0145) than those without RLS. Sleep latency increased progressively as the frequency of RLS symptoms increased from 5-15 days per month to 6-7 days per week. No differences in sleep stage percentages were observed between participants with and without RLS. Subjects with RLS also reported poorer HRQOL in all physical domains as well as in the Mental Health and Vitality domains.
Conclusions: These novel PSG data from a nonclinical, community-based sample of individuals with RLS document sleep disturbance in the home even in individuals with intermittent symptoms.
C1 [Winkelman, John W.] Harvard Univ, Sch Med, Brighton, MA 02135 USA.
[Redline, Susan] Case Western Reserve Univ, Ctr Clin Invest, Cleveland, OH 44106 USA.
[Baldwin, Carol M.] Arizona State Univ, Coll Nursing & Healthcare Innovat, Phoenix, AZ USA.
[Resnick, Helaine E.] Georgetown Univ, Inst Future Aging Serv, Amer Assoc Homes & Serv Aging, Washington, DC USA.
[Resnick, Helaine E.] Georgetown Univ, Dept Endocrinol, Washington, DC USA.
[Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Gottlieb, Daniel J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Gottlieb, Daniel J.] VA Boston Healthcare Syst, Boston, MA USA.
RP Winkelman, JW (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Sleep Med, 1505 Commonwealth Ave, Brighton, MA 02135 USA.
EM JWWinkelman@partners.org
RI Newman, Anne/C-6408-2013;
OI Newman, Anne/0000-0002-0106-1150; Baldwin, Carol/0000-0002-0732-2307
FU National Heart, Lung and Blood Institute Cooperative [U01 HL53940];
University of Washington [U01 HL53941]; Boston University [U01 HL53938];
Cooperative Agreement Supplement [HL53938-07S1]; University of Arizona
[U01 HL53916]; University of California, Davis [U01 HL53934]; University
of Minnesota [01 HL53931]; New York University [U01 HL53937, U01
HL64360]; Johns Hopkins University [U01 HL63463]; Case Western Reserve
University [U01 HL63429]; Missouri Breaks Research; Stanford University
[R01 HL71515]
FX This work was Supported by National Heart, Lung and Blood Institute
Cooperative agreements U01 HL53940 (University of Washington), U01
HL53941 (Boston University), U01 HL53938 and Cooperative Agreement
Supplement HL53938-07S1 (University of Arizona), U01 HL53916 (University
of California, Davis), U01 HL53934 (University of Minnesota), 01 HL53931
(New York University), U01 HL53937 and U01 HL64360 (Johns Hopkins
University), U01 HL63463 (Case Western Reserve University), and U01
HL63429 (Missouri Breaks Research), and research grant R01 HL71515
(Stanford University).
NR 19
TC 71
Z9 71
U1 0
U2 3
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2009
VL 32
IS 6
BP 772
EP 778
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 452WE
UT WOS:000266571100011
PM 19544754
ER
PT J
AU Platt, AB
Field, SH
Asch, DA
Chen, Z
Patel, NP
Gupta, R
Roche, DF
Gurubhagavatula, I
Christie, JD
Kuna, ST
AF Platt, Alec B.
Field, Samuel H.
Asch, David A.
Chen, Zhen
Patel, Nirav P.
Gupta, Rajesh
Roche, Dominic F.
Gurubhagavatula, Indira
Christie, Jason D.
Kuna, Samuel T.
TI Neighborhood of Residence is Associated with Daily Adherence to CPAP
Therapy
SO SLEEP
LA English
DT Article
DE Obstructive sleep apnea; continuous positive airway pressure; adherence;
socioeconomic status
ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; CORONARY
HEART-DISEASE; CHARLSON COMORBIDITY INDEX; SOCIOECONOMIC-STATUS;
ADMINISTRATIVE DATABASES; PRACTICE PARAMETERS; NASAL CPAP; HEALTH; RISK
AB Study Objectives: Adherence to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea is poor. Risk factors for nonadherence are not well understood but may reflect individual or neighborhood socioeconomic factors. We sought to determine the association of socioeconomic status and initial CPAP adherence.
Design: Retrospective cohort study, 2005 to 2006.
Setting: Philadelphia VA Medical Center.
Participants: Of 330 consecutive veterans who met study criteria for initiation of CPAP therapy for newly diagnosed sleep apnea, 266 had complete data for study inclusion.
Interventions: N/A.
Measurements: Through a multivariable logistic regression model, using an outcome of objectively measured CPAP use ! 4 h daily during the first week of treatment, we tested whether patients from higher socioeconomic neighborhoods had higher CPAP adherence. We measured neighborhood socioeconomic status with an index derived from the 2000 U.S. Census at the block group-level composed of median household income, male and female employment, adult high school completion, married households, and minority composition.
Results: CPAP adherence : >= 4 h occurred on 48.9% of 1,805 patient-days observed for the 266 subjects. After adjustment for individual sociodemographic characteristics and medical comorbidity, the probability of daily CPAP use >= 4 h ranged from 34.1% (95% CI, 26.4-42.7) for subjects from a low socioeconomic neighborhood (5th percentile) to 62.3% (95% CI, 53.8-70.1) for subjects from a high (95th percentile) neighborhood.
Conclusions: In a retrospective cohort of veterans, initial CPAP adherence was closely associated with higher neighborhood socioeconomic factors. Future investigation should target specific impediments to adherence in the home and neighborhood environment.
C1 [Platt, Alec B.; Field, Samuel H.; Asch, David A.; Roche, Dominic F.; Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Platt, Alec B.] Reading Hosp Med Ctr, Reading, PA USA.
[Field, Samuel H.] Univ N Carolina, Frank Porter Graham Child Dev Inst, Chapel Hill, NC USA.
[Asch, David A.; Patel, Nirav P.; Gurubhagavatula, Indira; Christie, Jason D.; Kuna, Samuel T.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Christie, Jason D.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Chen, Zhen] NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA.
[Patel, Nirav P.; Gupta, Rajesh; Gurubhagavatula, Indira; Kuna, Samuel T.] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA.
RP Platt, AB (reprint author), 2608 Keiser Blvd, Wyomissing, PA 19610 USA.
EM alecplatt@gmail.com
FU NHLBI NIH HHS [T-32 HL07713-14, T32 HL007713]; NIOSH CDC HHS
[R01-OH-009149-01, R01 OH009149]
NR 52
TC 53
Z9 53
U1 1
U2 6
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2009
VL 32
IS 6
BP 799
EP 806
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 452WE
UT WOS:000266571100014
PM 19544757
ER
PT J
AU Sauerwein, W
Jongen, Y
Stichelbaut, F
Hentschel, R
Brualla, L
Wittig, A
Herault, J
Busse, P
AF Sauerwein, W.
Jongen, Y.
Stichelbaut, F.
Hentschel, R.
Brualla, L.
Wittig, A.
Herault, J.
Busse, P.
TI Radiation protection issues in proton therapy
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Meeting Abstract
CT 15th Annual Conference of the Deutschen-Gesellschaft-fur-Radioonkologie
CY JUN 11-14, 2009
CL Bremen, GERMANY
SP Deutsch Gesell Radioonkol
C1 [Sauerwein, W.; Hentschel, R.; Brualla, L.; Wittig, A.] Univ Klinikum Essen, Strahlenklin, Essen, Germany.
[Jongen, Y.; Stichelbaut, F.] IBA Technol Grp, Louvain, Belgium.
[Herault, J.] Ctr Antoine La Cassagne, Nice, France.
[Busse, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RI Brualla, Lorenzo/B-4672-2013
OI Brualla, Lorenzo/0000-0003-3385-9623
NR 0
TC 1
Z9 1
U1 0
U2 1
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0179-7158
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD JUN
PY 2009
VL 185
BP 140
EP 141
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 473RD
UT WOS:000268225500365
ER
PT J
AU Furlong, C
Rosowski, JJ
Hulli, N
Ravicz, ME
AF Furlong, C.
Rosowski, J. J.
Hulli, N.
Ravicz, M. E.
TI Preliminary Analyses of Tympanic-Membrane Motion from Holographic
Measurements
SO STRAIN
LA English
DT Article
DE holographic measurements; middle-ear mechanics; nondestructive testing;
shape and deformation measurements; tympanic membrane
ID MIDDLE-EAR; VIBRATION MEASUREMENT; CAT; INTERFEROMETRY; MECHANICS
AB Computer-aided, personal computer (PC) based, optoelectronic holography (OEH) was used to obtain preliminary measurements of the sound-induced displacement of the tympanic membrane (TM) of cadaver cats and chinchillas. Real-time time-averaged holograms, processed at video rates, were used to characterise the frequency dependence of TM displacements as tone frequency was swept from 400 Hz to 20 kHz. Stroboscopic holography was used at selected frequencies to measure, in full-field-of-view, displacements of the TM surface with nanometer resolution. These measurements enable the determination and the characterisation of inward and outward displacements of the TM. The time-averaged holographic data suggest standing wave patterns on the cat's TM surface, which move from simple uni-modal or bi-modal patterns at low frequencies, through complicated multimodal patterns above 3 kHz, to highly ordered arrangements of displacement waves with tone frequencies above 15 kHz. The frequency boundaries of the different wave patterns are lower in chinchilla (simple patterns below 600 Hz, ordered patterns above 4 kHz) than cat. The stroboscopic holography measurements indicate wave-like motion patterns on the TM surface, where the number of wavelengths captured along sections of the TM increased with stimulus frequency with as many as 11 wavelengths visible on the chinchilla TM at 16 kHz. Counts of the visible number of wavelengths on TM sections with different sound stimulus frequency provided estimates of wave velocity along the TM surface that ranged from 5 m s(-1) at frequencies below 8 kHz and increased to 25 m s(-1) by 20 kHz.
C1 [Furlong, C.; Hulli, N.] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA.
[Rosowski, J. J.; Ravicz, M. E.] Mass Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Lab, Boston, MA USA.
[Rosowski, J. J.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Furlong, C (reprint author), Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA.
FU NIDCD; Worcester Polytechnic Institute; Mechanical Engineering
Department
FX This work was supported by the NIDCD and the Worcester Polytechnic
Institute, Mechanical Engineering Department. The authors would like to
thank the referees for providing constructive and valuable
recommendations and updates.
NR 30
TC 23
Z9 23
U1 1
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0039-2103
J9 STRAIN
JI Strain
PD JUN
PY 2009
VL 45
IS 3
BP 301
EP 309
DI 10.1111/j.1475-1305.2008.00490.x
PG 9
WC Materials Science, Characterization & Testing
SC Materials Science
GA 445TH
UT WOS:000266073900011
PM 20209120
ER
PT J
AU Yoo, AJ
Verduzco, LA
Schaefer, PW
Hirsch, JA
Rabinov, JD
Gonzalez, RG
AF Yoo, Albert J.
Verduzco, Luis A.
Schaefer, Pamela W.
Hirsch, Joshua A.
Rabinov, James D.
Gonzalez, R. Gilberto
TI MRI-Based Selection for Intra-Arterial Stroke Therapy Value of
Pretreatment Diffusion-Weighted Imaging Lesion Volume in Selecting
Patients With Acute Stroke Who Will Benefit From Early Recanalization
SO STROKE
LA English
DT Article
DE cerebral infarction; cerebral revascularization; magnetic resonance
imaging
ID ACUTE ISCHEMIC-STROKE; MIDDLE CEREBRAL-ARTERY; THROMBOLYTIC THERAPY;
HEMORRHAGIC TRANSFORMATION; MERCI TRIAL; OCCLUSION; HYPERGLYCEMIA;
INFARCT; MANAGEMENT; EVOLUTION
AB Background and Purpose-Recent studies demonstrate that an acute diffusion-weighted imaging lesion volume >70 cm(3) predicts poor outcome in patients with stroke. We sought to determine if this threshold could identify patients treated with intra-arterial therapy who would do poorly despite reperfusion. In patients with initial infarcts <70 cm(3), we sought to determine what effect recanalization and time to recanalization had on infarct growth and functional outcome.
Methods-We retrospectively studied 34 consecutive patients with anterior circulation stroke who underwent pretreatment diffusion-weighted imaging and perfusion-weighted imaging and subsequent intra-arterial therapy. Recanalization success and time to recanalization were recorded. Initial diffusion-weighted imaging and mean transit time lesion and final infarct volumes were determined. Patients were stratified based on initial infarct volume, recanalization status, and time to recanalization. Statistical tests were performed to assess differences in clinical and imaging outcomes. Good clinical outcome was defined as a 3-month modified Rankin Scale score <= 2.
Results-Among patients with initial infarcts >70 cm(3), all had poor outcomes despite a 50% recanalization rate with mean infarct growth of 114 cm(3). These patients also had the largest mean transit time volumes (P < 0.04). Patients with initial infarct volumes <70 cm(3) who recanalized early had the best clinical outcomes (P < 0.008) with a 64% rate of modified Rankin Scale score <= 2 and the least infarct growth (P < 0.03) with mean growth of 18 cm(3).
Conclusion-This study supports the use of an acute diffusion-weighted imaging lesion volume threshold as an imaging selection criterion for intra-arterial therapy. It also confirms the importance of early reperfusion in selected patients. (Stroke. 2009; 40: 2046-2054.)
C1 [Yoo, Albert J.; Verduzco, Luis A.; Schaefer, Pamela W.; Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA.
[Yoo, Albert J.; Hirsch, Joshua A.; Rabinov, James D.] Massachusetts Gen Hosp, Dept Intervent Neuroradiol, Boston, MA 02114 USA.
RP Yoo, AJ (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol & Intervent Neuroradiol, 55 Fruit St,Gray 241, Boston, MA 02114 USA.
EM ajyoo@partners.org
FU Neuroradiology Education and Research Foundation/Boston Scientific
Fellowship in Cerebrovascular Disease Research; Howard Hughes Medical
Institute Research Training Fellowships; National Institutes of Health;
National Institute of Neurological Disorders and Stroke [NS050041]
FX A.J.Y. was the 2007 recipient of the Neuroradiology Education and
Research Foundation/Boston Scientific Fellowship in Cerebrovascular
Disease Research. L. A. V. was a 2007 recipient of the Howard Hughes
Medical Institute Research Training Fellowships for Medical Students.
This study was supported in part by the National Institutes of Health
through a grant from the National Institute of Neurological Disorders
and Stroke NS050041 ( to R. G. G.).
NR 32
TC 158
Z9 159
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2009
VL 40
IS 6
BP 2046
EP 2054
DI 10.1161/STROKEAHA.108.541656
PG 9
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 449AD
UT WOS:000266302200020
PM 19359641
ER
PT J
AU Christensen, S
Mouridsen, K
Wu, O
Hjort, N
Karstoft, H
Thomalla, G
Rother, J
Fiehler, J
Kucinski, T
Ostergaard, L
AF Christensen, Soren
Mouridsen, Kim
Wu, Ona
Hjort, Niels
Karstoft, Henrik
Thomalla, Goetz
Roether, Joachim
Fiehler, Jens
Kucinski, Thomas
Ostergaard, Leif
TI Comparison of 10 Perfusion MRI Parameters in 97 Sub-6-Hour Stroke
Patients Using Voxel-Based Receiver Operating Characteristics Analysis
SO STROKE
LA English
DT Article
DE diffusion magnetic resonance imaging; magnetic resonance angiography;
perfusion weighted MRI; stroke
ID ACUTE HEMISPHERIC STROKE; ACUTE ISCHEMIC-STROKE; WEIGHTED MRI;
INTRAVENOUS THROMBOLYSIS; CEREBRAL INFARCT; DIFFUSION; TISSUE;
EVOLUTION; MISMATCH; RECANALIZATION
AB Background and Purpose-Perfusion-weighted imaging can predict infarct growth in acute stroke and potentially be used to select patients with tissue at risk for reperfusion therapies. However, the lack of consensus and evidence on how to best create PWI maps that reflect tissue at risk challenges comparisons of results and acute decision-making in trials. Deconvolution using an arterial input function has been hypothesized to generate maps of a more quantitative nature and with better prognostic value than simpler summary measures such as time-to-peak or the first moment of the concentration time curve. We sought to compare 10 different perfusion parameters by their ability to predict tissue infarction in acute ischemic stroke.
Methods-In a retrospective analysis of 97 patients with acute stroke studied within 6 hours from symptom onset, we used receiver operating characteristics in a voxel-based analysis to compare 10 perfusion parameters: time-to-peak, first moment, cerebral blood volume and flow, and 6 variants of time to peak of the residue function and mean transit time maps. Subanalysis assessed the effect of reperfusion on outcome prediction.
Results-The most predictive maps were the summary measures first moment and time-to-peak. First moment was significantly more predictive than time to peak of the residue function and local arterial input function-based methods (P < 0.05), but not significantly better than conventional mean transit time maps.
Conclusion-Results indicated that if a single map type was to be used to predict infarction, first moment maps performed at least as well as deconvolved measures. Deconvolution decouples delay from tissue perfusion; we speculate this negatively impacts infarct prediction. (Stroke. 2009; 40: 2055-2061.)
C1 [Christensen, Soren; Mouridsen, Kim; Hjort, Niels; Ostergaard, Leif] Aarhus Univ Hosp, Dept Neuroradiol, Ctr Functionally Integrat Neurosci, DK-8000 Aarhus C, Denmark.
[Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Boston, MA 02114 USA.
[Karstoft, Henrik] Engn Coll Aarhus, Aarhus, Denmark.
[Fiehler, Jens] Univ Med Ctr Hamburg Eppendorf, Dept Neuroradiol, Hamburg, Germany.
[Thomalla, Goetz] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany.
[Roether, Joachim] Univ Hannover, Acad Teaching Hosp, Klinikum Minden, Dept Neurol, Minden, Germany.
[Kucinski, Thomas] Karolinska Univ Hosp, Neuroradiol Kliniken Solna, Stockholm, Sweden.
RP Christensen, S (reprint author), Aarhus Univ Hosp, Dept Neuroradiol, Ctr Functionally Integrat Neurosci, Bldg 30,Norrebrogade 44, DK-8000 Aarhus C, Denmark.
EM sorenc@unimelb.edu.au
RI Bonefeld, Birgit/B-7936-2010; Ostergaard, Leif/A-9281-2008
OI Ostergaard, Leif/0000-0003-2930-6997
FU Danish National Research Foundation; Danish Medical Research Council;
Schering AG; GlaxoSmithKline
FX We thank the Danish National Research Foundation, the Danish Medical
Research Council, Schering AG, and GlaxoSmithKline for grant support.
NR 33
TC 72
Z9 72
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2009
VL 40
IS 6
BP 2055
EP 2061
DI 10.1161/STROKEAHA.108.546069
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 449AD
UT WOS:000266302200021
PM 19359626
ER
PT J
AU Conrad, AK
Jacoby, AM
Jobes, DA
Lineberry, TW
Shea, CE
Ewing, TDA
Schmid, PJ
Ellenbecker, SM
Lee, JL
Fritsche, K
Grenell, JA
Gehin, JM
Kung, S
AF Conrad, Amy K.
Jacoby, Aaron M.
Jobes, David A.
Lineberry, Timothy W.
Shea, Catherine E.
Ewing, Theresa D. Arnold
Schmid, Phyllis J.
Ellenbecker, Susan M.
Lee, Joy L.
Fritsche, Kathryn
Grenell, Jennifer A.
Gehin, Jessica M.
Kung, Simon
TI A Psychometric Investigation of the Suicide Status Form II with a
Psychiatric Inpatient Sample
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID SOMATIC ANXIETY STICSA; CLINICAL PREDICTORS; LIVING INVENTORY; TRAIT
INVENTORY; SCALE; HOPELESSNESS; IDEATION; REASONS; OUTPATIENTS; RISK
AB We investigated the psychometric validity and reliability of the Suicide Status Form-II (SSF-II) developed by Jobes, Jacoby, Cimbolic, and Hustead (1997). Participants were 149 psychiatric inpatients (108 suicidal; 41 nonsuicidal) at the Mayo Clinic. Each participant completed assessment measures within 24 hours of admission and 48-72 hours later. Factor analyses of the SSF core assessment produced a robust two-factor solution reflecting chronic and acute response styles. The SSF core assessment had good to excellent convergent and criterion validity; pre-post SSF ratings also demonstrated moderate test-retest reliability. The results replicated previous research and show that the SSF-II is psychometrically sound with a high-risk suicidal inpatient sample.
C1 [Jobes, David A.] Catholic Univ Amer, Dept Psychol, Washington, DC 20064 USA.
[Conrad, Amy K.] Walter Reed Army Med Ctr, Silver Spring, MD USA.
[Jacoby, Aaron M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Lineberry, Timothy W.; Shea, Catherine E.; Ewing, Theresa D. Arnold; Schmid, Phyllis J.; Ellenbecker, Susan M.; Lee, Joy L.; Fritsche, Kathryn; Grenell, Jennifer A.; Gehin, Jessica M.; Kung, Simon] Mayo Clin, Rochester, MN USA.
RP Jobes, DA (reprint author), Catholic Univ Amer, Dept Psychol, 314 OBoyle Hall, Washington, DC 20064 USA.
EM Jobes@cua.edu
NR 45
TC 30
Z9 30
U1 1
U2 3
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD JUN
PY 2009
VL 39
IS 3
BP 307
EP 320
PG 14
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 470CY
UT WOS:000267952900006
PM 19606922
ER
PT J
AU Seim, AR
Fagerhaug, T
Ryen, SM
Curran, P
Saether, OD
Myhre, HO
Sandberg, WS
AF Seim, Andreas R.
Fagerhaug, Tom
Ryen, Sveinung M.
Curran, Paige
Saether, Ola D.
Myhre, Hans O.
Sandberg, Warren S.
TI Causes of Cancellations on the Day of Surgery at Two Major University
Hospitals
SO SURGICAL INNOVATION
LA English
DT Article
CT Annual Meeting of the American-Society-of-Anesthesiologists
CY OCT 14-18, 2006
CL Chicago, IL
SP Amer Soc Anesthesiologists
DE cancellations; operating room management; preoperative
care/management/optimization; economics; quality; cancellations on day
of surgery; hospital capacity; causes of cancellations
AB Cancellations of elective cases on the day of surgery waste valuable operating-room time. The authors studied cancellations at an American hospital and a Norwegian university hospital to test (a) whether the quality of hospital administrative data on cancellations is sufficient for meaningful comparative analysis and (b) whether causes of cancellations at these 2 major academic hospitals are comparable. Large retrospective cause-of-cancellation data sets were obtained from each hospital. The authors then prospectively established root causes of cancellations by on-site investigation and interviews of the hospital personnel involved. The surgical department at the Norwegian hospital cancelled 14.58% of cases in 2003 and 16.07% in 2004. The American hospital cancelled 16.52% of all cases between May 1, 2003, and April 30, 2004. Administrative data may give a rough picture of causes of cancellations. However, most findings at either of the hospitals do not translate easily to the other.
C1 [Seim, Andreas R.] Norwegian Univ Sci & Technol, Dept Comp & Informat Sci, N-7491 Trondheim, Norway.
[Fagerhaug, Tom; Ryen, Sveinung M.] Norwegian Univ Sci & Technol, Dept Prod & Qual Engn, N-7034 Trondheim, Norway.
[Saether, Ola D.; Myhre, Hans O.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway.
[Curran, Paige] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA.
[Saether, Ola D.; Myhre, Hans O.] Univ Trondheim Hosp, Dept Surg, St Olavs Hosp, Trondheim, Norway.
[Sandberg, Warren S.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
[Sandberg, Warren S.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA.
RP Seim, AR (reprint author), Norwegian Univ Sci & Technol, Dept Comp & Informat Sci, Sem Saelands Vei 7-9, N-7491 Trondheim, Norway.
EM andreas.seim@sintef.no
NR 10
TC 12
Z9 13
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1553-3506
J9 SURG INNOV
JI Surg. Innov.
PD JUN
PY 2009
VL 16
IS 2
BP 173
EP 180
DI 10.1177/1553350609335035
PG 8
WC Surgery
SC Surgery
GA 479EQ
UT WOS:000268642900014
PM 19460816
ER
PT J
AU Bergman, H
Tsai, KY
Seo, SJ
Kvedar, JC
Watson, AJ
AF Bergman, Hagit
Tsai, Kenneth Y.
Seo, Su-Jean
Kvedar, Joseph C.
Watson, Alice J.
TI Remote Assessment of Acne: The Use of Acne Grading Tools to Evaluate
Digital Skin Images
SO TELEMEDICINE JOURNAL AND E-HEALTH
LA English
DT Article
DE acne assessment; grading tools; digital skin images
ID PATIENT-ASSISTED TELEDERMATOLOGY; FORWARD TELEDERMATOLOGY; VULGARIS;
RELIABILITY; COMMUNITY; THERAPY; TRIAL
AB Digital imaging of dermatology patients is a novel approach to remote data collection. A number of assessment tools have been developed to grade acne severity and to track clinical progress over time. Although these tools have been validated when used in a face-to-face setting, their efficacy and reliability when used to assess digital images have not been examined. The main purpose of this study was to determine whether specific assessment tools designed to grade acne during face-to-face visits can be applied to the evaluation of digital images. The secondary purpose was to ascertain whether images obtained by subjects are of adequate quality to allow such assessments to be made. Three hundred (300) digital images of patients with mild to moderate facial inflammatory acne from an ongoing randomized-controlled study were included in this analysis. These images were obtained from 20 patients and consisted of sets of 3 images taken over time. Of these images, 120 images were captured by subjects themselves and 180 were taken by study staff. Subjects were asked to retake their photographs if the initial images were deemed of poor quality by study staff. Images were evaluated by two dermatologists-in-training using validated acne assessment measures: Total Inflammatory Lesion Count, Leeds technique, and the Investigator's Global Assessment. Reliability of raters was evaluated using correlation coefficients and. statistics. Of the different acne assessment measures tested, the inter-rater reliability was highest for the total inflammatory lesion count (r = 0.871), but low for the Leeds technique (kappa = 0.381) and global assessment (kappa = 0.3119). Raters were able to evaluate over 89% of all images using each type of acne assessment measure despite the fact that images obtained by study staff were of higher quality than those obtained by patients (p < 0.001). Several existing clinical assessment measures can be used to evaluate digital images obtained from subjects with inflammatory acne lesions. The level of inter-rater agreement is highly variable across assessment measures, and we found the Total Inflammatory Lesion Count to be the most reliable. This measure could be used to allow a dermatologist to remotely track a patient's progress over time.
C1 [Bergman, Hagit; Kvedar, Joseph C.; Watson, Alice J.] Ctr Connected Hlth, Boston, MA USA.
[Bergman, Hagit; Tsai, Kenneth Y.; Seo, Su-Jean; Kvedar, Joseph C.; Watson, Alice J.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Bergman, Hagit; Tsai, Kenneth Y.; Seo, Su-Jean; Kvedar, Joseph C.; Watson, Alice J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Watson, AJ (reprint author), 25 New Chardon,Suite 400D, Boston, MA 02114 USA.
EM ajwatson@partners.org
FU Partners Healthcare
FX Funding for this study was from Partners Healthcare.
NR 17
TC 11
Z9 11
U1 0
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED J E-HEALTH
JI Telemed. J. e-Health
PD JUN
PY 2009
VL 15
IS 5
BP 426
EP 430
DI 10.1089/tmj.2008.0128
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 462FI
UT WOS:000267334300005
PM 19548822
ER
PT J
AU Bettinger, CJ
Kulig, KM
Vacanti, JP
Langer, R
Borenstein, JT
AF Bettinger, Christopher J.
Kulig, Katherine M.
Vacanti, Joseph P.
Langer, Robert
Borenstein, Jeffrey T.
TI Nanofabricated Collagen-Inspired Synthetic Elastomers for Primary Rat
Hepatocyte Culture
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID BIODEGRADABLE POLYMER SCAFFOLDS; SILK-BASED BIOMATERIALS;
EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ADHESION; SURFACE;
STAR-POLY(EPSILON-CAPROLACTONE-CO-D,L-LACTIDE); CYTOCOMPATIBILITY;
DIFFERENTIATION; ORGANIZATION
AB Synthetic substrates that mimic the properties of extracellular matrix proteins hold significant promise for use in systems designed for tissue engineering applications. In this report, we designed a synthetic polymeric substrate that is intended to mimic chemical, mechanical, and topological characteristics of collagen. We found that elastomeric poly(ester amide) substrates modified with replica-molded nanotopographic features enhanced initial attachment, spreading, and adhesion of primary rat hepatocytes. Further, hepatocytes cultured on nanotopographic substrates also demonstrated reduced albumin secretion and urea synthesis, which is indicative of strongly adherent hepatocytes. These results suggest that these engineered substrates can function as synthetic collagen analogs for in vitro cell culture.
C1 [Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Bettinger, Christopher J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
[Bettinger, Christopher J.; Borenstein, Jeffrey T.] Ctr Biomed Engn, Charles Stark Draper Lab, Cambridge, MA USA.
[Kulig, Katherine M.; Vacanti, Joseph P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Langer, R (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM rlanger@mit.edu; jborenstein@draper.com
RI Bettinger, Christopher/A-3895-2009
FU NINDS NIH HHS [F32 NS064771-01]
NR 51
TC 14
Z9 14
U1 0
U2 7
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JUN
PY 2009
VL 15
IS 6
BP 1321
EP 1329
DI 10.1089/ten.tea.2008.0134
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 449QH
UT WOS:000266344600012
PM 18847357
ER
PT J
AU Albers, AB
Biener, L
Siegel, M
Cheng, DM
Rigotti, NA
AF Albers, A. B.
Biener, L.
Siegel, M.
Cheng, D. M.
Rigotti, N. A.
TI Impact of parental home smoking policies on policy choices of
independently living young adults
SO TOBACCO CONTROL
LA English
DT Article
ID HOUSEHOLD SMOKING; COLLEGE-STUDENTS; CIGARETTE USE
AB Objective: To determine whether adolescents living in parental homes where smoking is banned are more likely to move into smoke-free living quarters when they leave home.
Methods: We analysed data on 693 youths from a 4-year, three-wave prospective study of a representative sample of Massachusetts adolescents (aged 12-17). All youths resided in independent living quarters at follow-up. The primary outcome was presence of a smoking ban in the living quarters at follow-up. The primary predictor was presence of a household smoking ban in the parental home, assessed 2 years before the outcome. Generalised linear mixed effects models examined the effect of a parental household smoking ban on the odds of moving into smoke-free living quarters at follow-up overall and stratified by smoking status at follow-up.
Results: Youths leaving home had much higher odds of moving to smoke-free living quarters if their parental household had had a smoking ban (odds ratio (OR)= 12.70, 95% CI, 6.19 to 26.04). Other independent predictors included moving into a school or college residence (OR=3.88, 95% CI 1.87 to 8.05), and not living with smokers at follow-up (OR=3.91, 95% CI 1.93 to 7.92).
Conclusions: A household smoking ban in the parental home appears to lead youths to prefer smoke-free living quarters once they leave home.
C1 [Albers, A. B.] Boston Univ, Sch Publ Hlth, Crosstown Ctr, Dept Social & Behav Sci, Boston, MA 02215 USA.
[Biener, L.] Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA.
[Cheng, D. M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Rigotti, N. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Rigotti, N. A.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Rigotti, N. A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
RP Albers, AB (reprint author), Boston Univ, Sch Publ Hlth, Crosstown Ctr, Dept Social & Behav Sci, 715 Albany St,3rd Floor, Boston, MA 02215 USA.
EM aalbers@bu.edu
OI Biener, Lois/0000-0002-4130-8138
FU Flight Attendant Medical Research Institute (FAMRI); National Cancer
Institute's (NCI's) State and Community Tobacco Control Interventions
Research Grant Program [CA86257]
FX This work was supported by grants from the Flight Attendant Medical
Research Institute (FAMRI) and the National Cancer Institute's (NCI's)
State and Community Tobacco Control Interventions Research Grant Program
(CA86257). FAMRI and NCI were not directly involved in the study design,
in the collection, analysis and interpretation of data; in the writing
of this brief report; or in the decision to submit this brief for
publication.
NR 14
TC 8
Z9 8
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
J9 TOB CONTROL
JI Tob. Control
PD JUN
PY 2009
VL 18
IS 3
BP 245
EP 248
DI 10.1136/tc.2008.025478
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 448PE
UT WOS:000266273700016
PM 19168475
ER
PT J
AU Sachs, DH
Sykes, M
Yamada, K
AF Sachs, David H.
Sykes, Megan
Yamada, Kazuhiko
TI Achieving tolerance in pig-to-primate xenotransplantation: Reality or
fantasy
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article
DE Xenotransplantation; Clinical xenografting; Transplantation; Tolerance;
Chimerism
ID GENE-KNOCKOUT PIGS; THYMIC LOBE TRANSPLANTATION; BONE-MARROW
ENGRAFTMENT; TRANSGENIC PORCINE KIDNEY; SKIN-GRAFT TOLERANCE; HUMAN
IMMUNE-SYSTEM; XENOGRAFT REJECTION; MINIATURE SWINE; THROMBOTIC
MICROANGIOPATHY; XENOGENEIC BARRIER
AB Because the immunologic differences between species are far greater than those within species, it is likely that the amount of immunosuppression that would be required for successful xenografting would be so much greater than that now used for allografting, that the side-effects and complications would be unacceptable. Tolerance approaches to xenotransplantation would overcome this concern. Studies in humanized mouse models have demonstrated that human T cells can be tolerized to porcine xenografts, providing important proofs of principle of the potential feasibility of pig-to-primate xenograft tolerance. The results available from studies of pig-to-primate xenotransplantation to date have demonstrated that while chronic immunosuppressive drugs have not completely avoided either T cell responses or humoral rejection, approaches directed toward tolerance induction have been encouraging with regard to avoiding immunization at both of these levels. (C) 2008 Published by Elsevier B.V.
C1 [Sachs, David H.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Sachs, DH (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
EM david.sachs@tbrc.mgh.harvard.edu
FU NIAID NIH HHS [P01 AI045897, P01 AI045897-08]
NR 70
TC 17
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD JUN
PY 2009
VL 21
IS 2
BP 101
EP 105
DI 10.1016/j.trim.2008.11.005
PG 5
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 467IW
UT WOS:000267733200009
PM 19059481
ER
PT J
AU Lang, K
Marciniak, MD
Faries, D
Stokes, M
Buesching, D
Earle, C
Treat, J
Babineaux, S
Morissette, N
Thompson, D
AF Lang, Kathleen
Marciniak, Martin D.
Faries, Douglas
Stokes, Michael
Buesching, Don
Earle, Craig
Treat, Joseph
Babineaux, Steve
Morissette, Nathalie
Thompson, David
TI Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in
Advanced Non-small-Cell Lung Cancer in the United States
SO VALUE IN HEALTH
LA English
DT Article
DE cost analysis; gemcitabine; longitudinal analysis; lung cancer;
pharmacoeconomics
ID TRIAL
AB The purpose of this study was to identify total lifetime medical-care costs and costs associated with first-line chemotherapy treatment among older patients with stage IIIB/IV non-small-cell lung cancer treated with commonly used two-drug chemotherapy ("doublet") regimens in the United States.
Study patients included individuals aged 65 years and older who received a diagnosis of stage IIIB/IV non-small-cell lung cancer in a Surveillance, Epidemiology and End Results cancer registry between 1997 and 2002 and who received first-line treatment with commonly used doublet regimens. Patients were followed retrospectively in the Surveillance, Epidemiology and End Results-Medicare database to evaluate lifetime medical-care costs and costs while on first-line chemotherapy treatment. Pairwise comparisons of treatment costs were estimated by using nonparametric bootstrap methods.
Lifetime medical-care costs totaled approximately $70,000 and on-treatment costs for first-line chemotherapy totaled approximately $30,000 among study patients and were dominated by hospitalization and physician costs. Lifetime costs were significantly higher among patients treated with first-line cisplatin/carboplatin (platinum) plus a taxane compared with those who received platinum plus gemcitabine [difference: $4781 ($1558-$8039)] or other doublet therapy [difference: $5961 ($2333-$9614)]. Total on-treatment costs for first-line chemotherapy were significantly higher among patients treated with platinum plus a taxane compared with those who received platinum plus gemcitabine [difference: $5825 ($3872-$7770)], platinum plus another agent [difference: $5968 ($3995-$7975)], or another doublet therapy [difference: $3663 ($1620-$5740)].
There is a cost differential between first-line doublet regimens in terms of lifetime and on-treatment costs. Although doublet therapy with platinum and a taxane was the most frequently utilized regimen, it was associated with the highest lifetime and on-treatment costs.
C1 [Marciniak, Martin D.] Eli Lilly & Co, Lilly Corp Ctr, Global Hlth Outcomes Res US, Indianapolis, IN 46285 USA.
[Lang, Kathleen; Stokes, Michael; Morissette, Nathalie; Thompson, David] I3 Innovus, Medford, MA USA.
[Earle, Craig] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Marciniak, MD (reprint author), Eli Lilly & Co, Lilly Corp Ctr, Global Hlth Outcomes Res US, DC 6831, Indianapolis, IN 46285 USA.
EM marciniak_martin@lilly.com
NR 20
TC 8
Z9 8
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2009
VL 12
IS 4
BP 481
EP 488
DI 10.1111/j.1524-4733.2008.00472.x
PG 8
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 451JZ
UT WOS:000266467800014
PM 18980633
ER
PT J
AU Kong, CY
McMahon, PM
Gazelle, GS
AF Kong, Chung Yin
McMahon, Pamela M.
Gazelle, G. Scott
TI Calibration of Disease Simulation Model Using an Engineering Approach
SO VALUE IN HEALTH
LA English
DT Article
DE algorithms; calibration; lung cancer; simulation model
ID LUNG-CANCER MORTALITY; SMOKING; COHORT; PERIOD; WOMEN; RATES; AGE;
ADENOCARCINOMA; TRENDS
AB Calibrating a disease simulation model's outputs to existing clinical data is vital to generate confidence in the model's predictive ability. Calibration involves two challenges: 1) defining a total goodness-of-fit (GOF) score for multiple targets if simultaneous fitting is required, and 2) searching for the optimal parameter set that minimizes the total GOF score (i.e., yields the best fit). To address these two prominent challenges, we have applied an engineering approach to calibrate a microsimulation model, the Lung Cancer Policy Model (LCPM).
First, 11 targets derived from clinical and epidemiologic data were combined into a total GOF score by a weighted-sum approach, accounting for the user-defined relative importance of the calibration targets. Second, two automated parameter search algorithms, simulated annealing (SA) and genetic algorithm (GA), were independently applied to a simultaneous search of 28 natural history parameters to minimize the total GOF score. Algorithm performance metrics were defined for speed and model fit.
Both search algorithms obtained total GOF scores below 95 within 1000 search iterations. Our results show that SA outperformed GA in locating a lower GOF. After calibrating our LCPM, the predicted natural history of lung cancer was consistent with other mathematical models of lung cancer development.
An engineering-based calibration method was able to simultaneously fit LCPM output to multiple calibration targets, with the benefits of fast computational speed and reduced the need for human input and its potential bias.
C1 [Kong, Chung Yin; McMahon, Pamela M.; Gazelle, G. Scott] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Kong, Chung Yin; McMahon, Pamela M.; Gazelle, G. Scott] Harvard Univ, Sch Med, Boston, MA USA.
[Gazelle, G. Scott] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Kong, CY (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 10th Floor,101 Merrimac St, Boston, MA 02114 USA.
EM joey@mgh-ita.org
FU NCI NIH HHS [R00 CA126147, K99 CA126147-02, R01 CA97337, R01
CA097337-03, R01 CA097337, K99 CA126147, R01 CA097337-03S1]
NR 42
TC 23
Z9 23
U1 1
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2009
VL 12
IS 4
BP 521
EP 529
DI 10.1111/j.1524-4733.2008.00484.x
PG 9
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 451JZ
UT WOS:000266467800018
PM 19900254
ER
PT J
AU Lasser, KE
Murillo, J
Medlin, E
Lisboa, S
Valley-Shah, L
Fletcher, RH
Emmons, KM
Ayanian, JZ
AF Lasser, Karen E.
Murillo, Jennifer
Medlin, Elizabeth
Lisboa, Sandra
Valley-Shah, Lisa
Fletcher, Robert H.
Emmons, Karen M.
Ayanian, John Z.
TI A multilevel intervention to promote colorectal cancer screening among
community health center patients: results of a pilot study
SO BMC FAMILY PRACTICE
LA English
DT Article
ID FECAL OCCULT BLOOD; CONTROLLED-TRIAL; NAVIGATION; MORTALITY; CARE;
SIGMOIDOSCOPY; DISPARITIES; COLONOSCOPY; POPULATION; BARRIERS
AB Background: Colorectal cancer screening rates are low among poor and disadvantaged patients. Patient navigation has been shown to increase breast and cervical cancer screening rates, but few studies have looked at the potential of patient navigation to increase colorectal cancer screening rates.
Methods: The objective was to determine the feasibility and effectiveness of a patient navigator-based intervention to increase colorectal cancer screening rates in community health centers. Patients at the intervention health center who had not been screened for colorectal cancer and were designated as "appropriate for outreach" by their primary care providers received a letter from their provider about the need to be screened and a brochure about colorectal cancer screening. Patient navigators then called patients to discuss screening and to assist patients in obtaining screening. Patients at a demographically similar control health center received usual care.
Results: Thirty-one percent of intervention patients were screened at six months, versus nine percent of control patients (p < .001).
Conclusion: A patient navigator-based intervention, in combination with a letter from the patient's primary care provider, was associated with an increased rate of colorectal cancer screening at one health center as compared to a demographically similar control health center. Our study adds to an emerging literature supporting the use of patient navigators to increase colorectal cancer screening in diverse populations served by urban health centers.
C1 [Lasser, Karen E.] Boston Med Ctr, Gen Internal Med Sect, Boston, MA USA.
[Lasser, Karen E.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Murillo, Jennifer] Cambridge Hlth Alliance, Dept Med, Cambridge, MA USA.
[Murillo, Jennifer; Lisboa, Sandra; Valley-Shah, Lisa] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Medlin, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Lisboa, Sandra] Cambridge Hlth Alliance, Dept Community Affairs, Cambridge, MA USA.
[Valley-Shah, Lisa] Cambridge Hlth Alliance, Dept Gastroenterol, Cambridge, MA USA.
[Fletcher, Robert H.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
[Fletcher, Robert H.] Harvard Pilgrim Hlth Care, Boston, MA USA.
[Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ayanian, John Z.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA.
[Ayanian, John Z.] Harvard Univ, Sch Med, Boston, MA USA.
RP Lasser, KE (reprint author), Boston Med Ctr, Gen Internal Med Sect, Boston, MA USA.
EM karen.lasser@bmc.org; jmurillo@challiance.org; bnd0@cdc.gov;
slisboa@challiance.org; lvalley@challiance.org;
robert_fletcher@hms.harvard.edu; Karen_M_Emmons@dfci.harvard.edu;
ayanian@hcp.med.harvard.edu
OI Lasser, Karen/0000-0003-3777-6075
FU American Cancer Society [MRSGT-05-007-01-CPPB]
FX We would like to acknowledge the patients and PCPs who participated in
the study. This study was supported by Mentored Research Scholar Grant
MRSGT-05-007-01-CPPB from the American Cancer Society. (Dr. Lasser)
NR 28
TC 42
Z9 45
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1471-2296
J9 BMC FAM PRACT
JI BMC Fam. Pract.
PD MAY 29
PY 2009
VL 10
AR 37
DI 10.1186/1471-2296-10-37
PG 7
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 467RE
UT WOS:000267759300001
PM 19480698
ER
PT J
AU Koenen, KC
DeVivo, I
Rich-Edwards, J
Smoller, JW
Wright, RJ
Purcell, SM
AF Koenen, Karestan C.
DeVivo, Immaculata
Rich-Edwards, Janet
Smoller, Jordan W.
Wright, Rosalind J.
Purcell, Shaun M.
TI Protocol for investigating genetic determinants of posttraumatic stress
disorder in women from the Nurses' Health Study II
SO BMC PSYCHIATRY
LA English
DT Review
ID ADVERSE CHILDHOOD EXPERIENCES; NATIONAL COMORBIDITY SURVEY; POPULATION
GROUP ASSIGNMENT; FACE-TO-FACE; RISK-FACTORS; ENVIRONMENTAL-INFLUENCES;
TRAUMA EXPOSURE; YOUNG-ADULTS; PSYCHIATRIC-DISORDERS; INITIAL
RELIABILITY
AB Background: One in nine American women will meet criteria for the diagnosis of posttraumatic stress disorder (PTSD) in their lifetime. Although twin studies suggest genetic influences account for substantial variance in PTSD risk, little progress has been made in identifying variants in specific genes that influence liability to this common, debilitating disorder.
Methods and design: We are using the unique resource of the Nurses Health Study II, a prospective epidemiologic cohort of 68,518 women, to conduct what promises to be the largest candidate gene association study of PTSD to date. The entire cohort will be screened for trauma exposure and PTSD; 3,000 women will be selected for PTSD diagnostic interviews based on the screening data. Our nested case-control study will genotype1000 women who developed PTSD following a history of trauma exposure; 1000 controls will be selected from women who experienced similar traumas but did not develop PTSD.
The primary aim of this study is to detect genetic variants that predict the development of PTSD following trauma. We posit inherited vulnerability to PTSD is mediated by genetic variation in three specific neurobiological systems whose alterations are implicated in PTSD etiology: the hypothalamic-pituitary-adrenal axis, the locus coeruleus/noradrenergic system, and the limbic-frontal neuro-circuitry of fear. The secondary, exploratory aim of this study is to dissect genetic influences on PTSD in the broader genetic and environmental context for the candidate genes that show significant association with PTSD in detection analyses. This will involve: conducting conditional tests to identify the causal genetic variant among multiple correlated signals; testing whether the effect of PTSD genetic risk variants is moderated by age of first trauma, trauma type, and trauma severity; and exploring gene-gene interactions using a novel gene-based statistical approach.
Discussion: Identification of liability genes for PTSD would represent a major advance in understanding the pathophysiology of the disorder. Such understanding could advance the development of new pharmacological agents for PTSD treatment and prevention. Moreover, the addition of PTSD assessment data will make the NHSII cohort an unparalleled resource for future genetic studies of PTSD as well as provide the unique opportunity for the prospective examination of PTSD-disease associations.
C1 [Koenen, Karestan C.; Wright, Rosalind J.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[DeVivo, Immaculata; Rich-Edwards, Janet] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Koenen, Karestan C.; DeVivo, Immaculata; Rich-Edwards, Janet; Wright, Rosalind J.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
[Smoller, Jordan W.; Purcell, Shaun M.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Ctr Genet Res, Boston, MA 02114 USA.
[Smoller, Jordan W.; Purcell, Shaun M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Purcell, Shaun M.] Broad Inst, Cambridge, MA 02141 USA.
RP Koenen, KC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM kkoenen@hsph.harvard.edu; devivo@channing.harvard.edu;
jr33@partners.org; jordan_smoller@hms.harvard.edu;
rosalind.wright@channing.harvard.edu; shaun@pngu.mgh.harvard.edu
RI Koenen, Karestan/K-5402-2014
OI Koenen, Karestan/0000-0003-3293-4281
FU [MH078828]; [CA50385]; [HL/MH 64108]; [K08 MH070627]
FX This study is supported by MH078828 ( PI, Karestan Koenen). The Nurses'
Health Study II is supported by CA50385 ( PI, Walter Willett).
Collection of data for the 2001 Violence Questionnaire was supported by
HL/MH 64108 ( PI, Rosalind Wright). Dr. Koenen is also supported by K08
MH070627.
NR 134
TC 15
Z9 15
U1 5
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-244X
J9 BMC PSYCHIATRY
JI BMC Psychiatry
PD MAY 29
PY 2009
VL 9
AR 29
DI 10.1186/1471-244X-9-29
PG 20
WC Psychiatry
SC Psychiatry
GA 471UF
UT WOS:000268083100003
PM 19480706
ER
PT J
AU Scholl, C
Frohling, S
Dunn, IF
Schinzel, AC
Barbie, DA
Kim, SY
Silver, SJ
Tamayo, P
Wadlow, RC
Ramaswamy, S
Dohner, K
Bullinger, L
Sandy, P
Boehm, JS
Root, DE
Jacks, T
Hahn, WC
Gilliland, DG
AF Scholl, Claudia
Froehling, Stefan
Dunn, Ian F.
Schinzel, Anna C.
Barbie, David A.
Kim, So Young
Silver, Serena J.
Tamayo, Pablo
Wadlow, Raymond C.
Ramaswamy, Sridhar
Doehner, Konstanze
Bullinger, Lars
Sandy, Peter
Boehm, Jesse S.
Root, David E.
Jacks, Tyler
Hahn, William C.
Gilliland, D. Gary
TI Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33
Suppression in Human Cancer Cells
SO CELL
LA English
DT Article
ID LENTIVIRAL RNAI LIBRARY; K-RAS ONCOGENE; MULTIPLE-MYELOMA; TUMOR-CELLS;
N-RAS; GROWTH; SCREEN; MUTATIONS; SURVIVAL; GENES
AB An alternative to therapeutic targeting of oncogenes is to perform "synthetic lethality'' screens for genes that are essential only in the context of specific cancer-causing mutations. We used high-throughput RNA interference (RNAi) to identify synthetic lethal interactions in cancer cells harboring mutant KRAS, the most commonly mutated human oncogene. We find that cells that are dependent on mutant KRAS exhibit sensitivity to suppression of the serine/threonine kinase STK33 irrespective of tissue origin, whereas STK33 is not required by KRAS-independent cells. STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells. These observations identify STK33 as a target for treatment of mutant KRAS-driven cancers and demonstrate the potential of RNAi screens for discovering functional dependencies created by oncogenic mutations that may enable therapeutic intervention for cancers with "undruggable'' genetic alterations.
C1 [Scholl, Claudia; Froehling, Stefan; Hahn, William C.; Gilliland, D. Gary] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Dunn, Ian F.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
[Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Hahn, William C.; Gilliland, D. Gary] Harvard Univ, Dana Farber Canc Inst, Sch Med, Dept Med Oncol, Boston, MA 02115 USA.
[Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Hahn, William C.] Harvard Univ, Dana Farber Canc Inst, Sch Med, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Hahn, William C.] Harvard Univ, Dana Farber Canc Inst, Sch Med, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Silver, Serena J.; Tamayo, Pablo; Ramaswamy, Sridhar; Boehm, Jesse S.; Root, David E.; Jacks, Tyler; Hahn, William C.; Gilliland, D. Gary] Broad Inst Harvard, Cambridge, MA 02142 USA.
[Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Silver, Serena J.; Tamayo, Pablo; Ramaswamy, Sridhar; Boehm, Jesse S.; Root, David E.; Jacks, Tyler; Hahn, William C.; Gilliland, D. Gary] MIT, Cambridge, MA 02142 USA.
[Barbie, David A.; Wadlow, Raymond C.; Ramaswamy, Sridhar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
[Wadlow, Raymond C.; Ramaswamy, Sridhar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc Res, Boston, MA 02114 USA.
[Wadlow, Raymond C.; Ramaswamy, Sridhar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA.
[Ramaswamy, Sridhar; Gilliland, D. Gary] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Doehner, Konstanze; Bullinger, Lars] Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany.
[Sandy, Peter; Jacks, Tyler] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Sandy, Peter; Jacks, Tyler] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Jacks, Tyler] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
[Gilliland, D. Gary] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Gilliland, D. Gary] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Hahn, WC (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
EM william_hahn@dfci.harvard.edu; ggilliland@rics.bwh.harvard.edu
OI Boehm, Jesse/0000-0002-6795-6336
FU National Institutes of Health [R33 CA128625, U54 CA112962, P01 CA095616,
P01 CA66996]; Starr Cancer Consortium; Doris Duke Charitable Foundation;
MPD Foundation; Leukemia and Lymphoma Society; Deutsche
Forschungsgemeinschaft [SCHO 1215/1-1, FR 2113/1-1]; Brain Science
Foundation
FX We thank Maricel Gozo for technical support, the Broad Institute RNAi
Platform for assistance with high-throughput screening, and John Blenis,
Benjamin G. Neel, Demetrios Kalaitzidis, Michael G. Kharas, Thomas
Kindler, Steven W. Lane, Stephen M. Sykes, and members of the Gilliland
and Hahn laboratories for valuable discussions and reagents. This work
was supported by National Institutes of Health grants R33 CA128625, U54
CA112962, P01 CA095616 ( to W. C. H.), and P01 CA66996 ( to D. G. G.),
and grants from the Starr Cancer Consortium ( to W. C. H. and D. G. G.),
the Doris Duke Charitable Foundation ( to D. G. G.), the MPD Foundation
( to D. G. G), and the Leukemia and Lymphoma Society ( to D. G. G.). C.
S. and S. F. were supported by grants SCHO 1215/1-1 and FR 2113/1-1 from
the Deutsche Forschungsgemeinschaft. I. F. D. was supported by the Brain
Science Foundation.
NR 63
TC 304
Z9 312
U1 6
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAY 29
PY 2009
VL 137
IS 5
BP 821
EP 834
DI 10.1016/j.cell.2009.03.017
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 451EZ
UT WOS:000266454800014
PM 19490892
ER
PT J
AU Luo, J
Emanuele, MJ
Li, DN
Creighton, CJ
Schlabach, MR
Westbrook, TF
Wong, KK
Elledge, SJ
AF Luo, Ji
Emanuele, Michael J.
Li, Danan
Creighton, Chad J.
Schlabach, Michael R.
Westbrook, Thomas F.
Wong, Kwok-Kin
Elledge, Stephen J.
TI A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal
Interactions with the Ras Oncogene
SO CELL
LA English
DT Article
ID ANAPHASE-PROMOTING COMPLEX; SMALL-MOLECULE INHIBITOR; XENOPUS-LAEVIS
EGGS; HUMAN CANCER-CELLS; POLO-LIKE KINASE-1; K-RAS; LUNG
ADENOCARCINOMA; ACTIVATING MUTATIONS; MITOTIC ENTRY; N-RAS
AB Oncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understanding of the vulnerabilities of these cancers is lacking. We undertook a genome-wide RNAi screen to identify synthetic lethal interactions with the KRAS oncogene. We discovered a diverse set of proteins whose depletion selectively impaired the viability of Ras mutant cells. Among these we observed a strong enrichment for genes with mitotic functions. We describe a pathway involving the mitotic kinase PLK1, the anaphase-promoting complex/cyclosome, and the proteasome that, when inhibited, results in prometaphase accumulation and the subsequent death of Ras mutant cells. Gene expression analysis indicates that reduced expression of genes in this pathway correlates with increased survival of patients bearing tumors with a Ras transcriptional signature. Our results suggest a previously underappreciated role for Ras in mitotic progression and demonstrate a pharmacologically tractable pathway for the potential treatment of cancers harboring Ras mutations.
C1 [Luo, Ji; Emanuele, Michael J.; Schlabach, Michael R.; Elledge, Stephen J.] Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med,Howard Hughes Med Inst, Boston, MA 02115 USA.
[Luo, Ji; Emanuele, Michael J.; Schlabach, Michael R.; Elledge, Stephen J.] Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med,Dept Genet, Boston, MA 02115 USA.
[Li, Danan; Wong, Kwok-Kin] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Li, Danan; Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Ctr, Dept Med Oncol, Boston, MA 02115 USA.
[Creighton, Chad J.] Baylor Coll Med, Div Biostat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Westbrook, Thomas F.] Baylor Coll Med, Dept Mol & Human Genet, Dan L Duncan Canc Ctr, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.
RP Elledge, SJ (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med,Howard Hughes Med Inst, Boston, MA 02115 USA.
EM selledge@genetics.med.harvard.edu
OI wong, kwok kin/0000-0001-6323-235X
FU AACR Prevent Cancer Foundation AstraZeneca Fellowship in Translational
Lung Cancer Research; Damon Runyon Cancer Research Foundation
[DRG-1996-08]; NIH [R01 CA122794, R01 AG2400401, P30 CA125123]; DF/HCC
Lung Cancer SPORE grant [P50 CA090578]; Susan G. Komen for the Cure
Foundation [KG090355]; Howard Hughes Medical Institute
FX We thank Drs. Bert Vogelstein and Victor Velculescu for the DLD-1 and
HCT116 cells and Dr. Nathanael Gray and SAI Advantium for help with the
synthesis of BI-2536. We thank Matthew Buttarazzi, Nicholas Kwiatkowski,
Dror Berel, and Dr. Chandra Miduturu for technical assistance and Drs.
Greg Hannon, Nicole Solimini, Tim Mitchison, and Randal King for helpful
discussions. J. L. is supported by the AACR Prevent Cancer Foundation
AstraZeneca Fellowship in Translational Lung Cancer Research. M. J. E.
is the Philip O'Bryan Montgomery Jr., MD fellow of the Damon Runyon
Cancer Research Foundation (DRG-1996-08). K.-K. W. is supported by NIH
grants R01 CA122794 and R01 AG2400401 and the DF/HCC Lung Cancer SPORE
grant P50 CA090578. C. J. C. and T. F. W. are supported in part by NIH
grant P30 CA125123. T. F. W. is supported by the Susan G. Komen for the
Cure Foundation ( KG090355). This work is supported by grants from NIH
and DOD to S. J. E., and S. J. E. is an investigator with the Howard
Hughes Medical Institute.
NR 50
TC 494
Z9 505
U1 6
U2 40
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAY 29
PY 2009
VL 137
IS 5
BP 835
EP 848
DI 10.1016/j.cell.2009.05.006
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 451EZ
UT WOS:000266454800015
PM 19490893
ER
PT J
AU Peterson, TR
Laplante, M
Thoreen, CC
Sancak, Y
Kang, SA
Kuehl, WM
Gray, NS
Sabatini, DM
AF Peterson, Timothy R.
Laplante, Mathieu
Thoreen, Carson C.
Sancak, Yasemin
Kang, Seong A.
Kuehl, W. Michael
Gray, Nathanael S.
Sabatini, David M.
TI DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma
Cells and Required for Their Survival
SO CELL
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; C-MAF; PHOSPHORYLATION; KINASE; RAPAMYCIN;
COMPLEX; AKT; PROTEASOME; CANCER; GROWTH
AB The mTORC1 and mTORC2 pathways regulate cell growth, proliferation, and survival. We identify DEPTOR as an mTOR-interacting protein whose expression is negatively regulated by mTORC1 and mTORC2. Loss of DEPTOR activates S6K1, Akt, and SGK1, promotes cell growth and survival, and activates mTORC1 and mTORC2 kinase activities. DEPTOR overexpression suppresses S6K1 but, by relieving feedback inhibition from mTORC1 to PI3K signaling, activates Akt. Consistent with many human cancers having activated mTORC1 and mTORC2 pathways, DEPTOR expression is low in most cancers. Surprisingly, DEPTOR is highly overexpressed in a subset of multiple myelomas harboring cyclin D1/D3 or c-MAF/MAFB translocations. In these cells, high DEPTOR expression is necessary to maintain PI3K and Akt activation and a reduction in DEPTOR levels leads to apoptosis. Thus, we identify a novel MTOR-interacting protein whose deregulated overexpression in multiple myeloma cells represents a mechanism for activating PI3K/Akt signaling and promoting cell survival.
C1 [Peterson, Timothy R.; Laplante, Mathieu; Thoreen, Carson C.; Sancak, Yasemin; Kang, Seong A.; Sabatini, David M.] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Peterson, Timothy R.; Laplante, Mathieu; Thoreen, Carson C.; Sancak, Yasemin; Kang, Seong A.; Sabatini, David M.] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
[Sabatini, David M.] MIT, Koch Ctr Integrat Canc Res, Cambridge, MA 02139 USA.
[Kuehl, W. Michael] NCI, Bethesda, MD 20814 USA.
[Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Sabatini, DM (reprint author), Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
EM sabatini@wi.mit.edu
FU National Institutes of Health [R01 AI47389, R01 CA103866]; Keck
Foundation; LAM Foundation; American Diabetes Association; Canadian
Institutes of Health Research; American Cancer Society; Intramural
Research Program; National Cancer Institute; Center for Cancer Research;
Dana Farber Cancer Institute High-Tech Research Fund; Howard Hughes
Medical Institute
FX The authors thank Thijn Brummelkamp for reviewing the manuscript and the
following for technical assistance: Leslie Brents, Stephen Carr, Jake
Jaffe, Xana Frias, Heather Keys, Stephanie Kinkel, Doug McMillin, Jan
Reiling, Eric Spooner, Ed Van Veen, and Marcel Van Vugt. We thank
members of the Sabatini lab for helpful discussions. This work was
supported by grants from the National Institutes of Health ( NIH; R01
AI47389 and R01 CA103866) to D. M. S.; awards from the Keck Foundation
and LAM Foundation to D. M. S.; a fellowship from the American Diabetes
Association to T. R. P.; a fellowship from the Canadian Institutes of
Health Research to M. L.; and a fellowship from the American Cancer
Society to S. A. K. W. M. K was supported in part by the Intramural
Research Program of the NIH, National Cancer Institute, Center for
Cancer Research. N. S. G. is funded in part by the Dana Farber Cancer
Institute High-Tech Research Fund. D. M. S. is an investigator of the
Howard Hughes Medical Institute.
NR 47
TC 472
Z9 487
U1 5
U2 54
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAY 29
PY 2009
VL 137
IS 5
BP 873
EP 886
DI 10.1016/j.cell.2009.03.046
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 451EZ
UT WOS:000266454800018
PM 19446321
ER
PT J
AU Vanhoorelbeke, K
De Meyer, SF
Pareyn, I
Melchior, C
Plancon, S
Margue, C
Pradier, O
Fondu, P
Kieffer, N
Springer, TA
Deckmyn, H
AF Vanhoorelbeke, Karen
De Meyer, Simon F.
Pareyn, Inge
Melchior, Chantal
Plancon, Sebastien
Margue, Christiane
Pradier, Olivier
Fondu, Pierre
Kieffer, Nelly
Springer, Timothy A.
Deckmyn, Hans
TI The Novel S527F Mutation in the Integrin beta 3 Chain Induces a High
Affinity alpha IIb beta 3 Receptor by Hindering Adoption of the Bent
Conformation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DISULFIDE BOND DISRUPTION; CYSTEINE-RICH REPEAT; CRYSTAL-STRUCTURE;
EXTRACELLULAR SEGMENT; STRUCTURAL BASIS; POINT MUTATION; ACTIVATION;
LIGAND; DOMAIN; ALPHA(IIB)BETA(3)
AB Three heterozygous mutations were identified in the genes encoding platelet integrin receptor alpha IIb beta 3 in a patient with an ill defined platelet disorder: one in the beta 3 gene (S527F) and two in the alpha IIb gene (R512W and L841M). Five stable Chinese hamster ovary cell lines were constructed expressing recombinant alpha IIb beta 3 receptors bearing the individual R512W, L841M, or S527F mutation; both the R512W and L841M mutations; or all three mutations. All receptors were expressed on the cell surface, and mutations R512W and L841M had no effect on integrin function. Interestingly, the beta 3 S527F mutation produced a constitutively active receptor. Indeed, both fibrinogen and the ligand-mimetic antibody PAC-1 bound to non-activated alpha IIb beta 3 receptors carrying the S527F mutation, indicating that the conformation of this receptor was altered and corresponded to the high affinity ligand binding state. In addition, the conformational change induced by S527F was evident from basal anti-ligand-induced binding site antibody binding to the receptor. A molecular model bearing this mutation was constructed based on the crystal structure of alpha IIb beta 3 and revealed that the S527F mutation, situated in the third integrin epidermal growth factor-like (I-EGF3) domain, hindered the alpha IIb beta 3 receptor from adopting a wild type-like bent conformation. Movement of I-EGF3 into a cleft in the bent conformation may be hampered both by steric hindrance between Phe(527) in beta 3 and the calf-1 domain in alpha IIb and by decreased flexibility between I-EGF2 and I-EGF3.
C1 [Vanhoorelbeke, Karen; De Meyer, Simon F.; Pareyn, Inge; Deckmyn, Hans] Katholieke Univ Leuven, Lab Thrombosis Res, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium.
[Melchior, Chantal; Plancon, Sebastien; Margue, Christiane; Kieffer, Nelly] Univ Luxembourg, Lab Biol & Physiol Integree, CNRS, GDRE ITI, L-1511 Luxembourg, Luxembourg.
[Fondu, Pierre] Univ Libre Bruxelles, Ctr Hosp Univ Brugmann, B-1050 Brussels, Belgium.
[Pradier, Olivier] Univ Libre Bruxelles, Hop Erasme, B-1050 Brussels, Belgium.
[Springer, Timothy A.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
RP Vanhoorelbeke, K (reprint author), Katholieke Univ Leuven, Lab Thrombosis Res, Interdisciplinary Res Ctr, Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.
EM Karen.Vanhoorelbeke@kuleuven-kortrijk.be
RI Deckmyn, Hans/L-9434-2015;
OI Deckmyn, Hans/0000-0003-3952-5501; Vanhoorelbeke,
Karen/0000-0003-2288-8277
FU National Institutes of Health [HL48675]; Katholieke Universiteit Leuven
[GOA/2004/09]; European Union-RTN [HPRN-CT-2002-00253]; "Fonds voor
Wetenschappelijk Onderzoek Vlaanderen" Belgium
FX Postdoctoral Fellow supported by the "Fonds voor Wetenschappelijk
Onderzoek Vlaanderen" Belgium.
NR 24
TC 11
Z9 12
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 29
PY 2009
VL 284
IS 22
BP 14914
EP 14920
DI 10.1074/jbc.M809167200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 448UT
UT WOS:000266288200027
PM 19329429
ER
PT J
AU Hutti, JE
Shen, RR
Abbott, DW
Zhou, AY
Sprott, KM
Asara, JM
Hahn, WC
Cantley, LC
AF Hutti, Jessica E.
Shen, Rhine R.
Abbott, Derek W.
Zhou, Alicia Y.
Sprott, Kam M.
Asara, John M.
Hahn, William C.
Cantley, Lewis C.
TI Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer
Oncogene IKK epsilon Promotes Cell Transformation
SO MOLECULAR CELL
LA English
DT Article
ID NF-KAPPA-B; DEUBIQUITINATING ENZYME CYLD; TOLL-LIKE-RECEPTORS; SIGNALING
PATHWAYS; ANTIVIRAL RESPONSE; MULTIPLE-MYELOMA; WIDE PREDICTION; KINASE;
PROTEIN; CYLINDROMATOSIS
AB The noncanonical IKK family member IKK epsilon is essential for regulating antiviral signaling pathways and is a recently discovered breast cancer oncoprotein. Although several IKK epsilon targets have been described, direct IKK epsilon substrates necessary for regulating cell transformation have not been identified. Here, we performed a screen for putative IKK epsilon substrates using an unbiased proteomic and bioinformatic approach. Using a positional scanning peptide library assay, we determined the optimal phosphorylation motif for IKK epsilon and used bioinformatic approaches to predict IKK epsilon substrates. Of these potential substrates, serine 418 of the tumor suppressor CYLD was identified as a likely site of IKK epsilon phosphorylation. We confirmed that CYLD is directly phosphorylated by IKK epsilon and that IKK epsilon phosphorylates serine 418 in vivo. Phosphorylation of CYLD at serine 418 decreases its deubiquitinase activity and is necessary for IKK epsilon-driven transformation. Together, these observations define IKK epsilon and CYLD as an oncogene-tumor suppressor network that participates in tumorigenesis.
C1 [Hutti, Jessica E.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Hutti, Jessica E.; Asara, John M.; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA.
[Shen, Rhine R.; Zhou, Alicia Y.; Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Shen, Rhine R.; Zhou, Alicia Y.; Hahn, William C.; Cantley, Lewis C.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Abbott, Derek W.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
[Sprott, Kam M.] Cell Signaling Technol Inc, Danvers, MA 01923 USA.
[Asara, John M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Cantley, LC (reprint author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
EM lcantley@hms.harvard.edu
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
FU NIH [R01 GM-56203, R01 CA130988]; DoD Breast Cancer Research Program
[W81XWH-07-01-0408]; Susan G. Komen for the Cure; Burroughs-Wellcome
Career Award for Biomedical Scientists
FX We thank members of the Cantley and Hahn labs for technical assistance
and critical comments. This work was supported by NIH R01 GM-56203
(L.C.C.), NIH R01 CA130988 (W.C.H.), DoD Breast Cancer Research Program
grant W81XWH-07-01-0408 (W.C.H.), a grant from Susan G. Komen for the
Cure (R.R.S.), and a Burroughs-Wellcome Career Award for Biomedical
Scientists (D.W.A.).
NR 40
TC 111
Z9 113
U1 3
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAY 29
PY 2009
VL 34
IS 4
BP 461
EP 472
DI 10.1016/j.molcel.2009.04.031
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 453NN
UT WOS:000266617600011
PM 19481526
ER
PT J
AU Loh, YH
Agarwal, S
Park, IH
Urbach, A
Huo, HG
Heffner, GC
Kim, KT
Miller, JD
Ng, KW
Daley, GQ
AF Loh, Yuin-Han
Agarwal, Suneet
Park, In-Hyun
Urbach, Achia
Huo, Hongguang
Heffner, Garrett C.
Kim, Kitai
Miller, Justine D.
Ng, Kitwa
Daley, George Q.
TI Generation of induced pluripotent stem cells from human blood
SO BLOOD
LA English
DT Article
ID HUMAN SOMATIC-CELLS; DEFINED FACTORS
AB Human dermal fibroblasts obtained by skin biopsy can be reprogrammed directly to pluripotency by the ectopic expression of defined transcription factors. Here, we describe the derivation of induced pluripotent stem cells from CD34(+) mobilized human peripheral blood cells using retroviral transduction of OCT4/SOX2/KLF4/MYC. Blood-derived human induced pluripotent stem cells are indistinguishable from human embryonic stem cells with respect to morphology, expression of surface antigens, and pluripotency-associated transcription factors, DNA methylation status at pluripotent cell-specific genes, and the capacity to differentiate in vitro and in teratomas. The ability to reprogram cells from human blood will allow the generation of patient-specific stem cells for diseases in which the disease-causing somatic mutations are restricted to cells of the hematopoietic lineage. (Blood. 2009; 113: 5476-5479)
C1 [Loh, Yuin-Han; Agarwal, Suneet; Park, In-Hyun; Urbach, Achia; Huo, Hongguang; Heffner, Garrett C.; Kim, Kitai; Miller, Justine D.; Ng, Kitwa; Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Loh, Yuin-Han; Agarwal, Suneet; Park, In-Hyun; Urbach, Achia; Huo, Hongguang; Heffner, Garrett C.; Kim, Kitai; Miller, Justine D.; Ng, Kitwa; Daley, George Q.] Harvard Univ, Sch Med, Dept Med,Dana Farber Canc Inst, Div Pediat Hematol Oncol,Childrens Hosp Boston, Boston, MA USA.
[Loh, Yuin-Han; Agarwal, Suneet; Park, In-Hyun; Urbach, Achia; Huo, Hongguang; Heffner, Garrett C.; Kim, Kitai; Miller, Justine D.; Ng, Kitwa; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA.
[Loh, Yuin-Han; Agarwal, Suneet; Park, In-Hyun; Urbach, Achia; Huo, Hongguang; Heffner, Garrett C.; Kim, Kitai; Miller, Justine D.; Ng, Kitwa; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
[Daley, George Q.] Manton Ctr Orphan Dis Res, Boston, MA USA.
RP Daley, GQ (reprint author), Childrens Hosp, Howard Hughes Med Inst, Karp Family Res Bldg 7214,300 Longwood Ave, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
RI Loh, Yuin-Han/E-1096-2014
OI Loh, Yuin-Han/0000-0002-4715-6454
FU National Institutes of Health (Bethesda, MD); A*Star (Agency of Science,
Technology and Research) International Fellowship; A*Star Graduate
Academy; Institute of Medical Biology, Singapore; BurroughsWellcome Fund
Clinical Scientist Award in Translational Research (Research Triangle
Park, NC).
FX This work was supported by grants from the National Institutes of Health
(Bethesda, MD) and the NIH Director's Pioneer Award of the NIH Roadmap
for Medical Research. Y.-H.L. is a recipient of the A*Star (Agency of
Science, Technology and Research) International Fellowship and was
funded by the A*Star Graduate Academy and the Institute of Medical
Biology, Singapore. G. Q. D. is a recipient of the BurroughsWellcome
Fund Clinical Scientist Award in Translational Research (Research
Triangle Park, NC).
NR 18
TC 302
Z9 324
U1 5
U2 23
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 28
PY 2009
VL 113
IS 22
BP 5476
EP 5479
DI 10.1182/blood-2009-02-204800
PG 4
WC Hematology
SC Hematology
GA 453TD
UT WOS:000266634700017
PM 19299331
ER
PT J
AU Jesneck, JL
Mukherjee, S
Yurkovetsky, Z
Clyde, M
Marks, JR
Lokshin, AE
Lo, JY
AF Jesneck, Jonathan L.
Mukherjee, Sayan
Yurkovetsky, Zoya
Clyde, Merlise
Marks, Jeffrey R.
Lokshin, Anna E.
Lo, Joseph Y.
TI Do serum biomarkers really measure breast cancer?
SO BMC CANCER
LA English
DT Article
ID MIGRATION INHIBITORY FACTOR; MASS-SPECTROMETRY; OVARIAN-CANCER;
PROTEOMIC ANALYSIS; MODEL UNCERTAINTY; TUMOR-MARKERS; CA 15-3;
FEATURE-SELECTION; INTERFERON-ALPHA; GENE-EXPRESSION
AB Background: Because screening mammography for breast cancer is less effective for premenopausal women, we investigated the feasibility of a diagnostic blood test using serum proteins.
Methods: This study used a set of 98 serum proteins and chose diagnostically relevant subsets via various feature-selection techniques. Because of significant noise in the data set, we applied iterated Bayesian model averaging to account for model selection uncertainty and to improve generalization performance. We assessed generalization performance using leave-one-out cross-validation (LOOCV) and receiver operating characteristic (ROC) curve analysis.
Results: The classifiers were able to distinguish normal tissue from breast cancer with a classification performance of AUC = 0.82 +/- 0.04 with the proteins MIF, MMP-9, and MPO. The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 +/- 0.05. However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06). The classification tasks of normal vs. cancer and normal vs. benign selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.
Conclusion: Overall, the selected serum proteins showed moderate ability for detecting lesions. However, they are probably more indicative of secondary effects such as inflammation rather than specific for malignancy.
C1 [Lo, Joseph Y.] Duke Univ, Med Ctr, Dept Radiol, Duke Adv Imaging Labs, Durham, NC 27710 USA.
[Jesneck, Jonathan L.] MIT, Cambridge, MA 02142 USA.
[Jesneck, Jonathan L.] Harvard Univ, Broad Inst, Canc Program, Cambridge, MA 02142 USA.
[Jesneck, Jonathan L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Mukherjee, Sayan; Clyde, Merlise] Duke Univ, Dept Stat Sci, Durham, NC 27708 USA.
[Mukherjee, Sayan; Marks, Jeffrey R.] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA.
[Mukherjee, Sayan] Duke Univ, Dept Comp Sci, Durham, NC 27708 USA.
[Yurkovetsky, Zoya; Lokshin, Anna E.] Univ Pittsburgh, Sch Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA.
[Yurkovetsky, Zoya; Lokshin, Anna E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.
[Marks, Jeffrey R.] Duke Univ, Med Ctr, Dept Expt Surg, Durham, NC 27710 USA.
[Lo, Joseph Y.] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
[Lo, Joseph Y.] Duke Univ, Med Phys Grad Program, Durham, NC 27708 USA.
RP Lo, JY (reprint author), Duke Univ, Med Ctr, Dept Radiol, Duke Adv Imaging Labs, Durham, NC 27710 USA.
EM JonathanL_Jesneck@dfci.harvard.edu; sayan@stat.duke.edu;
yurkovetskyz@upmc.edu; clyde@stat.duke.edu; marks003@mc.duke.edu;
loksax@UPMC.EDU; Joseph.Lo@duke.edu
OI Mukherjee, Sayan/0000-0002-6715-3920
FU NIH [NIH CA 84955, R01 CA-112437- 01]; U.S. Army [W81XWH-05-1-0292]
FX The work was supported in part by the NIH (NIH CA 84955 and R01
CA-112437- 01) and the U.S. Army Breast Cancer Research Program (Grant
No. W81XWH-05-1-0292).
NR 88
TC 31
Z9 31
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 28
PY 2009
VL 9
AR 164
DI 10.1186/1471-2407-9-164
PG 13
WC Oncology
SC Oncology
GA 466DA
UT WOS:000267639700002
PM 19476629
ER
PT J
AU Volandes, AE
Paasche-Orlow, MK
Barry, MJ
Gillick, MR
Minaker, KL
Chang, YC
Cook, EF
Abbo, ED
El-Jawahri, A
Mitchell, SL
AF Volandes, Angelo E.
Paasche-Orlow, Michael K.
Barry, Michael J.
Gillick, Muriel R.
Minaker, Kenneth L.
Chang, Yuchiao
Cook, E. Francis
Abbo, Elmer D.
El-Jawahri, Areej
Mitchell, Susan L.
TI Video decision support tool for advance care planning in dementia:
randomised controlled trial
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID LIFE-SUSTAINING TREATMENTS; SERIOUSLY ILL PATIENTS; PATIENT PREFERENCES;
HEALTH LITERACY; END; STABILITY; DIRECTIVES; COMMUNICATION;
RESUSCITATION; DISCUSSIONS
AB Objective To evaluate the effect of a video decision support tool on the preferences for future medical care in older people if they develop advanced dementia, and the stability of those preferences after six weeks.
Design Randomised controlled trial conducted between 1 September 2007 and 30 May 2008.
Setting Four primary care clinics (two geriatric and two adult medicine) affiliated with three academic medical centres in Boston.
Participants Convenience sample of 200 older people (>= 65 years) living in the community with previously scheduled appointments at one of the clinics. Mean age was 75 and 58% were women.
Intervention Verbal narrative alone (n=106) or with a video decision support tool (n=94).
Main outcome measures Preferred goal of care: life prolonging care (cardiopulmonary resuscitation, mechanical ventilation), limited care (admission to hospital, antibiotics, but not cardiopulmonary resuscitation), or comfort care (treatment only to relieve symptoms). Preferences after six weeks. The principal category for analysis was the difference in proportions of participants in each group who preferred comfort care.
Results Among participants receiving the verbal narrative alone, 68 (64%) chose comfort care, 20 (19%) chose limited care, 15 (14%) chose life prolonging care, and three (3%) were uncertain. In the video group, 81 (86%) chose comfort care, eight (9%) chose limited care, four (4%) chose life prolonging care, and one (1%) was uncertain (chi(2)=13.0, df=3, P=0.003). Among all participants the factors associated with a greater likelihood of opting for comfort care were being a college graduate or higher, good or better health status, greater health literacy, white race, and randomisation to the video arm. In multivariable analysis, participants in the video group were more likely to prefer comfort care than those in the verbal group (adjusted odds ratio 3.9, 95% confidence interval 1.8 to 8.6). Participants were re-interviewed after six weeks. Among the 94/106 (89%) participants re-interviewed in the verbal group, 27 (29%) changed their preferences (kappa=0.35). Among the 84/94 (89%) participants re-interviewed in the video group, five (6%) changed their preferences (kappa=0.79) (P<0.001 for difference).
Conclusion Older people who view a video depiction of a patient with advanced dementia after hearing a verbal description of the condition are more likely to opt for comfort as their goal of care compared with those who solely listen to a verbal description. They also have more stable preferences over time.
Trial registration Clinicaltrials.gov NCT00704886.
C1 [Volandes, Angelo E.; Barry, Michael J.; Minaker, Kenneth L.; Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Gen Med Unit, Boston, MA 02114 USA.
[Paasche-Orlow, Michael K.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Gillick, Muriel R.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Harvard Pilgrim, Boston, MA 02215 USA.
[Cook, E. Francis] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Abbo, Elmer D.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Mitchell, Susan L.] Hebrew SeniorLife, Boston, MA 02131 USA.
RP Volandes, AE (reprint author), Massachusetts Gen Hosp, Dept Med, Gen Med Unit, 50 Staniford St, Boston, MA 02114 USA.
EM avolandes@partners.org
OI Paasche-Orlow, Michael/0000-0002-9276-7190
FU Foundation for Informed Medical Decision Making; Alzheimer's
Association; Hartford Foundation
FX AEV was supported by a George Bennett Fellowship from the Foundation for
Informed Medical Decision Making, a New Investigator Research Grant from
the Alzheimer's Association, and a Center for Excellence Career
Development Award from the Hartford Foundation. Role of the sponsor:
None of the foundations participated in the collection, analysis, or
interpretation of the data or in preparation, review, or approval of the
manuscript.
NR 53
TC 103
Z9 103
U1 3
U2 21
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAY 28
PY 2009
VL 338
AR b1964
DI 10.1136/bmj.b2159
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 451WU
UT WOS:000266502400001
PM 19477893
ER
PT J
AU Greer, DM
Friday, RP
Romero, J
Auluck, PK
AF Greer, David M.
Friday, Robert P.
Romero, Javier
Auluck, Pavan K.
TI A Man with Progressive Neurologic Deficits Neuro-Behcet's disease
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; CNS INVOLVEMENT;
MANIFESTATIONS; MANAGEMENT; DIAGNOSIS; CRITERIA; MRI
C1 [Greer, David M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Friday, Robert P.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Romero, Javier] Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02114 USA.
[Auluck, Pavan K.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Greer, David M.] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA.
[Friday, Robert P.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Romero, Javier] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA.
[Auluck, Pavan K.] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA.
RP Greer, DM (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RI Auluck, Pavan/A-1160-2010
NR 35
TC 5
Z9 5
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 28
PY 2009
VL 360
IS 22
BP 2341
EP 2351
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449YO
UT WOS:000266367300012
PM 19474432
ER
PT J
AU Liu, SH
Howell, P
Ren, SP
Fodstad, O
Riker, AI
AF Liu, Suhu
Howell, Paul
Ren, Suping
Fodstad, Oystein
Riker, Adam I.
TI The 14-3-3 sigma gene promoter is methylated in both human melanocytes
and melanoma
SO BMC CANCER
LA English
DT Article
ID DNA METHYLATION; BREAST-CANCER; CPG ISLANDS; EARLY EVENT;
HYPERMETHYLATION; EXPRESSION; CARCINOMA; INACTIVATION; ASSOCIATION;
P16(INK4A)
AB Background: Recent evidence demonstrates that 14-3-3 sigma acts as a tumor suppressor gene inactivated by methylation of its 5' CpG islands in epithelial tumor cells, while remaining un-methylated in normal human epithelia. The methylation analysis of 14-3-3 sigma has been largely overlooked in melanoma.
Methods: The methylation status of 14-3-3 sigma CpG island in melanocytes and melanoma cells was analyzed by methylation-specific sequencing (MSS) and quantitative methylation-specific PCR (Q-MSP). 14-3-3 sigma mRNA and protein expression in cell lines was detected by real-time RT-PCR and western blot. Melanoma cells were also treated by 5-aza-2'-deoxycytidine (DAC), a demethylating agent, and/or histone deacetylase inhibitor, Trichostatin A (TSA), to evaluate their effects on 14-3-3 sigma gene expression.
Results: 14-3-3 sigma is hypermethylated in both human melanocytes and most melanoma cells in a lineage-specific manner, resulting in the silencing of 14-3-3 sigma gene expression and the active induction of 14-3-3 sigma mRNA and protein expression following treatment with DAC. We also observed a synergistic effect upon gene expression when DAC was combined with TSA. The promoter methylation status of 14-3-3 sigma was analyzed utilizing Q-MSP in 20 melanoma tissue samples and 10 cell lines derived from these samples, showing that the majority of melanoma samples maintain their hypermethylation status of the 14-3-3 sigma gene.
Conclusion: 14-3-3 sigma is hypermethylated in human melanoma in a cell-linage specific manner. Spontaneous demethylation and re-expression of 14-3-3 sigma is a rare event in melanoma, indicating 14-3-3 sigma might have a tentative role in the pathogenesis of melanoma.
C1 [Riker, Adam I.] Ochsner Canc Inst, Dept Surg, New Orleans, LA 70121 USA.
[Liu, Suhu] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Howell, Paul; Ren, Suping] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.
[Fodstad, Oystein] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.
[Fodstad, Oystein] Univ Oslo, Fac Med, Norwegian Radium Hosp, Fac Div, Oslo, Norway.
RP Riker, AI (reprint author), Ochsner Canc Inst, Dept Surg, 1514 Jefferson Highway,BH334, New Orleans, LA 70121 USA.
EM suhu_liu@dfci.harvard.edu; paulhowell@usouthal.edu; sren@usouthal.edu;
Oystein.Fodstad@rr-research.no; ariker@ochsner.org
FU Abraham A. Mitchell Clinical Research Scholar Fund
FX Adam I. Riker is the recipient of the Abraham A. Mitchell Clinical
Research Scholar Fund, providing the necessary funding and resources for
the completion of this manuscript.
NR 20
TC 4
Z9 8
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 27
PY 2009
VL 9
AR 162
DI 10.1186/1471-2407-9-162
PG 7
WC Oncology
SC Oncology
GA 466CX
UT WOS:000267639400002
PM 19473536
ER
PT J
AU Kolster, H
Mandeville, JB
Arsenault, JT
Ekstrom, LB
Wald, LL
Vanduffel, W
AF Kolster, Hauke
Mandeville, Joseph B.
Arsenault, John T.
Ekstrom, Leeland B.
Wald, Lawrence L.
Vanduffel, Wim
TI Visual Field Map Clusters in Macaque Extrastriate Visual Cortex
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID SUPERIOR TEMPORAL SULCUS; OCCIPITAL CORTEX; AREA TEO; MONKEY; MOTION;
FMRI; ORGANIZATION; CONNECTIONS; SELECTIVITY; HUMANS
AB The macaque visual cortex contains >30 different functional visual areas, yet surprisingly little is known about the underlying organizational principles that structure its components into a complete "visual" unit. A recent model of visual cortical organization in humans suggests that visual field maps are organized as clusters. Clusters minimize axonal connections between individual field maps that represent common visual percepts, with different clusters thought to carry out different functions. Experimental support for this hypothesis, however, is lacking in macaques, leaving open the question of whether it is unique to humans or a more general model for primate vision. Here we show, using high-resolution blood oxygen level-dependent functional magnetic resonance imaging data in the awake monkey at 7 T, that the middle temporal area (area MT/V5) and its neighbors are organized as a cluster with a common foveal representation and a circular eccentricity map. This novel view on the functional topography of area MT/V5 and satellites indicates that field map clusters are evolutionarily preserved and may be a fundamental organizational principle of the Old World primate visual cortex.
C1 [Kolster, Hauke; Mandeville, Joseph B.; Arsenault, John T.; Ekstrom, Leeland B.; Wald, Lawrence L.; Vanduffel, Wim] Massachusetts Gen Hosp East, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Kolster, Hauke; Mandeville, Joseph B.; Wald, Lawrence L.; Vanduffel, Wim] Harvard Univ, Sch Med, Dept Radiol, Charlestown, MA 02129 USA.
[Ekstrom, Leeland B.; Wald, Lawrence L.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Ekstrom, Leeland B.] MIT, Dept Nucl Sci & Engn, Cambridge, MA 02139 USA.
[Vanduffel, Wim] Katholieke Univ Leuven, Sch Med, Neuro & Psychofysiol Lab, B-3000 Louvain, Belgium.
RP Vanduffel, W (reprint author), Massachusetts Gen Hosp East, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM wim@nmr.mgh.harvard.edu
RI Wald, Lawrence/D-4151-2009
FU Natural Sciences and Engineering Research Council of Canada; Human
Frontier Science Program Organization; Geneeskundige Stichting Koningin
Elisabeth, Inter-university Attraction Pole; Excellentie Financiering
[EF/05/014]; Geconcerteerde Onderzoeksactie [GOA/10/019]
FX This work received support from a Natural Sciences and Engineering
Research Council of Canada postgraduate scholarship, the Human Frontier
Science Program Organization, Geneeskundige Stichting Koningin
Elisabeth, Inter-university Attraction Pole 5/04, Excellentie
Financiering EF/05/014, Geconcerteerde Onderzoeksactie GOA/10/019, Fonds
voor Wetenschappelijk Onderzoek Grants G.0622.08 and G.0593.09, National
Institute of Biomedical Imaging and Bioengineering Grants R01-EB00790
and R01EB006847, and National Science Foundation Grant BCS-0745436. The
Martinos Center is supported by the National Center for Research
Resources Grant P41RR14075 and the Mental Illness and Neuroscience
Discovery Institute. We thank H. Deng for animal training and care, R.
Tootell, A. Potthast, and B. Rosen for advice and support, and L.
Ungerleider, B. Wandell, G. Orban, K. Nelissen, and J. Polimeni for
valuable comments on the manuscript.
NR 45
TC 67
Z9 67
U1 0
U2 4
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 27
PY 2009
VL 29
IS 21
BP 7031
EP 7039
DI 10.1523/JNEUROSCI.0518-09.2009
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 450YV
UT WOS:000266438800029
PM 19474330
ER
PT J
AU Walker, RH
Koch, RJ
Sweeney, JE
Moore, C
Meshul, CK
AF Walker, Ruth H.
Koch, Rick J.
Sweeney, John E.
Moore, Cynthia
Meshul, Charles K.
TI Effects of subthalamic nucleus lesions and stimulation upon glutamate
levels in the dopamine-depleted rat striatum
SO NEUROREPORT
LA English
DT Article
DE deep brain stimulation; glutamate; 6-hydroxydopamine; microdialysis;
Parkinson's disease; rat; striatum; subthalamic nucleus
ID HIGH-FREQUENCY STIMULATION; PARKINSONS-DISEASE; BASAL GANGLIA;
SUBSTANTIA-NIGRA; NEURONS; TRANSMISSION; OVERACTIVITY; RETICULATA;
INCREASE
AB It is not known how neurosurgical interventions benefit patients with Parkinson's disease. We compared the effects of electrical stimulation and electrolytic lesions of the subthalamic nucleus upon striatal extracellular glutamate levels in awake rats, either intact or which had undergone unilateral 6-hydroxydopamine lesions. Two hours of subthalamic nucleus stimulation had no effect in either group. Subthalamic nucleus lesions of intact animals increased striatal glutamate levels. Subthalamic nucleus lesions of 6-hydroxydopamine-lesioned rats decreased striatal glutamate levels. As dopamine depletion alone increased striatal glutamate, subthalamic nucleus lesioning decreased levels to normal. Thus, subthalamic nucleus lesions and short-term stimulation have different effects upon striatal glutamate. The effects of lesions differed depending upon the presence of dopamine. These results suggest that short-term electrical stimulation does not result in a direct inhibitory effect upon the subthalamic nucleus. NeuroReport 20:770-775 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Walker, Ruth H.; Koch, Rick J.] James J Peters Vet Adm Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Sweeney, John E.; Moore, Cynthia; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA.
[Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA.
RP Walker, RH (reprint author), James J Peters Vet Adm Med Ctr, Dept Neurol, 130 W Kingsbridge Rd 127, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
FU Parkinson's Disease Foundation International Research Grant; Veterans
Affairs Merit awards
FX This study was supported by a Parkinson's Disease Foundation
International Research Grant to R.H.W and by Veterans Affairs Merit
awards to R.H.W and C.K.M.
NR 25
TC 19
Z9 20
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD MAY 27
PY 2009
VL 20
IS 8
BP 770
EP 775
DI 10.1097/WNR.0b013e32832ad556
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 446UP
UT WOS:000266147100007
PM 19373115
ER
PT J
AU Mottron, L
Dawson, M
Soulieres, I
AF Mottron, Laurent
Dawson, Michelle
Soulieres, Isabelle
TI Enhanced perception in savant syndrome: patterns, structure and
creativity
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT Joint Discussion Meeting of the Royal-Society/British Academy on Autism
and Talent
CY 2008
CL Royal Soc, London, ENGLAND
SP British Acad
HO Royal Soc
DE autism; savant syndrome; perception; creativity; pattern recognition;
redintegration
ID CALENDRICAL CALCULATORS; IDIOT-SAVANT; HYPERLEXIC CHILDREN;
VISUAL-PERCEPTION; SPECTRUM-DISORDER; AUTISTIC SAVANT; MEMORY;
PERFORMANCE; FMRI; TASK
AB According to the enhanced perceptual functioning (EPF) model, autistic perception is characterized by: enhanced low-level operations; locally oriented processing as a default setting; greater activation of perceptual areas during a range of visuospatial, language, working memory or reasoning tasks; autonomy towards higher processes; and superior involvement in intelligence. EPF has been useful in accounting for autistic relative peaks of ability in the visual and auditory modalities. However, the role played by atypical perceptual mechanisms in the emergence and character of savant abilities remains underdeveloped. We now propose that enhanced detection of patterns, including similarity within and among patterns, is one of the mechanisms responsible for operations on human codes, a type of material with which savants show particular facility. This mechanism would favour an orientation towards material possessing the highest level of internal structure, through the implicit detection of within- and between-code isomorphisms. A second mechanism, related to but exceeding the existing concept of redintegration, involves completion, or filling-in, of missing information in memorized or perceived units or structures. In the context of autistics' enhanced perception, the nature and extent of these two mechanisms, and their possible contribution to the creativity evident in savant performance, are explored.
C1 [Mottron, Laurent; Dawson, Michelle; Soulieres, Isabelle] Hop Riviere des Prairies, Clin Specialise Autisme, Montreal, PQ H1E 1A4, Canada.
[Mottron, Laurent; Soulieres, Isabelle] Univ Montreal, Dept Psychiat, Montreal, PQ H3T 1J4, Canada.
[Soulieres, Isabelle] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02215 USA.
RP Mottron, L (reprint author), Hop Riviere des Prairies, Clin Specialise Autisme, 7070 Blvd Perras, Montreal, PQ H1E 1A4, Canada.
EM mottronl@istar.ca
NR 64
TC 66
Z9 66
U1 2
U2 33
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD MAY 27
PY 2009
VL 364
IS 1522
BP 1385
EP 1391
DI 10.1098/rstb.2008.0333
PG 7
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 432AH
UT WOS:000265105400006
PM 19528021
ER
PT J
AU Ebrahimi, R
Dyke, C
Mehran, R
Manoukian, SV
Feit, F
Cox, DA
Gersh, BJ
Ohman, EM
White, HD
Moses, JW
Ware, JH
Lincoff, AM
Stone, GW
AF Ebrahimi, Ramin
Dyke, Cornelius
Mehran, Roxana
Manoukian, Steven V.
Feit, Frederick
Cox, David A.
Gersh, Bernard J.
Ohman, E. Magnus
White, Harvey D.
Moses, Jeffrey W.
Ware, James H.
Lincoff, A. Michael
Stone, Gregg W.
TI Outcomes Following Pre-Operative Clopidogrel Administration in Patients
With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery
The ACUITY (Acute Catheterization and Urgent Intervention Triage
strategY) Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE coronary artery bypass surgery; clopidogrel; acute coronary syndromes
ID ST-SEGMENT ELEVATION; UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; ASPIRIN;
REVASCULARIZATION; COMBINATION; MANAGEMENT; BENEFITS; IMPACT; CURE
AB Objectives This study sought to evaluate the impact of upstream clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Background Despite benefits of clopidogrel in patients with NSTE-ACS undergoing percutaneous coronary intervention, this agent is often not administered upstream (before angiography) as recommended by the American College of Cardiology/American Heart Association guidelines because of potential bleeding in the minority of patients who require CABG.
Methods The ACUITY trial enrolled 13,819 patients with NSTE-ACS undergoing early invasive management. The timing of clopidogrel initiation was per investigator discretion. A 5-day washout period before CABG was recommended for patients having received clopidogrel.
Results Of 13,819 patients enrolled, 1,539 (11.1%) underwent CABG before discharge. Clopidogrel-exposed patients had a longer median duration of hospitalization (12.0 days vs. 8.9 days, p < 0.0001), but fewer adverse composite ischemic events (death, myocardial infarction, or unplanned revascularization) at 30 days; 12.7% vs. 17.3%, p = 0.01), with nonsignificantly different rates of non-CABG-related major bleeding (3.4% vs. 3.2%, p = 0.87) and post-CABG major bleeding (50.3% vs. 50.9%, p = 0.83) compared with those patients not administered clopidogrel. By multivariable analysis, clopidogrel use before CABG was an independent predictor of reduced 30-day composite ischemia (odds ratio: 0.67, 95% confidence interval: 0.48 to 0.92, p = 0.001) but not of increased post-CABG major bleeding (odds ratio: 0.98, 95% confidence interval: 0.80 to 1.19, p = 0.80).
Conclusions Clopidogrel administration before catheterization in patients with NSTE-ACS requiring CABG is associated with significantly fewer 30-day adverse ischemic events without significantly increasing major bleeding, compared to withholding clopidogrel until after angiography. These findings support the American College of Cardiology/American Heart Association guidelines for upstream clopidogrel administration in all NSTE-ACS patients, including those who subsequently undergo CABG. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158). (J Am Coll Cardiol 2009; 53: 1965-72) c 2009 by the American College of Cardiology Foundation
C1 [Ebrahimi, Ramin] Greater Los Angeles VA Med Ctr, Dept Med, Cardiol Sect 111E, Los Angeles, CA 90073 USA.
[Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA 90073 USA.
[Dyke, Cornelius] Gaston Mem Hosp, Gastonia, NC USA.
[Mehran, Roxana; Moses, Jeffrey W.; Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA.
[Mehran, Roxana; Stone, Gregg W.] Cardiovas Res Fdn, New York, NY USA.
[Manoukian, Steven V.] Sarah Cannon Res Inst, Nashville, TN USA.
[Manoukian, Steven V.] Centennial Heart Ctr, Nashville, TN USA.
[Feit, Frederick] NYU, Sch Med, New York, NY USA.
[Cox, David A.] Lehigh Valley Hosp, Allentown, PA USA.
[Gersh, Bernard J.] Mayo Clin, Rochester, MN USA.
[Ohman, E. Magnus] Duke Univ, Med Ctr, Durham, NC USA.
[White, Harvey D.] Auckland City Hosp, Auckland, New Zealand.
[Ware, James H.] Harvard Univ, Boston, MA 02115 USA.
[Lincoff, A. Michael] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Ebrahimi, R (reprint author), Greater Los Angeles VA Med Ctr, Dept Med, Cardiol Sect 111E, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ebrahimi@UCLA.edu
NR 19
TC 86
Z9 94
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 26
PY 2009
VL 53
IS 21
BP 1965
EP 1972
DI 10.1016/j.jacc.2009.03.006
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 448BP
UT WOS:000266236800005
PM 19460609
ER
PT J
AU Ristow, M
Zarse, K
Oberbach, A
Kloting, N
Birringer, M
Kiehntopf, M
Stumvoll, M
Kahn, CR
Bluher, M
AF Ristow, Michael
Zarse, Kim
Oberbach, Andreas
Kloeting, Nora
Birringer, Marc
Kiehntopf, Michael
Stumvoll, Michael
Kahn, C. Ronald
Blueher, Matthias
TI Antioxidants prevent health-promoting effects of physical exercise in
humans
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE aging; hormesis; insulin resistance; oxidative stress; reactive oxygen
species
ID RANDOMIZED CONTROLLED-TRIAL; TYPE-2 DIABETES-MELLITUS;
INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; OXIDATIVE STRESS;
SKELETAL-MUSCLE; PLASMA-CONCENTRATIONS; VITAMIN-E; RISK; SUPPLEMENTATION
AB Exercise promotes longevity and ameliorates type 2 diabetes mellitus and insulin resistance. However, exercise also increases mitochondrial formation of presumably harmful reactive oxygen species (ROS). Antioxidants are widely used as supplements but whether they affect the health-promoting effects of exercise is unknown. We evaluated the effects of a combination of vitamin C (1000 mg/day) and vitamin E (400 IU/day) on insulin sensitivity as measured by glucose infusion rates (GIR) during a hyperinsulinemic, euglycemic clamp in previously untrained (n = 19) and pretrained (n = 20) healthy young men. Before and after a 4 week intervention of physical exercise, GIR was determined, and muscle biopsies for gene expression analyses as well as plasma samples were obtained to compare changes over baseline and potential influences of vitamins on exercise effects. Exercise increased parameters of insulin sensitivity (GIR and plasma adiponectin) only in the absence of antioxidants in both previously untrained (P < 0.001) and pretrained (P < 0.001) individuals. This was paralleled by increased expression of ROS-sensitive transcriptional regulators of insulin sensitivity and ROS defense capacity, peroxisome-proliferator-activated receptor gamma (PPAR gamma), and PPAR gamma coactivators PGC1 alpha and PGC1 beta only in the absence of antioxidants (P < 0.001 for all). Molecular mediators of endogenous ROS defense (superoxide dismutases 1 and 2; glutathione peroxidase) were also induced by exercise, and this effect too was blocked by antioxidant supplementation. Consistent with the concept of mitohormesis, exercise-induced oxidative stress ameliorates insulin resistance and causes an adaptive response promoting endogenous antioxidant defense capacity. Supplementation with antioxidants may preclude these health-promoting effects of exercise in humans.
C1 [Ristow, Michael; Zarse, Kim; Birringer, Marc] Univ Jena, Inst Nutr, Dept Human Nutr, D-07743 Jena, Germany.
[Ristow, Michael] German Inst Human Nutr, D-14558 Potsdam, Germany.
[Oberbach, Andreas; Kloeting, Nora; Stumvoll, Michael; Blueher, Matthias] Univ Leipzig, Dept Med, D-04103 Leipzig, Germany.
[Kiehntopf, Michael] Univ Jena, Inst Clin Chem & Lab Med, D-07743 Jena, Germany.
[Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
RP Ristow, M (reprint author), Univ Jena, Inst Nutr, Dept Human Nutr, D-07743 Jena, Germany.
EM mristow@mristow.org
RI Ristow, Michael/O-9858-2014; Zarse, Kim/D-2133-2016;
OI Ristow, Michael/0000-0003-2109-2453; Zarse, Kim/0000-0003-2542-6123;
Birringer, Marc/0000-0003-0343-4704
FU Deutsche Forschungsgemeinschaft [RI 1076/1-3, KFO 152]
FX The authors thank all 40 study subjects for their voluntary
participation. This work was supported by Deutsche
Forschungsgemeinschaft (German Research Association) Grant RI 1076/1-3
to M. R. and Grant KFO 152 "Atherobesity'' (and specifically BL 833/1-1)
to M. Bluher and M. S.
NR 35
TC 627
Z9 637
U1 18
U2 127
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 26
PY 2009
VL 106
IS 21
BP 8665
EP 8670
DI 10.1073/pnas.0903485106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 450WS
UT WOS:000266432700047
PM 19433800
ER
PT J
AU Tyner, JW
Deininger, MW
Loriaux, MM
Chang, BH
Gotlib, JR
Willis, SG
Erickson, H
Kovacsovics, T
O'Hare, T
Heinrich, MC
Druker, BJ
AF Tyner, Jeffrey W.
Deininger, Michael W.
Loriaux, Marc M.
Chang, Bill H.
Gotlib, Jason R.
Willis, Stephanie G.
Erickson, Heidi
Kovacsovics, Tibor
O'Hare, Thomas
Heinrich, Michael C.
Druker, Brian J.
TI RNAi screen for rapid therapeutic target identification in leukemia
patients
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE acute lymphoblastic leukemia; acute myeloid leukemia; chronic
myelomonocytic leukemia; molecular diagnosis; personalized medicine
ID ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE
LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; GROWTH-FACTOR
RECEPTOR; TYROSINE KINASE ROR1; CELL LUNG-CANCER; ACTIVATING MUTATION;
SOMATIC MUTATIONS; FOLLOW-UP
AB Targeted therapy has vastly improved outcomes in certain types of cancer. Extension of this paradigm across a broad spectrum of malignancies will require an efficient method to determine the molecular vulnerabilities of cancerous cells. Improvements in sequencing technology will soon enable high-throughput sequencing of entire genomes of cancer patients; however, determining the relevance of identified sequence variants will require complementary functional analyses. Here, we report an RNAi-assisted protein target identification (RAPID) technology that individually assesses targeting of each member of the tyrosine kinase gene family. We demonstrate that RAPID screening of primary leukemia cells from 30 patients identifies targets that are critical to survival of the malignant cells from 10 of these individuals. We identify known, activating mutations in JAK2 and K-RAS, as well as patient-specific sensitivity to down-regulation of FLT1, CSF1R, PDGFR, ROR1, EPHA4/5, JAK1/3, LMTK3, LYN, FYN, PTK2B, and N-RAS. We also describe a previously undescribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to downstream pharmacologic inhibition. Hence, the RAPID technique can quickly identify molecular vulnerabilities in malignant cells. Combination of this technique with whole-genome sequencing will represent an ideal tool for oncogenic target identification such that specific therapies can be matched with individual patients.
C1 [Tyner, Jeffrey W.; Deininger, Michael W.; Loriaux, Marc M.; Willis, Stephanie G.; Erickson, Heidi; Kovacsovics, Tibor; O'Hare, Thomas; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Loriaux, Marc M.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Chang, Bill H.] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97239 USA.
[Gotlib, Jason R.] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA.
[O'Hare, Thomas; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR 97239 USA.
[Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Druker, BJ (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA.
EM drukerb@ohsu.edu
OI Chang, Bill/0000-0003-3783-1820; Tyner, Jeffrey/0000-0002-2133-0960
FU Leukemia and Lymphoma Society; T.J. Martell Foundation; Doris Duke
Charitable Foundation; National Institutes of Health Roadmap for Medical
Research; National Institutes of Health Cancer Biology Training; William
Lawrence and Blanche Hughes Fund; Oregon Clinical and Translational
Research Institute; National Center for Research Resources [UL1
RR024140]; Veterans Affairs Merit Review grant; Oregon Health & Science
University (OHSU) [5 p30 CA069533]
FX This work is supported in part by The Leukemia and Lymphoma Society, the
T.J. Martell Foundation, and the Doris Duke Charitable Foundation. J. W.
T. is supported by the National Institutes of Health Roadmap for Medical
Research, by grants from the National Institutes of Health Cancer
Biology Training, and from the William Lawrence and Blanche Hughes Fund,
and by the Oregon Clinical and Translational Research Institute Grant
UL1 RR024140 from the National Center for Research Resources. M. C. H.
is supported in part by a Veterans Affairs Merit Review grant. B. J. D.
is an investigator of the Howard Hughes Medical Institute and prinicipal
investigator of the Oregon Health & Science University (OHSU) Cancer
Center Support Grant 5 p30 CA069533.
NR 42
TC 57
Z9 58
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 26
PY 2009
VL 106
IS 21
BP 8695
EP 8700
DI 10.1073/pnas.0903233106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 450WS
UT WOS:000266432700052
PM 19433805
ER
PT J
AU Pollack, CE
Armstrong, K
AF Pollack, Craig Evan
Armstrong, Katrina
TI The Geographic Accessibility of Retail Clinics for Underserved
Populations
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID CARE
AB Background: The extent to which retail clinics provide access to care for underserved populations remains largely unknown. The purpose of this study was to determine whether retail clinics tend to be located in census tracts with higher medical need.
Methods: The locations of retail clinics as of July 1, 2008, were mapped and linked to the 2000 US Census and 2008 Health Resources and Services Administration data. Bi-variate analyses and logistic regression models with random effects were used to compare the characteristics of census tracts with and without retail clinics. To determine whether retail clinics followed the underlying distribution of chain stores, the location of clinics conditional on there being a chain store was analyzed in 6 counties.
Results: Of the 932 retail clinics, 930 were successfully mapped. Eighteen states had no retail clinics, and 17 states had 25 or more clinics. Within counties with at least 1 retail clinic, census tracts with retail clinics had a lower black population percentage, lower poverty rates, and higher median incomes and were less likely to be medically underserved areas/populations compared with census tracts without retail clinics. Similarly, stores with retail clinics were less likely to be located in medically underserved areas compared with stores without retail clinics.
Conclusion: Retail clinics are currently located in more advantaged neighborhoods, which may make them less accessible for those most in need. Arch Intern Med. 2009; 169(10): 945-949
C1 [Pollack, Craig Evan] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Pollack, Craig Evan; Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Armstrong, Katrina] Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA.
[Pollack, Craig Evan] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Pollack, CE (reprint author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM craige@mail.med.upenn.edu
FU Robert Wood Johnson Foundation Clinical Scholars Program
FX Funding/Support: The Robert Wood Johnson Foundation Clinical Scholars
Program at the University of Pennsylvania provided funding for this
research.
NR 20
TC 27
Z9 27
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 25
PY 2009
VL 169
IS 10
BP 945
EP 949
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449AZ
UT WOS:000266304500006
PM 19468086
ER
PT J
AU Huskamp, HA
Keating, NL
Malin, JL
Zaslavsky, AM
Weeks, JC
Earle, CC
Teno, JM
Virnig, BA
Kahn, KL
He, YL
Ayanian, JZ
AF Huskamp, Haiden A.
Keating, Nancy L.
Malin, Jennifer L.
Zaslavsky, Alan M.
Weeks, Jane C.
Earle, Craig C.
Teno, Joan M.
Virnig, Beth A.
Kahn, Katherine L.
He, Yulei
Ayanian, John Z.
TI Discussions With Physicians About Hospice Among Patients With Metastatic
Lung Cancer
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID CARE OUTCOMES RESEARCH; MEDICARE MANAGED CARE; OF-LIFE DISCUSSIONS;
SERIOUSLY ILL; CONTROLLED-TRIAL; END; DEATH; PROGNOSIS; COMMUNICATION;
PREFERENCES
AB Background: Many terminally ill patients enroll in hospice only in the final days before death or not at all. Discussing hospice with a health care provider could increase awareness of hospice and possibly result in earlier use.
Methods: We used data on 1517 patients diagnosed as having stage IV lung cancer from a multiregional study. We estimated logistic regression models for the probability that a patient discussed hospice with a physician or other health care provider before an interview 4 to 7 months after diagnosis as reported by either the patient or surrogate or documented in the medical record.
Results: Half (53%) of the patients had discussed hospice with a provider. Patients who were black, Hispanic, non-English speaking, married or living with a partner, Medicaid beneficiaries, or had received chemotherapy were less likely to have discussed hospice. Only 53% of individuals who died within 2 months after the interview had discussed hospice, and rates were lower among those who lived longer. Patients who reported that they expected to live less than 2 years had much higher rates of discussion than those expecting to live longer. Patients reporting the most severe pain or dyspnea were no more likely to have discussed hospice than those reporting less severe or no symptoms. A third of patients who reported discussing do-not-resuscitate preferences with a physician had also discussed hospice.
Conclusions: Many patients diagnosed as having metastatic lung cancer had not discussed hospice with a provider within 4 to 7 months after diagnosis. Increased communication with physicians could address patients' lack of awareness about hospice and misunderstandings about prognosis. Arch Intern Med. 2009; 169(10): 954-962
C1 [Huskamp, Haiden A.; Keating, Nancy L.; Zaslavsky, Alan M.; He, Yulei; Ayanian, John Z.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Keating, Nancy L.; Ayanian, John Z.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Weeks, Jane C.] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA.
[Malin, Jennifer L.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Kahn, Katherine L.] Univ Calif Los Angeles, Div Gen Internal Med, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Malin, Jennifer L.] Vet Affairs Hlth Care Syst, Greater Los Angeles, Los Angeles, CA USA.
[Malin, Jennifer L.; Kahn, Katherine L.] RAND Corp, Santa Monica, CA USA.
[Earle, Craig C.] Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.
[Teno, Joan M.] Brown Univ, Ctr Gerontol & Hlth Care Res, Dept Community Hlth, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Virnig, Beth A.] Univ Minnesota, Dept Hlth Policy & Management, Minneapolis, MN USA.
RP Huskamp, HA (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM huskamp@hcp.med.harvard.edu
FU National Cancer Institute (NCI) [U01 CA093344, U01 CA093332, U01
CA093324, U01 CA093348, U01 CA093329, U01 CA01013, U01 CA093326];
Department of Veterans Affairs Health Services Research and Development
Service [CRS 02-164]
FX Funding/Support: This work of the Cancer Care Outcomes Research and
Surveillance (CanCORS) Consortium was supported by grants from the
National Cancer Institute (NCI) to the Statistical Coordinating Center
(grant U01 CA093344) and the NCI-supported Primary Data Collection and
Research Centers (Dana Farber Cancer Institute/Cancer Research Network
grant U01 CA093332, Harvard Medical School/Northern California Cancer
Center grant U01 CA093324, RAND/UCLA grant U01 CA093348, University of
Alabama at Birmingham grant U01 CA093329, University of Iowa grant U01
CA01013, and University of North Carolina grant U01 CA093326) and by a
Department of Veterans Affairs Health Services Research and Development
Service grant (CRS 02-164) to the Durham VA Medical Center.
NR 56
TC 62
Z9 62
U1 3
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 25
PY 2009
VL 169
IS 10
BP 954
EP 962
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449AZ
UT WOS:000266304500009
PM 19468089
ER
PT J
AU Pham, HH
Landon, BE
Reschovsky, JD
Wu, B
Schrag, D
AF Pham, Hoangmai H.
Landon, Bruce E.
Reschovsky, James D.
Wu, Beny
Schrag, Deborah
TI Rapidity and Modality of Imaging for Acute Low Back Pain in Elderly
Patients
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID PRIMARY-CARE PHYSICIANS; COMORBIDITY INDEX; QUALITY; MEDICARE;
PERFORMANCE; ICD-9-CM
AB Background: Most quality metrics focus on underuse of services, leaving unclear what factors are associated with potential overuse.
Methods: We analyzed Medicare claims from 20002002 and 2004-2006 for 35 039 fee-for-service Medicare beneficiaries with acute low back pain (LBP) who were treated by 1 of 4567 primary care physicians responding to the 2000-2001 or 2004-2005 Community Tracking Study Physician Surveys. We modified a measure of inappropriate imaging developed by the National Committee on Quality Assurance. We characterized the rapidity (< 28 days, 29-180 days, none within 180 days) and modality of imaging (computed tomography or magnetic resonance imaging [CT/MRI], only radiograph, or no imaging). We used ordered logit models to assess relationships between imaging and patient demographics and physician/practice characteristics including exposure to financial incentives based on patient satisfaction, clinical quality, cost profiling, or productivity.
Results: Of 35 039 beneficiaries with LBP, 28.8% underwent imaging within 28 days and an additional 4.6% between 28 and 180 days. Among patients who received imaging, 88.2% received radiography, while 11.8% received CT/MRI as their initial study. White patients received higher levels of imaging than black patients or those of other races. Medicaid patients received less rapid or advanced imaging than other patients. Patients had higher levels of imaging if their primary care physician worked in large practices. Compared with no incentives, clinical quality-based incentives were associated with less advanced imaging (10.5% vs 1.4% for within 28 days; P < .001), whereas incentive combinations including satisfaction measures were associated with more rapid and advanced imaging. Results persisted in multivariate analyses and when the outcome was redefined as the number of imaging studies performed.
Conclusions: Rapidity and modality of imaging for LBP is associated with patient and physician characteristics but the directionality of associations with desirable care processes is opposite of associations for measures targeting underuse. Metrics that encompass overuse may suggest new areas of focus for quality improvement. Arch Intern Med. 2009; 169(10): 972-981
C1 [Pham, Hoangmai H.; Reschovsky, James D.] Ctr Studying Hlth Syst Change, Washington, DC 20024 USA.
[Landon, Bruce E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Hlth Policy, Boston, MA 02215 USA.
[Landon, Bruce E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Wu, Beny] Social & Sci Syst, Silver Spring, MD USA.
[Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Pham, HH (reprint author), Ctr Studying Hlth Syst Change, 600 Maryland Ave SW,Ste 550, Washington, DC 20024 USA.
EM mpham@hschange.org
FU Robert Wood Johnson Foundation; National Institute on Aging [R01
AG027312-02S1]
FX Funding/Support: This study and the Community Tracking Study Physician
Survey were supported by the Robert Wood Johnson Foundation. This
analysis was also supported by grant R01 AG027312-02S1 from the National
Institute on Aging.
NR 31
TC 43
Z9 43
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 25
PY 2009
VL 169
IS 10
BP 972
EP 981
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449AZ
UT WOS:000266304500011
PM 19468091
ER
PT J
AU Singh, H
Mani, S
Espadas, D
Petersen, N
Franklin, V
Petersen, LA
AF Singh, Hardeep
Mani, Shrinidi
Espadas, Donna
Petersen, Nancy
Franklin, Veronica
Petersen, Laura A.
TI Prescription Errors and Outcomes Related to Inconsistent Information
Transmitted Through Computerized Order Entry A Prospective Study
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID ADVERSE DRUG EVENTS; HEALTH-CARE; UNINTENDED CONSEQUENCES; MEDICATION
ERRORS; SYSTEMS; TECHNOLOGY; PREVENTION; CPOE
AB Background: Although several types of computerized provider order entry (CPOE)-related errors may occur, errors related to inconsistent information within the same prescription (ie, mismatch between the structured template and the associated free-text field) have not been described, to our knowledge. We determined the nature and frequency of such errors and identified their potential predictive variables.
Methods: In this prospective study, we enrolled pharmacists to report prescriptions containing inconsistent communication over a 4-month period at a tertiary care facility. We also electronically retrieved all prescriptions written during the study period containing any comments in the free-text field and then randomly selected 500 for manual review to determine inconsistencies between free-text and structured fields. Of these, prescriptions without inconsistencies were categorized as controls. Data on potentially predictive variables from reported and unreported errors and controls were collected. For all inconsistencies, we determined their nature (eg, drug dosage or administration schedule) and potential harm and used multivariate logistic regression models to identify factors associated with errors and harm.
Results: Of 55 992 new prescriptions, 532 (0.95%) were reported to contain inconsistent communication, a rate comparable to that obtained from the unreported group. Drug dosage was the most common inconsistent element among both groups. Certain medications were more likely associated with errors, as was the inpatient setting (odds ratio, 3.30; 95% confidence interval, 2.18-5.00) and surgical subspecialty (odds ratio, 2.45; 95% confidence interval, 1.57-3.82). About 20% of errors could have resulted in moderate to severe harm, for which significant independent predictors were found.
Conclusions: Despite standardization of data entry, inconsistent communication in CPOE poses a significant risk to safety. Improving the usability of the CPOE interface and integrating it with workflow may reduce this risk. Arch Intern Med. 2009; 169(10): 982-989
C1 [Singh, Hardeep; Mani, Shrinidi; Espadas, Donna; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev VA HSR&D, Houston, TX 77030 USA.
[Singh, Hardeep; Mani, Shrinidi; Espadas, Donna; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA.
[Franklin, Veronica] Baylor Coll Med, Pharm Sect, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
RP Singh, H (reprint author), Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.tmc.edu
FU Veterans Affairs National Center for Patient Safety; National Institutes
of Health [K23CA125585]; Houston VA HSR&D Center of Excellence
[HFP90-020]
FX Funding/Support: This study was supported by the Veterans Affairs
National Center for Patient Safety; National Institutes of Health K23
career development award K23CA125585 (Dr Singh); and in part by grant
HFP90-020 from the Houston VA HSR&D Center of Excellence (Dr L. A.
Petersen).
NR 32
TC 45
Z9 49
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 25
PY 2009
VL 169
IS 10
BP 982
EP 989
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449AZ
UT WOS:000266304500012
PM 19468092
ER
PT J
AU Evans, CL
Rizvi, I
Hasan, T
de Boer, JF
AF Evans, Conor L.
Rizvi, Imran
Hasan, Tayyaba
de Boer, Johannes F.
TI In vitro ovarian tumor growth and treatment response dynamics visualized
with time-lapse OCT imaging
SO OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CANCER; VIVO; MICROSCOPY; APOPTOSIS;
MATRIX; TISSUE; CELLS; MODEL
AB In vitro three-dimensional models for metastatic ovarian cancer have been useful for recapitulating the human disease. These spheroidal tumor cultures, however, can grow in excess of 1 mm in diameter, which are difficult to visualize without suitable imaging technology. Optical coherence tomography (OCT) is an ideal live imaging method for non-perturbatively visualizing these complex systems. OCT enabled detailed observations of the model at both nodular and cellular levels, revealing growth dynamics not previously observed. The development of a time-lapse OCT system, capable of automated, multidimensional acquisition, further provided insights into the growth and chemotherapeutic response of ovarian cancer. (c) 2009 Optical Society of America
C1 [Evans, Conor L.; Rizvi, Imran; Hasan, Tayyaba] Harvard Univ, Sch Med, Wellman Ctr Photomed, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rizvi, Imran] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[de Boer, Johannes F.] Vrije Univ, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands.
RP Evans, CL (reprint author), Harvard Univ, Sch Med, Wellman Ctr Photomed, Massachusetts Gen Hosp, 40 Blossom St, Boston, MA 02114 USA.
EM jfdeboer@few.vu.nl
RI de Boer, Johannes/B-7590-2012;
OI de Boer, Johannes/0000-0003-1253-4950; Rizvi, Imran/0000-0001-9673-4700
FU Massachusetts Biomedical Research Corporation (MBRC) Tosteson
Postdoctoral Fellowship; Wellman Center for Photomedicine Fellowship;
National Institutes of Health [RO1 RR019768, R01 AR040352-09]
FX We thank Jon Celli and Adnan Abu- Yousif for their help with the three-
dimensional tumor model and for their insightful and enlightening
discussions. Hyle Park and Benjamin Vakoc were extremely helpful in the
programing of the OCT data collection, processing, and rendering
software. Our thanks go out to both the de Boer and Hasan groups for
their helpful and stimulating conversations regarding this work. C. L.
E. is supported by the Massachusetts Biomedical Research Corporation
(MBRC) Tosteson Postdoctoral Fellowship. I. R. is supported by a Wellman
Center for Photomedicine Fellowship. The OCT and multiphoton research
components were funded by a grant from the National Institutes of Health
(RO1 RR019768) to J. F. dB. The ovarian cancer model development is
funded by a National Institutes of Health (R01 AR040352-09) grant to T.
H.
NR 29
TC 25
Z9 25
U1 1
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAY 25
PY 2009
VL 17
IS 11
BP 8892
EP 8906
DI 10.1364/OE.17.008892
PG 15
WC Optics
SC Optics
GA 450DW
UT WOS:000266382200021
PM 19466138
ER
PT J
AU Tsibris, AMN
Korber, B
Arnaout, R
Russ, C
Lo, CC
Leitner, T
Gaschen, B
Theiler, J
Paredes, R
Su, ZH
Hughes, MD
Gulick, RM
Greaves, W
Coakley, E
Flexner, C
Nusbaum, C
Kuritzkes, DR
AF Tsibris, Athe M. N.
Korber, Bette
Arnaout, Ramy
Russ, Carsten
Lo, Chien-Chi
Leitner, Thomas
Gaschen, Brian
Theiler, James
Paredes, Roger
Su, Zhaohui
Hughes, Michael D.
Gulick, Roy M.
Greaves, Wayne
Coakley, Eoin
Flexner, Charles
Nusbaum, Chad
Kuritzkes, Daniel R.
TI Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large
Population Shifts during CCR5 Antagonist Therapy In Vivo
SO PLOS ONE
LA English
DT Article
AB High-throughput sequencing platforms provide an approach for detecting rare HIV-1 variants and documenting more fully quasispecies diversity. We applied this technology to the V3 loop-coding region of env in samples collected from 4 chronically HIV-infected subjects in whom CCR5 antagonist (vicriviroc [VVC]) therapy failed. Between 25,000-140,000 amplified sequences were obtained per sample. Profound baseline V3 loop sequence heterogeneity existed; predicted CXCR4-using populations were identified in a largely CCR5-using population. The V3 loop forms associated with subsequent virologic failure, either through CXCR4 use or the emergence of high-level VVC resistance, were present as minor variants at 0.8-2.8% of baseline samples. Extreme, rapid shifts in population frequencies toward these forms occurred, and deep sequencing provided a detailed view of the rapid evolutionary impact of VVC selection. Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists.
RP Tsibris, AMN (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM dkuritzkes@partners.org
OI Korber, Bette/0000-0002-2026-5757
FU NCRR NIH HHS [K24 RR016482]; NIAID NIH HHS [K08 AI081547, P30 AI060354,
R37 AI553537, T32 AI007387, U01 AI067854, U01 AI069472]
NR 32
TC 142
Z9 145
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2009
VL 4
IS 5
AR e5683
DI 10.1371/journal.pone.0005683
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 449LI
UT WOS:000266331700011
PM 19479085
ER
PT J
AU Jones, CCB
Kreklywich, CN
Messaoudi, I
Vomaske, J
McCartney, E
Orloff, SL
Nelson, JA
Streblow, DN
AF Jones, Carmen C. Baca
Kreklywich, Craig N.
Messaoudi, Illhem
Vomaske, Jennifer
McCartney, Erin
Orloff, Susan L.
Nelson, Jay A.
Streblow, Daniel N.
TI Rat cytomegalovirus infection depletes MHC II in bone marrow derived
dendritic cells
SO VIROLOGY
LA English
DT Article
DE Dendritic cells; Viral; MHC; Antigen presentation/processing;
Cytomegalovirus
ID MURINE CYTOMEGALOVIRUS; MOUSE CYTOMEGALOVIRUS; ANTIGEN PRESENTATION;
ENCODED INTERLEUKIN-10; INHIBITS MATURATION; T-CELLS; HLA-DR;
GLYCOPROTEIN; EXPRESSION; MOLECULES
AB While cytomegalovirus (CMV) infects and replicates in a Multitude of cell types, the ability of the virus to replicate in antigen presenting cells (APCs) is believed to play a critical role in the viral dissemination and latency. CMV infection of APCs and manipulation of their function are important areas of investigation. CMV down regulation of MHC 11 is reportedly mediated by the HCMV proteins US2, US3, UL83, UL111a (vIL10) or through the induction of cellular IL10. In this study, we demonstrate that rat CMV (RCMV) significantly reduces MHC 11 expression neither by mechanisms that do not involve orthologues of the known HCMV genes nor by an increase in cellular IL10. Rat bone marrow derived dendritic cells (BMDC) were highly Susceptible to infection with RCMV and a recombinant RCMV expressing eGFP. RCMV infection of BMDCs depleted both Surface and intracellular MHC 11 to nearly undetectable levels as well as reduced surface expression of MHC 1. The effect on MHC If only occurred in the infected GFP positive cells and is mediated by an immediate early or early viral gene product. Furthermore, treatment of uninfected immature DCs with virus-free conditioned supernatants from infected cells failed to down regulate MHC II. RCMV depletion of MHC II was sensitive to treatment with lysosomal inhibitors but not proteasomal inhibitors Suggesting that the mechanism of RCMV-mediated down regulation of MHC II Occurs through endocytic degradation. Since RCMV does not encode homologues of US2, US3, UL83 or UL111a, these data indicate a novel mechanism for RCMV depletion of MHC II. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Jones, Carmen C. Baca; Messaoudi, Illhem; Vomaske, Jennifer; McCartney, Erin; Orloff, Susan L.; Nelson, Jay A.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA.
[Jones, Carmen C. Baca; Messaoudi, Illhem; Vomaske, Jennifer; McCartney, Erin; Orloff, Susan L.; Nelson, Jay A.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
[Kreklywich, Craig N.; Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA.
[Orloff, Susan L.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 SW 185th, Beaverton, OR 97006 USA.
EM streblow@ohsu.edu
NR 45
TC 3
Z9 3
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY 25
PY 2009
VL 388
IS 1
BP 78
EP 90
DI 10.1016/j.virol.2009.02.050
PG 13
WC Virology
SC Virology
GA 448UY
UT WOS:000266288700010
ER
PT J
AU Jacobson, AM
AF Jacobson, Alan M.
TI Diabetes: finding "a clean well-lighted place"
SO LANCET
LA English
DT Editorial Material
ID COGNITIVE-BEHAVIOR THERAPY; DEPRESSION; PATIENT; CARE; MELLITUS; TRIAL
C1 Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Jacobson, AM (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA.
EM Alan.jacobson@joslin.harvard.edu
NR 12
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 23
PY 2009
VL 373
IS 9677
BP 1746
EP 1747
DI 10.1016/S0140-6736(09)60963-6
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449NM
UT WOS:000266337300010
PM 19465218
ER
PT J
AU Venkatachalam, K
Venkatesan, B
Valente, AJ
Melby, PC
Nandish, S
Reusch, JEB
Clark, RA
Chandrasekar, B
AF Venkatachalam, Kaliyamurthi
Venkatesan, Balachandar
Valente, Anthony J.
Melby, Peter C.
Nandish, Sailesh
Reusch, Jane E. B.
Clark, Robert A.
Chandrasekar, Bysani
TI WISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis
Factor-alpha (TNF-alpha)-stimulated Cardiac Fibroblast Proliferation but
Inhibits TNF-alpha-induced Cardiomyocyte Death
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ELEMENT-BINDING PROTEIN; NF-KAPPA-B; ACUTE MYOCARDIAL-INFARCTION;
MUSCLE-CELL MIGRATION; TISSUE GROWTH-FACTOR; INFLAMMATORY CYTOKINES;
CREB PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIVATED PROTEIN;
HEART-FAILURE
AB WNT1-inducible signaling pathway protein-1 (WISP1), a member of the CYR61/CTGF/Nov family of growth factors, can mediate cell growth, transformation, and survival. Previously we demonstrated that WISP1 is up-regulated in post-infarct heart, stimulates cardiac fibroblast proliferation, and is induced by the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Here we investigated (i) the localization of TNF-alpha and WISP1 in post-infarct heart, (ii) the mechanism of TNF-alpha-mediated WISP1 induction in primary human cardiac fibroblasts (CF), (iii) the role of WISP1 in TNF-alpha-mediated CF proliferation and collagen production, and (iv) the effects of WISP1 on TNF-alpha-mediated cardiomyocyte death. TNF-alpha and WISP1 expressions were increased in the border zones and non-ischemic remote regions of the post-ischemic heart. In CF, TNF-alpha potently induced WISP1 expression in cyclic AMP response element-binding protein (CREB)-dependent manner. TNF-alpha induced CREB phosphorylation in vitro and DNA binding and reporter gene activities in vivo. TNF-alpha induced CREB activation via ERK1/2, and inhibition of ERK1/2 and CREB blunted TNF-alpha-mediated WISP1 induction. Most importantly, WISP1 knockdown attenuated TNF-alpha stimulated collagen production and CF proliferation. Furthermore, WISP1 attenuated TNF-alpha-mediated cardiomyocyte death, thus demonstrating pro-mitogenic and pro-survival effects for WISP1 in myocardial constituent cells. Our results suggest that a TNF-alpha/WISP1 signaling pathway may contribute to post-infarct cardiac remodeling, a condition characterized by fibrosis and progressive cardiomyocyte loss.
C1 [Valente, Anthony J.; Melby, Peter C.; Nandish, Sailesh; Clark, Robert A.; Chandrasekar, Bysani] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Venkatachalam, Kaliyamurthi; Venkatesan, Balachandar; Melby, Peter C.; Clark, Robert A.; Chandrasekar, Bysani] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA.
[Reusch, Jane E. B.] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Metab & Diabet, Aurora, CO 80110 USA.
[Reusch, Jane E. B.] Denver Vet Affairs Med Ctr, Vet Affairs Res Serv, Denver, CO 80220 USA.
RP Chandrasekar, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM chandraseka@uthscsa.edu
FU Research Service of the Department of Veterans Affairs
FX This work was supported in part by the Research Service of the
Department of Veterans Affairs.
NR 66
TC 52
Z9 56
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 22
PY 2009
VL 284
IS 21
BP 14414
EP 14427
DI 10.1074/jbc.M809757200
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 448TY
UT WOS:000266286100048
PM 19339243
ER
PT J
AU Wildgruber, M
Lee, H
Chudnovskiy, A
Yoon, TJ
Etzrodt, M
Pittet, MJ
Nahrendorf, M
Croce, K
Libby, P
Weissleder, R
Swirski, FK
AF Wildgruber, Moritz
Lee, Hakho
Chudnovskiy, Aleksey
Yoon, Tae-Jong
Etzrodt, Martin
Pittet, Mikael J.
Nahrendorf, Matthias
Croce, Kevin
Libby, Peter
Weissleder, Ralph
Swirski, Filip K.
TI Monocyte Subset Dynamics in Human Atherosclerosis Can Be Profiled with
Magnetic Nano-Sensors
SO PLOS ONE
LA English
DT Article
AB Monocytes are circulating macrophage and dendritic cell precursors that populate healthy and diseased tissue. In humans, monocytes consist of at least two subsets whose proportions in the blood fluctuate in response to coronary artery disease, sepsis, and viral infection. Animal studies have shown that specific shifts in the monocyte subset repertoire either exacerbate or attenuate disease, suggesting a role for monocyte subsets as biomarkers and therapeutic targets. Assays are therefore needed that can selectively and rapidly enumerate monocytes and their subsets. This study shows that two major human monocyte subsets express similar levels of the receptor for macrophage colony stimulating factor (MCSFR) but differ in their phagocytic capacity. We exploit these properties and custom-engineer magnetic nanoparticles for ex vivo sensing of monocytes and their subsets. We present a two-dimensional enumerative mathematical model that simultaneously reports number and proportion of monocyte subsets in a small volume of human blood. Using a recently described diagnostic magnetic resonance (DMR) chip with 1 mu l sample size and high throughput capabilities, we then show that application of the model accurately quantifies subset fluctuations that occur in patients with atherosclerosis.
RP Wildgruber, M (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu; fswirski@mgh.harvard.edu
RI Etzrodt, Martin/P-3325-2015
OI Etzrodt, Martin/0000-0003-1928-3904
FU NCI NIH HHS [R24 CA69246, P01 CA069246, P50 CA086355, P50 CA86355];
NHLBI NIH HHS [U01 HL080731, K08 HL086672, R01 HL095629, R01 HL096576];
NIBIB NIH HHS [R01-EB004626]; PHS HHS [P01-A154904]
NR 34
TC 34
Z9 34
U1 3
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2009
VL 4
IS 5
AR e5663
DI 10.1371/journal.pone.0005663
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 449LD
UT WOS:000266331200003
PM 19461894
ER
PT J
AU Heiden, MGV
Cantley, LC
Thompson, CB
AF Heiden, Matthew G. Vander
Cantley, Lewis C.
Thompson, Craig B.
TI Understanding the Warburg Effect: The Metabolic Requirements of Cell
Proliferation
SO SCIENCE
LA English
DT Review
ID AEROBIC GLYCOLYSIS; GLUTAMINE-METABOLISM; GLUCOSE-METABOLISM;
TRANSFORMED-CELLS; PYRUVATE-KINASE; CANCER-CELLS; TUMOR-CELLS; GROWTH;
APOPTOSIS; MUTATIONS
AB In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect." Aerobic glycolysis is an inefficient way to generate adenosine 5'-triphosphate (ATP), however, and the advantage it confers to cancer cells has been unclear. Here we propose that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell. Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-associated mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP production. A better understanding of the mechanistic links between cellular metabolism and growth control may ultimately lead to better treatments for human cancer.
C1 [Heiden, Matthew G. Vander; Cantley, Lewis C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Heiden, Matthew G. Vander; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Heiden, Matthew G. Vander] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Thompson, Craig B.] Univ Penn, Abramson Canc Ctr, Dept Canc Biol, Philadelphia, PA 19104 USA.
RP Cantley, LC (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
EM lewis_cantley@hms.harvard.edu; craig@mail.med.upenn.edu
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
FU Damon Runyon Cancer Research Foundation; National Cancer Institute
(NCI); NIH; Abramson Family Cancer Research Institute
FX We thank A. Van den Abbeele (Department of Imaging, Dana-Farber Cancer
Institute, Boston) for the FDG-PET image. We also thank K. D. Courtney,
A. J. Shaywitz, and K. D. Swanson for thoughtful discussions and
critical reading of the manuscript and the Damon Runyon Cancer Research
Foundation for support (to M.G.V.H.). M.G.V.H. receives grant support
from the National Cancer Institute (NCI) and NIH; L.C.C. receives grant
support from the NIH; and C.B.T. receives grant support from the NCI,
NIH, and Abramson Family Cancer Research Institute to study aspects of
cancer cell metabolism. M.G.V.H., L.C.C., and C.B.T. hold patents
related to the targeting of cancer cell metabolism and have financial
interests in Agios Pharmaceuticals, a company that seeks to exploit
alterations in cancer metabolism for novel therapeutics.
NR 46
TC 181
Z9 187
U1 71
U2 371
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 22
PY 2009
VL 324
IS 5930
BP 1029
EP 1033
DI 10.1126/science.1160809
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 448EU
UT WOS:000266246700031
ER
PT J
AU Wang, P
Gonzalez, MC
Hidalgo, CA
Barabasi, AL
AF Wang, Pu
Gonzalez, Marta C.
Hidalgo, Cesar A.
Barabasi, Albert-Laszlo
TI Understanding the Spreading Patterns of Mobile Phone Viruses
SO SCIENCE
LA English
DT Article
ID COMMUNICATION-NETWORKS; EPIDEMIC; DYNAMICS; DISEASE
AB We modeled the mobility of mobile phone users in order to study the fundamental spreading patterns that characterize a mobile virus outbreak. We find that although Bluetooth viruses can reach all susceptible handsets with time, they spread slowly because of human mobility, offering ample opportunities to deploy antiviral software. In contrast, viruses using multimedia messaging services could infect all users in hours, but currently a phase transition on the underlying call graph limits them to only a small fraction of the susceptible users. These results explain the lack of a major mobile virus breakout so far and predict that once a mobile operating system's market share reaches the phase transition point, viruses will pose a serious threat to mobile communications.
C1 [Wang, Pu; Gonzalez, Marta C.; Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA.
[Wang, Pu; Gonzalez, Marta C.; Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Biol, Ctr Complex Network Res, Boston, MA 02115 USA.
[Wang, Pu; Gonzalez, Marta C.; Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Comp Sci, Ctr Complex Network Res, Boston, MA 02115 USA.
[Wang, Pu; Hidalgo, Cesar A.] Univ Notre Dame, Ctr Complex Network Res, Notre Dame, IN 46556 USA.
[Wang, Pu; Hidalgo, Cesar A.] Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA.
[Hidalgo, Cesar A.] Harvard Univ, John F Kennedy Sch Govt, Ctr Int Dev, Cambridge, MA 02139 USA.
[Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
RP Barabasi, AL (reprint author), Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA.
EM barabasi@gmail.com
RI Gonzalez, Marta/E-9456-2011;
OI Gonzalez, Marta/0000-0002-8482-0318; , /0000-0002-6031-5982
FU James S. McDonnell Foundation; NSF [CNS-0540348]; Information Technology
Research [DMR-0426737, IIS-0513650]; Defense Threat Reduction Agency
Award [HDTRA1-08-1-0027]; U.S. Office of Naval Research Award
[N00014-07-C]
FX The human mobility data that were used as a basis for the simulations
relied on an anonymized billing data set that was previously recorded by
a mobile provider as required by law and for billing purposes and not
for the purpose of this project. We thank D. Brockmann, M. Hypponen, J.
Park, Z. Qu, C. Song, A. Vazquez, A. Vespignani, and G. Xiao for
discussions and comments on the manuscript. We also thank M. Hypponen
for providing us the valuable mobile phone virus records data. This work
was supported by the James S. McDonnell Foundation 21st Century
Initiative in Studying Complex Systems; NSF within the Dynamic Data
Driven Applications Systems (CNS-0540348), Information Technology
Research (DMR-0426737), and IIS-0513650 programs; the Defense Threat
Reduction Agency Award HDTRA1-08-1-0027; and the U.S. Office of Naval
Research Award N00014-07-C.
NR 28
TC 203
Z9 217
U1 6
U2 54
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 22
PY 2009
VL 324
IS 5930
BP 1071
EP 1076
DI 10.1126/science.1167053
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 448EU
UT WOS:000266246700042
PM 19342553
ER
PT J
AU Cash, SS
Halgren, E
Dehghani, N
Rossetti, AO
Thesen, T
Wang, C
Devinsky, O
Kuzniecky, R
Doyle, W
Madsen, JR
Bromfield, E
Eross, L
Halasz, P
Karmos, G
Csercsa, R
Wittner, L
Ulbert, I
AF Cash, Sydney S.
Halgren, Eric
Dehghani, Nima
Rossetti, Andrea O.
Thesen, Thomas
Wang, ChunMao
Devinsky, Orrin
Kuzniecky, Ruben
Doyle, Werner
Madsen, Joseph R.
Bromfield, Edward
Eross, Lorand
Halasz, Peter
Karmos, George
Csercsa, Richard
Wittner, Lucia
Ulbert, Istvan
TI The Human K-Complex Represents an Isolated Cortical Down-State
SO SCIENCE
LA English
DT Article
ID SLOW-WAVE SLEEP; NEOCORTICAL NEURONS; NETWORK MECHANISMS; OSCILLATION;
MODEL; HZ
AB The electroencephalogram (EEG) is a mainstay of clinical neurology and is tightly correlated with brain function, but the specific currents generating human EEG elements remain poorly specified because of a lack of microphysiological recordings. The largest event in healthy human EEGs is the K-complex (KC), which occurs in slow-wave sleep. Here, we show that KCs are generated in widespread cortical areas by outward dendritic currents in the middle and upper cortical layers, accompanied by decreased broadband EEG power and decreased neuronal firing, which demonstrate a steep decline in network activity. Thus, KCs are isolated "down-states," a fundamental cortico-thalamic processing mode already characterized in animals. This correspondence is compatible with proposed contributions of the KC to sleep preservation and memory consolidation.
C1 [Cash, Sydney S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Epilepsy Div, Boston, MA 02114 USA.
[Halgren, Eric; Dehghani, Nima] Univ Calif San Diego, Dept Radiol, San Diego, CA 92093 USA.
[Halgren, Eric; Dehghani, Nima] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA.
[Halgren, Eric; Dehghani, Nima] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA.
[Thesen, Thomas; Wang, ChunMao; Devinsky, Orrin; Kuzniecky, Ruben; Doyle, Werner] NYU, Sch Med, Comprehens Epilepsy Ctr, New York, NY 10016 USA.
[Madsen, Joseph R.] Childrens Hosp, Boston, MA 02115 USA.
[Rossetti, Andrea O.; Bromfield, Edward] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Eross, Lorand; Wittner, Lucia; Ulbert, Istvan] Natl Inst Neurosurg, H-1145 Budapest, Hungary.
[Halasz, Peter] Epilepsy Ctr, Natl Inst Psychiat & Neurol, H-1145 Budapest, Hungary.
[Karmos, George; Csercsa, Richard; Wittner, Lucia; Ulbert, Istvan] Hungarian Acad Sci, Inst Psychol, H-1394 Budapest, Hungary.
[Halasz, Peter; Karmos, George; Ulbert, Istvan] Peter Pazmany Catholic Univ, Dept Informat Technol, H-1083 Budapest, Hungary.
RP Cash, SS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Epilepsy Div, Boston, MA 02114 USA.
EM scash@partners.org
RI Ulbert, Istvan/F-2213-2010; Wittner, Lucia/C-9386-2013; Rossetti,
Andrea/A-6712-2008;
OI Wittner, Lucia/0000-0001-6800-0953; Rossetti,
Andrea/0000-0002-7878-172X; Eross, Lorand/0000-0002-5796-5546; Devinsky,
Orrin/0000-0003-0044-4632; Dehghani, Nima/0000-0003-2032-8903
FU National Institute of Neurogical Disorders and Stroke (NIH) [NS18741,
NS44623]; Neuroprobes [IST-027017, OTKA49122, ETT135/2006]; Janos
Szentagothai Knowledge Center [RET 05/2004]
FX Supported by National Institute of Neurogical Disorders and Stroke (NIH)
grants NS18741 and NS44623 to E.H. and Neuroprobes IST-027017,
OTKA49122, ETT135/2006, Janos Szentagothai Knowledge Center RET 05/2004
grants to I.U. We thank L. Papp for technical support; and L. Grand, A.
Magony, B. Dombovari, and D. Fabo for support in data analysis and
recording. The authors dedicate this work to the memory of Edward
Bromfield, who passed away on 10 May 2009.
NR 27
TC 125
Z9 128
U1 6
U2 18
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 22
PY 2009
VL 324
IS 5930
BP 1084
EP 1087
DI 10.1126/science.1169626
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 448EU
UT WOS:000266246700045
PM 19461004
ER
PT J
AU Hideshima, T
Chauhan, D
Kiziltepe, T
Ikeda, H
Okawa, Y
Podar, K
Raje, N
Protopopov, A
Munshi, NC
Richardson, PG
Carrasco, RD
Anderson, KC
AF Hideshima, Teru
Chauhan, Dharminder
Kiziltepe, Tanyel
Ikeda, Hiroshi
Okawa, Yutaka
Podar, Klaus
Raje, Noopur
Protopopov, Alexei
Munshi, Nikhil C.
Richardson, Paul G.
Carrasco, Ruben D.
Anderson, Kenneth C.
TI Biologic sequelae of I kappa B kinase (IKK) inhibition in multiple
myeloma: therapeutic implications
SO BLOOD
LA English
DT Article
ID BONE-MARROW MICROENVIRONMENT; RESISTANCE CAM-DR; BETA INHIBITOR;
ANTIMYELOMA ACTIVITY; CELL-GROWTH; ACTIVATION; ADHESION; ALPHA;
MECHANISMS; CANCER
AB Nuclear factor-kappa B (NF-kappa B) has an important role in multiple myeloma (MM) cell pathogenesis in the context of the bone marrow (BM) microenvironment. In NF-kappa B signaling cascades, I kappa B kinase alpha (IKK alpha) and IKK beta are key molecules that predominantly mediate noncanonical and canonical pathways, respectively. In this study, we examined the biologic sequelae of the inhibition of IKK alpha versus IKK beta in MM cell lines. All MM cell lines have constitutive canonical NF-kappa B activity, and a subset of MM cell lines shows noncanonical NF-kappa B activity. Adhesion to BM stromal cells further activates both canonical and noncanonical NF-kappa B activity. IKK beta inhibitor MLN120B blocks canonical pathway and growth of MM cell lines but does not inhibit the noncanonical NF-kappa B pathway. Although IKK alpha knockdown induces significant growth inhibition in the cell lines with both canonical and noncanonical pathways, it does not inhibit NF-kappa B activation. Importantly, IKK alpha down- regulation decreases expression of beta-catenin and aurora-A, which are known to mediate MM cell growth and survival. Finally, IKK beta inhibitor enhances the growth inhibition triggered by IKK alpha down-regulation in MM cells with both canonical and noncanonical NF-kappa B activity. Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM. (Blood. 2009; 113: 5228-5236)
C1 [Hideshima, Teru; Chauhan, Dharminder; Kiziltepe, Tanyel; Ikeda, Hiroshi; Okawa, Yutaka; Podar, Klaus; Raje, Noopur; Protopopov, Alexei; Munshi, Nikhil C.; Richardson, Paul G.; Carrasco, Ruben D.; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
RP Anderson, KC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.
EM kenneth_anderson@dfci.harvard.edu
FU National Institutes of Health [IP50 CA10070, PO-1 78378, RO-1 CA 50947];
Multiple Myeloma Research Foundation; Lebow Family Fund
FX This work was supported by National Institutes of Health (grant nos.
SPORE IP50 CA10070, PO-1 78378, and RO-1 CA 50947), the Multiple Myeloma
Research Foundation (T. H., D. C.), and the Lebow Family Fund to Cure
Myeloma (K. C. A.).
NR 49
TC 45
Z9 46
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 21
PY 2009
VL 113
IS 21
BP 5228
EP 5236
DI 10.1182/blood-2008-06-161505
PG 9
WC Hematology
SC Hematology
GA 450ML
UT WOS:000266404500029
PM 19270264
ER
PT J
AU Banno, F
Chauhan, AK
Kokame, K
Yang, J
Miyata, S
Wagner, DD
Miyata, T
AF Banno, Fumiaki
Chauhan, Anil K.
Kokame, Koichi
Yang, Jin
Miyata, Shigeki
Wagner, Denisa D.
Miyata, Toshiyuki
TI The distal carboxyl-terminal domains of ADAMTS13 are required for
regulation of in vivo thrombus formation
SO BLOOD
LA English
DT Article
ID VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-IB-ALPHA; THROMBOCYTOPENIC PURPURA;
ADAMTS13-DEFICIENT MICE; PLATELET-AGGREGATION; FLOW CONDITIONS; MOUSE
MODEL; CLEAVAGE; DEFICIENCY; SUBSTRATE
AB ADAMTS13 is a multidomain protease that limits platelet thrombogenesis through the cleavage of von Willebrand factor (VWF). We previously identified 2 types of mouse Adamts13 gene: the 129/Sv-strain Adamts13 gene encodes the long-form ADAMTS13 having the same domains as human ADAMTS13, whereas the C57BL/6-strain Adamts13 gene encodes the short-form ADAMTS13 lacking the distal C-terminal domains. To assess the physiologic significance of the distal C-terminal domains of ADAMTS13, we generated and analyzed 129/Sv-genetic background congenic mice (Adamts13(S/S)) that carry the short-form ADAMTS13. Similar to wild-type 129/Sv mice (Adamts13(L/L)), Adamts13S/S did not have ultralarge VWF multimers in plasma, in contrast to 129/Sv-genetic background ADAMTS13-deficient mice (Adamts13(-/-)). However, in vitro thrombogenesis under flow at a shear rate of 5000 s(-1) was accelerated in Adamts13(S/S) compared with Adamts13(L/L). Both in vivo thrombus formation in ferric chloride-injured arterioles and thrombocytopenia induced by collagen plus epinephrine challenge were more dramatic in Adamts13(S/S) than in Adamts13(L/L) but less than in Adamts13(-/-). These results suggested that the C-terminally truncated ADAMTS13 exhibited decreased activity in the cleavage of VWF under high shear rate. Role of the C-terminal domains may become increasingly important under prothrombotic conditions. (Blood. 2009; 113: 5323-5329)
C1 [Banno, Fumiaki; Kokame, Koichi; Yang, Jin; Miyata, Toshiyuki] Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan.
[Chauhan, Anil K.; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Chauhan, Anil K.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
[Miyata, Shigeki] Natl Cardiovasc Ctr, Div Transfus Med, Suita, Osaka 565, Japan.
RP Miyata, T (reprint author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Osaka 5658565, Japan.
EM miyata@ri.ncvc.go.jp
FU Ministry of Health, Labor, and Welfare of Japan, Tokyo, Japan; Ministry
of Education, Culture, Sports, Science, and Technology of Japan, Tokyo,
Japan; Japan Society for the Promotion of Science, Tokyo, Japan; Program
for Promotion of Fundamental Studies in Health Sciences of the National
Institute of Biochemical Innovation of Japan, Ibaraki, Japan; Baxter
Bioscience, Vienna, Austria; National Heart, Lung, and Blood Institute
of the National Institutes of Health [P01-HL066105]
FX This work was supported in part by grants-in-aid from the Ministry of
Health, Labor, and Welfare of Japan, Tokyo, Japan (T. M.); the Ministry
of Education, Culture, Sports, Science, and Technology of Japan, Tokyo,
Japan (F. B., K. K., and T. M.); the Japan Society for the Promotion of
Science, Tokyo, Japan (K. K. and T. M.); and from the Program for
Promotion of Fundamental Studies in Health Sciences of the National
Institute of Biochemical Innovation of Japan, Ibaraki, Japan (T. M.); a
Sponsored Research Agreement from Baxter Bioscience, Vienna, Austria (A.
K. C. and D. D. W.) and a National Heart, Lung, and Blood Institute of
the National Institutes of Health grant P01-HL066105 (D. D. W.).
NR 38
TC 43
Z9 45
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 21
PY 2009
VL 113
IS 21
BP 5323
EP 5329
DI 10.1182/blood-2008-07-169359
PG 7
WC Hematology
SC Hematology
GA 450ML
UT WOS:000266404500040
PM 19109562
ER
PT J
AU Cheng, XH
Gupta, A
Chen, CC
Tompkins, RG
Rodriguez, W
Toner, M
AF Cheng, Xuanhong
Gupta, Amit
Chen, Chihchen
Tompkins, Ronald G.
Rodriguez, William
Toner, Mehmet
TI Enhancing the performance of a point-of-care CD4+T-cell counting
microchip through monocyte depletion for HIV/AIDS diagnostics
SO LAB ON A CHIP
LA English
DT Article
ID DIFFERENTIAL EXPRESSION; LYMPHOCYTE COUNTS; CELL; INFECTION; FLOW; RNA
AB CD4+ T cell counts are important tests used to stage HIV-postive patients, enabling clinicians to make informed antiretroviral treatment decisions and to monitor the therapeutic outcomes. However, state-of-the-art CD4 counting methods based on flow cytometry are not applicable in resource-limited settings, due to their high cost and technical requirements. In previous work, we reported the development of a cell isolation microchip that can be used at the point of care for CD4 Counts. In that microfluidic chip, CD4+ T cells were separated from 10 mu L of whole blood, and enumerated via either light microscopy or impedance sensing. The microchip Counts matched flow cytometry results in the intermediate CD4 count range, between 200-800 cells/mu L, but displayed a positive bias at absolute CD4 counts below 200 cells/mu L, due largely to monocyte contamination. To enhance the performance in the low CD4 Count range, we report here all improved design of a two-stage microfluidic device to deplete monocytes from whole blood, followed by CD4+ T cell capture. Using the double-stage device combined with a high viscosity rinsing solution, we obtained microchip CD4 counts comparable to flow cytometry results in the full clinically relevant range. In addition to CD4 counting, the strategy of contaminant depletion prior to target cell isolation call be easily adapted to immunoaffinity capture of other cell types that kick a unique surface marker from it complex biological fluid.
C1 [Cheng, Xuanhong; Gupta, Amit; Chen, Chihchen; Tompkins, Ronald G.; Toner, Mehmet] Harvard Univ, Sch Med, BioMEMS Resource Ctr, Massachusetts Gen Hosp, Boston, MA USA.
[Cheng, Xuanhong; Gupta, Amit; Chen, Chihchen; Tompkins, Ronald G.; Toner, Mehmet] Shriners Hosp Children, Boston, MA USA.
[Rodriguez, William] Harvard Univ, Sch Med, Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Cheng, Xuanhong; Gupta, Amit; Chen, Chihchen; Tompkins, Ronald G.; Toner, Mehmet] Harvard Univ, Sch Med, Surg Serv, Boston, MA USA.
[Rodriguez, William] Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA.
[Rodriguez, William] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Cheng, XH (reprint author), Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.
EM xuc207@lehigh.edu; wrodriguez@partners.org; mtoner@partners.org
OI Chen, Chihchen/0000-0002-2195-4802
FU National Institute of Biomedical Imaging and Bioengineering [P41
EB002503]; National Institutes of Health; Bill and Melinda Gates
Foundation; Doris Duke Charitable Foundation
FX We thank Mr Octavio Hurtado for technical Support with the
microfabrication procedures. This work was partially supported by the
National Institute of Biomedical Imaging and Bioengineering under Grant
No. P41 EB002503 (BioMEMS Resource Center). Dr William Rodriguez was
supported by grants from the National Institutes of Health, the Bill and
Melinda Gates Foundation, and the Doris Duke Charitable Foundation. The
authors (XC, WR, MT) acknowledge financial interest in Daktari
Diagnostics, Inc., which develops low-cost CD4 cell counting systems.
NR 19
TC 76
Z9 78
U1 0
U2 24
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PD MAY 21
PY 2009
VL 9
IS 10
BP 1357
EP 1364
DI 10.1039/b818813k
PG 8
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience
& Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
Other Topics
GA 473RU
UT WOS:000268227400007
PM 19417901
ER
PT J
AU Douglas, SM
Dietz, H
Liedl, T
Hogberg, B
Graf, F
Shih, WM
AF Douglas, Shawn M.
Dietz, Hendrik
Liedl, Tim
Hoegberg, Bjoern
Graf, Franziska
Shih, William M.
TI Self-assembly of DNA into nanoscale three-dimensional shapes
SO NATURE
LA English
DT Article
ID DOUBLE-CROSSOVER MOLECULES; CONDUCTIVE NANOWIRES; NANOSTRUCTURES;
OCTAHEDRON; NANOTUBES; COMPLEXES; LATTICES; DESIGN
AB Molecular self-assembly offers a 'bottom-up' route to fabrication with subnanometre precision of complex structures from simple components(1). DNA has proved to be a versatile building block(2-5) for programmable construction of such objects, including two-dimensional crystals(6), nanotubes(7-11), and three-dimensional wire-frame nanopolyhedra(12-17). Templated self-assembly of DNA(18) into custom two-dimensional shapes on the megadalton scale has been demonstrated previously with a multiple-kilobase 'scaffold strand' that is folded into a flat array of antiparallel helices by interactions with hundreds of oligonucleotide 'staple strands'(19,20). Here we extend this method to building custom three-dimensional shapes formed as pleated layers of helices constrained to a honeycomb lattice. We demonstrate the design and assembly of nanostructures approximating six shapes-monolith, square nut, railed bridge, genie bottle, stacked cross, slotted cross-with precisely controlled dimensions ranging from 10 to 100 nm. We also show hierarchical assembly of structures such as homomultimeric linear tracks and heterotrimeric wireframe icosahedra. Proper assembly requires week-long folding times and calibrated monovalent and divalent cation concentrations. We anticipate that our strategy for self-assembling custom three-dimensional shapes will provide a general route to the manufacture of sophisticated devices bearing features on the nanometre scale.
C1 [Douglas, Shawn M.; Dietz, Hendrik; Liedl, Tim; Hoegberg, Bjoern; Graf, Franziska; Shih, William M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Douglas, Shawn M.; Dietz, Hendrik; Liedl, Tim; Hoegberg, Bjoern; Graf, Franziska; Shih, William M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Douglas, Shawn M.; Graf, Franziska; Shih, William M.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Cambridge, MA 02138 USA.
RP Shih, WM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.
EM william_shih@dfci.harvard.edu
RI CHEN, Jin-dong/F-3610-2011; Liedl, Tim/O-7539-2014;
OI Liedl, Tim/0000-0002-0040-0173; Douglas, Shawn/0000-0001-5398-9041;
Hogberg, Bjorn/0000-0003-2715-7887
FU Claudia Adams Barr Program Investigator grant; Wyss Institute for
Biologically Inspired Engineering; NIH [1DP2OD004641-01]; Humboldt
Fellowship; Deutscher Akademischer Austauschdienst (DAAD); Swedish
Science Council (Vetenskapsra det)
FX We thank X. Su for assistance in cloning M13-based scaffold sequences
and G. Hess for pilot studies on the railed-bridge design. This work was
supported by a Claudia Adams Barr Program Investigator grant, a Wyss
Institute for Biologically Inspired Engineering at Harvard grant, and an
NIH New Investigator grant (1DP2OD004641-01) to W. M. S., a Humboldt
Fellowship to H. D., Deutscher Akademischer Austauschdienst (DAAD)
Fellowship to T. L., and Swedish Science Council (Vetenskapsra det)
Fellowship to B. H.
NR 29
TC 845
Z9 858
U1 52
U2 423
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 21
PY 2009
VL 459
IS 7245
BP 414
EP 418
DI 10.1038/nature08016
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 448DQ
UT WOS:000266243700043
PM 19458720
ER
PT J
AU Townsend, JA
Wright, DA
Winfrey, RJ
Fu, FL
Maeder, ML
Joung, JK
Voytas, DF
AF Townsend, Jeffrey A.
Wright, David A.
Winfrey, Ronnie J.
Fu, Fengli
Maeder, Morgan L.
Joung, J. Keith
Voytas, Daniel F.
TI High-frequency modification of plant genes using engineered zinc-finger
nucleases
SO NATURE
LA English
DT Article
ID HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; RESISTANCE; TOXICITY
AB An efficient method for making directed DNA sequence modifications to plant genes (gene targeting) is at present lacking, thereby frustrating efforts to dissect plant gene function and engineer crop plants that better meet the world's burgeoning need for food, fibre and fuel. Zinc-finger nucleases (ZFNs)-enzymes engineered to create DNA double-strand breaks at specific loci-are potent stimulators of gene targeting(1,2); for example, they can be used to precisely modify engineered reporter genes in plants(3,4). Here we demonstrate high-frequency ZFN-stimulated gene targeting at endogenous plant genes, namely the tobacco acetolactate synthase genes (ALS SuRA and SuRB), for which specific mutations are known to confer resistance to imidazolinone and sulphonylurea herbicides(5). Herbicide-resistance mutations were introduced into SuR loci by ZFN-mediated gene targeting at frequencies exceeding 2% of transformed cells for mutations as far as 1.3 kilobases from the ZFN cleavage site. More than 40% of recombinant plants had modifications in multiple SuR alleles. The observed high frequency of gene targeting indicates that it is now possible to efficiently make targeted sequence changes in endogenous plant genes.
C1 [Voytas, Daniel F.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
[Voytas, Daniel F.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA.
[Townsend, Jeffrey A.; Wright, David A.; Winfrey, Ronnie J.; Fu, Fengli] Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA.
[Maeder, Morgan L.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Maeder, Morgan L.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
[Maeder, Morgan L.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Voytas, DF (reprint author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
EM voytas@umn.edu
FU National Science Foundation; National Institutes of Health;
Massachusetts General Hospital Department of Pathology
FX We thank M. Eichtinger for help in making ZFA reagents. This work was
supported by grants to D. F. V. from the National Science Foundation and
to J. K. J. from the National Institutes of Health and the Massachusetts
General Hospital Department of Pathology.
NR 18
TC 315
Z9 345
U1 16
U2 78
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 21
PY 2009
VL 459
IS 7245
BP 442
EP U161
DI 10.1038/nature07845
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 448DQ
UT WOS:000266243700049
PM 19404258
ER
PT J
AU Giugliano, RP
White, JA
Bode, C
Armstrong, PW
Montalescot, G
Lewis, BS
van't Hof, A
Berdan, LG
Lee, KL
Strony, JT
Hildemann, S
Veltri, E
Van De Werf, F
Braunwald, E
Harrington, RA
Califf, RM
Newby, LK
AF Giugliano, Robert P.
White, Jennifer A.
Bode, Christoph
Armstrong, Paul W.
Montalescot, Gilles
Lewis, Basil S.
van't Hof, Arnoud
Berdan, Lisa G.
Lee, Kerry L.
Strony, John T.
Hildemann, Steven
Veltri, Enrico
Van de Werf, Frans
Braunwald, Eugene
Harrington, Robert A.
Califf, Robert M.
Newby, L. Kristin
CA EARLY ACS Investigators
TI Early versus Delayed, Provisional Eptifibatide in Acute Coronary
Syndromes
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ST-SEGMENT ELEVATION; PLATELET GLYCOPROTEIN IIB/IIIA; PLACEBO-CONTROLLED
TRIAL; UNSTABLE ANGINA; CLINICAL-OUTCOMES; RANDOMIZED-TRIAL;
MYOCARDIAL-INFARCTION; MEDICAL THERAPY; TASK-FORCE; INTERVENTION
AB BACKGROUND
Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown.
METHODS
We compared a strategy of early, routine administration of eptifibatide with delayed, provisional administration in 9492 patients who had acute coronary syndromes without ST-segment elevation and who were assigned to an invasive strategy. Patients were randomly assigned to receive either early eptifibatide (two boluses, each containing 180 mu g per kilogram of body weight, administered 10 minutes apart, and a standard infusion >= 12 hours before angiography) or a matching placebo infusion with provisional use of eptifibatide after angiography (delayed eptifibatide). The primary efficacy end point was a composite of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or the occurrence of a thrombotic complication during percutaneous coronary intervention that required bolus therapy opposite to the initial study-group assignment ("thrombotic bailout") at 96 hours. The key secondary end point was a composite of death or myocardial infarction within the first 30 days. Key safety end points were bleeding and the need for transfusion within the first 120 hours after randomization.
RESULTS
The primary end point occurred in 9.3% of patients in the early-eptifibatide group and in 10.0% in the delayed-eptifibatide group (odds ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P = 0.23). At 30 days, the rate of death or myocardial infarction was 11.2% in the early-eptifibatide group, as compared with 12.3% in the delayed-eptifibatide group (odds ratio, 0.89; 95% CI, 0.79 to 1.01; P = 0.08). Patients in the early-eptifibatide group had significantly higher rates of bleeding and red-cell transfusion. There was no significant difference between the two groups in rates of severe bleeding or nonhemorrhagic serious adverse events.
CONCLUSIONS
In patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion. (ClinicalTrials.gov number, NCT00089895.)
C1 [Giugliano, Robert P.; Braunwald, Eugene] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
[White, Jennifer A.; Berdan, Lisa G.; Lee, Kerry L.; Harrington, Robert A.; Califf, Robert M.; Newby, L. Kristin] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Bode, Christoph] Univ Freiburg Klinikum, Freiburg, Germany.
[Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada.
[Montalescot, Gilles] CHU Pitie Salpetriere, Paris, France.
[Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel.
[van't Hof, Arnoud] Isala Klin, Zwolle, Netherlands.
[Strony, John T.; Veltri, Enrico] Schering Plough Corp, Kenilworth, NJ USA.
[Hildemann, Steven] Essex Pharma, Munich, Germany.
[Van de Werf, Frans] Univ Ziekenhuis Gasthuisberg, Leuven, Belgium.
RP Giugliano, RP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, 350 Longwood Ave,1st Fl, Boston, MA 02115 USA.
EM rgiugliano@partners.org
RI Ponikowski, Piotr/O-6454-2015; Katus, Hugo/P-1712-2016; Widimsky,
Petr/P-8088-2016; Pershukov, Igor/D-2135-2016;
OI Ponikowski, Piotr/0000-0002-3391-7064; Widimsky,
Petr/0000-0001-5686-7752; Van de Werf, Frans/0000-0001-9479-7767;
Pershukov, Igor/0000-0002-5356-1886; Prabhakaran,
Dorairaj/0000-0002-3172-834X; Brilakis, Emmanouil/0000-0001-9416-9701
FU Schering-Plough and Millennium Pharmaceuticals
FX Supported by Schering-Plough and Millennium Pharmaceuticals.
NR 30
TC 247
Z9 263
U1 1
U2 17
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2009
VL 360
IS 21
BP 2176
EP 2190
DI 10.1056/NEJMoa0901316
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA 447QI
UT WOS:000266206000005
PM 19332455
ER
PT J
AU Lockwood, CJ
Nadel, AS
King, ME
Roberts, DJ
AF Lockwood, Charles J.
Nadel, Allan S.
King, Mary Etta
Roberts, Drucilla J.
TI A Pregnant Woman with an Abnormal Fetal Ultrasound Study Hydrops fetalis
and hydrops placentalis due to fetal (congenital) pulmonary
lymphangiectasia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID NONIMMUNE HYDROPS; NOONAN-SYNDROME; DIAGNOSIS; IDENTIFICATION;
CHYLOTHORAX; SEQUENCE
C1 [Lockwood, Charles J.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.
[Nadel, Allan S.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[King, Mary Etta] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Roberts, Drucilla J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Nadel, Allan S.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[King, Mary Etta] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Roberts, Drucilla J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Lockwood, CJ (reprint author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.
NR 32
TC 6
Z9 7
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2009
VL 360
IS 21
BP 2225
EP 2235
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 447QI
UT WOS:000266206000011
PM 19458368
ER
PT J
AU Kumagai, M
Mori, S
Sharp, GC
Asakura, H
Kandatsu, S
Endo, M
Baba, M
AF Kumagai, Motoki
Mori, Shinichiro
Sharp, Gregory C.
Asakura, Hiroshi
Kandatsu, Susumu
Endo, Masahiro
Baba, Masayuki
TI Dosimetric variation due to CT inter-slice spacing in four-dimensional
carbon beam lung therapy
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID PROTON DOSE CALCULATIONS; TUMORS; IRRADIATION; ALGORITHM; SCANNER;
MOTION
AB When CT data with thick slice thickness are used in treatment planning, geometrical uncertainty may induce dosimetric errors. We evaluated carbon ion dose variations due to different CT slice thicknesses using a four-dimensional (4D) carbon ion beam dose calculation, and compared results between ungated and gated respiratory strategies. Seven lung patients were scanned in 4D mode with a 0.5 mm slice thickness using a 256-multi-slice CT scanner. CT images were averaged with various numbers of images to simulate reconstructed images with various slice thicknesses (0.5-5.0 mm). Two scenarios were studied (respiratory-ungated and -gated strategies). Range compensators were designed for each of the CT volumes with coarse inter-slice spacing to cover the internal target volume (ITV), as defined from 4DCT. Carbon ion dose distribution was computed for each resulting ITV on the 0.5 mm slice 4DCT data. The accumulated dose distribution was then calculated using deformable registration for 4D dose assessment. The magnitude of over-and under-dosage was found to be larger with the use of range compensators designed with a coarser inter-slice spacing than those obtained with a 0.5 mm slice thickness. Although no under-dosage was observed within the clinical target volume (CTV) region, D95 remained at over 97% of the prescribed dose for the ungated strategy and 95% for the gated strategy for all slice thicknesses. An inter-slice spacing of less than 3 mm may be able to minimize dose variation between the ungated and gated strategies. Although volumes with increased inter-slice spacing may reduce geometrical accuracy at a certain respiratory phase, this does not significantly affect delivery of the accumulated dose to the target during the treatment course.
C1 [Kumagai, Motoki; Mori, Shinichiro; Kandatsu, Susumu; Baba, Masayuki] Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Chiba 260, Japan.
[Sharp, Gregory C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Sharp, Gregory C.] Harvard Univ, Sch Med, Boston, MA USA.
[Endo, Masahiro] Natl Inst Radiol Sci, Planning & Management Dept, Chiba 260, Japan.
[Asakura, Hiroshi] Accelerator Engn Corp, Chiba, Japan.
RP Mori, S (reprint author), Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Chiba 260, Japan.
EM shinshin@nirs.go.jp
OI Mori, Shinichiro/0000-0002-0412-4399
FU National Institute of Radiological Sciences, Japan
FX The authors wish to thank Drs Shuhei Komatsu and Tomoyasu Yashiro of the
National Institute of Radiological Sciences, Japan, for their support.
NR 27
TC 1
Z9 1
U1 0
U2 0
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 21
PY 2009
VL 54
IS 10
BP 3231
EP 3246
DI 10.1088/0031-9155/54/10/018
PG 16
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 442BY
UT WOS:000265816000018
PM 19420422
ER
PT J
AU Irimia, D
Balazsi, G
Agrawal, N
Toner, M
AF Irimia, Daniel
Balazsi, Gabor
Agrawal, Nitin
Toner, Mehmet
TI Adaptive-Control Model for Neutrophil Orientation in the Direction of
Chemical Gradients
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID HUMAN POLYMORPHONUCLEAR LEUKOCYTES; EUKARYOTIC GENE-EXPRESSION;
CELL-MIGRATION; MICROTUBULE DYNAMICS; CHEMOATTRACTANT-RECEPTOR;
SIGNAL-TRANSDUCTION; TEMPORAL MECHANISM; COFILIN ACTIVITY; RHO-GTPASES;
CHEMOTAXIS
AB Neutrophils have a remarkable ability to detect the direction of chemoattractant gradients and move directionally in response to bacterial infections and tissue injuries. For their role in health and disease, neutrophils have been extensively studied, and many of the molecules involved in the signaling mechanisms of gradient detection and chemotaxis have been identified. However, the cellular-scale mechanisms of gradient sensing and directional neutrophil migration have been more elusive, and existent models provide only limited insight into these processes. Here, we propose a what we believe is a novel adaptive-control model for the initiation of cell polarization in response to gradients. In this model, the neutrophils first sample the environment by extending protrusions in random directions and subsequently adapt their sensitivity depending on localized, temporal changes in stimulation levels. Our results suggest that microtubules may play a critical role in integrating all the sensing events from the cellular periphery through their redistribution inside the neutrophils, and may also be involved in modulating local signaling. An unexpected finding was that model neutrophils exhibit significant randomness in timing and directionality, of activation, comparable to our experimental observations in microfluidic devices. Moreover, their responses are robust against alterations of the rate and amplitude of the signaling reactions, and for a broad range in chemoattractant concentrations and spatial gradients.
C1 [Irimia, Daniel; Agrawal, Nitin; Toner, Mehmet] Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA.
[Irimia, Daniel; Agrawal, Nitin; Toner, Mehmet] Harvard Univ, Sch Med, Boston, MA USA.
[Balazsi, Gabor] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
RP Irimia, D (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA.
EM dirimia@hms.harvard.edu
OI Irimia, Daniel/0000-0001-7347-2082
FU NIBIB NIH HHS [P41 EB002503]
NR 103
TC 18
Z9 18
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD MAY 20
PY 2009
VL 96
IS 10
BP 3897
EP 3916
DI 10.1016/j.bpj.2008.12.3967
PG 20
WC Biophysics
SC Biophysics
GA 449EF
UT WOS:000266312900004
PM 19450463
ER
PT J
AU Cao, JX
Schulte, J
Knight, A
Leslie, NR
Zagozdzon, A
Bronson, R
Manevich, Y
Beeson, C
Neumann, CA
AF Cao, Juxiang
Schulte, Jennifer
Knight, Alexander
Leslie, Nicholas R.
Zagozdzon, Agnieszka
Bronson, Roderick
Manevich, Yefim
Beeson, Craig
Neumann, Carola A.
TI Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
SO EMBO JOURNAL
LA English
DT Article
DE oxidative stress; peroxiredoxin1; PTEN phosphatase; transformation;
tumour initiation
ID TUMOR-SUPPRESSOR PTEN; LIPID PHOSPHATASE-ACTIVITY; CYSTEINE-SULFINIC
ACID; SITE CYSTEINE; REVERSIBLE OXIDATION; 2-CYS PEROXIREDOXIN; ANGSTROM
RESOLUTION; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; TRANSGENIC MICE
AB It is widely accepted that reactive oxygen species (ROS) promote tumorigenesis. However, the exact mechanisms are still unclear. As mice lacking the peroxidase peroxiredoxin1 (Prdx1) produce more cellular ROS and die prematurely of cancer, they offer an ideal model system to study ROS-induced tumorigenesis. Prdx1 ablation increased the susceptibility to Ras-induced breast cancer. We, therefore, investigated the role of Prdx1 in regulating oncogenic Ras effector pathways. We found Akt hyperactive in fibroblasts and mammary epithelial cells lacking Prdx1. Investigating the nature of such elevated Akt activation established a novel role for Prdx1 as a safeguard for the lipid phosphatase activity of PTEN, which is essential for its tumour suppressive function. We found binding of the peroxidase Prdx1 to PTEN essential for protecting PTEN from oxidation-induced inactivation. Along those lines, Prdx1 tumour suppression of Ras- or ErbB-2-induced transformation was mediated mainly via PTEN. The EMBO Journal (2009) 28, 1505-1517. doi:10.1038/emboj.2009.101; Published online 16 April 2009
C1 [Cao, Juxiang; Schulte, Jennifer; Manevich, Yefim; Neumann, Carola A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut Med, Charleston, SC 29425 USA.
[Knight, Alexander] Whitworth Univ, Spokane, WA USA.
[Leslie, Nicholas R.] Univ Dundee, Div Mol Physiol, Coll Life Sci, Wellcome Trust,Bioctr, Dundee, Scotland.
[Zagozdzon, Agnieszka] Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst, Boston, MA USA.
[Beeson, Craig] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
RP Neumann, CA (reprint author), Med Univ S Carolina, Dept Cell & Mol Pharmacol, 173 Ashley Ave,MSC 505, Charleston, SC 29425 USA.
EM neumannc@musc.edu
RI Leslie, Nicholas/D-2699-2009; Cao, Juxiang/L-1489-2013;
OI Knight, Brent/0000-0003-2864-1347; LESLIE, Nicholas/0000-0001-5131-0541
FU Claudia Adams Barr Award-DFCI [NIEHS-K22 ES012985, ACS-IRG-97-219-05];
Abney research Foundation-MUSC
FX We especially thank Drs Yusuf Hannun, Peter Sicinski, Alex Toker, Steve
Rosenzweig and Scott Eblen for fruitful discussions. We thank Ningfei An
and Joe Blumer for assistance with GST-pull down experiments and Joseph
Moore for editorial assistance. We thank Dr Rick Van Etten for sharing
the Prdx1-constructs and knockout mice and Vic Stambolic for providing
PTEN-/- MEFs. We also thank Dr William Sellers for sharing
the PTEN wild-type construct through Addgene. This work was supported by
grants from the NIEHS-K22 ES012985, ACS-IRG-97-219-05, Claudia Adams
Barr Award-DFCI. All (CAN), and Abney research Foundation-MUSC (JC) and
(AK).
NR 46
TC 156
Z9 164
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD MAY 20
PY 2009
VL 28
IS 10
BP 1505
EP 1517
DI 10.1038/emboj.2009.101
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 448EV
UT WOS:000266246800013
PM 19369943
ER
PT J
AU Cheung, WY
Neville, BA
Cameron, DB
Cook, EF
Earle, CC
AF Cheung, Winson Y.
Neville, Bridget A.
Cameron, Danielle B.
Cook, E. Francis
Earle, Craig C.
TI Comparisons of Patient and Physician Expectations for Cancer
Survivorship Care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID LONG-TERM SURVIVORS; COLORECTAL-CANCER; CARDIOVASCULAR RISK; TESTICULAR
CANCER; PREVENTIVE CARE
AB Purpose
To compare expectations for cancer survivorship care between patients and their physicians and between primary care providers (PCPs) and oncologists.
Methods
Survivors and their physicians were surveyed to evaluate for expectations regarding physician participation in primary cancer follow-up, screening for other cancers, general preventive health, and management of comorbidities.
Results
Of 992 eligible survivors and 607 physicians surveyed, 535 (54%) and 378 (62%) were assessable, respectively. Among physician respondents, 255 (67%) were PCPs and 123 (33%) were oncologists. Comparing patients with their oncologists, expectations were highly discrepant for screening for cancers other than the index one ( agreement rate, 29%), with patients anticipating significantly more oncologist involvement. Between patients and their PCPs, expectations were most incongruent for primary cancer follow-up ( agreement rate, 35%), with PCPs indicating they should contribute a much greater part to this aspect of care. Expectations between patients and their PCPs were generally more concordant than between patients and their oncologists. PCPs and oncologists showed high discordances in perceptions of their own roles for primary cancer follow-up, cancer screening, and general preventive health ( agreement rates of 3%, 44%, and 51%, respectively). In the case of primary cancer follow-up, both PCPs and oncologists indicated they should carry substantial responsibility for this task. Conclusion
Patients and physicians have discordant expectations with respect to the roles of PCPs and oncologists in cancer survivorship care. Uncertainties around physician roles and responsibilities can lead to deficiencies in care, supporting the need to make survivorship care planning a standard component in cancer management.
C1 [Earle, Craig C.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Med Oncol, Ctr Outcomes & Policy Res, Boston, MA 02115 USA.
RP Earle, CC (reprint author), Inst Clin Evaluat Sci, 2075 Bayview Ave,G Wing 106, Toronto, ON M4N 3M5, Canada.
EM craig.earle@ices.on.ca
FU Perini Family Cancer Survivor's Center; Canadian Association of Medical
Oncologists; National Cancer Institute of Canada
FX Supported by funds from the Perini Family Cancer Survivor's Center, an
award from the Canadian Association of Medical Oncologists, and a grant
from the National Cancer Institute of Canada.
NR 18
TC 119
Z9 120
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
BP 2489
EP 2495
DI 10.1200/JCO.2008.20.3232
PG 7
WC Oncology
SC Oncology
GA 447MO
UT WOS:000266195400014
PM 19332716
ER
PT J
AU Granowetter, L
Womer, R
Devidas, M
Krailo, M
Wang, CG
Bernstein, M
Marina, N
Leavey, P
Gebhardt, M
Healey, J
Shamberger, RC
Goorin, A
Miser, J
Meyer, J
Arndt, CAS
Sailer, S
Marcus, K
Perlman, E
Dickman, P
Grier, HE
AF Granowetter, Linda
Womer, Richard
Devidas, Meenakshi
Krailo, Mark
Wang, Chenguang
Bernstein, Mark
Marina, Neyssa
Leavey, Patrick
Gebhardt, Mark
Healey, John
Shamberger, Robert Cooper
Goorin, Allen
Miser, James
Meyer, James
Arndt, Carola A. S.
Sailer, Scott
Marcus, Karen
Perlman, Elizabeth
Dickman, Paul
Grier, Holcombe E.
TI Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic
Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR; NEOADJUVANT CHEMOTHERAPY;
PEDIATRIC ONCOLOGY; DELAYED RESECTION; RADIATION-THERAPY; CHEST-WALL;
BONE; SURVIVAL; IMPACT; RADIOTHERAPY
AB Purpose
The Ewing sarcoma family of tumors (ESFT) is a group of malignant tumors of soft tissue and bone sharing a chromosomal translocation affecting the EWS locus. The Intergroup INT-0091 demonstrated the superiority of a regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over VDC for patients with nonmetastatic ESFT of bone. The goal of this study was to determine whether a dose-intensified regimen of VDC alternating with IE would further improve the outcome for patients with nonmetastatic ESFT of bone or soft tissue.
Methods
Patients with previously untreated, nonmetastatic ESFT of bone or soft tissue were eligible. They were randomly assigned to receive standard doses of VDC/IE over 48 weeks or a dose-intensified regimen of VDC/IE over 30 weeks.
Results
Four hundred seventy-eight patients met eligibility requirements: 231 patients received the standard regimen; 247 patients received the intensified regimen. The 5-year event-free survival (EFS) and overall survival rates for all eligible patients were 71.1% (95% CI, 67.7% to 75.0%) and 78.6% (95% CI, 74.6% to 82.1%), respectively. There was no significant difference (P = .57) in EFS between patients treated with the standard (5-year EFS, 72.1%; 95% CI, 65.8% to 77.5%) or intensified regimen (5-year EFS, 70.1%; 63.9% to 75%). Patients with soft tissue tumors accounted for 20% of the study population; there was no difference in outcome between patients with soft tissue and bone primary sites.
Conclusion
Dose escalation of alkylating agents as tested in this trial did not improve the outcome for patients with nonmetastatic ESFT of bone or soft tissue.
C1 Columbia Presbyterian Coll Phys & Surg, Div Pediat Oncol, New York, NY USA.
Mem Sloan Kettering Canc Ctr, Dept Surg, Orthoped Serv, New York, NY 10021 USA.
Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA.
Univ Florida, Childrens Oncol Grp, Ctr Data, Coll Med Ctr, Gainesville, FL USA.
Childrens Oncol Grp Operat Ctr, Arcadia, CA USA.
Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
City Hope Natl Med Ctr, Div Pediat, Duarte, CA 91010 USA.
IWK Hlth Ctr, Div Pediat Hematol Oncol, Dept Biostat, Halifax, NS, Canada.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Childrens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Gen Surg, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Div Radiat Oncol, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA.
Childrens Mem Med Ctr Chicago, Chicago, IL USA.
Phoenix Childrens Hosp, Dept Pathol, Phoenix, AZ USA.
RP Granowetter, L (reprint author), Columbia Univ, Med Ctr, Dept Pediat, Div Oncol, 161 Ft Washington Ave Irving 7, New York, NY 10032 USA.
EM lg519@columbia.edu
OI Granowetter MD, Linda/0000-0002-2399-9107
NR 25
TC 105
Z9 113
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
BP 2536
EP 2541
DI 10.1200/JCO.2008.19.1478
PG 6
WC Oncology
SC Oncology
GA 447MO
UT WOS:000266195400021
PM 19349548
ER
PT J
AU Kamoun, WS
Ley, CD
Farrar, CT
Duyverman, AM
Lahdenranta, J
Lacorre, DA
Batchelor, TT
di Tomaso, E
Duda, DG
Munn, LL
Fukumura, D
Sorensen, AG
Jain, RK
AF Kamoun, Walid S.
Ley, Carsten D.
Farrar, Christian T.
Duyverman, Annique M.
Lahdenranta, Johanna
Lacorre, Delphine A.
Batchelor, Tracy T.
di Tomaso, Emmanuelle
Duda, Dan G.
Munn, Lance L.
Fukumura, Dai
Sorensen, A. Gregory
Jain, Rakesh K.
TI Edema Control by Cediranib, a Vascular Endothelial Growth Factor
Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent
Brain Tumor Growth in Mice
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ANGIOGENESIS; BEVACIZUMAB; GLIOMAS; MRI; NORMALIZATION; GLIOBLASTOMA;
PERMEABILITY; CHEMOTHERAPY; EFFICACY; THERAPY
AB Purpose
Recent clinical trials of antivascular endothelial growth factor ( VEGF) agents for glioblastoma showed promising progression-free and overall survival rates. However, available clinical imaging does not separate antitumor effects from antipermeability effects of these agents. Thus although anti-VEGF agents may decrease tumor contrast-enhancement, vascularity, and edema, the mechanisms leading to improved survival in patients remain incompletely understood. Our goal was to determine whether alleviation of edema by anti-VEGF agents alone could increase survival in mice.
Methods
We treated mice bearing three different orthotopic models of glioblastoma with a VEGF-targeted kinase inhibitor, cediranib. Using intravital microscopy, molecular techniques, and magnetic resonance imaging (MRI), we measured survival, tumor growth, edema, vascular morphology and function, cancer cell apoptosis and proliferation, and circulating angiogenic biomarkers.
Results
We show by intravital microscopy that cediranib significantly decreased tumor vessel permeability and diameter. Moreover, cediranib treatment induced normalization of perivascular cell coverage and thinning of the basement membrane, as mirrored by an increase in plasma collagen IV. These rapid changes in tumor vascular morphology and function led to edema alleviation-as measured by MRI and by dry/wet weight measurement of water content-but did not affect tumor growth. By immunohistochemistry, we found a transient decrease in macrophage infiltration and significant but minor changes in tumor cell proliferation and apoptosis. Systemically, cediranib increased plasma VEGF and placenta growth factor levels, and the number of circulating CXCR4(+)CD45(+) cells. However, by controlling edema, cediranib significantly increased survival of mice in the face of persistent tumor growth.
Conclusion
Anti-VEGF agents may be able to improve survival of patients with glioblastoma, even without inhibiting tumor growth.
C1 [Jain, Rakesh K.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
Stephen E & Catherine Pappas Ctr Neurooncol, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA USA.
Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, 100 Blossom St,Cox 734, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
RI Munn, Lance/L-3950-2016
OI Munn, Lance/0000-0003-0698-7232
FU National Institutes of Health [P01-CA80124, R01-CA115767, K24-CA125440,
R01-CA129371]; Susan G. Komen Foundation; Damon Runyon Foundation;
United States Department of Defense; AstraZeneca Pharmaceuticals;
Montesi Family Research Fund
FX Supported in part by National Institutes of Health Grants No.
P01-CA80124 and R01-CA115767 ( to R. K. J.) and K24-CA125440 and
R01-CA129371 ( to T. T. B.), by postdoctoral fellowships from the Susan
G. Komen Foundation ( to W. S. K. and D. L.) and Damon Runyon Foundation
( to J. L.), by a predoctoral fellowship from the United States
Department of Defense ( A. M. D.), and by gifts from AstraZeneca
Pharmaceuticals and the Montesi Family Research Fund.
NR 26
TC 168
Z9 171
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
BP 2542
EP 2552
DI 10.1200/JCO.2008.19.9356
PG 11
WC Oncology
SC Oncology
GA 447MO
UT WOS:000266195400022
PM 19332720
ER
PT J
AU Adamia, S
Avet-Loiseau, H
Amin, SB
Moreau, P
Minvielle, SS
Treon, S
Li, C
Anderson, KC
Munshi, N
AF Adamia, S.
Avet-Loiseau, H.
Amin, S. B.
Moreau, P.
Minvielle, S. S.
Treon, S.
Li, C.
Anderson, K. C.
Munshi, N.
TI Clinical and biological significance of microRNA profiling in patients
with myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
CHU Nantes, F-44035 Nantes 01, France.
Hop Nantes, Nantes, France.
RI Minvielle, Stephane/K-8251-2015; richard, chrystelle/K-8595-2015
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8539
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605448
PM 27960934
ER
PT J
AU Amann, JM
Lee, J
Roder, H
Brahmer, J
Schiller, J
Carbone, DP
AF Amann, J. M.
Lee, J.
Roder, H.
Brahmer, J.
Schiller, J.
Carbone, D. P.
TI Genetic and proteomic features associated with survival after treatment
with erlotinib in first-line therapy of non-small cell lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Amann, J. M.; Lee, J.; Roder, H.; Brahmer, J.; Schiller, J.; Carbone, D. P.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Amann, J. M.; Lee, J.; Roder, H.; Brahmer, J.; Schiller, J.; Carbone, D. P.] Dana Farber Canc Inst, Cambridge, MA USA.
[Amann, J. M.; Lee, J.; Roder, H.; Brahmer, J.; Schiller, J.; Carbone, D. P.] Biodesix Corp, Steamboat Spring, CO USA.
[Amann, J. M.; Lee, J.; Roder, H.; Brahmer, J.; Schiller, J.; Carbone, D. P.] Johns Hopkins Univ, Baltimore, MD USA.
[Amann, J. M.; Lee, J.; Roder, H.; Brahmer, J.; Schiller, J.; Carbone, D. P.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8089
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605291
PM 27962664
ER
PT J
AU Anderson, KC
Jagannath, S
Jakubowiak, A
Lonial, S
Raje, N
Alsina, M
Ghobrial, I
Knight, R
Esseltine, D
Richardson, P
AF Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Alsina, M.
Ghobrial, I.
Knight, R.
Esseltine, D.
Richardson, P.
TI Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory
multiple myeloma (MM): Encouraging outcomes and tolerability in a phase
II study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
St Vincents Comprehens Canc Ctr, New York, NY USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Winship Canc Inst, Atlanta, GA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Celgene Inc, Summit, NJ USA.
Millennium Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8536
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605445
ER
PT J
AU Argiris, A
Ghebremichael, M
Gilbert, J
Burtness, B
Forastiere, A
AF Argiris, A.
Ghebremichael, M.
Gilbert, J.
Burtness, B.
Forastiere, A.
TI A phase III randomized, placebo-controlled trial of docetaxel (D) with
or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell
carcinoma of the head and neck (SCCHN): A trial of the Eastern
Cooperative Oncology Group (ECOG)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Pittsburgh, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Nashville, TN USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 6
Z9 6
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6011
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604217
PM 27962418
ER
PT J
AU Audeh, MW
Penson, RT
Friedlander, M
Powell, B
Bell-McGuinn, KM
Scott, C
Weitzel, JN
Carmichael, J
Tutt, A
AF Audeh, M. W.
Penson, R. T.
Friedlander, M.
Powell, B.
Bell-McGuinn, K. M.
Scott, C.
Weitzel, J. N.
Carmichael, J.
Tutt, A.
TI Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in
BRCA-deficient advanced ovarian cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Cedars Sinai Outpatient Canc Ctr, Samuel Oschin Canc Inst, Los Angeles, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
DF HCC, Boston, MA USA.
Prince Wales Canc Ctr, Sydney, NSW, Australia.
Kaiser Permanente, San Francisco, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Royal Melbourne Hosp, Victoria, Australia.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
AstraZeneca, Macclesfield, Cheshire, England.
Kings Coll London, Sch Med, London WC2R 2LS, England.
RI friedlander, michael/G-3490-2013
OI friedlander, michael/0000-0002-6488-0604
NR 0
TC 29
Z9 29
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5500
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600002
PM 27962445
ER
PT J
AU Balboni, TA
Paulk, ME
Balboni, MJ
Trice, ED
Wright, AA
Phelps, AC
Block, SD
Prigerson, HG
AF Balboni, T. A.
Paulk, M. E.
Balboni, M. J.
Trice, E. D.
Wright, A. A.
Phelps, A. C.
Block, S. D.
Prigerson, H. G.
TI Spiritual support of patients with advanced illness and associations
with end-of-life care and quality of death
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9514
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606133
PM 27964485
ER
PT J
AU Bastos, BR
Diamond, J
Hansen, R
Gustafson, D
Arnott, J
Bray, M
Sidor, C
Messersmith, W
Shapiro, G
AF Bastos, B. R.
Diamond, J.
Hansen, R.
Gustafson, D.
Arnott, J.
Bray, M.
Sidor, C.
Messersmith, W.
Shapiro, G.
TI An open-label, dose escalation, safety, and pharmacokinetic study of
ENMD-2076 administered orally to patients with advanced cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Colorado, Hlth Sci Ctr, Aurora, CO USA.
Colorado State Univ, Ft Collins, CO 80523 USA.
EntreMed Inc, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3520
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602410
PM 27961327
ER
PT J
AU Batchelor, T
Eichler, AF
Plotkin, SR
Drappatz, J
Wen, P
Sorensen, AG
Gerstner, E
AF Batchelor, T.
Eichler, A. F.
Plotkin, S. R.
Drappatz, J.
Wen, P.
Sorensen, A. G.
Gerstner, E.
TI Phase I trial of vatalanib (PTK787) in combination with standard
radiation and temozolomide in patients with newly diagnosed glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Batchelor, T.; Eichler, A. F.; Plotkin, S. R.; Drappatz, J.; Wen, P.; Sorensen, A. G.; Gerstner, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Batchelor, T.; Eichler, A. F.; Plotkin, S. R.; Drappatz, J.; Wen, P.; Sorensen, A. G.; Gerstner, E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2035
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602183
PM 27964624
ER
PT J
AU Bergman, J
Saigal, CS
Miller, DC
Hanley, J
Gore, JL
Lorenz, K
Litwin, MS
AF Bergman, J.
Saigal, C. S.
Miller, D. C.
Hanley, J.
Gore, J. L.
Lorenz, K.
Litwin, M. S.
CA Urol Dis Amer Project
TI Hospice utilization by men dying of prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, Los Angeles, CA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
RAND Corp, Santa Monica, CA USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9501
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606121
PM 27964452
ER
PT J
AU Bertagnolli, MM
Niedzwiecki, D
Hall, M
Jewell, SD
Mayer, RJ
Goldberg, RM
Colacchio, TA
Warren, RS
Redston, M
AF Bertagnolli, M. M.
Niedzwiecki, D.
Hall, M.
Jewell, S. D.
Mayer, R. J.
Goldberg, R. M.
Colacchio, T. A.
Warren, R. S.
Redston, M.
TI Presence of 18q loss of heterozygosity (LOH) and disease-free and
overall survival in stage II colon cancer: CALGB Protocol 9581
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Duke Univ, Med Ctr, Durham, NC USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Ohio State Univ, Columbus, OH 43210 USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Univ N Carolina, Chapel Hill, NC USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Bertagnolli, M. M.; Niedzwiecki, D.; Hall, M.; Jewell, S. D.; Mayer, R. J.; Goldberg, R. M.; Colacchio, T. A.; Warren, R. S.; Redston, M.] Ameripath, Needham, MA USA.
RI Goldberg , Richard/M-1311-2013
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4012
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600254
PM 27961506
ER
PT J
AU Blaszkowsky, LS
Hong, TS
Zhu, AX
Kwak, EL
Mamon, HJ
Shellito, PC
Cusack, JC
Berger, D
Horgan, K
Ryan, DP
AF Blaszkowsky, L. S.
Hong, T. S.
Zhu, A. X.
Kwak, E. L.
Mamon, H. J.
Shellito, P. C.
Cusack, J. C.
Berger, D.
Horgan, K.
Ryan, D. P.
TI A phase I/II study of bevacizumab (beva), erlotinib (erl), and
5-fluorouracil (5-FU) with concurrent external beam radiation therapy
(RT) in locally advanced rectal cancer (LARC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Blaszkowsky, L. S.; Hong, T. S.; Zhu, A. X.; Kwak, E. L.; Mamon, H. J.; Shellito, P. C.; Cusack, J. C.; Berger, D.; Horgan, K.; Ryan, D. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Blaszkowsky, L. S.; Hong, T. S.; Zhu, A. X.; Kwak, E. L.; Mamon, H. J.; Shellito, P. C.; Cusack, J. C.; Berger, D.; Horgan, K.; Ryan, D. P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4106
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601047
PM 27961180
ER
PT J
AU Brewster, AM
Etzel, C
Zhou, R
Wong, Y
Edge, SB
Blayney, DW
Wilson, J
Hudis, C
Weeks, JC
Theriault, RL
AF Brewster, A. M.
Etzel, C.
Zhou, R.
Wong, Y.
Edge, S. B.
Blayney, D. W.
Wilson, J.
Hudis, C.
Weeks, J. C.
Theriault, R. L.
TI The impact of obesity on adherence to the National Comprehensive Cancer
Network (NCCN) guidelines recommending chemotherapy for patients with
operable breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6517
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604366
PM 27964023
ER
PT J
AU Brown, JE
Lipton, A
Cook, RJ
Michaelson, D
Coleman, RE
Saad, F
AF Brown, J. E.
Lipton, A.
Cook, R. J.
Michaelson, D.
Coleman, R. E.
Saad, F.
TI Correlation of N-telopeptide of type I collagen (NTX) with survival and
fractures in patients (pts) with bone metastases from renal cell
carcinoma (RCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Canc Res UK Ctr Leeds, Leeds, W Yorkshire, England.
Penn State Milton S Hershey Med Ctr, Hershey, PA USA.
Univ Waterloo, Waterloo, ON N2L 3G1, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England.
Ctr Hospialier Univ Montreal, Montreal, PQ, Canada.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e16016
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604057
PM 27962910
ER
PT J
AU Buss, MK
Lessen, DS
Von Roenn, J
Sullivan, AM
Arnold, RM
Block, SD
AF Buss, M. K.
Lessen, D. S.
Von Roenn, J.
Sullivan, A. M.
Arnold, R. M.
Block, S. D.
TI National survey of oncology fellows on palliative care education
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
SE Florida Hematol Oncol, Ft Lauderdale, FL USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Virginia Commonwealth Univ, Sch Med, Richmond, VA USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9541
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606160
PM 27964527
ER
PT J
AU Cardenes, HR
Powell, M
Loehrer, PJ
Wagner, LI
Cella, DF
Brell, J
Ramanathan, RK
Crane, CH
Alberts, SR
Benson, AB
AF Cardenes, H. R.
Powell, M.
Loehrer, P. J.
Wagner, L. I.
Cella, D. F.
Brell, J.
Ramanathan, R. K.
Crane, C. H.
Alberts, S. R.
Benson, A. B.
TI E4201: Randomized phase II study of gemcitabine in combination with
radiation therapy versus gemcitabine alone in patients with locally
advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL)
analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] Dana Farber Canc Inst, IUPUI, Boston, MA USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] Indiana Univ, Indianapolis, IN 46204 USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] Northwestern Univ, Evanston, IL 60208 USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] NorthShore Univ Hlth Syst, Evanston, IL USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] Univ Hosp Syst Cleveland, Cleveland, OH USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] RUPMC Canc Pavilionanbury Hosp, Houston, TX USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] MD Anderson Canc Ctr, Houston, TX USA.
[Cardenes, H. R.; Powell, M.; Loehrer, P. J.; Wagner, L. I.; Cella, D. F.; Brell, J.; Ramanathan, R. K.; Crane, C. H.; Alberts, S. R.; Benson, A. B.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4627
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603215
PM 27964205
ER
PT J
AU Carlson, RW
O'Neill, A
Vidaurre, T
Gomez, HL
Badve, S
Sledge, G
AF Carlson, R. W.
O'Neill, A.
Vidaurre, T.
Gomez, H. L.
Badve, S.
Sledge, G.
CA Eastern Cooperative Oncology Grp
TI Randomized phase II trial of gefitinib plus anastrozole or fulvestrant
in postmenopausal, metastatic breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Carlson, R. W.; O'Neill, A.; Vidaurre, T.; Gomez, H. L.; Badve, S.; Sledge, G.] Stanford Univ, Stanford, CA 94305 USA.
[Carlson, R. W.; O'Neill, A.; Vidaurre, T.; Gomez, H. L.; Badve, S.; Sledge, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Carlson, R. W.; O'Neill, A.; Vidaurre, T.; Gomez, H. L.; Badve, S.; Sledge, G.] Inst Enfermedades Neoplas, Lima, Peru.
[Carlson, R. W.; O'Neill, A.; Vidaurre, T.; Gomez, H. L.; Badve, S.; Sledge, G.; Eastern Cooperative Oncology Grp] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 1013
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601490
PM 27960741
ER
PT J
AU Cella, D
Michaelson, MD
Cappelleri, JC
Bushmakin, AG
Charbonneau, C
Kim, ST
Li, JZ
Motzer, RJ
AF Cella, D.
Michaelson, M. D.
Cappelleri, J. C.
Bushmakin, A. G.
Charbonneau, C.
Kim, S. T.
Li, J. Z.
Motzer, R. J.
TI Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-alpha)
as first-line therapy in patients with metastatic renal cell carcinoma
(mRCC): Final results
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Northwestern Univ, Evanston, IL USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Pfizer, Oncol, New London, CT USA.
Pfizer, Oncol, Global Outcomes Res, New York, NY USA.
Pfizer, Oncol, La Jolla, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6529
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604378
PM 27964035
ER
PT J
AU Chang, SM
Kuhn, J
Lamborn, K
Cloughesy, T
Robins, I
Lieberman, F
Yung, A
Dancey, J
Prados, M
Wen, P
AF Chang, S. M.
Kuhn, J.
Lamborn, K.
Cloughesy, T.
Robins, I.
Lieberman, F.
Yung, A.
Dancey, J.
Prados, M.
Wen, P.
TI Phase I/II study of erlotinib and temsirolimus for patients with
recurrent malignant gliomas (MG) (NABTC 04-02)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] UCSF, Neuro Onc Svc, San Francisco, CA USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] Univ Wisconsin, Madison, WI USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] Univ Pittsburgh, Pittsburgh, PA USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] MD Anderson Canc Ctr, Houston, TX USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] NCI, Bethesda, MD 20892 USA.
[Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2004
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602152
PM 27964561
ER
PT J
AU Chen, RC
Hankinson, SE
Harris, JR
Chen, WY
AF Chen, R. C.
Hankinson, S. E.
Harris, J. R.
Chen, W. Y.
TI Coronary heart disease (CHD) and stroke risk associated with breast
cancer (CA) irradiation (RT) based on patient baseline cardiac risk
profile
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Chen, R. C.; Hankinson, S. E.; Harris, J. R.; Chen, W. Y.] Harvard Radiat Oncol Program, Brookline, MA USA.
[Chen, R. C.; Hankinson, S. E.; Harris, J. R.; Chen, W. Y.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chen, R. C.; Hankinson, S. E.; Harris, J. R.; Chen, W. Y.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 606
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601313
PM 27961467
ER
PT J
AU Cheville, AL
Basford, J
Troxel, A
Kornblith, A
AF Cheville, A. L.
Basford, J.
Troxel, A.
Kornblith, A.
TI Determinants of functional disability in stage IV breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
Univ Pennsylvania Hlth Syst, Philadelphia, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9567
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606186
PM 27963673
ER
PT J
AU Chi, AS
Gerstner, ER
Eichler, AF
Chea, HK
Drappatz, J
Wen, PY
Ivy, SP
Loeffler, JS
Sorensen, AG
Jain, RK
Batchelor, TT
AF Chi, A. S.
Gerstner, E. R.
Eichler, A. F.
Chea, H. K.
Drappatz, J.
Wen, P. Y.
Ivy, S. P.
Loeffler, J. S.
Sorensen, A. G.
Jain, R. K.
Batchelor, T. T.
TI Phase Ib study of cediranib in combination with daily temozolomide and
radiation in patients with newly diagnosed glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Chi, A. S.; Gerstner, E. R.; Eichler, A. F.; Chea, H. K.; Drappatz, J.; Wen, P. Y.; Ivy, S. P.; Loeffler, J. S.; Sorensen, A. G.; Jain, R. K.; Batchelor, T. T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Chi, A. S.; Gerstner, E. R.; Eichler, A. F.; Chea, H. K.; Drappatz, J.; Wen, P. Y.; Ivy, S. P.; Loeffler, J. S.; Sorensen, A. G.; Jain, R. K.; Batchelor, T. T.] BWH Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
[Chi, A. S.; Gerstner, E. R.; Eichler, A. F.; Chea, H. K.; Drappatz, J.; Wen, P. Y.; Ivy, S. P.; Loeffler, J. S.; Sorensen, A. G.; Jain, R. K.; Batchelor, T. T.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e13010
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602239
PM 27962847
ER
PT J
AU Cho, DC
Figlin, RA
Flaherty, KT
Michaelson, D
Sosman, JA
Ghebremichael, M
Bowers, ME
Mier, JW
Atkins, MB
McDermott, DF
AF Cho, D. C.
Figlin, R. A.
Flaherty, K. T.
Michaelson, D.
Sosman, J. A.
Ghebremichael, M.
Bowers, M. E.
Mier, J. W.
Atkins, M. B.
McDermott, D. F.
TI A phase II trial of perifosine in patients with advanced renal cell
carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5101
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603500
ER
PT J
AU Choueiri, TK
Regan, M
Oh, W
Clement, J
Amato, A
McDermott, D
Cho, D
Atkins, M
Signoretti, S
AF Choueiri, T. K.
Regan, M.
Oh, W.
Clement, J.
Amato, A.
McDermott, D.
Cho, D.
Atkins, M.
Signoretti, S.
TI Prognostic and predictive values of carbonic anhydrase IX (CAIX) and
pathologic features in patients with metastatic clear cell renal cell
carcinoma receiving targeted therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e16067
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604107
PM 27963063
ER
PT J
AU Cioffi, A
LeCesne, A
Blay, J
Delaloge, S
Yovine, A
Maki, R
Nieto, A
Jiao, JJ
Demetri, GD
AF Cioffi, A.
LeCesne, A.
Blay, J.
Delaloge, S.
Yovine, A.
Maki, R.
Nieto, A.
Jiao, J. J.
Demetri, G. D.
TI Trabectedin phase II clinical trials: Pooled analysis of safety in
patients with solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Cioffi, A.; LeCesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J. J.; Demetri, G. D.] Inst Cancerol Gustave Roussy, Villejuif, France.
[Cioffi, A.; LeCesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J. J.; Demetri, G. D.] Ctr Leon Berard, F-69373 Lyon, France.
[Cioffi, A.; LeCesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J. J.; Demetri, G. D.] PharmaMar, Madrid, Spain.
[Cioffi, A.; LeCesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J. J.; Demetri, G. D.] Mem Hosp, New York, NY USA.
[Cioffi, A.; LeCesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J. J.; Demetri, G. D.] Johnson & Johnson, Cambridge, MA USA.
[Cioffi, A.; LeCesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J. J.; Demetri, G. D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 2
Z9 2
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e13510
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602359
PM 27961298
ER
PT J
AU Come, SE
Parker, LM
Wulf, G
Kuter, I
Ryan, PD
Tkaczuk, K
Borges, V
Kasper, H
Gelman, R
Winer, EP
AF Come, S. E.
Parker, L. M.
Wulf, G.
Kuter, I.
Ryan, P. D.
Tkaczuk, K.
Borges, V.
Kasper, H.
Gelman, R.
Winer, E. P.
TI Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women
with estrogen receptor (ER) plus advanced breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Come, S. E.; Parker, L. M.; Wulf, G.; Kuter, I.; Ryan, P. D.; Tkaczuk, K.; Borges, V.; Kasper, H.; Gelman, R.; Winer, E. P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Come, S. E.; Parker, L. M.; Wulf, G.; Kuter, I.; Ryan, P. D.; Tkaczuk, K.; Borges, V.; Kasper, H.; Gelman, R.; Winer, E. P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Come, S. E.; Parker, L. M.; Wulf, G.; Kuter, I.; Ryan, P. D.; Tkaczuk, K.; Borges, V.; Kasper, H.; Gelman, R.; Winer, E. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Come, S. E.; Parker, L. M.; Wulf, G.; Kuter, I.; Ryan, P. D.; Tkaczuk, K.; Borges, V.; Kasper, H.; Gelman, R.; Winer, E. P.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
[Come, S. E.; Parker, L. M.; Wulf, G.; Kuter, I.; Ryan, P. D.; Tkaczuk, K.; Borges, V.; Kasper, H.; Gelman, R.; Winer, E. P.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 1050
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601527
PM 27961148
ER
PT J
AU Crowley, J
Bolejack, V
Robert, K
Anderson, K
Barlogie, B
AF Crowley, J.
Bolejack, V.
Robert, K.
Anderson, K.
Barlogie, B.
TI Prognostic factor analyses of myeloma (MM) survival outcomes on
intergroup trial S9321 (int 0141): Examining whether different variables
govern different time segments of survival
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Canc Res & Biostat, Seattle, WA USA.
Mayo Clin, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8599
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605507
PM 27962307
ER
PT J
AU Cruciani, RA
Zhang, J
Manola, JB
Cella, D
Ansari, B
Fisch, MJ
AF Cruciani, R. A.
Zhang, J.
Manola, J. B.
Cella, D.
Ansari, B.
Fisch, M. J.
TI Phase III randomized, placebo-controlled trial of L-carnitine
supplementation for fatigue in patients with cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Evanston NW Healthcare, Evanston, IL USA.
Mem Hosp S Bend, South Bend, IN USA.
MD Anderson Canc Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e20532
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606289
PM 27960980
ER
PT J
AU D'Amico, AV
Braccioforte, MH
Moran, BJ
Chen, M
AF D'Amico, A. V.
Braccioforte, M. H.
Moran, B. J.
Chen, M.
TI Diabetes and the risk of death in men with favorable or high-risk
prostate cancer following radiation therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Prostate Canc Fdn Chicago, Chicago, IL USA.
Univ Connecticut, Storrs, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5157
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604030
PM 27964473
ER
PT J
AU Dahlberg, SE
Sandler, AB
Brahmer, JR
Schiller, JH
Johnson, DH
AF Dahlberg, S. E.
Sandler, A. B.
Brahmer, J. R.
Schiller, J. H.
Johnson, D. H.
TI Clinical course of advanced non-small cell lung cancer (NSCLC) patients
(pts) experiencing hypertension (HTN) during treatment (TX) with
bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P)
on E4599
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Baltimore, MD USA.
SW Texas State Univ, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8042
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605244
PM 27962851
ER
PT J
AU Danila, DC
de Bono, J
Ryan, CJ
Denmeade, S
Smith, M
Taplin, M
Bubley, G
Molina, A
Haqq, C
Scher, HI
AF Danila, D. C.
de Bono, J.
Ryan, C. J.
Denmeade, S.
Smith, M.
Taplin, M.
Bubley, G.
Molina, A.
Haqq, C.
Scher, H. I.
TI Phase II multicenter study of abiraterone acetate (AA) plus prednisone
therapy in docetaxel-treated castration-resistant prostate cancer (CRPC)
patients (pts): Impact of prior ketoconazole (keto)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
UCSF, Ctr Comprehens Canc, San Francisco, CA USA.
Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Cougar Biotechnol, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5048
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603449
ER
PT J
AU De Groot, JF
Prados, M
Urquhart, T
Robertson, S
Yaron, Y
Sorensen, AG
Norton, A
Batchelor, T
Drappatz, J
Wen, P
AF De Groot, J. F.
Prados, M.
Urquhart, T.
Robertson, S.
Yaron, Y.
Sorensen, A. G.
Norton, A.
Batchelor, T.
Drappatz, J.
Wen, P.
TI A phase II study of XL184 in patients (pts) with progressive
glioblastoma multiforme (GBM) in first or second relapse
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P.] Exelixis Inc, San Francisco, CA USA.
[De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 12
Z9 12
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2047
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602195
PM 27964644
ER
PT J
AU Demetri, GD
Schuetze, S
Blay, J
Chawla, S
von Mehren, M
Casali, P
Morris, D
Bayever, E
Alfaro, V
LeCesne, A
AF Demetri, G. D.
Schuetze, S.
Blay, J.
Chawla, S.
von Mehren, M.
Casali, P.
Morris, D.
Bayever, E.
Alfaro, V.
LeCesne, A.
TI Long-term results of a randomized phase II study of trabectedin by two
different dose and schedule regimens in patients with advanced
liposarcoma or leiomyosarcoma after failure of prior anthracyclines and
ifosfamide
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Ctr Leon Berard, F-69373 Lyon, France.
Sarcoma Oncol Ctr Santa Monica, Santa Monica, CA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Ist Nazl Tumori, I-20133 Milan, Italy.
Tom Baker Canc Clin, Calgary, AB, Canada.
Johnson & Johnson, New Brunswick, NJ USA.
PharmaMar, Madrid, Spain.
Inst Gustave Roussy, Paris, France.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10509
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606572
ER
PT J
AU DePrimo, S
Wu, B
Huang, S
Bautista, R
Cancilla, B
Vysotskaia, V
De Groot, J
Prados, M
Buller, R
Wen, P
AF DePrimo, S.
Wu, B.
Huang, S.
Bautista, R.
Cancilla, B.
Vysotskaia, V.
De Groot, J.
Prados, M.
Buller, R.
Wen, P.
TI Correlative tumor molecular profiling and plasma biomarker analysis in a
phase II study of XL184 in patients with progressive or recurrent
glioblastoma multiforme (GBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [DePrimo, S.; Wu, B.; Huang, S.; Bautista, R.; Cancilla, B.; Vysotskaia, V.; De Groot, J.; Prados, M.; Buller, R.; Wen, P.] Exelixis Inc, San Francisco, CA USA.
[DePrimo, S.; Wu, B.; Huang, S.; Bautista, R.; Cancilla, B.; Vysotskaia, V.; De Groot, J.; Prados, M.; Buller, R.; Wen, P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[DePrimo, S.; Wu, B.; Huang, S.; Bautista, R.; Cancilla, B.; Vysotskaia, V.; De Groot, J.; Prados, M.; Buller, R.; Wen, P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[DePrimo, S.; Wu, B.; Huang, S.; Bautista, R.; Cancilla, B.; Vysotskaia, V.; De Groot, J.; Prados, M.; Buller, R.; Wen, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2049
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602197
ER
PT J
AU Dial, E
Duh, M
Fournier, A
Antras, L
Rodermund, D
Neary, MP
Oh, WK
AF Dial, E.
Duh, M.
Fournier, A.
Antras, L.
Rodermund, D.
Neary, M. P.
Oh, W. K.
TI Cost implications of intravenous bevacizumab treatment in patients with
renal cell carcinoma (RCC): A retrospective claims database analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Anal Grp Inc, Boston, MA USA.
GlaxoSmithKline Inc, Collegeville, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5112
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603511
PM 27964393
ER
PT J
AU Drappatz, J
Norden, AD
Wong, ET
Lassman, AB
Doherty, L
LaFrankie, D
Gerard, M
Phan, P
Schiff, D
Wen, PY
AF Drappatz, J.
Norden, A. D.
Wong, E. T.
Lassman, A. B.
Doherty, L.
LaFrankie, D.
Gerard, M.
Phan, P.
Schiff, D.
Wen, P. Y.
TI Phase I study of vandetanib with radiation therapy and temozolomide for
newly diagnosed glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Drappatz, J.; Norden, A. D.; Wong, E. T.; Lassman, A. B.; Doherty, L.; LaFrankie, D.; Gerard, M.; Phan, P.; Schiff, D.; Wen, P. Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Drappatz, J.; Norden, A. D.; Wong, E. T.; Lassman, A. B.; Doherty, L.; LaFrankie, D.; Gerard, M.; Phan, P.; Schiff, D.; Wen, P. Y.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Drappatz, J.; Norden, A. D.; Wong, E. T.; Lassman, A. B.; Doherty, L.; LaFrankie, D.; Gerard, M.; Phan, P.; Schiff, D.; Wen, P. Y.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Drappatz, J.; Norden, A. D.; Wong, E. T.; Lassman, A. B.; Doherty, L.; LaFrankie, D.; Gerard, M.; Phan, P.; Schiff, D.; Wen, P. Y.] Univ Virginia, Charlottesville, VA USA.
[Drappatz, J.; Norden, A. D.; Wong, E. T.; Lassman, A. B.; Doherty, L.; LaFrankie, D.; Gerard, M.; Phan, P.; Schiff, D.; Wen, P. Y.] Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2031
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602179
PM 27964631
ER
PT J
AU Duh, M
Toy, EL
Porter, CL
Books, PL
Vekeman, F
Barghout, V
Skarin, AT
AF Duh, M.
Toy, E. L.
Porter, C. L.
Books, P. L.
Vekeman, F.
Barghout, V.
Skarin, A. T.
TI Budget impact analysis of sargramostim use in patients with
chemotherapy-induced neutropenia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Anal Grp Inc, Boston, MA USA.
Anal Grp Inc, Lakewood, CO USA.
Grp Analyse Ltee, Montreal, PQ, Canada.
Bayer HealthCare Pharmaceut, Wayne, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e20596
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606349
PM 27961163
ER
PT J
AU Fernandez, HF
Sun, Z
Litzow, MR
Luger, SM
Paietta, EM
Dewald, G
Ketterling, RP
Rowe, JM
Lazarus, HM
Tallman, MS
AF Fernandez, H. F.
Sun, Z.
Litzow, M. R.
Luger, S. M.
Paietta, E. M.
Dewald, G.
Ketterling, R. P.
Rowe, J. M.
Lazarus, H. M.
Tallman, M. S.
TI A randomized trial of anthracycline dose intensification during
induction of younger patients with acute myeloid leukemia: Results of
Eastern Cooperative Oncology Group study E1900
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Univ Penn, Philadelphia, PA 19104 USA.
Montefiore Med Ctr, N Div, Bronx, NY 10467 USA.
Rambam Med Ctr, Haifa, Israel.
Univ Hosp Cleveland, Cleveland, OH 44106 USA.
Northwestern Univ, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 7003
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604563
PM 27961375
ER
PT J
AU Fisch, M
Lee, JW
Manola, J
Wagner, L
Chang, V
Gilman, P
Lear, K
Baez, L
Cleeland, C
AF Fisch, M.
Lee, J. W.
Manola, J.
Wagner, L.
Chang, V.
Gilman, P.
Lear, K.
Baez, L.
Cleeland, C.
TI Survey of disease and treatment-related symptoms in outpatients with
invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02,
the SOAPP study)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Northwestern Univ, Chicago, IL 60611 USA.
VA New Jersey Healthcare Syst, E Orange, NJ USA.
Mainline Hematol Oncol Associates, Waynnewood, PA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
San Juan Minority Based CCOP, San Juan, PR USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9619
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606237
PM 27963878
ER
PT J
AU Fischbach, NA
Spigel, D
Brahmer, J
Garst, J
Robles, R
Chung, C
Wang, L
Sing, A
Lynch, T
AF Fischbach, N. A.
Spigel, D.
Brahmer, J.
Garst, J.
Robles, R.
Chung, C.
Wang, L.
Sing, A.
Lynch, T.
CA ARIES Investigators
TI (BV) based treatment in subpopulations of patients (pts) with non-small
cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV)
treatment observational cohort study (OCS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Oncol Associates Bridgeport PC, Fairfield, CT USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Duke Comprehens Canc Ctr, Durham, NC USA.
Diablo Valley Oncol & Hematol Med, Pleasant Hill, CA USA.
Genentech Inc, San Francisco, CA 94080 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8040
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605242
PM 27962849
ER
PT J
AU Flinn, IW
Byrd, JC
Furman, RR
Brown, JR
Lin, TS
Bello, C
Giese, NA
Yu, AS
AF Flinn, I. W.
Byrd, J. C.
Furman, R. R.
Brown, J. R.
Lin, T. S.
Bello, C.
Giese, N. A.
Yu, A. S.
TI Preliminary evidence of clinical activity in a phase I study of CAL-101,
a selective inhibitor of the p1108 isoform of phosphatidylinositol
3-kinase (P13K), in patients with select hematologic malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Lin, T. S.; Bello, C.; Giese, N. A.; Yu, A. S.] Sarah Cannon Res Inst, Nashville, TN USA.
[Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Lin, T. S.; Bello, C.; Giese, N. A.; Yu, A. S.] Ohio State Univ, Columbus, OH 43210 USA.
[Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Lin, T. S.; Bello, C.; Giese, N. A.; Yu, A. S.] Weill Cornell Med Coll, New York, NY USA.
[Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Lin, T. S.; Bello, C.; Giese, N. A.; Yu, A. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Lin, T. S.; Bello, C.; Giese, N. A.; Yu, A. S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Lin, T. S.; Bello, C.; Giese, N. A.; Yu, A. S.] Calistoga Pharmaceut Inc, Seattle, WA USA.
NR 0
TC 6
Z9 6
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3543
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602433
PM 27961357
ER
PT J
AU Fuchs, C
Ogino, S
Meyerhardt, JA
Irahara, N
Niedzwiecki, D
Hollis, D
Saltz, LB
Mayer, RJ
Bertagnolli, MM
AF Fuchs, C.
Ogino, S.
Meyerhardt, J. A.
Irahara, N.
Niedzwiecki, D.
Hollis, D.
Saltz, L. B.
Mayer, R. J.
Bertagnolli, M. M.
TI KRAS mutation, cancer recurrence, and patient survival in stage III
colon cancer: Findings from CALGB 89803
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Fuchs, C.; Ogino, S.; Meyerhardt, J. A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Bertagnolli, M. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fuchs, C.; Ogino, S.; Meyerhardt, J. A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Bertagnolli, M. M.] Duke Univ, Med Ctr, Durham, NC USA.
[Fuchs, C.; Ogino, S.; Meyerhardt, J. A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Bertagnolli, M. M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Fuchs, C.; Ogino, S.; Meyerhardt, J. A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Bertagnolli, M. M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4037
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600277
PM 27961543
ER
PT J
AU Gandhi, L
Chu, QS
Stephenson, J
Johnson, BE
Govindan, R
Bonomi, P
Eaton, K
Fritsch, H
Munzert, G
Socinski, M
AF Gandhi, L.
Chu, Q. S.
Stephenson, J.
Johnson, B. E.
Govindan, R.
Bonomi, P.
Eaton, K.
Fritsch, H.
Munzert, G.
Socinski, M.
TI An open label phase II trial of the Plk1 inhibitor BI 2536, in patients
with sensitive relapse small cell lung cancer (SCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Alberta, Edmonton, AB, Canada.
Canc Ctr Carolinas, Greenville, SC USA.
Washington Univ, Sch Med, St Louis, MO USA.
Rush Univ, Med Ctr, Chicago, IL 60612 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 7
Z9 7
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8108
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605310
PM 27964286
ER
PT J
AU Geevarghese, SK
Chen, A
Geller, DA
de Haan, HA
Iagaru, A
Knoll, A
Nemunaitis, J
Reid, TR
Sze, DY
Tanabe, K
AF Geevarghese, S. K.
Chen, A.
Geller, D. A.
de Haan, H. A.
Iagaru, A.
Knoll, A.
Nemunaitis, J.
Reid, T. R.
Sze, D. Y.
Tanabe, K.
TI Phase II efficacy results using an oncolytic herpes simplex virus
(NV1020) in patients with colorectal cancer metastatic to liver (mCRC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Vanderbilt Univ, Nashville, TN USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] MediGene Inc, San Diego, CA USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Univ Pittsburgh, Pittsburgh, PA USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Mary Crowley Med Res Ctr, Dallas, TX USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Stanford Univ, Stanford, CA 94305 USA.
[Geevarghese, S. K.; Chen, A.; Geller, D. A.; de Haan, H. A.; Iagaru, A.; Knoll, A.; Nemunaitis, J.; Reid, T. R.; Sze, D. Y.; Tanabe, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4089
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601031
PM 27961663
ER
PT J
AU George, S
Lal, R
Camidge, DR
Arkenau, H
Chick, J
Poondru, S
Yap, TA
Eckhardt, SG
Demetri, GD
Scurr, M
AF George, S.
Lal, R.
Camidge, D. R.
Arkenau, H.
Chick, J.
Poondru, S.
Yap, T. A.
Eckhardt, S. G.
Demetri, G. D.
Scurr, M.
TI Final results of a dose escalation (DE), pharmacokinetic (PK), and
pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts)
with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Royal Marsden Hosp, Sutton, Surrey, England.
Univ Colorado, Ctr Canc, Denver, CO 80202 USA.
OSI Pharmaceut UK Ltd, Oxford, England.
OSI Pharmaceut UK Ltd, Boulder, CO USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3564
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602454
PM 27961683
ER
PT J
AU Gerstner, ER
Yip, S
Wang, DL
Louis, DN
Iafrate, AJ
Batchelor, TT
AF Gerstner, E. R.
Yip, S.
Wang, D. L.
Louis, D. N.
Iafrate, A. J.
Batchelor, T. T.
TI MGMT methylation status may predict survival in elderly patients with
newly diagnosed glioblastoma (GBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Gerstner, E. R.; Yip, S.; Wang, D. L.; Louis, D. N.; Iafrate, A. J.; Batchelor, T. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e13023
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602250
PM 27962794
ER
PT J
AU Gertz, MA
Abonour, R
Heffner, LT
Greipp, PR
Uno, H
Rajkumar, SV
AF Gertz, M. A.
Abonour, R.
Heffner, L. T.
Greipp, P. R.
Uno, H.
Rajkumar, S. V.
TI Long-lasting responses after four doses of rituximab in Waldenstrom's
macroglobulinemia: Clinical value of minor responses: A follow-up of the
Eastern Cooperative Oncology Group E3A98 trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
Indiana Univ, Indianapolis, IN 46204 USA.
Emory Clin, Atlanta, GA 30322 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8513
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605423
PM 27960876
ER
PT J
AU Ghobrial, IM
Matous, J
Padmanabhan, S
Badros, A
Chuma, S
Leduc, R
Rourke, M
Kunsman, J
Harris, B
Warren, D
Richardson, P
AF Ghobrial, I. M.
Matous, J.
Padmanabhan, S.
Badros, A.
Chuma, S.
Leduc, R.
Rourke, M.
Kunsman, J.
Harris, B.
Warren, D.
Richardson, P.
TI Phase II trial of combination of bortezomib and rituximab in relapsed
and/or refractory Waldenstrom macroglobulinemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Rocky Mt Canc Ctr, Denver, CO USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
Univ Maryland, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8535
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605444
PM 27960930
ER
PT J
AU Gilbert, MR
Wang, M
Aldape, K
Lassman, A
Sorensen, AG
Mikkelson, T
Groves, M
Werner-Wasik, M
Regine, W
Mehta, M
AF Gilbert, M. R.
Wang, M.
Aldape, K.
Lassman, A.
Sorensen, A. G.
Mikkelson, T.
Groves, M.
Werner-Wasik, M.
Regine, W.
Mehta, M.
TI RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent
glioblastoma (GBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Radiat Therapy Oncol Grp, Philadelphia, PA USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Henry Ford Hosp, Detroit, MI 48202 USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Univ Maryland, Baltimore, MD 21201 USA.
[Gilbert, M. R.; Wang, M.; Aldape, K.; Lassman, A.; Sorensen, A. G.; Mikkelson, T.; Groves, M.; Werner-Wasik, M.; Regine, W.; Mehta, M.] Univ Wisconsin, Madison, WI USA.
RI Gilbert, Mark/J-7494-2016
OI Gilbert, Mark/0000-0003-2556-9722
NR 0
TC 1
Z9 1
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2011
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602159
ER
PT J
AU Gold, JM
Najita, JS
Lester, S
Richardson, AL
Morganstern, DE
Chen, WY
Partridge, AH
Krop, IE
Winer, EP
Burstein, HJ
AF Gold, J. M.
Najita, J. S.
Lester, S.
Richardson, A. L.
Morganstern, D. E.
Chen, W. Y.
Partridge, A. H.
Krop, I. E.
Winer, E. P.
Burstein, H. J.
TI Personalizing treatment in early-stage breast cancer: The role of
standard clinical factors and genomic information in adjuvant
chemotherapy decision making
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Gold, J. M.; Najita, J. S.; Lester, S.; Richardson, A. L.; Morganstern, D. E.; Chen, W. Y.; Partridge, A. H.; Krop, I. E.; Winer, E. P.; Burstein, H. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gold, J. M.; Najita, J. S.; Lester, S.; Richardson, A. L.; Morganstern, D. E.; Chen, W. Y.; Partridge, A. H.; Krop, I. E.; Winer, E. P.; Burstein, H. J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 572
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601280
PM 27960736
ER
PT J
AU Goldberg, J
Demetri, GD
Choy, E
Rosen, L
Pappo, A
Dubois, S
Geller, J
Chai, F
Ferrari, D
Wagner, AJ
AF Goldberg, J.
Demetri, G. D.
Choy, E.
Rosen, L.
Pappo, A.
Dubois, S.
Geller, J.
Chai, F.
Ferrari, D.
Wagner, A. J.
TI Preliminary results from a phase II study of ARQ 197 in patients with
microphthalmia transcription factor family (MiT)-associated tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Premiere Oncol, Santa Monica, CA USA.
Texas Childrens Canc Ctr, Houston, TX USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
ArQule Inc, Woburn, MA USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10502
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606565
PM 27963690
ER
PT J
AU Greer, J
Temel, J
Admane, S
Solis, J
Lynch, T
Pirl, W
AF Greer, J.
Temel, J.
Admane, S.
Solis, J.
Lynch, T.
Pirl, W.
TI Code status documentation in the outpatient electronic medical records
of patients with metastatic cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Greer, J.; Temel, J.; Admane, S.; Solis, J.; Lynch, T.; Pirl, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9576
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606195
PM 27963711
ER
PT J
AU Guerin, A
Guo, A
Williams, D
Yu, AP
Wu, E
Latremouille-Viau, D
Tsaneva, M
Signorovitch, J
Griffin, JD
AF Guerin, A.
Guo, A.
Williams, D.
Yu, A. P.
Wu, E.
Latremouille-Viau, D.
Tsaneva, M.
Signorovitch, J.
Griffin, J. D.
TI Treatment patterns of chronic myelogenous leukemia patients with
suboptimal responses to imatinib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Anal Grp Inc, Boston, MA USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 7090
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605079
PM 27961257
ER
PT J
AU Haas, J
Phillips, KA
Hassett, MJ
Liang, S
Keohane, C
Armstrong, J
Toscano, M
AF Haas, J.
Phillips, K. A.
Hassett, M. J.
Liang, S.
Keohane, C.
Armstrong, J.
Toscano, M.
TI Breast cancer testing strategies and the utilization of targeted
therapies: Data from the real world
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Aetna, Hartford, CT USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e17518
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604498
PM 27963272
ER
PT J
AU Haas, N
Manola, J
Pins, M
Liu, G
McDermott, D
Nanus, D
Heath, E
Wilding, G
Dutcher, J
AF Haas, N.
Manola, J.
Pins, M.
Liu, G.
McDermott, D.
Nanus, D.
Heath, E.
Wilding, G.
Dutcher, J.
TI ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in
metastatic renal cell carcinoma (RCC) with sarcomatoid features
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Advocate Lutheran Gen Hosp, Chicago, IL USA.
Univ Wisconsin, Madison, WI USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
New York Presbyterian Hosp, New York, NY USA.
Karmanos Canc Inst, Detroit, MI USA.
Our Lady Mercy, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5038
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603439
PM 27962934
ER
PT J
AU Hanrahan, EO
Kim, F
Lin, HY
Tran, HT
Ryan, AJ
Krebs, AD
Lee, JJ
Johnson, BE
Heymach, JV
Kim, ES
AF Hanrahan, E. O.
Kim, F.
Lin, H. Y.
Tran, H. T.
Ryan, A. J.
Krebs, A. D.
Lee, J. J.
Johnson, B. E.
Heymach, J. V.
Kim, E. S.
TI Plasma cytokine concentrations and quality of life in patients with
non-small cell lung cancer in a phase II trial of first-line treatment
with carboplatin-paclitaxel and/or vandetanib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 MD Anderson Canc Ctr, Houston, TX USA.
AstraZeneca, Macclesfield, Cheshire, England.
AstraZeneca, Wilmington, DE USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9596,46
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606214
PM 27963731
ER
PT J
AU Harris, B
Leleu, X
Leduc, R
Yarar, D
Sam, A
Rourke, M
Chuma, S
Roccaro, A
Ghobrial, I
AF Harris, B.
Leleu, X.
Leduc, R.
Yarar, D.
Sam, A.
Rourke, M.
Chuma, S.
Roccaro, A.
Ghobrial, I.
TI Diagnostic and prognostic use of FDG-PET scans in Waldenstrom's
macroglobulinemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Harris, B.; Leleu, X.; Leduc, R.; Yarar, D.; Sam, A.; Rourke, M.; Chuma, S.; Roccaro, A.; Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e19518
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605530
PM 27960942
ER
PT J
AU Harzstark, AL
Rosenberg, JE
Weinberg, VK
Sun, J
Ryan, CJ
Lin, AM
Fong, L
Brocks, DR
Small, EJ
AF Harzstark, A. L.
Rosenberg, J. E.
Weinberg, V. K.
Sun, J.
Ryan, C. J.
Lin, A. M.
Fong, L.
Brocks, D. R.
Small, E. J.
TI A phase I study of sorafenib and RAD001 for metastatic clear cell renal
cell carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Alberta, Edmonton, AB, Canada.
NR 0
TC 0
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5104
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603503
PM 27964372
ER
PT J
AU Hassett, MJ
Weeks, JC
AF Hassett, M. J.
Weeks, J. C.
TI Identifying high-priority quality measures for breast cancer quality
improvement using data from a nationally representative sample
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Hassett, M. J.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6507
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604356
PM 27964009
ER
PT J
AU Hatoum, HT
Lin, S
Smith, MR
Lipton, A
AF Hatoum, H. T.
Lin, S.
Smith, M. R.
Lipton, A.
TI Effect of adherence to monthly zoledronic acid treatment on risk and
frequency of skeletal complications and follow-up duration in breast
cancer patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Illinois, Chicago, IL USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Penn State Univ, Coll Med, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9593,43
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606211
PM 27963730
ER
PT J
AU Hayes, JH
Chen, M
Moran, BJ
Braccioforte, MH
Dosoretz, D
Salenius, S
Katin, M
Ross, R
D'Amico, AV
AF Hayes, J. H.
Chen, M.
Moran, B. J.
Braccioforte, M. H.
Dosoretz, D.
Salenius, S.
Katin, M.
Ross, R.
D'Amico, A. V.
TI Short-course androgen suppression therapy prior to brachytherapy for
favorable-risk prostate cancer and the risk of all-cause mortality in
men with or without preexisting cardiovascular disease
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Connecticut, Storrs, CT USA.
Prostate Canc Fdn Chicago, Westmont, IL USA.
21st Century Oncol, Ft Myers, FL USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5066
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603466
PM 27964251
ER
PT J
AU Heinrich, MC
Carden, R
Griffith, D
Liang, C
Marino-Enriquez, A
McKinley, A
Presnell, A
Fletcher, JA
AF Heinrich, M. C.
Carden, R.
Griffith, D.
Liang, C.
Marino-Enriquez, A.
McKinley, A.
Presnell, A.
Fletcher, J. A.
TI In vitro activity of sorafenib against imatinib- and sunitinib-resistant
kinase mutations associated with drug-resistant GI stromal tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Portland VA Med Ctr, Portland, OR USA.
OHSU, Knight Canc Inst, Portland, OR USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 2
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10500
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606563
PM 27963686
ER
PT J
AU Heist, RS
Fain, J
Chinnasami, B
Khan, W
Molina, J
Brainerd, V
Leopold, L
Lynch, T
AF Heist, R. S.
Fain, J.
Chinnasami, B.
Khan, W.
Molina, J.
Brainerd, V.
Leopold, L.
Lynch, T.
TI A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T)
in patients with relapsed or refractory small cell lung cancer (SCLC)
after prior platinum-containing first-line chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Newton, MA USA.
Texas Oncol, Austin, TX USA.
Emerywood Hematol Oncol, High Point, NC USA.
Canc Care N Florida PA, Lake City, FL USA.
[Heist, R. S.; Fain, J.; Chinnasami, B.; Khan, W.; Molina, J.; Brainerd, V.; Leopold, L.; Lynch, T.] Mayo Clin, Rochester, MN USA.
Ascenta Therapeut Inc, Malvern, PA USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8106
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605308
PM 27964282
ER
PT J
AU Henderson, TO
Hlubocky, F
Diller, L
Daugherty, C
AF Henderson, T. O.
Hlubocky, F.
Diller, L.
Daugherty, C.
TI Preferences and knowledge gaps among pediatric oncologists regarding the
care of childhood cancer survivors: A survey of nearly 1,200 physicians
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
Univ Chicago, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6561
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604409
PM 27963799
ER
PT J
AU Heng, DY
Xie, W
Regan, MM
Cheng, T
North, S
Knox, JJ
Kollmannsberger, C
McDermott, D
Rini, BI
Choueiri, TK
AF Heng, D. Y.
Xie, W.
Regan, M. M.
Cheng, T.
North, S.
Knox, J. J.
Kollmannsberger, C.
McDermott, D.
Rini, B. I.
Choueiri, T. K.
TI Prognostic factors for overall survival (OS) in patients with metastatic
renal cell carcinoma (RCC) treated with vascular endothelial growth
factor (VEGF)-targeted agents: Results from a large multicenter study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Tom Baker Canc Clin, Calgary, AB, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
BC Canc Agcy, Vancouver, BC, Canada.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5041
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603442
PM 27962941
ER
PT J
AU Hensley, ML
Kravetz, S
Sima, C
Tew, W
Pereira, L
Sabbatini, P
Whalen, C
Aghajanian, CA
Zarwan, C
Berlin, S
AF Hensley, M. L.
Kravetz, S.
Sima, C.
Tew, W.
Pereira, L.
Sabbatini, P.
Whalen, C.
Aghajanian, C. A.
Zarwan, C.
Berlin, S.
TI Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant
epithelial ovarian cancer (PR-EOC): A CTEP-sponsored phase II study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Hensley, M. L.; Kravetz, S.; Sima, C.; Tew, W.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C. A.; Zarwan, C.; Berlin, S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Hensley, M. L.; Kravetz, S.; Sima, C.; Tew, W.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C. A.; Zarwan, C.; Berlin, S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hensley, M. L.; Kravetz, S.; Sima, C.; Tew, W.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C. A.; Zarwan, C.; Berlin, S.] Lahey Clin Fdn, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5561
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600062
PM 27962570
ER
PT J
AU Herbst, RS
Sun, Y
Korfee, S
Germonpre, P
Saijo, N
Zhou, C
Wang, J
Langmuir, P
Kennedy, SJ
Johnson, BE
AF Herbst, R. S.
Sun, Y.
Korfee, S.
Germonpre, P.
Saijo, N.
Zhou, C.
Wang, J.
Langmuir, P.
Kennedy, S. J.
Johnson, B. E.
TI Vandetanib plus docetaxel versus docetaxel as second-line treatment for
patients with advanced non-small cell lung cancer (NSCLC): A randomized,
double-blind phase III trial (ZODIAC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Canc Hosp Beijing, Beijing, Peoples R China.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Univ Duisburg Essen, W German Tumor Ctr, Essen, Germany.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Univ Antwerp Hosp, Edegem, Belgium.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] East Hosp, Natl Canc Ctr, Chiba, Japan.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Tongji Univ, Shanghai 200092, Peoples R China.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Beijing Inst Canc Res, Beijing, Peoples R China.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] AstraZeneca, Wilmington, DE USA.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] AstraZeneca, Macclesfield, Cheshire, England.
[Herbst, R. S.; Sun, Y.; Korfee, S.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S. J.; Johnson, B. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 8
Z9 8
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA CRA8003
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605205
PM 27962043
ER
PT J
AU Hickish, T
Wheatley, D
Lin, N
Carey, L
Houston, S
Mendelson, D
Solca, F
Uttenreuther-Fischer, M
Jones, H
Winer, E
AF Hickish, T.
Wheatley, D.
Lin, N.
Carey, L.
Houston, S.
Mendelson, D.
Solca, F.
Uttenreuther-Fischer, M.
Jones, H.
Winer, E.
TI Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase
inhibitor (TKI), to treat patients with HER2-positive metastatic breast
cancer after failure of treatment with trastuzumab
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Royal Bournemouth Hosp, Bournemouth, Dorset, England.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Royal Cornwall Hosp, Truro, England.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Univ N Carolina, Chapel Hill, NC USA.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Royal Surrey Cty Hosp, Guildford, Surrey, England.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Premiere Oncol Arizona, Scottsdale, AZ USA.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany.
[Hickish, T.; Wheatley, D.; Lin, N.; Carey, L.; Houston, S.; Mendelson, D.; Solca, F.; Uttenreuther-Fischer, M.; Jones, H.; Winer, E.] Boehringer Ingelheim Ltd, Bracknell, Berks, England.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 1023
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601500
PM 27961052
ER
PT J
AU Hirte, HW
McGuire, W
Edwards, R
Husain, A
Hoskins, P
Michels, J
Matulonis, U
Sexton, C
Michelson, G
AF Hirte, H. W.
McGuire, W.
Edwards, R.
Husain, A.
Hoskins, P.
Michels, J.
Matulonis, U.
Sexton, C.
Michelson, G.
TI A phase II trial of voreloxin in women with platinum-resistant ovarian
cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] Juravinski Canc Ctr, Hamilton, ON, Canada.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] Weinberg Canc Ctr, Baltimore, MD USA.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] Univ Pittsburgh, Pittsburgh, PA USA.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] Stanford Univ, Palo Alto, CA 94304 USA.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] British Columbia Canc Agcy, Victoria, BC, Canada.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hirte, H. W.; McGuire, W.; Edwards, R.; Husain, A.; Hoskins, P.; Michels, J.; Matulonis, U.; Sexton, C.; Michelson, G.] Sunesis Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5559
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600060
PM 27962535
ER
PT J
AU Hoffman, KE
D'Amico, AV
AF Hoffman, K. E.
D'Amico, A. V.
TI Prostate cancer screening practice among men age 75 and older: Results
from a national survey
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e16034
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604075
PM 27962959
ER
PT J
AU Hofmeister, CC
Richardson, P
Zimmerman, T
Spear, MA
Palladino, MA
Longenecker, AM
Cropp, GF
Lloyd, GK
Hannah, AL
Anderson, K
AF Hofmeister, C. C.
Richardson, P.
Zimmerman, T.
Spear, M. A.
Palladino, M. A.
Longenecker, A. M.
Cropp, G. F.
Lloyd, G. K.
Hannah, A. L.
Anderson, K.
TI Clinical trial of the novel structure proteasome inhibitor NPI-0052 in
patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Ohio State Univ, Columbus, OH 43210 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago, Chicago, IL 60637 USA.
Nereus Pharmaceut, San Diego, CA USA.
Multiple Myeloma Res Consortium, Norwalk, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8505
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605415
ER
PT J
AU Hong, T
Ryan, DP
Blaszkowsky, LS
Mamon, HJ
Mino-Kenudson, M
Adams, J
Yeap, B
Winrich, B
DeLaney, TF
Fernandez-del Castillo, C
AF Hong, T.
Ryan, D. P.
Blaszkowsky, L. S.
Mamon, H. J.
Mino-Kenudson, M.
Adams, J.
Yeap, B.
Winrich, B.
DeLaney, T. F.
Fernandez-del Castillo, C.
TI Phase I study of preoperative (pre-op) short course chemoradiation (CRT)
with proton beam therapy (PBT) and capecitabine (cape) for resectable
pancreatic ductal adenocarcinoma (PDAC) of the head
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, DFCI, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e15536
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603255
PM 27962312
ER
PT J
AU Hough, B
Posner, M
Chung, C
Hainsworth, J
Horan, J
Chick, J
Gibson, MK
AF Hough, B.
Posner, M.
Chung, C.
Hainsworth, J.
Horan, J.
Chick, J.
Gibson, M. K.
TI A phase II study of single agent OSI-7904L in patients with metastatic
or recurrent squamous cell carcinoma of the head and neck (SCCHN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sarah Cannon Res Inst, Nashville, TN USA.
OSI Pharmaceut, Oxford, England.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e17005
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604296
PM 27961620
ER
PT J
AU Hu, J
Wen, PY
Abrey, LE
Fadul, C
Drappatz, J
Salem, N
Amato, A
Carminati, P
Supko, J
Hochberg, F
AF Hu, J.
Wen, P. Y.
Abrey, L. E.
Fadul, C.
Drappatz, J.
Salem, N.
Amato, A.
Carminati, P.
Supko, J.
Hochberg, F.
TI Phase II trial of oral gimatecan in adults with recurrent glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Massachusetts Gen Hosp, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02114 USA.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Sigma Tau Res Inc, Gaithersburg, MD USA.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Sigma Tau Ind Farmaceut Reiunite SpA, Pomezia, Italy.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Harvard Univ, Ctr Canc, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hu, J.; Wen, P. Y.; Abrey, L. E.; Fadul, C.; Drappatz, J.; Salem, N.; Amato, A.; Carminati, P.; Supko, J.; Hochberg, F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2009
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602157
PM 27964558
ER
PT J
AU Hughes, ME
Ottesen, R
Niland, JC
Edge, SB
Theriault, RL
Wilson, J
Blayney, DW
Wong, Y
Weeks, JC
AF Hughes, M. E.
Ottesen, R.
Niland, J. C.
Edge, S. B.
Theriault, R. L.
Wilson, J.
Blayney, D. W.
Wong, Y.
Weeks, J. C.
TI Quality of breast cancer care in NCCN centers as assessed by the
ASCO/NCCN quality measures: Overall performance and reasons for
nonconcordance
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] Roswell Pk, Buffalo, NY USA.
[Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] MD Anderson Canc Ctr, Houston, TX USA.
[Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
[Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Hughes, M. E.; Ottesen, R.; Niland, J. C.; Edge, S. B.; Theriault, R. L.; Wilson, J.; Blayney, D. W.; Wong, Y.; Weeks, J. C.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6506
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604355
PM 27964006
ER
PT J
AU Hunter, Z
Sun, J
Tseng, H
Hatjiharissi, E
Maghsoudi, K
Xu, L
Manning, R
Munshi, N
Anderson, K
Treon, S
AF Hunter, Z.
Sun, J.
Tseng, H.
Hatjiharissi, E.
Maghsoudi, K.
Xu, L.
Manning, R.
Munshi, N.
Anderson, K.
Treon, S.
CA Bing Ctr Waldenstroms Res
J Lipper UpperCtr Multiple Myeloma
TI TNF-a, retinoid acid and STAT4 pathways are differentially regulated by
the HDAC inhibitors, SAHA, TSA and Sirtinol in Waldenstrom's
Macroglobulinemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RI Hunter, Zachary/H-3018-2013
OI Hunter, Zachary/0000-0002-1689-1691
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e14582
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603030
PM 27963754
ER
PT J
AU Ikeda, H
Hideshima, T
Perrone, G
Okawa, Y
Raje, N
Kawabe, T
Sakakibara, K
Saito, N
Richardson, P
Anderson, K
AF Ikeda, H.
Hideshima, T.
Perrone, G.
Okawa, Y.
Raje, N.
Kawabe, T.
Sakakibara, K.
Saito, N.
Richardson, P.
Anderson, K.
TI Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
CanBas Co Ltd, Numazu, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8601
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605509
PM 27962614
ER
PT J
AU Jackman, DM
Cioffredi, L
Lindeman, NI
Morse, LK
Lucca, J
Weckstein, D
Huberman, MS
Lynch, TJ
Johnson, BE
Janne, PA
AF Jackman, D. M.
Cioffredi, L.
Lindeman, N. I.
Morse, L. K.
Lucca, J.
Weckstein, D.
Huberman, M. S.
Lynch, T. J.
Johnson, B. E.
Janne, P. A.
TI Phase II trial of erlotinib in chemotherapy-naive women with advanced
pulmonary adenocarcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Jackman, D. M.; Cioffredi, L.; Lindeman, N. I.; Morse, L. K.; Lucca, J.; Weckstein, D.; Huberman, M. S.; Lynch, T. J.; Johnson, B. E.; Janne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jackman, D. M.; Cioffredi, L.; Lindeman, N. I.; Morse, L. K.; Lucca, J.; Weckstein, D.; Huberman, M. S.; Lynch, T. J.; Johnson, B. E.; Janne, P. A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Jackman, D. M.; Cioffredi, L.; Lindeman, N. I.; Morse, L. K.; Lucca, J.; Weckstein, D.; Huberman, M. S.; Lynch, T. J.; Johnson, B. E.; Janne, P. A.] DFCI, Londonderry, NH USA.
[Jackman, D. M.; Cioffredi, L.; Lindeman, N. I.; Morse, L. K.; Lucca, J.; Weckstein, D.; Huberman, M. S.; Lynch, T. J.; Johnson, B. E.; Janne, P. A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Jackman, D. M.; Cioffredi, L.; Lindeman, N. I.; Morse, L. K.; Lucca, J.; Weckstein, D.; Huberman, M. S.; Lynch, T. J.; Johnson, B. E.; Janne, P. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8065
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605267
PM 27962638
ER
PT J
AU Jackson, VA
Jacobsen, J
Greer, J
Dahlin, C
Billings, JA
Pirl, W
Cruz, PP
Admane, S
Blinderman, C
Temel, J
AF Jackson, V. A.
Jacobsen, J.
Greer, J.
Dahlin, C.
Billings, J. A.
Pirl, W.
Cruz, P. Perez
Admane, S.
Blinderman, C.
Temel, J.
TI Components of early intervention outpatient palliative care consultation
in patients with incurable NSCLC
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Jackson, V. A.; Jacobsen, J.; Greer, J.; Dahlin, C.; Billings, J. A.; Pirl, W.; Cruz, P. Perez; Admane, S.; Blinderman, C.; Temel, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e20635
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606386
PM 27961577
ER
PT J
AU Jacobson, JO
Brozovic, S
Stahl, JE
Papi, M
Stankiewicz, R
AF Jacobson, J. O.
Brozovic, S.
Stahl, J. E.
Papi, M.
Stankiewicz, R.
TI Risk factors for severe cancer chemotherapy toxicity in the outpatient
setting: Results of a nested case control study using a novel patient
cohort
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 N Shore Med Ctr, Salem, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
N Shore Canc Ctr, Peabody, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6545
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604394
PM 27964061
ER
PT J
AU Jakubowiak, AJ
Hofmeister, CC
Campagnaro, EL
Zimmerman, TM
Schlossman, RL
Lonial, S
Reece, DE
Kaminski, MS
Anderson, KC
Richardson, PG
AF Jakubowiak, A. J.
Hofmeister, C. C.
Campagnaro, E. L.
Zimmerman, T. M.
Schlossman, R. L.
Lonial, S.
Reece, D. E.
Kaminski, M. S.
Anderson, K. C.
Richardson, P. G.
TI Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride,
and dexamethasone in newly diagnosed multiple myeloma: Initial results
of phase I/II MMRC trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Univ Chicago, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Emory Univ, Sch Med, Atlanta, GA 30322 USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8517
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605426
PM 27960880
ER
PT J
AU Janne, PA
Reckamp, K
Koczywas, M
Engelman, JA
Camidge, DR
Rajan, A
Khuri, F
Liang, JQ
O'Connell, J
Giaccone, G
AF Janne, P. A.
Reckamp, K.
Koczywas, M.
Engelman, J. A.
Camidge, D. R.
Rajan, A.
Khuri, F.
Liang, J. Q.
O'Connell, J.
Giaccone, G.
TI Efficacy and safety of PF-00299804 (PF299) in patients (pt) with
advanced NSCLC after failure of at least one prior chemotherapy regimen
and prior treatment with erlotinib (E): A two-arm, phase II trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] City Hope Natl Med Ctr, Duarte, CA USA.
[Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] Univ Colorado, Denver, CO 80202 USA.
[Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] Natl Canc Inst, Bethesda, MD USA.
[Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Janne, P. A.; Reckamp, K.; Koczywas, M.; Engelman, J. A.; Camidge, D. R.; Rajan, A.; Khuri, F.; Liang, J. Q.; O'Connell, J.; Giaccone, G.] Pfizer Oncol, New London, CT USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8063
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605265
PM 27962636
ER
PT J
AU Jenab-Wolcott, J
Catalano, PJ
Fillingham, B
Ferriere, M
O'Dwyer, PJ
Giantonio, BJ
AF Jenab-Wolcott, J.
Catalano, P. J.
Fillingham, B.
Ferriere, M.
O'Dwyer, P. J.
Giantonio, B. J.
TI Voluntary submission of biological specimens from cancer clinical
trials: An update of the Eastern Cooperative Oncology Group experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Hosp Univ Penn, Philadelphia, PA 19104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
ECOG, Coordinating Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6597
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604445
PM 27963897
ER
PT J
AU Josephs, DH
Hutson, TE
Pickering, LM
Larkin, JM
Choueiri, TK
Patel, TV
Mcdermott, DF
Powles, T
Harper, PG
Chowdhury, S
AF Josephs, D. H.
Hutson, T. E.
Pickering, L. M.
Larkin, J. M.
Choueiri, T. K.
Patel, T. V.
Mcdermott, D. F.
Powles, T.
Harper, P. G.
Chowdhury, S.
TI Efficacy and toxicity of sunitinib in patients with metastatic renal
cell carcinoma (mRCC) with severe renal impairment or on haemodialysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Guys Hosp, London SE1 9RT, England.
Baylor Sammons Canc Ctr, Dallas, TX USA.
Royal Marsden Hosp, London SW3 6JJ, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Barts & London Hosp, London, England.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5109
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603508
PM 27964363
ER
PT J
AU Kaley, TJ
Raizer, JJ
Paleologos, N
Kewalramani, T
Grimm, S
Louis, DN
Cairncross, JG
Abrey, LE
AF Kaley, T. J.
Raizer, J. J.
Paleologos, N.
Kewalramani, T.
Grimm, S.
Louis, D. N.
Cairncross, J. G.
Abrey, L. E.
TI Phase II trial of temozolomide (TMZ) followed by myeloablative
chemotherapy with autologous peripheral blood progenitor cell rescue
(APBPCR) for newly diagnosed anaplastic oligodendroglioma: An
Oligodendroglioma Study Group trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Kaley, T. J.; Raizer, J. J.; Paleologos, N.; Kewalramani, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Abrey, L. E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kaley, T. J.; Raizer, J. J.; Paleologos, N.; Kewalramani, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Abrey, L. E.] NW Mem Hosp, Chicago, IL 60611 USA.
[Kaley, T. J.; Raizer, J. J.; Paleologos, N.; Kewalramani, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Abrey, L. E.] Evanston Hosp Corp, Evanston, IL USA.
[Kaley, T. J.; Raizer, J. J.; Paleologos, N.; Kewalramani, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Abrey, L. E.] Lahey Clin Med Ctr, Burlington, MA 01803 USA.
[Kaley, T. J.; Raizer, J. J.; Paleologos, N.; Kewalramani, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Abrey, L. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kaley, T. J.; Raizer, J. J.; Paleologos, N.; Kewalramani, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Abrey, L. E.] Univ Calgary, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2055
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602203
PM 27964668
ER
PT J
AU Kantoff, PW
Schuetz, T
Blumenstein, BA
Glode, MM
Bilhartz, D
Gulley, J
Schlom, J
Laus, R
Godfrey, W
AF Kantoff, P. W.
Schuetz, T.
Blumenstein, B. A.
Glode, M. M.
Bilhartz, D.
Gulley, J.
Schlom, J.
Laus, R.
Godfrey, W.
TI Overall survival (OS) analysis of a phase II randomized controlled trial
(RCT) of a poxviral-based PSA targeted immunotherapy in metastatic
castration-resistant prostate cancer (mCRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Trial Architecture Consulting, Washington, DC USA.
Univ Colorado, Aurora, CO USA.
Urol Associates, Nashville, TN USA.
Natl Canc Inst, Bethesda, MD USA.
BN Immunotherapeut, Mountain View, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5013
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603417
PM 27962903
ER
PT J
AU Kauh, JS
Cohen, R
Clarke, JW
Harvey, R
Mulligan, G
Venkatakrishnan, K
Berger, A
Smith, PG
Petruzelli, L
Sarantopoulos, J
AF Kauh, J. S.
Cohen, R.
Clarke, J. W.
Harvey, R.
Mulligan, G.
Venkatakrishnan, K.
Berger, A.
Smith, P. G.
Petruzelli, L.
Sarantopoulos, J.
TI Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and
skin
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Kauh, J. S.; Cohen, R.; Clarke, J. W.; Harvey, R.; Mulligan, G.; Venkatakrishnan, K.; Berger, A.; Smith, P. G.; Petruzelli, L.; Sarantopoulos, J.] Emory Univ, Atlanta, GA 30322 USA.
[Kauh, J. S.; Cohen, R.; Clarke, J. W.; Harvey, R.; Mulligan, G.; Venkatakrishnan, K.; Berger, A.; Smith, P. G.; Petruzelli, L.; Sarantopoulos, J.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Kauh, J. S.; Cohen, R.; Clarke, J. W.; Harvey, R.; Mulligan, G.; Venkatakrishnan, K.; Berger, A.; Smith, P. G.; Petruzelli, L.; Sarantopoulos, J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Kauh, J. S.; Cohen, R.; Clarke, J. W.; Harvey, R.; Mulligan, G.; Venkatakrishnan, K.; Berger, A.; Smith, P. G.; Petruzelli, L.; Sarantopoulos, J.] Winchip Canc Inst, Atlanta, GA USA.
[Kauh, J. S.; Cohen, R.; Clarke, J. W.; Harvey, R.; Mulligan, G.; Venkatakrishnan, K.; Berger, A.; Smith, P. G.; Petruzelli, L.; Sarantopoulos, J.] Millennium Pharmaceut Inc, Cambridge, MA USA.
[Kauh, J. S.; Cohen, R.; Clarke, J. W.; Harvey, R.; Mulligan, G.; Venkatakrishnan, K.; Berger, A.; Smith, P. G.; Petruzelli, L.; Sarantopoulos, J.] UTHSCS, CTRC, Inst Drug Dev, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2562
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602328
PM 27961887
ER
PT J
AU Khambata-Ford, S
Harbison, C
Woytowitz, D
Awad, M
Horak, C
Xu, LA
Dakhil, S
Hermann, RC
Lynch, TJ
Weber, MR
AF Khambata-Ford, S.
Harbison, C.
Woytowitz, D.
Awad, M.
Horak, C.
Xu, L. A.
Dakhil, S.
Hermann, R. C.
Lynch, T. J.
Weber, M. R.
TI K-Ras mutation (mut), EGFR-related, and exploratory markers as response
predictors of cetuximab in first-line advanced NSCLC: Retrospective
analyses of the BMS099 trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Bristol Myers Squibb Co, Princeton, NJ USA.
Florida Canc Specialists, Ft Myers, FL USA.
Canc Ctr Kansas, Wichita, KS USA.
NW Georgia Oncol Ctr, Marietta, GA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8021
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605223
ER
PT J
AU Kollmannsberger, CK
Hurwitz, H
Vlahovic, G
Maroun, C
Dumouchel, J
Reid, G
Martell, R
Shapiro, G
AF Kollmannsberger, C. K.
Hurwitz, H.
Vlahovic, G.
Maroun, C.
Dumouchel, J.
Reid, G.
Martell, R.
Shapiro, G.
TI Phase I study of daily administration of MGCD265 to patients with
advanced malignancies (Study 265-101)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Duke Univ, Med Ctr, Durham, NC USA.
MethylGene Inc, Montreal, PQ, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e14525
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602501
PM 27963572
ER
PT J
AU Kosty, MP
Kumar, P
Wozniak, A
Jahanzeb, M
Chung, C
Wang, L
Sing, A
Lynch, T
AF Kosty, M. P.
Kumar, P.
Wozniak, A.
Jahanzeb, M.
Chung, C.
Wang, L.
Sing, A.
Lynch, T.
CA ARIES Investigators
TI Development of cavitation while on bevacizumab (BV) therapy in patients
(pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A
bevacizumab (BV) treatment observational cohort study (OCS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Kosty, M. P.; Kumar, P.; Wozniak, A.; Jahanzeb, M.; Chung, C.; Wang, L.; Sing, A.; Lynch, T.] Scripps Clin, La Jolla, CA 92037 USA.
[Kosty, M. P.; Kumar, P.; Wozniak, A.; Jahanzeb, M.; Chung, C.; Wang, L.; Sing, A.; Lynch, T.] Univ Minnesota, Minneapolis, MN USA.
[Kosty, M. P.; Kumar, P.; Wozniak, A.; Jahanzeb, M.; Chung, C.; Wang, L.; Sing, A.; Lynch, T.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Kosty, M. P.; Kumar, P.; Wozniak, A.; Jahanzeb, M.; Chung, C.; Wang, L.; Sing, A.; Lynch, T.] Boca Raton Community Hosp, Aptium Oncol, Boca Raton, FL USA.
[Kosty, M. P.; Kumar, P.; Wozniak, A.; Jahanzeb, M.; Chung, C.; Wang, L.; Sing, A.; Lynch, T.] Genentech Inc, San Francisco, CA USA.
[Kosty, M. P.; Kumar, P.; Wozniak, A.; Jahanzeb, M.; Chung, C.; Wang, L.; Sing, A.; Lynch, T.; ARIES Investigators] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e19045
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605352
PM 27962105
ER
PT J
AU Krasner, CN
Poveda, A
Herzog, T
Vermorken, J
Monk, B
Zintl, P
Li, J
Su, Y
Dhawan, R
Kaye, S
AF Krasner, C. N.
Poveda, A.
Herzog, T.
Vermorken, J.
Monk, B.
Zintl, P.
Li, J.
Su, Y.
Dhawan, R.
Kaye, S.
TI Health-related quality of life/patient-reported outcomes in relapsed
ovarian cancer: Results from a randomized phase III study of trabectedin
with pegylated liposomal doxorubicin (PLD) versus PLD alone
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] Fdn Inst Valenciano Oncol, Valencia, Spain.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] Columbia Univ, Med Ctr, New York, NY USA.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] Univ Ziekenhuis Antwerpen, Edegem, Belgium.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] UC, Chao Family Comprehens Canc Ctr, Orange, CA USA.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] PharmaMar SA, Madrid, Spain.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] Johnson & Johnson, Raritan, NJ USA.
[Krasner, C. N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S.] Royal Marsden Hosp, Sutton, Surrey, England.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5526
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600028
PM 27962478
ER
PT J
AU Krop, IE
Burris, HA
Rugo, H
O'Shaughnessy, J
Vogel, CL
Amler, L
Strauss, A
Wong, EK
Klencke, B
Pippen, J
AF Krop, I. E.
Burris, H. A.
Rugo, H.
O'Shaughnessy, J.
Vogel, C. L.
Amler, L.
Strauss, A.
Wong, E. K.
Klencke, B.
Pippen, J.
TI Quantitative assessment of HER2 status and correlation with efficacy for
patients (pts) with metastatic breast cancer (MBC) in a phase II study
of trastuzumab-DM1 (T-DM1)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Sarah Cannon Canc Ctr, Nashville, TN USA.
[Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Baylor Sammons Canc Ctr, Texas Oncol PA, Dallas, TX USA.
[Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Lynn Reg Canc Ctr W, Boca Raton, FL USA.
[Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Genentech Inc, San Francisco, CA 94080 USA.
[Krop, I. E.; Burris, H. A.; Rugo, H.; O'Shaughnessy, J.; Vogel, C. L.; Amler, L.; Strauss, A.; Wong, E. K.; Klencke, B.; Pippen, J.] Roche Diagnost GmbH, Penzberg, Germany.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 1003
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601482
PM 27960714
ER
PT J
AU Kuhn, JG
Gilbert, M
Wen, P
Cloughesy, T
Cooper, J
Puduvalli, V
DeAngelis, L
Lieberman, F
Lamborn, K
Prados, M
AF Kuhn, J. G.
Gilbert, M.
Wen, P.
Cloughesy, T.
Cooper, J.
Puduvalli, V.
DeAngelis, L.
Lieberman, F.
Lamborn, K.
Prados, M.
TI Interaction between sorafenib and erlotinib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] S Texas Accelerated Res Therapeut, San Antonio, TX USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Kuhn, J. G.; Gilbert, M.; Wen, P.; Cloughesy, T.; Cooper, J.; Puduvalli, V.; DeAngelis, L.; Lieberman, F.; Lamborn, K.; Prados, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2500
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602266
ER
PT J
AU Kuter, I
Anderson, E
Emeribe, U
Finlay, P
Nicholson, R
Gee, J
AF Kuter, I.
Anderson, E.
Emeribe, U.
Finlay, P.
Nicholson, R.
Gee, J.
TI Comparison of methods for detection of fulvestrant-induced changes in
breast tumor estrogen and progesterone receptor expression in a
neoadjuvant trial (NEWEST)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kuter, I.; Anderson, E.; Emeribe, U.; Finlay, P.; Nicholson, R.; Gee, J.] AstraZeneca, Macclesfield, Cheshire, England.
[Kuter, I.; Anderson, E.; Emeribe, U.; Finlay, P.; Nicholson, R.; Gee, J.] AstraZeneca, Wilmington, DE USA.
[Kuter, I.; Anderson, E.; Emeribe, U.; Finlay, P.; Nicholson, R.; Gee, J.] Tenovus Ctr Canc Res, Cardiff, Wales.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e11602
PG 3
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601443
PM 27961051
ER
PT J
AU Kwak, EL
Camidge, DR
Clark, J
Shapiro, GI
Maki, RG
Ratain, MJ
Solomon, B
Bang, Y
Ou, S
Salgia, R
AF Kwak, E. L.
Camidge, D. R.
Clark, J.
Shapiro, G. I.
Maki, R. G.
Ratain, M. J.
Solomon, B.
Bang, Y.
Ou, S.
Salgia, R.
TI Clinical activity observed in a phase I dose escalation trial of an oral
c-met and ALK inhibitor, PF-02341066
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Univ Chicago, Chicago, IL 60637 USA.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Peter MacCallum Canc Ctr, Melbourne, Australia.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] UC Irvine Med Ctr, Orange, CA USA.
[Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R.] Univ Chicago, Ctr Canc, Chicago, IL 60637 USA.
NR 0
TC 85
Z9 91
U1 0
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3509
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602399
PM 27961297
ER
PT J
AU Lee, RJ
Stott, SL
Nagrath, S
Ulkus, LE
Dahl, DM
Smith, MR
Toner, M
Maheswaran, S
Haber, DA
AF Lee, R. J.
Stott, S. L.
Nagrath, S.
Ulkus, L. E.
Dahl, D. M.
Smith, M. R.
Toner, M.
Maheswaran, S.
Haber, D. A.
TI Analyses of circulating tumor cell (CTC) dynamics and treatment response
in prostate cancer using the CTC-chip microfluidic device
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Lee, R. J.; Stott, S. L.; Nagrath, S.; Ulkus, L. E.; Dahl, D. M.; Smith, M. R.; Toner, M.; Maheswaran, S.; Haber, D. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 1
U1 1
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5149
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604022
PM 27964441
ER
PT J
AU Lewis, L
Frank, R
Dandamudi, UB
Gallagher, J
Zhao, L
Woo, M
Hirawat, S
Shapiro, GI
AF Lewis, L.
Frank, R.
Dandamudi, U. B.
Gallagher, J.
Zhao, L.
Woo, M.
Hirawat, S.
Shapiro, G. I.
TI Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589),
an orally active histone deacetylase inhibitor, in patients with
advanced cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Lewis, L.; Frank, R.; Dandamudi, U. B.; Gallagher, J.; Zhao, L.; Woo, M.; Hirawat, S.; Shapiro, G. I.] Dartmouth, Lebanon, NH USA.
[Lewis, L.; Frank, R.; Dandamudi, U. B.; Gallagher, J.; Zhao, L.; Woo, M.; Hirawat, S.; Shapiro, G. I.] Norwalk Hosp, Whittingham Canc Ctr, Norwalk, CT 06856 USA.
[Lewis, L.; Frank, R.; Dandamudi, U. B.; Gallagher, J.; Zhao, L.; Woo, M.; Hirawat, S.; Shapiro, G. I.] Novartis Oncol, Florham Pk, NJ USA.
[Lewis, L.; Frank, R.; Dandamudi, U. B.; Gallagher, J.; Zhao, L.; Woo, M.; Hirawat, S.; Shapiro, G. I.] Novartis Oncol, E Hanover, NJ USA.
[Lewis, L.; Frank, R.; Dandamudi, U. B.; Gallagher, J.; Zhao, L.; Woo, M.; Hirawat, S.; Shapiro, G. I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2550
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602316
PM 27961876
ER
PT J
AU Lin, NU
Vanderplas, A
Hughes, ME
Theriault, RL
Edge, SB
Wong, Y
Blayney, DW
Niland, JC
Winer, EP
Weeks, JC
AF Lin, N. U.
Vanderplas, A.
Hughes, M. E.
Theriault, R. L.
Edge, S. B.
Wong, Y.
Blayney, D. W.
Niland, J. C.
Winer, E. P.
Weeks, J. C.
TI Clinicopathological features and sites of recurrence according to breast
cancer subtype in the National Comprehensive Cancer Network (NCCN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Lin, N. U.; Vanderplas, A.; Hughes, M. E.; Theriault, R. L.; Edge, S. B.; Wong, Y.; Blayney, D. W.; Niland, J. C.; Winer, E. P.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lin, N. U.; Vanderplas, A.; Hughes, M. E.; Theriault, R. L.; Edge, S. B.; Wong, Y.; Blayney, D. W.; Niland, J. C.; Winer, E. P.; Weeks, J. C.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Lin, N. U.; Vanderplas, A.; Hughes, M. E.; Theriault, R. L.; Edge, S. B.; Wong, Y.; Blayney, D. W.; Niland, J. C.; Winer, E. P.; Weeks, J. C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Lin, N. U.; Vanderplas, A.; Hughes, M. E.; Theriault, R. L.; Edge, S. B.; Wong, Y.; Blayney, D. W.; Niland, J. C.; Winer, E. P.; Weeks, J. C.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Lin, N. U.; Vanderplas, A.; Hughes, M. E.; Theriault, R. L.; Edge, S. B.; Wong, Y.; Blayney, D. W.; Niland, J. C.; Winer, E. P.; Weeks, J. C.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Lin, N. U.; Vanderplas, A.; Hughes, M. E.; Theriault, R. L.; Edge, S. B.; Wong, Y.; Blayney, D. W.; Niland, J. C.; Winer, E. P.; Weeks, J. C.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
NR 0
TC 2
Z9 3
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 543
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601252
PM 27960656
ER
PT J
AU Lipshultz, SE
Scully, RE
Lipsitz, SR
Sallan, SE
Silverman, LB
Miller, TL
Orav, EJ
Colan, SD
AF Lipshultz, S. E.
Scully, R. E.
Lipsitz, S. R.
Sallan, S. E.
Silverman, L. B.
Miller, T. L.
Orav, E. J.
Colan, S. D.
TI Gender differences in long-term dexrazoxane cardioprotection in
doxorubicin-treated children with acute lymphoblastic leukemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Lipshultz, S. E.; Scully, R. E.; Lipsitz, S. R.; Sallan, S. E.; Silverman, L. B.; Miller, T. L.; Orav, E. J.; Colan, S. D.] Dana Farber Canc Inst, Acute Lymphoblast Leukemia Consortium, Boston, MA USA.
[Lipshultz, S. E.; Scully, R. E.; Lipsitz, S. R.; Sallan, S. E.; Silverman, L. B.; Miller, T. L.; Orav, E. J.; Colan, S. D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Lipshultz, S. E.; Scully, R. E.; Lipsitz, S. R.; Sallan, S. E.; Silverman, L. B.; Miller, T. L.; Orav, E. J.; Colan, S. D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Lipshultz, S. E.; Scully, R. E.; Lipsitz, S. R.; Sallan, S. E.; Silverman, L. B.; Miller, T. L.; Orav, E. J.; Colan, S. D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lipshultz, S. E.; Scully, R. E.; Lipsitz, S. R.; Sallan, S. E.; Silverman, L. B.; Miller, T. L.; Orav, E. J.; Colan, S. D.] Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10005
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606502
PM 27962530
ER
PT J
AU Luketich, J
Pennathur, A
Catalano, PJ
Swanson, SJ
de Hoyos, AL
Maddaus, MA
Nguyen, N
Benson, AB
Fernando, HC
AF Luketich, J.
Pennathur, A.
Catalano, P. J.
Swanson, S. J.
de Hoyos, A. L.
Maddaus, M. A.
Nguyen, N.
Benson, A. B., III
Fernando, H. C.
TI Results of a phase II multicenter study of minimally invasive
esophagectomy (Eastern Cooperative Oncology Group Study E2202)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NW Mem Hosp, Chicago, IL 60611 USA.
Univ Minnesota Hosp, Minneapolis, MN USA.
Univ Calif Irvine, Irvine, CA USA.
Northwestern Univ, Chicago, IL 60611 USA.
Boston Univ, Med Ctr, Boston, MA USA.
NR 0
TC 8
Z9 8
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4516
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603107
PM 27962698
ER
PT J
AU MacRae, C
Richardson, PG
Walker, J
Grayzel, DS
Demetri, GD
AF MacRae, C.
Richardson, P. G.
Walker, J.
Grayzel, D. S.
Demetri, G. D.
TI Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a
novel Hsp90 inhibitor: Results from two independent phase I trials in
patients with advanced cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Infin Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e14539
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602512
PM 27963557
ER
PT J
AU Malempati, S
Weigel, B
Ingle, AM
Ahern, CH
Carroll, JM
Roberts, CT
Fox, FE
Voss, S
Adamson, PC
Blaney, SM
AF Malempati, S.
Weigel, B.
Ingle, A. M.
Ahern, C. H.
Carroll, J. M.
Roberts, C. T., Jr.
Fox, F. E.
Voss, S.
Adamson, P. C.
Blaney, S. M.
TI A phase I trial and pharmacokinetic study of IMC-A12 in pediatric
patients with relapsed/refractory solid tumors: A Children's Oncology
Group Phase I Consortium study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Minnesota, Ctr Canc, Minneapolis, MN USA.
Childrens Oncol Grp, Arcadia, CA USA.
Texas Childrens Canc Ctr, Houston, TX USA.
Oregon Natl Primate Res Ctr, Beaverton, OR USA.
ImClone Syst, Branchburg, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10013
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606511
PM 27962525
ER
PT J
AU Malogolowkin, MH
Krailo, M
Frazier, LA
Olson, TA
AF Malogolowkin, M. H.
Krailo, M.
Frazier, L. A.
Olson, T. A.
TI Study of cisplatin, etoposide, bleomycin, and escalating dose
cyclophosphamide therapy for children with high-risk germ cell tumors: A
Children's Oncology Group report
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 USC, Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA USA.
Childrens Oncol Grp, Arcadia, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Emory Univ, Childrens Hlth Care Atlanta, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10035
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606532
PM 27962582
ER
PT J
AU Mandelblatt, J
Sheppard, V
Hurria, A
Kimmick, G
Isaacs, C
Taylor, K
Luta, G
Noone, A
Kornblith, A
Barry, W
AF Mandelblatt, J.
Sheppard, V.
Hurria, A.
Kimmick, G.
Isaacs, C.
Taylor, K.
Luta, G.
Noone, A.
Kornblith, A.
Barry, W.
CA Canc & Leukemia Grp B
TI Patient preference as a determinant of breast cancer adjuvant
chemotherapy use in older women: CALGB #369901
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Mandelblatt, J.; Sheppard, V.; Hurria, A.; Kimmick, G.; Isaacs, C.; Taylor, K.; Luta, G.; Noone, A.; Kornblith, A.; Barry, W.] Lombardi Comprehens Canc Ctr, Washington, DC USA.
[Mandelblatt, J.; Sheppard, V.; Hurria, A.; Kimmick, G.; Isaacs, C.; Taylor, K.; Luta, G.; Noone, A.; Kornblith, A.; Barry, W.] City Hope Natl Med Ctr, Los Angeles, CA USA.
[Mandelblatt, J.; Sheppard, V.; Hurria, A.; Kimmick, G.; Isaacs, C.; Taylor, K.; Luta, G.; Noone, A.; Kornblith, A.; Barry, W.] Duke Univ, Med Ctr, Durham, NC USA.
[Mandelblatt, J.; Sheppard, V.; Hurria, A.; Kimmick, G.; Isaacs, C.; Taylor, K.; Luta, G.; Noone, A.; Kornblith, A.; Barry, W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mandelblatt, J.; Sheppard, V.; Hurria, A.; Kimmick, G.; Isaacs, C.; Taylor, K.; Luta, G.; Noone, A.; Kornblith, A.; Barry, W.; Canc & Leukemia Grp B] Duke Univ, Sch Med, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9544
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606163
PM 27963610
ER
PT J
AU Mann, P
Schapira, L
Lynch, T
Penson, R
AF Mann, P.
Schapira, L.
Lynch, T.
Penson, R.
TI Utility of Schwartz Center Rounds in fostering compassion,
communication, teamwork, and caregiver support
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Kenneth B Schwartz Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e20640
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606391
PM 27961662
ER
PT J
AU Maris, MB
Ravandi, F
Stuart, R
Stone, R
Cripe, L
Cooper, M
Strickland, S
Turturro, F
Stock, W
Berman, C
AF Maris, M. B.
Ravandi, F.
Stuart, R.
Stone, R.
Cripe, L.
Cooper, M.
Strickland, S.
Turturro, F.
Stock, W.
Berman, C.
TI A phase II study of voreloxin as single agent therapy for elderly
patients (pts) with newly diagnosed acute myeloid leukemia (AML)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA.
MD Anderson Canc Ctr, Houston, TX USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
St Francis Hosp, Indianapolis, IN USA.
Vanderbilt Univ, Nashville, TN USA.
Louisiana Hlth Sci Ctr, Shreveport, LA USA.
Univ Chicago, Chicago, IL 60637 USA.
Sunesis Pharmaceut, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 7048
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605038
PM 27961427
ER
PT J
AU Mayer, E
Baurain, J
Sparano, J
Strauss, L
Campone, M
Fumoleau, P
Rugo, H
Awada, A
Sy, O
Llombart, A
AF Mayer, E.
Baurain, J.
Sparano, J.
Strauss, L.
Campone, M.
Fumoleau, P.
Rugo, H.
Awada, A.
Sy, O.
Llombart, A.
TI Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast
cancer: Phase II study CA180088
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Univ St Luc, Oncol Med Clin, Brussels, Belgium.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Montefiore Einstein Canc Ctr, New York, NY USA.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Ctr Lutte Canc Nantes Atlant, St Herblain, France.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Ctr George Francois Leclerc, Dijon, France.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Inst Jules Bordet, B-1000 Brussels, Belgium.
[Mayer, E.; Baurain, J.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart, A.] Hosp Arnau Vilanova, Lleida, Spain.
NR 0
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 1011
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601488
PM 27960737
ER
PT J
AU McCleary, NAJ
Meyerhardt, J
Green, E
Yothers, G
de Gramont, A
Van Cutsem, E
O'Connell, M
Twelves, C
Saltz, L
Sargent, D
AF McCleary, N. A. Jackson
Meyerhardt, J.
Green, E.
Yothers, G.
de Gramont, A.
Van Cutsem, E.
O'Connell, M.
Twelves, C.
Saltz, L.
Sargent, D.
CA ACCENT Collaborative Group
TI Impact of older age on the efficacy of newer adjuvant therapies in >
12,500 patients (pts) with stage II/III colon cancer: Findings from the
ACCENT Database
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] Mayo Clin, Rochester, MN USA.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] Univ Pittsburgh, Pittsburgh, PA USA.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] Hop St Antoine, F-75571 Paris, France.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] Univ Leuven, Louvain, Belgium.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.] St James Univ Hosp, Leeds, W Yorkshire, England.
[McCleary, N. A. Jackson; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.; ACCENT Collaborative Group] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 13
Z9 13
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4010
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600252
ER
PT J
AU Meyerhardt, JA
McCleary, NJ
Niedzwiecki, D
Hollis, D
Venook, A
Mayer, R
Goldberg, R
AF Meyerhardt, J. A.
McCleary, N. Jackson
Niedzwiecki, D.
Hollis, D.
Venook, A.
Mayer, R.
Goldberg, R.
TI Impact of age and comorbidities on treatment effect, tolerance, and
toxicity in metastatic colorectal cancer (mCRC) patients treated on
CALGB 80203
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Meyerhardt, J. A.; McCleary, N. Jackson; Niedzwiecki, D.; Hollis, D.; Venook, A.; Mayer, R.; Goldberg, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Meyerhardt, J. A.; McCleary, N. Jackson; Niedzwiecki, D.; Hollis, D.; Venook, A.; Mayer, R.; Goldberg, R.] Canc & Leukemia Grp B, Chapel Hill, NC USA.
[Meyerhardt, J. A.; McCleary, N. Jackson; Niedzwiecki, D.; Hollis, D.; Venook, A.; Mayer, R.; Goldberg, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Meyerhardt, J. A.; McCleary, N. Jackson; Niedzwiecki, D.; Hollis, D.; Venook, A.; Mayer, R.; Goldberg, R.] Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4038
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600278
PM 27961542
ER
PT J
AU Michaels, M
Blakeney, N
Schapira, L
Britton, A
Swords, L
Bitow, N
Gibbs, B
Yeun, S
Rytkonen, B
Goodman, R
AF Michaels, M.
Blakeney, N.
Schapira, L.
Britton, A.
Swords, L.
Bitow, N.
Gibbs, B.
Yeun, S.
Rytkonen, B.
Goodman, R.
CA NOVA Research Co
TI ENACCT's pilot education program (PEP): A model to enhance understanding
of cancer clinical trials for community providers and community leaders
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Michaels, M.; Blakeney, N.; Schapira, L.; Britton, A.; Swords, L.; Bitow, N.; Gibbs, B.; Yeun, S.; Rytkonen, B.; Goodman, R.] Educ Network Adv Canc Clin Trials, Silver Spring, MD USA.
[Michaels, M.; Blakeney, N.; Schapira, L.; Britton, A.; Swords, L.; Bitow, N.; Gibbs, B.; Yeun, S.; Rytkonen, B.; Goodman, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Michaels, M.; Blakeney, N.; Schapira, L.; Britton, A.; Swords, L.; Bitow, N.; Gibbs, B.; Yeun, S.; Rytkonen, B.; Goodman, R.] Decatur Mem Hosp, Decatur, GA USA.
[Michaels, M.; Blakeney, N.; Schapira, L.; Britton, A.; Swords, L.; Bitow, N.; Gibbs, B.; Yeun, S.; Rytkonen, B.; Goodman, R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Michaels, M.; Blakeney, N.; Schapira, L.; Britton, A.; Swords, L.; Bitow, N.; Gibbs, B.; Yeun, S.; Rytkonen, B.; Goodman, R.] Tacoma Pierce Cty Hlth Dept, Tacoma, WA USA.
[Michaels, M.; Blakeney, N.; Schapira, L.; Britton, A.; Swords, L.; Bitow, N.; Gibbs, B.; Yeun, S.; Rytkonen, B.; Goodman, R.; NOVA Research Co] Indiana Univ, Bloomington, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e17514
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604494
PM 27963275
ER
PT J
AU Miller, DS
Blessing, JA
Krasner, CN
Drake, RD
Higgins, R
McMeekin, DS
Puneky, LV
AF Miller, D. S.
Blessing, J. A.
Krasner, C. N.
Drake, R. D.
Higgins, R.
McMeekin, D. S.
Puneky, L. V.
TI A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the
treatment of recurrent or persistent endometrial carcinoma: A phase II
study of the Gynecologic Oncology Group
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Fairview Hosp, Cleveland Clin, Ctr Canc, Cleveland, OH USA.
[Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Carolinas Med Ctr, Charlotte, NC 28203 USA.
[Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Univ Oklahoma, Oklahoma City, OK USA.
[Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Drake, R. D.; Higgins, R.; McMeekin, D. S.; Puneky, L. V.] Univ Mississippi, Jackson, MS 39216 USA.
RI Miller, David/H-4604-2011
OI Miller, David/0000-0002-8215-5887
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e16507
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600104
PM 27960769
ER
PT J
AU Morgan, JA
Guo, A
Williams, D
Guerin, A
Latremouille-Viau, D
Tsaneva, M
Yu, AP
Wu, E
Signorovitch, J
Demetri, GD
AF Morgan, J. A.
Guo, A.
Williams, D.
Guerin, A.
Latremouille-Viau, D.
Tsaneva, M.
Yu, A. P.
Wu, E.
Signorovitch, J.
Demetri, G. D.
TI Real world treatment patterns of gastrointestinal stromal tumor patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Anal Grp Inc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e15602
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603320
PM 27962678
ER
PT J
AU Moy, B
Rappold, E
Williams, L
Kelly, T
Nicolodi, L
Maltzman, JD
Goss, PE
AF Moy, B.
Rappold, E.
Williams, L.
Kelly, T.
Nicolodi, L.
Maltzman, J. D.
Goss, P. E.
TI Hepatobiliary abnormalities in patients with metastatic cancer treated
with lapatinib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Moy, B.; Rappold, E.; Williams, L.; Kelly, T.; Nicolodi, L.; Maltzman, J. D.; Goss, P. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Moy, B.; Rappold, E.; Williams, L.; Kelly, T.; Nicolodi, L.; Maltzman, J. D.; Goss, P. E.] GlaxoSmithKline Inc, Collegeville, PA USA.
NR 0
TC 10
Z9 10
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 1043
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601520
PM 27961107
ER
PT J
AU Munshi, NC
Li, C
Minvielle, S
Moreau, P
Amin, SB
Magrangeas, M
Anderson, KC
Avetloiseau, H
AF Munshi, N. C.
Li, C.
Minvielle, S.
Moreau, P.
Amin, S. B.
Magrangeas, M.
Anderson, K. C.
Avetloiseau, H.
TI Use of alternate splicing to identify subgroups in uniformly treated
newly-diagnosed myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Hop Nantes, Nantes, France.
RI Minvielle, Stephane/K-8251-2015; richard, chrystelle/K-8595-2015
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8602
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605510
PM 27962617
ER
PT J
AU Nabors, LB
Mikkelsen, T
Batchelor, T
Lesser, G
Rosenfeld, M
Ye, X
Piantadosi, S
Olson, J
Brem, S
Grossman, S
AF Nabors, L. B.
Mikkelsen, T.
Batchelor, T.
Lesser, G.
Rosenfeld, M.
Ye, X.
Piantadosi, S.
Olson, J.
Brem, S.
Grossman, S.
TI NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction
with concomitant and adjuvant temozolomide with radiation therapy in
patients with newly diagnosed glioblastoma multiforme (GBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Univ Alabama, Birmingham, AL USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Henry Ford Hosp, Detroit, MI 48202 USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Univ Penn, Philadelphia, PA 19104 USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] Emory Univ, Atlanta, GA 30322 USA.
[Nabors, L. B.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2001
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602149
PM 27964566
ER
PT J
AU Nguyen, PL
Chen, MH
Beard, CJ
Loffredo, M
Renshaw, AA
Suh, WW
Kantoff, PW
D'Amico, AV
AF Nguyen, P. L.
Chen, M. H.
Beard, C. J.
Loffredo, M.
Renshaw, A. A.
Suh, W. W.
Kantoff, P. W.
D'Amico, A. V.
TI Postrandomization analysis assessing survival following radiation
therapy (RT) with or without 6 months of androgen suppression therapy
(AST) for localized prostate cancer (PCa)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5129
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604002
PM 27964400
ER
PT J
AU Norden, AD
Raizer, JJ
Lamborn, KR
Abrey, LE
Chang, SM
Gilbert, MR
Cloughesy, TF
Prados, MD
Lieberman, F
Wen, P
AF Norden, A. D.
Raizer, J. J.
Lamborn, K. R.
Abrey, L. E.
Chang, S. M.
Gilbert, M. R.
Cloughesy, T. F.
Prados, M. D.
Lieberman, F.
Wen, P.
TI Phase II trials of erlotinib or gefitinib in patients with recurrent
meningiomas
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Norden, A. D.; Raizer, J. J.; Lamborn, K. R.; Abrey, L. E.; Chang, S. M.; Gilbert, M. R.; Cloughesy, T. F.; Prados, M. D.; Lieberman, F.; Wen, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Norden, A. D.; Raizer, J. J.; Lamborn, K. R.; Abrey, L. E.; Chang, S. M.; Gilbert, M. R.; Cloughesy, T. F.; Prados, M. D.; Lieberman, F.; Wen, P.] Northwestern Univ, Chicago, IL 60611 USA.
[Norden, A. D.; Raizer, J. J.; Lamborn, K. R.; Abrey, L. E.; Chang, S. M.; Gilbert, M. R.; Cloughesy, T. F.; Prados, M. D.; Lieberman, F.; Wen, P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Norden, A. D.; Raizer, J. J.; Lamborn, K. R.; Abrey, L. E.; Chang, S. M.; Gilbert, M. R.; Cloughesy, T. F.; Prados, M. D.; Lieberman, F.; Wen, P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Norden, A. D.; Raizer, J. J.; Lamborn, K. R.; Abrey, L. E.; Chang, S. M.; Gilbert, M. R.; Cloughesy, T. F.; Prados, M. D.; Lieberman, F.; Wen, P.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Norden, A. D.; Raizer, J. J.; Lamborn, K. R.; Abrey, L. E.; Chang, S. M.; Gilbert, M. R.; Cloughesy, T. F.; Prados, M. D.; Lieberman, F.; Wen, P.] Univ Pittsburgh, Pittsburgh, PA USA.
RI Gilbert, Mark/J-7494-2016
OI Gilbert, Mark/0000-0003-2556-9722
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2062
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602210
PM 27964693
ER
PT J
AU Oh, WK
Febbo, PG
Richie, JP
Fennessy, FM
Scibelli, G
Hayes, JH
Choueiri, TK
Tempany, CM
Taplin, ME
Ross, RW
AF Oh, W. K.
Febbo, P. G.
Richie, J. P.
Fennessy, F. M.
Scibelli, G.
Hayes, J. H.
Choueiri, T. K.
Tempany, C. M.
Taplin, M. E.
Ross, R. W.
TI A phase II study of neoadjuvant chemotherapy with docetaxel and
bevacizumab in patients (pts) with high-risk localized prostate cancer:
A Prostate Cancer Clinical Trials Consortium trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Durham, NC USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5060
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603460
PM 27962979
ER
PT J
AU Patel, T
Dreisbach, L
McCleod, M
Heim, WJ
Hermann, RC
Woytowitz, D
Lu, H
Weber, MR
Lynch, TJ
AF Patel, T.
Dreisbach, L.
McCleod, M.
Heim, W. J.
Hermann, R. C.
Woytowitz, D.
Lu, H.
Weber, M. R.
Lynch, T. J.
TI Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line
advanced NSCLC: Analysis of the BMS099 trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Mid Ohio Oncol Hematol Inc, Columbus, OH USA.
Desert Hematol Oncol Med Grp, Rancho Mirage, CA USA.
Florida Canc Specialists, Ft Myers, FL USA.
Hematol & Oncol Associates NE Pennsylvania, Dunmore, PA USA.
NW Georgia Oncol Ctr, Marietta, GA USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e19011
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605322
PM 27962626
ER
PT J
AU Patil, S
Figlin, RA
Hutson, TE
Michaelson, MD
Negrier, S
Kim, ST
Huang, X
Motzer, RJ
AF Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, M. D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
TI Prognostic factors for overall survival with sunitinib as first-line
therapy in patients with metastatic renal cell carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
Texas Oncol PA, Baylor Sammons Canc Ctr, Dallas, TX USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Ctr Leon Berard, F-69373 Lyon, France.
Pfizer Oncol, La Jolla, CA USA.
NR 0
TC 0
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5042
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603443
PM 27962940
ER
PT J
AU Phelps, AC
Maciejewski, PK
Nilsson, M
Balboni, TA
Wright, AA
Trice, E
Block, SD
Prigerson, HG
AF Phelps, A. C.
Maciejewski, P. K.
Nilsson, M.
Balboni, T. A.
Wright, A. A.
Trice, E.
Block, S. D.
Prigerson, H. G.
TI Coping with cancer: Associations between coping methods and use of
intensive life-prolonging care near death
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9575
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606194
PM 27963713
ER
PT J
AU Piao, Y
Heymach, JV
Bekele, B
Camphausen, K
Wen, PY
Liu, J
Yung, WK
De Groot, J
AF Piao, Y.
Heymach, J. V.
Bekele, B.
Camphausen, K.
Wen, P. Y.
Liu, J.
Yung, W. K.
De Groot, J.
TI Circulating cytokine and angiogenic factors as predictive biomarkers of
glioblastoma response to aflibercept (VEGF Trap)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Piao, Y.; Heymach, J. V.; Bekele, B.; Camphausen, K.; Wen, P. Y.; Liu, J.; Yung, W. K.; De Groot, J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Piao, Y.; Heymach, J. V.; Bekele, B.; Camphausen, K.; Wen, P. Y.; Liu, J.; Yung, W. K.; De Groot, J.] NCI, Bethesda, MD 20892 USA.
[Piao, Y.; Heymach, J. V.; Bekele, B.; Camphausen, K.; Wen, P. Y.; Liu, J.; Yung, W. K.; De Groot, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2029
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602177
PM 27964597
ER
PT J
AU Pirl, WF
Solis, J
Temel, JS
Admane, S
Rosovsky, R
Prigerson, HG
Greer, J
AF Pirl, W. F.
Solis, J.
Temel, J. S.
Admane, S.
Rosovsky, R.
Prigerson, H. G.
Greer, J.
TI Longitudinal course of suicidal ideation in patients with newly
diagnosed thoracic cancers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9606,56
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606224
PM 27963838
ER
PT J
AU Plotkin, SR
Singh, M
Cai, W
O'Donnell, C
Esparza, S
Smith, MJ
Harris, GJ
Muzikansky, A
Bredella, MA
Kassarjian, A
AF Plotkin, S. R.
Singh, M.
Cai, W.
O'Donnell, C.
Esparza, S.
Smith, M. J.
Harris, G. J.
Muzikansky, A.
Bredella, M. A.
Kassarjian, A.
TI Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor
suppressor syndromes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Plotkin, S. R.; Singh, M.; Cai, W.; O'Donnell, C.; Esparza, S.; Smith, M. J.; Harris, G. J.; Muzikansky, A.; Bredella, M. A.; Kassarjian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2074
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602222
PM 27964382
ER
PT J
AU Prados, M
Gilbert, M
Kuhn, J
Lamborn, K
Cloughesy, T
Lieberman, F
Puduvalli, V
Robins, HI
Lassman, A
Wen, PY
AF Prados, M.
Gilbert, M.
Kuhn, J.
Lamborn, K.
Cloughesy, T.
Lieberman, F.
Puduvalli, V.
Robins, H. I.
Lassman, A.
Wen, P. Y.
TI Phase I/II study of sorefenib and erlotinib for patients with recurrent
glioblastoma (GBM) (NABTC 05-02)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] UCSF, San Francisco, CA USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] MD Anderson Canc Ctr, Houston, TX USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] UT San Antonio, San Antonio, TX USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] Univ Pittsburgh, Pittsburgh, PA USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] Univ Wisconsin, Madison, WI USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Prados, M.; Gilbert, M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Lieberman, F.; Puduvalli, V.; Robins, H. I.; Lassman, A.; Wen, P. Y.] DFCI, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2005
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602153
PM 27964562
ER
PT J
AU Prigerson, HG
Wright, AA
Block, SD
Maciejewski, PK
AF Prigerson, H. G.
Wright, A. A.
Block, S. D.
Maciejewski, P. K.
TI Tailoring end-of-life discussions to advanced cancer patients' state of
grief
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9500
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606120
PM 27964453
ER
PT J
AU Priolo, C
Loda, M
AF Priolo, C.
Loda, M.
TI Unraveling the metabolome in prostate tumorigenesis: Effects by an
oncogenic isopeptidase
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
BWH, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e16148
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604187
PM 27963423
ER
PT J
AU Quant, EC
Silver, M
Yip, S
Ryg, P
Provencher, K
McCormack, K
Louis, DN
Betensky, R
Nutt, C
Batchelor, TT
AF Quant, E. C.
Silver, M.
Yip, S.
Ryg, P.
Provencher, K.
McCormack, K.
Louis, D. N.
Betensky, R.
Nutt, C.
Batchelor, T. T.
TI Case-control study of long-term survivors of glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Quant, E. C.; Silver, M.; Yip, S.; Ryg, P.; Provencher, K.; McCormack, K.; Louis, D. N.; Betensky, R.; Nutt, C.; Batchelor, T. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Quant, E. C.; Silver, M.; Yip, S.; Ryg, P.; Provencher, K.; McCormack, K.; Louis, D. N.; Betensky, R.; Nutt, C.; Batchelor, T. T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e13021
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602248
PM 27962816
ER
PT J
AU Rao, SR
Hassett, M
Schwartz, JH
Maloney, B
Jacobson, JO
AF Rao, S. R.
Hassett, M.
Schwartz, J. H.
Maloney, B.
Jacobson, J. O.
TI Admissions for chemotherapy-related serious adverse effects (CR-SAEs)
and rates of mortality among community cancer center patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
N Shore Med Ctr, Salem, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6571
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604419
PM 27963798
ER
PT J
AU Raza, A
Galili, N
Borthakur, G
Carter, TH
Claxton, DF
Erba, HP
DeAngelo, DJ
Berger, MS
Schimmer, A
AF Raza, A.
Galili, N.
Borthakur, G.
Carter, T. H.
Claxton, D. F.
Erba, H. P.
DeAngelo, D. J.
Berger, M. S.
Schimmer, A.
TI A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in
previously untreated older patients with acute myeloid leukemia (AML)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 St Vincents Comprehens Canc Ctr, New York, NY USA.
MD Anderson Canc Ctr, Houston, TX USA.
Univ Iowa Hosp, Coralville, IA USA.
Milton S Hershey Med Ctr, Hershey, PA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Gemin X Pharmaceut, Malvern, PA USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3579
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602469
PM 27961704
ER
PT J
AU Richardson, PG
Chanan-Khan, A
Lonial, S
Krishnan, A
Carroll, M
Alsina, M
Albitar, M
Berman, D
Kaplita, S
Anderson, K
AF Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Kaplita, S.
Anderson, K.
TI Tanespimycin plus bortezomib in patients with relapsed and refractory
multiple myeloma: Final results of a phase I/II study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Emory Univ, Sch Med, Atlanta, GA 30322 USA.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
Sutter Reg Canc Inst, Sacramento, CA USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Nichols Inst, San Juan Capistrano, CA USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 8503
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605413
ER
PT J
AU Rini, BI
Halabi, S
Rosenberg, J
Stadler, WM
Vaena, DA
Atkins, JN
Picus, J
Czaykowski, P
Dutcher, J
Small, EJ
AF Rini, B. I.
Halabi, S.
Rosenberg, J.
Stadler, W. M.
Vaena, D. A.
Atkins, J. N.
Picus, J.
Czaykowski, P.
Dutcher, J.
Small, E. J.
TI Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in
patients with metastatic renal cell carcinoma: Results of overall
survival for CALGB 90206
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
CALGB, Stat Off, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Iowa, Iowa City, IA USA.
SE Canc Control Consortium Inc, Winston Salem, NC USA.
Washington Univ, St Louis, MO USA.
Natl Canc Inst Canada, Kingston, ON, Canada.
New York Med Coll, New York, NY USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA LBA5019
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603422
PM 27961198
ER
PT J
AU Roberts, AW
Wilson, W
Gandhi, L
O'Connor, OA
Rudin, CM
Brown, JR
Xiong, H
Chiu, Y
Enschede, S
Krivoshik, AP
AF Roberts, A. W.
Wilson, W.
Gandhi, L.
O'Connor, O. A.
Rudin, C. M.
Brown, J. R.
Xiong, H.
Chiu, Y.
Enschede, S.
Krivoshik, A. P.
TI Ongoing phase I studies of ABT-263: Mitigating Bcl-X-L induced
thrombocytopenia with lead-in and continuous dosing
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Roberts, A. W.; Wilson, W.; Gandhi, L.; O'Connor, O. A.; Rudin, C. M.; Brown, J. R.; Xiong, H.; Chiu, Y.; Enschede, S.; Krivoshik, A. P.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Roberts, A. W.; Wilson, W.; Gandhi, L.; O'Connor, O. A.; Rudin, C. M.; Brown, J. R.; Xiong, H.; Chiu, Y.; Enschede, S.; Krivoshik, A. P.] Natl Canc Inst, Bethesda, MD USA.
[Roberts, A. W.; Wilson, W.; Gandhi, L.; O'Connor, O. A.; Rudin, C. M.; Brown, J. R.; Xiong, H.; Chiu, Y.; Enschede, S.; Krivoshik, A. P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Roberts, A. W.; Wilson, W.; Gandhi, L.; O'Connor, O. A.; Rudin, C. M.; Brown, J. R.; Xiong, H.; Chiu, Y.; Enschede, S.; Krivoshik, A. P.] Columbia Univ, New York, NY USA.
[Roberts, A. W.; Wilson, W.; Gandhi, L.; O'Connor, O. A.; Rudin, C. M.; Brown, J. R.; Xiong, H.; Chiu, Y.; Enschede, S.; Krivoshik, A. P.] Johns Hopkins Univ, Baltimore, MD USA.
[Roberts, A. W.; Wilson, W.; Gandhi, L.; O'Connor, O. A.; Rudin, C. M.; Brown, J. R.; Xiong, H.; Chiu, Y.; Enschede, S.; Krivoshik, A. P.] Abbott Labs, Abbott Pk, IL 60064 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3505
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602395
PM 27961281
ER
PT J
AU Roccaro, AM
Sacco, A
Leleu, X
Thompson, B
Azab, A
Runnels, J
Lin, C
Witzig, T
Anderson, K
Ghobrial, I
AF Roccaro, A. M.
Sacco, A.
Leleu, X.
Thompson, B.
Azab, A.
Runnels, J.
Lin, C.
Witzig, T.
Anderson, K.
Ghobrial, I.
TI MicroRNAs 15a and 16-1 regulates tumor proliferation in multiple myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Wellman Ctr Photomed, Boston, MA USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e14640
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603083
PM 27964233
ER
PT J
AU Romanus, D
Weiser, M
TerVeer, A
Skibber, J
Wilson, J
Rajput, A
Wong, Y
Benson, A
Niland, J
Schrag, D
AF Romanus, D.
Weiser, M.
TerVeer, A.
Skibber, J.
Wilson, J.
Rajput, A.
Wong, Y.
Benson, A.
Niland, J.
Schrag, D.
CA NCCN Colerectal Canc Outcome
TI How often is adjuvant FOLFOX (Adj FOLFOX) discontinued for toxicity
among colon cancer patients in the routine care setting?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol (ASCO)
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
MD Anderson Canc Ctr, Houston, TX USA.
Ohio State Univ, Columbus, OH 43210 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9530
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606149
PM 27964503
ER
PT J
AU Rosenfeld, MR
Chamberlain, M
Grossman, SA
Peereboom, DM
Lesser, GJ
Batchelor, TT
Desideri, S
Salazar, AM
Ye, X
AF Rosenfeld, M. R.
Chamberlain, M.
Grossman, S. A.
Peereboom, D. M.
Lesser, G. J.
Batchelor, T. T.
Desideri, S.
Salazar, A. M.
Ye, X.
TI A phase II study of chemoradiation followed by adjuvant temozolomide and
poly-ICLC in patients with newly diagnosed glioblastoma: 12-and 18-month
survival data (NABTT 0501)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Penn, Philadelphia, PA 19104 USA.
Univ Washington, Seattle, WA 98195 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Oncovir Inc, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 2002
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602150
PM 27964563
ER
PT J
AU Ross, RW
Bankaitis-Davis, D
Siconolfi, L
Katz, L
Storm, K
Magidson, J
Wassmann, K
Oh, WK
AF Ross, R. W.
Bankaitis-Davis, D.
Siconolfi, L.
Katz, L.
Storm, K.
Magidson, J.
Wassmann, K.
Oh, W. K.
TI Sensitivity and specificity of a whole-blood RNA transcript-based
diagnostic test for the diagnosis of prostate cancer (CaP) compared with
prostate-specific antigen (PSA) alone
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Source MDx, Boulder, CO USA.
Stat Inovat, Belmont, MA USA.
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5052
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603452
PM 27962956
ER
PT J
AU Ruddy, KJ
Gelber, S
Tamimi, R
Schapira, L
Come, S
Kereakoglow, S
Lin, NU
Winer, EP
Partridge, AH
AF Ruddy, K. J.
Gelber, S.
Tamimi, R.
Schapira, L.
Come, S.
Kereakoglow, S.
Lin, N. U.
Winer, E. P.
Partridge, A. H.
TI Presentation of breast cancer in young women
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 6608
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604456
PM 27961738
ER
PT J
AU Ryan, C
Efstathiou, E
Smith, M
Taplin, M
Bubley, G
Logothetis, C
Kheoh, T
Haqq, C
Molina, A
Small, EJ
AF Ryan, C.
Efstathiou, E.
Smith, M.
Taplin, M.
Bubley, G.
Logothetis, C.
Kheoh, T.
Haqq, C.
Molina, A.
Small, E. J.
TI Phase II multicenter study of chemotherapy (chemo)-naive
castration-resistant prostate cancer (CRPC) not exposed to ketoconazole
(keto), treated with abiraterone acetate (AA) plus prednisone
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
MD Anderson Canc Ctr, Houston, TX USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
Cougar Biotechnol, Los Angeles, CA USA.
NR 0
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5046
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603447
PM 27962951
ER
PT J
AU Ryan, PD
Tung, NM
Isakoff, SJ
Golshan, M
Richardson, A
Corben, AD
Smith, BL
Gelman, R
Winer, EP
Garber, JE
AF Ryan, P. D.
Tung, N. M.
Isakoff, S. J.
Golshan, M.
Richardson, A.
Corben, A. D.
Smith, B. L.
Gelman, R.
Winer, E. P.
Garber, J. E.
TI Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer
(TNBC): Safety and efficacy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Ryan, P. D.; Tung, N. M.; Isakoff, S. J.; Golshan, M.; Richardson, A.; Corben, A. D.; Smith, B. L.; Gelman, R.; Winer, E. P.; Garber, J. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ryan, P. D.; Tung, N. M.; Isakoff, S. J.; Golshan, M.; Richardson, A.; Corben, A. D.; Smith, B. L.; Gelman, R.; Winer, E. P.; Garber, J. E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Ryan, P. D.; Tung, N. M.; Isakoff, S. J.; Golshan, M.; Richardson, A.; Corben, A. D.; Smith, B. L.; Gelman, R.; Winer, E. P.; Garber, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 2
Z9 2
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 551
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601259
PM 27960664
ER
PT J
AU Saad, F
Smith, MR
Egerdie, B
Tammela, TL
Feldman, RA
Heracek, J
Szwedowski, M
Ke, C
Leder, B
Goessl, C
AF Saad, F.
Smith, M. R.
Egerdie, B.
Tammela, T. L.
Feldman, R. A.
Heracek, J.
Szwedowski, M.
Ke, C.
Leder, B.
Goessl, C.
TI Denosumab for prevention of fractures in men receiving androgen
deprivation therapy (ADT) for prostate cancer (PC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Montreal, Ctr Hosp, Montreal, PQ, Canada.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Urol Associates, Urol Med Res, Kitchener, ON, Canada.
Tampere Univ Hosp, Tampere, Finland.
Connecticut Clin Res Ctr, Urol Specialists, Middlebury, CT USA.
Androgeos, Prague, Czech Republic.
Wojewodzkie Ctr Medyczne, Opole, Poland.
Amgen Inc, Thousand Oaks, CA 91320 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5056
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603456
PM 27962972
ER
PT J
AU Saltz, L
Infante, J
Schwartzberg, L
Stephenson, J
Rocha-Lima, C
Galimi, F
Dillingham, K
Hsu, M
Wiezorek, J
Fuchs, C
AF Saltz, L.
Infante, J.
Schwartzberg, L.
Stephenson, J.
Rocha-Lima, C.
Galimi, F.
Dillingham, K.
Hsu, M.
Wiezorek, J.
Fuchs, C.
TI Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and
bevacizumab (B) for the first-line treatment of patients (pts) with
metastatic colorectal cancer (mCRC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Sarah Cannon Res Inst, Nashville, TN USA.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] W Clin, Memphis, TN USA.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Canc Ctr Carolinas, Greenville, SC USA.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Univ Miami, Miami, FL USA.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Amgen Ltd, Cambridge, England.
[Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Galimi, Francesco/J-4238-2012
NR 0
TC 8
Z9 8
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4079
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606601021
PM 27961630
ER
PT J
AU Schellens, JH
Leijen, S
Shapiro, GI
Pavlick, AC
Tibes, R
O'Day, SJ
Demuth, T
Viscusi, J
Xu, Y
Oza, AM
AF Schellens, J. H.
Leijen, S.
Shapiro, G. I.
Pavlick, A. C.
Tibes, R.
O'Day, S. J.
Demuth, T.
Viscusi, J.
Xu, Y.
Oza, A. M.
TI A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase
inhibitor, in both monotherapy and in combination with gemcitabine,
cisplatin, or carboplatin in patients with advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] Netherlands Canc Inst, Amsterdam, Netherlands.
[Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] NYU, New York, NY USA.
[Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] Translat Genom Res Inst, Scottsdale, AZ USA.
[Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] Angeles Clin & Res Inst, Santa Monica, CA USA.
[Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] Merck & Co Inc, N Wales, PA USA.
[Schellens, J. H.; Leijen, S.; Shapiro, G. I.; Pavlick, A. C.; Tibes, R.; O'Day, S. J.; Demuth, T.; Viscusi, J.; Xu, Y.; Oza, A. M.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 3510
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606602400
ER
PT J
AU Schellhorn, S
Lessen, DS
Levine, RL
Panagopoulos, G
Arnold, RM
Block, SD
Buss, MK
AF Schellhorn, S.
Lessen, D. S.
Levine, R. L.
Panagopoulos, G.
Arnold, R. M.
Block, S. D.
Buss, M. K.
TI Palliative care training and burnout in oncology fellows
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
SE Florida Hematol Grp, Ft Lauderdale, FL USA.
Lenox Hill Hosp, New York, NY 10021 USA.
Univ Pittsburgh Hosp, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9540
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606159
PM 27964528
ER
PT J
AU Scher, HI
Beer, TM
Higano, CS
Taplin, M
Efstathiou, E
Anand, A
Hung, D
Hirmand, M
Fleisher, M
AF Scher, H. I.
Beer, T. M.
Higano, C. S.
Taplin, M.
Efstathiou, E.
Anand, A.
Hung, D.
Hirmand, M.
Fleisher, M.
CA Prostate Canc Clin Trials
TI Antitumor activity of MDV3100 in a phase I/II study of
castration-resistant prostate cancer (CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Washington, SCCA, Seattle, WA 98195 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Medivation Inc, San Francisco, CA USA.
RI Anand, Aseem/P-1214-2014
OI Anand, Aseem/0000-0002-3606-540X
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 5011
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606603415
ER
PT J
AU Scher, K
Tisnado, DM
Rose-Ash, D
Rastegar, A
Adams, J
Ko, CY
Ganz, PA
Kahn, KL
AF Scher, K.
Tisnado, D. M.
Rose-Ash, D.
Rastegar, A.
Adams, J.
Ko, C. Y.
Ganz, P. A.
Kahn, K. L.
TI Physician and practice characteristics influencing tumor board
attendance: Results from the provider survey of the Los Angeles Women's
Health Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Vet Affairs Greater Los Angeles, Los Angeles, CA USA.
RAND Corp, Santa Monica, CA USA.
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e17501
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604482
PM 27963245
ER
PT J
AU Schiller, GJ
O'Brien, SM
Vey, N
Pigneux, A
DeAngelo, DJ
Karp, JE
Hudak, D
Kell, J
Stuart, RK
Giles, FJ
AF Schiller, G. J.
O'Brien, S. M.
Vey, N.
Pigneux, A.
DeAngelo, D. J.
Karp, J. E.
Hudak, D.
Kell, J.
Stuart, R. K.
Giles, F. J.
TI Comorbidity description using the hematopoietic cell
transplantation-specific comorbidity index (HCT-CI) in elderly de novo
poor-risk AML patients (pts) treated with laromustine
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Inst J Paoli I Calmettes, F-13009 Marseille, France.
Hop Haut Leveque, Bordeaux, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Vion Pharmaceut Inc, New Haven, CT USA.
Univ Wales Hosp, Cardiff, Wales.
Med Univ S Carolina, Charleston, SC 29425 USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 7050
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605040
PM 27961414
ER
PT J
AU Schiller, JH
Dahlberg, SE
Mehta, M
Johnson, DH
AF Schiller, J. H.
Dahlberg, S. E.
Mehta, M.
Johnson, D. H.
TI A phase III trial of carboplatin, paclitaxel, and thoracic radiation
therapy with or without thalidomide in patients with stage III non-small
cell carcinoma of the lung (NSCLC): E3598
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 SW Texas State Univ, Dallas, TX USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Wisconsin, Madison, WI USA.
Vanderbilt Univ, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 7503
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606605104
ER
PT J
AU Schrag, D
Naughton, M
Kesselheim, A
Archer, L
Niedzwiedcki, D
Romanus, D
Goldberg, R
Venook, A
AF Schrag, D.
Naughton, M.
Kesselheim, A.
Archer, L.
Niedzwiedcki, D.
Romanus, D.
Goldberg, R.
Venook, A.
CA Canc Leukemia Grp B
TI Clinical trial participants' strategies for coping with prescription
drug costs: A companion study to CALGB 80405
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Wake Forest Univ, Wake Forest, NC USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
CALGB, Chicago, IL USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9503
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606123
ER
EF